<rdf:RDF
    xmlns:MA="http://purl.org/obo/owl/MA#"
    xmlns:UO="http://purl.org/obo/owl/UO#"
    xmlns:IMR="http://purl.org/obo/owl/IMR#"
    xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#"
    xmlns:OBI="http://purl.obolibrary.org/obo/"
    xmlns:NCI="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#"
    xmlns:FAO="http://purl.org/obo/owl/FAO#"
    xmlns:ncbitax="http://purl.org/obo/owl/NCBITaxon#"
    xmlns:SHORT="http://dc-research.eu/shortforms#"
    xmlns:BTO="http://purl.org/obo/owl/BTO#"
    xmlns:swrlb="http://www.w3.org/2003/11/swrlb#"
    xmlns:CCO="http://www.cellcycleontology.org/ontology/owl/CCO#"
    xmlns:FMA="http://purl.org/obo/owl/FMA#"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:NEWT="http://purl.uniprot.org/taxonomy/"
    xmlns:EFO="http://www.ebi.ac.uk/experimentalfactors.owl/"
    xmlns:MI="http://purl.org/obo/owl/psi-mi#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
    xmlns:UBERON="http://purl.org/obo/owl/UBERON#"
    xmlns:DC_CL="http://purl.org/obo/owl/DC_CL#"
    xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#"
    xmlns:DO="http://purl.org/obo/owl/DOID#"
    xmlns:CL="http://purl.org/obo/owl/CL#"
    xmlns:mesh="http://purl.org/obo/owl/MESH#"
    xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#"
    xmlns:MGED="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#"
    xmlns:MAO="http://purl.org/obo/owl/MAO#"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:p3="http://purl.org/obo/owl/CARO#"
    xmlns:p1="http://purl.org/obo/owl/PRO#"
    xmlns:CLA="http://dc-research.eu/classannotations#"
    xmlns:owl="http://www.w3.org/2002/07/owl#"
    xmlns:p2="http://purl.org/obo/owl/SO#"
    xmlns:GO="http://purl.org/obo/owl/GO#"
    xmlns:ECO="http://purl.org/obo/owl/ECO#"
    xmlns:swrl="http://www.w3.org/2003/11/swrl#"
    xmlns:dcr="http://dc-research.eu#"
    xmlns:j.0="http://purl.obofoundry.org/obo/"
    xmlns:CHEBI="http://purl.org/obo/owl/CHEBI#"
    xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
    xmlns:IDO="http://purl.org/obo/owl/ID#" > 
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/94">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/286"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/151"/>
    <rdfs:label>Clinical trials of DC-based immmunotherapy of melanoma patients</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <rdfs:comment>During the previous period we obtained data from our continued pilot clinical trials of DC-based immunotherapy of melanoma patients.  After an initial cohort of patients treated with monocyte-derived DCs matured with inflammatory cytokines and subsequently electroporated with mRNA encoding 6 tumor-associated antigens, we persued this trial in a next cohort where DC-based vaccines were combined with low dose IFN-alfa (3 x 10e6 U per wk).  In a significantly higher number of patients we observed vaccine-induced depigmentation and vitiligo.  Further improvement and careful analysis of these patients is ongoing.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/82"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTerm_5">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTerm"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_126283">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10294"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HSV unknown type</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">herpes simplex virus unknown type</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000190">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ratio</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000046"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A dimensionless unit which denotes an amount or magnitude of one quantity relative to another.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_175">
    <rdfs:label>mature dendritic cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mature dendritic cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_502">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gene delivery function</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A gene delivery function is a function whose aim is to introduce foreign DNA into host cells.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/122">
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We annotated DC specific pathways and integrated them in the pathway tool. Initially we have annotated DC specific pathways using information publically available on the web. A preliminary curated non exhaustive pathway list can be found in the DC-THERA version of the program DC_Eu.Gene. </rdfs:comment>
    <rdfs:label>Annotation of DC specific pathways and integration in the pathway tool</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/115">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These HIV strains were used to infect Human Hemato-Lymphoid System Rag2gc-/- mice to closely resemble HIV infection in humans.</rdfs:comment>
    <rdfs:label>CCR5 tropic HIV-1 strains</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_588">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A genetic modification design type is where an organism(s) has had genetic material removed, rearranged, mutagenized or added, such as knock out</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">growth condition design experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/58">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/31"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000010"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have developed a MAGE-ML export feature in collaboration with the European Bioinformatics Institute (EBI).</rdfs:comment>
    <rdfs:label>MAGE-ML export feature</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A0">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_581">
    <rdfs:subClassOf rdf:nodeID="A1"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">anti-CD40 blocking antibody</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/72">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:comment>A retrotranscriptional reaction is performed on RNA extracted from T cells or DCs. Transcripts for interested genes are quantified by real-time quantitative PCR on an Perkin-Elmer Applied Biosystems with predesigned TaqMan Gene Expression Assays according to the manufacturer’s instructions.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30317"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/93"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:label>Real Time PCR</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/280">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The DC are transfected with RNA encoding MelanA, Mage3 and Survivin +/- E/L-selectin.
They are used in the DERMA-ER-DC 06 trial.</rdfs:comment>
    <rdfs:label>Transfected DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_617">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bone marrow-derived dendritic cell</rdfs:label>
    <owl:equivalentClass rdf:nodeID="A2"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_389">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">flagellin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/MESH#MESH_E.05.478.594.410.320.200">
    <rdfs:label>Blotting, Western</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Western blotting is a method specifying the identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Blotting, Western</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasTissue">
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasTissueType</dcr:hasClassAsRangeProperty>
    <rdfs:range rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with the biomaterial. As this would make the ontology OWL full, the annotation property hasTissueType is used instead.</rdfs:comment>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasBodilyPart"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tissue</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_540">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A financial responsible role is a DCTHERA role of DCTHERA persons who assume the financial responsibility for the institution/company they work for with regard to the DCTHERA project.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000102"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Financial responsible</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/111">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The CD8 T cells become evaluated on their cytokine secretion, cytotoxicity and % of antigen specific T cells.</rdfs:comment>
    <rdfs:label>Evaluation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_208">
    <rdfs:label>ImmunoVexHSV2 vaccine</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ImmunoVexHSV2 vaccine</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ImmunoVexHSV2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_470">
    <rdfs:label>Gene gun</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gene gun</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A gene gun is a device for transforming cells with foreign DNA that works by propelling small metal spheres covered with a DNA molecule into living cells.</OBI:IAO_0000115>
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.everythingbio.com/glos/definition.php?word=gene+gun</OBI:IAO_0000119>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#MaterialEntity"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Biolistic Particle Delivery System</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/524">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We established tumor cell lines from pancreatic cancer in our laboratory.</rdfs:comment>
    <rdfs:label>Tumor cell lines from pancreatic cancer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/166">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001452"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/16"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3</rdfs:label>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704352"/>
    <rdfs:comment>Data has been obtained on the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.

Using specific inhibitors we have previously found that src-family tyrosine kinases are required for cytokines and chemokines production during maturation of human monocyte-derived dendritic cells (DCs) upon stimulation with several toll like receptor (TLR) agonists. We have now evaluated the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3. We tested if src-family tyrosine kinases inhibitors had any effect on the high levels of cytokine production induced in monocyte-derived DCs upon the synergistic stimulation of TLRs. Using the DNA microarray technology we have also analyzed which are the genes that require activation of Src kinases during TLR3 stimulation of monocyte-derived DCs. This pathway analysis will be of help in the elucidation of the molecular mechanism by which Src kinases regulate inflammatory cytokine production in DCs. </rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001461"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_503">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Separation function</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000372</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/21">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/12"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Exosomes bearing functional MHC-peptide complexes have been shown to be presented at the surface of recipient DCs as intact "antigen-presenting microdomains", without the need for internalisation and reprocessing by the DC.</rdfs:comment>
    <rdfs:label>exosomes bearing functional MHC-peptide complexes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000229">
    <rdfs:label xml:lang="en">obsolete_lymphoblast</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/UBERON#UBERON_0000338</dcr:replaced_by>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/34">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/177"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000278"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001438"/>
    <rdfs:label>Demonstration of calcineurin-dependent NFAT activation in DC via CD14 but not TLR4</rdfs:label>
    <rdfs:comment>Our group obtained data on molecular signaling triggered by LPS in dendritic cells and the role of CD14 in the regulation of the DC life cycle through NFAT activation. Toll-like receptors (TLRs) are the best-characterized pattern recognition receptors (PRRs). Individual TLRs recruit diverse combinations of adapter proteins, and thereby trigger signal transduction pathways leading to the activation of various transcription factors, including nuclear factor (NF)-kB, activation protein (AP)-1, and interferon regulatory factors (IRFs). Interleukin-2 (IL-2) is one of the molecules produced by mouse dendritic cells (DCs) after stimulation by TLR agonists. By analogy with the events following T-cell receptor (TCR) engagement leading to IL-2 production, it is therefore plausible that the stimulation of TLRs on DCs may lead to activation of the Ca2+/calcineurin and NFAT pathway. Our contribution to the project has been the finding that the DC stimulation with lipopolysaccharide (LPS) induces Src-family kinase and phospholipase C (PLC)?2 activation, influx of extracellular Ca2+ and calcineurin-dependent nuclear NFAT translocation. The initiation of this pathway is independent of TLR4 engagement, and dependent exclusively on CD14. We also show that LPS-induced NFAT activation via CD14 is necessary to cause death of terminally differentiated DCs (supplementary Fig. 1), an event that is essential for maintaining self-tolerance and preventing autoimmunity. Consequently, blocking this pathway in vivo causes prolonged DC survival and an increase in T cell priming capability. Our findings reveal novel aspects of the molecular signaling triggered by LPS in DCs and identify a new role for CD14: the regulation of the DC life cycle through NFAT activation. </rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100031"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/176"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_492">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DC-THERA Resource is a Public Resource in the underlying network.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA Resource</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_174">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rev</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Regulator of Virion</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_211"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239">
    <rdfs:label>Viruses</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">viral</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vira</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Viridae</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">viruses</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTerm_4">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTerm"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasExperimentalDesign">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">experimental design</rdfs:label>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir datasets may have an experimental design type assign. As this would make the ontology OWL full, the annotation property hasExperimentalDesignType is used instead as a shortcut.</rdfs:comment>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasExperimentalDesignType</dcr:hasClassAsRangeProperty>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/90">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Maria Goetz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/93">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/53"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/221"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/120"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/541"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/538"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/242"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/222"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/128"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/97"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_171"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/223"/>
    <rdfs:label>Phase I/II clinical trial  on the use of long peptides plus adjuvant for end-stage cervical cancer or VIN patients</rdfs:label>
    <rdfs:comment>We have obtained data from a phase I/II clinical trial of patients with end stage cervical cancer and of patients with vulvar intraepithelial neoplasia (VIN) grade III.  Preclinical animal studies have shown that long peptides of 25-35 amino acids in length upon injection are only processed efficiently for MHC class I by dendritic cells in vivo. Long peptide injection is followed by appropriate cognate interactions between such DC, CD4+ T helper cells and CD8+ CTL precursors.

Three groups of end stage cervical cancer patients (in total N=35) were subcutaneously vaccinated with HPV16 E6 combined with or separated from HPV16 E7 overlapping long peptides in Montanide ISA-51 adjuvant, 4 times at three week intervals. Group 1 received 300 microgram per peptide at a single site, group 2 received 100 microgram per peptide of the E6 peptides in one limb, and 300 microgram per peptide of the E7 peptides in a second limb. Group 3 received separate injections of E6 and E7 peptides, each at a dose of 50 micrograms per peptide. The primary endpoint was to determine safety and toxicity of the HPV16 long peptide vaccine. In addition, the vaccine-induced T-cell response was assessed by IFN gamma-ELISPOT. No toxicity beyond grade II was observed during and after 4 vaccinations. In a few patients transient flu-like symptoms were observed. ELISPOT analysis of the vaccine-induced immune response revealed that co-injection of the E6 and E7 peptides resulted in a strong and broad T-cell response dominated by immunity against E6. Injection of the E6 and E7 peptides at two different sites increased the E7-response but did not affect the magnitude of the E6-induced immune response.

The HPV16 E6 and E7 long-peptide based vaccine is well tolerated and capable of inducing a broad IFN gamma-associated T-cell response, even in end stage cervical cancer patients. 5 out of 20 patients showed complete clearance of all VIN III disease and in 4 of these this was also associated with complete clearance of HPV16 virus. In conclusion, our peptide based vaccine is safe, elicits a strong and broad HPV16 specific T cell response, even under sub-optimal clinical conditions. We have now observed 9 months later, without further vaccination, that another 4 patients have achieved complete remission of all disease, confirmed by microscopy. Sustained benefit was observed in all 9 patients with complete remission of disease. This is also expected, because the 5 complete responders at 3 months after the last vaccination were also shown to be free of HPV16 at the site of the original vaccination. We conclude that this therapeutic vaccine trial caused complete disease regression in 9 out of 20 patients (45%), whereas spontaneous complete regression of VIN3 lesions occurs in less than 1.5% of patients. Another 6 patients had objective partial regressions of lesions 12 months after the last vaccination. At three months after vaccination there was a highly significant positive correlation between the strength of the interferon gamma and proliferative T cell response and the clinical response.  In summary, clinical benefit was observed in 15 out of 20 patients (75%). A paper describing these results has been submitted for publication. Preclinical evidence has shown that these long peptides act so well as a therapeutic vaccine, because only dendritic cells can efficiently process all potential epitopes from the long peptides and because concentrated antigen is offered to the immune system in the absence of antigenic competition. 


Additionally tissue biopsies of the last vaccination site and of the VIN lesion prior to the first vaccination and 3 months after the last vaccination were analysed for the presence of HPV16-specific T cells. The IFN?-ELISPOT analysis and proliferation with its accompanying cytokine production revealed a strong and broad vaccine-induced T cell response. The strength of the immune response (defined as breath and magnitude of the response) was significantly higher in the patients with a complete remission (CR) than in the patients with no changes (NC) in the lesion size. Phenotypical anlaysis revealed a strong induction of CD4+ T-cells specifically against HPV16 E6 and E7, whereas CD8+ T cells were found merely against HPV16 E6 and to a less broad array of epitopes within each patient. This analysis was done after one in vitro restimulation, however, by directly ex vivo flow cytometric analysis hardly any CD8+ T cell response could be detected. 

The T cell cultures obtained from the biopsies taken of the last vaccination site were found to be HPV16 peptides specific in 3/5 tested NR patients and in 4/5 tested CR. However, recognition of the recombinant HPV16 E6 and/or E7 protein was observed in 1/5 cultures from NR patients and 4/5 cultures of the CR patients, suggesting the differences in vaccine-induced T-cell reactivity. Tissue biopsies of the VIN lesion before and after vaccination showed only in one patient a HPV16-specific T-cell response, which was against HPV16 E6 and merely of the type 2 cytokine producing T cells. Notably, no T-cell cultures could be obtained from VIN biopsies taken from the CR patients.

In conclusion, the HPV16 E6 and E7 synthetic long peptides vaccine is highly immunogenic, in that it increases the number and activity of HPV16-specific CD4+ and CD8+ T-cells to a broad array of epitopes in all patients. The expansion of CD4+ and CD8+ tumor-specific T-cells, both considered to be important in the anti-tumor response indicates the immunotherapeutic potential of this vaccine. Addition of a strong toll-like receptor ligand might increase the CD8 response in frequency and to a broader set of epitopes.

Conducting a new clinical trial in which the peptide vaccination is combined with the application of Aldara? on the vaccination site in order to induce a strong CD4+ but more importantly a CD8+ T cell response, which can be detected directly ex vivo.


N.B. information relevant to design of one arm of proposed DC-THERA trial</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/540"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/67"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/224"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/51"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_170"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/52"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/539"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/96"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/123">
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <rdfs:comment>Data is available from a re-analysis of existing microarray data; we started experimental work to assess the reliability and completeness of the DC_Eu.Gene pathway set using stimulation of DCs with S.cerevisiae cells, pseudohyphae, spores in comparison with the results obtained with LPS, R848, LPS and R848, Zymosan and Curdlan.</rdfs:comment>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <rdfs:label>Re-analyzes of existing microarray data and experimental work to assess the reliability and completeness of the DC_Eu.Gene pathway set</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_212"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FAO#FAO_0001002"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_616">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Th17 cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/116">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These HIV strains were used to infect Human Hemato-Lymphoid System Rag2gc-/- mice to closely resemble HIV infection in humans.</rdfs:comment>
    <rdfs:label>CXCR4 tropic HIV-1 strains</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A3">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A0"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/57">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/31"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/154"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The Genopolis microarray database serves as an easy interface for the data generated by the Affymetrix GeneChip platform.

DC transcriptomic data produced in the past 4 years has made been  an accessible resource for data sharing and data integration accessible to all the DC community. The experiments on mice and rat are currently being annotated and conserved in the Genopolis database. Direct access to the primary data held in the Biopolo database is responsibility of the BIOPOLO Project Management System (see http://www.biopolo.it/).</rdfs:comment>
    <rdfs:label>Genopolis Microarray Database</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_388">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD141</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Thrombomodulin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BDCA3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BDCA-3</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A4"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_580">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stimulation by molecular entity factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000283"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000136">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/281">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The autologous, apoptotic, leukemic cells (Apo-DC) vaccine was given to 2 cohorts of patients: without additional adjuvants and with GM-CSF as an adjuvant. These two cohorts were monitored for 52 weeks. The clinical and immune monitoring data is being currently analyzed. </rdfs:comment>
    <rdfs:label>Apo-DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/112">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/581"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/580"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/323"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/322"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/324"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_729"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The DCs are treated with the receptor antagonist laminarin, with chitin and mannan.</rdfs:comment>
    <rdfs:label>DC receptor blocking</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_541">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Scientific responsible</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000102"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A scientific responsible role is a DCTHERA role of DCTHERA persons who assume the scientific responsibility for the institution/company they work for with regard to the DCTHERA project.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/523">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We established tumor cell lines from melanoma in our laboratory.</rdfs:comment>
    <rdfs:label>Tumor cell lines from melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/167">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasStimulusType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001461"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/16"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001450"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000108"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704352"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001452"/>
    <rdfs:label>Study of the role of src-family tyrosine kinases in the maturation of human monocytes</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701799"/>
    <rdfs:comment>We obtained data using specific inhibitors on the role of src-family tyrosine kinases in the maturation of human monocytes derived dendritic cells upon stimulation with several toll like receptor (TLR) agonists.  The effect of these kinase inhibitors on the capacity of DC to be activated by a TLR2 (PAM3CSK4), TLR3 (Poly I:C), TLR5 (Flagellin),  and TLR8 (Poly U) agonist was evaluated. Src kinases were found to be required for the initiation of some maturation characteristics but not of others, since their inhibition was able to dissociate cytokines and chemokines production from the induction of surface maturation markers. Additional studies of the signal transduction pathways revealed that active src kinases are required for c-Jun phosphorylation and stabilization, induced by triggering of TLRs.</rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_192"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_389"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/145"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/18">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have expertise in performing toll-like receptor (TLR)-driven luciferase reporter assays. For example, in a study on the activation of DC we applied a TLR-driven luciferase reporter assay which showed dose-dependent activation of TLR2, TLR3, and TLR8, which was independent of the pseudotype, production, or transduction protocol and was abrogated on heat inactivation. </rdfs:comment>
    <rdfs:label>A Toll-like receptor (TLR)-driven luciferase reporter assay </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ifomis.org/bfo/1.1/span#Process">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_504">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A counting function is a function with the aim of repeatedly adding (or subtracting) one, usually to find out how many objects there are or to set aside a desired number of objects.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Counting function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_1000000">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Disposition"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_47812">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">1alpha25-Dihydroxyvitamin D3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24-Kdhvd3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C27H42O4</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24-oxo-1alpha 25(OH)2D3</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_491">
    <rdfs:label>Person</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Person</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A person is a human being, whether man, woman, or child.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdfs:subClassOf rdf:nodeID="A5"/>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#MaterialEntity"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/120">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/67"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_50847"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <rdfs:comment>Data has been obtained from the application of a DC-based assay aimed at identifying new adjuvant molecules potentially capable to induce Th1 responses, determining the effects of new chemical compounds on dendritic cell capacity to produce type I IFNs. The selected molecules could be potential new vaccine adjuvants.</rdfs:comment>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdfs:label>DC-based assay aimed at identifying new adjuvant molecules potentially capable to induce Th1 responses</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/339">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>In January 2010 I started a Postdoc project on Immunology of Hepatitis B infection at the Dept. of Gastroenterology and Hepatology in Erasmusmc Rotterdam, focussing on the role of dendritic cells. In addition, I am finishing my PhD project in LUMC Leiden. The aim of the PhD project is to study the application of antigen-antibody complexes as vaccine vehicles for immunotherapy. The last years I have been studying the cell biology of dendritic cells after uptake of the antigen-antibody complexes by the so-called Fc receptors.</rdfs:comment>
    <rdfs:label>Nadine Pronk - van Montfoort</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_500">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Monitoring function</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A monitoring function is a function whose aim is to provide awareness of the state of a system.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_863">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000652</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Physical characteristics factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_173">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_211"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Trans-activator of transcription</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tat</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400168">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/271">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Christian Mayer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/96">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/97"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/71"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/234"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/90"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/237"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/94"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/91"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/89"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000601"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_159"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/96"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0049622"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/87"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_342"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/93"/>
    <rdfs:label>Clinical trials of cancer patients treated with exosomes</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/88"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/95"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/98"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/285"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/99"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.obofoundry.org/obo/OBI_0100017"/>
    <rdfs:comment>Our lab obtained data on the ability of NK cell IFN-gamma production to predict long term survival in advanced GISTs treated with IM.

Background: Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for imatinib mesylate (IM) (Gleevec®, Novartis), a specific inhibitor of these tyrosine kinase receptors. Predictive factors for the response to IM pertain to the intrinsic features of GIST tumor cells but not to the host. Besides its direct antiproliferative activity on tumor cells, IM can trigger NK cell effectors which contribute to tumor regression in mice. 

Therefore, we addressed whether NK cell functions could be independent prognostic factors predicting long term survival to IM therapy.

Methods: The functional phenotype of NK cells was followed up in 77 GIST patients enrolled in two Phase III trials from 2 institutions testing dosing or duration of IM administration (EORTC 62005 and BFR14 trials). “Immunological responders” were defined as patients whose NK cell IFN-gamma values after 2 months of IM were higher or equal to the baseline value at entry in the trial. The prognostic impact of IFN-gamma on progression-free survival was assessed by a Wald test in a Cox regression analysis using the landmark method and stratified by trial and on the c-kit mutational status. 

Results: 
56 patients were evaluable for the NK cell IFN-gamma responses at baseline and 2 months. Their median follow-up for progression-free survival was 3.7 years. 34/56 patients were “immunological responders” to IM. In the Cox regression analysis stratified by trial, immunological responders possessed a hazard ratio of progression or death equal to 0.29 (95% CI [0.12-0.70], p=0.006) as compared to non-responders. Kaplan-Meier two-year survival estimates were 85% for immunological responders and 50% for non-responders. Moreover, the immunological response added prognostic value to the c-kit mutation. 

Conclusion: 
The NK cell IFN-gamma production after two months of treatment could be considered as an independent predictor of long term survival in advanced GISTs treated with IM.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/92"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_583">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antineoplastic agent</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTerm_3">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTerm"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/282">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/50"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/477"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>4 metastatic melanoma patients were actively vaccinated and additional injections were performed in disease free patients, in patients with stable disease or with slowly progressive disease.</rdfs:comment>
    <rdfs:label>Metastatic melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/380">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/91"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/92"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These monocyte-derived dendritic cells are loaded with tumor lysate generated from the excised metastatic lesion of stage III/IV melanoma patients. They will be used for vaccine generation.</rdfs:comment>
    <rdfs:label>Tumor lysate loaded DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000037">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label xml:lang="en">obsolete_vitamin role</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/67">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/272"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/271"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_772"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Monitoring of immunological responses elicited by the DC vaccine and transferred T cells during the clinical trial</rdfs:comment>
    <rdfs:label>Monitoring</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_387">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD1c</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A6"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-1c</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000042">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TGF beta 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Transforming growth factor-beta 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TGFbeta1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Transforming growth factor-beta 1</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/56">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our laboratory has expertise in applying a fluorescence microscopy method to analyse proximal signalling events induced by cross-linking C-type lectins.</rdfs:comment>
    <rdfs:label>Fluorescence microscopy method to analyse proximal signalling events</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A7">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0003700"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/117">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We found a novel M-CSF dependent DC developmental pathway that is independent of Flt3L. These DC have unique characteristics and precursor origin. The cells can be found in vivo in Flt3L gene deleted (-/-) mice injected with recombinant M-CSF.</rdfs:comment>
    <rdfs:label>Flt3L gene deleted (-/-) mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_615">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">kinase inhibitor PP2</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000272"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_206">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">anti-DEC205 antigen</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A8"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/164">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_452"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/42"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <rdfs:comment>Our data demonstrate that treatment of primed mice with intact anti-CTLA-4 antibodies induces the development of regulatory T cells expressing high levels of ICOS and producing IL-10. These regulatory T cells inhibit Th1 responses, in vitro and in vivo, and repress experimental intestinal inflammation, by a mechanism involving IL-10 and IDO. These ICOS+ regulatory T cells appear distinct from the naturally occurring regulatory T cells described above, suggesting that two populations can inhibit DC-induced Th1 responses in vivo.  Experiments are under way to identify the respective role and the synergy of IL-10 and IDO in the down-regulation of inflammatory responses in vivo. We have demonstrated the major role of IL-10 and indoleamine 2, 3 dioxygenase. We are presently trying to identify the cells expressing IDO (dendritic cells or epithelial cells?), using chimeras (WT/IDO KO) and purification of various cell populations from the lamina propria from control versus treated mice.
Our recent results have also shown that ICOS+ regulatory T cells are present in the colon of untreated mice, but absent in axenic animals, suggesting that their development is dependent on the intestinal flora. We will complete our experiments to further test the role of CD70 in Th1 priming in the presence or absence of regulatory T cells, and try to identify the mechanism by which these cells may downregulate the CD70 pathway. We will also pursue our study to identify the cells expressing indoleamine 2,3 dioxygenase in the colon following anti-CTLA-4 treatment. 

Recent reports have suggested that regulatory T cells may affect the phenotype, survival and function of dendritic cells.
We have therefore tested whether the enhanced Th1 response correlated with increased expression of costimulatory molecules or increased production of IL-12 by dendritic cells. Our data (in vitro and in vivo) clearly show that the phenotype of these cells was not changed in the absence of regulatory T cells and that IL-12 was not required for enhanced Th1 priming. Our preliminary results point to a role of CD70, a membrane-associated molecule of the tumor necrosis  factor family. </rdfs:comment>
    <rdfs:label>Effect of regulatory T cells on the amplitude and polarisation of T cell responses</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_234"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200769"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A9">
    <owl:intersectionOf rdf:nodeID="A10"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_542">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pathway</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A pathway is a "sequence of chemical reactions leading from one compound to another; if taking place in living tissue, usually referred to as a biochemical pathway".</OBI:IAO_0000115>
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.biology-online.org/dictionary/Pathway</OBI:IAO_0000119>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/113">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/324"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/325"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The DC with blocking receptors are exposed to fungi.</rdfs:comment>
    <rdfs:label>Exposure of DC to fungi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/526">
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0610"/>
    <rdfs:comment>Attenuated Expression of A20 Markedly Increases the Efficacy of Double Stranded RNA-Activated Dendritic Cells as an Anti-Cancer Vaccine

A20 is a zinc finger protein with ubiquitine-modifying activity.  It has been described that A20 negatively regulates signaling induced by the tumor necrosis factor receptor and toll like receptor (TLR) family in a number of cell types, including mouse bone marrow-derived dendritic cells (DCs).  However, the expression and effect of A20 in activated monocyte-derived DCs have not been previously evaluated.  We report that DCs activated with the TLR3 ligand poly(I:C), upregulate A20.  Downregulating A20 demonstrated its role in the functional activation of DCs.  A20 downregulated DCs showed higher activation of the transcription factors nuclear factor-kB (NF-kB) and activator protein-1 (AP-1), which resulted in increased and sustained production of interleukin (IL) -6, IL-10 and IL-12p70.  We additionally silenced the immunosuppressive IL-10 and demonstrated that IL-10 inhibits T cell proliferation.  We further demonstrated that A20 downregulated DCs skew naive CD4+ T cells towards IFN-g producing T helper 1 cells, a process which is dependent on IL-12p70 and which is unaffected by IL-10.  Furthermore, A20 and/or IL-10 downregulated DCs had an enhanced capacity to prime Melan-A/MART-1 specific CD8+ T cells.  Finally, we demonstrated that potent T cell stimulatory DCs are generated by the simultaneous delivery of poly(I:C12U), A20 or A20/IL-10 small interfering RNA (siRNA) and antigen-encoding mRNA, introducing a one step approach to improve DC-based vaccines.  Together these findings demonstrate that A20 negatively regulates NF-kB and AP-1 in DCs and that silencing of A20 results in DCs with enhanced T cell stimulatory capacity.

The generated DC will be clinically tested.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_243"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_309"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000382"/>
    <rdfs:label>DC transfected with siRNA for downregulation of A20 or A20/IL-10</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#elementsTypeOfType">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Property to connect aggregates to an ontological type.
X dct:elementsSubClassOf Y iif elements that compose instances of X have type Y
instance - class relationship</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">elements are of type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate this aggregate object with an ontology term of which the elements are a type. Example: the patients in a hospital might be the object aggregate which might be annotated with the ontology type "homo sapiens".</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/74">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>In 2008, much effort was spent to optimize protocols for RNA transfection in human sDCs. 

- fusion proteins of the DC specific receptor DC-SIGN fused to GFP 
- use of rna to express melanoma associated antigens in dendritic cells to prepare better vacines for the treatment of melanoma patients. </rdfs:comment>
    <rdfs:label>RNA transfection in human sDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_494">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_501"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A data analysis function is an analysis function that has the aim to subdivide data into smaller pieces to get a better understanding of them.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Data analysis function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/23">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/13"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The exosomes were used to immunize mice, hybridomas were  generated that produce antibodies recognizing at least the human exosomes.</rdfs:comment>
    <rdfs:label>human DC derived-exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/10">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/139"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/71"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/20"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/232"/>
    <rdfs:label>Gosse Adema</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/198"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/199"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <rdfs:comment>Molecular Immunology
UMC St Radboud, Faculteit der Medische Wetenschappen</rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/197"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/511"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/19"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/502"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/4"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/73"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/522"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/140"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/501"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/311"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/36">
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/394"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_264"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_611"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/395"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Identification of STAT-1 pathway in response of DC to Th1-inducing stimuli</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000375"/>
    <rdfs:comment>We have obtained data on the STAT-1 pathway in response of DC to Th1-inducing stimuli. We have identified some genes differentially expressed in the different conditions. In particular, the most relevant gene upregulated in presence of stimuli typically inducing Th1 responses (LPS, CpG, Poly I:C) but not in presence of the Th2 stimulus, Pam3Cys, was Stat-1. We then evaluated whether STAT-1 was phosphorylated in DC following activation with TLR-dependent Th1 and Th2 stimuli and we found that only in presence of TLR stimuli able to induce Th1 responses STAT-1 was activated. This observation strongly suggested that the molecules selectively produced by DC in presence of Th1 stimuli and not in presence of Th2 stimuli were type I IFNs and that these cytokines were presumably required for NK cell activation. In fact, our preliminary results confirmed this hypothesis with all of the Th1 stimuli tested including the Poly I-C stimulus that mimics viral infections.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/15">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_472"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our laboratory we carry out multiplex assays. For instance, multiplex analysis was used to study the response of human MoDC to yeast, spheroplasts, pseudohyphae and spores.</rdfs:comment>
    <rdfs:label>multiplex assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_501">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Analysis function</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An analysis function is a function whose aim is to break a process, topic or substance into parts to gain a better understanding of them.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/270">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lisa Persson</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/121">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab generated integrated microarray data on cellular pathways and gene ontology annotation. This has been done in the context of the program DC_Eu.Gene freely available for the DC-THERA users, using ENSEMBL as a conversion table.</rdfs:comment>
    <rdfs:label>Integration of microarray data on cellular pathways and gene ontology annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/338">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Active in tumorimmunology.</rdfs:comment>
    <rdfs:label>Sonja Buschow</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_67184">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A11"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">neurotransmitter receptors</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">neurotransmitter receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTerm_2">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTerm"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400167">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ifomis.org/bfo/1.1/snap#Function</dcr:replaced_by>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_device function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_172">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Negative regulatory factor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nef</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_211"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090">
    <rdfs:label>Mus musculus</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mus musculus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">murine</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">house mouse</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mouse</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/95">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_174"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/225"/>
    <rdfs:label>Clinical trials of DC-based immmunotherapy of HIV infected individuals</rdfs:label>
    <rdfs:comment>A phase I/II study of immunization of HIV infected individuals stable under HAART has been initiated which will provide us with immunological data.  These patients are being vaccinated with cytokine cocktail matured DCs electroporated with mRNA encoding Tat, Rev and Nef.  The cDNA’s encoding these early expressed HIV antigens have been human codon optimized and modified with lysosomal targeting sequences.  Four vaccines separated by 4 weeks.  Two weeks after the 4th vaccine, an analytical HAART interruption was started. So far, 17 patients have been included in this study.  

Background:
The limitations of highly active anti-retroviral therapy (HAART) have necessitated the development of alternative therapeutic strategies. One of the approaches that has gained prominence in recent years is therapeutic vaccination. We decided to assess the capacity of mature dendritic cells, derived from blood monocytes of HIV-1 infected patients, to generate functional T-cell responses. For this purpose, we constructed a chimeric mRNA encoding the proteins Tat, Rev and Nef. The TaReNef encoding information was linked to the HLA class II-targeting sequence of DC-LAMP. Broadly directed HIV-specific CD4(+) and CD8(+) cytotoxic T cells exhibiting a poly-functional cytokine secretion pattern were generated by co-culturing with autologous chimeric mRNA electroporated dendritic cells. Thus, administration of ex vivo generated dendritic cells expressing the early proteins Tat, Rev and Nef might offer a promising approach for therapeutic vaccination in HIV-1 infection.

Clinical and immunological follow-up is ongoing.</rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/70"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_172"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/69"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_173"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/55">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_462"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Experience has been gained in identifying DC presenting a specific peptide via a sensitive immunofluorescent staining technique.</rdfs:comment>
    <rdfs:label>Immunofluorescent staining method</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000083">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001839</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD5</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/73">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_884"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>These procedures have led to an improvement in processing of small RNA samples. Studies of 3’ IVT microarrays expression profiling are obtainable starting from 2 ng of total RNA.</rdfs:comment>
    <rdfs:label>Optimized procedures for microarray hybridization, further reducing the amount of biological material required for analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_582">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">anti-CD154 antibody</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A12"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/118">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/74"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_326"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/327"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We also show that DCs derived from ashen mice, which are defective for the small GTPase Rab27a, fail to cross present antigens efficiently, due to increased phagosome acidification and antigen degradation. This defect in Rab27a-deficient DCs results from the impaired recruitment to phagosomes of the NOX2 membrane components. Therefore phagosomal alkalinization by NOX2 is controlled by Rab27a, and is required for efficient cross presentation in DCs.</rdfs:comment>
    <rdfs:label>DCs derived from ashen mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A13">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_490"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasClassAsRangeProperty">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has class as range</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Property to be used for linking an object property to an annotation property.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_614">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">as from email contact with Damariz + mailing list:
Ciao Damariz,
ho di nuovo cercato un po' e proporrei lo seguente (gli altri, cosa ne dite?):
 
1. inserire nel tuo controlled vocabulary i termini che servono a voi, ad es. human neutrophil ectosome.
2. mettere, nella versione estesa del controlled vocabulary, la definizione come ha l'proposta Andrea. Tipo:
type: "human neutrophil ectosome" (qua potrei creare in'ID DCTHERADIR io)
"human neutrophil ectosomes" "derived_from" "human neutrophil" (anche qua potrei creare in'ID DCTHERADIR io)
"human neutrophil" isA "neutrophil" (con l'ID da un'onto per neutrophil: CL:0000775)
 
Forse ectosome potrebbe, nell'ontologia DCTHERADIR, diventare una sottoclasse di http://www.ebi.ac.uk/ego/GTerm?id=GO:0031988 ?? (membrane-bound vesicle) Secondo te avrebbe senso o meno?</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0031988"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">neutrophil ectosome</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/68">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/241"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/237"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_757"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Patients with stage III or stage IV melanoma will undergo surgical resection of a melanotic lesion.</rdfs:comment>
    <rdfs:label>Surgical resection</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_543">
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.businessdictionary.com/definition/skill.html</OBI:IAO_0000119>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A skill is the "ability and capacity acquired through deliberate, systematic, and sustained effort to smoothly and adaptively carryout complex activities or job functions involving ideas (cognitive skills), things (technical skills), and/or people (interpersonal skills)."</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Skill</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/165">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/111"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704239"/>
    <dcr:hasStimulusType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:comment>Our lab has obtained data on the dependence of IL-10 as well as IL-12 production on signalling adaptor molecules.

Dendritic cells (DC) arise in the bone marrow and circulate through blood or tissue; upon pathogen challenge DC subsequently migrate to lymphoid organs to initiate immune responses (Banchereau et al., 1998). DC act as sentinels for pathogens forming the interface between the innate and adaptive immune response. In addition they are flexible in driving both Th1 and Th2 responses (Boonstra, Rajsbaum et al., 2003). Mouse DC can be derived from bone marrow (BM), which, after culture results in myeloid DC and plasmacytoid precursor DC (pDC), or can be directly isolated from the spleen, lymph nodes or tissue as classical DC (CD11cbright, CD8+ or CD8-) or plasmacytoid pDC. 

We have shown that macrophages, myeloid DC and plasmacytoid DC have the intrinsic capacity to produce different amounts of IL-12 upon stimulation through TLR9 and TLR4.  Some of this, but not all is accounted for by endogenous IL-10 production which inhibits the subsequent production of IL-12. In this respect we have identified specific regulatory elements in the IL-10 locus which are present in DC and macrophages but not T cells (Saraiva et al., 2005). 

We have now shown that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC. This work has been published in the J.Immunology (Boonstra, Rajsbaum et al, 2006).</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_195"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/111"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Identification of specific regulatory elements in the IL-10 locus. Dependence of IL-10 as well as IL-12 production on signalling adaptor molecules</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/129"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/16">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_473"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our laboratory has an electroporator at its disposal. It was used, e.g., for an assessment whether functional activation of human monocyte-derived DCs can be achieved by electroporation of an activation signal in the form of double-stranded (ds) RNA and whether simultaneous electroporation of the dsRNA with tumor antigen encoding mRNA can lead to the induction of a cytotoxic T-lymphocyte (CTL) response. </rdfs:comment>
    <rdfs:label>Electroporator</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Lectin">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lectin</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Complex molecules that contain both protein and sugar. Lectins specifically bind to the branching sugar molecules of glycoproteins and glycolipids on cell surfaces to cause biochemical changes. They are often classified according to either the saccharide or sugar specificity.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17089"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/525">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We established tumor cell lines from renal cell cancer in our laboratory.</rdfs:comment>
    <rdfs:label>Tumor cell lines from renal cell cancer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/114">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/211"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/210"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/212"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_747"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Untouched naive CD4+ T cells are co-coltured with fungi -pulsed DCs</rdfs:comment>
    <rdfs:label>Coculture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/22">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/48"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/12"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It has been shown that DCs express specific receptors for exosomes. Since ICAM-1 on exosomes is required for their ability to activate T cells via DCs in vitro, the role of Mac-1 and LFA-1 (the major ligands for ICAM-1) as potential receptors for exosomes has been investigated. A new role for LFA-1 on DCs, as a receptor for exosomes has been proposed. </rdfs:comment>
    <rdfs:label>LFA-1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_493">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Function</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ifomis.org/bfo/1.1/snap#Function</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/337">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Postdoc, molecular biology, regulation of transcription in DCs</rdfs:comment>
    <rdfs:label>Maria Queralt Seguin-Estevez</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0049622">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Activating natural killer receptors p30</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK-p30</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD337 antigen</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Activating natural killer receptor p30</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD337 antigens</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NKp30 gene</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NKp30</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Natural killer cell p30-related protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Natural killer cells p30-related proteins</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_613">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <OBI:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Trehalose-6,6-dimycolate</OBI:IAO_0000118>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TDM</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TDM</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Trehalose-6,6-dimycolate</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mycobacterial cord factor</rdfs:comment>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">una molecola del mycobacterium</rdfs:comment>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted as molecular entity together with Damariz</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasExperimentalDesignType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">experimental design type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type "experimental design".</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/520">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have chemically coupled the S-epimer of the Pam3CSK4 to long peptides containing a CTL epitope and used this structure to investigate the behaviour of the diastereomer.</rdfs:comment>
    <rdfs:label>S-epimer of the Pam3CSK4</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/69">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/237"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/238"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_752"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Leukapheresis will be performed on the following day.</rdfs:comment>
    <rdfs:label>Leukapheresis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/1">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>AND</rdfs:comment>
    <rdfs:label>AND</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/108">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have know-how on assays to measure the proportions of Treg cells. For instance, we set up an assay to measure the proportions of Treg cells in tissues or cells that is based on the demethylation of a region of the FOXP3 promoter, which is observed in human Treg cells but not in the other T cells that can express FOXP3 transiently after activation. Starting from DNA, two quantitative PCR are used, which amplify the methylated and unmethylated FOXP3 promoter sequences. The ratio between the expression levels is, in our hands, a faithful Treg marker. 

We will pursue our genetic analysis of T lymphocytes inside melanoma metastases: analyze their activation status, compare them with T cells infiltrating DTH reactions, explore the reasons for their apparent quiescence.</rdfs:comment>
    <rdfs:label>Assay to measure the proportions of Treg cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/337">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD4 surface markers (and additionally, CD8, CD3, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD4 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/54">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000049"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our laboratory has a mass spectrometer at its disposal.</rdfs:comment>
    <rdfs:label>Mass spectrometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/273">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cyrille Mionnet</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_585">
    <rdfs:label>Aggregate biomaterial</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#ObjectAggregate"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Aggregate biomaterial</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTerm_1">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTerm"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000094">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">granulocytes</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">granulocyte</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0001466">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PHB</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">YGR132C</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PHB1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prohibitin 1 gene</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prohibitin-1 gene</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PHB</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prohibitin-1 gene</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/13">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/40"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_470"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This gene gun was used for the delivery of vectors engineered to express distinct chemokines at the local skin site of mice.</rdfs:comment>
    <rdfs:label>Gene gun</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/25">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/24"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We decided to analyze the protein changes that occur at the cell surface of a maturing DC, induced by a prototypical maturation stimulus such as LPS. Results obtained from the LC-MS/MS analysis of the integral plasma membrane proteome of D1 cells stimulated for 24 hours with LPS have been compared to the results obtained from immature D1 cells.</rdfs:comment>
    <rdfs:label>D1 cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75">
    <rdfs:label>Treatment protocol</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">All protocols which involve treatment of a biomaterial or an array during the course of a microarray experiment.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Treatment protocol</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Microarray experimental protocol</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/12">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Josianne de Smet</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/336">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Technician, specialized in cell culture and DC derivation</rdfs:comment>
    <rdfs:label>Antoine Geinoz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/93">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Alexandra Vedel left the IGR in 2008. She was replaced by Olmos Seraphin.</rdfs:comment>
    <rdfs:label>Alexandra Vedel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_279">
    <rdfs:label>small hairpin RNA</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">small hairpin RNA</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">short hairpin RNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">small hairpin RNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">shRNA</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_507">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Conversion function</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000392"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A conversion function is a function with the aim of transforming one thing into another.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_2144">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">malignant neoplasm of ovary</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0031988">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">membrane-bounded vesicle</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Any small, fluid-filled, spherical organelle enclosed by a lipid bilayer.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/76">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/244"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>(A new protocol will probably be started in the near future.)</rdfs:comment>
    <rdfs:label>Active immunotherapy in pancreatic carcinoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A14">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/ID#ID_0000043">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">toxin role</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">substance has the role of being a toxin in a given circumstance</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/30">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/8"/>
    <rdfs:comment>We have obtained imaging data by confocal microscopy of translation activation in DC-activated T cells and have pursued our efforts on the definition of a novel way of monitoring DC and T cell activation as well as studying viral infections. We also have now applied the puromycin-based technology developed in our laboratory (SUnSET, surface sensing of translation) to monitor translation by FACs in individual or cell populations. We have demonstrated that translation activation is an excellent read-out for early antigen specific T cell activation by DCs. We hope that this technology will become rapidly popular among the DC-THERA participants.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://purl.obofoundry.org/obo/OBI_0300311"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/34"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17939"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Confocal microscropic analysis of translation activation in DC-activated T cells</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/111">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/75"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The mice were infected with EBV and mount an immune response (i.e. cytotoxic T cell proliferation, some control of EBV driven B cell proliferation, perforine and granzyme expressing T cell infiltration in B cell infected areas in lymphoid organs in situ), however, specific T cells could not be detected directly ex vivo by looking at the most common EBV derived/presented epitopes (tetramer staining). Some animals developed EBV induced B cell lymphoproliferative disease. </rdfs:comment>
    <rdfs:label>Human Hemato-Lymphoid System Rag2-/-gc-/- mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_612">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">synthetic analogue of TDM</rdfs:comment>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted as chemical compound together with Damariz</rdfs:comment>
    <OBI:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Trehalose-6,6-dibehenate</OBI:IAO_0000118>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TDB</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TDB</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Trehalose-6,6-dibehenate</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_544">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Document</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/IAO_0000310</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/115">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/212"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The polarization is assessed by flow cytofluorimetry and cytokine production.</rdfs:comment>
    <rdfs:label>Assessment of polarization</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/338">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000147"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD3 surface markers (and additionally, CD8, CD4, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD3 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/107">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/299"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400040"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In march 2009 we obtained the new BD ARIA II, which not only allows 14 parameter flow cytometry, but also sorting of even very small antigen specific T cell subpopulations for further molecular analysis in  close collaboration with Pierre Coulie´s group in Brussels. [PhD student Steve Voland]</rdfs:comment>
    <rdfs:label>BD ARIA II</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/53">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/127"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Pathway Processor is a tool for integrating whole-genome expression results into metabolic networks.</rdfs:comment>
    <rdfs:label>Pathway Processor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/272">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cindy Hespel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/97">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/72"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/73"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/346"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000147"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704043"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_245"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/340"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/22"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/342"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/343"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/337"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_242"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/345"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/339"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/336"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_180"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/119"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000082"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/24"/>
    <rdfs:label>Establishment of immunomonitoring vaccination trials with RNA transfected DC by using overlapping peptides covering the whole protein sequence of the tumor antigens / RNAs used</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/21"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://dc-research.eu#dctheradir_646"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/341"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/338"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/106"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700262"/>
    <rdfs:comment>In 2007 we established routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry and obtained immunological data from this. For this purpose we used multimers kindly provided by Pierre Coulie (Brussels) together with surface markers (such as CD8, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally we used functional markers such as CD107a and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.

Monitoring of the ongoing vaccination trial with RNA transfected autologous DC was done with overlapping peptides covering the whole protein sequence of the tumor antigens MageA3, MelanA and Survivin. With this approach we monitored the immune responses of 8 vaccinated patients and of more than 15 other stage IV melanoma patients. Results showed broad preexisting T-cell responses in some patients and de novo immune reactivity in 3 vaccinated patients. The fine specificity of these immune responses needs to be further defined. 

Demonstration that defined re-stimulation Elispot correlates very well with MPLC assay.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0050147"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/344"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000089">
    <rdfs:label>CD8</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/11">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/15"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/199"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/522"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/18"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/412"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/27"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/312"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/513"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/19"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/501"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/168"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/20"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/71"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/37"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/198"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/139"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/169"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/17"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/26"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/512"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/4"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/197"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/109"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/73"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/232"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/511"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/19"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/413"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/28"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/502"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/140"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/108"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/74"/>
    <rdfs:label>Carl Figdor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/14">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have expertise on an HSV-based technology for the delivery of antigens to dendritic cells.</rdfs:comment>
    <rdfs:label>Technology for delivery of antigens to DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/335">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Technician, specialized in molecular biology and biochemistry</rdfs:comment>
    <rdfs:label>Emmanuèle Barras</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_666">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vibrio cholerae</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/24">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/16"/>
    <dcr:hasStimulusType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>For a transcriptional profiling of dendritic cells, DC were stimulated with PolyI:C, pretreated or not with PP2, and microarray analysis was performed.</rdfs:comment>
    <rdfs:label>polyI:C stimulated dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_508">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0500000</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Experimental design</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/94">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/13"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Francesca Zolezzi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/75">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>GMP SOPs covering the protocol are also available.</rdfs:comment>
    <rdfs:label>Generation of tumour peptides extracted from whole melanoma cells in GMP conditions</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/MESH#MESH_E.05.200.750.551.512">
    <rdfs:label>Immunohistochemistry</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Immunohistochemistry is a method specifying localizing antigens (eg. proteins) in cells of a tissue section exploiting the principle of antibodies binding specifically to antigens in biological tissues.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Immunohistochemistry</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A15">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/116">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>PBMC are stimulated in limiting dilution conditions with a pool of overlapping peptides (15 amino acids) covering the protein.  </rdfs:comment>
    <rdfs:label>Stimulation of PBMC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_611">
    <rdfs:label>STAT-1 gene</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">STAT-1 gene</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/112">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Perforine expressing T cells were observed in human Hemato-Lymphoid System Rag2-/-gc-/- mice after being infected with EBV and mounting an immune response. They  infiltrated in B cell infected areas in lymphoid organs in situ.</rdfs:comment>
    <rdfs:label>perforine expressing T cell</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000664">
    <rdfs:label>K562 cell line</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">K562 cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">K-562 cell</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/52">
    <dcr:is_manufactured_by rdf:resource="http://dc-research.eu/rdf/participant/81"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/32"/>
    <rdfs:comment>In the DC-THERA effort to create new dendritic cell-based therapies, a wide range of information arising from genomics, proteomics, molecular cell biology and pre-clinical models is gathered and applied to the conduction of clinical trials. The DC-THERA Directory is intended to collect and semantically organize this data and to serve as a tool for collaboration among researchers and as a reference point for the information contained. As such it is a directory that provides summarized information and relations between resources and people involved. 

In particular, we have defined a data model that mixes aspect of Object Oriented design and RDF-like features (RDF is the language at the basis of the Semantic Web). We have used this data-model to develop the DC-THERA Directory, a web application based on the Symfony web framework and Doctrine, an object-relational mapping (ORM).

As for the content of the directory, it has initially been populated it with information drawn from DC-THERA annual reports.

The semantic organization of the directory is based on fragments of standard ontologies, in particular OBI (Ontology for Biomedical Investigation) and terminologies developed within DC-ATLAS.
The first release of the DC-THERA directory was based on this information and ontologies, and provided the skeleton of the application, as well as a set of basic functionalities (semantic links among entities, lexical variations and generalization in searches).
Following this release, we have assembled a panel of reviewers, we have authored a document describing current functionalities and aims of the project, and we have asked for feedback on the current release as a well as a ranking, by relevance, of future functionalities to be implemented.

We will continue the development of functionalities of the DC-THERA Directory, following suggestions from reviewers and the user-base, and fostering the integration with other DC-THERA resources.
</rdfs:comment>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000010"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/34"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/35"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <dcr:is_manufactured_by rdf:resource="http://dc-research.eu/rdf/participant/10"/>
    <dcr:is_manufactured_by rdf:resource="http://dc-research.eu/rdf/person/33"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdfs:label>DC-THERA Knowledge Portal / Directory</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/33"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/275">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Galit Eisenberg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_238">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD83 receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000095</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_70803">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_28901"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Salmonella minnesota</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701457">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD11b</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001012</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/339">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001015"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establish routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD45RA surface markers (and additionally, CD8, CD4, CD3, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD45RA surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/106">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Using this peptide library technique and ELISPOT analysis patients´ PBMC are pre-screened for CD4- and CD8- T cell responses and individual sets of 4 to 8 peptides chosen for further analysis.</rdfs:comment>
    <rdfs:label>Overlapping peptide library technique for monitoring RNA-DC vaccinated patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001992">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Beta chemokine exodus-1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C-C motif chemokine 20</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MIP-3-alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Liver and activation-regulated chemokine</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Macrophage inflammatory protein 3 alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CC chemokine ST38</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CC chemokine LARC</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A C/C-C motif small inducible chemokine that is a translation product of the CCL20 gene.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCL20(2-70)</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Small-inducible cytokine A20</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCL20</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000100">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_44088">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Canarypox virus</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ALVAC canarypox virus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000088">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001945</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD71</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/91">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Amanda Howell left the IGR.</rdfs:comment>
    <rdfs:label>Amanda Howell</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/32">
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FMA#FMA_83624"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdfs:comment>We have obtained data by fluorescence microscopy analysing DC distribution in spleen and how this is affected during inflammation driven by stromal cells or hematopoietic cells. One of our images of DC was selected as the cover for the June 2007 issue of Nature Immunology.</rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FMA#FMA_83598"/>
    <rdfs:label>Fluorescence microscopy of splenic DC during inflammatory responses</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_808"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/11"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/11">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/146"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/32"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/223"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/36"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_468"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>For our work, we have a fluorescence microscope at our disposal. We use it, among other things, to analyse DC distribution in spleen and how this is affected during inflammation driven by stromal cells or hematopoietic cells.</rdfs:comment>
    <rdfs:label>Fluorescence microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_505">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An organising function is a function whose aim is to rearrange elements according to one or more rules.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Organising function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/168">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_192"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_389"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_388"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701377"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001483"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36704"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdfs:label>Identification of specific markers: CD16, CD1c and BDCA-3 in mDCs and pDCs</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_387"/>
    <rdfs:comment>Data was obtained on the properties of the CD16, CD1c and BDCA-3 DC populations and their production of cytokines in response to different Toll-like receptor (TLR).

We studied two major blood populations of DCs, myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Among mDCs, three populations could be further identified by specific markers: CD16, CD1c and BDCA-3. The properties of these DC populations and their production of cytokines in response to different Toll-like receptor (TLR) agonists were evaluated. The TLR agonists used were: PAM3CSK4, Poly I:C, LPS, Flagellin, Imiquimod, Resiquimod, CpG 2216, CpG 2006. While BDCA-3+ cells seem not have any capability to respond to TLR agonists, CD16 and CD1c produce a number of cytokines in response to these stimuli, with the exception of CpGs. In addition, we have found that CD16+ DCs are the major producers of TNF-alpha and IL-6, while CD1c+ DCs produce primarily IL-8.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_490">
    <rdfs:label>Participant</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A participant is a an institution/company/institute or other legal association that collaborates in a scientific way in one of the network represented in the Directory.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">_Participant</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/334">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Catharina Schrauf</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/27">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/38"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We are currently performing gene silencing experiments in human monocyte-derived DCs (MDDCs) with the dual aim of generating relevant knowledge on 

(i) the transcriptional regulation of DC differentiation, and 
(ii) the safe and rationale in vitro manipulation of gene expression in DCs.</rdfs:comment>
    <rdfs:label>human monocyte-derived DCs (MDDCs)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/522">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704043"/>
    <rdfs:comment>Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial. 

Most patients having received the vaccine already demonstrated broad responses to numerous peptides prior vaccination. Significantly enhanced responses to several peptides and occurrence of new responses was seen in 6 patients, 5 of which were vaccinated with E/L-S+ DC. These data provide evidence for a superior immunopotency of  E/L-selectin expressing DC. </rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <rdfs:label>13 melanoma patients</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000182"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_610">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pre-clinical protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A pre-clinical protocol is a protocol applied for pre-clinical processes.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/117">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_770"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>After 2 rounds of in vitro stimulation, the microcultures are left without stimulation for 2 weeks.  </rdfs:comment>
    <rdfs:label>Leave microcultures for 2 weeks</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/14">
    <rdfs:label>Muriel Moser</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/426"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/160"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/448"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/446"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/213"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/42"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/209"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/427"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/425"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/170"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/212"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/447"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/332"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/211"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/307"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/210"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/406"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/136"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/75"/>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/333"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/268"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/212"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/374"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/407"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_546">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Platform</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000050</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/78">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/251"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>We have adapted the cDNA amplification method of Kurimoto et al. (Nat Protoc 2007, 2:739) to cDNA extracted from small numbers (±100) of cells microdissected from human tumor sections. We are currently checking the accuracy and reproducibility of microarray (Affymetrix) data obtained through this procedure.</rdfs:comment>
    <rdfs:label>Adaptation of Kurimoto cDNA amplification method</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A16">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000017"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/113">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_205488"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Granzyme expressing T cells were observed in human Hemato-Lymphoid System Rag2-/-gc-/- mice after being infected with EBV and mounting an immune response. They  infiltrated in B cell infected areas in lymphoid organs in situ.</rdfs:comment>
    <rdfs:label>granzyme expressing T cell</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_428">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000245"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">generic organization</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_239">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lactoferrin</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lf</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_237">
    <rdfs:label>Ovalbumin</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A17"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OVA</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ovalbumin </rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/99">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab conducted an immunomonitoring study, such as on effector memory T cells, which led to corresponding immunological data.</rdfs:comment>
    <rdfs:label>Immunomonitoring, e.g. effector memory T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_176">
    <rdfs:label>immature dendritic cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immature dendritic cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_548">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Web address</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/114">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/75"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were infected with both CXCR4 as well as CCR5 tropic HIV-1 strains. HIV causes a disseminated infection and spreads in all newly generated lymphoid tissues, thus closely resembling HIV infection in humans. We are now aiming to improve the recipient mouse background by co-transplanting human mesenchymal stroma cells, and by adding human cytokines as well as human MHC. Furthermore, we use the mice to evaluate targeted therapies directed at human immune system cells as T cells, B cells, and dendritic cells.</rdfs:comment>
    <rdfs:label>Human Hemato-Lymphoid System Rag2gc-/- mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/105">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/81"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_458"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have a confocal microscope available. This microscope was is used, for instance, for the characterization of antigen depots.</rdfs:comment>
    <rdfs:label>Confocal microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701456">
    <rdfs:subClassOf rdf:nodeID="A18"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell surface glycoprotein MAC1 subunit alpha</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mac1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ITAM</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell surface glycoprotein MAC1 subunit alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Integrin alpha M precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell surface glycoprotein MAC 1 subunit alpha</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000032">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">clinical research coordinator</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/92">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/98"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/235"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/178"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/100"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/92"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/93"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/242"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/285"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/234"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/96"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/97"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/91"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/51"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/238"/>
    <rdfs:label>Laurence Zitvogel</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/78"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/245"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/246"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/233"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/71"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/90"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/434"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/239"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/95"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/435"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/241"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/531"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/153"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/249"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/87"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/88"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/236"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/237"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/13"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/243"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/94"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/244"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/397"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/96"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/99"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/141"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/133"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/240"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/134"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/247"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/248"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000087">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD7</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001836</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_866">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000689</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Sampling time point factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/274">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fernando Sousa</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701384">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 12a</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin-12A</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin-12A (mouse)</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytotoxic lymphocyte maturation factor 35 kDa subunit</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-12 subunit alpha precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Il12a</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 12A</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CLMF p35</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-12 p35</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p35</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/333">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Louisa Jacobs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/229">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We obtained data on MHC II transport during human monocyte-derived DC maturation. We have published that the E3-ubiquitin ligase MARCH I is responsible for peptide-loaded MHC II ubiquitination and their subsequent internalization in immature DC.s The ligase MARCH I has been shown to be down-regulated upon activation. (De gassart et al, PNAS 2008).

We will also investigate further the role of the ubiquitin ligases of the MARCH family in antigen processing, in particular we will focus on cross-presentation and CD1a molecule transport.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/128"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdfs:label>Characterization of transport of MHC II molecules during human monocyte-derived DC maturation</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_241"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/180"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/26">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/29"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We observed that ICAM-1 expression by mature DCs is critical for long-lasting contacts with CD8+ T cells, but dispensable for short-lived antigen-specific interactions. Serial brief T cell-dendritic cell contacts induced early CD8+ T cell activation, proliferation and effector CTL differentiation in the first few days after immunization. </rdfs:comment>
    <rdfs:label>CD8+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/12">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_E.05.478.594.410.320.200"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience in western blotting, which we use for example for the assessment of the efficiency of gene silencing. 

</rdfs:comment>
    <rdfs:label>Western blot analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_506">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Detection function</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A detection function is a function whose aim is to extract information from any clear or clouded ambient or otherwise accessible information.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/169">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17823"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_47812"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdfs:label>Evaluation of calcitriol and its analogues for its effect on the DC differentiation/activation pathway induced by type I IFN</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdfs:comment>We obtained data on the Pharmacological compound 1alpha,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the biologically active metabolite of Vitamin D3, and its analogues, and its effect on the DC differentiation/activation pathway induced by type I IFN. 1,25(OH)2D3 prevented the generation of IFN-DCs when added to freshly isolated monocytes, and is capable to redirect already differentiated IFN-DCs toward a more immature stage. Interestingly the suppressive effect of 1,25(OH)2D3 was associated with a potent impairment of DC migration in response to inflammatory and lymph node homing chemokines, thus unraveling a novel mechanism involved in 1,25(OH)2D3-mediated immunomodulation. Experiments to characterise the molecular mechanisms underlining this inhibitory effect, including the expression of ILT-receptors and a panel of adhesion molecules known for their role in leukocyte migration are ongoing. Further studies are focussed on the dissection of the signal transduction pathway of 1,25(OH)2D3 in DCs, and on its interference with chemokine receptor signalling. </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A19">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/118">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_768"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>All the individual microcultures are then screened for recognition of autologous EBV-B cells transduced with a retrovirus encoding the protein. Non transduced EBV-B cells are used as control stimulator cells.  </rdfs:comment>
    <rdfs:label>Screening of the microcultures</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/13">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ode Guissard</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/521">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1476"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Aiming at finding possible reasons for the discrepancies between our findings and published data could be the amount of ONTAK used in patients, we filed an amendment to the clinical trial allowing the inclusion of additional 4 patients. These patients will receive higher doses (12microg/kg 3x and 18microg/kg 1x) before vaccination. Taking into account direct effects of ONTAK on DC, patients will be vaccinated some days after last ONTAK treatment (as soon as blood DC have recovered to 50% of pre ONTAK amount).

Third stage of DERMA-ER-DC 05 clinical trial.</rdfs:comment>
    <rdfs:label>4 melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/51">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/person/33"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/33"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/126"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>RDFScape is a plugin that has been developed to extend a software oriented to biological analysis with support for reasoning on ontologies in the semantic web framework. We show with this plugin how the use of ontological knowledge in biological analysis can be extended through the use of inference. In particular, we present two examples relative to ontologies representing biological pathways: we demonstrate how these can be abstracted and visualized as interaction networks, and how reasoning on causal dependencies within elements of pathways can be implemented.

A core component of RDFScape was re-engineered in 2008 for continuing ‘Affymetrix’ analyses. This component allows the definition of functions based on ontology patterns, and their computation on numeric values. It is intended in particular to be used to define pathway scoring functions, based on microarray data, that will include  causal and functional information found in pathway ontologies.

This project is relevant also for the Pathway based analysis and it now attributes an increased value to pathway-based information. For these reasons, we have chosen to provide this module as independent from RDFScape.

We will explore the possibilities offered by RDFScape and the related function evaluator on pathways curated within DC-THERA and the database provided by Duccio Cavalieri.</rdfs:comment>
    <rdfs:label>RDFScape</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/31">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/10"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Flow cytometric analysis data were obtained of translation activation in DC-activated T cells.</rdfs:comment>
    <rdfs:label>Flow cytometric analysis of translation activation in DC-activated T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/77">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>
We set up a method to detect, count, and eventually clone CD4 or CD8 T cells against any peptide encoded by a given gene and presented by any HLA molecule. PBMC are stimulated in limiting dilution conditions with a pool of overlapping peptides (15 amino acids) covering the protein. After 2 rounds of in vitro stimulation, the microcultures are left without stimulation for 2 weeks, and all the individual microcultures are then screened for recognition of autologous EBV-B cells transduced with a retrovirus encoding the protein. Non transduced EBV-B cells are used as control stimulator cells. Activated T cells are detected by their expression of CD137.</rdfs:comment>
    <rdfs:label>Detection, counting, and eventually cloning CD4 or CD8 T cells against any peptide encoded by a given gene and presented by any HLA molecule</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_6495">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lipoprotein</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lipoproteins</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/129">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Janet Fernihough</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/103">
    <rdfs:label>Pathway analysis and signature search similarity</rdfs:label>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/308"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This tool is available through the DC-THERA Directory (see "Pathway Signature Repository ").

The procedure allows a user to compare his/her microarray data to the corpus of public immunology experiments stored in DC-BASE using pathway signatures. The procedure is made up by several steps.

1.Raw data normalization: the user uploads raw data (Affymetrix or Illumina gene expression platforms are supported) and select the species. Upon succesful upload, raw data is normalized using a standard procedure.

2.Comparison selection: The user is then asked to select which samples correspond to the treatment group, and which to the control group. Subsequently, the user has to select which treated-untreated comparisons to make (using single sample). The pipeline takes these information and combines them with the normalized data to create treated-reference paired ratios corresponding to all comparisons the user has selected.

3.Generation of pathway signatures: the pipeline takes the produced ratios and runs a Fisher's Exact Test analysis over a pathway set of 82 immunologically-related pathways, obtaining signed p-values for each of the pathway in the set (positive indicates up-regulation, negative down-regulation). Those p-values are then converted into a “pathway signature” for each comparison: each p-value for a specific pathway under a threshold (0.05) is converted to either 1 (up-regulated), -1 (down-regulated), or 0 if above the threshold.

4.Similarity assessment: a matrix containing all the signatures for all the pathways is compared with the signatures calculated from the DC-BASE experiments using a  method known as clustering with multiscale bootstrap resampling. The result is a clustering image in PDF format (downloadable by the user)  which shows the pathway activation state for all the samples and which indicates very similar samples with red branches in the clustering tree. The user can also download the table used for clustering to use it with other programs.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/102"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/101"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/220">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/56"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The agonists were used as adjuvants in vivo to induce DC activation and CD4+ T cell and antibody responses.</rdfs:comment>
    <rdfs:label>Agonists of the dectin-1/Syk pathway </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_761">
    <rdfs:label>adding substance to cell culture step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">adding substance to cell culture step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An adding substance to cell culture step is a step in a protocol that specifies how to add  a material substance to a cell culture.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/29">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/38"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Lentiviral transduction of shRNAs: to this aim, shRNA specific for IRF4 and STAT3 are in the process to be cloned into the pLVTHM lentiviral vector (obtained from the repository Addgene). This vector has been already successfully used to generate self-inactivating lentiviral vectors previously tested in DCs for transfection efficiency and absence of effects on their phenotype. 
</rdfs:comment>
    <rdfs:label>pLVTHM lentiviral vector</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A20">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/ID#ID_0000035"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/227">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Aldo Tagliabue</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5207">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5204"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cryptococcus neoformans</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Filobasidiella neoformans</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001464">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR 9</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR-9</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR9</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll like receptor 9</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A21">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasCellLineType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type "cell line".</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell line type</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/228">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:label>Priming of CD8+ T cells: regulation of proliferation and development into effector and/or memory cells</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7195"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdfs:comment>We obtained microarray and RT-PCR data on the priming of CD8+ T cells in mice and their regulation of proliferation and development into effector and/or memory cells.

The positive influence of a reactive lymph node on the priming of CD8+ T-cells was already analyzed in 2007. We set up experiments to determine if this effect would benefit a response against a second infection. We infected mice with CD8+ T-cells primed with or without the influence of a reactive lymph node with a flu-virus encoding the specific antigen. After several days we determined the viral load in the lungs with RT-PCR. The results show that in mice with CD8+ T-cells primed with a reactive lymph node the viral load in the lungs was significantly smaller then in a control mice. 
We also determined that suboptimally primed CD8+ T-cells can develop into functional memory cells. Although suboptimally primed CD8+ T-cells do not display good effector function, as previously enclosed, we found that they were efficient at eradicating tumors in the memory phase. 
Micro-array data obtained from samples from suboptimally primed CD8+ T-cells compared with optimally primed CD8+ T-cells showed several interesting genes involved in regulation of proliferation and development. 
 
We are currently working on verifying the data obtained with micro-arrays through RT-PCR, and comparing data from in vitro primed CD8+ T-cells to in vivo primed CD8+ T-cells. We intend to analyse the candidate genes through overexpression and siRNA experiments.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/104"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/3">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Eileen S Kennedy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000207">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_enzyme</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000427</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/228">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lucia Massi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/104">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/228"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our lab we have experience in performing real time PCR analyses.</rdfs:comment>
    <rdfs:label>RT-PCR assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/128">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Jacques Bartholeyns</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/68">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients were treated with monocyte-derived DCs matured with inflammatory cytokines and subsequently electroporated with mRNA encoding 6 tumor-associated antigens.</rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/5">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/463"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/139"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/140"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_753"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Cells are subsequently separated into monocytes and lymphocytes by elutriation in a closed system (Elutra). 
The two most monocyte-rich fractions collected contained &gt; 80% monocytes, the fraction richest in lymphocytes contained &gt; 90% lymphocytes and viability in both fractions was &gt; 95%.</rdfs:comment>
    <rdfs:label>Monocyte isolation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/446">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/42"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>IDO appears critical for the regulation of TNBS colitis upon CTLA-4 engagement, as the beneficial effect of anti-CTLA-4 treatment was lost in IDO-deficient mice. By contrast, the absence of IDO did not alter the course of inflammation in mice injected with TNBS only, an unexpected finding which suggests that IDO-dependent counter-regulation requires other factors/cells in addition to IDO production and T cell activation by TNBS.</rdfs:comment>
    <rdfs:label>IDO-deficient mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/277">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/267"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sandra Van Lint</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_236">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FOXP-3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FOXP3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">forkhead box P3 gene</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">forkhead box P3</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FOXP3 gene</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_760">
    <rdfs:label>material combination step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A material combination step is a step in a protocol that specifies how to combine two or more material entities as input into a single material entity as output.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">material combination step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A22">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000050">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">colony forming unit erythroid megakaryocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CFU-EM</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">megakaryocyte erythroid progenitor cell</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MEP</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">colony forming unit erythroid megakaryocyte</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MEP</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/221">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/110"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These plasmacytoid pDC that were stimulated with both CpG and the TLR-7 ligand R848 were shown to produce very high levels of IL-12p70 (in the ng/ml range per 5 x 105 cells/ml) and IFN-gamma. </rdfs:comment>
    <rdfs:label>stimulated pDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/102">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000052"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>An Illumina transcriptional profiling platform is available for microarray analyses.</rdfs:comment>
    <rdfs:label>Illumina transcriptional profiling platform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/226">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corinne Cumin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/227">
    <rdfs:label>Micro RNA (miR) profiling</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdfs:comment>To understand whether these regulators of gene expression could somehow contribute to the fine tuning of CCL2 expression in MD-DCs, a quantitative microarray approach that detects 723 human mature miR (miRBase 10.1, Dec 2007), was used to measure miR expression profile in these cells, either untreated or stimulated with LPS, R848, or their combination for 8 h. The analysis of the microarray data generated from 4 independent experiments is in progress.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_240"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A23">
    <rdf:rest rdf:nodeID="A21"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/10">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/31"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have a flow cytometer analyzer at our disposal.</rdfs:comment>
    <rdfs:label>flow cytometer analyzer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasOrgan">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organ</rdfs:label>
    <rdfs:range rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasOrganType</dcr:hasClassAsRangeProperty>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with the biomaterial. As this would make the ontology OWL full, the annotation property hasOrganType is used instead.</rdfs:comment>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasBodilyPart"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/2">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Gray Institute for Radiation Oncology &amp; Biology</rdfs:comment>
    <rdfs:label>Pamela G Nieto</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#inverse_of_has_document_1">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#is_document_of"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/69">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/95"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>An HIV infected individuals stable under HAART study has been initiated.  These patients are being vaccinated with cytokine cocktail matured DCs electroporated with mRNA encoding Tat, Rev and Nef.  The cDNA’s encoding these early expressed HIV antigens have been human codon optimized and modified with lysosomal targeting sequences.  

So far, 17 patients have been included in the study.</rdfs:comment>
    <rdfs:label>17 HIV patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/127">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/184"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Postdoc, molecular biology, regulation by microRNAs in DCs</rdfs:comment>
    <rdfs:label>Isabelle Dunand-Sauthier</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0704202">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear factor NF- kappa-B p50 subunit</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p50 subunit of NF kappaB</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF-kappaB</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EBP- 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nuclear factor of kappa light chain gene enhancer in B-cells 1 p105</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nfkb1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DNA-binding factor KBF1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nuclear factor kappaB p50</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF-kappa-B1 p84/NF-kappa-B1 p98</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p50</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear factor NF-kappa-B p105 subunit</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF kappaB1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p50 subunit of NF kappaB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p50/p105</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A24">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_28892">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ganglioside</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sialoglycosphingolipids</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gangliosides</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_235">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-12 p70</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-12p70</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL12p70</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/447">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/42"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have investigated the respective role of IL-10 and IDO, both required for Th1 suppression in this model. As IL-10 has been shown to indirectly dampen Th1 responses through the inhibition of IL-12 production by antigen-presenting-cells, we monitored mRNA expression specific for the inducible chain IL-12 p35 in lymph nodes draining the site of injection or in mesenteric lymph nodes of mice instilled intra-colonically with TNBS. Our results clearly show that IL-12 production early after the onset of the response was unaffected by anti-CTLA-4 treatment. By contrast, our data confirm previous data showing that IL-10 is critical for IDO production by DC in vitro, suggesting that IL-10 may act upstream by modulating the expression of IDO. As IDO expression was detected in the colon but not in the spleen or mesenteric lymph nodes, we postulate that IDO may act as anti-inflammatory agent in the intestine and that IL-10 may inhibit Th1 activation in the lymphoid organs and enhance IDO expression in the gut.</rdfs:comment>
    <rdfs:label>IL-10 in colitis model</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/276">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Iain Welsby</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/101">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/339"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/211"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/341"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/147"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/51"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/269"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/33"/>
    <rdfs:label>DC-ATLAS database</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/308"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/305"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/112"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/307"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/226"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/340"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/127"/>
    <rdfs:comment>We have been developing the DC-ATLAS DC-pathway database. For this, we have set about identifying key signalling pathways that were likely to be of most relevance to dendritic cell functions. We have designed a DC-ATLAS data model to effectively describe pathways, their genes, and their interaction. We produced a controlled vocabulary that contains at least 400 ontological terms, prepared on the basis of the proposals and discussions among the researchers involved in DC-ATLAS project. We defined the pathway representation where each pathway was described using three different means: a PDF format, a gene list, and a graphical representation. The pathways data model and controlled vocabulary was developed in collaboration with Sorin Draghici and the Leaf Bioscience group lead by A. Splendiani.

DC ATLAS integrates the signalling modules of the DC, curating specifically 
(i) the pathways leading from immature dendritic cells to mature dendritic cells, and 
(ii) the pathways depending on interaction between different cell types (e.g. DC and T cells interaction, leading to Th1/Th2/Th17/Treg polarisation, and apoptosis). 

Given the complexity of the problem we have built a unique group of curators with the primary purpose of describing separately: 
(1) the section of the pathway sensing the stimulus and transmitting the stimulus to the general signal transduction pathway; 
(2) the principal signal transduction modules used by the DC; and 
(3) the outcomes (e.g. cytokine production, apoptosis, migration, differentiation). 

From over 200 pathways, a list of some 30-40 was prioritised for immediate attention. These were then assigned to individual curators, drawn from across the Network and including some of its Third Parties. Among the curated pathways are TCR/ slam receptor; PPAR P PPAR Gamma; TCR Ag proc/pres; TLR4; TLR7+8; TLR 2 + 1; TLR6+2; MHC1 MHC2 pathways- antigen presentation; TLR3; DC-Sign; TLR 5+; TCR – motility; Dectin-1.

The curation process revealed substantial inaccuracies and errors in publicly-available databases. For the first time, this initiative clarified differences between homologous pathways operating in dendritic cells from human versus mouse (and other species), and in dendritic cells from different sources (e.g. human monocytes-derived versus mouse bone marrow-derived DC, and different primary DC subsets). Draft manuscripts, describing this initiative and its first results were prepared and will be submitted as DC-THERA joint publications.

DC-ATLAS Curation Team:
- Francesca Granucci / Ivan Zanoni, Università di Milano-Bicocca
- Ugo D’Oro / Mirela Kuka, Novartis
- Sonja Buschow, University of Nijmegen
- Sandra Gessani / Maria Cristina Gauzzi, ISS
- Philippe Pierre, Centre d’Immunologie de Marseille-LuminyCNRS-INSERM-Univ. Med.
- Nadine Montfoort, LUMC
- Vassili Soumelis, Curie Institute
- Arpad Lanyi, University of Debrecen
- Eva Rajnavolgyi, University of Debrecen
- Walter Reith, Isabelle Dunand, University of Geneva
- Sebastian Amigorena, Curie Institute
- Herman Wagner, TUM
- Carl Figdor, University of Nijmegen
- Gabriella Torcia, University of Florence
- Matthijs Kramer, Radboud University Nijmegen Medical Centre</rdfs:comment>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/87"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/145"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/338"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/163"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/127"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/20">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/312"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/311"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/313"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_758"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Staining of the cells in PEalphaDC80 in PBS + 2 % FCS</rdfs:comment>
    <rdfs:label>Staining</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isDefinedBy">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The property rdfs:isDefinedBy is a subproperty of rdfs:seeAlso, and indicates the resource defining the subject resource. As with rdf:seeAlso, this property can be applied to any instance of rdfs:Resource and may have as its value any rdfs:Resource. 

The most common anticipated usage is to identify an RDF schema, given a name for one of the properties or classes defined by that schema. Although XML namespace declarations will typically provide the URI where RDF vocabulary resources are defined, there are cases where additional information is required. 

For example, constructs such as 
&lt;rdfs:subPropertyOf rdf:resource="http://purl.org/dc/elements/1.0/Creator"/&gt;
do not indicate the URI of the schema that includes the vocabulary item Creator (i.e., http://purl.org/dc/elements/1.0/). 

In such cases, the rdfs:isDefinedBy property can be used to explicitly represent that information. This approach will also work when the URIs of the namespace and its components have no obvious relationship, as would be the case if they were identified using schemes such as GUIDs or MD-5 hashes.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is defined by</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/222">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/56"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were co-electroporated with constitutively active TLRs and TAA encoding mRNA. They were used to compare different maturation methods.</rdfs:comment>
    <rdfs:label>Co-electroporated moDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A25">
    <rdf:rest rdf:nodeID="A23"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0302729">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0704821">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">INTERLEUKIN 1-BETA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin 1 beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL1-BETA</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-1 beta</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-1B</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL1B</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Catabolin</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-1 beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-1 beta precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-1 beta precursors</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL1F2</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100468">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ctx</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0043234"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">[wikipedia:] Cholera toxin (sometimes abbreviated to CTX, Ctx, or CT) is a protein complex secreted by the bacterium Vibrio cholerae.[1][2] CTX is responsible for the harmful effects of cholera infection.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cholera toxin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/226">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001438"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdfs:label>TLR4-CD14 signalling in DCs</rdfs:label>
    <rdfs:comment>Concerning the pathway based analysis and database we have started the curation of the TLR4-CD14 pathway in DCs and we have described the events occurring at the DC membrane level. We have also started global gene expression analyses to better difine the role of NFAT in DCs. </rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/319"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5811">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_423054"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">toxoplasma gondii</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#relatedTo">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Related to</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Any public resource can be relatedTo some ontological class. As this would make the ontology OWL full, we use as a shortcut the annotation property relatedToType.</rdfs:comment>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:relatedToType</dcr:hasClassAsRangeProperty>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/1">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/9"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/449"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/450"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/5"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/12"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/14"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/195"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <rdfs:label>Gordon G MacPherson</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/67"/>
    <rdfs:comment>Following my retirement my research group has departed and my lab has closed. The studies on rat dendritic cells are however being continued by Dr Simon Milling, an ex-post doc who is now a University Lecturer at Glasgow University. Dr Vuk Cerovic (ex-post doc with me) has taken a post-doc position with Dr Milling.</rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/6"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/68"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/196"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/13"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/14"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/46"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/66"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_234">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICOS</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Inducible T-cell co-stimulator</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/279">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Achille Broggi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A26">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBiomaterialOutput">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relationship between a protocol step and a bio-material used in the concretization and realization of the protocol step.</OBI:IAO_0000115>
    <owl:inverseOf rdf:resource="http://dc-research.eu#isBiomaterialOutputOf"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has biomaterial output</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/448">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/42"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200769"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have investigated the respective role of IL-10 and IDO, both required for Th1 suppression in this model. As IL-10 has been shown to indirectly dampen Th1 responses through the inhibition of IL-12 production by antigen-presenting-cells, we monitored mRNA expression specific for the inducible chain IL-12 p35 in lymph nodes draining the site of injection or in mesenteric lymph nodes of mice instilled intra-colonically with TNBS. Our results clearly show that IL-12 production early after the onset of the response was unaffected by anti-CTLA-4 treatment. By contrast, our data confirm previous data showing that IL-10 is critical for IDO production by DC in vitro, suggesting that IL-10 may act upstream by modulating the expression of IDO. As IDO expression was detected in the colon but not in the spleen or mesenteric lymph nodes, we postulate that IDO may act as anti-inflammatory agent in the intestine and that IL-10 may inhibit Th1 activation in the lymphoid organs and enhance IDO expression in the gut.</rdfs:comment>
    <rdfs:label>IDO in colitis model</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/3">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/463"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/138"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_752"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>A HLA-A2 positive healthy donor undergoes leukapheresis.</rdfs:comment>
    <rdfs:label>Leukapheresis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1476">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Denileukin diftitox</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_583"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Denileukin diftitox, otherwise known as Ontak is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ONTAK</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/110">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We established “human hemato-lymphoid-system mice” by transplanting human CD34+ cord blood cells into irradiated newborn Rag2-/-gc-/- mice, leading to de novo development of human B, T, and dendritic cells.</rdfs:comment>
    <rdfs:label>human hemato-lymphoid-system mice </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/100">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <rdfs:comment>The experiments on human monocyte-derived DC are being annotated in DC-BASE, a unique DC-dedicated database integrated with data mining tools. The database uses a LIMS system based on the structure of Base2.9. The database currently contains 240 microarray experiments  annotated accordingly to MIAME standards and thoroughly analyzed in order to pass severe quality control tests. A meeting will be organized for defining policies on data sharing within the DC-THERA community and beyond. 

In order to populate DC-BASE with data obtained from the literature, we used the GEO Import Perl program to download the required experiments from the Gene Expression Omnibus (GEO) database, and to convert them into a spreadsheet based format called MAGE-TAB. MAGE-TAB data has then been imported into DC-BASE.

We have collaborated with the team lead by Andrea Splendiani for the definition of shared terminologies for the annotation of the microarray datasets. These terminologies are at the basis of semantic interoperability with other resources, and the DC-THERA Directory in particular. More specifically, a query to to the Directory will propagate to the DC-ATLAS microarray repository. The DC-THERA Directory will then present a summary of results found.

Access to DC-BASE is provided through the DC-THERA Directory.</rdfs:comment>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/132"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/51"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <rdfs:label>DC-BASE database</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/235"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/33"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400120">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A18">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100390">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000029"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon gamma</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFN gamma</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/225">
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001461"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_615"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:label>TLR8 triggered gene expression</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>During 2008, we extended all the data regarding TLR3 signaling to TLR8 signaling. Cytokines assays and immunoblotting studies suggest that Src kinases play a crucial role in the control of both MyD88- and TRIF-dependent pathways. We also extended microarray analysis on human MoDC stimulated with R848 (TLR8 agonist), pretreated or not with PP2. In summary, the new generated data on TLR8 triggered gene expression are similar to previous data obtained with TLR3 stimulation, and confirmed that src kinases inhibition is associated to inhibition of key genes in the inflammatory cytokine response. Interestingly, however, the expression of IL-23 p19 was not decreased by PP2. Cytokine assays, indeed, showed that inhibition of Src kinases in human DC stimulated with TLR agonists alone or simultaneously resulted in a dramatic unbalance in the production of IL-12 and IL-23 :since IL-12 impairment was associated to a normal production of IL-23. Moreover the finding that IL-23 is not affected by PP2 treatment was also confirmed in a murine system of Bone Marrow derived Dendritic Cells stimulated with TLR agonists. Real-time qPCR in human MoDC showed that mRNA levels for IL-23A subunit exactly correlated with IL-23 cytokine levels suggesting that the IL-23A chain is the limiting component for the production of a complete IL-23 complex. Moreover,  transcriptional analysis showed that the role of Src kinases on specific transcription factors accounts for unbalanced IL-12/IL-23 production.

We will investigate if normal IL-23 production associated to inhibition of IL-12 observed upon stimulation of PP2-treated MoDC would result in a milieu able to induce a Th17 response. Eventually we will evaluate if src kinase inhibitors are able to modulate in-vivo the type of DC driven immune response.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/224">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Isabelle Decot</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0344">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_1000036</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_cell lysate</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/60">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/147"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/146"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_772"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The patients are monitored for safety and toxicity of the treatment and for clinical response. T cell stimulatory activity of DC is monitored by induction of KLH specific T cells, tumor specific responses are evaluated by induction of SK-Mel 24 peptides specific T cells. </rdfs:comment>
    <rdfs:label>Monitoring</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/278">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Theres Matjeka</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/170">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were treated with intact anti-CTLA-4 antibodies. This induced the development of regulatory T cells expressing high levels of ICOS and producing IL-10. These regulatory T cells inhibit Th1 responses, in vitro and in vivo, and repress experimental intestinal inflammation, by a mechanism involving IL-10 and IDO. </rdfs:comment>
    <rdfs:label>Primed mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000156">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A27"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc receptors</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcR</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A28">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/449">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We are characterising (in collaboration with Sebastian Amigorena) rat lymph exosomes and will determine if they transport intestinally-delivered scrapie ME7.</rdfs:comment>
    <rdfs:label>Rat lymph exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/2">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>OR</rdfs:comment>
    <rdfs:label>OR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0010259">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SA-36</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glucose 6 phosphate isomerase</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GPI</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neuroleukin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphoglucose isomerase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SA36</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SA 36</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sperm antigen 36</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphohexose isomerase</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NLK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sperm antigen-36</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PHI</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Glucose-6-phosphate isomerase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PGI</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UBERON#UBERON_0000338">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphoblast</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/8">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Louise de Jager</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/38">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000377"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/358"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/27"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/574"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700880"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_279"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/29"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/43"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We are currently performing gene silencing experiments in human monocyte-derived DCs (MDDCs) with the dual aim of generating relevant knowledge and data on 

(i) the transcriptional regulation of DC differentiation, and 
(ii) the safe and rationale in vitro manipulation of gene expression in DCs. 

One of the two different approaches that have been set up in parallel is: 

Lentiviral transduction of shRNAs:  to this aim, shRNA specific for IRF4 and STAT3 are in the process to be cloned into the pLVTHM lentiviral vector (obtained from the repository Addgene). This vector has been already successfully used to generate self-inactivating lentiviral vectors previously tested in DCs for transfection efficiency and absence of effects on their phenotype. A self-inactivating lentiviral vector expressing shRNA specific for STAT3 is now available in the laboratory, and experiments are in progress to optimize their transduction efficiency and silencing in MDDCs. </rdfs:comment>
    <dcr:hasExperimentalDesignType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0788"/>
    <rdfs:label>Gene-silencing in human DC by shRNA approaches</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/41"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/224">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Work has continued to characterise the function of a novel tick-derived DC modulator that perturbs various signalling pathways of human DC but not others; transcriptional profiling and pathways-based analysis will be undertaken in the next phase and data will become available.</rdfs:comment>
    <rdfs:label>Function of a novel tick-derived DC modulator</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A29">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_489"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A30">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/528">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells acquire a mature phenotype along with an enhanced secretion of several cytokines/chemokines. Moreover, these DCs are very potent in inducing naive CD4(+) T cells to differentiate into interferon-gamma (IFN-gamma)-secreting type 1 T helper (Th1) cells. </rdfs:comment>
    <rdfs:label>Immature DCs electroporated with CD40L and/or caTLR4 mRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/162">
    <rdfs:label>Effects of LPS on rat intestinal and hepatic DC in vivo</rdfs:label>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/68"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:comment>Data was obtained on the DC-activating, TLR-4-mediated stimulus, LPS, on rat intestinal and hepatic DC in vivo.

DC present peripheral Ags to T cells in lymph nodes, but also influence their differentiation (tolerance/immunity, Th1/Th2). To investigate how peripheral conditions affect DC properties and might subsequently regulate T cell differentiation, we examined the effects of a potent DC-activating, TLR-4-mediated stimulus, LPS, on rat intestinal and hepatic DC in vivo. Our results suggest that any explanation of switching between tolerance and immunity as well as involving changes in DC activation status must also take into account differential migration of DC subsets.</rdfs:comment>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7197"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/9">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/469"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/468"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>After peptide pulsation cells are diluted in medium containing 20 ng/mL TNF-?, plus IL-4 and GM-CSF as stated above.</rdfs:comment>
    <rdfs:label>Dilution of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_765">
    <rdfs:label>exposure of material to environment step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">exposure of material to environment step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An exposure of material to environment step is a step in a protocol that specifies how to exposea material to a defined set of conditions in a controlled environment.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_48706">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antagonist role</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">subclass of "pharmacological role" ISA "biological role"</rdfs:comment>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Substance that attaches to and blocks cell receptors that normally bind naturally occurring substances.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/22">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/313"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_766"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>FACS analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000652">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phenotypic factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400121">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0001965">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAW 264.7 cell</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mouse, monocytic-macrophage, ascitic fluid, leukemia cell line. Established from ascites of a tumour induced in a male mouse by intraperitoneal injection of Abselon Leukaemia Virus (A-MuLV).</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A31">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_232">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A32"/>
    <rdfs:subClassOf rdf:nodeID="A33"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD154</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 154</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD154R</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-154</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD154 receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/171">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The properties of this DC population and its production of cytokines in response to different Toll-like receptor (TLR) agonists were evaluated. The TLR agonists used were: PAM3CSK4, Poly I:C, LPS, Flagellin, Imiquimod, Resiquimod, CpG 2216, CpG 2006. We found that CD16 and CD1c produce a number of cytokines in response to these stimuli, with the exception of CpGs. In addition, we found that CD16+ DCs are the major producers of TNF-alpha and IL-6, while CD1c+ DCs produce primarily IL-8.</rdfs:comment>
    <rdfs:label>CD16+ CD</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0000049">
    <rdfs:label>mass spectrometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/567">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Manufacturing of cGMP RNA to be used as an API (active pharmaceutical ingredient) in the planned Tri-Mix DC RNA Trial will be performed after obtaining the manufacturing license for RNA loaded DCs.</rdfs:comment>
    <rdfs:label>cGMP RNA as API for Tri-Mix Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_171">
    <rdfs:label>HPV16 E7 long peptide</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HPV16 E7</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HPV16 E7 long peptide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/90">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <rdfs:comment>Summary of the completed RCC clinical study and the data obtained: 

RCC subjects were deficient in T cell IFN-gamma and IL-2 production pre-vaccination.  The  IL-2 defect was corrected in 7/12 patients post-vaccination. Vaccination resulted in an increase in tumor antigen-specific T cells in 8/12 patients. 7/12 subjects had a response to more than one antigen post-vaccination. Median overall survival was ~25 months compared to ~11 months for historical controls (confirmed by matched pair analysis).</rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/65"/>
    <rdfs:label>Clinical trials of DC-based immunotherapy for RCC</rdfs:label>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/42"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/118"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/121"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/7">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>skype: miriam.mendes.skype</rdfs:comment>
    <rdfs:label>Miriam Mendes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001461">
    <rdfs:label>Toll like receptor 8</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR 8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR-8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR8</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll like receptor 8</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/37">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0610"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000377"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0788"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/185"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/72"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/359"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/89"/>
    <rdfs:label>Gene-silencing in human DC by siRNA approaches</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdfs:comment>We are currently performing gene silencing experiments in human monocyte-derived DCs (MDDCs) with the dual aim of generating relevant knowledge and data on 

(i) the transcriptional regulation of DC differentiation, and 
(ii) the safe and rationale in vitro manipulation of gene expression in DCs. 

One of the two different approaches that have been set up in parallel is: 

Transient transfection of synthetic siRNA: to this aim, commercially available siRNA Smart Pool from Dharmacon targeted against the STAT3 transcription factor have been successfully transfected in human MDDCs (Lipofectamine 2000 as transfection reagent). The efficiency of silencing, as detected by western blot or FACS analysis of the protein was of 50-80% (depending on the donor), and peaked at 72 h post-transfection. Transfection efficiency was reproducibly higher than 80% and did not induce any type I IFN production. A total of 9  different donors have been transfected under these optimized conditions and a detailed analysis of the phenotypic and functional consequences of STAT3 silencing have been performed upon 

(a) Toll-like receptor (TLR) mediated DC activation (e.g LPS or pI:C) and 
(b) activation in a tolerogenic microenvironment (e.g. combined stimulation TLR-L + IL-10). 

In particular, we analysed the immunophenotype, the antigen up-take activity, the secretion of cytokines/chemokines, and the ability of silenced MDDCs to stimulate T cell allogenic proliferation in classical MLR assays. 

No consistent and reproducible differences in the immunophenotype and antigene uptake capability of both iMDDCs and TLR-matured MDDCs have been observed. Modest inhibitory effects have instead been observed in the production IL-10 and IL-6, whose biological activity is controlled through STAT3. We noticed, however, that the transfection itself caused a non specific activation of MDDCs (of variable extent from donor to donor) that rendered difficult the interpretation of the results (especially MLR).

Global microarrays were used to define differentially modulated genes in STAT3 silenced MDDCs versus control cells.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/12"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A34">
    <rdf:rest rdf:nodeID="A29"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/223">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/11"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_302"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have used fluorescence microscopy to analyse the endocytic pathway in DC and to track C-type lectins that are internalised from the cell surface. From these analyses, there is data available.

As part of this work, we have used microscopy to study the effect of Dectin-1 uptake on its ability to signal for downstream responses. Finally, we have shown that fluorescently-labelled antibodies against a novel C-type lectin, DNGR-1, can be used to mark DC upon injection into mice and might therefore be useful for in vivo imaging studies.

Microscopy will continue to be used to understand molecular dynamics in cell biology and immunology, including studies of signalling pathways in dendritic cells. In particular, we are using imaging approached to define the endocytic ability of DNGR-1 and its ability to intersect with antigen processing compartments. We are also creating knock-in and transgenic reporter mice in which specific mouse DC subsets are  marked with fluorescent proteins for in vivo imaging studies.</rdfs:comment>
    <rdfs:label>Analysis of the endocytic pathway in DC and tracking internalised C-type lectins</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A35">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000473">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD28 receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A36"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-28</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 28</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD28</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_764">
    <rdfs:label>stimulation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A stimulation step is a step in a protocol that specifies how to use an agent, such as a bio-material, to evoke a certain activity in another material. Example: stimulation of cells with yeast.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stimulation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/163">
    <rdfs:comment>Data was obtained on Fabs that bind strongly to L-SIGN, but to a lesser degree or not at all to dendritic cell-specific ICAM-grabbing nonintegrin (DC-SIGN).

The C-type lectin L-SIGN is expressed on liver and lymph node endothelial cells,where it serves as a receptor for a variety of carbohydrate ligands, including ICAM-3, Ebola, and HIV. To consider targeting liver/lymph node-specific ICAM-3-grabbing nonintegrin (L-SIGN) for therapeutic purposes in autoimmunity and infectious disease, we isolated and characterized Fabs that bind strongly to L-SIGN, but to a lesser degree or not at all to dendritic cell-specific ICAM-grabbing nonintegrin (DC-SIGN). As a first step to consider the potential of these Abs for Ab-mediated Ag delivery, we evaluated specific peptide delivery to human dendritic cells. A durable human T cell response was induced when a tetanus toxide epitope embedded into a L-SIGN/DC-SIGN-cross-reactive Ab was targeted to dendritic cells. We believe that the isolated Abs may be useful for selective delivery of Ags to DC-SIGN- or L-SIGN-bearing APCs for the modulation of immune responses and for blocking viral infections.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_381"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001990"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Isolation and characterization of Fabs that bind strongly to L-SIGN, but to a lesser degree or not at all to dendritic cell-specific ICAM-grabbing nonintegrin (DC-SIGN)</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#CD209_Antigen"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000115"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_205488"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7197"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/527">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have shown recently that the T cell stimulatory capacity of DCs pulsed with tumorantigen-derived peptides can be considerably increased by activating the DCs through electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA (TriMix DCs).

This vaccine will also be tested in the multicentre trial.</rdfs:comment>
    <rdfs:label>Tri-Mix-mRNA DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33709">
    <rdfs:label>amino acids</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/21">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/313"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/313"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_765"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Fc-block for 30 min on ice</rdfs:comment>
    <rdfs:label>Fc-block</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/8">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/468"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/467"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/141"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>On day 5 cells are counted and pulsed with tumor antigen derived peptides (one per culture) at a concentration of 5 µg/mL in approximately 5 mL and at a cell density of 20 x 10e6/mL for 1 h. </rdfs:comment>
    <rdfs:label>Pulsing with tumor antigen derived peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000245">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/172">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The properties of this DC population and its production of cytokines in response to different Toll-like receptor (TLR) agonists were evaluated. The TLR agonists used were: PAM3CSK4, Poly I:C, LPS, Flagellin, Imiquimod, Resiquimod, CpG 2216, CpG 2006. We found that CD16 and CD1c produce a number of cytokines in response to these stimuli, with the exception of CpGs. In addition, we found that CD16+ DCs are the major producers of TNF-alpha and IL-6, while CD1c+ DCs produce primarily IL-8.</rdfs:comment>
    <rdfs:label>CD1c+ CDs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000576">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0005539">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkBKA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">I kappa-B kinase alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IKK1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkappaB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NFKBIKA</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkappaB kinases</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkappaB kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Conserved helix-loop-helix ubiquitous kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear factor NF-kappa-B inhibitor kinase alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkB</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0010050"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">I-kappa-B kinase 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IKK-alpha</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkappaB</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IKK-A</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/6">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/102"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/522"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/423"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/79"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/13"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/40"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/568"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/569"/>
    <rdfs:label>Jonathan M Austyn</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/347"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/1"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_170">
    <rdfs:label>HPV16 E6 long peptide</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HPV16 E6 long peptide</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HPV16 E6</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/568">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/569"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A long-standing collaboration with Centre for Ecology &amp; Hydrology (CEH, UK) has led to the identification of an activity in salivary gland extracts of the tick Rhipicephalus appendiculatus that profoundly modulates the responses of human monocyte-DC towards extrinsic stimuli. 

Recombinant  protein has been generated from the gene for this molecule (Japanin) which had been cloned. This material inhibits the up-regulation of costimulatory molecules in response to certain TLR agonists, and some cytokines but not others, and modulates the function of the DC in ‘in vitro’ assays. A patent was filed by CEH in September 2008 with Austyn named as inventor relating to the potential use of Japanin as a DC modulator for human therapy.</rdfs:comment>
    <rdfs:label>Recombinant protein generated from Japanin gene</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A37">
    <rdf:rest rdf:nodeID="A34"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A38">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_F0001662">
    <rdfs:subClassOf rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Lectin"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mannose binding lectins</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mannose binding</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mannose binding lectin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_658">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C3H/HeN mouse strain</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_655"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/24">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_746"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 2: transfection </rdfs:comment>
    <rdfs:label>Transfection </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#OBI_0000260_4">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OBI_0000260"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/160">
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7163"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <rdfs:comment>We obtained data from a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines: 

DC loaded with a single MAA-derived peptide (MAGE-3.A1 or -A2 or Na17.A2) or pulsed with 2 to 3 MAA-derived peptides (combinations of MAGE-3.A2, MAGE-C2.A2 or Na17.A2) or G4-DC loaded with 8 different peptides. 

Our experiences can be summarized as follows: 
(1) preparation of an autologous dendritic cell based vaccine was feasible for every patient enrolled in our studies; 
(2) we did not observe vaccination related toxicities beside mild local skin reactions (CTCAEv3.0 grade 1/2) at the injection sites; 
(3) objective tumor regression was observed in 4 patients (1 CR and 1 CR after resection of residual disease following regression of metastases) on a total of 10 patients that were able to receive the planned 6 biweekly vaccinations; 
(4) all patients with regression of melanoma lesions following vaccination were found to have mounted a significant increase in the frequency of vaccine specific CTL in their peripheral blood and the appearance of a measurable CTL-frequency was seen between 8-13w after the first vaccine, furthermore, regression or stabilization of metastases has been coincident with the appearance of detectable or a significant rise (&gt;10-fold) of CTL-frequencies; 
(5) 2 patients with no residual disease following surgical metastasectomy who were vaccinated remain disease free at &gt;18 months of follow-up, one of these patients qualifies for a CTL-response, the other for a borderline response; 
(6) CTL-responses have been observed in 1 out of 3 patients treated with a mRNA-G4DC vaccine; this small number of patients does not allow for a comparison of efficacy between mRNA and MAA-peptide pulsed DC-vaccines.  

An important conclusion that can be made from these pilot-observations is that the potential therapeutic effect of our DC-based MAA-vaccination approach does not occur instantly but is delayed by 8-12w following the first vaccination (i.e.12-16w after the isolation of PBMC by leukapheresis given the 4w that are necessary for preparation of the DC-vaccine and the extensive quality control).  All patients in whom a benefit was seen in our study had a normal LDH and all but one patient, were chemo-naïve. </rdfs:comment>
    <rdfs:label>Clinical trial of patients treated with DC vaccines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_763">
    <rdfs:label>injection step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An injection step is a step in a protocol that specifies how to introduce a compound or a mixture into a material entity (either biological entity or instrument) by relying on devices such as syringe or injector connection, attached or forced into a vascular system (veins of an organism or tubes of a machine) or in a tissue.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">injection step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_619">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">D1 cell line</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C57BL/6 mice</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_49662">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">indomethacin</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36683"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/70">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/113"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/112"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/111"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Cytokine production by DCs and T cells is assessed by ELISA assay according to the manufacturer’s instructions of ELISA kit.

After the times indicated, supernatants were collected and cytokine detection was performed. MesoScale Assay 7-spot (Meso Scale Discovery) or Luminex® Assay (Invitrogen) were used for detection of IL-1beta, IL-8, IL-6, TNFalpha, IL-10, IL-12p70, IFNg and IL-17A according to the manufacturer’s instructions. 
These procedures allowed simultaneously measurement of different cytokines in the same supernatants. The multiplex assay format differs from conventional ELISA in one significant way: the multiplex capture antibody is attached to a polystyrene bead whereas the ELISA capture antibody is attached to the microplate well. The use of the suspension bead-based technology enables multiplexing. Microspheres are internally dyed with red and infrared fluorophores of differing intensities. Each bead is given a unique number, or bead region, allowing differentiation of one bead from another. Beads covalently bound to different antibodies can be mixed in the same assay, utilizing a 96-well microplate format.
At the completion of the sandwich immunoassay, beads were read, using the Bioplex® 200™ detection system, in single-file by dual lasers for classification and quantification of each analyte. 
Alternatively, ELISA assay was performed according to the manufacturer’s instructions. ELISA kits were from Biosource rather than ELISA for IL-12p70 that was from R&amp;D System and IL-17 from e-Bioscience.
In blocking experiment, after 2 hors of exposure with the inhibitor, supernatants were collected after 8 or 24 hours or for T cell cytokine detection, 5 days of incubation.</rdfs:comment>
    <rdfs:label>ELISA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/7">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/467"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/466"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/465"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/464"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/139"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>2 x 200 x 10e6 monocytes are transferred into culture bags by sterile welding and cultured for 5 days at a density of 2.5-5 x 10e6 cells/mL in serum free medium (CellGro, Cell Genix) in the presence of 100 ng/mL GM-CSF (Leukine, Berlex) and 20 ng/mL IL-4 (Cell Genix). After 2 days one volume fresh medium containing 2x concentrated cytokines is added. </rdfs:comment>
    <rdfs:label>Cell culture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000151">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T cell receptors</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-cell receptors</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TCR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-cell receptor</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:label>T cell receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TCR family</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A39"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T cell receptor family</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T cell receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/5">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/4"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/274"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/41"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/275"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/172"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/273"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/253"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/173"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/166"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/171"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/165"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/169"/>
    <rdfs:label>Vincenzo Cerundolo</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/215"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/218"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/170"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/216"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/217"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/164"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/168"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/278"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/1"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/162"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/214"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/163"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/167"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/277"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/305"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/5"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/58"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/6"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/276"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/92">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_555"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.obofoundry.org/obo/OBI_1000036"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Clinical trials of melanoma patients treated with DC and tumour lysate plus adoptive transfer of T cells</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>We are planning clinical trials of melanoma patients treated with DC and tumour lysate plus adoptive transfer of T cells which will result in corresponding data.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_36357">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">polyatomic entity</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/173">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The properties of this DC population and its production of cytokines in response to different Toll-like receptor (TLR) agonists were evaluated. The TLR agonists used were: PAM3CSK4, Poly I:C, LPS, Flagellin, Imiquimod, Resiquimod, CpG 2216, CpG 2006. BDCA-3+ cells seem not have any capability to respond to TLR agonists.</rdfs:comment>
    <rdfs:label>BDCA-3+ DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/569">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/568"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A long-standing collaboration with Centre for Ecology &amp; Hydrology (CEH, UK) has led to the identification of an activity in salivary gland extracts of the tick Rhipicephalus appendiculatus that profoundly modulates the responses of human monocyte-DC towards extrinsic stimuli. 

The gene for this molecule, which we have termed Japanin, has been cloned and recombinant protein has been generated. This material inhibits the up-regulation of costimulatory molecules in response to certain TLR agonists, and some cytokines but not others, and modulates the function of the DC in ‘in vitro’ assays. A patent was filed by CEH in September 2008 with Austyn named as inventor relating to the potential use of Japanin as a DC modulator for human therapy.</rdfs:comment>
    <rdfs:label>Japanin gene</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5085">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Aspergillus fumigatus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/110">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>This step is repeated several times to do several stimulations.</rdfs:comment>
    <rdfs:label>Stimulation of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/529">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells do not acquire a mature phenotype and do not lead to an enhanced secretion of several cytokines/chemokines. </rdfs:comment>
    <rdfs:label>Immature DCs electroporated with CD70 mRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A40">
    <owl:unionOf rdf:nodeID="A37"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/23">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_743"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 1: 4 x 10^6 293 FT in 10 ml DMEM (+10 % FCS (Tet-frei), +P/S) in a 10cm plate</rdfs:comment>
    <rdfs:label>Plating of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/39">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <rdfs:label>Definition of novel innate signalling pathway in DC via dectin-1</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/300"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700564"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000225"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000226"/>
    <rdfs:comment>We have data on a novel innate signalling pathway in DC. Using curdlan as a specific agonist of dectin-1, we have shown that this C-type lectin couple to Syk kinase leads to activation of ERK, JNK and p38 MAPKs, as well as NF-kappaB. However, signalling terminates rapidly once the receptor is internalised, thereby explaining previous observations that large, non-phagocytisable Dectin-1 ligands are much more potent agonists than smaller ones.

This is the first example of a bona fide signalling pathway from a cell surface innate receptor other than a TLR. 

We will continue to study innate signalling pathways in dendritic cells. Our focus will be on TLR-independent signalling pathways involved in viral recognition, including RIG-I and MDA5, as well as signalling via C-type lectins related to Dectin-1, such as Dectin-2 and DNGR-1.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/67"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000227"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/64"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000382"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0702411"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_659">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">129/Sv mouse strain</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_655"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A41">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_48705">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">agonist role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/170">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Annalisa Macagno</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_762">
    <rdfs:label>vaccination step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vaccination step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A vaccination step is a step in a protocol that specifies how to 'administer substance in vivo' that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intend to invoke a protective immune response.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/221">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/31"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/260"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/15"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data is available from an evaluation of different stimulation conditions for the cytometric assessment of antigen-specific Th-cells based on CD154 expression induced during short-term in vitro activation, a method established by us during previous DC-THERA activities. This is important and essential for implementation of the technology into clinical immune monitoring in e.g. vaccination trials.

Moreover, the affect of stimulation length was determined. Differences with respect to the induced frequencies of antigen-specific, activated CD154+ Th-cells were minor. Interestingly, longer stimulation times (16h) were characterised by a slightly reduced coefficient of variation. However, longer stimulation times resulted also in slightly enhanced background, implying that overnight stimulations cannot be performed when low frequencies of antigen-specific Th-cells are expected (Meier, Stark et al., 2008). </rdfs:comment>
    <rdfs:label>Evaluation of different stimulation conditions for the cytometric assessment of antigen-specific Th-cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#applicationGenerates">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a protocol to a dataset that was generated using that protocol.</OBI:IAO_0000115>
    <OBI:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Guendel</OBI:IAO_0000117>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">generates dataset</rdfs:label>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#derivedFromAnApplicationOf"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/161">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <rdfs:label>Interaction between the T cell receptor and peptide antigen presented by the MHC molecules</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <rdfs:comment>Central to all T cell responses is the interaction between the T cell receptor and peptide antigen presented by the MHC molecules. This interaction selects the dominant T cell clones with the most favourable (not necessarily highest) affinity and determines the extent of cross-reaction with epitope variants. 

I am currently collaborating with the structural biology group of Professor Yvonne Jones in the Nuffield Department of Medicine (NDM) at the Wellcome Trust Centre for Human Genetics. This collaboration has led to structural data on the CD1b in complex with several glycolipids, the NY-ESO-1 specific TCR in complex with the wild type NY-ESO-1 157-165 peptide and super agonist peptides with a modified carboxyl-terminal end, and more recently on the structure of CD1d in complex with a-galactosylceramide  and the structure of the  iNKT T Cell Receptor.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_249"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTerm">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_618">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon producing killer dendritic cells</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/6">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/473"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/472"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/140"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/139"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_765"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The majority of monocytes (1 x 10e9) and all lymphocytes (6,4 x 10e9) are frozen in 90% A-plasma and 10% GMP-grade DMSO.</rdfs:comment>
    <rdfs:label>Freezing of monocytes and lymphocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/227">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The kinetic of the transcriptional profiling of D1 cells treated with either DMSO or LPS was analysed.</rdfs:comment>
    <rdfs:label>D1 cells treated with LPS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000269">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">colon</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The part of the large intestine that extends from the cecum to the rectum.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000421">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A42"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear factor of activated T-cells</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NFAT</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF-AT</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/59">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The laboratory has expertise in the use of MACS anti-CD14 microbeads by Miltenyi Biotec, Bergisch-Gladbach, Germany. They were used for isolation of monocytes from PBMCs.</rdfs:comment>
    <rdfs:label>MACS anti-CD14 microbeads</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0600062">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_planned process</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000011</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/91">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/114"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/66"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/281"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdfs:label>Clinical trials of B-CLL patients treated with Apo-DC +/- GM-CSF in progress</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/64"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_167"/>
    <rdfs:comment>We have further data available on a clinical trial on vaccination of B-CLL patients with autologous, apoptotic, leukemic cells (Apo-DC). Cohort 1 with the vaccine alone and cohort 2 (5 patients) combining the vaccine together with GM-CSF as an adjuvant has finished accrual and all patients in these two cohorts have been monitored for 52 weeks.  The clinical and immune monitoring data is being currently analyzed. 

The third cohort consisting of the vaccine and GM-CSF administered after a single dose of cyclophosphamide (300 mg/ sq. meter) is currently being accrued.  Four of the five patients in this cohort have already received their vaccine and the final patient will be accrued in January.  Further cohorts that combine Apo-DC vaccination with leukemia debulking therapy is currently being considered for submission to the Swedish Medical Products Agency.

Immunological monitoring in these patients involving leukemia-specific lymphocyte proliferation and ELISPOT assays, phenotyping of immune cells, assaying cytokine using luminex technology and expression of CD107 as a surrogate marker for cytotoxicity, before and after vaccination is ongoing.


Further cohorts that combine Apo-DC vaccination with leukemia debulking therapy is currently being considered for submission to the Swedish Medical Products Agency.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_168"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/229">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fabrizio Ledda</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/4">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Martin S Wilkins</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_131567">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0100026</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Organism</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/174">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>1,25(OH)2D3 was added to the freshly isolated monocytes; this prevented the generation of IFN-DCs and directed already differentiated IFN-DCs toward a more immature stage.</rdfs:comment>
    <rdfs:label>Freshly isolated monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000243">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sponsor</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/30">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/36"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/92"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/49"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <rdfs:comment>We submitted descriptions of protocols (SOPs exist) used for expanding patient derived T cells into tumor reactive CTLs, based on our special skills in monocyte isolation by elutriation or adherence methods and in DC-T cell co-cultures as well as in immunomonitoring (all applied in our clinical studies described in the knowledge portal). We also included information on transfection of mature DC by electorporation or using adenoviral constructs.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label>Expanding patient derived T cells into tumor reactive CTLs</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/44">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Experimental High Energy Physics is a research department at the Faculty of Science of the Radboud University Nijmegen. 
It is a constituent of the "Institute for Mathematics, Astrophysics and Particle Physics" IMAPP and a partner of the "Research School Subatomic Physics" OSAF. 
The department is participating in the ATLAS  experiment (CERN),  DØ (Fermilab), and the Pierre Auger Observatory (Argentina).  
Nijmegen is the initiator of the HiSPARC project to measure extended air showers due to cosmic particles at ultra high energy in collaboration with highschools.

Some history: 
Experimental High Energy Physics was a participant in the CERN experiments EHS-NA22 and L3 and was a constituent of the former "High Energy Physics Institute" HEFIN. 

The Radboud University is one of the partners in the Dutch joint venture "National Institute for High Energy and Nuclear Physics" NIKHEF. </rdfs:comment>
    <rdfs:label>University of Nijmegen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_656">
    <rdfs:label>BALBc mouse strain</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BALBc mouse strain</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_655"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400099">
    <rdfs:label>flow cytometer sorter</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/164">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Small cohorts of patients (3-9) were vaccinated with differently composed DC-vaccines: DC loaded with a single MAA-derived peptide (MAGE-3.A1 or -A2 or Na17.A2) or pulsed with 2 to 3 MAA-derived peptides (combinations of MAGE-3.A2, MAGE-C2.A2 or Na17.A2) or G4-DC loaded with 8 different peptides.

An important conclusion that can be made from these pilot-observations is that the potential therapeutic effect of our DC-based MAA-vaccination approach does not occur instantly but is delayed by 8-12w following the first vaccination (i.e.12-16w after the isolation of PBMC by leukapheresis given the 4w that are necessary for preparation of the DC-vaccine and the extensive quality control).  All patients in whom a benefit was seen in our study had a normal LDH and all but one patient, were chemo-naïve. </rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_50144">
    <rdfs:label>sodium pyruvate</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sodium pyruvate</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sodium 2-oxopropanoate</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24866"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/131">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/84"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <rdfs:label>Juri Rappsilber</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/24"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/452"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/40"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/260">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/259"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/258"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>This test, described for glioblastoma, performed with PBMC from newly diagnosed glioblastoma patients will verify the ability of tumour-specific T-cells to recognize the fusion vaccine. Data will be made available.

BruCells has met with the Dutch MEB for a Scientific Advice Meeting on January 10, 2008 in The Hague. 
The Dutch authorities consider that the proposed in-vitro pre-clinical tests are adequate to check the pharmacodynamic activity of the fusion vaccines and that no animal model tests would be necessary. </rdfs:comment>
    <rdfs:label>In vitro recognition of fusion vaccine by T-cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000949">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_protein</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000000001</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_769">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">material maintenance step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A material maintenance step is a step in a protocol that specifies how to maintain some or all of the characteristics of an input material over time.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A43">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/172">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Arun Kamath</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/230">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/1"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/136"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Giuseppe Masucci</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/72">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These multimers were provided by P. Coulie and used to establish routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry.</rdfs:comment>
    <rdfs:label>Multimers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_30317">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bone</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bones</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/401">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were vaccinated with 4 peptides (MAGE-A3, gp100, NA17 and tyrosinase) presented by HLA-A2 and monitored. We measured responses to these peptides injected with Montanide, but did not know whether the Montanide adjuvant was important for these T cell responses. We therefore injected the same peptides without adjuvant, and no response was observed. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.</rdfs:comment>
    <rdfs:label>Tyrosinase peptide vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000465">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_antigen</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_23367</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/564">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>aHLA-DR fluorescein isothiocyanate was used to label yeast and spores.</rdfs:comment>
    <rdfs:label>aHLA-DR-FITC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A44">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <owl:onProperty rdf:resource="http://www.obofoundry.org/ro/ro.owl#derives_from"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/13">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/496"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/495"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/494"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/143"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_758"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Staining of D2SC1/Flt3-DC and staining of the cells to be taken up by Mini67-1KT or Mini26-1KT (PKH67/PKH26 green/red fluorescent cell linker mini kit for general cell membrane labelling) from Sigma</rdfs:comment>
    <rdfs:label>Staining of D2SC1/Flt3-DC and of the cells to be taken up</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_657">
    <rdfs:label>C57BL/6 mouse strain</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_655"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C57BL/6 mouse strain</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasMolecule">
    <rdfs:range rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:domain rdf:nodeID="A45"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">molecule</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with thebiomaterial. As this would make the ontology OWL full, the annotation property hasMoleculeType is used instead.</rdfs:comment>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasMoleculeType</dcr:hasClassAsRangeProperty>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/43">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Institute of Immunology (ÚI) was established in 1995. It was created from the merger of the Department of Clinical Immunology at the Motol Teaching Hospital and the Institute of Immunology of the Second Medical Faculty into a single institution active in health care and teaching. Since 1995, the Institute of Immunology underwent many changes in terms of the organization of its activities, a significant expansion of its health care and teaching components and an intensifying of its research activities. The Institute is awarded research grants from the Ministries of Education a Health and International EU grants. Employees of the institute published many original articles in renowned journals and are authors of textbooks and monographs. At present, the Institute is one of the most significant immunology workplaces in the Czech Republic; it plays an important role through the cooperation with other departments of the Motol Teaching Hospital in the diagnosis and treatment of primary immunodeficiencies, autoimmune disorders and leukemia primarily in children. Successful developments in the field of cancer immunology based on the research into tumour vaccines on the basis of dendritic cells. In 2003, the Institute was recognized as a workplace fulfilling the requirements of the American Federation of Societies for Clinical Immunology (FOCIS) and became part of the international chain of Centers for Clinical Immunology.

Research  &gt;  Working groups

* Immunotherapy
Research Aim: Long term goal of the group of tumor immunotherapy is the development of dendritic cell based cancer vaccine. Administration of this vaccine should induce tumor cell-specific induce response and contribute to current treatment options. Dendritic cells represent the most efficient antigen presenting cells as they activate primary immune response. Protocols developed in 1990s allow for generation of large numbers of dendritic cells from monocytes circulating in peripheral blood. Dendritic cell biology and their use in the immunotherapy of tumors have been studied at the Institute of Immunology for more than 10 years as documented by the list of publications . In collaboration with renowned European laboratories, we develop protocols for dendritic cell-based vaccines for the treatment of ovarian cancer, prostate cancer and for patients with hematological malignancies. First step of vaccine development is generation of large numbers of denritic cells from patient's monocytes. Dendritic cells are then incubated with various forms of tumor antigens, activated and subsequently administered to patients in defined vaccination programs. Cancer vaccine generation has to be done under strictly aseptic conditions. In 2007, University hospital Motol built a Cell therapy unit, first unit in Czech republic that allows for generation of clinical grade products for cellular therapy, including cancer vaccines. 

Principal Investigators prof. Jirina Bartunková, M.D., Ph.D., MBA., Radek Špíšek, M.D., Ph.D. 

Financial support: Research of dendritic cells at the Institute of Immunology, Charles University, 2nd Medical School has been supported by grants from Ministry of Education, grant agencies, grants form European Union.

* Primary immunodeficiencies</rdfs:comment>
    <rdfs:label>Institute of Immunology 2nd Medical School, Charles University</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0600065">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_defined protocol application</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_655">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A mouse or a rat strain is a group of animals that is genetically uniform. Strains are used in laboratory experiments. Mouse strains can be inbred, mutated or genetically engineered, while rat strains are usually inbred.</OBI:IAO_0000115>
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://en.wikipedia.org/wiki/Strain_(biology)</OBI:IAO_0000119>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">strain</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_240">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCL2</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chemokine (C-C motif) ligand 2</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/163">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Four patients are enrolled in a clinical trial for vaccination with DC loaded with apoptotic leukemic cells. A strong type I T cell response has been induced. Preliminary data also indicate reduction of circulating tumor cells. No adverse effects have been observed.</rdfs:comment>
    <rdfs:label>4 patients with chronic lymphocytic leukemia</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/50">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/361"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/183"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/356"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/357"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/362"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/184"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/516"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/217"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/306"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/75"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/517"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/149"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/363"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/44"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/182"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/364"/>
    <rdfs:label>Nicolas Glaichenhaus</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/367"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/158"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/159"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/365"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/42"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/43"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/366"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/48"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/360"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/132">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Justin John</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A46">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400002">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_735</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/171">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Anette Bauer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/220">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/8"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>There is data available on translation during DC/T cell interaction in presence or absence of cognate antigenic peptides. 

Efforts on the definition of a novel way of monitoring DC and T cell activation as well as studying viral infections were finalized. The puromycin-based technology (SUnSET, surface sensing of translation) was applied to monitor translation by FACs during DC/T cell interaction in presence or absence of cognate antigenic peptides. It was demonstrated that translation activation is an excellent read-out for early antigen specific T cell activation by DCs. Surprisingly, this phenomenon was mTOR independent (Rapamycin insensitive).</rdfs:comment>
    <rdfs:label>Monitoring translation during DC/T cell interaction</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/71">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/96"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>77 patients have been enrolled in two Phase III trials from 2 institutions testing dosing or duration of IM administration (EORTC 62005 and BFR14 trials).</rdfs:comment>
    <rdfs:label>77 GIST patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_35341">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">steroid</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000057">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fibroblast</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CL: A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules.
BTO: A connective-tissue cell of mesenchymal origin that secretes proteins and especially molecular collagen from which the extracellular fibrillar matrix of connective tissue forms.</OBI:IAO_0000115>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fibroblasts</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000912">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/400">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were vaccinated with 4 peptides (MAGE-A3, gp100, NA17 and tyrosinase) presented by HLA-A2 and monitored. We measured responses to these peptides injected with Montanide, but did not know whether the Montanide adjuvant was important for these T cell responses. We therefore injected the same peptides without adjuvant, and no response was observed. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.</rdfs:comment>
    <rdfs:label>NA17 peptide vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/231">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Daniel Francal</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A47">
    <owl:intersectionOf rdf:nodeID="A48"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/563">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>APC-labeled streptavidin was used to detect intracellular yeasts/spores.</rdfs:comment>
    <rdfs:label>APC-labeled streptavidin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_729">
    <rdfs:label>blocking step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A blocking step is a step in a protocol that specify how to carry out a blocking of a biomaterial so it can no longer for a certain period of time fulfil its function.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">blocking step</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inhibition</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/14">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/498"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/497"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_758"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Staining of GM-DC/Raw with anti-CD11c antibodies</rdfs:comment>
    <rdfs:label>Staining of GM-DC/Raw</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0070743">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin-23 complex</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-23</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin 23</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-23</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-23 complex</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A49">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/566">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/140"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>To assess the importance of ROS production in DC killing ability, 2-(3,4-Dihydroxyphenylimino)-imidazolidine (10 microM) was added to the dendritic cells 30 minutes before stimulation.</rdfs:comment>
    <rdfs:label>DPI</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/480">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/37"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/36"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocyte-derived DCs were added to the yeast at a final concentration of 5x105 cells/ml into 96-well plates.</rdfs:comment>
    <rdfs:label>Yeast strains with added MoDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_654">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000180"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mg/ml</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/166">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This vaccine is composed of DC pulsed with 2 to 3 MAA-derived peptides (combinations of MAGE-3.A2, MAGE-C2.A2 or Na17.A2). It was tested in a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines.</rdfs:comment>
    <rdfs:label>MAA-derived peptide pulsed DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000214">
    <rdfs:label>Cell culture</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell culture</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400008">
    <rdfs:label>flow cytometer analyzer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/133">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Luis Graca</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_767">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An immunofluorescence assay step is a step in a protocol that specifies how to produce information on an evaluant using immunofluorescent dyes.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_766"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immunofluorescence assay step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/75">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Post-vaccination frequencies of the T cells of anti-NY-ESO-1.A2 and anti-Tyrosinase.A2 were found to be &gt;= 10-fold higher than that of pre-vaccinations, indicating a specific CTL response to these vaccinations.

An analysis performed on PBL collected after the 3 vaccinations of cycle 2 clearly shows that the frequencies for both anti-NY-ESO-1.A2 and anti-Tyrosinase.A2 T cells are still elevated.</rdfs:comment>
    <rdfs:label>anti-NY-ESO-1.A2 T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasKnowledgeable">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#isKnowledgeableAbout"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any DC-THERA resource to a person who is a knowledgeable contact person for this resource.</OBI:IAO_0000115>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has knowledgeable contact person</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A50">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_766">
    <rdfs:label>assay step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">assay step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An assay step is a step in a protocol that specifies how to produce information about some evaluant.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/74">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:hasTissueType rdf:resource="http://dc-research.eu#dctheradir_445"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tests were performed on frozen peripheral blood leukocytes (PBL) obtained from leukapheresis or buffy-coat collections performed before and after the 6 vaccinations in Cycle 1 and after the 3 vaccinations of Cycle 2. The fresh PBL samples were collected from UTCM (Hôpital Erasme, ULB) and were transferred to Ludwig Institute where the freezing of the samples and analyses were performed. </rdfs:comment>
    <rdfs:label>frozen peripheral blood leukocytes (PBL)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/174">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/12"/>
    <rdfs:label>Chris Jenkins</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/11"/>
    <rdfs:comment>Lab Manager
Professor Fiona Powrie Group
Mr Jenkins is no longer working with Dr Macpherson who has retired and was a partner in DC THERA.</rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/195"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/9"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/441">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The crude population of DC is divided into the three known splenic subsets (CD8+, CD4+, DN DC) using Fluorescence activated cell sorting (BD FACS Aria). This procedure allowed to obtain highly pure fractions of each subset. However, because DC are a very rare population, this method is very material- and cost-intensive. Furthermore, it is not surprising that the obtained cell numbers of each subset after isolation are below 107. However, these cell numbers should be sufficient for proteomic investigations. The proteomes of all three subsets using mass spectrometry is in progress.</rdfs:comment>
    <rdfs:label>CD4+ DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasProtocolStep">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has protocol step</rdfs:label>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000059">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD1a</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000002025</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/15">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/498"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/495"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/496"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_747"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Coculture of DCs and cells to be taken up (1(-2)x10^5 + 1(-2)x10^5 cells in 12-well) for 4 h to 24 h at 37°C</rdfs:comment>
    <rdfs:label>Coculture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A51">
    <owl:unionOf rdf:nodeID="A52"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0043234">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/47">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Academic Hospital, Afd Inwendige Geneeskunde</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_728">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">the partial or complete removal of an organ or other bodily structure.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0600022"/>
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia</OBI:IAO_0000119>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">resection</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/165">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This vaccine consists of DC loaded with a single MAA-derived peptide (MAGE-3.A1 or -A2 or Na17.A2). It was tested in a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines. </rdfs:comment>
    <rdfs:label>Single MAA-derived peptide DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A53">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_653">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ng/ml</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000180"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/565">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/125"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000427"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Zymolyase was used to treat DC, which were used in a study of microrganism survival following uptake by DCs.</rdfs:comment>
    <rdfs:label>zymolyase for the treatment of DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/481">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/38"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>MoDC were stimulated with yeast.</rdfs:comment>
    <rdfs:label>MoDC, stimulated</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A48">
    <rdf:rest rdf:nodeID="A49"/>
    <rdf:first rdf:nodeID="A44"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/45">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Università degli Studi di Foggia</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000794">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-Killer cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytotoxic T cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CTL</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD8+ T-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">killer T cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytotoxic T cell</dcr:hasExactSynonym>
    <rdfs:label>cytotoxic T lymphocyte</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytotoxic T lymphocyte</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-Killer cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD8+ T-cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000625"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">killer T cell</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000471">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">study design execution</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A54">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000234">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">trial statistician</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/134">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mai-Britt Zocca</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_768">
    <rdfs:label>substance detection step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A substance detection step is a step in a protocol that specifies how to detect a specific substance.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_766"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">substance detection step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/440">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The crude population of DC was divided into the three known splenic subsets (CD8+, CD4+, DN DC) using Fluorescence activated cell sorting (BD FACS Aria). This procedure allowed to obtain highly pure fractions of each subset. However, because DC are a very rare population, this method is very material- and cost-intensive. Furthermore, it is not surprising that the obtained cell numbers of each subset after isolation are below 107. However, these cell numbers should be sufficient for proteomic investigations. The proteomes of all three subsets using mass spectrometry is in progress.</rdfs:comment>
    <rdfs:label>CD8+ DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001458">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000109</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Toll-like receptor 7</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_9675">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pulmonary emphysema</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/73">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A vaccination trial with RNA transfected autologous DC was done with overlapping peptides covering the whole protein sequence of the tumor antigens MageA3, MelanA and Survivin. With this approach we monitored the immune responses of 8 vaccinated patients and of more than 15 other stage IV melanoma patients.</rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/173">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/274"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/277"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/121"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/279"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/276"/>
    <rdfs:label>Aude Bonehill</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/226"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/264"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/275"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/278"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/272"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/225"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/282"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/122"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_727">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prf1tm1Sdz/Prf1tm1Sdz transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C57BL/6-Prf1tm1Sdz/J</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_726"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#replaced_by">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">replaced by</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Annotation property to be used for obsolete classes to indicate by which class it has been replaced.</OBI:IAO_0000115>
    <OBI:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">(obsolete_class_A) replaced_by  (namespace_longform#new_class_A)</OBI:IAO_0000112>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/46">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Department of Medical and Molecular Genetics occupies 3 floors of Guy’s Tower which are currently undergoing total refurbishment into state-of-the art laboratories and IT facilities through a Wellcome Trust JIF/SRIF award, and also supported by the Guy’s and St Thomas’ Charity. Closely associated with, and embedded within, the Department are the NHS clinical diagnostic laboratories and the SE Thames clinical genetics service.

Over the last five years the emphasis of our research has shifted from mapping of Mendelian disease-related genes towards functional genomics and cell and molecular biology, in areas including cancer genetics, neurogenetics, the control of gene expression and epigenetics. We have the necessary expertise and instrumentation (eg microarray expression analysis, bioinformatics, confocal microscopy), and have established a high-throughput genomics and proteomics facility (in collaboration with the Dental Institute). 

Diseases on which we are working at a cellular, functional level include; breast cancer, leukaemia, Fanconi anaemia, Huntington’s disease, various developmental anomalies, the muscular dystrophies, and osteopetrosis.</rdfs:comment>
    <rdfs:label>King's College London School of Medicine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A52">
    <rdf:rest rdf:nodeID="A53"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/16">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_765"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Take supernatant and freeze at -80°C for analysis of DC-stimulation</rdfs:comment>
    <rdfs:label>Supernatant freezing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/77">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The patients were vaccinated with 4 peptides (MAGE-A3, gp100, NA17 and tyrosinase) presented by HLA-A2. 

We measured responses to these peptides injected with Montanide, but did not know whether the Montanide adjuvant was important for these T cell responses. Indeed, melanoma patients may mount spontaneous responses to these antigenic peptides. We therefore injected the same peptides without adjuvant, and no response was observed. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.</rdfs:comment>
    <rdfs:label>Melanoma patients vaccinated with peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/135">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/147"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/146"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/145"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Head of team 4 : 
Immune therapy in mesothelioma and AML</rdfs:comment>
    <rdfs:label>Marc Gregoire</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000322">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell line factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasExperimentalFactorType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">experimental factor type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type experimental factor.</OBI:IAO_0000115>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DCTHERADIR dataset has at least one DCTHERADIR experimental factor. SHORTCUT.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/53">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Linda Forsberg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/168">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Fabs that bind strongly to L-SIGN, but to a lesser degree or not at all to dendritic cell-specific ICAM-grabbing nonintegrin (DC-SIGN) were isolated and characterized. We believe that the isolated Abs may be useful for selective delivery of Ags to DC-SIGN- or L-SIGN-bearing APCs for the modulation of immune responses and for blocking viral infections.</rdfs:comment>
    <rdfs:label>Fab fragments antibody</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/24">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>(Basic manufacturing and QC SOPs (Generation of Peptide loaded DCs, Generation of cytokines and media components, Generation of autologous plasma and serum, Staining of cells for FACS Analysis, Cell Counting by Trypanblue Staining) have been provided to DC-THERA participants and associated partners via DC-THERA intranet. )</rdfs:comment>
    <rdfs:label>Cell Counting by Trypanblue Staining</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/482">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In a process of total RNA extraction from S. cerevisia, the cells were collected and the pellet were resuspend in 3.6 ml AE Buffer.</rdfs:comment>
    <rdfs:label>Yeast cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A55">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0003700"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100015">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_652">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000190"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stimuli:DCs</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/377">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/87"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <rdfs:comment>The leukapheresis product is from patients with advanced (stage III or IV) melanoma. It is used to provide sources for tumor antigens as well as monocytes and T cells, which are isolated from the leukapheresis product by elutriation.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdfs:label>Leukapheresis product</rdfs:label>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/88"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/560">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have conducted a phase I long peptide vaccination trial with p53 peptides in Montanide adjuvant in patients with colorectal cancer or ovarium cancer.</rdfs:comment>
    <rdfs:label>Patients with ovarium cancer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/176">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/136"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Helena Harlin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_469">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_western blot</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/MESH#MESH_E.05.478.594.410.320.200</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/17">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/500"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_749"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Trypsinize cells and fix in 4 % PFA (or formalin)</rdfs:comment>
    <rdfs:label>Trypsinize</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/234">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Carmen Bäuerle</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17089">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Glycoprotein</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A compound in which a carbohydrate component is covalently bound to a protein component.</OBI:IAO_0000115>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glycoproteins</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/49">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Institute of Tropical Medicine in Antwerp, Belgium (ITM) is one of the world's leading institutes for training, research and services delivery in tropical medicine and health care in developing countries. It is strongly committed to academic excellence and genuine partnership for the promotion of "Health Care for All". 
</rdfs:comment>
    <rdfs:label>Institute of Tropical Medicine Antwerp</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/405">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were vaccinated with peptide-pulsed DC (MAGE-A3, gp100, NA17 and tyrosinase), while other patients were vaccinated with peptides +/s adjuvant or viral vectors (ALVAC canarypox virus containing a MAGE-A3 minigene). There was a correlation between tumor regression and detection of anti-MAGE-3.A1 CTL responses. </rdfs:comment>
    <rdfs:label>Melanoma patients vaccinated with peptide-pulsed DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000422">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CARO#CARO_0000043">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000222">
    <rdfs:label xml:lang="en">obsolete_property1</rdfs:label>
    <rdfs:subPropertyOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteProperty"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/443">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/23"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_63836"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A proteomics map of lysosomes purified from non-activated and activated mouse DCs was established. </rdfs:comment>
    <rdfs:label>Lysosomes from mouse DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000188">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pathology review board</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000057">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001483</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD16</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/76">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Post-vaccination frequencies of the T cells of anti-NY-ESO-1.A2 and anti-Tyrosinase.A2 were found to be &gt;= 10-fold higher than that of pre-vaccinations, indicating a specific CTL response to these vaccinations.

An analysis performed on PBL collected after the 3 vaccinations of cycle 2 clearly shows that the frequencies for both anti-NY-ESO-1.A2 and anti-Tyrosinase.A2 T cells are still elevated.</rdfs:comment>
    <rdfs:label>anti-Tyrosinase.A2 T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/54">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/1"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/293"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/281"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/383"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/292"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/110"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/2"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/378"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/536"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/294"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/535"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <rdfs:label>Håkan Mellstedt</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/375"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/380"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/382"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/49"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/379"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/296"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/537"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/381"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/114"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/377"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/64"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/92"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/29"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/136">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Miodrag Colic</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A56">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/483">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_35225"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In a process of total RNA extraction from S. cerevisia, yeast cells were collected and the pellet were resuspend in 3.6 ml AE Buffer (AE=50mM NaAcetate pH 5.2, 10mM EDTA).</rdfs:comment>
    <rdfs:label>AE Buffer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/23">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>(Basic manufacturing and QC SOPs (Generation of Peptide loaded DCs, Generation of cytokines and media components, Generation of autologous plasma and serum, Staining of cells for FACS Analysis, Cell Counting by Trypanblue Staining) have been provided to DC-THERA participants and associated partners via DC-THERA intranet. )</rdfs:comment>
    <rdfs:label>Staining of cells for FACS Analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/167">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This vaccine consists of G4-DC loaded with 8 different peptides.  It was tested in a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines.</rdfs:comment>
    <rdfs:label>peptide-loaded G4-DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_651">
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://en.wikipedia.org/wiki/Multiplicity_of_infection</OBI:IAO_0000119>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000190"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The multiplicity of infection or MOI is the ratio of infectious agents (e.g. phage or virus) to infection targets (e.g. cell). For example, when referring to a group of cells inoculated with infectious virus particles, the multiplicity of infection or MOI is the ratio defined by the number of infectious virus particles deposited in a well divided by the number of target cells present in that well.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MOI</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33575">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24833"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">carboxylic acid</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/18">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_766"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>FACS analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/378">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdfs:comment>This tumor lysate is from patients with advanced (stage III or IV) melanoma. It is used for the generation of a vaccine and loading of DC.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/90"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/88"/>
    <rdfs:label>Tumor lysate</rdfs:label>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/91"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/404">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Some melanoma patients were vaccinated with the MAGE-A3, gp100, NA17 and tyrosinase peptides presented by HLA-A2 plus the montanide adjuvant, while others were vaccinated with the peptides without the adjuvant or with ALVAC canarypox virus (containing a MAGE-A3 minigene) viral vectors. There was a correlation between tumor regression and detection of anti-MAGE-3.A1 CTL responses. </rdfs:comment>
    <rdfs:label>Melanoma patients vaccinated with peptides plus adjuvant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_36976">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nucleotides</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/235">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cristina Torriero</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/48">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The European Institute of Oncology was established to implement an innovative model for health and advanced research in the international oncology field. Its Division and Unit Directors come from eight European countries.
 
Conceived by Umberto Veronesi and inaugurated in May 1994, the Institute became a research hospital and treatment centre (IRCCS or “Istituto di Ricovero e Cura a Carattere Scientifico”) through the Ministerial Decree issued in January 1996. The European Institute of Oncology adopts the non-profit private-law organisation model and provides services through agreements with Italy’s National Health Service. 


 
In keeping with the standards of the most advanced international oncology centres, the Institute fully integrates different activities involved in the fight against cancer: prevention and diagnosis, health education and training, research and treatment.</rdfs:comment>
    <rdfs:label>Istituto Europeo di Oncologia IEO / European Institute of Oncology</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000423">
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/OBI_1000024"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_1100000">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/175">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Deborah Lynch</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/442">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The crude population of DC is divided into the three known splenic subsets (CD8+, CD4+, DN DC) using Fluorescence activated cell sorting (BD FACS Aria). This procedure allowed to obtain highly pure fractions of each subset. However, because DC are a very rare population, this method is very material- and cost-intensive. Furthermore, it is not surprising that the obtained cell numbers of each subset after isolation are below 107. However, these cell numbers should be sufficient for proteomic investigations. The proteomes of all three subsets using mass spectrometry is in progress.</rdfs:comment>
    <rdfs:label>DN DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/137">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/1"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Regis Josien</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/79">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/46"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC pulsed with MAGE-A3, gp100, NA17 and tyrosinase were used for vaccination of melanoma patients.</rdfs:comment>
    <rdfs:label>Peptide-pulsed dendritic cells (DC)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/51">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ann-Charlotte Ekelöf</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/445">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/80"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1773"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The role of IL-10 in the immune response to MTb was studied. We have identified that IL-10 plays an early and transient role in the control of the immune response to MTb and now show that this involves enhanced migration of IFNgamma producing CD4+ and CD8+ T cells into the lung rather than enhanced mycobacterial killing. The effects are accompanied by enhanced G-CSF, GM-CSF, TNF, IL-6 and IL-17 levels although the enhanced clearance of bacilli in IL-10 deficient mice we now show is independent of IL-17.</rdfs:comment>
    <rdfs:label>Mycobacterium tuberculosis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100017">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/484">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In a process of total RNA extraction from S. cerevisia, 2 ml of preheated acid phenol (pH 4.3) were added to yeast cells that had been collected and the pellet resuspend in 3.6 ml AE Buffer (AE=50mM NaAcetate pH 5.2, 10mM EDTA).</rdfs:comment>
    <rdfs:label>preheated acid phenol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_650">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UBERON#UBERON_0000029"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">peripheral lymph node</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/26">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/118"/>
    <rdfs:label>Improving the efficacy of DC vaccines - ArcelisTM</rdfs:label>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/77"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Argos has developed a novel DC maturation method that dramatically improves DC immunopotency as assessed by in vitro assays compared to DCs matured using the common ‘cytokine cocktail’ method. This new maturation protocol involves transfecting CD40L-encoding RNA along with the tumor RNA payload after maturation with TNF-alpha, IFN-gamma, and PGE2.  DC prepared by this method secrete large amounts of IL-12 and no IL-10. This DC platform is now known as ArcelisTM.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A57">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_294708">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_exosome vesicle</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/GO#GO_0070062</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/562">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000427"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>10 mg/ml sulfo-NHS-LC-biotin (Sigma-Aldrich) in 50 mM NaHCO3 pH 8.5 were used to biotinylate yeasts / spores for 2 hours at 4°C. The remaining reactive biotin molecules were inactivated by incubation in 100 mM Tris-HCl pH 8.0 for 40 minutes at 4°C. DCs were then treated with biotinylated spores/yeasts.</rdfs:comment>
    <rdfs:label>sulfo-NHS-LC-biotin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/379">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/90"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/88"/>
    <rdfs:comment>These monocyte come from an elutriation process from a metastatic lesion from stage III/IV melanoma patients and will be used for the generation of a vaccine and generation of tumour-lysated loaded DC.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/91"/>
    <rdfs:label>Monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/19">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/310"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/309"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/308"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/311"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_771"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Incubate cells in Fc-block (1:50 in PBS + 2 % FCS) 30 min on ice</rdfs:comment>
    <rdfs:label>Incubation of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/403">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were administered ALVAC canarypox virus containing a MAGE-A3 minigene, while others were vaccinated with MAGE-A3 peptide presented by HLA-A1, administered as peptide, and peptide-pulsed DCs. There was a correlation between tumor regression and detection of anti-MAGE-3.A1 CTL responses. </rdfs:comment>
    <rdfs:label>Melanoma patients vaccinated with ALVAC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_2377">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">multiple sclerosis</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/232">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Christine Raulfs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/178">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/219"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ivana Munitic</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750">
    <rdfs:label>Databases, factual</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Databases, factual</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">database</dcr:dcthera_label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Extensive collections, reputedly complete, of facts and data garnered from material of a specialized subject area and made available for analysis and application. The collection can be automated by various contemporary methods for retrieval. The concept should be differentiated from DATABASES, BIBLIOGRAPHIC which is restricted to collections of bibliographic references.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_50816">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">iron oxides</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000420">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_86697">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">peripheral blood cells</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">peripheral blood cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/138">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rik Scheper</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A58">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/444">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We examined whether plasmacytoid pDC are infected and/or activated by MTb, and whether they play a role in regulating bacterial clearance during acute MTb infection and if so how. We have compared these DC with myeloid DC and macrophages with respect to MTb infection. </rdfs:comment>
    <rdfs:label>Plasmacytoid DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000147">
    <rdfs:label>CD3 receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-3</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A59"/>
    <rdfs:subClassOf rdf:nodeID="A60"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD3 receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/52">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/375"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/379"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/380"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/537"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/114"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/382"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/383"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/378"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/64"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/536"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/2"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/377"/>
    <rdfs:label>Pavel Pisa</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/1"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/281"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/535"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/92"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/381"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/135"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/29"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/78">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The melanoma patients were vaccinated with a MAGE-A3 peptide presented by HLA-A1 without adjuvant, while other melanoma patients were vaccinated with ALVAC canarypox virus containing a MAGE-A3 minigene, or peptide-pulsed dendritic cells (DC). There was a correlation between tumor regression and detection of anti-MAGE-3.A1 CTL responses. </rdfs:comment>
    <rdfs:label>Melanoma patients vaccinated with peptides without adjuvant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/485">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/40"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The yeast cells were resuspent in 3.6 ml AE Buffer and then transferred in 15 ml tubes wit 200 µl 10% SDS (w/v). 2 ml of preheated acid phenol (pH 4.3) were added and the falcon were mixed by vortex.</rdfs:comment>
    <rdfs:label>Buffered S. cerevisia cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100016">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_933">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A binding site identification design type investigates protein binding sites on nucleic acids non-exact synonym: ChIP, chromatin immunoprecipitation, chromatin IP</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chromatin immunoprecipitation experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/25">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>BruCells has been actively involved in the discussion of the EMEA guideline on Cell Based Medicinal Products (CBMP). Catherine De Greef was present at the DC-THERA Cluster 4 Meeting in Bamberg (July 2007) where among other topics these guidelines were discussed and where the basis for a written statement has been worked out. During the finalisation of the statement BruCells has mainly put forward the notion that the guidelines are not suitable to CBMP for the authorization of investigational trials, but are applicable in the procedure of obtaining market approval.</rdfs:comment>
    <rdfs:label>EMEA guideline on Cell Based Medicinal Products (CBMP)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_F0001414">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">N ligand</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interacting selectively with the Notch (N) protein, a surface receptor.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Notch ligand</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A61"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_63887"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A62">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/169">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tetanus toxide epitope embedded into a L-SIGN/DC-SIGN-cross-reactive Ab was targeted to dendritic cells. We believe that the isolated Abs may be useful for selective delivery of Ags to DC-SIGN- or L-SIGN-bearing APCs for the modulation of immune responses and for blocking viral infections.</rdfs:comment>
    <rdfs:label>L-SIGN/DC-SIGN-cross-reactive antibody</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/561">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This vaccine was used in patients with colorectal cancer or ovarium cancer. It was well tolerated and robust p53-specific T cell responses were induced.</rdfs:comment>
    <rdfs:label>p53 peptides in Montanide adjuvant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_468">
    <rdfs:label>fluorescence microscope</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0400169"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">epifluorescent microscope</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fluorescence microscope</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/402">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were vaccinated with peptides (MAGE-A3, gp100, NA17 and tyrosinase), with and without montanide as adjuvant. No response was observed when vaccinating without the adjuvant. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.</rdfs:comment>
    <rdfs:label>Montanide as adjuvant for vaccination with peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/177">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/214"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/200"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>PhD 
Department of Tumor Immunology, NCMLS/278 TIL
Radboud University Nijmegen Medical Center</rdfs:comment>
    <rdfs:label>Ingrid Zeelenberg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000056">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001456</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD15</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400044">
    <rdfs:label>flow cytometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Oncogene">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cancer Promoting Genes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cancer Promoting Gene</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cancer-Promoting Genes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">oncogenes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cancer-Promoting Gene</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oncogene</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000798">
    <rdfs:label>gamma-delta t cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gamma-delta t cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gamma-delta T-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gamma-delta T-lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gamma-delta t lymphocyte</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/409">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were matured using CpG-DNA as TLR9 ligand. Mature DCs upregulated CD80, CD86, MHC class II and produced cell type specific cytokines. CD8+ myeloid DCs “cross-presented” exogeneous Ags (Ovalbumin).</rdfs:comment>
    <rdfs:label>Matured myeloid DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000313">
    <rdfs:label xml:lang="en">obsolete_utilizes_device</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:subPropertyOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteProperty"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/67">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_37163"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4751"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Beta-glucan receptor, mannan receptor and chitin receptor are blocking by a pre-treatment of DCs with the ligand antagonist laminarin (500 micrograms/ml) mannan (500 micrograms/ml) and chitin (500 micrograms/ml) respectively before exposure to fungi.</rdfs:comment>
    <rdfs:label>Inhibition assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_487">
    <rdfs:label>Post-clinical protocol</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Post-clinical protocol</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A post-clinical protocol is a protocol to be used after the clinical trial. Example: Monitoring of patients after conclusion of a surgery.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/61">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/176"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/109"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_470"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The gene gun system available to the laboratory was used, e.g., for micro-particle bombardment of murine skin.</rdfs:comment>
    <rdfs:label>Gene gun</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_427">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CRO</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_424"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000053">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD133</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001786</dcr:replaced_by>
    <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD133</oboInOwl:hasOBONamespace>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1000024">
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/OBI_1000023"/>
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/OBI_0100067"/>
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/OBI_0000423"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/343">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Senior Microarray Facility Manager</rdfs:comment>
    <rdfs:label>Dilair Baban</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_74402">
    <rdfs:label>gene</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">genes</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gene</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/98">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Antonella Palmiero</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A63">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/373">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This is spleen from patients that undergo surgery due to clinical situations that do not affect the immune system (most frequently malformations). 

We have attempted to identify and characterize CD8T lymphocyte populations in humans. We compared the distribution of phenotypically distinct cell sets using seven color staining in the blood, lymph nodes and spleen. We found that the addition of other markers allow to subdivide N, CM, TEM and TEMRA populations in additional cell types.</rdfs:comment>
    <rdfs:label>Spleen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/57">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sonja Croes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_3371">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chondrosarcoma</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/277">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/98"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_249"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CD1 molecules that are subsequently to be refolded in vitro in order to generate CD1 tetramers.</rdfs:comment>
    <rdfs:label>CD1 molecules</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_392">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD69</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-69</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CLEC2C</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A64"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_63887"/>
    <rdfs:subClassOf rdf:nodeID="A65"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701386">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-12 subunit p40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CYTOTOXIC LYMPHOCYTE MATURATION FACTOR 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytotoxic lymphocyte maturation factor 40 kDa subunit</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL23</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL12p40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CLMF p40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-23</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-12B</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 23</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-23</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-12 p40</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CLMF2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-12 subun</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NKSF</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK cell stimulatory factor chain 2</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL12B</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/486">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/40"/>
    <rdfs:comment>After 10’ of incubation in 65 °C water bath, the samples were incubated on ice.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/42"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/41"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/42"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdfs:label>Buffered S. cerevisia cells, incubated</rdfs:label>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/41"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/43"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_721">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Susceptibility to Asthma-model mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies are distinct</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A66">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_25029">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_35366"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cysteinyl leukotrienes</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Linear C20 endogenous metabolites of arachidonic acid (icosa-5,8,11,14-tetraenoic acid) containing a terminal carboxy function and four or more double bonds (three or more of which are conjugated) as well as other functional groups.

wikipedia: Examples of leukotrienes are LTA4, LTB4, LTC4, LTD4, LTE4, and LTF4.

LTC4, LTD4 and LTE4 are often called cysteinyl leukotrienes due to the presence of the amino acid in their structure. Together, the cysteinyl leukotrienes make up the slow-reacting substance of anaphylaxis (SRS-A).</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/89">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/64"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_337"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/74"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/61"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/120"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/75"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/76"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/62"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_338"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdfs:label>A Phase IB/II Study of Immunotherapy with Autologous Dendritic Cells Pulsed with Multiple HLA-A2 and MAGE-3.DP4 Peptides in Metastatic Cutaneous Melanoma Patients</rdfs:label>
    <rdfs:comment>At the end of 2004 BruCells has initiated two identical clinical studies entitled: “A Phase IB/II Study of Immunotherapy with Autologous Dendritic Cells Pulsed with Multiple HLA-A2 and MAGE-3.DP4 Peptides in Metastatic Cutaneous Melanoma Patients”. Patients received sequential immunizations with autologous dendritic cells pulsed with 8 HLA-restricted HLA-A2 peptides and a MAGE-3.DP4 peptide. They were randomized to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4). At the end of 2005 the study was prematurely terminated due to low recruitment, data on patient responses is available.

2 patients received vaccines up to cycle 3. One of them is an I3 patient (E501) who has received 9 vaccines with peptides only. The other one is a G4 patient (E507) who has received 6 vaccines with peptide only. Both patients received a sequence of six immunizations every two weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4 in Cycle 1. In Cycle 2, they received a sequence of three immunizations every six weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4. Initially, in Cycle 3, immunizations have been continued with peptide-only injections of all 9 peptides except Tyrosinase at 12 weeks intervals. For the continuation of the vaccinations the clinicians have decided to inject the patients at 6 months intervals. Both patients who clinically showed Partial Response at the end of cycle 1 are currently doing well under this treatment, but at the beginning of 2008 the vaccination program has been ended.
Both patients had clinically shown Partial Response at the end of cycle 1 and were in complete remission in the course of cycle 3.

For the analysis of the immune responses, specific CTL directed against the 8 antigens was assessed by using restimulation in vitro, followed by staining with the corresponding tetramer and cloning of the tetramer-positive lymphocytes. The result of these tests were considered positive if the post-immunization frequency of the different anti-TAA CTLp among the CD8+ T cells was 10-fold higher than the one encountered before vaccination.
For both patients the tests were performed on frozen peripheral blood leukocytes (PBL) obtained from leukapheresis or buffy-coat collections performed before and after the 6 vaccinations in Cycle 1 and after the 3 vaccinations of Cycle 2.

The fresh PBL samples were collected from UTCM (Hôpital Erasme, ULB) and were transferred to Ludwig Institute where the freezing of the samples and analyses were performed.

Frequencies of precursors of CD8 T cells stained by a tetramer containing the specific peptide had shown for patient E501 post-vaccination frequencies of the T cells of anti-NY-ESO-1.A2 and anti-Tyrosinase.A2 that were &gt;=10-fold higher than that of pre-vaccinations, indicating a specific CTL response to these vaccinations.

An analysis performed on PBL collected after the 3 vaccinations of cycle 2 clearly shows that the frequencies for both anti-NY-ESO-1.A2 and anti-Tyrosinase.A2 T cells are still elevated.

For E507 no immunological response to the vaccinations had been observed after cycle 1 and a new analysis on PBL collected after cycle 2 did not show any change.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/334">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These conjugates were tested in vivo by either direct vaccination or ex vivo DC loading prior to vaccination. Both approaches show similar effectiveness in CTL priming.</rdfs:comment>
    <rdfs:label>TLRligand-long peptide conjugates</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/28">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/27"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/77"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>A Phase II Study Testing the Activity and Safety in successfully ART-Treated Subjects Infected with HIV in Combination with ART Followed by ART Interruption. 

Study Design: The study design is identical to the Phase I study except that after the fourth dose patients will begin a drug treatment interruption period while receiving additional immunizations during that period. This provides an opportunity to assess the impact of the Arcelis therapy on viral load. Current status: Argos has received regulatory approval for this study and is actively accruing patients.</rdfs:comment>
    <rdfs:label>Phase 2a Protocol for the Phase 2 HIV study</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/68">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/210"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdfs:label>Isolation of naive T cells</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/478"/>
    <rdfs:comment>Untouched naive CD4+ T cells are isolated from CD14- PBMC with a combination of magnetic sorting.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_488">
    <rdfs:label>Other protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Other protocol</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Undefined protocol</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/408">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Studies were carried out demonstrating that DC and other cell types can be activated in vitro by transfection with single stranded viral or synthetic RNA containing 5’ phosphates.</rdfs:comment>
    <rdfs:label>Single stranded viral or synthetic RNA containing 5’ phosphates</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_426">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A67"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glucocorticoid-induced tumor necrosis factor receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GITR</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/62">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/158"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_475"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The MRI facility available in the laboratory is used, among other things, to image vaccines.</rdfs:comment>
    <rdfs:label>MRI facility</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/ID#ID_0000035">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fusion protein role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000054">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD135</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000002001</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000427">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_63887"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/333">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These Treg were induced after treatment of primed mice with intact anti-CTLA-4 antibodies. These regulatory T cells inhibit Th1 responses, in vitro and in vivo, and repress experimental intestinal inflammation, by a mechanism involving IL-10 and IDO.</rdfs:comment>
    <rdfs:label>Regulatory T cells expressing high levels of ICOS and producing IL-10</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_313">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33839"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PLGs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PLG</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">poly(D,L-lactide-co-glycolide)</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1000023">
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/OBI_1000024"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/179">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/264"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/265"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/416"/>
    <rdfs:label>Joeri Aerts</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/274"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/415"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/272"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/269"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/225"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/80"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400170">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/97">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/161"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/160"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/5"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/35"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Christian Luber</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/276">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>By immunizing mice with ovalbumin-conjugated anti-Siglec-H Ab in the presence of CpG, we demonstrated generation of antigen-specific CD8 T cells in vivo.</rdfs:comment>
    <rdfs:label>Immunized mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_393">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">aminobiphosphonate</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">aminobiphosphonates</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24833"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A68">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_27649">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dextran</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_37163"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/487">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/42"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>2 ml of acid phenol were added to the buffered and incubated S. cerevisia cells after transferral of the supernatant to a new tube.</rdfs:comment>
    <rdfs:label>Acid phenol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/374">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The cell populations which infiltrate progressive versus regressing P815 mastocytoma were examined in order to identify cells which display immunosuppressive properties. We found changes in regulatory T cells populations as well as in the “myeloid suppressor cells”.</rdfs:comment>
    <rdfs:label>Cell populations which infiltrate progressive P815 mastocytoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_720">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">either: 129Rl.Cg-Foxp3sf or (involves: 101/Rl * C3Hf/Rl * STOCK MR)</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Foxp3sf/Y transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_719"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_86713">
    <rdfs:label>Peripheral Blood Mononuclear Cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Peripheral Blood Mononuclear Cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_86697"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Peripheral blood monocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PBMC</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_425">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SME</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_424"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000070">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/27">
    <rdfs:label>Phase 1 Protocol for phase 1 HIV clinical study</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.obofoundry.org/obo/OBI_0100016"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/119"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_211"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/77"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/28"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/92"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>This is a Pilot Study (Phase I/II) Testing the Immunologic Activity and Safety of AGS-004, an Autologous HIV Immunotherapeutic, in HIV-Infected Adults on HAART. 

Study Design: Patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART will be administered 4 monthly doses of the Arcelis product.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/119">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_768"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Activated T cells are detected by their expression of CD137.</rdfs:comment>
    <rdfs:label>Detection of activated T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_549">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cellular microparticle</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">microparticles</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/267">
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000634"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/SO#SO_0000276"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>The goal of this initiative is to obtain sufficient genomic data and a reference data set from retrospective studies of a large number of stored human DC samples to understand the genetic basis of inter-donor variability in responses to DC maturation stimuli. ‘Illumina’ microarrays rather than the ‘Affymetrix’ platform will be used for the necessary transcriptional profiling and subsequent data analysis.

Jointly, P2 and P6 identified a large number of stored samples of DC from melanoma patients (who had been treated in clinical trials of DC-based therapy at the two respective centres) that would be suitable for subsequent analysis. However, it further became clear that there were differences in the techniques that had been used to freeze the samples at different period. This necessitated a pilot experiment to compare and assess the suitability (e.g. RNA stability) of different samples frozen in different ways. First results are available. These revealed that all stored samples could be analysed in detail, and it was further decided to process the samples such that analysis of micro-RNA expression could be undertaken at a later stage. Patient samples have been shipped from the two centres to the Wellcome Trust Centre for Human Genetics and the main ‘reference experiment’ commenced at the beginning of 2009.</rdfs:comment>
    <rdfs:label>Genetic variability data</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000311">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:subPropertyOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteProperty"/>
    <rdfs:label xml:lang="en">obsolete_is_device_for</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/69">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Untouched naive CD4+ T cells are co-coltured with fungi -pulsed DCs and then the polarization is assessed by flow cytofluorimetry and cytokine production.</rdfs:comment>
    <rdfs:label>Priming of naive T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasMoleculeType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">molecule type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type molecule.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_489">
    <rdfs:label>Protocol step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Protocol step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdfs:subClassOf rdf:nodeID="A69"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_286">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/IMR#IMR_0000151</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_TCR</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000236">
    <rdfs:label>B cell</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/279">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The moDCs are used in the DERMA-ER-DC 05 trial.  
They are multipeptide loaded cytokine matured moDC + prior Treg elimination by 3x ONTAK treatment [5µg/kg]. 8 patients are enrolled and receive this substance.</rdfs:comment>
    <rdfs:label>Multipeptide loaded cytokine matured moDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001013">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17239">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36976"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytidine diphosphate</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytidine 5'-pyrophosphate</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CDP</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/407">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The immunotherapy potential of DC, pulsed with tumor antigens, was evaluated in EG7-OVA and P815 tumor models. 

Depletion of natural regulatory T cells in these tumor bearing mice resulted in rejection of P815 cells, but not EG7-OVA, suggesting that regulatory T cells have a stronger impact on immune responses against weakly immunogenic or auto-antigen (P1A). </rdfs:comment>
    <rdfs:label>Tumor-bearing mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_463">
    <rdfs:label>analysis software</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">analysis software</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000010"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Analysis software is a type of software that has the purpose of performing analysis.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/341">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Matthijs Kramer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/488">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>4 ml of chloroform (Fischer BP1145-1) were added to buffered and incubated S. cerevisia cells in a process of total RNA extractions.</rdfs:comment>
    <rdfs:label>Chloroform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/96">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/442"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/5"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/4"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/6"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/47"/>
    <rdfs:label>Matthias Mann</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/102"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/160"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/158"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/159"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/161"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/153"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/143"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/439"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/440"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/441"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/293"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/157"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasStimulus">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:domain rdf:nodeID="A70"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bio material stimulus</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset or a bio-material with a biomaterial. As this would make the ontology OWL full, the annotation property hasStimulusType is used instead.</rdfs:comment>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasStimulusType</dcr:hasClassAsRangeProperty>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0004872">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0003674"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">receptor activity</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/375">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/86"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/87"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Patients underwent surgical removal of a metastatic lesion and leukapheresis at the beginning of the trial to provide sources for tumor antigens as well as monocytes and T cells, which will be isolated from the leukapheresis product by elutriation. </rdfs:comment>
    <rdfs:label>Metastatic lesion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/266">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Currently there is no knowledge about the relevance of MDSC in ovarian cancer patients. However, it is known that both Tregs and suppressive macrophages are increased in this malignancy and have been suggested to correlate with worse prognosis. 

In order to obtain data, we are collecting blood and ascitic fluid of ovarian cancer patients to study the presence of immature myeloid populations as compared to healthy donor blood. We have identified two candidate populations that will be tested for the ability to suppress T cells. We also aim to characterize these cells phenotypically and will study potential suppressive mechanisms. Collection of material for this project is ongoing.</rdfs:comment>
    <rdfs:label>Phenotype and function of myeloid derived suppressor cells in ovarian cancer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/55">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/290"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/38"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/296"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/114"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/327"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/382"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/36"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/536"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/331"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/92"/>
    <rdfs:comment></rdfs:comment>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/375"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/161"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/128"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/236"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/155"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/110"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/215"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/281"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/195"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/326"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/62"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/312"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/381"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/330"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/289"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/380"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/329"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/379"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/49"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/535"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/160"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/136"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/579"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/1"/>
    <rdfs:label>Rolf Kiessling</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/578"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/291"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/377"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/197"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/328"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/29"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/378"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/45"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/135"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/383"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/163"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/62"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/537"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/162"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/577"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/196"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/64"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_424">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000245"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">industrial organization</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/336">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establish routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD8 surface markers (and additionally, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD8 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/129">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11623"/>
    <rdfs:label>« In vivo » responses to Ags</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_215"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <rdfs:comment>Our lab obtained data on the kinetics of effector gene expression and association in TCR-Tg CD8 cells responding to the male antigen and to Listeria-OVA with regard to « in vivo » responses to Ags. Surprisingly, instead of a single program of differentiation leading to the coordinated expression of all effector genes; we found that individual effector genes had different kinetics of expression and associated randomly generating several new effector cell types. These results are published in J. Exp. Med. Since these results were obtained in TCR-Tg mice, and thus could be different from those of normal cells, we initiated a long program comparing the behaviour of TCR-Tg cells specific for GP-33 peptide, with LCMV-specific populations: 

1) sharing the same GP33 specificity 
1a) present either in the same or 
1b) in normal mice; 

2) or other LCMV peptide specificities. 

We thus could demonstrate that the rules established for TCR-Tg cells also apply to endogenous T cells i.e, all CD8 T cells behave similarly. This Ms. is submitted to publication. </rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/76"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1637"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_168">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A71"/>
    <rdfs:subClassOf rdf:nodeID="A72"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 107</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-107</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107 receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700316">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IgG Fc receptor III</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type III FcgammaR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD16</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Low affinity immunoglobulin gamma Fc region receptor III precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcRIII</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type III FcgammaR (mouse)</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD16 antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcgammaRIII</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_402"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcg receptor III</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gamma RIII</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcgr3</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/60">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The lab has a midi-MACS magnetic cell sorting device by Miltenyi Biotec, Bergisch-Gladbach, Germany, that is used, e.g., to isolate monocytes from PBMC.</rdfs:comment>
    <rdfs:label>Midi-MACS® magnetic cell sorting device</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/40">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.obolibrary.org/obo/OBI_0000737"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000561"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/13"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/285"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Studies have continued and data obtained on the effects of biolistic (Gene Gun) delivery of vectors engineered to express distinct chemokines at the local skin site of mice. In particular, attention has been focussed on the recruitment of distinct subsets of DC to skin. This work, which is being performed in collaboration with PowderMed, a former SME now owned by Pfizer, may lead to the development of more targeted strategies to induce distinct T cell responses using this technology. A publication has resulted from this work.</rdfs:comment>
    <rdfs:label>Modulation of DC subsets in skin after Gene Gun adminstration of immuno-modulatory agents</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7163"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/3"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/423"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A73">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000143">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHC class Ia molecules</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHC class Ia molecule</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">classical MHC c</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHC class I molecule</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHC class I molecules</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Major histocompatibility complex class I</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">classical MHC class I molecule</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHC class I</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">major histocompatibility complex class I molecule</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">major histocompatibility complex class I molecules</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/406">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DC pulsed with tumor antigens were evaluated for their immunotherapy potential in EG7-OVA and P815 tumor models. Depletion of natural regulatory T cells in tumor bearing mice resulted in rejection of P815 cells, but not EG7-OVA, suggesting that regulatory T cells have a stronger impact on immune responses against weakly immunogenic or auto-antigen (P1A). </rdfs:comment>
    <rdfs:label>DC pulsed with tumor antigens</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_464">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_database</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001012">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/95">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/158"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/293"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/47"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/5"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lyris de Godoy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/489">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/45"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/45"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/44"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/43"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/46"/>
    <rdfs:label>extracted yeast RNA</rdfs:label>
    <rdfs:comment>Total RNA was extracted from yeast cells after buffering, incubation and centrifugation by phenol extraction.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/44"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/342">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/115"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/40"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/263"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/50"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/53"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lucia Conti</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000052">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001865</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD123</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/376">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/93"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/94"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/94"/>
    <rdfs:comment>These stage III/IV melanoma patients underwent surgical removal of a metastatic lesion and lymphodepletion prior to vaccination and adoptive transfer of autologous T cells.</rdfs:comment>
    <rdfs:label>Stage III/IV melanoma patients</rdfs:label>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/93"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/377"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/86"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/265">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data has been obtained on the phenotype and function of myeloid derived suppressor cells in melanoma in patients.

Accumulation of myeloid derived suppressor cells (MDSC) with the ability to suppress T cells has been observed in serveral types of cancer, including melanoma. Using blood from melanoma patients we are investigating phenotypic markers that can be used to further characterize MDSC, focusing on molecules that are related to their suppressive function. As it is believed that recruitment from the bone marrow by tumor derived factors leads to increased presence of immature myeloid cells in the blood, we are testing substances that could induce maturation and thereby turn immature suppressor cells into mature cells capable of efficient antigen presentation.
So far we have collected blood from &gt;10 melanoma patients and compared the MDSC phenotype and function with healthy donor derived cells. 

We will collect further material to perform detailed studies of phenotype and function of MDSC in melanoma patients. Using some model substances we are testing a group of drugs for its ability to induce MDSC maturation. We are also interested in studying the effect of MDSC on other immune cells.</rdfs:comment>
    <rdfs:label>Phenotype and function of myeloid derived suppressor cells in melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_45732">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">parenchyma</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/278">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/99"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/98"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_249"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CD1 molecules are refolded in vitro in order to generate CD1 tetramers.</rdfs:comment>
    <rdfs:label>CD1 molecules, refolded</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/56">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/258"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/105"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/221"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/48"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/81"/>
    <rdfs:label>C.J.M. Melief</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/259"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/254"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/49"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/224"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/46"/>
    <rdfs:comment>Professor: Department of Immunohematology and Blood Transfusion (UL)

Expertise: Immunity against viruses and against cancer; Vaccinology; Immunogenetics; Antigen processing and presentation; Blood transfusion; Immunotherapy 

Relation to current research activities
(the most recent research is placed on top)

    * Project leader: TLR ligand-peptide conjugates as optimal vaccine vehicles for specific immunotherapy of HPV16-induced lesions.
    * Project leader: Immunotherapy in ovarian cancer patients; involvement and manipulation of regulatory T cells.
    * Project leader: Treatment of HPV positive penile and cervical cancer by induction of HPV E7-specific T cell immunity through DNA vaccination
    * Project leader: Integrated analysis of melanoma-T cell interactions in situ; relevance for immunotherapy</rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/54"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/257"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/47"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/222"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/218"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/255"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/223"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/121"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/53"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/50"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/128"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/102"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/51"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/104"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/120"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/29">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/241"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdfs:comment>We are preparing a protocol for a phase I clinical trial in patients with advanced (stage III or IV) melanoma. Patients will receive a DC vaccination regimen followed by 3 adoptive transfers of autologous in vitro expanded T cells. This novel approach combines in vivo priming by the DC vaccine with passive immunotherapy by lymphocyte infusion. 

Patients will undergo surgical removal of a metastatic lesion and leukapheresis at the beginning of the trial to provide sources for tumor antigens as well as monocytes and T cells, which will be isolated from the leukapheresis product by elutriation. Patients will undergo lymphodepletion prior to vaccination and prior to adoptive transfer of autologous T cells. The DC vaccine will consist of monocyte derived DC loaded with tumor lysate generated from the excised lesion. The T cell transfer will consist of T cells expanded by co-culture with tumor lysate loaded DC. 

The primary objective of this trial is to determine toxicity and feasibility of treatment of patients with advanced melanoma with DC vaccine and adoptive transfer. The secondary objective is to generate large numbers of tumor reactive T cells, characterize these T cells and evaluate immunological and clinical responses in treated patients.

Recently we have optimized our T cell expansion protocol by testing different cytokines and evaluating whether T cell expansion can be improved by using antigen loaded DC as stimulators at all times. We find that mixed PBMCs have superior stimulatory capacity and that IL-2 had the best cost-benefit ratio and will therefore not modify the original protocol. The study protocol has been reviewed by the local ethical committee and is now ready to be submitted to Läkemedelsverket, the Swedish regulatory authority for clinical trials.

Upon approval by swedish authorities we plan to include, treat and evaluate 10 patients during a period of one to two years. </rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label>Phase I clinical trial protocol in patients with advanced (stage III or IV) melanoma</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700315">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD16</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001483</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD16</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-16</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/335">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/104"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The normal donors were studied for effector vs. memory T cell responses.</rdfs:comment>
    <rdfs:label>Normal donors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_423">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">academic organization</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000245"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/128">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Identification of versatile central memory CD8+ T-cells capable of high IL-2 secretion </rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_764"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_345"/>
    <rdfs:comment>We obtained data from our activity to establish the identification of versatile central memory CD8+ T-cells capable of high IL-2 secretion according to new markers. Versatile human CD8+ T-cells represent up to 30% of the CD8+ central memory pool in healthy adults and are characterised by unique functional capabilities (ability to secrete IL-2 after restimulation in concordance with low effector cytokine (e.g. IFN) and lack of  cytotoxic mediator (e.g. perforin) expression (Frentsch et al., unpublished)). They might present an attractive candidate memory/effector CD8+ T-cells to be induced in treatments based on dendritic cell priming.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A74">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_483">
    <rdfs:label>cytometric bead array assay</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CBA assay</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytometric bead array assay</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CBA assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytometric bead array assay</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001015">
    <rdfs:label>CD45RA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_726">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Susceptibility To Multiple Sclerosis-model mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies are distinct</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000142">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HLA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human leukocyte antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHC</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Major histocompatibility complex</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_461">
    <rdfs:label>method</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">method</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A method is a specification of a "body of techniques for investigating phenomena, acquiring new knowledge, or correcting and integrating previous knowledge" [wikipedia].</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_284">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">invariant natural killer cell</dcr:hasExactSynonym>
    <rdfs:label>iNKT cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">iNKT cell</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">iNKT cell</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">iNKT cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">invariant NK cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">invariant NK cell</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">invariant natural killer cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">invariant natural killer cells</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/82">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>test</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/330">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This PSA was used as a control in the transfection of immature DC. Transfection of immature DCs was done with different constructs encoding for the oncogene Her-2/neu or an adeno virus Her-2 full length construct.</rdfs:comment>
    <rdfs:label>Prostate specific antigen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A75">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A76">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A77"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/127">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_171"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:label>Monitoring of tumour antigen specific CD4+ T cell responses</rdfs:label>
    <rdfs:comment>We obtained data from an in vitro system to study ex-vivo responses able to detect bona fide in vivo primed CD4+ T cells.

We focused on the monitoring of tumour antigen specific CD4+ T cell responses. We select the following tumour associated antigens: 
i) the E6 and E7 proteins of human papilloma viruses, 
ii) the carcinoembryonic antigen (CEA) and 
iii) the tumour specific antigen MAGE-A3. 

We investigated spontaneous CD4+ T cell responses to these antigens in normal donors and in patients with high-grade cervical lesions, pancreas adenocarcinoma and advanced melanoma. HPV-18 E6 specific CD4+ T cells were found in a high percentage of patients with cervical lesions and we showed that the quality of the response (i.e. the level of IFN-? produced) could predict the clinical outcome after surgery. CEA specific CD4+ T cells were found both in normal donors and in patients but CD4+ T cells from the patients compared to normal donors showed impaired IFN-gamma production. MAGE-A3 specific CD4+ T cells were found also in a high percentage of melanoma patients but CD4+ T cells showed an unpolarized or Th2 skewed phenotype. We have optimized the MAGE-A3 peptides to load onto HLA-DR*1101 tetramers. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0008515"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/61"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/57"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/59"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_170"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/58"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/150"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/62"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10566"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/55"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/60"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/56"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/264">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/136"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/128"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data has been obtained on the BRAF/NRAS mutation status and expression of COX-2 and iNOS comparing their prognostic value for overall survival in stage III malignant melanoma. 

New prognostic markers for malignant melanoma are urgently needed. Inducible nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) have been described to correlate with progression of melanoma. Moreover, activating mutations in BRAF/NRAS oncogenes are often detected in melanoma. We have examined the BRAF/NRAS mutation status and expression of COX-2 and iNOS to compare their prognostic value for overall survival in stage III malignant melanoma.   

Real time and immunohistochemistry analysis showed that both iNOS and COX-2 alone significantly predicted OS. The BRAF/NRAS mutation status did not significantly differ between patient groups, although iNOS significantly correlated with BRAF mutation frequency. Furthermore, iNOS and COX-2 were significantly linked to a number of metastatic lymph nodes. However, iNOS maintained its statistical significance together with a number of lymph nodes in the multivariate analysis and predicted OS, whereas COX-2 did.

We will now move on to study iNOS and COX-2 expression in fresh melanoma tumors. Here we aim to determine the exact phenotype of the iNOS and COX-2 expressing cells. We are especially interested to study expression of these enzymes by tumor infiltrating myeloid cells. Expression of iNOS is a known suppressive mechanism employed by myeloid derived suppressor cells. We will study the presence and function of such suppressive myeloid cells within the tumor.</rdfs:comment>
    <rdfs:label>Study on iNOS as prognostic factor in stage III melanoma survival</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isBioMatUsedIn">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is biomaterial used in</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any bio-material to the protocol / data set they were used in.</OBI:IAO_0000115>
    <rdfs:range rdf:nodeID="A78"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#usesBioMat"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400007">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_317">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nano particles</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nano particle</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nanoparticles</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nanoparticle</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/273">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/99"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The CD1d tetramers were generated from in vitro refolded CD1 molecules. The ability to generate CD1d tetramers has provided us with the opportunity of comparing a broad panel of CD1d binding compounds for their ability to stimulate iNKT cells.</rdfs:comment>
    <rdfs:label>CD1d tetramers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Oncoprotein">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">oncoproteins</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">oncoprotein</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/40">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Medical and Health Science Centre of University of Debrecen in 2003. has established an international award for molecular medicine. It is called „Debrecen Award for Molecular Medicine”. By bestowing the award yearly, they try to acknowledge the merits of those scientists who have made an outstanding contribution to the development of medical research. Every autumn the award is granted on an internationally acknowledged scientist or group of scientists whose research in the field of molecular medicine has resulted substantial advance. The amount of money given with the award is 1000 Euros. The designation for the award is made by a group consisting of 12 members, all outstanding physicians, professors and doctors, biologist-scientists.</rdfs:comment>
    <rdfs:label>University of Debrecen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_725">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_721"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S6/SvEvTac * C57BL/6</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tbx21tm1Glm/Tbx21tm1Glm transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/81">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>IntelliLeaf ltd is 'bio semantic' company, which was founded in 2011 to continue the activities of Leaf Bioscience s.r.l.</rdfs:comment>
    <rdfs:label>IntelliLeaf ltd</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_462">
    <rdfs:label>labeling method</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">labeling method</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A labeling method is a method specifying the addition of a labeling reagent to a biomaterial in order to detect the labeled material in the future.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_1111000">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/340">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Gabriella Torcia</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_484">
    <rdfs:label>two-photon excitation microscope</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0400169"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">two-photon microscope</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2-photon excitation microscope</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2-photon microscope</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">two-photon excitation microscope</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_83558">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chlamydia pneumoniae</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000473">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CARO#CARO_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">defensive cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A77">
    <owl:onProperty rdf:resource="http://purl.org/obo/owl/obo#has_high_plasma_membrane_amount_relative_to_leukocyte"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/119">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial. </rdfs:comment>
    <rdfs:label>Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A32">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_397">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCL19</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001128">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A54"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chemokine receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/126">
    <rdfs:comment>We have continued recruitment of patients and obtained first data in the two clinical trials of active vaccination in metastatic melanoma. Structural works that have been performed to up-grade the GMP facility for conduction of phase III clinical trials has limited the number of patients recruited. Nonetheless, we were able to complete the vaccination schedule in 4 patients and to perform additional injections in disease free patients, in patients with stable disease or with slowly progressive disease. We could not recruit new patients because the generation in GMP conditions of additional aliquots of the vaccines (i.e. the supernatant containing the infective MAGE-3 encoding viruses and the natural tumour peptides) is taking longer then predicted because of new viral controls required by the Regulatory Agency and of difficulties in purchasing clinical grade dialysis’ membranes for peptides production. As far as the planning of new protocols concerns we are waiting to know whether grant applications we applied for the specific issues will be funded.

Thus so far the 2 clinical trials are on hold until problems in GMP production of the vaccine have been solved.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/65"/>
    <rdfs:label>Clinical trials of active vaccination in metastatic melanoma patients</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/51"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/50"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/370">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/117"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/88"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>An HSV vector expressing full length tyrosinase, gp100 and MART-1 was used to transduce DC from melanoma patients which were then to be used for vaccination. </rdfs:comment>
    <rdfs:label>DC from melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/263">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/342"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/50"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Based on the data we recently reported  concerning the role of GM-CSF in regulating human DC differentiation (Conti et al., EJI 2008), we will perform a detailed analysis of mRNA and microRNA expression in immature and TLR ligand-stimulated GM-DCs in order to identify specific mechanisms that control the generation/activation of these cells. Data obtained in this study will become available. Moreover, the role of microRNAs in controlling the switch of GM-CSF-exposed monocyte precursors toward DCs or macrophages will also be investigated. </rdfs:comment>
    <rdfs:label>Mechanisms controlling the generation/activation of GM-DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_318">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">concept to be revised</rdfs:comment>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">soluble factors</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">soluble factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/272">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/67"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/75"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were generated from monocytes after elutriation of leukapheresis product (patients with stage III or stage IV melanoma) and pulsed with irradiated tumor cells (apoptotic bodies) prepared from the removed lesion and matured for 48 hours in presence of TNF-alpha, and subsequently frozen.</rdfs:comment>
    <rdfs:label>pulsed DC, frozen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0704352">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Proto-oncogene tyrosine-protein kinase Src</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-SRC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC PROTOONCOGENE</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Proto-oncogene tyrosine-protein kinase Src</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AVIAN SARCOMA VIRUS</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pp60c src</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p60-Src</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pp60c-src</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ONCOGENE SRC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC</dcr:hasExactSynonym>
    <rdfs:label>SRC human</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC human</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c- Src</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ASV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p60 Src</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-src</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC human</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PROTOONCOGENE SRC</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC ONCOGENE</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4891">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hemiascomycetes</dcr:hasExactSynonym>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">includes the yeasts</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saccharomycetes</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Tobacco_Smoke">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tobacco smoke</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NCI: Smoke from burning tobacco (cigarettes, cigars, or pipes) and exhaled by a smoker. Tobacco smoke contains nicotine, a stimulant, and other biologically active chemicals having carcinogenic properties.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_724">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">either: (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1)</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_721"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Runx3tm1Yg/Runx3tm1Yg transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000848">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">melanoma cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">melanoma cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/80">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Our mission is to advance the understanding of genetically-related conditions through multi-disciplinary research.

The Centre is composed of scientific research groups that work to understand the genetic foundations of human variation and disease. Scientists in the Centre work in diverse fields, developing and applying statistical, computational, and experimental methods to a wide range of medical conditions. The main areas of research include bioinformatics, cardiovascular disease, genomics, immunity and inflammation, metabolism, neurogenetics, statistical genetics and transgenics.
</rdfs:comment>
    <rdfs:label>The Wellcome Trust Centre for Human Genetics, University of Oxford</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6279">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Brugia malayi</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">agent of lymphatic filariasis</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/332">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Primed mice were treated with these antibodies. This treatment induced the development of regulatory T cells expressing high levels of ICOS and producing IL-10.</rdfs:comment>
    <rdfs:label>Intact anti-CTLA-4 antibodies</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_485">
    <rdfs:label>Tools and Methods</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A tool, broadly defined, is an entity that interfaces between two or more domains; that facilitates more effective action of one domain upon the other; a method refers to a body of techniques for investigating phenomena, acquiring new knowledge, or correcting and integrating previous knowledge.</OBI:IAO_0000115>
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://en.wikipedia.org/wiki</OBI:IAO_0000119>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tools and Methods</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/70">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/95"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The cDNA’s encoding these early expressed HIV antigens have been human codon optimized and modified with lysosomal targeting sequences.</rdfs:comment>
    <rdfs:label>cytokine cocktail matured DCs electroporated with mRNA encoding Tat, Rev and Nef</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A79">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000386"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701799">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ONCOGENE JUN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p39</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Proto-oncogene c-jun</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-Jun</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">JUN</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">jun oncogene</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Activator protein AP1 human</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AP1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Transcription factor AP-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">V-jun avian sarcoma virus 17 oncogene homolog</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_590">
    <rdfs:subClassOf rdf:nodeID="A43"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CMV pp65 peptide antigen</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CMVpp65 antigen</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A80">
    <rdf:rest rdf:nodeID="A76"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/262">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data on the role of STAT3 signalling in directing DC-mediated responses toward immunogenicity or tolerance will be generated.

To this purpose, we will identify 
(i) genes and 
(ii) micro-RNA 

selectively controlled by STAT3 in human MDDCs treated with proinflammatory or tolerogenic stimuli (including TLR ligands, cytokines and vitamin D3). This will shed light on the role of STAT3 signalling.</rdfs:comment>
    <rdfs:label>Role of STAT3 signalling in immunogenicity or tolerance</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000232">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">erythrocyte</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">red blood cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RBC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">erythrocytes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/42">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>IRCCS Ospedale Oncologico di Bari</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_394">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A58"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RIG-I</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RIG-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">retinoid-inducible gene</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RIG1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">retinoid-inducible gene protein</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/275">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The protein vaccines were injected combined with a combination of iNKT cell-agonist alpha-GalCer and MPL, a detoxified version of LPS that signals through TLR4. This combination treatment stimulates antigen-specific T and B cell responses that are greater than those elicited with alpha-GalCer or MPL alone.</rdfs:comment>
    <rdfs:label>Protein vaccines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_4027">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Cyclophosphamide (the generic name for Endoxan, Cytoxan, Neosar, Procytox, Revimmune), also known as cytophosphane, is a nitrogen mustard alkylating agent, from the oxazophorines group. It is used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_32988"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytophosphane</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cyclophosphamide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/59">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/218"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ferry Ossendorp</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/371">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This is blood from patients that undergo surgery due to clinical situations that do not affect the immune system (most frequently malformations). 

We have attempted to identify and characterize CD8T lymphocyte populations in humans. We compared the distribution of phenotypically distinct cell sets using seven color staining in the blood, lymph nodes and spleen. We found that the addition of other markers allow to subdivide N, CM, TEM and TEMRA populations in additional cell types.</rdfs:comment>
    <rdfs:label>Human blood</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/99">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Danilo Petroni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_723">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_721"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Itgb6tm1Des/Itgb6tm1Des transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S4/SvJae * C57BL/6J</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#elementsBiomaterialTypeOf">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#elementsTypeOf"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">elements are of biomaterial type</rdfs:label>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect aggregates to an ontological biomaterial type. As this would make the ontology OWL full, the annoation property elementsBiomatTypeOfAnno is used instead.</rdfs:comment>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:elementsBiomatTypeOfType</dcr:hasClassAsRangeProperty>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000601">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-18</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 18</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-18</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 18</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL18</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/31">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/49"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The model antigen OVA was fused to the C1C2 exosome-binding domain of MFG-E8/lactadherin. This construct was used in a study on the capture of antigen-bearing exosomes by DCs and cross-presentation of tumour antigen in exosomes.</rdfs:comment>
    <rdfs:label>Exosome-bound OVA antigen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/331">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/97"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This construct was used as in the transfection of immature DC.</rdfs:comment>
    <rdfs:label>Adeno virus Her-2 full length construct</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700262">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CDw127</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-7R-alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL7R-ALPHA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CDW127</dcr:hasExactSynonym>
    <rdfs:label>human CD127 receptor</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human CD127 receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL7R</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-7 receptor alpha chain precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD127 antigen</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A81"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD127</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">INTERLEUKIN 7 RECEPTOR-ALPHA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 7 receptor</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A82"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_486">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000272</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/19">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/144"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/71"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/231"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_475"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has an MRI scanner at its disposal. We use it, e.g., to track dendritic cells in melanoma patients for monitoring of cellular therapy.</rdfs:comment>
    <rdfs:label>MRI</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Milk_Fat_Globule-EGF_Factor-8_Protein">
    <rdfs:subClassOf rdf:nodeID="A83"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MFGE8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lactadherin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Milk Fat Globule-EGF Factor 8 Protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Breast Epithelial Antigen BA46</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lactadherin Precursor</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Milk Fat Globule-EGF Factor 8 Protein</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000710">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Strain factor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Line</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A36">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/124">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/31"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/7"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704821"/>
    <rdfs:comment>We obtained transcriptional and pathway analysis data of human monocyte-derived DCs stimulated with yeast, spheroplasts, pseudohyphae, spores, purified RNA and not purified RNA and LPS.

We propose the role of cell wall in the mechanisms of DC-Pathogen interaction as an experiment that could serve as reference in bioinformatics approaches for the reconstruction of DC activation signalling pathways. We have stimulated human Monocyte derived Dendritic Cells (hMoDC) with yeast, spheroplasts, pseudohyphae, spores, purified RNA and not purified RNA, LPS. We have measured IL-6, IL-8, TNFalpha, IL-1beta, IFNgamma, IL-10, IL-12p70, IL-12p40. We are performing transcriptional analysis on the above mentioned samples, using the Genomics facilities at Genopolis (P32). The results are being analyzed with DC_Eu.Gene Analyzer and compared with other experiments in order to identify DC- and immunological pathway differentially affected by the different stimuli. 

We have collaborated actively with Ugo D'Oro, Giorgio Napolitani, Federica Sallusto and Antonio Lanzavecchia. This integration of efforts and information is instrumental to the fruition of the genomics information in the field of dendritic cells research. Regarding the knowledge portal, we submitted microarray data and SOPS on the above mentioned experiments. </rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdfs:label>Transcriptional and pathway analysis of human monocyte-derived Dendritic Cells stimulated with yeast, spheroplasts, pseudohyphae, spores, purified RNA and not purified RNA, LPS</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700009"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701377"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/81"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/94"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FAO#FAO_0001002"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/66"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/74"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701386"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0005618"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/76"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/205"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/83"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000524"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/79"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_591">
    <rdfs:label>Immunofluorescence assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Immunofluorescence assay</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Immunofluorescence assay is a method specifying the use of labeling of antibodies or antigens with fluorescent dyes.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700319">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcgr2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc- gamma RII</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcgr2b</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gamma-RIIB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FCgamma R-II</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IgG Fc receptor II beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD32 antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcRII</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc gamma receptor IIB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcgammaRII</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ly-17</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gammaRII</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcgammaRIIB</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcgamma R-II (mouse)</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Low affinity immunoglobulin gamma Fc region receptor II precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type II FcgammaR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lymphocyte antigen 17</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_722">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_721"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Il4ratm1Tch/Il4ratm1Tch transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129X1/SvJ * BALB/c</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/261">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>BruCells is collaborating with Professor De Witte from ULB for the preclinical study in which circulating tumour-specific CD8+ T-cells will be detected in the blood of newly diagnosed glioblastoma patients and from which data will be obtained.

In order to obtain the blood samples and tumour biopsies from the glioblastoma patients, a file has been submitted to the Ethics Committee of the Erasme Hospital and has been recently approved.</rdfs:comment>
    <rdfs:label>Detection of tumour-specific CD8+ T-cells in the blood of glioblastoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/41">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Division of Infection and Immunity has two constituent Research Departments: Immunology and Infection.</rdfs:comment>
    <rdfs:label>Windeyer Institute of Medical Sciences/University College London</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/30">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/48"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have finalized analysis of the receptors on DCs responsible for capture of exosomes secreted by mature DCs. We have shown that expression of LFA-1, but not of Mac-1, integrin, on DCs is required for capture of ICAM-1-bearing exosomes.</rdfs:comment>
    <rdfs:label>ICAM-1-bearing exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_471">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Labeling protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_738</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/130">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/191"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/60"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/59"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/186"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/384"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/32"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/187"/>
    <rdfs:label>Jirina Bartunkova</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/189"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/190"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/245"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/244"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/274">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>iNKT cells were stimulated in vivo with the synthetic CD1d ligand alpha-GalCer. This significantly enhanced immune responses to protein and peptide based vaccines, due to rapid iNKT dependent DC maturation.</rdfs:comment>
    <rdfs:label>Stimulated iNKT cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_316">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">etx</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0043234"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">enterotoxin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A84">
    <owl:intersectionOf rdf:nodeID="A80"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/372">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These are lymph nodes from patients that undergo surgery due to clinical situations that do not affect the immune system (most frequently malformations). 

We have attempted to identify and characterize CD8T lymphocyte populations in humans. We compared the distribution of phenotypically distinct cell sets using seven color staining in the blood, lymph nodes and spleen. We found that the addition of other markers allow to subdivide N, CM, TEM and TEMRA populations in additional cell types.</rdfs:comment>
    <rdfs:label>Lymph nodes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/62">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Active immunotherapy in advanced melanoma patients</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200674"/>
    <rdfs:comment>The vaccine is composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasBioSourceType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#gp100_Antigen"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_452"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/129">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment> We set an in vitro system to study ex-vivo responses able to detect fona fide in vivo primed CD4+ T cells. We investigated spontaneous CD4+ T cell responses to these antigens in normal donors and in patients with high-grade cervical lesions, pancreas adenocarcinoma and advanced melanoma. 

The antigens were: 
i) the E6 and E7 proteins of human papilloma viruses, 
ii) the carcinoembryonic antigen (CEA) and 
iii) the tumour specific antigen MAGE-A3.</rdfs:comment>
    <rdfs:label>Patients with high-grade cervical lesions</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000096">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001412</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD86</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/44">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/154"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has expertise in performing thymidine-incorporation assays. The assay is used, for instance, for the monitoring of the vaccine induced specific anti-tumor T cell responses.</rdfs:comment>
    <rdfs:label>Thymidine-incorporation assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000145">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pathologist</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_81494">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stroma</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#is_manufactured_by">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a tool or a bio-material to the person or participant that manufactured the tool / bio-material.</OBI:IAO_0000115>
    <owl:inverseOf rdf:resource="http://dc-research.eu#manufactures"/>
    <rdfs:range rdf:nodeID="A85"/>
    <rdfs:domain rdf:nodeID="A86"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is manufactured by</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_603">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.geneontology.org/formats/oboInOwl#ObsoleteClass</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_ObsoleteClass</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000054">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_receptor</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000000001</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasCellLine">
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasCellLineType</dcr:hasClassAsRangeProperty>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset or a bio-material with the biomaterial. As this would make the ontology OWL full, the annotation property hasCellLineType is used instead.</rdfs:comment>
    <rdfs:domain rdf:nodeID="A87"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell line</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A88">
    <rdf:rest rdf:nodeID="A89"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_485"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/132">
    <rdfs:comment>We have data available on some functional immune responses in a small animal model to study the development and function of the human hematopoietic and immune system as well as human specific infections in vivo. 

We established “human hemato-lymphoid-system mice” by transplanting human CD34+ cord blood cells into irradiated newborn Rag2-/-gc-/- mice, leading to de novo development of human B, T, and dendritic cells; formation of structured primary and secondary lymphoid organs; and production of some limited functional immune responses.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0702099"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/78"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/74"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/73"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001003"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000513"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7647"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Small animal model to study the development and function of the human hematopoietic and immune system as well as human specific infections in vivo</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/327">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/31"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/118"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/215"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/32"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/216"/>
    <rdfs:comment>Research Scientist 1st class 
INSERM

Group: Antigen presentation in dendritic cells</rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/47"/>
    <rdfs:label>Ariel Savina</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/392">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_70803"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The LPS was used for stimulating DC. It was shown in mice that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC.

Manufacturer: Alexis</rdfs:comment>
    <rdfs:label>Salmonella minnesota LPS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/55">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/235"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/234"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_742"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are generated from adherent peripheral blood monocytes.</rdfs:comment>
    <rdfs:label>DC generation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/84">
    <rdfs:label>Studies of responses to viral infection in TLR K/O mice</rdfs:label>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/56"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <rdfs:comment>Data were obtained on responses to viral infections in TLR9 -/- mice, C57Bl/6 mice and IFNalpha receptor -/- mice.

Toll receptor 9 (TLR9) is an important pattern recognition receptor. It is stimulated by foreign DNA or CpG motivs. 

We found that TLR9 -/- mice were very susceptible to infection with the mouse pox virus Ectromelia. In contrast to DC from C57Bl/6 mice, DC from TLR9 -/- produced little if any interferon alpha. However, MVA-BN induced IFNalpha in presence or absence of TLR9 -/-. Moreover, coinfection with MVA-BN and Ectromilia protected TLR9 -/- mice against death. Surprisingly, coinfection with MVA-BN and Ectromilia also protected IFNalpha receptor -/- mice. The data show that MVA-BN can induce potent innate immune responses able to control viral replication to allow the specific immune response to eliminate Ectromelia in immune deficient mice.

We furthermore defined that protection by using the attenuated Vaccinia virus MVA to protect mice against poxvirus infection, if used before or at the onset of infection, partially depends on the induction of the antiviral cytokines IFN- type I, but fully depends on the presence of adaptive immune responses. Importantly we were able to demonstrate that post-exposure application for up to three days of MVA rescued mousepox virus infected mice from death. This is the first demonstration of the effectiveness of post-exposure vaccination against pathogenic poxviruses.

We will explore the innate and adaptive immune elements involved in the protection.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_12643"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_332"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/55"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000513"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/454"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100388">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferon beta</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFN beta</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/8">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/220"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/30"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/21"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/155"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_782"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This puromycin-based technology was developed in our laboratory to monitor translation by FACs in individual or cell populations. It is a non-invasive method to monitor protein synthesis and cellular activation in single cells or heterologous populations. </rdfs:comment>
    <rdfs:label>Surface sensing of translation (SUnSET)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/98">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The GenePix 4000 software package was used to quantify microarray fluorescence in a yeast microarray experiment.</rdfs:comment>
    <rdfs:label>GenePix 4000 software package</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_764">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell type comparison experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cell type comparison design experiment design type compares cells of different type for example different cell lines.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9031">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bantam</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chickens</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chicken</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gallus gallus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/35">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/53"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC are exposed to HIV-1 to examine if this can directly modulate their functions or interfere with their cross-talk.</rdfs:comment>
    <rdfs:label>monocyte-derived DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/48">
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701456"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/12"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000618"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000650"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdfs:comment>Our lab has generated data on receptors on dendritic cells necessary for capture of exosomes. In 2007, we have finalized analysis of the receptors on DCs responsible for capture of exosomes secreted by mature DCs. We have shown that expression of LFA-1, but not of Mac-1, integrin, on DCs is required for capture of ICAM-1-bearing exosomes. Furthermore, the CD8+ subpopulation of DCs in lymph nodes expresses LFA-1 at higher levels than the CD8- subpopulation, and is responsible for in vivo capture of injected exosomes. We have thus proposed a new role for LFA-1 on DCs, as a receptor to favor antigen transfer via exosomes in vivo. These results have been published in 2007 (Segura et al, JI).</rdfs:comment>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/30"/>
    <rdfs:label>Receptors for capture of exosomes by DC</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/29"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_533"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/22"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/326">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/49"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/214"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/200"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Research Director 2nd class
Immunity and cancer - Institut Curie / Inserm Unit 932</rdfs:comment>
    <rdfs:label>Clothilde Théry</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000811">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000094</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD80</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/22">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Eckhart Kämpgen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000010">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin 6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-6</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-6</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/176">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/48"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/61"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000021"/>
    <rdfs:label>Assessment of cell death in the viable epidermis </rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7163"/>
    <rdfs:comment>The use of gene guns in ballistically delivering DNA vaccine coated gold micro-particles to skin can potentially damage targeted cells, including Langerhans cells, therefore influencing transfection efficiencies. We have assessed and obtained data on cell death in the viable epidermis by non-invasive near infrared two-photon microscopy following micro-particle bombardment of murine skin. We showed that the ballistic delivery of micro-particles to the viable epidermis can result in localised cell death. Furthermore, experimental results show the degree of cell death is dependant on the number of micro-particles delivered per unit of tissue surface area. These results suggest that optimization of transfection by genes administered with gene guns is - among other effects - a compromise of micro-particle payload and cell death. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_549"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_480">
    <rdfs:label>lipofection</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">liposome transfection</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lipofection</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lipofection is a method specifying the injection of genetic material into a cell by means of liposomes.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0610">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">siRNAs</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_309"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">siRNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">micro RNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dicer RNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">small interfering rnas</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">small interfering rna</dcr:hasExactSynonym>
    <rdfs:label>small interfering RNA</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">small interfering RNA</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBodilyPart">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with a biomaterial. As this would make the ontology OWL full, the annotation property hasBodilyPartType is used instead.</rdfs:comment>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:domain rdf:nodeID="A90"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bodily part</rdfs:label>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasBodilyPartType</dcr:hasClassAsRangeProperty>
    <rdfs:range rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/101">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/186"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/244"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/187"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Autologous DC are pulsed with the apoptotic allogenic prostate carcinoma cell line LNCap to produce the vaccine for patients with advanced prostate carcinoma..</rdfs:comment>
    <rdfs:label>Cell pulsing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000095">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD83</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001310</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/43">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our laboratory we perform 51Cr-release assays, for instance in the monitoring of vaccine induced T cell responses.</rdfs:comment>
    <rdfs:label>51Cr-release assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/61">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Multicolour analysis of human blood dendritic cells subsets.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_374">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CX chemokine receptor 4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCR4</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001128"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CX chemokine receptor 4</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_36704">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C14H16N4</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Imiquimod</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A91"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33595"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/391">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The CpG was used for stimulating DC. It was shown in mice that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC.
</rdfs:comment>
    <rdfs:label>Phosphorothioate CpG DNA </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/56">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/234"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/266"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>At day 6 DC are pulsed with the peptides and KLH in the presence of TNF-alpha overnight.</rdfs:comment>
    <rdfs:label>DC pulsing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A92">
    <rdf:rest rdf:nodeID="A88"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/133">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_373"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000513"/>
    <rdfs:comment>Our lab has immunological data available on human Hemato-Lymphoid System Rag2-/-gc-/- mice infected with EBV. 

Both Epstein Bar Virus (EBV) and Human Immunodeficiency Virus (HIV) are human specific lymphotropic viruses. Human Hemato-Lymphoid System Rag2-/-gc-/- mice were infected with EBV and mount an immune response (i.e. cytotoxic T cell proliferation, some control of EBV driven B cell proliferation, perforine and granzyme expressing T cell infiltration in B cell infected areas in lymphoid organs in situ), however, specific T cells could not be detected directly ex vivo by looking at the most common EBV derived/presented epitopes (tetramer staining). Some animals developed EBV induced B cell lymphoproliferative disease. All types of B-cell proliferation (polyclonal, oligoclonal, monoclonal) were observed, reflecting B cell proliferation incuced in immuno-suppressed human beings.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0702099"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Granzyme"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Infection of human Hemato-Lymphoid System Rag2-/-gc-/- mice with EBV </rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10376"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/75"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/78"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_12721">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human immunodeficiency virus</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HIV</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/271">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/67"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/75"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC had been generated from monocytes after elutriation of leukapheresis product (patients with stage III or stage IV melanoma), were not pulsed and were frozen.</rdfs:comment>
    <rdfs:label>generated DC, unpulsed, frozen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/83">
    <rdfs:comment>Our lab gathered data on the responses to EBV and HIV in hu-SCID mice.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/453"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/78"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/75"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/76"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10376"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/74"/>
    <rdfs:label>Studies of responses to EBV and HIV in hu-SCID mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400116">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/34">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/52"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These monocyte-derived DCs received combined stimulation with TLR ligands. They were used in our study on DC activation by pathogen-derived stimuli.</rdfs:comment>
    <rdfs:label>MDDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/97">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400104"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A GenePix 4000 microarray scanner is available in our lab (manufacturer: Axon, Foster City, CA).</rdfs:comment>
    <rdfs:label>GenePix 4000 microarray scanner </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/325">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/200"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/174"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/120"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/33"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Unité Inserm 653, Immunité et Cancer</rdfs:comment>
    <rdfs:label>Alexandre Boissonnas</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000011">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-1</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/9">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/15"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/122"/>
    <rdfs:label>Eu.Gene Analyzer</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/132"/>
    <rdfs:comment>Eu.Gene Analyzer is an easy-to-use, stand-alone application that allows rapid and powerful microarray data analysis in the context of biological pathways. Its intuitive graphical user interface makes it an easy and flexible tool, even for the first-time user. Eu.Gene supports a variety of array platforms, organisms and pathway ontologies, transparently deals with multiple nomenclature systems and seamlessly integrates data from different sources. Two different statistical methods, the Fisher Exact Test and the Gene Set Enrichment Analysis (GSEA), are implemented to identify biological pathways transcriptionally affected under experimental conditions. A suite of tools is offered to define, visualize and share custom non-redundant pathway sets. 

In conclusion, Eu.Gene Analyzer is a new software application that takes advantage of information from multiple pathway databases to build a comprehensive interpretation of experimental results in a simple, intuitive environment.

Meanwhile, we have developed a new version of EuGene,  EuGene 1.5,  now available for download from the new EuGene Website at www.duccioknights.org,which has several advantages:
a-Adds new functionality or optimize already present features to meet the requirements for DC-STUDIO. 
b-set up a method to convert pathway deregulation into a categorical value, the signed Binary Enrichment Factor (sBEF),  a three state variable (significantly up-regulated, significantly down-regulated and not significant) associated to each pathway of the curated pathway set for a particular sample. DC-STUDIO was engineered to store collections of sBEFs, as a sort of “barcodes”, for each sample analyzed, in a way that would be compatible with future integration with DC-BASE. </rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/18"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/89"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/121"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/123"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000492">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-helper lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T cell</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000624"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-helper cell</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000912"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T helper</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD4-positive T helper cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-cell</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/21">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/21"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/522"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/336"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/338"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/368"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/126"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/84"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/17"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/341"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/29"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/570"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/344"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/86"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/506"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/279"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/107"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/13"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/107"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/521"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/150"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/55"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/337"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/318"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/54"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/125"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/46"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/280"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/18"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/86"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/571"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/343"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/346"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/170"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/131"/>
    <rdfs:label>Gerold Schuler</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/73"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/22"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/24"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/12"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/17"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/479"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/567"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/339"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/18"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/30"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/340"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/342"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/53"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/22"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/369"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/41"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/85"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/87"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/345"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/24"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/47">
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab has obtained data on maturation stimuli for GMP-grade DC.</rdfs:comment>
    <rdfs:label>Optimisation of maturation stimuli for GMP-grade DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_219">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">myelin oligodendrocyte glycoprotein peptide</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MOG</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MOG peptide</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Lectin"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000442">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">author</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/513">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have prepared several new constructs for the expression of c-type lectin receptors in DC.</rdfs:comment>
    <rdfs:label>Constructs for the expression of c-type lectin receptors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/177">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Monitoring of the capacity of splenic DC to induce immunity</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <rdfs:comment>Data was obtained of the capacity of splenic DC, pulsed in vitro with protein antigens or peptides, to induce immunity after transfer into syngeneic animals.  To improve existing strategies, the amplitude and polarisation of T cell responses was monitored in the presence or absence of regulatory T cells. Natural regulatory T cells (CD4+ CD25+) were depleted by injection of anti-CD25 mAbs, whereas regulatory T cells were induced by injection of (presumably agonistic) anti-CTLA-4 mAbs. Our observations demonstrate that natural and CTLA-4 induced regulatory T cells are distinct populations. Both cell types downregulate Th1-type responses, suggesting new strategies to optimize DC-based immunotherapy to induce tumor resistance. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000062">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">amastigote</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">amastigotes</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/102">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/191"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/190"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/189"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Pulsing of autologous DCs with apoptotic autologous ovarian carcinoma cells.</rdfs:comment>
    <rdfs:label>Cell pulsing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/46">
    <rdfs:comment>This platform with its state-of-the-art mass spectrometry facilities is led by Mann (P33). To enhance the platform, two additional groups were recruited as Third Parties: P114 Edwin Lasonder in Nijmegen (NL), and P113 Juri Rappsilber in Edinburgh (GB).

The mass spectrometer has been used, for instance, to identify and quantify chemokine dependent tyrosine phosphorylation events. Furthermore, the success of SILAC labelling was analysed using the mass spectrometer.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/175"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/95"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000050"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/35"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdfs:label>Proteomics platform</rdfs:label>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/34"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A39">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/390">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_195"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was shown in mice that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC.
</rdfs:comment>
    <rdfs:label>Signalling adaptor molecule TRIF</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0500000">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Experimental design</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">experimental design</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_605">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">the role of a protein to be bound to a ligand, realized in a process of ligand binding</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">receptor role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001202">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CC-CKR-6</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A chemokine receptor that is a translation product of the CCR6 gene. The preferred ligand is CCL20.</OBI:IAO_0000115>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DRY6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chemokine receptor-like 3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GPRCY4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LARC receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C-C CKR-6</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KY411</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR-6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">G-protein coupled receptor 29</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CKR-L3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD196</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C-C chemokine receptor type 6</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chemokine receptor CCR6</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001128"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GPR-CY4</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_28940">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_35341"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Calciol</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vitamin D3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cholecalciferol</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/60">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>The vaccine is composed by autologous DCs pulsed with apoptotic autologous ovarian carcinoma cells. Apoptosis is induced by UV.</rdfs:comment>
    <rdfs:label>Preclinical protocol of immunotherapy in ovarian carcinoma with dendritic cells loaded with apoptotic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/53">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_776"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Data are normalized to mean ratio intensity.</rdfs:comment>
    <rdfs:label>Normalization</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/134">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_374"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0702099"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/78"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_81494"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label>Infection of human Hemato-Lymphoid System Rag2gc-/- mice with both CXCR4 as well as CCR5 tropic HIV-1 strains</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_246"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:comment>Data is available on human Hemato-Lymphoid System Rag2gc-/- mice infected with both CXCR4 as well as CCR5 tropic HIV-1 strains. 

HIV causes a disseminated infection and spreads in all newly generated lymphoid tissues, thus closely resembling HIV infection in humans. However, as in EBV infected animals, adaptive T and B cell responses were not consistently detected.

Thus, although these “humanized” mice represent a major step forward in generating an in vivo preclinical testing system, they still harbor limitations as inconsistent/weak adaptive immune responses, questionable T (and B) cell selection, insufficient human hematopoietic stem cell maintenance, and myeloid cell constitution. To address these issues, we are now aiming to improve the recipient mouse background by co-transplanting human mesenchymal stroma cells, and by adding human cytokines as well as human MHC. Furthermore, we use the mice to evaluate targeted therapies directed at human immune system cells as T cells, B cells, and dendritic cells.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/75"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000763"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000134"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000738">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HL-60 cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HL60 cell</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman with acute myeloid leukemia (AML FAB M2) in 1976.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/329">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/215"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Audrey PERES</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/82">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our laboratory obtained data on the induction of immune responses after targeting antigens to DC via TLR agonists.</rdfs:comment>
    <rdfs:label>Induction of immune responses after targeting antigens to DC via TLR agonists</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/20">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Erica Lomnes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/96">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400147"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The yeast oligonucleotide array was constructed using the S. cerevisiae Genome Oligo Set ™ (Operon Technologies, CA, USA) composed of 6240 optimized oligonucleotides (70mers) each representing one yeast gene.</rdfs:comment>
    <rdfs:label>yeast oligonucleotide array</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000012">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-3</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin-3</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/33">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/51"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_239"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The question was addressed of whether bLf, whose immunomodulant properties are now recognized, could influence MDDC differentiation/activation. </rdfs:comment>
    <rdfs:label>MDDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITAXON_7200">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lutzomyia longipalpis</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_7148"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0702013">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PDE6D</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GMP-PDE delta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RETINAL ROD PHOTORECEPTOR cGMP PHOSPHODIESTERASE, DELTA SUBUNIT</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p17</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PDED</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p17 protein</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">phosphodiesterase 6D, cGMP-specific, rod, delta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EC 3.1.4.17</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PDE6D_HUMAN</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/46">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701377"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000524"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/17"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FAO#FAO_0001002"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/429"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/430"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/15"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704821"/>
    <rdfs:label>Multiplex analysis of human DC stimulated with microbial pathogen derivatives</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701386"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdfs:comment>Data has been generated by multiplex analysis on the response of human MoDC to yeast, spheroplasts, pseudohyphae and spores. Human blood contains myeloid (mDCs) and plasmacytoid (pDCs) dendritic cells that differ in cytokine secretion pattern and responsiveness to microbial stimuli. We found that LPS-stimulated mDCs are able to induce up-regulation of co-stimulatory molecules on co-cultured pDCs. Likewise, CpG-stimulated pDCs activate co-cultured mDCs. The cross talk between these two populations of DC is very efficient since it can be observed at mDC/pDC ratio ranging from 1/10 to 10/1. Activation of the co-cultured population is restricted to up-regulation of co-stimulatory molecules since it does not involve cytokine secretion by the indirectly activated cells. The process is cell contact-dependent, although CD40-CD40L interaction is not involved, but it is also partly dependent on soluble factors. Indeed TNFa produced by LPS-activated mDCs plays a role in the activation of the co-cultured pDC. On the other hand type I interferons produced by CpG-activated pDCs is required for activation of the mDC. We also observed a strong synergistic response of both cell types, using limiting conditions of stimulus on co-cultured mDCs and pDCs. 

The study on the response of human MoDC to yeast, spheroplasts, pseudohyphae and spores was performed in collaboration with Duccio Cavalieri's group (partner 15). Analysis of IL-6, IL-8, TNFalpha, IL-1beta, IFNgamma, IL-10, IL-12p70, IL-12p40 secretion was performed with a multiplex assay.
We will evaluate the capacity of MoDC stimulated by different forms of S. cerevisiae and Candida albicans to differentially induce T cell polarization.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/431"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000057"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1110112">
    <rdfs:subPropertyOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteProperty"/>
    <rdfs:label xml:lang="en">obsolete_property2</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400113">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_482">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_ELISA assay</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000661</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000066">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">investigation</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400143">
    <rdfs:label>fluorometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/512">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have prepared several new constructs for the expression of (modified) adhesion receptors in DC.</rdfs:comment>
    <rdfs:label>Constructs for the expression of (modified) adhesion receptors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_562">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bacterium coli</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bacterium coli commune</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bacillus coli</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Escherichia coli</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">E. coli</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/128">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients were treated in a long peptide trial. Analysis of the local immune response demonstrated the presence of HPV16-specific Th1/Th2 cells infiltrating the vaccination site and the VIN lesion after vaccination. 5 out of 20 patients showed complete clearance of all VIN III disease and in 4 of these this was also associated with complete clearance of HPV16 virus. </rdfs:comment>
    <rdfs:label>Patients with VIN III lesion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A89">
    <rdf:rest rdf:nodeID="A25"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_604">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Experimental factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/135">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/77"/>
    <rdfs:label>Novel M-CSF dependent DC developmental pathway</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_808"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:comment>We have data available on a novel M-CSF dependent DC developmental pathway that is independent of Flt3L. These DC have unique characteristics and precursor origin. The cells can be found in vivo in Flt3L gene deleted (-/-) mice injected with recombinant M-CSF. </rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_369"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_307"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A93">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700345">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">selectin P (granule membrane protein 140kDa</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <OBI:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">P-selectin</OBI:IAO_0000118>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PSEL</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leukocyte-endothelial cell adhesion molecule 3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GMP140</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antigen CD62)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GRMP</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLJ45155</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">P-selectin precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PADGEM</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GMRP</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SELP</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LECAM3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Granule membrane protein 140</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GMP-140</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD62P antigen</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD62P</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A94"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD62</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000097">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001843</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD90</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000057">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 40 receptors</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A95"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 40</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD40 receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-40</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A96"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD40 receptors</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-40 receptors</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/95">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_778"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have expertise in performing ELISA assays. For instance, we use the ELISA kit for IL-12 and IL-10 from Biosource to evaluate cytokine accumulation in supernatants at 24h, according to a standard protocol and it was measured at 450n 

</rdfs:comment>
    <rdfs:label>ELISA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/300">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Using curdlan as a specific agonist of dectin-1, we have shown that this C-type lectin couple to Syk kinase leads to activation of ERK, JNK and p38 MAPKs, as well as NF-kappaB. </rdfs:comment>
    <rdfs:label>Curdlan as agonist</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000542">
    <rdfs:label>lymphocyte</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphocytes</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lymphocyte</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/81">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/54"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <rdfs:comment>We have obtained data from an analysis of the uptake, conservation and cross-presentation of the model antigen OVA after Fc receptor-mediated uptake by DC and from an analysis of the immunological consequences of the antigen depot. 

We found that MHC class I presentation is relatively short-lived in contrast to MHC class II. However, CD8 cross-priming capacity of OVA-loaded DC was functionally retained for many days, while peptide-pulsed DC had lost their priming capacity after 24 hours. Strikingly, OVA protein antigen was conserved intracellularly in DC for many days. Antigen-derived peptide presentation was efficiently restored after peptide elution from MHC class I at the cell surface, providing a strong association between intracellular antigen depot and the prolonged cross-priming potency of DC. Characterization of the storage compartments shows that these resemble lysosome-like structures, distinct from MHC class II loading compartments. We speculate that DC have adapted an endogenous compartment facilitating prolonged MHC class I presentation from exogenous antigen for effective CD8 T cell cross-priming. 

We have further analyzed the immunological consequences of the antigen depot. T cells that were induced by dendritic cells several days after a short antigen pulse had full proliferative capacity and could kill tumors in vivo. Furthermore, we studies the mechanism of cross-presentation of antigen from the antigen depot. By using inhibitors for the proteasome, we observed that the proteasome is crucial in the presentation of the antigen in MHC class I. 

By using TAP deficient cells, we found that TAP is also necessary for this process. We further characterized the antigen depot by confocal microscopy and found that the antigen co-localized with the lysosomal marker LAMP1, but not with the endosomal marker EEA1, TAP, MHC class I or MHC class II. We conclude that the antigen depot is a storage compartment and not a loading compartment. We have started to examine depot formation by targeting antigen to other receptors. For example, we have found that presentation of TLR ligand- long peptide conjugates was also long-lived, while presentation of OVA, targeted via the mannose receptor, was not long-lived.

We will address the requirement of antigen depot formation in dendritic cells for effective tumor elimination, by pulse-loading experiments of short and long peptides, whole protein immune complexes and TLRL-conjugated peptides. Our goal is to better understand the molecular requirements for antigen depot formation in dendritic cells. To accomplish this, we will further characterize the antigen storage compartment by proteomics. In addition, we want to address the mechanism of processing and presentation in MHC class I and MHC class II from the antigen depot in more detail. Furthermore, we plan to address the question why antigen is not degraded as would be expected in compartments with lysosomal characteristics.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000156"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/46"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/200"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/53"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/105"/>
    <rdfs:label>Induction of immune responses after targeting antigens to DC via Fc receptors </rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/518"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/54">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/146"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/147"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/235"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_752"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>HLA-A1 and/or HLA-A2 positive patients with stage III/IV melanoma undergo leukapheresis.</rdfs:comment>
    <rdfs:label>Leukapheresis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400153">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/328">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/215"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Group: Antigen presentation in dendritic cells</rdfs:comment>
    <rdfs:label>Ignacio CEBRIAN</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/179">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100468"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/130"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We obtained data on priming of an immune response through a series of critical interactions between the cholera toxin (CT) adjuvant and the dendritic cells (DC) of the splenic marginal zone (MZ).

The in vivo mechanisms of action of most vaccine adjuvants are poorly understood. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect. We demonstrated in mice that a series of critical interactions between the cholera toxin adjuvant and the dendritic cells of the splenic marginal zone lead to effective priming of an immune response. Thus, for the first time, we have followed adjuvant targeting of MZ DC in vivo.</rdfs:comment>
    <rdfs:label>In vivo mechanisms of action of vaccine adjuvants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/45">
    <rdfs:comment>We have obtained data on a possible cooperation between myeloid and plasmacytoid DCs in response to different microbial stimuli and a characterization of the mechanisms of this cooperation. For this, we have studied co-culture of mDCs and pDCs in response to CpGs, LPS and bacterial particles. 

Taking advantage on the fact that human myeloid and plasmacitoid DC show a selective response to LPS and CpG respectively, we have previously identified a cross-talk between two type of cells. Indeed it was observed that LPS-stimulated mDCs are able to induce up-regulation of co-stimulatory molecules on co-cultured pDCs. Similarly, CpG-stimulated pDCs activate co-cultured mDCs. Activation of the co-cultured population was restricted to up-regulation of co-stimulatory molecules and was partially cell contact-dependent. We have now investigated if co-operation between mDCs and pDCs is able to facilitate the induction of adaptive immunity in conditions of low stimulation, which can be encountered in the very early phase of a pathogen infection or in the presence of very low amounts of pathogen. In particular we analyzed if the synergy between mDCs and pDCs stimulated by their respective selective stimulus is important for increasing their ability at inducing T cell activation. Indeed we established that the mDC/pDC cross-talk has a functional effect on T cell activation. In fact the mDC/pDC cooperation event is able to significantly increase the ability of these cells to drive the proliferation and IFN? production by alloreactive T cells. In addition, we discovered that pDCs are not able to respond to whole fixed or live bacteria and consequently, these cells are incapable of phagocytosing   bacterial particles. These finding strongly suggest that pDCs is a cellular population that plays a very specialized antiviral function, although, through a cross-talk with mDC, it can also be indirectly recruited during a bacterial infection, synergizing in the induction of an adaptive immune response.

We will investigate the molecular mechanism through which a mDC/pDC cross-activation occurs. In particular, since the mDC/pDC cross-talk process that we identified is dependent on cell-contact events, we will try to identify the molecule/s responsible for cross-activation between mDCs and pDCs. 
</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/178"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdfs:label>Cross-talk between human mDC and pDC</rdfs:label>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/295"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_2"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#manufactures">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a person or a participant to a biomaterial or tool manufactured by that person or participant.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">manufactures</rdfs:label>
    <rdfs:domain rdf:nodeID="A97"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#is_manufactured_by"/>
    <rdfs:range rdf:nodeID="A98"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000812">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000096</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD86 receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/32">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/50"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We investigated the interactions between human monocyte derived DCs (MDDC), generated in the presence of GM-CSF and IL-4 (IL-4 DC), and antigen-stimulated circulating gamma delta T lymphocytes, bearing the Vgamma2 TCR. </rdfs:comment>
    <rdfs:label>MDDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/100">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/245"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/186"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_762"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Patients with advanced prostate carcinoma are vaccinated with the DC vaccine.</rdfs:comment>
    <rdfs:label>Vaccination of patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400114">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/ID#ID_0000052">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/ID#ID_0000047"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vaccine role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_481">
    <rdfs:label>electron microscope</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">electron microscope</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0400169"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/511">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In these patients, dendritic cells were tracked for monitoring of cellular therapy by MRI. MRI cell tracking using iron oxides appears clinically safe and well suited to monitor cellular therapy in humans. </rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/263">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/137"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Department:  	Microbiology
Unit: 	Microbiology
Subunit: 	Virology </rdfs:comment>
    <rdfs:label>Ellen van Gulck</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_36498">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">galactosylceramide</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">galactosylceramides</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/94">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/43"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The FAX analyser available in the laboratory is used, e.g., to measure transfection efficiency.</rdfs:comment>
    <rdfs:label>FACS analyser</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000545">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TH1 cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T cell type 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-helper 1 cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T lymphocyte type 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T cells type 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-cell type 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-lymphocyte type 1</dcr:hasExactSynonym>
    <rdfs:label>T helper cell 1</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T helper cell 1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TH1 cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/88">
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_357"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>Our lead product for the treatment of cancer is OncoVex GMCSF. OncoVexGMCSF is completing a 50-patient Phase II clinical trial for the treatment of unresectable metastatic melanoma, as a monotherapy, in the second line/salvage therapy setting. Data so far indicates that OncoVex can destroy both injected and un-injected melanoma deposits. The trial is still in progress.</rdfs:comment>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/79"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/213"/>
    <rdfs:label>50 patient phase II clinical trial for melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/257">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/181"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We found that Indium111 labelled DC should not be loaded with tumor antigens if applied in patients, which may result in loss of specific immune responses and are testing this in-vivo.

Analysis of DC migration in vivo in a first patient by i.v. application of  indium labelled E/L-S DC (without antigen loading) is scheduled for March 2009. Data will become available.</rdfs:comment>
    <rdfs:label>Analysis of DC migration by i.v. application of  indium labelled E/L-S DC </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/59">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/147"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/146"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/145"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_763"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Patients receive V administrations with eventual additional ones depending on clinical outcome.</rdfs:comment>
    <rdfs:label>Intradermal administration</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_534">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1#Entity"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A Public Resource is a thing that can possibly be included in the DC-THERA Directory.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Public Resource</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/39">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/60"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells were associated with multiple markers into 14 different cell types to identify subsets. 

The findings thus describe new CD8+ cell subsets, allow the identification of relatively homogeneous CD8+ subpopulations, provide a predictable and precise correlation between particular cell surface markers and CD8+ T-cell functional properties, and identify effector cells present in both CCR7-CD45RA+ and CCR7-CD45R0+ compartments. The results also indicate that activated cells might modulate the expression of CD45RA/R0 asynchronously rather than CCR7-CD45RA+ cells always issuing from CD45RA- precursors.</rdfs:comment>
    <rdfs:label>CD8+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/510">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/66"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Subcutaneous injection of hypoxic DCs into the footpads of mice results in defective DC homing to draining lymph nodes, but enhanced leukocyte recruitment at the site of injection. </rdfs:comment>
    <rdfs:label>Mice used in an experiment on the effects of tumour hypoxia on DC differentiation and maturation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/26">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Julie Woodhouse</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/105">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/196"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/195"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/197"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_744"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Electroporation of autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce the vaccine</rdfs:comment>
    <rdfs:label>Electroporation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/66">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <rdfs:label>Fungi stimulation</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdfs:comment>DC activation is induced by Saccharomyces cerevisiae yeast in different culture conditions, Candida albicans yeast or hyphae  at different ratio stimuli:DCs. As control stimuli DCs are stimulated with LPS, Curdlan or Zymosan.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_212"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A99">
    <owl:allValuesFrom rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <owl:onProperty rdf:resource="http://dc-research.eu#hasOrganism"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/230">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/17"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The kinetic of the transcriptional profiling of purified mouse DC treated with IL10 was analysed.</rdfs:comment>
    <rdfs:label>Purified mouse DC treated with IL10</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000060">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">trial monitor</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_9600">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">prostate</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400119">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/322">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Karin Drenth</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/218">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/158"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Proteomic data has been obtained using used yeast as a model organism to optimize technological approaches for the quantitative assessment of molecular components in yeast proteomics. We compared protein levels of essentially all endogenous proteins in haploid yeast cells to their diploid counterparts. Our analysis spanned more than four orders of magnitude in protein abundance with no discrimination against membrane or low level regulatory proteins (deGodoy et al.). </rdfs:comment>
    <rdfs:label>Proteomic analysis of yeast cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000689">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sampling time factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000737">
    <rdfs:label>cloning vector</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000020">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">contract research organization</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_164">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_324"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE 3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE-3 antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE-3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE3 antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE 3 antigen</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">melanoma antigen MAGE-3</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/93">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/72"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have know-how on TaqMan gene expression assays by Perkin-Elmer Applied Biosystems. They are used, for instance, for PCR analysis.</rdfs:comment>
    <rdfs:label>TaqMan® Gene Expression Assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/262">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Katherine Corr</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/87">
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/24"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000182"/>
    <rdfs:label>DERMA-ER-DC 06 trial: RNA-based DC vaccine</rdfs:label>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_216"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/247"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704043"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/16"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/522"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/23"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/181"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://purl.obofoundry.org/obo/OBI_0300310"/>
    <rdfs:comment>Design of this trial: sequential adaptive design, 2nd cohort, mature DC transfected with RNA encoding MelanA, Mage3 and Survivin +/- E/L-selectin, i.v. route, 13 evaluated patients. Comparison of pre-existing and vaccine-induced immune responses in stage IV melanoma patients.

We have efficiently transfected DC with RNA encoding a functional protein (E/L-selectin), which allows entry of DC into LN from HEV. These DC rolled in vitro on sialyl-LewisX-coated slides, and in vivo, mouse E/L-selectin-transfected DC homed to LN after i.v. application. Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial. To increase RNA stability and to obtain a longer-lasting expression of E/L-selectin on DC, thereby providing a higher chance that DC can migraten efficiently to LN, the RNA was modified by introducing different RNA caps, introducing different 3’ UTRs, and by elongation of the poly A tail. Furthermore, mouse experiments have been started in collaboration with P02 to perform quantification of E/L-selectin-transfected DC that migrated into LN by labelling these cells with Indium or SPIO beads.  

Immunomonitoring of this trial was based on ELISPOT assays with overlapping peptides covering the whole protein sequence of the tumor antigens MageA3, MelanA and Survivin. Most patients already demonstrated broad responses to numerous peptides prior vaccination. Significantly enhanced responses to several peptides and occurrence of new responses was seen in 6 patients, 5 of which were vaccinated with E/L-S+ DC. These data provide evidence for a superior immunopotency of  E/L-selectin expressing DC. The distribution of i.v. given DC is currently being analyzed using Indium labelling.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/22"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/119"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/258">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/260"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/259"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data will be available from in-vitro pre-clinical tests on the pharmacodynamic activity of the fusion vaccines.

This test will verify the capacity of the fusion vaccine to present certain tumour-antigen derived peptides corresponding to antigens present in the fused cancer cells. 

BruCells has met with the Dutch MEB for a Scientific Advice Meeting on January 10, 2008 in The Hague.
The Dutch authorities consider that the proposed in-vitro pre-clinical tests are adequate to check the pharmacodynamic activity of the fusion vaccines and that no animal model tests would be necessary.</rdfs:comment>
    <rdfs:label>In vitro antigen presentation assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_536">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC researcher</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DC researcher role is a DCTHERA role that involves that the person assuming the role does dendritic cell research.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000116"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A100">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/106">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/236"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/197"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_762"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Advanced melanoma patients are vaccinated with the DC vaccine.</rdfs:comment>
    <rdfs:label>Vaccination of patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/25">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brigitte Zuleger</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1000042">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/65">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>FACS analysis
Type I IFN- production
We established a very sensitive, fibroblast based assay for the detection of interferon (outside collaboration)
Add the supernatant from the uptake experiments to these reporter cells. We use the Luciferase Assay System from Promega for analysis.</rdfs:comment>
    <rdfs:label>DC stimulation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/321">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Seraphin Olmos</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000124">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll like receptor</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A101"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_63887"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll-like receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/217">
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data were obtained from profiling of human monocyte-derived DC exposed to different maturation cocktails and various activators or inhibitors.</rdfs:comment>
    <rdfs:label>Profiling of human monocyte-derived DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/43">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our laboratory has obtained data on the role of DC-derived cytokines in NK cell production of IFN-gamma.</rdfs:comment>
    <rdfs:label>Role of DC-derived cytokines in NK cell production of IFN-gamma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/38">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/57"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_81494"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We showed that, in the absence of additional stimuli, inflammatory signals such as pro-inflammatory stroma-derived cytokines on DC are ineffectual in promoting DC activation and cannot substitute for engagement of innate receptors directly on DC.</rdfs:comment>
    <rdfs:label>pro-inflammatory stroma-derived cytokines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/92">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>There is a MACS separator (Miltenyi Biotech) at the disposal of our lab. It is used, for example, to purify CD8 T cells.</rdfs:comment>
    <rdfs:label>MACS Separator</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400158">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/261">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Angus Dalgleish</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/86">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/18"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/41"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/150"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>Our lab has data from an interim statistical analysis of the DERMA-ER-DC 04 trial (multipeptide loaded cytokine matured moDC +/- CD40L activation, 70 evaluated patients). This analysis for the first time showed a clinical correlation of induced immune responses as measured in the blood with outcome, as there have been so far statistically significantly less events in stage III patients showing good CTL reponses (IFN-y Elispot) to multiple class I and II peptides compared to low responders of the stage III cohort. Additional in vitro maturation of DC by CD40L (leucine zipper, Immunex) did not result in better immunity compard to standard cytokine cocktail matured DC.

The trial was closed in 2007. Ongoing monitoring has confirmed a clinical correlation of induced immunes responses. In stage IV patients very rapidly progressing patients showed in general weak immune responses after the first vaccinations. The strength and breadth of induced immune responses was, however, identical in patients living up to 24 months or significantly beyond 24 months. Interestingly, we could distinguish between these two groups by transcriptome analysis of pre-vaccination metastases in that long survivors had a preexisting “friendly” non-suppressive micromilieu. This is obviously an exciting finding and will influence future study design, and possibly allow a preselection of  patients responsive to immune intervention.</rdfs:comment>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/46"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdfs:label>DERMA-ER-DC 04 clinical trial of DC-based therapy of melanoma patients +/- CD40L activation</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/130">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/76"/>
    <rdfs:label>Study of functional homogeneity by transcriptional screening of subsets of CD8 PBL </rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/70"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:comment>Our lab obtained data on functional homogeneity from a gene expression analysis at single-cell level for the expression of 8 effector genes from normal donors. 

Until 2006 we subdivided CD8 PBL from normal donors in 14 different cell sets based in the expression levels and the co-expression of 5 different cell surface markers and studied functional homogeneity by screening cells from each subset at single-cell level for the expression of 8 effector genes (Blood, 2007). Although these studies allowed us isolate some homogeneous cell types, we yet found heterogeneity within some TEM subsets. 

Our current efforts involve a transition to 8 colours surface staining, and the evaluation of antigen-specific cell sets identified with MHC tetramers. For the later process, we initiated data collection of EBV, CMV and HIV specific T cell sets. </rdfs:comment>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_344"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_12305"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10376"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/69"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/57">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/266"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/145"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_771"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The next day the peptides and KLH are replaced and incubated for further 4h and then used for quality controls and intradermal administration.</rdfs:comment>
    <rdfs:label>Incubation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_215">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gp33 peptide</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gp33</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/259">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/260"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/258"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>This test will verify whether the fusion vaccine possesses the properties of both parental cell types for inducing primary CD8+ T-cell responses (data will become available).  
Detection of circulating tumour-specific CD8+ T-cells. 

BruCells has met with the Dutch MEB for a Scientific Advice Meeting on January 10, 2008 in The Hague.
The Dutch authorities consider that the proposed in-vitro pre-clinical tests are adequate to check the pharmacodynamic activity of the fusion vaccines and that no animal model tests would be necessary.</rdfs:comment>
    <rdfs:label>In vitro priming of tumor-antigen specific T-cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/42">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/154"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_780"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have know-how about LDA assays; for instance, we use LDA assays to monitor vaccine induced T cell responses.</rdfs:comment>
    <rdfs:label>LDA assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBioSource">
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasBioSourceType</dcr:hasClassAsRangeProperty>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">connects a biomaterial to an ontology term from the biomaterial branch: biological source is the biomaterial that something was taken from, the biomaterial that is at the basis of some investigation/transformation etc.
particular - universal relationship</rdfs:comment>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">biomaterial source</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_167">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Apo-DC</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">apoptotic, leukemic cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/103">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/384"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/191"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_762"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Vaccination with a vaccine composed by autologous DCs pulsed with apoptotic autologous ovarian carcinoma cells. Apoptosis is induced by UV.  </rdfs:comment>
    <rdfs:label>Vaccination of patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_229">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SK-Mel 24 peptide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/42">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_236"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_234"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/446"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200769"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_289"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label>Role of IL-10 and IDO in relation to Th1 and inflammatory responses in colitis model</rdfs:label>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/448"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/164"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_45615"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_292"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Our lab has obtained data on the role of IL-10 and IDO in relation to Th1 and inflammatory responses in a colitis model tested on mice. IDO appears critical for the regulation of TNBS colitis upon CTLA-4 engagement, as the beneficial effect of anti-CTLA-4 treatment was lost in IDO-deficient mice. By contrast, the absence of IDO did not alter the course of inflammation in mice injected with TNBS only, an unexpected finding which suggests that IDO-dependent counter-regulation requires other factors/cells in addition to IDO production and T cell activation by TNBS. Our observations would suggest a critical role for activated Treg, producing IL-10 and expressing high levels of CTLA-4, ICOS and FoxP3. 

We have investigated the respective role of IL-10 and IDO, both required for Th1 suppression in this model. As IL-10 has been shown to indirectly dampen Th1 responses through the inhibition of IL-12 production by antigen-presenting-cells, we monitored mRNA expression specific for the inducible chain IL-12 p35 in lymph nodes draining the site of injection or in mesenteric lymph nodes of mice instilled intra-colonically with TNBS. Our results clearly show that IL-12 production early after the onset of the response was unaffected by anti-CTLA-4 treatment.  By contrast, our data confirm previous data showing that IL-10 is critical for IDO production by DC in vitro, suggesting that IL-10 may act upstream by modulating the expression of IDO. As IDO expression was detected in the colon but not in the spleen or mesenteric lymph nodes, we postulate that IDO may act as anti-inflammatory agent in the intestine and that IL-10 may inhibit Th1 activation in the lymphoid organs and enhance IDO expression in the gut.

We will complete these experiments by (1) testing whether IL-10 is required for IDO expression in vivo; (2) evaluating the role of ICOShi regulatory T cells in the intestine in steady state conditions and (3) the role of intestinal flora in the development of these cells using axenic mice. In parallel, we are testing whether the population of natural regulatory T cells (CD25+) control immune responses by acting on antigen-presenting-cells and in particular on dendritic cells.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701384"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/213"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/447"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/64">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Purified CD8 T cells using MACS cell separation were co-cultured with electroporated DC. After several stimulations, the CD8 T cells become evaluated on their cytokine secretion, cytotoxicity and % of antigen specific T cells. </rdfs:comment>
    <rdfs:label>In vitro CD8 T cell stimulatory capacity of DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400147">
    <rdfs:label>microarray</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/24">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>(part time: Mo - Fr morn.)

Vice manager of Dezernat/Dept. 7</rdfs:comment>
    <rdfs:label>Sabine Klostermeier</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/123">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This patient experienced an outstanding response to immunotherapy. The patient received several adoptive T cell transfers and regressed from stage IV melanoma to a disease free state and has remained tumor free for several years.</rdfs:comment>
    <rdfs:label>Melanoma patient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_600">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000116"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA PhD student</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/324">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/228"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Department of Internal Medicine</rdfs:comment>
    <rdfs:label>Bart Lambrecht</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_267">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC 205</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-205 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC 205 receptor</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD205</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC205</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 205 receptor</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC-205</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-205</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 205</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD205 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC205 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC-205 receptor</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A102"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/37">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/54"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Experiments using these mice and IL-7R blocking antibody were carried out on the phases of cytotoxic T lymphocyte (CTL) responses.</rdfs:comment>
    <rdfs:label>CD40 and IL-12 knock out mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_848">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">arthritis</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasExperimentalFactor">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">experimental factor</rdfs:label>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasExperimentalFactorType</dcr:hasClassAsRangeProperty>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with an experimental factor. As this would make the ontology OWL full, the annotation property hasExperimentalFactorType is used instead.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400117">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_816">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000351</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Clinical information factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_856">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">comparative genome hybridization experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Experiment design type in which genomic content is studied using an array based assay.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/85">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/59"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/58"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/57"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/60"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/227"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000848"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Induction of effective therapeutic anti-tumour immunity using lentiviral vectors</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:comment>We have data available on the induction of effective therapeutic antitumor immunity by direct in vivo administration of ovalbumin (OVA) encoding lentiviral vectors.

Ex vivo lentivirally transduced dendritic cells (DC) have been described to induce CD8+ and CD4+ T-cell responses against various tumor-associated antigens (TAAs) in vitro and in vivo. 

We report here that direct administration of ovalbumin (OVA) encoding lentiviral vectors caused in vivo transduction of cells that were found in draining lymph nodes (LNs) and induced potent anti-OVA cytotoxic T cells similar to those elicited by ex vivo transduced DC. The cytotoxic T-lymphocyte (CTL) response following direct injection of lentiviral vectors was highly effective in eliminating target cells in vivo up to 30 days after immunization and was efficiently recalled after a boost immunization. Injection of lentiviral vectors furthermore activated OVA-specific CD4+ T cells and this CD4 help was shown to be necessary for an adequate primary and memory CTL response. When tested in therapeutic tumor experiments with OVA+ melanoma cells, direct administration of lentiviral vectors slowed down tumor growth to a comparable extent with the highest dose of ex vivo transduced DC. Taken together, these data indicate that direct in vivo administration of lentiviral vectors encoding TAAs has strong potential for anticancer vaccination.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_334"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/260">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Dr Rita G Nunes

Honorary Research Fellow
Division of Clinical Sciences</rdfs:comment>
    <rdfs:label>Rita G Nunes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000144">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">independent data monitoring committee</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CARO#CARO_0000013">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <owl:equivalentClass rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CL#CL_0000000</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000546">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-cells type 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TH2 cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-lymphocytes type 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T helper cells 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T lymphocytes type 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T lymphocyte type 2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T cells type 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-helper 2 cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-lymphocyte type 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">helper T-cell type 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-helper 2 cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TH2 cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T helper cell 2</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/131">
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_220"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000182"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_245"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/74"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_345"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700345"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17239"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_366"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdfs:comment>We have data available on the role of chemokine receptors in regulating migration of mature DC and subsets of effector and memory T cells in secondary lymphoid organs. CCR7 is a chemokine receptor that is expressed by mature DCs and central memory T cells (TCM) and regulate migration of these cells in secondary lymphoid organs in the steady state.  T lymphocytes lacking the lymph node homing receptors L-selectin and CCR7 do not migrate to lymph nodes in the steady state. In contrast it was found that lymph nodes that drain sites of mature DC or adjuvant inoculation recruited L-selectin- CCR7- effector and memory CD8+ T cells. This cell recruitment required CXCR3 expression on T cells and occurred through high endothelial cells (HEV) in concert with HEV luminal expression of the CXCR3 ligand CXCL9. In reactive lymph nodes, recruited T cells established stable interactions with and killed antigen-bearing DC, limiting the ability of these DCs to activate naive CD4+ and CD8+ T cells. The inducible recruitment of blood-borne effector and memory T cells to lymph nodes may represent a mechanism for terminating primary and limiting secondary immune responses. In addition to CD8+ TEM, CD4+ TEM also migrated in a CD62P-dependent fashion into reactive lymph nodes that were induced to stably express CD62P on high endothelial venules. CD4+ TEM, but not naïve or TCM cells, constitutively expressed CD40L at levels sufficient to induce DC maturation in vitro and in vivo in the absence of antigenic stimulation. Presentation of a MOG peptide by TEM-licensed DC was sufficient to induce experimental allergic encephalomyelitis. Importantly, DC maturation and autoimmunity were inhibited by antibodies to CD62P that prevented CD4+ TEM migration into lymph nodes. These results provide a mechanistic link between lymphocyte traffic in lymph nodes and induction of autoimmune diseases.

We are currently investigating how CDP to cDC and pDC development is guided by external stimuli in vitro and in vivo. To this end, we evaluate the differentiation pathways upon inflammatory stimuli as TLR agonists. Furthermore, we have generated cytokine deficient animals (GM-CSF-/-Flt3L-/-) with the intention to test the combined effects of these cytokines on DC development in vivo. Also, we are in collaboration with Dr. Tim Sparwasser's laboratory at the TU Munich currently generating Flt3 and Flt3L reporter mice with the intention to elucidate in vivo DC developmental regions in steady state and inflammation in situ.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/71"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_216"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_367"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_369"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_217"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_219"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/207"/>
    <rdfs:label>DC-induction of T cell responses</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/58">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/145"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/145"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Quality controls</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_216">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">high endothelial cells</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HEV</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000115"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700314">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcRI</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gamma RI</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">High affinity immunoglobulin gamma Fc receptor I precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcgr1</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcg1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IgG Fc receptor I</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD64</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcgammaRI</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gamma RI</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD64 antigen</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_227">
    <rdfs:label>GM-DC</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GM-DC</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_66836">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytosol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hyaloplasm</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytoplasmic matrix</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/41">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_483"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our laboratory, we have experience in performing CBA assays. We use them, e.g., in the monitoring of vaccine induced T cell responses.</rdfs:comment>
    <rdfs:label>CBA assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/63">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_232"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/68"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <dcr:hasBioSourceType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0050147"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_180"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_487"/>
    <rdfs:label>Immune monitoring of DC vaccinated advanced melanoma patients</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/122"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/286"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:comment>IFNgamma ELISPOT of peptide pulsed, leukapheresis derived PBMC
Tumor antigen specific activation of CD8 and CD4 DTH infiltrating T cells (CD137, CD107a, CD154, cytokines TNFalpha and IFNgamma) </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/41">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/165"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/162"/>
    <rdfs:comment>Data has been obtained on the activation of human DC by Toll like receptor ligands (TLR-L) that modulates the lipid biosynthetic pathway, resulting in enhanced recognition of CD1d-associated lipids by iNKT cells. DC derived soluble factors further increase CD1d-restricted iNKT cell activation, as defined by IFN-alpha secretion. Finally, using soluble tetrameric iNKT TCR as a staining reagent we demonstrate specific up-regulation of CD1d-bound ligands upon TLR-mediated APC maturation. The ability of innate stimuli to modulate the lipid profile of DC resulting in iNKT cell activation, underscores the role of iNKT cells in assisting priming of antigen specific immune responses.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/4"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <rdfs:label>Capacity of innate stimuli to modulate DC - iNKT crosstalk; role of lipids in signalling from TcR of iNKT cells</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/168"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/5"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/166"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_228">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Flt3-DC</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11309">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">avian influenza virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Influenza virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Influenzavirus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Influenza virus sp.</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">unidentified influenza virus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_16991">
    <rdfs:label>deoxyribonucleic acids</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000636">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/124">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These are RCC patients with clear cell histology, treated using the PME-CD40L DC product. At present, 6 of the 12 patients that have been restaged using RECIST criteria have less tumor burden that when they enrolled in the study (15 weeks earlier).</rdfs:comment>
    <rdfs:label>12 RCC patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/104">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_766"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The DC populations were CD123+, CD11c+CD16+, CD11c+BDCA1+, CD11c+BDCA3+ DC.</rdfs:comment>
    <rdfs:label>9-colour FACS analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_217">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCL9</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/23">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/345"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/339"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/506"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/140"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/344"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/338"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/73"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/336"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/26"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/343"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/337"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/342"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/18"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/340"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/341"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/17"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/567"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/522"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/24"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/22"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/21"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <rdfs:label>Alexander Steinkasserer</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/346"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/150"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/310"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/36">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/54"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_300"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells were primed in vitro by engineered antigen-presenting cells and used to investigate the effect of environmental factors on development of high affinity cytotoxic T lymphocytes (CTL).</rdfs:comment>
    <rdfs:label>OT-1 cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/323">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/134"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/133"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/132"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Silvano Sozzani</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/219">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/174"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/29"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data was obtained on the regulatory T cells (Tregs) and their role in effective anti-tumor immune responses in FoxP3-DTR DEREG mice.

Although multiple mechanisms of Treg action have been proposed, the actual mechanism involved in the suppression of anti tumor T cell responses are still unclear. 
Treg inactivation by anti-CD25 antibodies or by depletion in FoxP3-DTR DEREG mice resulted in effective rejection of the tumors upon adoptive transfer of antigen-specific CD8+ T cells. Treg inactivation or depletion induces a marked arrest in the migration of anti-tumor CD8+ T cells selectively in tumor-draining lymph nodes. Reduced T cell motility in lymph nodes was associated with an amplification of the effector cells, increased IFN? production, and tumor rejection. 
We also show that Tregs make multiple brief contacts with the CD8+ T cells in the lymph nodes of tumor bearing mice. The frequency of these interactions, but not their duration, was inhibited by the treatment with anti-CD25 antibodies. We conclude that direct contacts between CD8+ T cells and Tregs in tumor-draining lymph nodes may contribute to the inhibition of anti-tumor immune responses. However, we were unable to establish the functional relevance of the direct Treg-CD8+ T cell contacts that we imaged.
Besides, Treg inactivation also induces an increase in the number of dendritic cells (DCs) in these tumor-draining lymph nodes. Therefore Tregs could influence CD8+ T cell arrest by modulating the number of antigen presenting cells in the tumor-draining lymph nodes.

DCs have developed numerous specializations to adapt their internalization pathway to efficient antigen processing. Recruitment of ER components to phagosomes has been postulated as one of the high specializations required to allow exogenous antigens to reach MHC class I pathway. However, no direct evidence of a fusion between those compartments has been reported. We will use a lentiviral-based approach to knock down protein expression of molecules potentially involved in ER-phagosome and we will test how this affect cross presentation in BMDCs.
Also, we are planning to investigate the mechanisms by which Tregs limit DC accumulation in tumor-draining lymph nodes. Preliminary results suggest that Treg may reduce DC survival in tumor draining lymph nodes. Therefore, we will use two photon microscopy to analyse DC survival in vivo and unravel the molecular mechanisms involved.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdfs:label>Regulatory T cells (Tregs) limit the onset of effective anti-tumor immune responses</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400118">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A103">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_8">
    <rdfs:label>Clinical protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A clinical protocol is a protocol that is applied in the clinic to the treatment of (a) patient(s).</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Clinical protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/214">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data will become available on the safety, antitumoral immune response and DC migration in the organism in patients with advance renal cell carcinoma and melanoma from this trial using cellular immunotherapy with dendritic cells loaded with tumor antigens.

This study is not yet open for participant recruitment. 
ClinicalTrials.gov Identifier: NCT00610389

Purpose
Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has shown clinical activity, although in a small number of patients. Therefore, it is mandatory to improve the results of this strategy and to closely monitor immunologic response and cell migration in order to improve our understanding of mechanisms of action and to settle future fields of development.

Objectives
Primary: to confirm clinical activity of this strategy, determining tumor response (RECIST criteria). 
Secondary: to determine: 
  (1) safety; 
  (2) antitumoral immune response and 
  (3) DC migration in the organism

Methodology
Phase II trial in patients with advanced renal cell carcinoma and melanoma. We will perform repeated immunizations with DC loaded with the patient´s tumor.</rdfs:comment>
    <rdfs:label>Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/213">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pauline Verdijk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/121">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/90"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This vaccine was used for RCC patients who were deficient in T cell IFN-gamma and IL-2 production pre-vaccination.</rdfs:comment>
    <rdfs:label>DC-based vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/234">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/56"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/55"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DCs were generated from adherent peripheral blood monocytes and will subsequently be used as a vaccine for HLA-A1 and/or HLA-A2 positive patients with stage III/IV melanoma.</rdfs:comment>
    <rdfs:label>Generated DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A104">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_859">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000710</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Strain or line factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_000235">
    <rdfs:label>macrophage</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">macrophage</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#AXL_Protein">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A105"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tyrosine-Protein Kinase Receptor UFO</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AXL</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AXL protein</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AXL receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/267">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>S. S. Jensen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A106">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_579">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stimulation by chemical entity factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000283"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_353">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphoma</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/131">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/234"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/257"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000050"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This platform with its enhanced GMP facilities for production of clinical-grade DC is established in Erlangen DE (P6, Schuler / Schuler-Thurner). However, later it was decided to seek a licence for the production of GMP-grade mRNA that will be used for the (revised) multi-centre clinical trial.</rdfs:comment>
    <rdfs:label>Cell therapeutics platform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_7">
    <rdfs:label>Laboratory protocol</rdfs:label>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A laboratoy protocol is a protocol that is applied in the laboratory.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Laboratory protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/212">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/307"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/210"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Nicolas Kesteman was enrolled as PhD student at the University of Brussels . 
He passed  his PhD at the end of  2007. He is now appointed as teacher in a High School in biotechnology in Belgium. </rdfs:comment>
    <rdfs:label>Nicolas Kesteman</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A107">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A103"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/213">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data was obtained on the efficacy in a phase I/II study investigating multiple injections of CLL-DCV01 in patients with previously treated B-cell chronic lymphocytic leukemia. 

This study is fully enrolled (n=9). Efficacy data will be assessed via tumor burden data collected over the next two months. Absolute lymphocyte counts and immunomonitoring data will be compiled by the end of Q1’08.</rdfs:comment>
    <rdfs:label>Phase 1/2 CLL clinical study</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/IAO_0000064">
    <rdfs:label>algorithm</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_45615">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gut</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/122">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DC-based vaccines that were given to these patients were combined with low dose IFN-alfa (3 x 10e6 U per wk). In a number of patients we observed vaccine-induced depigmentation and vitiligo.</rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/266">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Razvan Popovici</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000168">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Uvomorulin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">L-CAM</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">E-cadherin</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A108"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell-CAM120/80</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Epithelial-cadherin</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Arc-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cadherin-1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001764">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">D1 dopamine receptor</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">D1 cell</rdfs:label>
    <rdfs:label>D1 cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">D1-receptor</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">D1 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dopamine D1 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">D1-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dopamine 1 receptor</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell type factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/235">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/55"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/54"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These adherent peripheral blood monocytes are produced from leukapheresis from HLA-A1 and/or HLA-A2 positive patients with stage III/IV melanoma, used to generate DCs from. The latter will subsequently be used to vaccinate the HLA-A1 and/or HLA-A2 positive patients.</rdfs:comment>
    <rdfs:label>Adherent peripheral blood monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A109">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_578">
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000283"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stimulation by cell line factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000566">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/130">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_782"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have developed immunological techniques for monitoring of tumour antigen specific CD4+ T cell responses. We set an in vitro system able to detect fona fide in vivo primed CD4+ T cells. Purified CD4+ T cells are first stimulated in vitro once in the presence peptides, previously identified as containing naturally processed epitopes on tumour-associated antigens. After two weeks, proliferation and cytokine secretion (IFN-?, IL-5, IL-4, IL-2, TNF-?, IL-10, TGF-?, IL-17, granzyme and perforin) are tested. To estimate the frequency of antigen specific CD4+ T cell we used intracellular staining for IFN-? and/or IL-13, following indications from restimulation assays. We investigated the spontaneous CD4+ T cell immunity to MAGE-A3 and CEA in normal donors and in patients with advanced melanoma and pancreas carcinoma, respectively. We found that MAGE-A3 specific CD4+ T cells, which showed an unpolarized or Th2 skewed phenotype, were present in the blood of a high percentage of melanoma patients. We also found that pancreatic cancer patients compared to normal donors have impaired quantitative (i.e., reduced number of responders) and qualitative (i.e., Th2 skew) anti-CEA CD4+ T cell response. Importantly, anti-viral CD4+ T immunity was preserved. These results suggest that local more than systemic immunoregulatory mechanisms are active in pancreatic cancer. We have optimized the MAGE-A3 peptides to load onto HLA-DR*1101 tetramers by generating minimal peptide analogues containing a single anchor residue and we succeeded to produce functional HLA-DR*1101 tetramers.

We plan to continue the monitoring of vaccine and tumour specific T cell responses in vaccinated melanoma patients and the spontaneous anti-tumour CD4+ T cell immunity in patients with MAGE-A3, CEA and HPV expressing neoplastic lesions by the use of the strategies developed inclusive of the HLA-DR*1101 tetramers.</rdfs:comment>
    <rdfs:label>Immunological techniques for monitoring of tumour antigen specific CD4+ T cell responses</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasOrganism">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organism</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset or a bio-material with an organism. As this would make the ontology OWL full, the annotation property hasOrganismType is used instead.</rdfs:comment>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/OBI_0100026"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasOrganismType</dcr:hasClassAsRangeProperty>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:domain rdf:nodeID="A110"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_37577">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Chemical compound</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">salts (hold together by ionic bonds) and metallic compounds (hold together by metallic bonds)

wikipedia: A chemical compound is a pure chemical substance consisting of two or more different chemical elements[1][2][3] that can be separated into simpler substances by chemical reactions[4] and that have a unique and defined chemical structure. Chemical compounds consist of a fixed ratio of atoms[3] that are hold together in a defined spatial arrangement by chemical bonds. Chemical compounds can be compound molecules hold together by covalent bonds, salts hold together by ionic bonds, metallic compounds hold together by metallic bonds, or complexes hold together by coordinate covalent bonds. Substances such as pure chemical elements and elemental molecules consisting of multiple atoms of a single element (such as H2, S8, etc.) are not considered chemical compounds.[5]</OBI:IAO_0000115>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chemical compound should actually be a superclass of molecular entities, salt, metallic compound and complexes. However, for visualization purposes in the DC-THERA Directory, we keep it as a sibling of the other concepts (for now).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_24431</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/216">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Transcriptional data is available on macrophage knockout BALB/c and C57BL/6 mice using different stimuli at different time points in the presence or absence of a kinase inhibitors.</rdfs:comment>
    <rdfs:label>Transcriptional profiling of macrophage knockout BALB/c and C57BL/6 mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_2">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eubacteria</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bacteria</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A111">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/232">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/71"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Constructs for fusion proteins of the DC specific receptor DC-SIGN fused to GFP have been completed and tested. </rdfs:comment>
    <rdfs:label>DC-SIGN/GFP fusion proteins</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A112">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <owl:onProperty rdf:resource="http://dc-research.eu#hasStimulus"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_211">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HIV antigen</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A113"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/170">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/37"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/35"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11276"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700621"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_394"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data using electron microscopy to document the production and secretion of tubulovesicular structures by cells overexpressing VSV-G glycoprotein. These tubulovesicular structures contaminate recombinant viral preparations and play an important role in determining their innate activating potential. The protocols used in those studies have been published and expression vectors for GFP-RIG-I have been made available.</rdfs:comment>
    <rdfs:label>Definition of the mode of activation of RIG-I</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/458">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/192"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7474"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/140"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The organization of bmDC, B lymphocytes and plasma cells in the BM of the long bones was studied by immunochistochemistry. Using CX3CR1GFP mice, in which bmDC are green fluorescent (GFP), the bmDC localization was analyzed and it was found that the cells were organized in unique clusters, mainly located in the endosteum of the BM. These DC co-localize with B cells and these clusters are occupying architecturally definable niches and are reminiscent to the niches that were found in the cranial BM parenchyma. By using Fibronectin antibody the stroma of the BM could be visualized. In addition, a large fraction of IgA positive plasma cells is located in the BM. Staining for these cells revealed that plasma cells are scattered through the BM and are not preferentially found in DC-B cell niche. However, depletion of DC led to reduction in IgA+ plasma cells, which might indicate that bmDC are critical for survival of these cells in the BM. </rdfs:comment>
    <rdfs:label>Bone marrow of long bones</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/265">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Radek Spisek</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/559">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have conducted a phase I long peptide vaccination trial with p53 peptides in Montanide adjuvant in patients with colorectal cancer or ovarium cancer.</rdfs:comment>
    <rdfs:label>Patients with colorectal cancer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_5">
    <rdfs:label>clinical study dataset</rdfs:label>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">clinical study dataset</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A clinical study data set is a data set that is produced as the output of a clinical study of any stage, such as efficacy and safety data.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_577">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stimulation by cell type factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000283"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#tool_used_in">
    <owl:inverseOf rdf:resource="http://dc-research.eu#uses_tool"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any tool to the protocol or data set it was used in.</OBI:IAO_0000115>
    <rdfs:range rdf:nodeID="A40"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is tool used in</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/214">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/316"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/74"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Rebekka Geiger is now working at the Benaroya Research Institute, US.</rdfs:comment>
    <rdfs:label>Rebekka Geiger</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/215">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Pathway data is available form a comparative pathways-based analysis of proteomic data performed from same sources.</rdfs:comment>
    <rdfs:label>Transcriptional profiling of human monocyte-derived DC matured with a cytokine cocktail</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/519">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have chemically coupled the R-epimer of the Pam3CSK4 to long peptides containing a CTL epitope and used this structure to investigate the behaviour of the diastereomer.</rdfs:comment>
    <rdfs:label>R-epimer of the Pam3CSK4</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000045">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000003"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">base unit</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A unit which is one of a particular measure to which all measures of that type can be related.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A10">
    <rdf:rest rdf:nodeID="A107"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/171">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab has obtained data on indirect activation of DC by immunomodulatory mediators.

TLRs signal directly for DC activation but also promote production of immunomodulatory mediators by many other cell types. These mediators could be sufficient to activate DC indirectly, thereby potentially allowing responses to organisms with which DC do not come into direct contact. 

We tested this hypothesis and, surprisingly, found that indirect signals alone led only to partial DC activation and resulted in clonal expansion of T cells lacking typical Th1 or Th2 function. These results show that indirect signals by themselves cannot fully substitute for TLR triggering in DC and further suggest that the function of TLRs and other pattern recognition receptors expressed by APC is to regulate production of Th-directing cytokines, allowing APC to couple the class of adaptive immune response to the nature of the pathogen. This has important implication for the design of cancer vaccines and is of direct relevance to the goals of the network.</rdfs:comment>
    <rdfs:label>Indirect activation of DC by immunomodulatory mediators</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/120">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <rdfs:label>G4 patient (E507) </rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <rdfs:comment>This patient has received 6 vaccines with peptide only in a randomized trial to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4).

The patient received a sequence of six immunizations every two weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4 in Cycle 1. In Cycle 2, the patient received a sequence of three immunizations every six weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4.  The patient  had clinically shown Partial Response at the end of cycle 1 and was in complete remission in the course of cycle 3.

No immunological response to the vaccinations had been observed after cycle 1 and a new analysis on PBL collected after cycle 2 did not show any change.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A114">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/139">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/300"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Shalin Naik</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/459">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/64"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/84"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_244"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have completed and published our work on biodegradable poly (D, L-lactide-co-glycolide) (PLGS) micropsheres (MS) coencapsulating ligands for endosomally expressed TLRs plus exogeneous Antigen (Ag) to deliver its cargo to endosomes of murine Dendritic cells (DCs), thus initiating TLR mediated DC maturation as well as processing of MHC class I and class II restricted epitopes.</rdfs:comment>
    <rdfs:label>PLGS microspheres</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_212">
    <rdfs:subClassOf rdf:nodeID="A115"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_37163"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zymosan</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/264">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Marc Schweneker</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400040">
    <rdfs:label>FACSAria</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_6">
    <rdfs:label>preclinical study dataset</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A preclinical study data set is a data set that is produced as the output of preclinical studies, such as feasibility, iterative testing and safety data.</OBI:IAO_0000115>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">preclinical study dataset</rdfs:label>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_37537">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Esters are chemical compounds derived formally from an oxoacid (one containing an oxo group, X=O), and a hydroxyl compound such as an alcohol or phenol.[1] Esters consist of an inorganic acid or organic acid in which at least one -OH (hydroxyl) group is replaced by an -O-alkyl (alkoxy) group. They are analogous to salts, using organic alcohols instead of metallic hydroxides.</OBI:IAO_0000115>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMA</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phorbol 13-acetate 12-myristate</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/210">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data on the immunogenicity induced by chemotherapeutics.</rdfs:comment>
    <rdfs:label>Immunogenicity induced by chemotherapeutics</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_751">
    <rdfs:label>material component separation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">material component separation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A material component separation step is a step in a protocol that specifies how to segregate components of an input material in space.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400111">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/181">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/265"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/543"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/269"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/227"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/274"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/40"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/277"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/263"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/415"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/225"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/266"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/272"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/267"/>
    <rdfs:label>Karine Breckpot</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/261"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/231"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/282"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/278"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/416"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/280"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/275"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/264"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/279"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/273"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/268"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/283"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/542"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/262"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/281"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/271"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/276"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasExactSynonym">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has exact synonym</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">in oboInOwl there previously was this hasExactSynonym property which I used to annotate classes with synonyms. oboInOwl eliminated this property, so I inserted it as a dctheradir property in order not to lose the synonyms.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/172">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_245"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_195"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>We obtained data on the biological activity of an LPS-like molecule extracted from the freshwater cyanobacterium Oscillatoria Planktothrix FP1 that we named CyP. We found that CyP acts as a potent and selective antagonist of bacterial LPS. CyP did not induce any detectable response in human DCs and competitively inhibited LPS binding to the extracellular domain of TLR4. Addition of CyP together with LPS completely inhibited both MyD88- and TRIF-dependent pathways and suppressed the whole LPS-induced gene transcription program. CyP was effective in protecting mice from endotoxin shock in spite of a lower capacity to inhibit LPS stimulation of mouse DCs.  Remarkably, delayed addition of CyP to DCs responding to LPS strongly inhibited signaling and cytokine production by immediate down-regulation of inflammatory cytokine mRNAs, while not affecting other aspects of DC maturation such as expression of MHC, costimulatory molecules and CCR7. These results open promising perspectives for the use of CyP as a therapeutic agent able to modulate innate and adaptive immune responses and reveal the requirement of sustained TLR4 stimulation for induction of cytokine gene expression in human DCs.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_212357"/>
    <rdfs:label>Biological activity of an LPS-like molecule extracted from the freshwater cyanobacterium Oscillatoria Planktothrix FP1</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704239"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A116">
    <rdf:rest rdf:nodeID="A117"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_490"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/100">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/66"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/190"/>
    <rdfs:label>Alberto Mantovani</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/194"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/104"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/191"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/509"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/180"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/192"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/385"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/510"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/65"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/386"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/105"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000046">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A unit which is derived from base units.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">derived unit</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000003"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/518">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/81"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>By using TAP deficient cells, we found that TAP is also necessary for the process of presentation of the antigen in MHC class I. 

We further characterized the antigen depot by confocal microscopy and found that the antigen co-localized with the lysosomal marker LAMP1, but not with the endosomal marker EEA1, TAP, MHC class I or MHC class II. We conclude that the antigen depot is a storage compartment and not a loading compartment. We have started to examine depot formation by targeting antigen to other receptors. For example, we have found that presentation of TLR ligand- long peptide conjugates was also long-lived, while presentation of OVA, targeted via the mannose receptor, was not long-lived.</rdfs:comment>
    <rdfs:label>TAP deficient cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000068">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">reporting party</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A118">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_9608">
    <rdfs:label>human bone marrow</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">medulla ossea</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/12">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/470"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_765"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>After thawing cells showed good viability (&gt;90%) and the recovery was approximately 80%.</rdfs:comment>
    <rdfs:label>Thawing of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_646">
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cellular modification design: RNA interfering experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_533">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transcript identification experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A transcript identification design type characterizes the length and position of transcripts and allows identification of all forms of transcripts in the genome.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/218">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Zoltan Magyarics</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_3">
    <rdfs:label>signalling dataset</rdfs:label>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">signalling dataset</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A signalling data set is a data set that is produced as the output of a study about cell signalling, such as signalling pathways, signal transduction or crosstalk.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/557">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/134"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DMSO was used to dissolve blue formazan particles.</rdfs:comment>
    <rdfs:label>DMSO</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_645">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hsp70</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/80">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/445"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/52"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1773"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_808"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7195"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdfs:comment>Our lab has obtained data on the mechanism of how IL-10 regulates the immune response to MTb infection in mice. 

Control and clearance of intracellular pathogens such as MTb is dependent on the production of TNF and the induction of the T-helper 1 (Th1) cytokine IFN-gamma by IL-12.  Conversely, IL-10 is a suppressive cytokine essential for dampening the immune response to a number of intracellular pathogens to limit host immune pathology.  IL-10 has been shown to exert its suppressive effect by directly acting on the antigen presenting cell (APC), therefore functioning to down-regulate macrophage antimicrobial activity or the induction of Th1 responses by dendritic cells (DC).  However, during infection with pathogens such as T. gondii, IL-10 hinders pathogen clearance but is critical for blocking fatal immune pathology.  In patients with chronic tuberculosis (TB), T cells are present that produce both IL-10 and IFN-gamma and stimulation of MTb-antigen specific T cells ex-vivo in the presence of anti-IL-10 antibodies results in their increased proliferation and IFN- production.  Although this suggests a role for IL-10 in the regulation of the response to MTb, this has not been demonstrated and it is possible that a major role at this stage is to limit immune pathology in chronic disease.  To date in murine models of MTb, a role for IL-10 is controversal. 

We have identified that IL-10 plays an early and transient role in the control of the immune response to MTb and now show that this involves enhanced migration of IFNgamma producing CD4+ and CD8+ T cells into the lung rather than enhanced mycobacterial killing. The effects are accompanied by enhanced G-CSF, GM-CSF, TNF, IL-6 and IL-17 levels although the enhanced clearance of bacilli in IL-10 deficient mice we now show is independent of IL-17.

The work describing the mechanism of how IL-10 regulates the immune response to MTb infection is now being completed for publication (a manuscript will be submitted for publication in the next few months; Redford, O’Garra et al., 2009). Work on determining the ability of IL-10 depletion to enhance vaccination against MTb infection is being initiated now to continue this programme, but the majority of this work is the scope of the future outside the remits of DC-THERA.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5811"/>
    <rdfs:label>Responses to mycobacterium tuberculosis infection</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/51">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_775"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The arrays are scanned immediately. Each comparison is performed in duplicate. Fluorescent cDNA bound to the microarray is detected with a GenePix 4000 microarray scanner (Axon Instruments, Foster City, CA), using the GenePix 4000 software package to quantify microarray fluorescence.</rdfs:comment>
    <rdfs:label>Image acquisition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/161">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Three patients were enrolled in a clinical trial and DC vaccine was produced. The DC vaccine was administered into irradiated tumours in RCC of one patient only due to cancer progression in the other two patients. The patient treated is in complete remission 6 months after treatment.</rdfs:comment>
    <rdfs:label>DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A119">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_607">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An extraction protocol is a treatment protocol that is applied for a material separation to recover the nucleic acid fraction of an input material.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Extraction protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/48">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/176"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/109"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_484"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our lab we have a two-photon microscope. For instance, cell death was assessed in the viable epidermis by non-invasive near infrared two-photon microscopy following micro-particle bombardment of murine skin. </rdfs:comment>
    <rdfs:label>Two-photon microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/238">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/70"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/69"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These monocytes have been obtained from leukapheresis of tissue from patients with stage III or stage IV melanoma (tissue taken from a surgical resection of a melanotic lesion). They will subsequently be used to generate dendritic cells.</rdfs:comment>
    <rdfs:label>Monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isBiomaterialInputOf">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Property to connect a bio-material with a ProtocolStep in which the bio-material is an input.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is input of ProtocolStep</rdfs:label>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#hasBiomaterialInput"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/182">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/85"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Postdoctoral fellow
Butcher Lab
Bldg. 101, Room C4-111</rdfs:comment>
    <rdfs:label>Katharina Ines Lahl</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_750">
    <rdfs:label>establishing cell culture step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An establishing cell culture step is a step in a protocol that specifies how to create an in vitro environment in which cells are sustained from input material containing cells.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">establishing cell culture step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/11">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/142"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/471"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/470"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The frozen MoDC are subsequently used for tumor peptide specific stimulation of autologous T lymphocytes at a ratio of 1 DC per 10 T cells.

Co-cultures led to antigen specific, IFN-? secreting T cells after 1 restimulation at a DC:T cell ratio of 1:20, as evaluated by IFN- ? Elispot, showing that the generated DC have good antigen presenting and co-stimulatory capacity. </rdfs:comment>
    <rdfs:label>Tumor specific stimulation of autologous T lymphocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/517">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/75"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_57983"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_250"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/516"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have prepared two plasmids coding for LACK linked to either eGFP or mCherry fluorescent proteins, under the control of the beta-casein promoter.

In order to identify the APCs that were responsible for the development of this state of immune tolerance, we aimed to generate a transgenic mouse that express a recombinant fluorescent protein in the mammary glands, an approach that should result in high levels of expression of the fluorescent protein in the milk. We thus should be able to detect the cells that capture, degrade and present this antigen to T cells. Since we had previously generated a monoclonal antibody, 2C44, that reacts to a peptide derived from the Leishmania LACK protein bound to I-Ad MHC class II molecules, we chose to use LACK as a model antigen in these experiments.  

These constructs have been injected into fertilized eggs and transgenic animals are expected for march 2009. </rdfs:comment>
    <rdfs:label>Plasmids coding for LACK linked to either eGFP or mCherry fluorescent proteins</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/173">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_243"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data on the induction of CTL responses in vivo by immunization of in vitro matured DC versus CTL responses induced by sustained delivery of a maturation signal from a comparison in a murine model.  PolyI:C12U (Ampligen) did not activate the murine bone-marrow derived DC.  Similar experiments are being performed using a stabilised form of polyI:C.</rdfs:comment>
    <rdfs:label>Comparison of induction of CTL responses in vivo</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400112">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A120">
    <owl:unionOf rdf:nodeID="A116"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_647">
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cellular modification design: antibody target experiment design</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A121">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A118"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/216">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Severine Navarro</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000069">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000011</dcr:replaced_by>
    <rdfs:label xml:lang="en">obsolete_protocol application</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/52">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_775"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Intensity values are adjusted by subtracting surrounding background from spots. The median of spot intensities is corrected for background. To eliminate signals that are most prone to estimation error, any spot is excluded from analysis if both the Cy3 and Cy5 mean fluorescence signals are within two standard deviations of the mean background signals for that spot. This procedure avoids artificially inflated measurements of expression due to low signals. Additional to eliminating flagged spots, spots are also visually inspected and flawed ones discarded from the analysis.</rdfs:comment>
    <rdfs:label>Adjustment of intensity values</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/217">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/196"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Yasmine Sebti</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_4">
    <rdfs:label>imaging dataset</rdfs:label>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">imaging dataset</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An imaging data set is a data set that is produced as the output of biological imaging, such as microscopy, molecular imaging or magnetic resonance imaging.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/558">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/54"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The effect of environmental factors on development of high affinity CTL was investigated using a system whereby OT-1 cells were primed in vitro by engineered APC. After a 20 h priming phase, CTL were transferred to recipient mice that were either naïve, or had been injected with activated dendritic cells one day earlier, thus creating a reactive lymph node.</rdfs:comment>
    <rdfs:label>Mice injected with activated DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/162">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Autologous dendritic cells are loaded with apoptotic leukemic cells from patients with B-CLL to be used as vaccine in patients with chronic lymphocytic leukemia. Preliminary data from a clinical study indicate reduction of circulating tumor cells. No adverse effects have been observed.</rdfs:comment>
    <rdfs:label>DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_606">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">biomarker role</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">the role of a biomaterial to act as a biomarker</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dcthera_label">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA label</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/239">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/71"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These monocytes were obtained after elutriation of a leukapheresis product (patients with stage III or stage IV melanoma) and are used to obtain dendritic cells from. </rdfs:comment>
    <rdfs:label>Monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/47">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/175"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/35"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/95"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400099"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This FACS analyser that is available to us is used, e.g.,  for the analysis of dendritic cells.</rdfs:comment>
    <rdfs:label>FACS analyser</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/174">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001452"/>
    <rdfs:comment>Data have been obtained on Mart-1 specific T cell priming and/or NK cell triggering in HHD2 mice. 

We have used DC exosomes along with various TLR ligands or cytokines such as IL-2 or alpha IFN to promote Mart-1 specific T cell priming and/or NK cell triggering in HHD2 mice. We demonstrated that only TLR3 and 9 ligation is able to induce CTL priming in vivo. However, exosomes in the absence of adjuvants can induce NK cell activation. DC exosome-mediated NK cell triggering depends upon NKG2D ligands presented on the exosome surface</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_159"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label>Promotion of Mart-1 specific T cell priming and/or NK cell triggering in HHD2 mice using DC exosomes along with various TLR ligands or cytokines</rdfs:label>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/516">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/75"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/517"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_57983"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_250"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In order to identify the APCs that were responsible for the development of this state of immune tolerance, we aimed to generate a transgenic mouse that express a recombinant fluorescent protein in the mammary glands, an approach that should result in high levels of expression of the fluorescent protein in the milk. We thus should be able to detect the cells that capture, degrade and present this antigen to T cells. Since we had previously generated a monoclonal antibody, 2C44, that reacts to a peptide derived from the Leishmania LACK protein bound to I-Ad MHC class II molecules, we chose to use LACK as a model antigen in these experiments. We have thus prepared two plasmids coding for LACK linked to either eGFP or mCherry fluorescent proteins, under the control of the beta-casein promoter. These constructs have been injected into fertilized eggs and transgenic animals are expected for march 2009. </rdfs:comment>
    <rdfs:label>Transgenic mouse that express a recombinant fluorescent protein in the mammary glands</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_753">
    <rdfs:label>isolation of cell population step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">isolation of cell population step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An isolation of cell population step is a step in a protocol that specifies how to isolate a population of cells with certain characteristics from a larger population.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_265784">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Artemisia iwayomogi</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_102804"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/10">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/470"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/469"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_765"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>On day 7 of culture 35/40 x 10e6 mature peptide pulsed DC are frozen at 5 x 10e6 cells per vial in freezing medium as above.</rdfs:comment>
    <rdfs:label>Freezing of DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_648">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">genetic modification design: mutation insertion experiment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_447"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A70">
    <owl:unionOf rdf:nodeID="A122"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/212">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/7"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data was generated on DC activation by different forms of the non-pathogenic yeast Saccharomyces cerevisiae. A special focus was laid on the response of MDDCs to the non pathogenic fungi.</rdfs:comment>
    <rdfs:label>Transcriptional data on the activation of DC by yeast</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10566">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human papillomavirus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HPV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human Papilloma Virus</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/102">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/78"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/307"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/73"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/21"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/130"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/308"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/152"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/24"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/221"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/57"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/452"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/177"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/212"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/84"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/17"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/14"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/1"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/58"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/411"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/40"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/protocol/13"/>
    <rdfs:label>Paola Ricciardi-Castagnoli</rdfs:label>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/175"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/31"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/154"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/503"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/110"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.geneontology.org/formats/oboInOwl#ObsoleteProperty">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A123">
    <owl:intersectionOf rdf:nodeID="A124"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_1">
    <rdfs:label>transcriptomic dataset</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A transcriptomic data set is a data set that is produced as the output of a transcriptomic analysis, such as microarray analysis.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transcriptomic dataset</rdfs:label>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100386">
    <rdfs:label>interferon alpha</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFN alpha</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferon alpha</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/269">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sorin Draghici</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/236">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/106"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients receive a DC vaccine composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).</rdfs:comment>
    <rdfs:label>Advanced melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_220">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chemokine receptor CXCR3</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001128"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCR3</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A125">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/90">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/383"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/379"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/378"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_742"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The DC vaccine will consist of monocyte derived DC loaded with tumor lysate generated from the excised lesion.</rdfs:comment>
    <rdfs:label>Generation of vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_752">
    <rdfs:label>leukapheresis step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A leukapheresis step is a step in a protocol tha specifies how to separate white blood cells from a sample of blood.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">leukapheresis step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBioSourceType">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">connects any biomaterial to an ontology term from the biomaterial branch. SHORTCUT.
particular - universal relationship</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">biomaterial type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type bio-material.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/92">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/382"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/381"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/380"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_747"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The T cell transfer will consist of T cells expanded by co-culture with tumor lysate loaded DC. </rdfs:comment>
    <rdfs:label>Coculture: expansion of T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/515">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001992"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001202"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_616"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We found that CCR6–deficient (CCR6-KO) mice were resistant to induction of EAE but became susceptible when transferred with small number of CCR6-sufficient T cells. CCR6 was found to be required on a first wave of TH-17 cells that entered the CNS through the choroid plexus epithelial cells, which constitutively expressed CCL20 in both mice and humans.</rdfs:comment>
    <rdfs:label>CCR6-KO mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/175">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/107"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdfs:comment>We have compiled a comprehensive protein profile of DCs and obtained data on changes in protein level and post-translational modifications involved in the regulation of specific signalling pathways or cell processes.

First, we have set up a system for SILAC labelling of bone marrow derived murine dendritic cells (BM-DC). The principal method for generating BM-DC with GM-CSF was adapted from Lutz et al. (J Immunol Methods 1999, 223: 77-92). After some modifications of the protocol the FACS analysis of DC, which were generated in conditions described by Lutz et al. or in modified SILAC conditions did not show differences in the expression levels of the common DC markers CD11c, CD80, CD86. Analysis by mass spectrometry showed successful labelling. For the investigation of chemokine dependent CCR7 signalling, we have stimulated mature DCs with CCL19 or CCL21 for different time points. Western Blot analysis of phosphotyrosines showed a chemokine dependent and stimulation-time dependent phosphorylation pattern. We are now identifying and quantifying these chemokine dependent tyrosine phosphorylation events by mass spectrometry-based proteomics, as established in the optimization steps described above.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/5"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_397"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_245"/>
    <rdfs:label>Proteomic profiling of DC</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001013"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/47"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_398"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001412"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400110">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/180">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Kajsa Lundberg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/211">
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_45732"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/85"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0002091"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000786"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/151"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_81494"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7474"/>
    <rdfs:comment>DC-THERA applicant : Anita Sapoznikov
Institution: The Weizmann Institute of Science, Israel
Supervisor: Dr. Steffen Jung

Data has been obtained on the  cellular organization of the marrow of long bones.

The bone marrow (BM) is a primary lymphoid organ, where diverse hematopoietic lineages arise from common multi-potential progenitors [1]. However, aside from this established role in hematopoiesis, the BM also serves as secondary lymphoid organ in the generation of adaptive T and B cell immune responses [2,3]. It has been shown that the BM is also populated by mature lymphocytes, which home to the BM and seem to inhabit specific niches [2,4]. Two photon microscopic analysis of mouse skull BM revealed that the BM-resident Dendritic cells (bmDC) in the cranial BM parenchyma are organized in unique peri-vascular clusters tightly wrapped around distinct BM blood vessels and occupying architecturally definable niches. Interestingly, these clusters are reminiscent of recently reported peri-sinusoidal niches that are defined by mature re-circulating B cells [2]. We showed that grafted B and T cells efficiently homed to the BM and their distribution was restricted to the extra-vascular areas covered by bmDC. Using a conditional in vivo DC ablation system, we analyzed the BM and periphery of DC-depleted mice and found that bmDC ablation led to a profound B cell reduction. The effect was specific to the BM, since the frequencies of B cells in the spleen and lymph nodes were not impaired. Moreover, the reduction was specific for recirculating mature B cell compartment, whereas B cell development was unaffected by bmDC ablation. This phenotype could be reverted by B cell over-expression of the anti-apoptotic factor bcl2. Moreover, we showed that re-circulating B cell survival requires the presence of bmDC, which produce macrophage migration inhibitory factor (MIF) in the perivascular BM niches [5]. 

The aim of my visit at the Deutsches Rheuma-Forschungszentrum (DRFZ) and the laboratory of Prof. Andreas Radbruch was to study the organization of bmDC, B lymphocytes and plasma cells in the BM of the long bones by immunochistochemistry. During my visit I learned the preparation of the bones for histology, crysectioning, immunohistochemistry and analysis of the stained sections by confocal microscope.
Using a CX3CR1GFP mice, in which bmDC are green fluorescent (GFP), I analyzed the bmDC localization and found the the cells organized in unique clusters, mainly located in the endosteum of the BM. These DC co-localize with B cells and these clusters are occupying architecturally definable niches and are reminiscent to the niches that were found in the cranial BM parenchyma. By using Fibronectin antibody I could visualize the stroma of the BM. In addition, a large fraction of IgA positive plasma cells is located in the BM. Staining for these cells revealed that plasma cells are scattered through the BM and are not preferentially found in DC-B cell niche. However, depletion of DC led to reduction in IgA+ plasma cells, which might indicate that bmDC are critical for survival of these cells in the BM. Thus, additional experiments will be conducted in order to understand the interactions between bmDC and plasma cells.

References
1. Nagasawa, T. et al. Microenvironmental niches in the bone marrow required for B-cell development. Nature Immunol. 6, 107-116 (2006)
2. Cariappa, A. et al. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. Immunity 23, 397-407 (2005)
3. Cavanagh, L. et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nature Immunol. 6, 1029-1037 (2006)
4. Tokoyoda, K. et al. Cellular niches controlling B lymphocytes behavior within bone marrow during development. Immunity 20, 707-718 (2004)
5. Sapoznikov A. et al. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat. Immunol. 9, 388-395 (2008)</rdfs:comment>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_32692"/>
    <rdfs:label>Studying the cellular organization of the marrow of long bones by Immunohistochemistry and Confocal Microscopy.</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/33"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000546"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">in vitro design experiment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An experiment done in a test tube or a culture dish, e.g. A bacterial invasion assay in an established cell culture.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_649">
    <rdfs:label>tumor biopsy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CARO#CARO_0000043"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor biopsy</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A124">
    <rdf:rest rdf:nodeID="A121"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/49">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/200"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/326"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdfs:comment>We have obtained data from a study where we addressed a model antigen to exosomes secreted by tumor cells in vivo, to allow capture of antigen-bearing exosomes by DCs and cross-presentation of the antigen. For this purpose, the model antigen OVA was fused to the C1C2 exosome-binding domain of MFG-E8/lactadherin. Tumors secreting the exosome-bound antigen grow slower than tumors secreting soluble OVA, because they induce activation of OVA-specific CD8+ T cells into killer cells. In addition, inducing in vivo secretion of the C1C2-coupled antigen by DNA vaccination induces prevention against subsequent tumor growth. These results show for the first time a function for exosome secretion in vivo. A paper describing these results has been published in 2008 (Zeelenberg et al., Cancer Research).
Our goal is now to develop the C1C2-based DNA vaccination approach to obtain an efficient anti-tumor therapeutic vaccine in mouse models. In parallel, we are analysing the mechanisms of exosome secretion in vitro. The goal of this project is to identify tools to inhibit or increase exosome secretion in vivo, and thus decipher their physiological roles, as well as modulate exosome-dependent immune responses.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/31"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/30"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <rdfs:label>Capture of antigen-bearing exosomes by DCs and cross-presentation of tumour antigen in exosomes</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://dc-research.eu#dctheradir_647"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/101">
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/190"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/104"/>
    <rdfs:label>Antonio Sica</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/106"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/193"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/191"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/194"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/105"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/103"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/192"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A117">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_491"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/50">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_759"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Hybridized slides are washed in a solution of water, 20× SSC, and 10% SDS, rinsed in water and 20× SSC, and dried via centrifugation for 2 min at 1000 rpm.</rdfs:comment>
    <rdfs:label>Washing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/49">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/199"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_473"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our laboratory has an Amaxa electroporator at its disposal.

The electroporator is used, among other things, for the transfection of immature DCs with different constructs encoding for the oncogene Her-2/neu and as control PSA.</rdfs:comment>
    <rdfs:label>Amaxa electroporator</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Cytotoxic_T-Lymphocyte-Associated_Protein-4">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A16"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CTLA-4</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytotoxic T-Lymphocyte-Associated Protein 4</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/219">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Linda Polik</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/556">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/134"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>2M KOH were used to dissolve blue formazan particles.</rdfs:comment>
    <rdfs:label>Potassium hydroxide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_2">
    <rdfs:label>proteomics dataset</rdfs:label>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">proteomics dataset</rdfs:label>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A proteomics data set is a data set that is produced as the output of a study of proteins, particularly their structures and functions.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000763">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">myeloid cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A126">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_36706">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">R-848</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">R 848</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">resiquimod</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">R848</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A15"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33595"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">resiquimod</rdfs:label>
    <rdfs:label>resiquimod</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A14"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/237">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/69"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/68"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This tissue was taken from a surgical resection of a melanotic lesion. The electrophoresis product will then be used to generate dendritic cells from the monocytes which in their turn will be used as vaccines.</rdfs:comment>
    <rdfs:label>Tissue from patients with stage III or stage IV melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/268">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Shoshana Frankenburg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/160">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Three patients were enrolled in a clinical trial of a DC vaccine administered into irradiated tumours in RCC. However only this one patient received the vaccine due to cancer progression in the other two patients. The DC were labelled with 111In. The following patients will receive DC labelled with Endorem and the vaccine will be imaged with MRI. 

The patient treated is in complete remission 6 months after treatment.</rdfs:comment>
    <rdfs:label>Cancer patient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/91">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/380"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/379"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/378"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_742"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Generation of tumor lysate loaded DC.</rdfs:comment>
    <rdfs:label>DC generation and loading</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_608">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A scanning protocol is a treatment protocol used for scanning a microarray after hybridzation in a microarray scanner to visualize fluorescence of the two fluorophores after excitation with a laser beam of a defined wavelength.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Scanning protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_928">
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Feature extraction protocol</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The process of obtaining quantifiable values from the scanned image of the 
    array. Exact synonyms: image analysis, image quantification</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ifomis.org/bfo/1.1/snap#ObjectAggregate">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/87">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients received multipeptide loaded cytokine matured moDC + prior Treg elimination by 3x ONTAK treatment [5µg/kg]; first phase of DERMA-ER-DC 05 trial.</rdfs:comment>
    <rdfs:label>8 melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000109">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">toll-like receptor 7</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR7</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/145">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/184"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Walter Reith is full professor in the Department of Pathology and Immunology in the section of Fundamental Medicine of the Faculty of Medicine at the University of Geneva (UNIGE). Walter Reith will become chairman of the Department of Pathology and Immunology in 2011.</rdfs:comment>
    <rdfs:label>Walter Reith</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_9256">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">colorectal cancer</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/8">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Using pharmacological inhibitors, or macrophages and DC from mice carrying a null mutation in MAP kinase signalling molecule(s), we have evidence for a role of certain MAP kinases in the regulation of IL-10 and IL-12, IFN-gamma production. </rdfs:comment>
    <rdfs:label>DC from mice carrying a null mutation in MAP kinase signalling molecule(s)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/10">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_229"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>We have a current clinical protocol for active immunotherapy in advanced melanoma patients (GMP SOPs covering the protocols are also available).
The vaccine is composed by autologous DCs pulsed with allogenic melanoma peptides (SK-Mel 24, HLA-A1 and HLA-A2 positive) plus KLH as immunological tracer and it is produced under GMP condition at MolMed S.p.A. (DIBIT, San Raffaele, Milan, Italy).
HLA-A1 and/or HLA-A2 positive patients with stage III/IV melanoma undergo leukapheresis. DCs are generated from adherent peripheral blood monocytes, at day 6 DC are pulsed with the peptides and KLH in the presence of TNF-??overnight, next day the peptides and KLH are replaced and incubated for further 4h and then used for quality controls and intradermal administration. Patients receive V administrations with eventual additional ones depending on clinical outcome. The patients are monitored for safety and toxicity of the treatment and for clinical response. T cell stimulatory activity of DC is monitored by induction of KLH specific T cells, tumor specific responses are evaluated by induction of SK-Mel 24 peptides specific T cells. </rdfs:comment>
    <rdfs:label>Active immunotherapy in advanced melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_50847">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Immunological adjuvant role</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000813">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T-cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T-lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T-lymphocytes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:label>memory T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T lymphocyte</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T lymphocytes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory T-cell</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700572">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TPL-2</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tumor progression locus 2</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/154">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The kinetic of the transcriptional profiling of D1 cells treated with either DMSO or LPS was analysed.</rdfs:comment>
    <rdfs:label>D1 cells treated with DMSO</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_642">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_240</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CCL-2</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/492">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/44"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In the process of total RNA extraction from yeast cells, the supernatants were precipitated in RNase-free centrifuge tube by adding 1/10 volume 3 M NaAcetate (pH 5.3) and 2.5 volumes of cold ETOH 100%.</rdfs:comment>
    <rdfs:label>NaAcetate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/59">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Institute for Medical Research is an organisation which conducts fundamental and applied research in the field of biomedicine. Our goal is application and dissemination of knowledge through publication, education and international co-operation. 

Institute for Medical Research (IMR), the only Yugoslav governmental research institute in the field of biomedicine, was founded 58 years ago by the Serbian Academy of Science. From the beginning the main orientation of IMR was directed towards basic and applied investigations in several different fields. Today, IMR comprises more than 45 researchers (medical doctors, biologists, molecular biologists, chemists, pharmacists, biochemists etc.) organized in seven research units. The overall bibliography of IMR amounts to over 2.000 original papers, published mainly in international scientific journals. IMR researchers have also edited ten published scientific books. </rdfs:comment>
    <rdfs:label>Institute for Medical Research</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A122">
    <rdf:rest rdf:nodeID="A127"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_716">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_713"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S2/SvPas * C57BL/6</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Il10rbtm1Agt/Il10rbtm1Agt transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_16412">
    <rdfs:label>lipopolysaccharide</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A73"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18154"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LPS</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lipopolysaccharides</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lipopolysaccharide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001045">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD45 antigen protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000082</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/411">
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These marginal zone dendritic cells, interacting with the cholera toxin (CT) adjuvant, lead to effective priming of an immune response in vivo. For the first time, we have followed adjuvant targeting of MZ DC in vivo.</rdfs:comment>
    <rdfs:label>Dendritic cells (DC) of the splenic marginal zone (MZ)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_754">
    <rdfs:label>extraction step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">extraction step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An extraction step is a step in a protocol that specifies how to separate  a desired component of an input material from the remainder.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/94">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/382"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The primary objective of this trial is to determine toxicity and feasibility of treatment of patients with advanced melanoma with DC vaccine and adoptive transfer. </rdfs:comment>
    <rdfs:label>Adoptive transfer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/453">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Hu-SCID mice were used to study responses to EBV and HIV.</rdfs:comment>
    <rdfs:label>Hu-SCID mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/186">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/207"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/71"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Miroslav Hons</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000047">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD10</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001898</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/340">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_245"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with surface markers (such as CD8, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CCR7 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/146">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/21"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/395"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/120"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Filippo Petralia</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/394"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/36"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/20"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/73"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/67"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_756">
    <rdfs:label>centrifugation step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">centrifugation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A centrifugation step is a step in a protocol that specifies how to separate molecules by size or density using centrifugal forces generated by a spinning rotor.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/86">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Analysing antigen loading strategies for DC, we found that the priming capacity of MelanA/HLA-A2-specific autologous CD8+ T cells by lipofected DC was higher compared to electroprated DC. </rdfs:comment>
    <rdfs:label>MelanA/HLA-A2-specific autologous CD8+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0004278">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">granzyme H gene</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000814">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK T-lymphocyte</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK T-cell</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural killer T-lymphocyte</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural killer T-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK T lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural killer T lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural killer T cell</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_8857">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lupus erythematosus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110054"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/9">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Using pharmacological inhibitors, or macrophages and DC from mice carrying a null mutation in MAP kinase signalling molecule(s), we have evidence for a role of certain MAP kinases in the regulation of IL-10 and IL-12, IFN-gamma production. </rdfs:comment>
    <rdfs:label>mice carrying a null mutation in MAP kinase signalling molecule(s)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_641">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Thymic Stromal Lymphopoietin</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Thymic Stromal Lymphopoietin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TSLP</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/153">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We identified a novel DC subset called IKDC producing IFNg and expressing TRAIL which can recognize and kill transformed tumor cells in vitro and in vivo.

Cultures were generated of tumor cells with IKDC producing IFNg and expressing TRAIL which can recognize and kill transformed tumor cells in vitro and in vivo.  IKDC generate long contacts and synapses with tumor cells and ultimately kill them within 4 hours. </rdfs:comment>
    <rdfs:label>IKDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/410">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were matured using CpG-DNA as TLR9 ligand. Mature DCs upregulated CD80, CD86, MHC class II and produced cell type specific cytokines. Matured pDCs pDCs produced type 1 Interferons.</rdfs:comment>
    <rdfs:label>Matured pDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/493">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/44"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In the process of total RNA extraction from yeast cells, the supernatants were precipitated in RNase-free centrifuge tube by adding 1/10 volume 3 M NaAcetate (pH 5.3) and 2.5 volumes of cold ETOH 100%.</rdfs:comment>
    <rdfs:label>cold ETOH 100%</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000134">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mesenchymal cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mesenchymal cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_28262">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33261"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">(methanesulfinyl)methane</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dimethyl sulfoxide</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dimethyl sulfoxide</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Dimethyl sulfoxide (DMSO) is the chemical compound with the formula (CH3)2SO. It was first synthesized in 1866 by the Russian scientist Alexander Saytzeff, who reported his findings in a German chemistry journal in 1867.[1][2] This colorless liquid is an important polar aprotic solvent that dissolves both polar and nonpolar compounds and is miscible in a wide range of organic solvents as well as water.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A33">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0010050">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transferases</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transferase</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/553">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/131"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DCs were exposed to cytochalasin D (10 microg/ml, TebuBio) for 30 minutes at 4°C. </rdfs:comment>
    <rdfs:label>cytochalasin D</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000207">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">health care provider</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A127">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_715">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gnai2tm1Uru/Gnai2tm1Uru transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_713"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S7/SvEvBrd * C57BL/6J</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/185">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Michaela Schmidt</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/93">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/383"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_762"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The patients will be vaccined with the DC vaccine that consists of monocyte derived DC loaded with tumor lysate generated from the excised lesion.</rdfs:comment>
    <rdfs:label>Vaccination of patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/452">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>D1 cells will be stimulated with LPS and harvested at different time-points for GeneChip analysis and for tandem mass spectrometry-based analysis of the integral plasma membrane proteome. </rdfs:comment>
    <rdfs:label>D1 cells stimulated with LPS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_72289">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">epithelial cell of gut</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_69075"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_755">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An RNA extraction step is an extraction step in a protocol that specifies how to extract as desired output material RNA.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RNA extraction step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_754"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/85">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/111"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have determined mechanisms for DC-induced Th1 development and the molecular pathways for inducing Th1 cells producing IFN-gamma solely, or Th1 cells producing IFN-gamma and IL-10, which have important implications for regulation of the immune response to eradicate pathogens with minimum pathology. </rdfs:comment>
    <rdfs:label>Th1 cells producing IFN-gamma and IL-10</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000048">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000002062</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD115</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/143">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Tina Zavasnik Bergant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/61">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/30"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/181"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/31"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/182"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/128"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/54"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/183"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/54"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/255"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/184"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/55"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/155"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/180"/>
    <rdfs:label>Philippe Pierre</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/443"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_757">
    <rdfs:label>resection step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A resection step is a step in a protocol that specifies how to partially or completely remove an organ or other bodily structure.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">resection step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/490">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In the process of extracting total RNA from yeast cells, the pellets were washed with 70% Ethanol two times.</rdfs:comment>
    <rdfs:label>Ethanol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A27">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_644">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Galectin-1</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0001577"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/56">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Instituto de Medicina Molecular (IMM) is a research institute located in the campus of the University of Lisbon Medical School and of the Santa Maria Hospital, which has acquired the special status of Laboratório Associado from the Portuguese Ministry of Science and Higher Education. IMM is a non-profit private research Institute created in 2004, mainly supported by national public funds, European Union funds, and private foundations. The mission of IMM is to foster basic, clinical and translational biomedical research with the aim of contributing to a better understanding of disease mechanisms, developing novel predictive tests, diagnostics and therapeutic approaches. IMM hosts 31 independent research groups (circa 350 researchers), whose wide range of interests fall within three major research lines: Molecular &amp; Developmental Biology, Immunology &amp; Infection, and Neurosciences. The proximity with the Hospital and the Medical School creates privileged opportunities to bridge with “bedside” research, promoting translational research. In addition, the institute hosts and collaborates with a number of start-up and biotechnology companies in areas of biomedical technologies and sophisticated health care delivery. IMM is committed to excellence in Science. This goal is pursued by developing coherent R&amp;D activities, an advanced training program, and the recruitment of outstanding international young group leaders to establish leading research teams in Biomedicine. The thrive for excellence is also reflected in the international collaborations established by IMM research teams, and by the high profile international grants list awarded to IMM researchers (http://www.imm.fm.ul.pt).</rdfs:comment>
    <rdfs:label>Universidade de Lisboa, Faculdade de Medicina</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A128">
    <rdf:rest rdf:nodeID="A129"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_485"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/152">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Shuttle plasmids into which antigens are inserted are available from a discontinued clinical program where an HSV vector expressing full length tyrosinase, gp100 and MART-1 was used to transduce DC from melanoma patients which were then to be used for vaccination.

These could be of use to the project if partners would like to use HSV-based technology for the delivery of antigens to DC.</rdfs:comment>
    <rdfs:label>shuttle plasmids</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/413">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Migration of DCs was studied in vivo in melanoma patients exploring MRI. From isolated lymphnodes obtained after surgery we could identify single DC after staining with Prussian blue for iron. We are in the process of analysing the T cell rosettes (activation stage) that surround these DC to get insight in the functional activity.</rdfs:comment>
    <rdfs:label>T cell rosettes surrounding DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0003824">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">enzyme activity</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A130">
    <owl:unionOf rdf:nodeID="A128"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/552">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/130"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/129"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/122"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5476"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Serotype A C. albicans strain SC5314 was cultured overnight in Saboraud medium at 28°C and then shifted to RPMI medium for 18 hours at 37°C to allow hyphal growth.</rdfs:comment>
    <rdfs:label>Serotype A C. albicans strain SC5314</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_718">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Il2ratm1Dw/Il2ratm1Dw transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S4/SvJae * C57BL/6</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_713"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/57">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>DanDrit Biotech A/S is a Danish biotech company. We develop and manufacture cancer vaccines and intent to launch innovative therapeutic and prophylactic treatments in Denmark and internationally. Our vaccines will improve the patients’ immune response against solid tumours and their metastases. Our vaccines will be administered as mono therapy as well as adjuvant (complementary) to other cancer treatments.</rdfs:comment>
    <rdfs:label>DanDrit Biotech A/S</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasPlatform">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">platform</rdfs:label>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasPlatformType</dcr:hasClassAsRangeProperty>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/OBI_0000050"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset to a platform type. As this would make the ontology OWL full, the annotation property hasPlatformType is used instead.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/96">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/327"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/328"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The monocytes are cultured for five days to immature DC (imDC´s).</rdfs:comment>
    <rdfs:label>Monocyte culture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000049">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD117</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000002065</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/84">
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label>myeloid and splenic CD8alpha+ DC</rdfs:label>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/UBERON#FMA_7196-MA_0000141-MIAA_0000085-XAO_0000328-ZFA_0000436"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <rdfs:comment>We found that BM-myeloid and splenic CD8alpha+ DC produced at least fivefold less IL-12p70 than plasmacytoid pDC responding to both CpG and the TLR-7 ligand R848.</rdfs:comment>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/UBERON#FMA_9608-MA_0000134-MIAA_0000084-XAO_0000123-ZFA_0000669"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/110"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/184">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/195"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mark Nassar</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_384">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Clinical treatment factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/451">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/50"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000798"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We investigated the interactions between human monocyte derived DCs (MDDC), generated in the presence of GM-CSF and IL-4 (IL-4 DC), and antigen-stimulated circulating gamma delta T lymphocytes, bearing the Vgamma2 TCR. The studies demonstrated for the first time the existence of a bidirectional activating interaction between DCs and gamma delta T lymphocytes activated by aminobiphosphonates. These data suggest a potential adjuvant role of this early cross-talk in the therapeutic activity of aminobiphosphonate drug that are currently used as anti-tumor drugs.</rdfs:comment>
    <rdfs:label>Antigen-stimulated circulating gamma delta T lymphocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0200723">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prostaglandin-H2 D-isomerase precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Glutathione-independent PGD synthetase </dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LIPOCALIN-TYPE PROSTAGLANDIN D SYNTHASE</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">prostaglandin D2 synthase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PGD2 synthase</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">prostaglandin D2 synthase gene</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LPGDS</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PGDS2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prostaglandin-D2 synthase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Glutathione-independent PGD synthetase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BETA-TRACE</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/144">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/137"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Prof. dr. Viggo Van Tendeloo
Vaccine &amp; Infectious Disease Institute (VIDI) 
Laboratory of Experimental Hematology 
Head, Cellular Immunology Unit
Faculty of Medicine - Antwerp University 
Scientific Director, Center for Cell Therapy and Regenerative Medicine
Antwerp University Hospital (UZA)

Academic functions	

Research Professor - Faculty of Medicine UA
Group Leader - Cellular Immunotherapy Unit - Lab of Experimental Hematology UA
Scientific Director - Center for Cell Therapy and Regenerative Medicine UZA
Board member Vaccine &amp; Infectious Disease Institute UA
Biosafety Coordinator UZA

Research interests	

- dendritic cells
- cellular immunology
- nonviral gene therapy
- vaccines
- cancer vaccines
- HIV immunology &amp; vaccines
- cellular therapy</rdfs:comment>
    <rdfs:label>Viggo van Tendeloo</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_758">
    <rdfs:label>staining step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A staining step is a step in a protocol that specifies how to perform an addition of a class-specific (DNA, proteins, lipids, carbohydrates) dye to a substrate to qualify or quantify the presence of a specific compound.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">staining step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/62">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Véronica Goudot</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000571">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">manufacturer</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/491">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/46"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>At the end of a process of total RNA extraction from yeast cells, when the pellets were dry, they were resuspended in RNase-free water.</rdfs:comment>
    <rdfs:label>RNase-free water</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_643">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SEA</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Schistosoma soluble egg antigen</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A57"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A129">
    <rdf:rest rdf:nodeID="A131"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/55">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The expansion of research in cell biology was planned in 1992 as a result of the vision of Professor Sir Kenneth Murray, who was at the time Biogen Professor at the Institute of Cell and Molecular Biology. A seed contribution of £2.5 million from the Darwin Trust was followed by financial commitments from The Wolfson Foundation, the University and the Wellcome Trust, allowing construction of the Michael Swann Building. The majority of research space was earmarked for Wellcome Trust-funded research. Recruitment, based on research excellence at all levels in the area of cell biology, began in earnest in 1993, mostly but not exclusively, through the award of Research Fellowships from the Wellcome Trust. The Swann Building was first occupied by new arrivals in January 1996 and became “The Welcome Trust Centre for Cell Biology” from October 2001.</rdfs:comment>
    <rdfs:label>Wellcome Trust Centre for Cell Biology, University of Edinburgh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_680">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000695</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Sex factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/151">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/94"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were matured with inflammatory cytokines and subsequently electroporated with mRNA encoding 6 tumor-associated antigens. They were used for DC-based immmunotherapy of melanoma patients.</rdfs:comment>
    <rdfs:label>Monocyte-derived DCs </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/412">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Migration of DCs was studied in vivo in melanoma patients exploring MRI. From isolated lymphnodes obtained after surgery we could identify single DC after staining with Prussian blue for iron. </rdfs:comment>
    <rdfs:label>Lymph nodes from melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000442">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">follicular dendritic cell</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cell with extensive dendritic processes found in the B cell areas (primary follicles and germinal centers) of lymphoid tissue. They are unrelated to the dendritic cell associated with T cells. Follicular dendritic cells have Fc receptors and C3b receptors, but unlike other dendritic cells, they do not process or present antigen in a way that allows recognition by T cells. Instead, they hold antigen in the form of immune complexes on their surfaces for long periods and can present antigen to B cells during an immune response.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000473"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A132">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_717">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_713"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129P2/OlaHsd * C57BL/6</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Il2tm1Hor/Il2tm1Hor transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/551">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/121"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000427"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In a spore culture, zymolyase (2 mg/ml) was used to digest ascum and liberate spores. We initially performed experiments to evaluate zymoliase sensitivity of asci for this specific strain and we assessed that 15 minutes incubation was the minimum time needed to damage the ascus, without touching the spore cell wall. Zymoliase was inactivated by heat (65°C for 2 minutes) and washed away carefully together with the remainings of the empty ascus, by resuspending twice the spore culture in 500 µl of distilled water centrifuging and discarding the supernatant; the spores were then resuspended to a concentration of 108 cells/ml. In order to exclude damage on the spore cell wall or effects on spore viability 100 µl of a culture of 1000 spores per ml was plated on YPD in triplicate, the spores showed 100% viability.</rdfs:comment>
    <rdfs:label>zymolyase </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/450">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6181"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We are examining the effects of a schistosome-derived protein on intestinal immune responses, and have shown that oral administration leads to the rapid appearance of cytokines in lymph.</rdfs:comment>
    <rdfs:label>Schistosome-derived protein</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400038">
    <rdfs:label>FACS Canto2</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/83">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/110"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <rdfs:label>myeloid and splenic CD8alpha- DC</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <rdfs:comment>We found that CD8alpha- DC produced undetectable levels of IL-12p70 upon stimulation with CpG.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_83598">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hematopoietic cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hematopoietic cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/95">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/326"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/327"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Leukapheresis products from cancer patients is used as a starting material for monocyte enrichment by elutriation technology with ELUTRA®  (Gambro).</rdfs:comment>
    <rdfs:label>Elutriation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/183">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Left the Institut Curie and now works in a different field outside of research.</rdfs:comment>
    <rdfs:label>Marianne Lasaulce</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#derivedFromAnApplicationOf">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">derived from protocol</rdfs:label>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any data set to the protocol that was applied for its generation.</OBI:IAO_0000115>
    <OBI:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Guendel</OBI:IAO_0000117>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#applicationGenerates"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/496">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/15"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/13"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The dead cells were stained (Mini67-1KT or Mini26-1KT (PKH67/PKH26 green/red fluorescent cell linker mini kit for general cell membrane labelling) from Sigma) for a process of dead cell uptake by DC.</rdfs:comment>
    <rdfs:label>Stained dead cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/4">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/73"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have electroporated these DC with melanoma antigen RNA for a cross-presentation study and showed that they express the proteins ex vivo and in vivo.</rdfs:comment>
    <rdfs:label>DC electroporated with melanoma antigen RNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A133">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000263"/>
    <owl:onProperty rdf:resource="http://dc-research.eu#hasOrganism"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#relatedToType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">related to type</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">connects any public resource to an ontology term. SHORTCUT.
particular - universal relationship</rdfs:comment>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/149">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Alessandra Mancino</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/63">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/62"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/131"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/59"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/525"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/42"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/132"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/524"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/130"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/75"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/117"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/50"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/76"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/296"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/43"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/299"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/297"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/55"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/477"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/133"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/134"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/116"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/428"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/39"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/95"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/282"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/118"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/65"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/474"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/284"/>
    <rdfs:label>Maria Pia Protti</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/57"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/475"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/44"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/130"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/56"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/51"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/60"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/129"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/298"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/461"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/41"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/523"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/476"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/126"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/99"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/58"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/284"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/295"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_759">
    <rdfs:label>washing step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A washing step is a step in a protocol that specifies how to remove a material entity acting as contaminant (e.g. excess staining reagent) by application of one or more cycles of solution in flow.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">washing step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/457">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704352"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Src kinases were found to be required for the initiation of some maturation characteristics of human monocytes derived dendritic cells upon stimulation with several toll like receptor (TLR) agonists but not of others, since their inhibition was able to dissociate cytokines and chemokines production from the induction of surface maturation markers. </rdfs:comment>
    <rdfs:label>Src kinases</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000303">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ifomis.org/bfo/1.1/snap#Function</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_instrument_function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/98">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/277"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/278"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_745"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>CD1 molecules are refolded in vitro.</rdfs:comment>
    <rdfs:label>Refolding of CD1 molecules</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000051">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">concentration unit</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000046"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/158">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Soluble recombinant HLADR1101 MHC class II molecules receptive for loading with either pathogen or tumor-derived peptides were constructed for a study of CD4+ T cell responses against pathogens or tumors in humans.</rdfs:comment>
    <rdfs:label>MHC class II molecules</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/415">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/179"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_243"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Electroporation of immature DCs with poly(I:C(12)U), a dsRNA analogue, resulted in phenotypic as well as functional changes, indicative of DC maturation. </rdfs:comment>
    <rdfs:label>poly(I:C(12)U)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/550">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/121"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/137"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/130"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <rdfs:comment>In order to test homogeneous yeast populations, pure spore cultures were obtained by using this strain whose sporulation efficiency is 100%. To prepare spores, cells were grown on YPD plates, replicated on SPOIV medium (2% potassium acetate, 0.25% yeast extract, 0,1% glucose). Zymolyase (2 mg/ml) was used to digest ascum and liberate spores. Zymoliase was inactivated by heat (65°C for 2 minutes) and washed away carefully together with the remainings of the empty ascus, by resuspending twice the spore culture in 500 µl of distilled water centrifuging and discarding the supernatant; the spores were then resuspended to a concentration of 108 cells/ml. In order to exclude damage on the spore cell wall or effects on spore viability 100 µl of a culture of 1000 spores per ml was plated on YPD in triplicate, the spores showed 100% viability. 

The spores were then biotinylated, labeled and - after treatment of DCs - detected using APC-labeled streptavidin and analyzed by flow cytometry.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/133"/>
    <rdfs:label>Spore cultures</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/129"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/220">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Martin Day</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0043226">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organelle</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_487">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neisseria meningitidis</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7143">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/FMA#FMA_67498</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_lymphoid organ</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/497">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/14"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_227"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These stained were stained for a process of dead cell uptake by DC.</rdfs:comment>
    <rdfs:label>GM-DC/Raw</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/13">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/94"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/251"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/2"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Sample pre-processing and biotin labeling were performed using the Affymetrix GeneChipH cDNA Synthesis Kit and IVT Labeling Kit (Affymetrix) according to the manufacturer’s protocols. Microarrays were then hybridized on Affymetrix GeneChipH HG-U133A 2.0 microarrays, and scanned according to the manufacturer’s instructions on a GeneChipH Scanner 3000 (Affymetrix). Extraction, hybridization and scanning were performed by the Genopolis consortium (University of Milano-Bicocca, Italy).</rdfs:comment>
    <rdfs:label>Affymetrix reference protocols</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/5">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <rdfs:label>Intestinal lymph DC subsets</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/68"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <rdfs:comment>We are defining the differential roles of intestinal lymph DC subsets in activation of naïve and memory T cells. Two of the three DC subsets are highly potent activators of naïve CD4+ T cells, and do not appear to be constitutively suppressed in any way. </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/64">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Maria Romano</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/456">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We used specific inhibitors to study the role of src-family tyrosine kinases in the maturation of human monocyte derived dendritic cells upon stimulation with several toll like receptor (TLR) agonists. The effect of these kinase inhibitors on the capacity of DC to be activated by a TLR2 (PAM3CSK4), TLR3 (Poly I:C), TLR5 (Flagellin), and TLR8 (Poly U) agonist was evaluated.</rdfs:comment>
    <rdfs:label>Human monocyte derived dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000304">
    <rdfs:domain rdf:nodeID="A134"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#is_manufactured_by</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000286">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_792">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Disease staging factor</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000410</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/97">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/331"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/330"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/329"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/328"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/155"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_746"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Transfection of immature DCs with different constructs encoding for the oncogene Her-2/neu and as control PSA using the technology of Amaxa biosystems or an adeno virus Her-2 full length construct.</rdfs:comment>
    <rdfs:label>Transfection of immature DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/309">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/19"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>PBS (cells in FC-block 1:50) + 2 % FCS was used in incubation of cells for FACS staining for activation markers.</rdfs:comment>
    <rdfs:label>Phosphate buffered saline (PBS)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_467">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000246</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Age factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_719">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies involve orthologs</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Immunodysregulation, Polyendocrinopathy, and Enteropathy-model mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/189">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Stephen Preston</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0043227">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/221">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Michelle  Swain</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/414">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We demonstrated using a syngeneic mouse tumor model, expressing an Ag derived from the early region 1A of human adenovirus type 5, that the inadequate nature of the antitumor CTL response is not due to direct Ag presentation by the tumor cells, but results from presentation of tumor-derived Ag by nonactivated CD11c(+) APC.</rdfs:comment>
    <rdfs:label>Syngeneic mouse tumor model</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/494">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/13"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The dead cells were stained and used in the uptake of dead cells by DC.</rdfs:comment>
    <rdfs:label>Dead cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/12">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>cGMP DC generation</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdfs:comment>We have a clinical protocol for immunotherapy of melanoma patients in preparation, however many details are not yet finalized. 

Everything is carried out under GMP conditions according to SOPs.

In brief, patients with stage III or stage IV melanoma will undergo surgical resection of a melanotic lesion and leukapheresis will be performed on the following day. DCs will be generated from monocytes after elutriation of the leukapheresis product. On day 5 of culture immature DC will be pulsed with irradiated tumor cells (apoptotic bodies) prepared from the removed lesion and matured for 48 hours in presence of TNF-alpha.  Monocyte and DC viability as well as functionality will be continuously monitored. Such prepared DC will be used as DC vaccine, but also to expand T cells (isolated during the elutriation) for subsequent adoptive transfer. Before injection all cell products will be thoroughly tested to exclude contamination and presence of viable tumor cells. A portion of pulsed and unpulsed mature dendritic cells will be frozen and used to monitor immunological responses elicited by the DC vaccine and transferred T cells during the clinical trial. Treatment induced T cell responses will be evaluated by flow cytometry based methods (T cell phenotype, proliferation, perforin degranulation) and cytokine detection (Elispot, Elisa). The patients will be monitored for safety and toxicity of the treatment and for clinical response to immunotherapy.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/6">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/67"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have studied the immuno-physiology of rat and mouse intestinal dendritic cells. We have used a known adjuvant, E. coli heat-labile toxin (Etx) and a potential adjuvant R-848, a small TLR7/8 ligand. </rdfs:comment>
    <rdfs:label>rat intestinal dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0200674">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tumor rejection antigen AB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OCA1A</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Monophenol monooxygenase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Monophenol monooxygenases</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tyrosinase precursors</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TYROSINASES</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TYR</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SK29-AB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LB24-AB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OCAIA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tyrosinase precursor</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tyrosinase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/132">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/307"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>DC-STUDIO is a bioinformatics environment enabling the interrogation of DC genomics experiments according to a pathway-based logic. It is integrated with DC-BASE.</rdfs:comment>
    <rdfs:label>DC-STUDIO</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_640">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AM 580</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">4-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalen yl)carboxamido]benzoic acid</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RARa specific agonists</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AM580</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_30746"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/89">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0610"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Commercially available siRNA Smart Pool from Dharmacon targeted against the STAT3 transcription factor have been successfully transfected in human MDDCs.</rdfs:comment>
    <rdfs:label>transfected synthetic siRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000815">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T-lymphocytes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T-cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">suppressor T lymphocyte</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">suppressor T lymphocytes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T lymphocytes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T-lymphocyte</dcr:hasExactSynonym>
    <rdfs:label>regulatory t cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory t cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulatory T cells</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10535">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">unidentified adenovirus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">adenovirus</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/455">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We studied the correlation between CD8 multiple cell surface markers and functional profiles studied at single cell level. For that purpose, we subdivided peripheral CD8 T cells into eleven different cell subtypes based on the association of multiple cell surface markers. In each subtype, we isolated single-cells. In each single cell, we quantified the expression of multiple genes. Moreover, we isolated and studied cells from different normal donors.</rdfs:comment>
    <rdfs:label>CD8 T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#gp100_Antigen">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gp 100</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gp100 antigens</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gp100</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glycoprotein 100</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A119"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gp100 antigen</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/147">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Eva Rajnavölgyi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/65">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/88"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/33"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
    <rdfs:label>Andreas Radbruch</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/301"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/85"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/15"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/458"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/192"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ifomis.org/bfo/1.1/snap#Object">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/188">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sascha Nussbaum</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/389">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704239"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was shown in mice that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC. 
</rdfs:comment>
    <rdfs:label>Signalling adaptor molecule  MyD88</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/222">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ms. K. (Kitty) C.J. Berns</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/155">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Immature DC (imDC´s) are transfected with different constructs encoding for the oncogene Her-2/neu and as control PSA. The technology of Amaxa biosystems or an adeno virus Her-2 full length construct are used.</rdfs:comment>
    <rdfs:label>Transfected immature DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.uniprot.org/taxonomy/NEWT_55429">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Giant keyhole limpet</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Giant keyhole limpet</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KLH</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/7">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/73"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The DC were matured with TLR ligand R848 and polyI:C. Using these DC, we obtained best results in our evaluation whether antigens could be rerouted from the endosomal into the cytosolic compartment by combining antigen with cell penetrating peptides to further enhance cross-presentation.</rdfs:comment>
    <rdfs:label>DCs matured with a combination of ligands</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001990">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule 3, human</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Intercellular adhesion molecule 3 precursor, human</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD50 antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD50</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CDW50</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule 3</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICAM3 human</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000178"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICAM-R</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/495">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/15"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/13"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The D2SC1/Flt3-DC were stained (Mini67-1KT or Mini26-1KT (PKH67/PKH26 green/red fluorescent cell linker mini kit for general cell membrane labelling) from Sigma) for a process of dead cell uptake.</rdfs:comment>
    <rdfs:label>Stained D2SC1/Flt3-DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100026">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_28808">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mannan</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A125"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18154"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mannans</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/88">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/117"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/370"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OBI_0000737"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>HSV vector expressing full length tyrosinase, gp100 and MART-1optimised for antigen delivery to dendritic cells by the deletion of HSV genes which usually inhibit DC function. These deliver antigens to DC at very high efficiency and activate the transduced cells similarly to LPS. 

Biovex provides the possibility of using these vectors for a variety of pre-clinical, and ultimately clinical studies.</rdfs:comment>
    <rdfs:label>HSV-based vectors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/66">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Massimiliano Meoni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/148">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Krystina Snaith</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.uniprot.org/taxonomy/NEWT_45202">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_plasmid</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000430</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000840">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immature myeloid dendritic cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/99">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/278"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/273"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_742"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>refolded CD1 molecules are used to generate CD1 tetramers</rdfs:comment>
    <rdfs:label>generation of CD1 tetramers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000046">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001083</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD2</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/454">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These K/O mice were studied with regard to responses to viral infections. We used the mouse pox virus Ectromelia and MVA-BN. Coinfection with MVA-BN and Ectromilia protected the IFNalpha receptor -/- mice. The data show that MVA-BN can induce potent innate immune responses able to control viral replication to allow the specific immune response to eliminate Ectromelia in immune deficient mice.</rdfs:comment>
    <rdfs:label>IFNalpha receptor -/- mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/223">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Joëlle INGBER</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/187">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/76"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Noboyuki Onai</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#has_document">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has related document</rdfs:label>
    <OBI:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Guendel</OBI:IAO_0000117>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any DC-THERA resource to a document that describes this resource.</OBI:IAO_0000115>
    <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
    <rdfs:domain rdf:nodeID="A135"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#is_document_of"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/416">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/179"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Co-electroporation of immature DCs with both poly(I:C(12)U) and Melan-A/MART-1 encoding mRNA induced strong anti-Melan-A/MART-1 CD8(+) T-cell responses in vitro. Higher numbers of Melan-A/MART-1-specific CTLs were consistently obtained with poly(I:C(12)U)-activated DCs compared to DCs matured in the presence of an inflammatory cytokine cocktail. </rdfs:comment>
    <rdfs:label>Melan-A/MART-1 encoding mRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/268">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/78"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/73"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells had been obtained from isolation during elutriation and will be used for subsequent adoptive transfer.</rdfs:comment>
    <rdfs:label>Expanded T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_475">
    <rdfs:label>MRI scanner</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Magnetic Resonance Imaging scanner</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000566"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MRI scanner</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedDocument_4">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedDocument"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_322">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_iron oxide</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_50816</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A136">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/306">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5664"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A recombinant Leishmania major parasite expressing a fluorescent tracer was used for the infection of BALB/c (H2-d) mice. This was done to investigate whether infected DC process pathogen-derived antigen and stimulate antigen-specific CD4+ T cells in vivo.</rdfs:comment>
    <rdfs:label>Leishmania major parasite</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0200769">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Indoleamine-pyrrole 2,3-dioxygenase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107B</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">3-dioxygenase</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Indoleamine 2,3-dioxygenase</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Indoleamine 2,3-dioxygenase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">I23O_HUMAN</dcr:hasExactSynonym>
    <rdfs:label>IDO</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IDO</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">INDO</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IDO</dcr:dcthera_label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/51">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001310"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/33"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001412"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <rdfs:comment>We obtained data on the influence of bLf, whose immunomodulant properties are now recognized, on  MDDC differentiation/activation. We found that bLF interferes with the activation of MD-DC induced by different TLR agonists, but not by T cell mediated signals. Although bLF did not significantly influence monocyte differentiation in DCs, we found that it markedly reduced the up-modulation of CD83, co-stimulatory and MHC molecules (i.e. CD80, CD86, MHC class I and II), and cytokine secretion (IL-12, TNF-? and IL-23) induced by LPS or polyI-C. Consistently with an impaired MDDC maturation, bLF exposed cells retained antigen uptake capacity and exhibited a lower capacity to promote T cell proliferation and Th1 polarization. Although bLF did not affect the phenotype of R848 activated MDDC, these cells exhibited a reduced capacity to produce IL-12 and TNF-? and to promote Th1 polarization, and retained antigen uptake capacity. In contrast, no major effects on the phenotypic and functional properties of CD40L activated MD-DCs were observed in the presence of bLF. Overall, these results provide evidence for an antinflammatory role of bLF in the modulation of MDDC function, independently of its capacity to bind LPS (Puddu et al.). Of note, human recombinant Lf (Talactoferrin) has been shown to exhibit different effects on human MDDC, since exposure of these cells to talactoferrin provides an activation stimulus leading to enhanced Th1 responses and production of effector cytokines. These different effects are likely due to the recognition of different receptors, expressed in MDDC by talactoferrin and bLf.

Future studies will focus on: 
(1a)  investigating bLf effects on DC activation  triggered by TLR agonists in terms of:
   i) migratory capacity, 
   ii) chemokine receptors expression (CCR5 versus CCR7), 
   iii) chemokine secretion; 
(1b) characterizing mechanisms underlying the capacity of bLf to attenuate inflammation and to define whether this property is linked to its function in the regulation of iron homeostasis; 
(1c) analysis of the cellular determinants involved in the interaction of MDDC with bLf as well as of their role in mediating the antinflammatory activity of bLf.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_239"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/179"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdfs:label>Roles of lactoferrin in human DC differentiation</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_892"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701386"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/17">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/137"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/230"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>April Poster</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_437">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Siglec-H receptor</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A109"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Siglec-H</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000007">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/419">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>B cell proliferation (polyclonal, oligoclonal, monoclonal) was observed in human Hemato-Lymphoid System Rag2-/-gc-/- mice after being infected with EBV and mounting an immune response. </rdfs:comment>
    <rdfs:label>B cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/57">
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/189"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>A single step procedure for the in vitro maturation and antigen loading of human moDC was optimized. DC were electroporated with mRNA encoding tumor antigens and a putative TLR3 ligand. In vitro stimulation of naïve T cells indicated the superiority of this approach compared to in vitro stimulation with DC matured with inflammatory cytokines followed by electroporation with TAA encoding mRNA.</rdfs:comment>
    <rdfs:label>Single step procedure for the in vitro maturation and antigen loading of human moDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/18">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Draft templates for IMP</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/67">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Petra Starke</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/348">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17823"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The Pharmacological compound 1?,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the biologically active metabolite of Vitamin D3, and its analogues, was evaluated for its effect on the DC differentiation/activation pathway induced by type I IFN. The suppressive effect of 1,25(OH)2D3 was associated with a potent impairment of DC migration in response to inflammatory and lymph node homing chemokines, thus unraveling a novel mechanism involved in 1,25(OH)2D3-mediated immunomodulation.</rdfs:comment>
    <rdfs:label>Calcitriol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A137">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_35222"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/79">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/347"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab has gathered data in establishing a per-clinical model of breast cancer.</rdfs:comment>
    <rdfs:label>Establishment of per-clinical model of breast cancer; preparation of viral constructs for vaccination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/387">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was shown that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC. 
</rdfs:comment>
    <rdfs:label>IL-10 in mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/50">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The University offers 27 official undergraduate degree programs and more than 300 graduate programs in 10 Schools, 2 Superior Colleges, the IESE Business School, 2 University Schools, the ISSA, and other centers and institutions.
During the 2006-2007 academic year, 815 full-time faculty members worked at the University, teaching 10,153 students in its undergraduate programs and 4,667 in its graduate programs. At the University of Navarra Hospital, 500 doctors are employed, along with 700 nurses and another 850 professionals. More than 100,000 patients are cared for each year.
The University was founded in 1952 by St Josemaría Escrivá de Balaguer, who summarized the mission of the University with the following words: "The University of Navarra strives to make present in all its activities the awareness of the idea that work is a testimony of the supremacy of the human being over the material world, a means of personal development, a bond between people and a fundamental way of contributing to the progress of humankind".

Since 1952, the University of Navarra has been linked with Opus Dei, an institution of the Catholic Church founded by St. Josemaría Escrivá de Balaguer, and which spreads the message that work and the ordinary realities of life are the road of Christian life. The Prelature of Opus Dei provides the spiritual and pastoral means necessary in order that the University may maintain and develop its Christian identity.</rdfs:comment>
    <rdfs:label>Universidad de Navarra / University of Navarra</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/267">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/73"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells were isolated during elutriation of a leukapheresis product (patients with stage III or stage IV melanoma) .</rdfs:comment>
    <rdfs:label>Isolated T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100036">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/BTO#BTO_0002217</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_supernatant</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/254">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/255"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Collaborative work with P34 (Sica) has been started to study the effects of Japanin on DC exposed to hypoxia (below) and to perform transcriptional profiling of the treated cells. This work, which could not have been undertaken at this stage without support from DC-THERA, has now led to a joint publication in 2008 (Mancino et al.). Transcriptional data are available.</rdfs:comment>
    <rdfs:label>Study on the effects of hypoxia on human monocyte-derived DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/418">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Cytotoxic T cells proliferation was observed in human Hemato-Lymphoid System Rag2-/-gc-/- mice after being infected with EBV and mounting an immune response. </rdfs:comment>
    <rdfs:label>Cytotoxic T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTermClass">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToType"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001024">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A138">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedDocument_3">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedDocument"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/52">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:label>Activation of DC by TLR agonists</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_240"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/34"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <rdfs:comment>Our lab gathered data on DC activation by pathogen-derived stimuli. We focused on the study of the response of MDDCs to the combined stimulation with TLR ligands and we observed that simultaneous activation of TLR4 and TLR8 signaling cascades results in a marked inhibition of the secretion of the proinflammatory chemokine CCL2 with respect to stimulation through a single TLR. This inhibition is specific for both CCL2 and TLR agonist combination and could represent a novel regulatory mechanism evolved to maintain immunological balance (Del Cornò et al.).

Future studies will focus on 
- characterizing the mechanism(s) by which cross-tolerance between TLRs induce different functional states of DCs that favour different T cell effector phenotypes. Moreover, a further characterization of the molecular mechanisms underlying CCL2 regulation, will be also performed; 
- defining the role of selected miR on the differentiation/activation of MDDCs. </rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/156"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/264"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/18">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/154"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/227"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/21"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/138"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/15"/>
    <rdfs:label>Francesca Granucci</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/177"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/112"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/43"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/28"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/14"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/176"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdfs:comment></rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932">
    <rdfs:label>Saccharomyces cerevisiae</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saccharomyces cerevisiae</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">baker's yeast</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saccharomyces capensis</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">S. cerevisiae</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saccharomyces uvarum var. melibiosus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">brewer's yeast</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saccharomyces oviformis</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Saccharomyces italicus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lager beer yeast</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/10">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Leaf Bioscience is a company operating in Italy in the area of Bioinformatics/ IT. Its mission is to provide professional IT support, bioinformatic software development and consultancy to the life science community and in new emerging biotech areas. Leaf Bioscience know-how covers the more relevant fields in bioinfomatics: IT, Computer Science, Biology, Chemistry, Statistics, coming from both industrial and academic experience. It can thus provide a full range of services. Furthermore Leaf Bioscience's attention to opensource, vendor neutral solutions, and its close contact to the academic community, allows it to offer cutting edge technology at competitive costs.</rdfs:comment>
    <rdfs:label>Leaf Bioscience s.r.l.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/58">
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_249"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/209"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Protocols were developed to refold in vitro CD1 molecules, which were used for the generation of CD1 tetramers. The ability to generate CD1d tetramers has provided us with the opportunity of comparing a broad panel of CD1d binding compounds for their ability to stimulate iNKT cells.</rdfs:comment>
    <rdfs:label>Protocols to refold in vitro CD1 molecules, which were used for the generation of CD1 tetramers </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/109">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/201"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_747"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Purified CD8 T cells using MACS cell separation are co-cultured with electroporated DC.</rdfs:comment>
    <rdfs:label>Coculture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_84092">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_MHC class II protein</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000103</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/17">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Draft templates for CTP</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_539">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Assistant</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000116"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An assistant role is a DCTHERA role of DCTHERA persons who act as assistant to another person.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0049521">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GR1 protein</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GR1</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A139">
    <rdf:rest rdf:nodeID="A140"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/347">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/79"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These constructs were prepared for a per-clinical model of breast cancer.</rdfs:comment>
    <rdfs:label>Viral constructs for vaccination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/388">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was shown that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC. 
</rdfs:comment>
    <rdfs:label>IL-12 in mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/68">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/88"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/15"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/63"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/31"/>
    <rdfs:label>Alexander Scheffold</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/301"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/38"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/55"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/48"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/128"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/110"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/253">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>A worldwide first randomized adjuvant trial in a subgroup of high risk melanoma patients (monosomy 3) using autologous DC transfected with amplified total tumor RNA derived from patients' uvea melanomas was to be started in 2009 and data will become available.</rdfs:comment>
    <rdfs:label>Phase III RNA-DC trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701377">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin-8 (human)</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-8</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000104">
    <rdfs:comment xml:lang="en">2/3/2009 Comment from OBI review. Action specification not well enough 
    specified. Conditional specification not well enough specified. Question 
    whether all plan specifications have objective specifications. Request 
    that IAO either clarify these or change definitions not to use them</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/266">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/57"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/56"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DCs were pulsed with allogenic melanoma peptides (SK-Mel 24, HLA-A1 and HLA-A2 positive) plus KLH as immunological tracer and subsequently used to produce a vaccine for melanoma.</rdfs:comment>
    <rdfs:label>DCs pulsed with peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_324">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">melanoma antigen</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17334">
    <rdfs:label>penicillin</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33575"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">penicillin</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">penicillins</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A class of substituted penams that includes the natural penicillins and synthetic analogues.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/331">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Gilles Capart</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1000036">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/308">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/19"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The FC-block was used for incubation of cells (1:50 in PBS + 2 % FCS) for FACS staining of activation markers.</rdfs:comment>
    <rdfs:label>FC-block</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0702099">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">recombination activating gene 2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Importin subunit alpha-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Karyopherin subunit alpha-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">karyopherin alpha 1 (importin alpha 5)</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RECOMBINATION ACTIVATING GENE COHORT 2</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAG2</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RCH2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NPI-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RECOMBINATION ACTIVATING GENE COHORT 2</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAG cohort protein 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IMPORTIN ALPHA-5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KARYOPHERIN ALPHA-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nucleoprotein interactor 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KPNA1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAG-2</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAG2</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRP1-beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IPOA5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRP1</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/199">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/109"/>
    <rdfs:comment>Purified CD8 T cells using MACS cell separation were co-cultured with electroporated DC and subequently became evaluated on their cytokine secretion, cytotoxicity and % of antigen specific T cells.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/109"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdfs:label>purified CD8 T cells</rdfs:label>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/110"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/110"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/107"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/111"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_499">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Storing function</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A storing function is a function whose aim is to store data or other material to make it available for possible later usage.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/15">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/445"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/15"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/221"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/129"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/149"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/388"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/505"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/393"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/389"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/230"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/392"/>
    <rdfs:label>Anne O'Garra</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/111"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/390"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/84"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/117"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/110"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/503"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/308"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/175"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/444"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/391"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/150"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/85"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/118"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/9"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/387"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/111"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/504"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/309"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/81"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/55">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdfs:comment>We have efficiently transfected DC with RNA encoding a functional protein (E/L-Selectin) which allows entry of DC into LN from HEV. 

RNA transfected human DC could be frozen and thawed without loosing their functionality. </rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000182"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/181"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_216"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdfs:label>Transfection of DC with RNA encoding E/L-Selectin</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/368"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/369"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/77">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1637"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/219"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_764"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/69"/>
    <rdfs:comment>We obtained data from studies of CD8 T cell properties in man comparing HIV, CMV and EBV-specific cells. 

It is usually assumed that effector gene expression in CD8 T cells may be similar in all immune responses, CD8 T cells in vivo differentiating into cytotoxic T cells that also produce g-inf. In contrast we published in 2007 that CD8 follow several differentiation waves and that effector gene expression is heterogeneous, different effector genes having different kinetics of expression-down regulation and associating randomly, suggesting that different immune responses could induce diverse differentiation patterns. 

In the present year: 
1° We studied the first differentiation wave, that occurs immediately after antigen stimulation, when cells able to induce inflammation are produced. We found a major expression of pro-inflammatory chemokines that is restricted to this period. We also developed an in vivo test where these effectors are transplanted in a matrigel, to study their capacity to attract other cell types. 

2° We initiated a vast comparison between CD8 T cells responding to very different stimuli. Our preliminary results show that CD8 T cells responding either to virus or Listeria have very different properties, indicating that the inflammatory context defines CD8 T cells with different properties. </rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdfs:label>Gene expression in CD8 T cells in different inflammatory contexts</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/220"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/346">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A vaccination trial with RNA transfected autologous DC was done with overlapping peptides covering the whole protein sequence of the tumor antigens MageA3, MelanA and Survivin. </rdfs:comment>
    <rdfs:label>RNA transfected autologous DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_538">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000014"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An administration role is a DCTHERA role of DCTHERA persons who do administrative work.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Administration</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/256">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/286"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/126"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We explored for the first time transfection of CD4(+) and CD8(+) T cells with mRNA encoding recombinant immunoreceptors for use in the adoptive immunotherapy of cancer and obtained data from this study.

CD4(+) and CD8(+) T cells were efficiently transfected with immunoreceptors specific for ErbB2 and CEA. The immunoreceptor expression was transient with half-maximal expression at day 2 and no detectable immunoreceptor expression at day 9 after electroporation. Immunoreceptor-transfected T cells were specifically activated upon coincubation with ErbB2(+) and CEA(+) tumor cells, respectively, resulting in secretion of interferon-gamma (IFNgamma), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNFalpha). Furthermore, immunoreceptor-transfected CD8(+) T cells specifically lysed ErbB2(+) and CEA(+) tumor cells, respectively. The RNA-transfected T cells retained their cytotoxic function after 2 days of activation and exhibited cytolytic activities like retrovirally transduced T cells. Opposed to  standard procedures using retroviral gene transduction to constitutively express immunoreceptors in T cells, transient immunoreceptor expression by RNA transfection should minimize the risk of persistence of potential autoaggression.</rdfs:comment>
    <rdfs:label>Transfection of CD4(+) and CD8(+) T cells with mRNA encoding recombinant immunoreceptors for use in cancer immunotherapy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/108">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/201"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_744"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Dendritic cells are electroporated.</rdfs:comment>
    <rdfs:label>electroporation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0002279">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mouse macrophage cell line</OBI:IAO_0000115>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">J774 cell</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">J-774 cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000105">
    <rdfs:label xml:lang="en">obsolete_document</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_544</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A141">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/69">
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/167"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/260"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/88"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/316"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/15"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/31"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/214"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/301"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/314"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/315"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/110"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
    <rdfs:label>Andreas Thiel</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/63"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0005618">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell wall</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell walls</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/2">
    <dcr:is_manufactured_by rdf:resource="http://dc-research.eu/rdf/participant/13"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/11"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have developed, at the Curie Institute, a unique methodology dedicated to the identification of phagosome proteins in dendritic cells, under various experimental conditions. This methodoly incorporates a unique sample preparation procedure based on 96 well plate complex sample trypsinization, a nano-LC-based peptide separation coupled to MSMS analysis sequencing. This procedure led us to the identification of 600 phagosomal proteins from murine DC phagosomes. An integrated software solution has been developed to analyse these results and to perform comparative analysis of phagosome proteomes obtained in various conditions. 

This methodology has been applied successfully to identify: 

a) a set of proteins specifically associated to phagosomes in DCs but not other phagocytes, such as macrophages, 
b) a set of proteins specifically recruited to phagosomes during DCs maturation induced by various Toll-Like Receptors.</rdfs:comment>
    <rdfs:label>Phagosome proteome analysis software</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/385">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000064"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>When identifying molecular signatures for alternatively activated DC (AA-DC) it was found that the hallmark of AA-DC was the production of the angiogenic cytokine VEGF in vitro, and in vivo when the cells were implanted into the chicken embryo CAM assay. VEGF production by DC was selectively observed only when the DC where alternatively activated. Therefore, VEGF production by DC can be considered a signature of this state of activation.</rdfs:comment>
    <rdfs:label>Angiogenic cytokine VEGF</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/498">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/15"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/14"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_227"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells were stained with anti-CD11c antibodies for a process of dead cell uptake by DC.</rdfs:comment>
    <rdfs:label>Stained GM-DC/raw</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/332">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Maria Rosa Pedrazzi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_325">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0043020"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NADPH oxidase 2</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NOX-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NOX2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_478">
    <rdfs:label>medium pressure liquid chromatography assay</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MPLC assay</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MPLC assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">medium pressure liquid chromatography assay</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">medium pressure liquid chromatography</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/499">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/15"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/18"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/17"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This supernatant was created during a co-culture of the stained cells and subsequently frozen at -80°C for analysis of DC-stimulation.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/16"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdfs:label>Supernatant from culture of  D2SC1/Flt3-DC, GM-DC and dead cells</rdfs:label>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/16"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0002217"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/17"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedDocument_5">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedDocument"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_758">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Growth protocol</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A ComplexAction or ProtocolType describing growth of an organism or cell culture.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/159">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>HLA-DP4/MAGE3 molecules have been prepared to stain ex vivo PBL from immunized melanoma patients for a study of anti-tumor responses in melanoma patients that were vaccinated with autologous DCs loaded with a combination of tumor Ag peptides.</rdfs:comment>
    <rdfs:label>HLA-DP4/MAGE3 molecules </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/307">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The DC were matured with inflammatory cytokines followed by electroporation with TAA encoding mRNA. They were used to compare different maturation methods.</rdfs:comment>
    <rdfs:label>Cytokine-matured DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/16">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>David Jones</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/56">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/222"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We previously described mRNA electroporation as an efficient gene delivery method to introduce tumor-antigens (Ag) into murine immature dendritic cells (DC). 

We have further optimized the protocol and evaluated the capacity of mRNA-electroporated DC as a vaccine for immunotherapy.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/189"/>
    <rdfs:label>In vitro charging of moDC with antigens</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0200499">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33838"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nucleoside triphosphate</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nucleoside triphosphate</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NTP</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/107">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/198"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>CD8 T cells are purified using MACS cell separation.</rdfs:comment>
    <rdfs:label>MACS cell purification</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/50">
    <dcr:is_manufactured_by rdf:resource="http://dc-research.eu/rdf/person/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/32"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Microarray and gene expression are fundamental tools of nowadays Biology research. While standard formats and software systems have been developed to represent and publicly share information about microarray experiments, existing computational solutions give limited support to the representation of the outcomes, experimental hypotheses or conclusions about biological questions that are dealt with in gene expression analysis. We propose an OWL-based model and a Semantic Web-based approach to address the issue. We show that the formalization of microarray-related knowledge has the potential to enhance the access and the sharing of gene expression data; it promotes the collaboration on analysing them and, in general, it can improve the achievements of the scientific community working in the field.

The thesis paper and a software demo are available at http://brandizi.webhop.net/phdthesis.</rdfs:comment>
    <rdfs:label>Research-level tool for ontology based micro-array data analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000008">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-2</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TCGF</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000103">
    <rdfs:label>Major histocompatibility complex class II</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Major histocompatibility complex class II</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MHCII</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/50">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_393"/>
    <rdfs:label>Role of GM-CSF in human DC differentiation</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/115"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_764"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/32"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000798"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000002025"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/342"/>
    <rdfs:comment>We investigated and obtained data on the interactions between human monocyte derived DCs (MDDC), generated in the presence of GM-CSF and IL-4 (IL-4 DC), and antigen-stimulated circulating gamma delta T lymphocytes, bearing the Vgamma2 TCR. Co-cultures of IFN-DCs with zoledronate-stimulated gamma delta T lymphocytes were also performed. gamma delta T-cell activation, as demonstrated by their up-modulation of activation marker expression levels (e.g. CD25 and CD69), was observed. These studies demonstrated for the first time the existence of a bidirectional activating interaction between DCs and gamma delta T lymphocytes activated by aminobiphosphonates. These data suggest a potential adjuvant role of this early cross-talk in the therapeutic activity of aminobiphosphonate drug that are currently used as anti-tumor drugs. A further characterization of the functional activities of activated gamma delta T lymphocytes and the reciprocal activation of the IFN-DCs are currently in progress. 

In the context of a different research project, it was observed that GM-CSF can promote, in the absence of any other stimulus, the differentiation of human monocytes into dendritic cells. These GM-DCs are endowed with distinct immuno-stimulatory and migratory properties. In particular, GM-DCs are activated CD1a+ DCs expressing co-stimulatory molecules, MHC class I and II, able to induce the proliferation and IFN-gamma production of allogeneic T lymphocytes and to *migrate toward both inflammatory and homeostatic chemokines. Interestingly the responsiveness of individual donors to this DC-differentiation promoting activity of GM-CSF positively correlates with their basal expression level of GM-CSF receptor.

The results have been accepted for publication (Conti et al., EJI). The detailed protocol might be submitted to the knowledge portal.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/263"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_392"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/40"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/175"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/78">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/51"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label>Phase I trial: Exosomes and mouse NK cell responses in vivo</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/233"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_251"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/234"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/239"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasCellLineType rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000664"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/531"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_330"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/208"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <rdfs:comment>In our lab, data was obtained from a phase I trial using peptide-pulsed Dex. Dendritic cell (DC) derived-exosomes (Dex) are nanomeric vesicles harboring functional MHC/peptide complexes promoting T cell -dependent tumor rejection.  
In this Phase I trial using peptide-pulsed Dex, the observation of clinical regressions in the absence of T cell responses prompted the search for alternate effector mechanisms. Mouse studies unraveled the bioactivity of Dex onto NK cells, Dex promoting a IL-15Ra-dependent NK cell proliferation and a NKG2D-dependent activation resulting in an anti-metastatic effect. In humans, Dex bear functional IL-15R? which allow proliferation and IFNg secretion by NK cells. In contrast to immature DC, human Dex harbor NKG2D ligands on their surface leading to a direct engagement of NKG2D and NK cell activation ex vivo. In our phase I clinical trial, we highlight the capacity of Dex based-vaccines to restore the number and NKG2D-dependent function of NK cells in 7/14 patients. In conclusion, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors. Therefore, NK cell activation represents a new bioactivity for Dex leading to tumor recognition and regression in vivo.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_159"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/345">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0050147"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with surface markers (such as CD8, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. 

Additionally, these CD107a functional markers were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD107a functional markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasTissueType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type tissue.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tissue type</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/49">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_771"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Incubation at 65 °C for 12–15 h. </rdfs:comment>
    <rdfs:label>Hybridization</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400099">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/ID#ID_0000047">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">treatment role</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#RealizableEntity"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A98">
    <owl:unionOf rdf:nodeID="A142"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_537">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An Executive Committee role is a DCTHERA role of a DCTHERA person who is part of the DCTHERA Executive Committee.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Executive Committee</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000016"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100035">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_159">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-314 </dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KLRK 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KLRK-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD314</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NKG2D</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KLRK1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 314 </dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A104"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/255">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/254"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Pathways-based analysis will be done in collaboration with P15 (Cavalieri) to identify the intracellular target of Japanin and data will become available from this study. </rdfs:comment>
    <rdfs:label>Pathways-based analysis on Japanin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_381">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">L-SIGN</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CLEC4M</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD209L</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A114"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/264">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/52"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>TLR ligands (simultaneous activation of TLR4 and TLR8 signaling cascades) were used as stimuli for MDDC and resulted in a marked inhibition of the secretion of the proinflammatory chemokine CCL2 with respect to stimulation through a single TLR.</rdfs:comment>
    <rdfs:label>TLR ligands</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A143">
    <owl:allValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000263"/>
    <owl:onProperty rdf:resource="http://dc-research.eu#hasOrganism"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/15">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:label>Flow cytometric assessment of Th subsets</rdfs:label>
    <rdfs:comment>We possess an SOP for the assessment of Th subsets via flow cytometry.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/88"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/221"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/386">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_408"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In a study aiming at the identification of molecular signatures for alternatively activated DC it was found that AA-DC induced in the presence of LPS and IL-10 also produced high levels of the long pentraxin PTX3. DC produced conspicuous amounts of PTX3 when stimulated with LPS and this production is further increased in the presence of IL-10. However, PTX3 production was not increased in other alternative conditions of activation, such as in the presence of dexamethasone or calcitriol. PTX3 has properties similar to antibodies. Its production is induced by pathogen recognition, it recognizes microbial moieties, activates complement and facilitates recognition by phagocytes. Thus, this long pentraxin behaves as a bona fide ante-antibody.</rdfs:comment>
    <rdfs:label>Long pentraxin PTX3</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000695">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sex factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/1">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/2"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/31"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/152"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have developed an automated microarray data analysis (AMDA) software, which provides scientists with an easy and integrated system for the analysis of Affymetrix microarray experiments. AMDA is free and it is available as an R package. It is based on the Bioconductor project that provides a number of powerful bioinformatics and microarray analysis tools. This automated pipeline integrates different functions available in the R and Bioconductor projects with newly developed functions. AMDA covers all of the steps, performing a full data analysis, including image analysis, quality controls, normalization, selection of differentially expressed genes, clustering, correspondence analysis and functional evaluation. Finally, a LaTEX document is dynamically generated depending on the performed analysis steps. The generated report contains comments and analysis results as well as the references to several files for a deeper investigation. 

This tool was further improved in 2008 with regard to the application of existing (and start of development of new) advanced statistics, pattern recognition, and signal processing algorithms for expression data analysis.</rdfs:comment>
    <rdfs:label>AMDA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_24866">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">salt</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36357"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/344">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700262"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD127 surface markers (and additionally, CD8, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD137) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD127 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/82">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established by using high accuracy, high sensitivity protein identification technology. We have identified 2794 proteins in DCs by liquid chromatography tandem mass spectrometry. Prior to MS analysis, DC were lysed and divided into a soluble fraction containing cytosolic proteins and into an insoluble fraction enriched for membrane containing proteins. Highly complex protein mixtures of DC cellular fractions were separated on 1 D SDS-PAGE into 20 gel slices (fractions), followed by in-gel digestion with trypsin. Purified tryptic peptides were analysed in triplicate by LC-MS/MS using a linear ion trap/ Fourier Transform (LTQ-FT) hybrid mass spectrometer.</rdfs:comment>
    <rdfs:label>clinical grade immature and cytokine cocktail matured monocyte derived human dendritic cells (DC) </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_497">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000403</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Sorting function</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_270">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Langerin</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-207 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 207 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-207</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD207</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 207</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD207 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Langerin receptor</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/89">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/28"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400169"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In the lab, there is a multi-photon microscope available. It is used, for instance, in the analysis of in vivo distribution and motility of NK cells.</rdfs:comment>
    <rdfs:label>Multi-photon microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700235">
    <rdfs:subClassOf rdf:nodeID="A144"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nr1b1</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000090"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear receptor subfamily 1 group B member 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Retinoic acid receptor alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">retinoic acid receptor, alpha</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A99"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rara</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAR-alpha</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RARalpha1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RARa mouse</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAR alpha 1</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000390">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_712">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S1/Sv * 129X1/SvJ * FVB/N</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_711"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Myctm1Lbox/Myc+ transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/42">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/62"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CD83 overexpression on Melan-A/MART-1-specific tumor-infiltrating lymphocytes (TIL) circumvents the need for CD83 expression on DC. </rdfs:comment>
    <rdfs:label>Melan-A/MART-1-specific tumor-infiltrating lymphocytes (TIL)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/5">
    <rdfs:label>SILAC (Stable Isotope Labelling by Amino Acids in Cell Culture) </rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/175"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/95"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <rdfs:comment>For quantitative proteomic studies, our group recently described the SILAC (Stable Isotope Labelling by Amino Acids in Cell Culture) approach. In this method, independent populations of cells are grown in medium containing different non-radioactive isotope forms of essential amino acids (e.g. arginine and lysine). Because the cells cannot synthesize these amino acids, after some generations all proteins are labelled and therefore can be distinguished and quantified by the mass spectrometer. To generate a proteomic map of DCs which includes quantitative information that can be used further to study signalling cascades it is also necessary to optimize the SILAC labelling of DCs. This work was performed by Christian A. Luber.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_462"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/160"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/34"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/97"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000202">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">investigation agent</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_326">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ashen mice</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ashen mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is this a strain?</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/141">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Suzanne Watts</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_327">
    <rdfs:label>2C44</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2C44 monoclonal antibody</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2C44 antibody</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A136"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2C44</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/263">
    <rdfs:comment>These dendritic cells were generated from monocytes isolated from buffy coats, activation was induced by lipopolisaccaride (LPS 1microgram/ml, Sigma, St. Louis, MO), by Curdlan (100 micrograms/ml, Wako), by R848 and yeast RNA and by yeast cells in different conditions of culture.  </rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/133"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/131"/>
    <rdfs:label>Activated DC</rdfs:label>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/4">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/143"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400040"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have a FACS Aria cell sorter at our disposition from BD Biosciences (URL: http://www.bdbiosciences.com/features/products/display_product.php?keyID=53).

We used this FACS Aria among other things for fluorescence activated cell sorting for proteomic investigations. Using Fluorescence activated cell sorting allowed us to obtain highly pure fractions of CD8+, CD4+ and DN DC subsets. However, because DC are a very rare population, this method is very material- and cost-intensive. Furthermore, it is not surprising that the obtained cell numbers of each subset after isolation are below 107. However, these cell numbers should be sufficient for proteomic investigations. </rdfs:comment>
    <rdfs:label>BD FACS Aria</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/250">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>High-throughput data is available on tumour-associated antigen (TAA) specific T-cells in breast cancer patients using the Becton Dickinson Lyoplate™ technology.

Therefore we have established multiparameter assessments of antigen-specific CD4+ and CD8+ T-cells enabling a simultaneous quantitative and qualitative analysis.</rdfs:comment>
    <rdfs:label>High-throughput assessment of tumour-associated antigen (TAA) specific T-cells in breast cancer patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_711">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies involve orthologs</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Burkitt Lymphoma-model mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/41">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/62"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Down-regulation of CD83 expression on human DC through RNA interference (RNAi) results in a less potent induction of allogeneic T cell proliferation, reduced IFN-gamma secretion by established T cells and decreased capacity in the priming of functional tumor antigen-specific CD8+ T lymphocytes. </rdfs:comment>
    <rdfs:label>functional tumor antigen-specific CD8+ T lymphocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/54">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>SBL is a (Community Interest) Company dedicated to improving patient treatment options through high quality, collaborative and clinically focused research.

SBL has a strong scientific team with a variety of academic and industrial backgrounds. We have particular strengths in all aspects of immunology and molecular biology. Clinical applications for our work include:

- Cancer immunotherapy
- Repair of DNA damage by agents such as UV
- Memory formation</rdfs:comment>
    <rdfs:label>Systems Biology Laboratory UK c.i.c.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/383">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/90"/>
    <rdfs:comment>This DC vaccine was produced from the Leukapheresis product, after elutriation, of a metastatic lesion of stage III/IV melanoma patients.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/93"/>
    <rdfs:label>DC vaccine</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000016">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulator defined by legislation or governmental orders</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/14">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The ICP is a multidisciplinary biomedical research institute hosting several laboratories of the faculty of medicine of UCL (Université catholique de Louvain), as well as the Brussels branch of the Ludwig Institute. 

The ICP is based on three principles: 
priority to basic research and to the freedom of the investigators 
special attention to medical benefits potentially resulting from basic discoveries 
multidisciplinary collaboration within a critical mass of competences, equipment and techniques. 

ICP is located on the Brussels Campus of UCL, next to the university hospital St-Luc, at about 10 km from the center of Brussels</rdfs:comment>
    <rdfs:label>Christian de Duve Institute of Cellular Pathology, ICP 75.50</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A145">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_629"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#usesBioMat">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#isBioMatUsedIn"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <OBI:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Guendel</OBI:IAO_0000117>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a data set or a protocol to a bio-material that was used during the creation of the data set or the application of the protocol.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">uses biomaterial</rdfs:label>
    <rdfs:domain rdf:nodeID="A146"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/137">
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/17"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our laboratory has obtained data on the kinetic of the transcriptional profiling of purified mouse DC treated with IL10.</rdfs:comment>
    <rdfs:label>Analysis of the kinetic of the transcriptional profiling of purified mouse DC treated with IL10</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A142">
    <rdf:rest rdf:nodeID="A147"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_498">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A labeling function is a function whose aim is to mark things to make them identifiable.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Labeling function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/343">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_180"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD137 surface markers (and additionally, CD8, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD137 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/81">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were used in an experiment for identification of antigens recognised by T cells from melanoma patients responding to immunotherapy.</rdfs:comment>
    <rdfs:label>Monocyte derived DC pulsed with tumor lysate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4751">
    <rdfs:label>Fungi</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fungi</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fungus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_472">
    <rdfs:label>multiplex assay</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">multiplex assay</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">multiplex analysis</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1279">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Staphylococcus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/301">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We used a MHC II presentation pathway targeting vector originally published by Wang et al. 1999 for the delivery of antigens in both murine and human DC.</rdfs:comment>
    <rdfs:label>MHC II presentation pathway targeting vector</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/43">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/62"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000664"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Co-culture of immature DC with TIL or K562 cells overexpressing CD83 results in the production of enhanced levels of pro-inflammatory cytokines, whereas this production is less pronounced or even absent in co-cultures with non-modified TIL or K562 cells.</rdfs:comment>
    <rdfs:label>K562 cells overexpressing CD83</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000002">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_453</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_ligand</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_710">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zap70m1Saka/Zap70m1Saka transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: BALB/c</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_705"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000090">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">retinoic acid receptor</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Retinoic acid receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/262">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Yeast cells in different conditions of culture (along with R848, Curdland, yeast RNA and LPS) were used to induce DC activation.</rdfs:comment>
    <rdfs:label>Yeast cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/3">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/141"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_458"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>There is a confocal microscope at our disposal for confocal imaging.</rdfs:comment>
    <rdfs:label>Confocal microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_328">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_dendritic cell-derived exosome</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/GO#GO_0070062</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0013559">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCL-1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCL1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GRO</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GRO1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SCYB1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MGSA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GROA</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/142">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>MD, MBA
Associate Professor of Immunology, Medical University Vienna

CEO, Trimed Biotech GmbH &amp; St. Anna Children's Cancer Research Institute</rdfs:comment>
    <rdfs:label>Thomas Felzmann</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11623">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lymphocytic Choriomeningitis Virus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LCMV</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/384">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/103"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These ovarian carcinoma patients are treated with a vaccine composed by autologous DCs pulsed with apoptotic autologous ovarian carcinoma cells.</rdfs:comment>
    <rdfs:label>Ovarian carcinoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/53">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>IDM Pharma is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer.

We are currently developing two types of products designed to:

• Destroy cancer cells by activating innate immunity
• Prevent tumor recurrence by triggering a specific adaptive immune response</rdfs:comment>
    <rdfs:label>IDM Pharma S.A.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700233">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RARa human</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAR-alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">retinoic acid receptor, alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NR1B1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear receptor subfamily 1 group B member 1</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000090"/>
    <rdfs:subClassOf rdf:nodeID="A143"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Retinoic acid receptor alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RARA</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">RAR, ALPHA FORM</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A133"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A148">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/15">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The University of Florence can trace its origins to the Studium Generale, which was established by the Florentine Republic in 1321. Initially, Civil and Canon Law, Literature, and Medicine were among the subjects taught at the Studium, and various famous scholars were invited to teach there: Giovanni Bocaccio was asked to lecture on the Divine Comedy. 

However, the importance of the Studium was fully recognized with a Bull by Popo Clemente VI in 1349, in which he officially authorised the Studium to grant regular degrees, extended the Privilegia maxima, and established that the first Italian Faculty of Theology would be in Florence. 

In 1364, with Emperor Carlo VII, the Florentine Studium became an Imperial University. However, when Lorenzo the Magnificent gained control of Florence and much of Tuscany, the Studium was moved to Pisa, in 1473. Carlo VIII moved it back to Florence from 1497-1515, but with the return of the Medici family it was once again transferred to Pisa. 

In spite of these moves, many teaching activities continued in Florence, and scientific research found substantial support in the various Academies of the time, like the Crusca and the Cimento. 

Only in 1859, when the Grand Duke was exiled, were all these separate teaching activities reunited in a suitable system called the Istituto di Studi Pratici e di Perfezionamento; a year later this was recognized as a full fledged university by the Government of Unified Italy. 

In 1923, with a special Act of Parliament the Instututo was officially denominated a University. Later, the new University was organized into the various faculties: Agriculture, Architecture, Arts, Economics, Education, Law, Mathematics, Physical and Natural Sciences, Medicine and Surgery, Pharmacy, and Political Science. The Faculty of Engineering was added to the 10 faculties in 1970 and the Faculty of Psychology in 2002.</rdfs:comment>
    <rdfs:label>Università degli Studi di Firenze</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_30746">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">benzoic acid</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">benzoic acids</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24833"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000092">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001014</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD45R</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/136">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704239"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data has been obtained from an analysis of immature DC and mature DC from two strains of mice: the MyD88 deficient and the wild-type mice.</rdfs:comment>
    <rdfs:label>Transcriptional profiling of DC from MyD88 deficient and wild-type mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A147">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_485"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBodilyPartType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bodily part type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type "bodily part", such as organ, tissue, ...</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000017">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulation</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11234">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">rougeole virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Subacute sclerosing panencephalitis virus</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">measles virus MV</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">subacute sclerosing panencephalitis virus, SSPEV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">rubeola virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell-associated subacute sclerosing panencephalitis</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">measles virus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">subacute sclerose panencephalitis virus</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/59">
    <dcr:hasBioSourceType rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>The vaccine is composed by autologous DCs pulsed with apoptotic  allogenic prostate carcinoma cell line  LNCap.</rdfs:comment>
    <rdfs:label>Clinical protocol for treatment advance prostate carcinoma with dendritic cells loaded with apoptotic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/11">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/37"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Argos Therapeutics, Inc. is developing breakthrough immunotherapies that target unique features of a patient’s disease. This new generation of personalized cancer and infectious disease therapeutics trains the immune system to recognize and attack the disease. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. 	


Argos, a private biotechnology company, is headquartered in Research Triangle Park, NC. The Company has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company, Limited.</rdfs:comment>
    <rdfs:label>Argos Therapeutics, Inc.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/80">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A functional analysis of anti-MAGE-3.A1 CTL clones derived from vaccinated patients (either ALVAC canarypox virus vector, peptide-pulsed DC or peptide vaccination +/- montanide adjuvant) who displayed tumor regression was done.  

The functional avidities of these CTL clones, evaluated in lysis assays, were surprisingly low, suggesting that high avidity was not part of the putative capability of these CTL to trigger tumor rejection. Most anti-MAGE-3.A1 CTL clones obtained after DC vaccination, but not after peptide or ALVAC vaccination, produced IL-10. Transcript profiling confirmed this result and indicated that about 20 genes, including CD40L, prostaglandin D2 synthase, granzyme K and granzyme H, were differentially expressed between the anti-MAGE-3.A1 CTL clones derived from patients vaccinated with peptide-ALVAC or with peptide-pulsed DC. These results indicate that the modality of vaccination with a tumor-specific antigen influences the differentiation pathway of the anti-vaccine CD8 T cells, which may have an impact on their capacity to trigger a tumor rejection response.</rdfs:comment>
    <rdfs:label>anti-MAGE-3.A1 CTL clones</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001612">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GTPase Rab27a</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rab27a</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/342">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_242"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD27 surface markers (and additionally, CD8, CD4, CD3, CD45RA, CCR7, CD25, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD27 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_495">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Gene annotation function</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ifomis.org/bfo/1.1/snap#Function</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/304">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/54"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The effect of environmental factors on development of high affinity CTL was investigated using a system whereby OT-1 cells were primed in vitro by engineered APC. After a 20 h priming phase, CTL were transferred to recipient mice that were either naïve, or had been injected with activated dendritic cells one day earlier, thus creating a reactive lymph node.</rdfs:comment>
    <rdfs:label>Naïve mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/7">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/32"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/157"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The MaxQuant software is designed to make it possible to compare cell subsets quantitatively based on the extracted ion current (XIC) and without any need of stable isotope labels. </rdfs:comment>
    <rdfs:label>MaxQuant: Analysis software for quantitative comparison of cell subsets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedDocument_2">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedDocument"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_714">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129 * C57BL/6</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">B2mtm1Unc/B2mtm1Unc Il2tm1Hor/Il2tm1Hor transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_713"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/87">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/83"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400143"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The flow cytofluorometer available to the laboratory is used, for example, for the assessment of differentiation, maturation, and intracellular cytokine production of DCs.</rdfs:comment>
    <rdfs:label>Flow cytofluorometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ifomis.org/bfo/1.1/snap#FiatObjectPart">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_473">
    <rdfs:label>electroporator</rdfs:label>
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://medical-dictionary.thefreedictionary.com/Electroporator</OBI:IAO_0000119>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An electroporator is a device for performing "a type of osmotic transfection in which an electric current is used to produce temporary holes in cell membranes, allowing the entry of nucleic acids or macromolecules (a way of introducing new deoxyribonucleic acid into the cell)".</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#MaterialEntity"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">electroporator</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/252">
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/88"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We can provide Illumina microarray data for four experiments composed of 4 microarrays each on DCs stimulated with pathogenic and non pathogenic fungi. RNA preparation, labeling, hybridization on a HT12 array (Illumina), and scanning were performed according to Illumina instructions by Genomics Lab, Wellcome Trust Centre for Human Genetics (Univeristy of Oxford).</rdfs:comment>
    <rdfs:label>MICROARRAY ANALYSIS OF DC FUNGAL CHALLENGE II</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/381">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/88"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/92"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells stem from an elutriation process from a metastatic lesion of stage III/IV melanoma patients. Subsequently, these T cells will be expanded by co-culture with tumor lysate loaded DC.  </rdfs:comment>
    <rdfs:label>T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0704043">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BIRC5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor antigen survivin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Apoptosis inhibitor survivin</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EPR-1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">survivin</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IAP4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">API4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BIRC5 human</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">baculoviral IAP repeat-containing 5 (survivin)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Baculoviral IAP repeat-containing protein 5</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Apoptosis inhibitor 4</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/52">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>UNIGE is the second-largest university in Switzerland. With its 17 faculties, institutes and research centers, it offers a wide range of teaching and conducts academic research in all major scientific disciplines. Biomedical sciences are among the most prominent research areas of UNIGE. For the management of European research projects and fellowships, UNIGE has set-up a European grants office (http://www.unige.ch/recherche/euresearch/index.html) working closely together with specialized accounting, legal and human resource support services.
The Faculty of Medicine is the second largest faculty of UNIGE. It is closely partnered with the University Hospital of Geneva (http://www.hug-ge.ch/) and consists of three sections, Fundamental Medicine, Clinical Medicine and Dental Medicine. The section of Fundamental Medicine comprises six departments focussing on research themes that have been attributed high priorities by the Faculty of Medicine on the basis of academic excellence and an outstanding scientific track record. The Department of Pathology and Immunology comprises 10 basic research teams and 5 affiliated groups from the section of Clinical Medicine. The majority of these groups concentrate on research in the fields of immunology and immunopathology.
To promote excellence in cutting-edge research, the Faculty of Medicine has made a major investment in the establishment and maintenance of numerous state-of-the-art core facilities. The latter notably include facilities that are directly relevant to research performed in DC-THERA (genomics, proteomics, high-throughput sequencing, animal housing, generation of genetically modified mice, flow-cytometry). 
The laboratory of Walter Reith has a longstanding interest and expertise in the transcriptional regulation of gene expression in cells of the immune system, with a particular accent on human and mouse antigen presenting cells, including B lymphocytes, macrophages and DCs. Experimental strategies applied routinely in his laboratory encompass standard molecular, biochemical and cellular techniques for analyzing transcriptional and post-transcriptional control mechanisms, the generation of transgenic and knockout mice to study the functional consequences of perturbing specific regulatory pathways in vivo, and high-throughput technologies for characterizing regulatory networks, including microarray gene expression profiling, and genome-wide ChIP-chip and ChIP-seq methods for study transcription factor binding and epigenetic chromatin modifications.</rdfs:comment>
    <rdfs:label>University of Geneva - Université de Genève</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/261">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Yeast RNA (along with R848, Curdland, LPS and yeast cells in different conditions of culture) was used to induce DC activation.</rdfs:comment>
    <rdfs:label>Yeast RNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000018">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">supplier</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#downloadableFrom">
    <rdfs:domain rdf:nodeID="A130"/>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_548"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any DC-THERA Directory resource to a URI it can be downloaded from.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is downloadable from</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000107">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">toll-like receptor 10</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR10</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A97">
    <owl:unionOf rdf:nodeID="A149"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0005773">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vacuoles</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vacuole</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A150">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000386"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7474">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_30317"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">long bones</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">long bone</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/12">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Sekmed is a biotechnology company working in the drug discovery and gene hunting field. Our fishing nets are our DC-based bioassays, and we are looking for the best catch: new drug candidates to create vaccines, improve transplant acceptance and treat autoimmunity.

That is Sekmed's job: from genes to targets.</rdfs:comment>
    <rdfs:label>SEKMED S.R.L.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_57983">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mammary gland</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mammary glands</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_496">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000453</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Microscope function</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/341">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Surface markers were used to establishe routine monitoring of tumor-specific T-cell subsets by multicolor flow cytometry. For this purpose multimers were used kindly provided by Pierre Coulie (Brussels) together with CD25 surface markers (and additionally, CD8, CD4, CD3, CD45RA, CCR7, CD27, CD137, CD127) in different 8-color panels on the BD FACSCanto II. Additionally, functional markers such as CD107a were used and intracellular cytokine staining for the further analysis of individual T-cell populations and T-cell clones.</rdfs:comment>
    <rdfs:label>CD25 surface markers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/88">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/15"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400044"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The flow cytometer at the disposal of the laboratory is used, for example, to assess Th subsets.</rdfs:comment>
    <rdfs:label>Flow cytometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/6">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/32"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/159"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/153"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Mass spectrometry (MS)-based proteomics has become a powerful technology to map the protein composition of organelles, cell types and tissues. In our department, a large-scale effort to map these proteomes is complemented by the Max-Planck Unified (MAPU) proteome database. 	

MAPU contains several body fluid proteomes; including plasma, urine, and cerebrospinal fluid. Cell lines have been mapped to a depth of several thousand proteins and the red blood cell proteome has also been analyzed in depth. The liver proteome is represented with 3200 proteins. By employing high resolution MS and stringent validation criteria, false positive identification rates in MAPU are lower than 1:1000. Thus MAPU datasets can serve as reference proteomes in biomarker discovery. MAPU contains the peptides identifying each protein, measured masses, scores and intensities using a clickable interface of cell or body parts. Proteome data can be queried across proteomes by protein name, accession number, sequence similarity, peptide sequence and annotation information. More than 4500 mouse and 2500 human proteins have already been identified in at least one proteome. 	

Basic annotation information and links to other public databases are provided in MAPU and we plan to add further analysis tools.</rdfs:comment>
    <rdfs:label>Max-Planck Unified Proteome Database (MAPU)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedDocument_1">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedDocument"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_713">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies are distinct</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Inflammatory Bowel Disease 11-model mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001026">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_474">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">reporter assay</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">reporter gene assay</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A144">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <owl:onProperty rdf:resource="http://dc-research.eu#hasOrganism"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/382">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/94"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/92"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdfs:comment>These T cells were generated from the Leukapheresis product, after elutration, of a metastatic lesion of stage III/IV melanoma patients, expanded by co-culture with tumor lysate loaded DC.</rdfs:comment>
    <rdfs:label>autologous T cells, expanded</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/40">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/152"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We wanted to assess whether functional activation of human monocyte-derived DCs can be achieved by electroporation of an activation signal in the form of double-stranded (ds) RNA and whether simultaneous electroporation of the dsRNA with tumor antigen encoding mRNA can lead to the induction of a cytotoxic T-lymphocyte (CTL) response. </rdfs:comment>
    <rdfs:label>human monocyte-derived DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/260">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>R848 (along with LPS, Curdlan, yeast RNA and yeast cells in different conditions of culture) was used to induce DC activation.

</rdfs:comment>
    <rdfs:label>R848</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/51">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Danish Institute for Medical Simulation is an educational body with primary focus on research and training activities related to doctors’ and nurses’ postgraduate education. We utilise a diverse range of teaching methods spanning from full scale simulation to part task simulators. 

In 2006 we had about 5500 course participants primarily from the Capital Region of Denmark, but also from the rest of Scandinavia and other parts of the world. 

In our courses, medical simulation makes it possible to create a working situation that reflects the real situation in the clinic. Thereby practical skills and clinical decision-making can be trained without exposing the patients to risks. Furthermore, health care personnel can use simulation to train and develop their competencies in their own speed and in a safe environment.</rdfs:comment>
    <rdfs:label>Center for Cancer Immune Therapy,  University Hospital Herlev</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/140">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/85"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/458"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/151"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/192"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Steffen Jung</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/251">
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/88"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/13"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Affymetrix and Illumina microarray data is available on 3X106 DCs that were either not stimulated or stimulated with different stimuli. Cells were harvested after 4 hours of stimulation. RNA extraction was done with TRIzol reagent (Invitrogen). microarray hybridization were performed on the basis of technology used. Affymetrix array data files (CEL files) were pre-processed and normalized using the Robust Multichip Average procedure (RMA). Annotations were updated following a procedure devised by Dai and co-workers (Dai et al., 2005). Computation was performed with the RMAExpress program (http://rmaexpress.bmbolstad.com) . Bead-summary data saved from Illumina BeadStudio was pre-processed in several steps. Firstly, the background signal was assessed and corrected using the intensity signal from the control probes present on the array, then quantile normalization was performed. In addition to background correction, Illumina probe identifiers were converted to nucleotide universal IDentifiers (nuIDs) (Du et al., 2007) specific for the nucleotide sequence of each probe. The computation was performed using the lumi package (Du et al., 2008), written in the R programming language.</rdfs:comment>
    <rdfs:label>DC TRANSCRIPTIONAL ANALYSIS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000094">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001438</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD80</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000108">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">toll-like receptor 5</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">toll-like receptor 5</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A140">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A137"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_39026">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">low-density lipoprotein</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A class of lipoproteins of small size (18-25 nm) and low density (1.019-1.063 g/ml) particles with a core composed mainly of cholesterol esters and smaller amounts of triglycerides. The surface monolayer consists mostly of phospholipids, a single copy of apolipoprotein B-100, and free cholesterol molecules. The main function of LDL is to transport cholesterol and cholesterol esters from the liver.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_6495"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Low density lipoprotein</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/138">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_28262"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_533"/>
    <rdfs:comment>We have generated data on the kinetic of the transcriptional profiling of D1 cells treated with either DMSO or LPS.</rdfs:comment>
    <rdfs:label>Analysis of the kinetic of the transcriptional profiling of D1 cells treated with either DMSO or LPS</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10310">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HSV-2</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10294"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HSV2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">herpes simplex virus type 2 HSV-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Herpes simplex virus 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">herpes simplex virus type 2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A149">
    <rdf:rest rdf:nodeID="A13"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_491"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/19">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Identification of preclinical tests for cellular vaccines and release criteria for DC vaccines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/13">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/2"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>A key player in 21st century oncology

Since its creation in 1909 and its state approval as a foundation in 1921, the Institut Curie has brought together scientists and physicians with a common goal: to defeat cancer. Marie Curie's legacy of the “Curie model” is defined by the seamless interface between cutting-edge basic research and innovative and quality healthcare. Its originality stems from its unique approach in a unique setting, the bringing together of scientists, nurses and patients so as to expedite access to diagnosis and new treatments. The Curie model benefits patients and inspires other institutes in France and beyond. 

The Research Center of the Institut Curie is one of the most important in Europe and the largest in France dedicated to cancer research. It houses 61 joint Institut Curie - CNRS or INSERM research groups whose common goal is to increase knowledge and ameliorate patient management using state-of-the-art technology platforms. 

The Technology Transfer Department spearheads translational research and forms a vital link between basic research and healthcare, thus expediting transfer of scientific innovations from bench to bedside. It is developing new diagnostic techniques and more effective and safer approaches to treatment. 

The Institut Curie Hospital is a private organization which contributes to the public health system. With its diagnostic (imaging, pathology, laboratory testing) and therapeutic (surgery, radiotherapy, medical treatments, support treatment) armory, it blends technology and care, and ensures national and international dissemination of medical innovations. 
A pioneer in a number of conservative treatments, the Hospital is a reference center throughout the world for breast cancer, pediatric tumors, sarcomas, eye tumors and numerous advanced techniques such as oncogenetics and precision radiotherapy (curietherapy, proton therapy). 

The Institut Curie has a Scientific Board whose remit is to guide its research policy and validate scientific choices. The Board's members are internationally recognized leaders in research and medicine. 

Various departments ensure that the Institut Curie runs smoothly: financial management, development, communications, fundraising, legal, working hand in hand with the institutional services. 
Aiming at excellence and innovation

The Institut Curie's fame is rooted in the excellence of its scientific and medical work, carried out by highly skilled personnel, and also in the quality of its technological platforms and equipment. The Institut itself funds ambitious research projects, their transfer to medical applications, and diagnostic and therapeutic innovation. 
Through its innovative programs and the dissemination of their findings around the world, Institut Curie scientists and clinicians contribute to the development of new treatments.</rdfs:comment>
    <rdfs:label>Institut Curie</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/37">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Argos has made extensive progress in automating a closed, GMP- compliant system for DC manufacturing. This system involves a computer-controlled workstation that links a GAMBRO Elutra device (to harvest monocytes from pheresis products) to closed-system cell culture process. All media changes and washes are automated and limited operator intervention is required throughout the entire process. A second computer-controlled work station harvests the matured DC, electroporates them with RNA, and aliquots, vials, and freezes individual vaccine doses. Argos has consulted with the U.S. FDA on the design of the automated DC platform and received a favourable review.  Two apha units of each workstation have been built and the various sub-systems are undergoing additional testing and validation at Argos.</rdfs:comment>
    <rdfs:label>Automated closed system </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11276">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vesicular stomatitis virus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_3068">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glioblastoma</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/240">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/75"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/72"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/71"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DCs have been generated from monocytes after elutriation and have not been pulsed with irradiated tumor cells (apoptotic bodies).</rdfs:comment>
    <rdfs:label>Dendritic cells, unpulsed</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/196">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/105"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This is mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3). It was used to electroporate autologous dendritic cells in order to produce a vaccine for advanced melanoma patients.</rdfs:comment>
    <rdfs:label>mRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_781">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">substance detection method</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/65">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Children's Cancer Research Institute (CCRI) conducts specialized research into the causes and improved treatment of malignant childhood diseases. The director of St. Anna Children´s Hospital, Prof. Gadner, had recognised the necessity of this research to improve the situation of young patients treated for cancer at the hospital in the 1980s. It was their parents who shared the vision of Prof. Gadner and consequently founded an association in 1986, which is now called "St. Anna Kinderkrebsforschung" and acts as the supporting organisation for the CCRI. 
</rdfs:comment>
    <rdfs:label>St. Anna Children's Cancer Research Institute</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/36">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/28"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/121"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/92"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/316"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/432"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/314"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/433"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/37"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/118"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/317"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/90"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/42"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/65"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/47"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/315"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/321"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/26"/>
    <rdfs:label>Charles Nicolette</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/27"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/119"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/318"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/91"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/99"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/90"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/77"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/78">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/24"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000049"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The integral plasma membrane proteome of D1 cells stimulated for 24 hours with LPS has been analyzed with this LC-MS/MS analyser and compared to the results obtained from immature D1 cells.</rdfs:comment>
    <rdfs:label>LC-MS/MS Analyser</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/45">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/490"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_759"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The pellets are washed with 70% Ethanol two times.</rdfs:comment>
    <rdfs:label>Washing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stimulus or stress response experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A stimulus or stress experiment design type is where the response of an organism(s) to the stress or stimulus is studied, e.g. osmotic stress, heat shock, radiation exposure, behavioral treatment etc</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0624">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000283</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Stimulation factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_369">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fms-related tyrosine kinase 3 ligand</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Flt3L</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fms-related tyrosine kinase 3 ligands</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:subClassOf rdf:nodeID="A151"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/313">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/22"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/21"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/21"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Cells stained in PE-alpha DC80 in PBS + 2 % FCS for FACS analysis for activation markers.</rdfs:comment>
    <rdfs:label>Stained cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000227">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p42/p44 MAPK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ERK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ERK1/2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p42/p44 MAP kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAPK/ERK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Extracellular signal-regulated kinase</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Extracellular signal-regulated kinase ERK</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/74">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/31"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/327"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_325"/>
    <dcr:hasOrganismType rdf:resource="http://dc-research.eu#dctheradir_326"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001612"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/216"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/215"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/328"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/118"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_83022"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/47"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/329"/>
    <rdfs:label>Studies of DC phagosomes and cross-presentation using K/O and mutant mouse strains</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/32"/>
    <rdfs:comment>Our laboratory obtained data from studies of DC phagosomes and cross-presentation using K/O and mutant mouse strains. Cross presentation is the process by which Dendritic cells (DC) phagocytose pathogens or dying cell fragments, and present proteolytic peptides derived from these antigens in association with MHC class I molecules. The reasons why DCs are the only antigen presenting cells that efficiently cross present antigens are not well understood. 

We have demonstrated that the NADPH oxidase NOX2 is recruited to DC early phagosomes mediating a sustained production of low levels of reactive oxygen species and causing a maintained alkalynization of the phagosomal lumen. DCs lacking NOX2 show increased antigen degradation due to an enhanced phagosome acidification. As a result, the efficiency of in vitro and in vivo antigen cross presentation is significantly reduced in NOX2-deficient DCs. We also show that DCs derived from ashen mice, which are defective for the small GTPase Rab27a, fail to cross present antigens efficiently, due to increased phagosome acidification and antigen degradation. This defect in Rab27a-deficient DCs results from the impaired recruitment to phagosomes of the NOX2 membrane components. Therefore phagosomal alkalinization by NOX2 is controlled by Rab27a, and is required for efficient cross presentation in DCs.

In vivo, different subsets of DCs are considered with different competences to cross present antigens. The reasons why CD8+ DCs subset is the only one that efficiently carry out this phenomenon are not well understood. We have found that only CD8+ DCs display a NOX2 activity selectively localized to in phagosomes, causing alkalynization and preventing Ag degradation. In contrast, CD8- DCs, which exhibit higher total NOX2 activity than their counterparts but lack phagosomal ROS production, acidify their phagosomes causing more important antigen degradation which is unfavourable for cross presentation. Rac proteins are key components of NOX2 activation. Interestingly, we found that differential expression of Rac1 and Rac2 in the two DCs subsets, are responsible for the differential localization of ROS production in both cell types. </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/201">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/108"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/109"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/108"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were electroporated, co-cultured with purified CD8 T cells using MACS cell separation to asses the in vitro CD8 T cell stimulatory capacity of DC.</rdfs:comment>
    <rdfs:label>Dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_740">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Support in DC-THERA</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A participant providing support in DC-THERA is a an institution/company/institute or other legal association that collaborates in a supporting, non-scientific way inside the DC-THERA network. Example: entity providing organisational support.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000245"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_780">
    <rdfs:label>LDA assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LDA assay</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/48">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/75"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/17"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_327"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have generated a monoclonal antibody, 2C44, that reacted to a peptide derived from the Leishmania LACK protein bound to I-Ad MHC class II molecules. We have successfully used the 2C44 mAb to visualize LACK-presenting DCs in mice infected with the L. major.</rdfs:comment>
    <rdfs:label>monoclonal antibody 2C44</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000064">
    <rdfs:label>vascular endothelial growth factor receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Flt</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">VEGF-R</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vascular endothelial growth factor receptor</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A152"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/241">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/72"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/68"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells are prepared from the removed lesion from patients with stage III or stage IV melanoma and are subsequently used to pulse a portion of the immature dendritic cells.</rdfs:comment>
    <rdfs:label>Irradiated tumor cells (apoptotic bodies) </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/195">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/105"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These autologous DC were electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce a vaccine for immunotherapy of advanced melanoma patients.</rdfs:comment>
    <rdfs:label>Autologous DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/66">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>ABOUT THE JOZEF STEFAN INSTITUTE

The Jozef Stefan Institute is the leading Slovenian scientific research institute, covering a broad spectrum of basic and applied research. The staff of more than 850 specializes in natural sciences, life sciences and engineering. The subjects concern production and control technologies, communication and computer technologies, knowledge technologies, biotechnologies, new materials, environmental technologies, nanotechnologies, and nuclear engineering. The mission of the Jozef Stefan Institute is the accumulation and dissemination of knowledge at the frontiers of natural science and technology to the benefit of society at large through the pursuit of education, learning, research, and development of high technology at the highest international levels of excellence. The Institute was founded in 1949. Initially established as an institute for Physics within the Slovenian Academy of Sciences and Arts, it is today involved in a wide variety of fields of both scientific and economic interest. After close to 60 years of scientific achievement, the Institute has become part of the image of Slovenia. The basic goals of the Institute are to provide expert scientific and applied output in the form of processes, products and consultancy, and to produce well-trained young scientists. The underlying philosophy is that these objectives can be achieved only if based on international class scientific research. With this in mind, the in-house research has been reinforced by building strong links to universities, other research institutions and industry. The Institute is closely connected with the Slovenian universities, where many scientists who initially developed their research talents at the Institute have been appointed to teaching posts, while still retaining their research positions or research teams at the Institute. Since 1985 more than 800 postgraduate students have gained their Ph.D. degrees at the Institute. Close collaboration with the Slovenian University Medical Centre has resulted in the development of medical equipment (tomography, electrical stimulators and appliances), the provision of isotopes for clinical research and treatment of patients, and the introduction of new research techniques and diagnostic methods into clinical medicine. The Institute devotes a considerable amount of effort to transferring the results of its research and knowledge to productive applications and to the market. 

ABOUT THE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR AND STRUCTURAL BIOLOGY 

Research areas:
- Protein biochemistry 
- Proteolysis and its regulation by inhibitors 
- Programmed cell death 
- Regulation of immune response 
- Protein folding and aggregation 
- Structural biology 
- Physiological and pathophysiological role of proteases in cancer, inflammation and neurodegenerative disorders 
- Proteomics 
- Chemical genomics 
- Nanobiology 
- Development of computational methods for structural biology 
- Biotechnological methods for production of recombinant proteins and antibodies 

The major goals of our research are to characterize the individual proteases (primarily from the cathepsin family) and their inhibitors (stefins, cystatins and related proteins) and to unravel the molecular mechanisms of processes leading to programmed cell death or regulating the immune response of the organism. In addition, our research is focused towards understanding the roles of proteases in various pathological processes, such as cancer, rheumatoid arthritis and osteoarthritis, and different neurological disorders (Huntington disease, …). An important area of research is also formation of amyloid fibers. For a better understanding of these processes a number of tools are needed, and therefore we are developing production of various antibodies and recombinant proteins (proteases and their inhibitors). We also participate in the development of activity-based probes for proteases suitable for work in cellular and in vivo models, and for testing pharmacologically-relevant compounds. In addition, we have a key role in establishing a center for proteomic research, which would cover the needs of whole Slovenia. One of the important areas is also understanding of the 3-D structures of biological macromolecules and their complexes at the atomic level, thereby linking the sequencing information with the mechanism of molecule action. In this way, the research is focused in target identification and validation, which are key areas of research in the field of biomedicine in connection with biotechnology. </rdfs:comment>
    <rdfs:label>Jozef Stefan Institute</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/35">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Michaela is a bioinformatician and has worked in the following areas of bioinformatics:

- Construction and implementation of a microarray analysis workflow for Agilent, Affymetrix and Amersham chip data, especially normalization, finding differentially expressed genes and clustering and functional analyses using GO clustering (EU @neurist programme on intracranial aneurism)

- Analyst for the DC-THERA Directory based on (mainly) OBO ontologies

- Mapping of ontological concepts in OpenGALEN and MeSH to the NEUROWEB ontology (EU NEUROWEB project)

- Descriptive data analyses: ocular trauma patient data, analysis of surveys conducted by AIDO (Associazione Italiana per la Donazione di Organi, Tessuti e Cellule); implementation of a data analysis web service

- Ontology in various contexts (VPH and disease contexts) (ongoing work)</rdfs:comment>
    <rdfs:label>Michaela Gündel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/38">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_470"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have expertise in DNA vaccination with the gene-gun available to us to directly transfect skin DC in vivo either with expression plasmids or siRNA plasmids to knockdown target genes and follow the effect on the resulting T cell response. </rdfs:comment>
    <rdfs:label>Gene gun</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/46">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/491"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>When the pellets are dry, they are resuspended in RNase-free water.</rdfs:comment>
    <rdfs:label>Resuspension of pellets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Granzyme">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">granzymes</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">granzyme</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/77">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/26"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/119"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/28"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/27"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The Challenge of Cancer: Individual Cancers and Mutations

Every individual´s cancer is unique. Therefore, the most effective treatment is one customized to a particular cancer´s genetic configuration. Genetic mutations and chromosomal abnormalities are commonly associated with human cancers. Unfortunately, since the genetic mutations leading to the development of cancer are often random events, every patient's tumor can contain a unique repertoire of antigens. This characteristic of human cancer requires that each patient's immune system be able to recognize and target the specific antigens present.

To address the challenge of the unique genetic profile of each cancer and the genetic mutations of that cancer, Argos' Arcelis personalized immunotherapy technology for cancer captures the complete, unique genetic information of individual tumors, loads a patient's own dendritic cells with the total tumor RNA and uses these dendritic cells to trigger an appropriate immune response. The Arcelis iummnotherapy for cancer, is therefore, customized to the unique antigenic repertoire of each patient's tumor, equipping the immune system to recognize and fight that particular disease. This approach precludes the need to identify or isolate specific tumor antigens and enables targeting of unknown tumor antigens and treatment of patients from whom only a minute amount of tumor material can be obtained.

Creating a Personalized Cancer Product
Argos’ Arcelis immunotherapy for cancer starts with precursors of the patient's dendritic cells, which, when matured for the immunotherapeutic, are currently considered the most effective antigen-presenting cells within the immune system. Argos amplifies whole tumor RNA from each individual patient (whether from the primary tumor site, distant metastatic sites or from tumor cells present in circulation) and then transfects the same patient's dendritic cells with the patient's tumor RNA. This process offers the opportunity for most cancer types at any stage of disease to be target opportunities for the Company's cancer immunotherapy approach.

Unique Advantages
- Dendritic cells transfected with RNA-encoding tumor antigens have been shown to stimulate potent immune cell responses equal or superior to other competing approaches
- The Arcelis immunotherapeutic is completely autologous (derived from the patient’s body), potentially offering maximum safety with minimal side effects
- The Arcelis immunotherapeutic targets the entire antigenic repertoire of the tumor including ‘private mutations’ unique to that patient
- A single production run makes enough product to continuously treat the patient for several years
Production requires only a minute tumor specimen, allowing treatment both of earlier stage and later stage patients 
- Argos´ centralized, automated manufacturing process is optimized for ‘day-old’ monocytes, allowing for production that provides the flexibility to access patients and clinical sites nationwide 
- Formulation requires no specialized manipulation at the clinical sites, maximizing site participation (thaw in vial, load syringe, inject)

HIV &amp; OTHER INFECTIOUS DISEASES
Chronic viral infections, such as those caused by human immunodeficiency virus (HIV) and hepatitis C virus (HCV), are difficult to treat and often incurable. Argos is applying its Arcelis technology platform to transfect dendritic cells with patients’ own viral RNA antigens, promoting immune responses perfectly matched to the patient’s unique viral variants.

The Arcelis HIV process utilizes small plasma samples from infected patients to amplify large quantities of messenger RNA that encode selected viral antigens. This technique has the added advantage of amplifying the multitude of patient-specific viral variants evolving in the infected patient, allowing for the creation of a therapy perfectly suited to the individual. Therefore, the viral sequences presented to the immune system to recognize and attack are completely compatible with the virus that has infected the host. The simultaneous presence of autologous viral sequences and dendritic cells should result in a novel immune response, personalized to each patient, that potentially has a greater probability of success in controlling residual virus or a rebound of virus following the cessation of therapy.

Studies published in Nature Medicine and The Journal of Infectious Diseases have demonstrated how patient-specific immunotherapeutic approaches similar to Argos´ have the potential to be effective treatment for people with chronic HIV infection. Additionally, a Phase 1 trial of Argos´ HIV candidate AGS-004, presented at the 2008 International AIDS conference, demonstrated that AGS-004 achieved the trial´s primary endpoint of induction of T cells response to patient-specific HIV antigens. Click here

In October 2006, Argos was awarded a $21M National Institutes of Health (NIH) contract to develop its Arcelis HIV immunotherapy platform. In addition to determining the immunogenicity of the Arcelis HIV product currently in the clinic, the goal of the five-year contract is to subsequently develop then test in the clinic even more potent next generation product candidates.

Argos believes its Arcelis technology can also be used to create immunotherapies for other chronic infectious diseases that don’t respond to current treatments. Infections such as hepatitis C virus (HCV) and herpes represent some of the largest and most significant areas of unmet medical need. In fact, any disease subject to immune surveillance is potentially addressable.

Unique Advantages
- The Arcelis immunotherapeutic can be comprised of any number of strategically selected viral antigens (chosen to not adversely affect the biology of dendritic cells) 
- Amplification of viral antigens includes patient-specific dominant and quasispecies (important for highly mutagenic viruses such as HIV and HCV) 
- Immune responses generated are 100% relevant for that patient 
- Production requires only a small plasma sample that can be obtained during leukapheresis 
- If virus escape occurs at some point post-treatment, the product can be ‘updated’ using a new plasma sample 
- Argos knows of no other dendritic cell-based technology that could feasibly produce an autologous anti-viral immunotherapeutic</rdfs:comment>
    <rdfs:label>Arcelis therapeutic platform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000025">
    <rdfs:label>Tumor necrosis factor alpha</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tumor necrosis factor alpha</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TNF alpha</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/314">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were used in a maturation step for subsequent production of a DC vaccine.</rdfs:comment>
    <rdfs:label>Immature DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000226">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p38 MAPK</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000224"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p38 MAP kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p38</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/73">
    <dcr:hasCellComponentType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_C0000351"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_808"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/199"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <rdfs:comment>We obtained data from an evaluation whether antigens could be rerouted from the endosomal into the cytosolic compartment by combining antigen with cell penetrating peptides to further enhance cross-presentation. 

We made significant progress using biodegradable polymers to enhance cross-presentation of loaded antigens, and the best results were obtained by maturing DCs with a combination of the TLR ligands R848 and polyI:C. Furthermore, we have shown that DC electroporated with melanoma antigen RNA express the proteins ex vivo and in vivo.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/4"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_66836"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/16"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdfs:label>Studies of antigen presentation and cross-presentation by DC, inc. electroporation</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_324"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#CD209_Antigen"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/7"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_741">
    <rdfs:label>material processing step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A material processing step is a step in a protocol that specifies how to perform a material processing which results in physical changes in a specified input material.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">material processing step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FAO#FAO_0001002">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pseudohyphae</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A chain of cells, formed under specific growth conditions, in which yeast-form fungal cells become elongated, bud only at the cellular pole distal to the mother cell, and fail to separate after division. Pseudohyphae exhibit constrictions at the cell-cell junctions, in contrast to true hyphae which are of more uniform diameter.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pseudohypha</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/143">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/4"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdfs:label>Proteomic investigations on the three known splenic subsets (CD8+, CD4+, DN DC) using mass spectrometry</rdfs:label>
    <rdfs:comment>Our group has obtained proteomic data on the three known splenic subsets (CD8+, CD4+, DN DC). 

Despite the significant advances in mass spectrometry, which has enabled much of proteomics, due to various analytical challenges so far no eukaryotic total cell proteome has been sequenced completely. An alternative approach is to purify single organelles or DC components in order to generate the proteomic data.

An additional problem is to obtain highly pure fractions of DC from crude population of untouched splenic cells with a purity of 70-80%. This includes several sophisticated steps for depletion of all unwanted cell types. The crude population of DC is divided into the three known splenic subsets (CD8+, CD4+, DN DC) using Fluorescence activated cell sorting (BD FACS Aria). This procedure allowed to obtain highly pure fractions of each subset. However, because DC are a very rare population, this method is very material- and cost-intensive. Furthermore, it is not surprising that the obtained cell numbers of each subset after isolation are below 107. However, these cell numbers should be sufficient for proteomic investigations. The proteomes of all three subsets using mass spectrometry is in progress.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0043226"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000111">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-7</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 7</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL7</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-7 receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A153"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/35">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/170"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_481"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have used the electron microscope that is available to our lab, e.g., to document the production and secretion of tubulovesicular structures by cells overexpressing VSV-G glycoprotein and for documentation of production and secretion of tubulovesicular structures.</rdfs:comment>
    <rdfs:label>Electron microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/198">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells are to be purified using MACS cell separation to contain only CD8+ T cells. The latter are then co-cultured with electroporated DC, stimulated and become evaluated on their cytokine secretion, cytotoxicity and % of antigen specific T cells.  </rdfs:comment>
    <rdfs:label>Unpurified T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/242">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/72"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>TNF-alpha is used during maturation of the DCs.
</rdfs:comment>
    <rdfs:label>TNF-alpha</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/38">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rossella Ferrari</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/318">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Ms Cornillie replaced Mrs. Myriam Essiaf.

Responsibilities:
VUB - FA - BEFO
EU-Projects
Building M - Room 3M331</rdfs:comment>
    <rdfs:label>Inge Cornillie</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0324">
    <rdfs:label>messenger RNA</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">messenger RNA</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">messenger rna</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mRNA</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/63">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Weizmann Institute of Science, located in Rehovot, Israel, is one of the top-ranking multidisciplinary research institutions in the world. Noted for its wide-ranging exploration of the sciences and technology, the Institute gathers together 2,500 scientists, technicians and research students devoted to adventuring into the unknown. In their labs, located in a landscaped campus environment, they share a vision: To better understand nature and our place within it. Inquisitiveness is their predominant trait. It is this curiosity that propelled Homo sapiens up the slope of evolution. It is this driving curiosity that sees man -- and woman -- through their greatest discoveries. It is the force which pushed earliest civilization to develop agriculture, to learn the hows of constructing shelter, to create the written word, to harness electricity to the wagon of industry and commerce, to contemplate far-off galaxies, to find the cure for disease, to form new materials, and to decipher the genetic code stamped on all living things, be they plant or animal. The desire to continue in this forward stride is the force behind every Institute scientist's efforts to penetrate realms formerly incomprehensible to humankind. And what dwells in these domains? The unknown. The only certainty: revelation encountered along their path. We invite you along to view a selection of landmark discoveries established by Weizmann scientists on a number of their scientific excursions. To look over the shoulder of these scientific trailblazers who go that one step more in furthering this, our civilization. The Weizmann Institute of Science: Shaping the future.</rdfs:comment>
    <rdfs:label>Weizmann Institute of Science</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/315">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>TNF alpha was used for DC maturation with the final aim to produce a DC vaccine.</rdfs:comment>
    <rdfs:label>TNF alpha</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000064">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001375</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD217</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/76">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/191"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/87"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our work, we have experience in applying peptide-tetramer assays. Primary and secondary CTL response against the C8 T cell epitope SIINFEKL was monitored in a study for maturing myeloid DCs and plasmacytoid DCs.</rdfs:comment>
    <rdfs:label>Peptide-tetramer assays</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0703942">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkappaBalpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IKBA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Major histocompatibility complex enhancer- binding protein MAD3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">I-kappa-B-alpha</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0005539"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NFKBI</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAD-3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NFKBIA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkB-alpha</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAD3</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IkappaBalpha (human)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_367">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_345"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">effector memory T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">effector memory T cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/47">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_742"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The yeast oligonucleotide array is constructed using the S. cerevisiae Genome Oligo Set ™ (Operon Technologies, CA, USA) composed of 6240 optimized oligonucleotides (70mers) each representing one yeast gene. </rdfs:comment>
    <rdfs:label>Array construction</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/251">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/537"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/536"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/535"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Dr.</rdfs:comment>
    <rdfs:label>Ola Winqvist</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000225">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-jun N-terminal kinases</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stress-activated protein kinases</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-jun N-terminal kinases</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-jun N-terminal kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stress-activated protein kinase</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">JNK / SAPK</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">c-jun N-terminal kinases</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/140">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have data on the kinetic of the transcriptional profiling of human MoDC treated with IL2 in vitro.</rdfs:comment>
    <rdfs:label>Analysis of the kinetic of the transcriptional profiling of human MoDC treated with IL2 in vitro</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/36">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/199"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/38"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A Gambro BCT Elutra Cell Separation System is available to us. We have experience, e.g., in using it for monocyte enrichment.</rdfs:comment>
    <rdfs:label>Elutra Cell Separation System</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/319">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Beit Buchholz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/37">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Anna Ranghetti</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/243">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/73"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/76"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/72"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/74"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/75"/>
    <rdfs:label>Pulsed mature DCs</rdfs:label>
    <rdfs:comment>A portion of the DCs is pulsed with irradiated tumor cells (apoptotic bodies) prepared from the removed lesion and matured for 48 hours in presence of TNF-alpha.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/74"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_1909">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">melanoma</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/64">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>About the National Blood Service

The National Blood Service is not to be confused with the National Health Service.

We are an integral part of the NHS, and we guarantee to deliver blood, blood components, blood products and tissues from our 15 blood centres to anywhere in England and North Wales.

Naturally, we also ensure that the blood we supply is properly screened and is safe for patients. Every year we collect, test, process, store and issue 2.1 million blood donations. We depend entirely on voluntary donations from the general public, and try to encourage our existing donors to give three times a year. (It's amazing what the promise of a free cup of tea and some biscuits will do...)

But we also have a number of other functions. Such as continually carrying out new research into improving the safety of blood. And new ways it can be used to help save more lives.

We also provide specialist medical advice and clinical support to hospitals, as well as educating and training transfusion medicine specialists. It's a huge undertaking. But we're dedicated to keeping Britain's blood supply moving.

Our core purpose 
To save and improve patients' lives.

Our mission
We will deliver world-class services, building ever stronger partnerships with donors and the healthcare community

Our values 
We value people
• We listen and communicate clearly
• We strive to meet the needs of all our customers
• We recognise the achievements of others

We trust people
• To work to the highest possible standards of safety and quality
• To take responsibility for solving problems
• To embrace change for the better

We encourage people
• To be creative and innovative
• To work together to get things right
• To enjoy themselves and celebrate success.</rdfs:comment>
    <rdfs:label>National Blood Service</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A154">
    <rdf:rest rdf:nodeID="A111"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/197">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/106"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/105"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The vaccine is composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).</rdfs:comment>
    <rdfs:label>Advanced melanoma DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A155">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0003700"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000224">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mitogen-activated protein kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAP kinase</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAPK</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAPK</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mitogen-activated protein kinase</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000063">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001300</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD209</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000023">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD40 ligand</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A156"/>
    <rdfs:subClassOf rdf:nodeID="A157"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD40L</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/75">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/194"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>An assay for measuring cytotoxic T lymphocytes was used for the monitoring of T cell activation in the evaluation of the immunotherapy potential of DC pulsed with tumor antigens.</rdfs:comment>
    <rdfs:label>CTL assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/316">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>IFN alpha was used in a DC maturation process with the final aim to produce a DC vaccine.</rdfs:comment>
    <rdfs:label>IFN alpha</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/48">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_748"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Indirect labeling method. Briefly, the reactive amine derivative of dUTP, 5-(3-
aminoallyl)-2?-deoxyuridine 5?-triphosphate (Sigma) is incorporated into cDNA using the Superscript II reverse transcriptase (Invitrogen) and oligo dT (Invitrogen) and random examers (Roche). After synthesis of cDNA (2–3 h at 42 °C), RNA is hydrolyzed by addition of sodium hydroxide and EDTA to a final concentration of 100 mM and 10 mM, respectively and incubated at 65 °C for 10 min. The hydrolysis reaction is neutralized with 1 M HEPES. After removing free nucleotides by purification and concentration using Microcon-30 microconcentrators, the aminoallyl-labeled samples are coupled to succinimidyl ester of cyanine-3 (Cy3) and cyanine-5 (Cy5) (Amersham) combined with 1 M NaHCO3, pH 9. Coupling takes place in the dark at 25 °C for 1 h. Appropriate Cy3 and Cy5 labeled cDNA samples are purified following Qiagen Qiaquick PCR Purification Kit instructions. Poly-dA (12–18 mer), 20× SSC, and HEPES pH 7.0 are added. After the resultant mix was filtered through a Millipore 0.45 ?M filter, 10% SDS is added. The samples are incubated for 2 min at 100 °C and cooled in a microcentrifuge prior to loading and then applied to microarray.</rdfs:comment>
    <rdfs:label>Probe preparation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_9670">
    <rdfs:label>Blood</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_210">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Helicobacter pylori</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_366">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">central memory T cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">central memory T cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_C0000351">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endosome</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endosomes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/MESH#M0522828">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Clec9a protein, mouse</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DNGR-1 protein, mouse</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Lectin"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000056">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">notified body</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/141">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <rdfs:label>Confocal for dynamics between DC and NK cells</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>The group has data available on a newly identified DC subset called IKDC producing IFNg and expressing TRAIL which can recognize and kill transformed tumor cells in vitro and in vivo. They performed a video-confocal microscopy overnight on cultures of tumor cells with IKDC. We visualized that IKDC generate long contacts and synapses with tumor cells and ultimately kill them within 4 hours. </rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/245"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0702273"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/document/240"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/240"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/250">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/127"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/129"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/132"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/125"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <rdfs:label>Luca Beltrame</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/9"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/75">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/211"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/217"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/149"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/44"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/517"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_327"/>
    <rdfs:comment>We obtained data on immune tolerance in mice breast-fed by antigen-exposed lactating mothers. 

We have previously generated a monoclonal antibody, 2C44, that reacted to a peptide derived from the Leishmania LACK protein bound to I-Ad MHC class II molecules. We have successfully used the 2C44 mAb to visualize LACK-presenting DCs in mice infected with the L. major. In 2007, we have attempted to identify the APCs that are responsible for the development of immune tolerance in mice that have been breast-fed by antigen-exposed lactating mothers. Recent experiments performed in our laboratory have shown that the exposure of a mother to an airborne antigen during lactation impacts asthma development in their progeny. We found that airborne allergens were efficiently transferred from the mother to the neonate through the milk and that this transfer resulted in the development of antigen-specific tolerance. Breastfeeding-induced tolerance did not require the transfer of immunoglobulins, relied on the presence of TGF-beta during lactation and was mediated by regulatory CD4+ T lymphocytes. Adoptive transfer experiments of LACK-specific TCR transgenic T cells into newborn mice breastfed by LACK-exposed mothers demonstrated that LACK was readily processed and presented to T cells in the neonate.

We then investigated whether the immune status of the mother has an effect on the development of tolerance in the breast-fed mouse. We found that mice breastfed on allergen exposed allergic mothers were more resistant to allergic airway inflammation as compared to those breastfed on non allergic mothers. This phenomenon was demonstrated  to be dependent on the presence of allergen-specific Immunoglobulins (Ig) in the breastmilk of allergic mothers and on the transfer of immunecomplexes across the intestinal barrier of the newborn. In order to identify the APCs that were responsible for the development of this state of immune tolerance, we aimed to generate a transgenic mouse that express a recombinant fluorescent protein in the mammary glands, an approach that should result in high levels of expression of the fluorescent protein in the milk. We thus should be able to detect the cells that capture, degrade and present this antigen to T cells. Since we had previously generated a monoclonal antibody, 2C44, that reacts to a peptide derived from the Leishmania LACK protein bound to I-Ad MHC class II molecules, we chose to use LACK as a model antigen in these experiments. We have thus prepared two plasmids coding for LACK linked to either eGFP or mCherry fluorescent proteins, under the control of the beta-casein promoter. These constructs have been injected into fertilized eggs and transgenic animals are expected for march 2009. The characterization of antigen presenting cells will be performed using FACS analysis or confocal microscopy.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/43"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/516"/>
    <rdfs:label>Studies of immune tolerance in mice breast-fed by antigen-exposed lactating mothers</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_250"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/48"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/42"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5664"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000556">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">megalocaryocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">megalokaryocyte</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">megakaryocyte</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_63836">
    <rdfs:label>lysosome</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lysosome</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lysosoma</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0043227"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#uses_tool">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:domain rdf:nodeID="A158"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#tool_used_in"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">uses tool</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a protocol or a data set to a tool that was used in the creation/the application of the data set/protocol.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/135">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Absorbance is measured using a microplate reader at 620 nm.</rdfs:comment>
    <rdfs:label>Measuring of absorbance</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/61">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The VU university medical centre has defined a number of clusters of research interest and patient care. The research themes primarily emcompass multi- and interdisciplinary research projects which include the entire spectrum of basic, strategic and applied research and are related to intramural, transmural and extramural medicine.</rdfs:comment>
    <rdfs:label>VU University Medical Center/Amsterdam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/500">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/17"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Cells (co-cultured and frozen stained GM-DC, D2SC1/Flt3-DC and dead cells) were trypsinzed and fixed in 4 % PFA (or formalin).</rdfs:comment>
    <rdfs:label>PFA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/32">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/50"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/154"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/50"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Marco Brandizi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_32234">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TiO2</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: An oxide is a chemical compound contaning at least one oxygen atom as well as at least one other element.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">titanium dioxide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/10">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/24"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/40"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/31"/>
    <rdfs:comment>Affymetrix data will be gathered through an integrated Functional Genomics approach to study DC maturation with an unprecedented detail. D1 cells will be stimulated with LPS and harvested at different time-points for GeneChip analysis and for tandem mass spectrometry-based analysis of the integral plasma membrane proteome. A protocol for obtaining highly pure integral membrane proteins has already been set up in the last two months in the lab of Paola Castagnoli in collaboration with the lab of Juri Rappsilber at IFOM. 

A pilot project has already been performed on untreated D1 cells and on D1 cells matured for 24 hours with LPS. The two protein sample are currently being analyzed by tandem mass spectrometry by the lab of Juri Rappsilber. Data will be compared with previously collected microarray data. 

From a purely immunological perspective, we will identify new genes that change their expression at the cell surface during DC maturation, that may serve as novel maturation markers or that may tell us something new about DC maturation. From a more systems biology perspective, we will determine the amount of correlation between transcriptome and proteome dynamic changes and reconstruct the first transcript-protein network of DC maturation.</rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/452"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/84"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_738"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <rdfs:label>Transcriptional analysis of the integral plasma membrane proteome of D1 cells stimulated  with LPS harvested at different time-points</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/192">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/458"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/140"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CX3CR1 GFP mice, in which bmDC are green fluorescent (GFP), were analyzed according to their bmDC localization. It was found that the cells were organized in unique clusters, mainly located in the endosteum of the BM. These DC co-localize with B cells and these clusters are occupying architecturally definable niches and are reminiscent to the niches that were found in the cranial BM parenchyma.</rdfs:comment>
    <rdfs:label>CX3CR1 GFP mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000111">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000097</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label xml:lang="en">obsolete_study participant role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/41">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_756"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The samples are centrifugated at 5000 rpm in an tabletop centrifuge.</rdfs:comment>
    <rdfs:label>Centrifugation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/70">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/4"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <rdfs:label>Activation of DC by TLR and iNKT cell agonists in vivo</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_249"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/5"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/41"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/218"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/216"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_318"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36498"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/214"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67184"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/217"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/215"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:comment>My laboratory obtained data from a continued analysis of the ability of invariant NKT (iNKT) cells to assist priming of antigen specific T and B cell responses. We have carried out three complementary lines of research:

1) We have demonstrated that activation of human DC by Toll like receptor ligands (TLR-L) modulates the lipid biosynthetic pathway, resulting in enhanced recognition of CD1d-associated lipids by iNKT cells. 

2) We have clarified the mechanisms by which CD1d-restricted lymphocytes translate T cell receptor (TCR) recognition of lipids with similar group heads into distinct biological responses. Using a soluble iNKT TCR and a newly engineered antibody specific for alpha-galactosylceramide (alpha-GalCer)-human CD1d (hCD1d) complexes, we measured the affinity of binding of iNKT TCR to hCD1d molecules loaded with a panel of alpha-GalCer analogues and assessed the rate of dissociation of alpha-GalCer and alpha-GalCer analogues from hCD1d molecules. We have extended this analysis by studying iNKT cell synapse formation and iNKT cell activation by the same panel of alpha-GalCer analogues. Our results indicate the unique role of the lipid chain occupying the hCD1d F' channel in modulating TCR binding affinity to hCD1d-lipid complexes, the formation of stable immunological synapse, and cell activation. Our results indicate a general mechanism by which lipid-specific lymphocytes are capable of recognizing both the group head and the length of lipid antigens, ensuring greater specificity of antigen recognition.

3) We demonstrated that pathogen-derived signals to DC mediated via TLRs can be modulated by activated iNKT cells 
(Hermans et al, 2007). DC maturation induced in vivo with any one of a variety of TLR ligands was greatly improved through simultaneous administration of the iNKT cell ligand alpha-galactosylceramide. DC isolated from animals treated simultaneously with TLR and iNKT cell ligands were potent stimulators of naive T cells in vitro compared with DC from animals treated with the ligands individually. Injection of protein Ags with both stimuli resulted in significantly improved T cell and Ab responses to coadministered protein Ags over TLR stimulation alone. Ag-specific CD8(+) T cell responses induced in the presence of the TLR4 ligand monophosphoryl lipid A and alpha-galactosylceramide showed faster proliferation kinetics, and increased effector function, than those induced with either ligand alone. Human DC exposed to TLR ligands and activated iNKT cells in vitro had enhanced expression of maturation markers, suggesting that a cooperative action of TLR ligands and iNKT cells on DC function is a generalizable phenomenon across species. 

These studies highlight the potential for manipulating the interactions between TLR ligands and iNKT cell activation in the design of effective vaccine adjuvants. </rdfs:comment>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_248"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/146">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/36"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/11"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_394"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700621"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab has proteomic data available on the interaction between RIG-I and NS1 in influenza A.

We have used fluorescence microscopy to analyse the interaction between RIG-I, a viral sensing protein, and NS1, an inhibitor of interferon production that is encoded by influenza A virus. This approach enabled us to determine that the two proteins form a complex in influenza infected cells.</rdfs:comment>
    <rdfs:label>Proteomic analysis of the interaction between RIG-I and NS1 in influenza A</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/317">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_15551"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This PGE2 was used in a DC maturation process with the final aim to produce a DC vaccine.</rdfs:comment>
    <rdfs:label>PGE2</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A110">
    <owl:unionOf rdf:nodeID="A154"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0043020">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_250"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NADPH</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NADPH oxidase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">respiratory-burst oxidase</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NADPH oxidase complex</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000062">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001293</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD207</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/581">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/112"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18154"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Chitin (500 micrograms/ml) was added to DCs in order to block their beta-glucan receptors.</rdfs:comment>
    <rdfs:label>Chitin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/62">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>VU University Amsterdam aims to be inspiring, innovative and involved.

Inspiring
VU University Amsterdam is working hard to ensure that all of its courses rank among the best in the country. VU University Amsterdam offers an inspiring study environment capable of providing students with the most suitable course for their needs.

Innovative
VU University Amsterdam stands for high quality, fundamental, innovative and socially oriented research. The university has several leading research groups, all of which enjoy international recognition. In recent years, capacity and expertise have been pooled in large-scale programmes, enabling interactions between different disciplines to be exploited to the full.

Involved
VU's origins are rooted in the Christian faith. This is why we attach such great importance to our social role. We take the view that academic work cannot be divorced from the concerns of society, in terms of standards, values, philosophy and religion.</rdfs:comment>
    <rdfs:label>VU Medical Center/Amsterdam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_954">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000635</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Organism part factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/136">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/562"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/546"/>
    <rdfs:label>Phagocytosis assay</rdfs:label>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/564"/>
    <rdfs:comment>Yeasts/spores are biotinylated using 10 mg/ml sulfo-NHS-LC-biotin (Sigma-Aldrich) in 50 mM NaHCO3 pH 8.5 for 2 hours at 4°C. The remaining reactive biotin molecules are inactivated by incubation in 100 mM Tris-HCl pH 8.0 for 40 minutes at 4°C. DCs are then treated with biotinylated spores/yeasts. After 1 hour, cells are permeabilized and labeled with aHLA-DR-FITC. After zymolyase treatment, intracellular yeasts/spores are detected using APC-labeled streptavidin and analyzed by flow cytometry.</rdfs:comment>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/563"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/546"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/263"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/31">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/172"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/430"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/173"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/24"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/429"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/171"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/457"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/352"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/28"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/295"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/15"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/211"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/353"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/350"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/456"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/45"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/351"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/431"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:label>Ugo D'Oro</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000561">
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_447"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">genetic modification design: knock-in experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/191">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/102"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/103"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The vaccine for ovarian carcinoma is composed by autologous DCs pulsed with apoptotic autologous ovarian carcinoma cells. Apoptosis is induced by UV.  </rdfs:comment>
    <rdfs:label>Ovarian carcinoma DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_241981">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chemokines</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chemokine</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/42">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/487"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_770"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The supernatants are transferred to a new tube and 2 ml of acid phenol is added to repeat the extraction. </rdfs:comment>
    <rdfs:label>Transferral of supernatants to new tube</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000021">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tumor necrosis factor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TNF</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasStimulusType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type bio-material that has been used as a stimulus.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stimulus type</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A159">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_492"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/318">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/85"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Dendritic cells were matured with TNF alpha, IFN gamma and PGE2. These DC were used to produce a DC vaccine.</rdfs:comment>
    <rdfs:label>Matured DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1637">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">listeria</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Listerella</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_807">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pathogenicity experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A pathogenicity experiment design type is where an infective agent such as a bacterium, virus, protozoan, fungus etc. infects a host organism(s) and the infective agent is assayed.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0320">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_RNA</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_33697</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/39">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has know-how in performing 3H-thymidine-incorporation assays. This assay was used in the monitoring of vaccine induced T cell responses.</rdfs:comment>
    <rdfs:label>3H-thymidine-incorporation assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_408">
    <rdfs:label>PTX3</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pentraxin-3</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PTX3</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/137">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/546"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_766"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Immature DCs are allowed to adhere onto fibronectin and subsequently incubated with FITC-labeled yeast or spores for 5, 15, 30 minutes at 37°C. At the end of the incubation period, the samples are fixed in 4% PFA, permeabilized in Methanol, and labeled for DC-SIGN and/or MR using specific mAb and isotype-specific fluorescent secondary Abs. Samples are analyzed using a Zeiss LSM 510 confocal microscope. Alexa647-conjugated goat-anti-mouse IgG, and Alexa568 goat-anti-mouse IgG2b from Molecular Probes. </rdfs:comment>
    <rdfs:label>Receptor mediated-internalization assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/502">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/501"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_622"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This cytokine cocktail was used to mature human monocyte-derived dendritic cells, on which subsequently, transcriptional profiling was performed.</rdfs:comment>
    <rdfs:label>cytokine cocktail</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/188">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data has been obtained on MVA BN (a powerful poxvirus vaccine system) from a thorough analysis on the nucleotide level on safety in cell cultures in immune deficient mice as well as in healthy, HIV–infected and other immune deficient humans.

We have furthered our interaction with Dr.Markus Manz, (Partner group 27) IBR, Bellinzona, Switzerland to strengthen vaccine developments with an improved  humanized mouse model. We focus on recombinant vaccines against HIV driven by a powerful poxvirus vaccine system termed MVA BN. To improve our understanding MVA BN has been analyzed thoroughly on the nucleotide level, safety in cell cultures, immune deficient mice as well as in healthy, HIV–infected and other immune deficient humans.</rdfs:comment>
    <rdfs:label>Recombinant vaccines against HIV driven by a powerful poxvirus vaccine system</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/12">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000650"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/29"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/48"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Proteomic analysis of DC-derived organelles such as the exosomes</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701456"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000618"/>
    <rdfs:comment>Proteomic data was obtained from a proteomic analysis of DC-derived organelles such as the exosomes. Following the extensive proteomic analysis of immature and mature DC-derived exosomes, ICAM-1 was identified as the major protein on mature DC-derived exosomes, required for their functional activity. In order to functionally validate the proteomic data, the antigen-presenting function has been investigated. Exosomes bearing functional MHC-peptide complexes have been shown to be presented at the surface of recipient DCs as intact "antigen-presenting microdomains", without the need for internalisation and reprocessing by the DC. It has been shown that DCs express specific receptors for exosomes. Since ICAM-1 on exosomes is required for their ability to activate T cells via DCs in vitro, the role of Mac-1 and LFA-1 (the major ligands for ICAM-1) as potential receptors for exosomes has been investigated. A new role for LFA-1 on DCs as a receptor for exosomes has been proposed. </rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/21"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/22"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/47">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/74"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/327"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have demonstrated that the NADPH oxidase NOX2 is recruited to DC early phagosomes mediating a sustained production of low levels of reactive oxygen species and causing a maintained alkalynization of the phagosomal lumen. DCs lacking NOX2 show increased antigen degradation due to an enhanced phagosome acidification. As a result, the efficiency of in vitro and in vivo antigen cross presentation is significantly reduced in NOX2-deficient DCs.</rdfs:comment>
    <rdfs:label>NOX2-deficient DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/34">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ciro Scognamiglio</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FAO#FAO_0001001">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hyphae</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hypha</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A threadlike, tubular filamentous fungal structure.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_887">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">time series design experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Groups of assays that are related as part of a time series.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/144">
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdfs:comment>Our group has MRI data available on the migration of DCs in vivo in melanoma patients. From isolated lymphnodes obtained after surgery we could identify single DC after staining with Prussian blue for iron. We are in the process of analysing the T cell rosettes (activation stage) that surround these DC to get insight in the functional activity. 
It was also demonstrated that DCs transfected with RNA produce derived proteins in vivo in the lymph nodes.

Also efforts were spent to get further information on the dynamics of immature and mature DCs. We discovered (van Helden et al JI 2006) that podosomes are present in immature DCs but absent on highly migratory mature monocytes derived DCs. Interestingly, PGE2 treatment almost instantaneously resulted in the resolution of the podosomes, indicating that PGE2 mediated signalling is one of the earliest steps to induce a more migratory phenotype. Currently, we attempt to resolve the signalling pathway that is responsible for these phenotypical changes. Furthermore, we observed that the integrin LFA-1, while being active on monocytes is completely inactive on immature DCs. We discovered that this is not due to a downregulation of LFA-1 at the surface of the DC but rather to a different  organization at the cell surface. While on monocytes LFA-1 is organized in small nanosized clusters, on immature DCs LFA-1 is distributed randomly at the cell surface (Cambi et al Mol. Biol. Cell 2006)</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_15551"/>
    <rdfs:label>In vivo migration of DCs in melanoma patients exploring MRI</rdfs:label>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000650"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/109"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/19"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/108"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/43">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/488"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_754"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>After the centrifugation (10’ at 5000 rpm) the supernatant is transferred into a pre-spun (5’ at 1500 rpm) 50 ml Phase Lock Gel tube (Eppendorf 0032 005.330) and 4 ml of chloroform (Fischer BP1145-1) are added into the falcon. </rdfs:comment>
    <rdfs:label>Phenol extraction</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/72">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_892"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab obtained data on maturation of DC by TLR agonists.</rdfs:comment>
    <rdfs:label>Maturation of DC by TLR agonists</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0002093">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A160"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IgE</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immunoglobulin E</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/319">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/85"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This RNA was used to transfect matured DC with the final aim to produce a DC vaccine.</rdfs:comment>
    <rdfs:label>CD40L-encoding RNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A161">
    <rdf:rest rdf:nodeID="A159"/>
    <rdf:first rdf:resource="http://www.ifomis.org/bfo/1.1/snap#MaterialEntity"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_808">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An experiment design where all or part of an organism is removed and studied in vitro, e.g. part of a mouse is removed and cultured in vitro. A cell culture with an established cell line is an in vitro experiment.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ex vivo design experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400109">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/189">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/56"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001452"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_243"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:label>Alternatives to the ‘classical’ maturation method (i.e. a cocktail of inflammatory cytokines) for moDC</rdfs:label>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/57"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_415"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdfs:comment>Our lab generated data on alternatives to the ‘classical’ maturation method (i.e. a cocktail of inflammatory cytokines) for moDC (e.g. ‘clinical grade reagents such as Ampligen TM and Hiltonol TM). Moreover the possibility to co-electroporate moDC with constitutively active TLRs and TAA encoding mRNA was persued. The in vitro charging of monocyte derived DC (moDC) with antigens has been optimised.  In contrast to previous studies, the electroporation of TAA encoding mRNA after in vitro maturation of the moDC resulted in a better electroporation efficiency and antigen presentation.  

We evaluated the capacity of mRNA-electroporated DC as a vaccine for immunotherapy. First, the early DC maturation kinetics and the effect of different lipopolysaccharide incubation periods on the phenotypic maturation profile of DC were determined. Next, we showed that either immature or mature DC are equally well electroporated and express and present the transgene at a comparable level after electroporation. We point out that the mRNA electroporation results in a negative effect on the interleukin (IL)-12p70, IL-6, and tumor necrosis factor-alpha secretion after maturation. Nevertheless, mRNA-electroporated DC induce an effective cytotoxic T lymphocyte (CTL) response in vivo. Mature electroporated DC are significantly more potent in eliciting an Ag-specific CD8+ CTL response compared to their immature electroporated counterparts. In addition, a significant improvement in CTL response is obtained both in the primary and in the memory effector phases when CD4+CD25+ regulatory T cells (Treg) are depleted in vivo prior to immunization. These findings are further substantiated in tumor protection experiments and hold convincing evidence for the merit of Treg cell depletion prior to immunization with mRNA-electroporated DC.

These results facilitate the preparation of DC-vaccines for clinical use. 

A single step procedure for the in vitro maturation and antigen loading of human moDC was optimized. DC were electroporated with mRNA encoding tumor antigens and a putative TLR3 ligand.  In vitro stimulation of naïve T cells indicated the superiority of this approach compared to in vitro stimulation with DC matured with inflammatory cytokines followed by electroporation with TAA encoding mRNA.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/501">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/502"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>On these cells, transcriptional profiling was performed and a comparative pathway-based analysis was done.</rdfs:comment>
    <rdfs:label>Human monocyte-derived DC matured with a cytokine cocktail</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/60">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The objective of the creation of the Institut de Transplantation et de Recherche en Transplantation (ITERT) was to promote a medical-biological dynamic entity capable of promoting transplantation medicine and its research to a level of European excellence. The ITERT was created in 1991 based on article L6.146-8 of the code of public health offering the possibility to experiment with new forms of medical organisation linking, for example, a clinical activity and a biological activity. 
The ITERT is located in the Jean Monnet building on the Hôtel-Dieu site of Nantes University Hospital where it occupies different floors including the basement (animal section), the garden level (consultations, secretariat, medical offices, conference room, DIVAT –database-and annex of Etablissement Français des Greffes (French Transplant Organisation), the upper ground floor (Nephrology and Clinical Immunology Department, including acute haemodialysis care unit and graft intensive care), and the first floor (INSERM UMR 643). Only the Large Animal Laboratory, for obvious technical reasons, is located in the Hôtel-Dieu away from Jean Monnet. The main part of the clinical and biological activity of the ITERT is therefore grouped together on one single site: the Jean Monnet building of the Hôtel-Dieu. 
The ITERT is one of the two leading European centres in the number of transplanted kidneys (175 in 2004). For the last three years, the ITERT is one of the two leading French centre for pancreas transplantation (31 in 2004). The length of the waiting list of patients for transplants at the ITERT is 427 for kidneys and 36 for the pancreas. 

Since 1991, the ITERT has published 440 scientific articles and 264 of them were original ones. 

The ITERT has an international scientific council and has been supported since its creation by the Fondation Progreffe, a charitable foundation of companies. 

The ITERT has contributed to the creation of three companies in the domain of biotechnology and healthcare databanks. 

The ITERT is part of a local biomedical institute of research (Institut Fédératif de Recherche 26) which gathers more of 650 scientific personnel. 

The ITERT has close links to OUEST-Génopole through their common facilities (rat transgenesis and transcriptome). A center for regenerative medicine (Centre d’Investigations Clinique en Biothérapie) has recently been created in Nantes University Hospital and the ITERT was one of the initiators of the proposal. The recently awarded Atlantic Biotherapies National Competitivity Pole encompasses academic and industrial partners in this area, including the ITERT (President, J-P. Soulillou).</rdfs:comment>
    <rdfs:label>ITERT / INSERM U643</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000620">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Intercellular adhesion molecule 3</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule 3</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A162"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000178"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0200878">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MGC1460</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphoserine aminotransferase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EC 2.6.1.52</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PSAT</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphohydroxythreonine aminotransferase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">phosphoserine aminotransferase 1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphoserine aminotransferase</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EPIP</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PSAT1</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/11">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0702411"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000156"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_83022"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/32"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Identification of phagosome proteins in dendritic cells</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/252"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Proteomic map data will be generated for phagosomes formed after phagocytosis through different phagocytic receptors (FcRs, DEC-205, mannose receptor). We will do this by applying a unique methodology dedicated to the identification of phagosome proteins in dendritic cells, under various experimental conditions, that we developed at the Curie Institute. This methodology incorporates a unique sample preparation procedure based on 96 well plate complex sample trypsinization, a nano-LC-based peptide separation coupled to MSMS analysis sequencing. This procedure led us to the identification of 600 phagosomal proteins from murine DC phagosomes. 

An integrated software solution has been developed to analyse these results and to perform comparative analysis of phagosome proteomes obtained in various conditions. This methodology has been applied successfully to identify: 
a) a set of proteins specifically associated to phagosomes in DCs but not other phagocytes, such as macrophages, 
b) a set of proteins specifically recruited to phagosomes during DCs maturation induced by various Toll-Like Receptors. 

In collaboration with Norman Pavelka and Paola Ricciardi-Castagnoli (P32), a special effort is put to understand the impact of transcriptome remodelling on phagosome proteome remodelling during DC maturation. This task requires the development of dedicated software solutions that are currently on the way and should open new possibilities for transcriptomic data analysis from the DC-THERA network. 

Proteomic maps will be established for phagosomes formed after phagocytosis through different phagocytic receptors (FcRs, DEC-205, mannose receptor).</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_F0001662"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/33">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/126"/>
    <rdfs:comment>Andrea Splendiani is a partner and founder of Leaf Bioscience s.r.l., which focus on the development of open solutions for bioinformatics.
Outside dc-thera, he has been active in systems biology (standards for pathway representation), medical informatics (terminologies) and he's active in the Semantic Web community.
</rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/154"/>
    <rdfs:label>Andrea Splendiani</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/250"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/51"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/51"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/46">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/67"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have studied the immuno-physiology of rat and mouse intestinal dendritic cells. We have used a known adjuvant, E. coli heat-labile toxin (Etx) and a potential adjuvant R-848, a small TLR7/8 ligand. </rdfs:comment>
    <rdfs:label>mouse intestinal dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/44">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/493"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/492"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_756"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>After the spin (10’ at 3,000 rpm), the supernatants are precipitated in RNase-free centrifuge tube by adding 1/10 volume 3 M NaAcetate (pH 5.3) and 2.5 volumes of cold ETOH 100% overnight at -20°C.  Centrifugation (30’ at 12000 rpm).</rdfs:comment>
    <rdfs:label>Centrifugation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/71">
    <rdfs:label>Antigen targeting to DC via DC-SIGN</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_50816"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/15"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdfs:comment>We have obtained data from an analysis of antigen loading of DCs via targeting DC-SIGN, which resulted in enhanced class II-mediated presentation. Constructs for fusion proteins of the DC specific receptor DC-SIGN fused to GFP have been generated.  

</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/19"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/17"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/232"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/18"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#CD209_Antigen"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/145">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/34"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our group has obtained imaging data on the role of DALIS and related aggregates in antigen presentation and their interaction with the regulation of translation in response to pathogens.

We have implemented in collaboration with lead coordinator Carl Figdor, the organization of the imaging core-facility of the DC-THERA NoE. Experimentally, we have been applying confocal microscopy to the study of DALIS and related aggregates in order to understand their role in antigen presentation and their interaction with the regulation of translation in response to pathogens. We are still in the process of testing the use of translation monitoring by imaging technology as a novel way of defining DC activation. </rdfs:comment>
    <rdfs:label>Application of confocal microscopy to the study of DALIS and related aggregates</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/209">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/76"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/24"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Michael A. Schmid</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0002094">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IgG</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immunoglobulin G</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A30"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000125">
    <rdfs:label>blast cell</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">In the monophyletic theory, the least differentiated, totipotential blood cell without commitment as to its particular series, from which all blood cells are derived, preceding a stem cell.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">blast cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/580">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/112"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18154"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Mannan (500 micrograms/ml) was added to DCs in order to block their mannan receptors.</rdfs:comment>
    <rdfs:label>Mannan</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_63832">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/GO#GO_0043226</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_organelle</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_779">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The process of combining two or more BioMaterials.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pooling protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A134">
    <owl:unionOf rdf:nodeID="A161"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/79">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000064"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established. To this aim, iterative calibration algorithms were used to achieve a final, absolute mass accuracy of better than 10 parts per million (p.p.m.) for all peptide ions. </rdfs:comment>
    <rdfs:label>Iterative calibration algorithms</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/257">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/131"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/22"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/254"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Beatrice Schuler-Thurner</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0002091">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IgA</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A35"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immunoglobulin A</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/248">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/31"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocytes were isolated from PBMC to generate dendritic cells.</rdfs:comment>
    <rdfs:label>Isolated monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/311">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/293"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Karin Widén</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/420">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We found that the cooperation between IFNalpha,beta and Flt3L (FL) plays an important role in the defense against Herpes simplex virus type 1 (HSV-1) in neonates. Treatment of neonatal mice with recombinant IFNalpha has a short-term, FL-independent and a long-term, FL-dependent protective effect against HSV-1. In mice lacking FL, neonatal resistance against HSV-1 is very low and DC numbers in the spleen are reduced. The treatment of these mice with rIFNalpha at day 6 resulted in an increased resistance against infection with HSV-1 at day 7. In C57BL/6 mice, treatment with rIFNalpha at birth induced both FL and plasmacytoid DC (pDC) that resulted in enhanced resistance against HSV-1 at day 7. In contrast, in mice lacking FL, IFNalpha treatment at birth did not influence splenic cell composition and had no effect on viral protection. The transfer of pDC to mice lacking FL enhanced viral resistance.</rdfs:comment>
    <rdfs:label>Flt3L- neonatal mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000051">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A2">
    <owl:intersectionOf rdf:nodeID="A163"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/543">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0610"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>There is siRNA available in the lab.</rdfs:comment>
    <rdfs:label>siRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/208">
    <rdfs:label>Lisa Rizzetto</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/581"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/251"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/478"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/262"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/2"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/484"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/580"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/144"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/261"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/482"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/489"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/481"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/95"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/254"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/protocolstep/135"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/564"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/210"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/255"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/211"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/252"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/60"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/565"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/246"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/546"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/556"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/67"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/125"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/13"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/96"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/111"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/263"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/485"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/492"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/9"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/493"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/483"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/256"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/322"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/212"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/6"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/490"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/551"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/323"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/557"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/552"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/248"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/97"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/112"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/566"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/247"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/257"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/98"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/113"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/1"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/487"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/68"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/59"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/260"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/488"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/311"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/88"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/480"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/553"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/563"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/325"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/87"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/93"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/33"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/562"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/258"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/324"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/253"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/249"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/259"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/250"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A164">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_636">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">anti-FcgRIIB antibody</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A41"/>
    <rdfs:subClassOf rdf:nodeID="A38"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/14">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data were obtained from rat DC subsets by transcriptional profiling. </rdfs:comment>
    <rdfs:label>Transcriptional profiling of rat DC subsets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A45">
    <owl:unionOf rdf:nodeID="A165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_18050">
    <rdfs:label>L-Glutamine</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Glutamine (abbreviated as Gln or Q; the abbreviation Glx or Z represents either glutamine or glutamic acid) is one of the 20 amino acids encoded by the standard genetic code. Its side chain is an amide formed by replacing the side-chain hydroxyl of glutamic acid with an amine functional group. It can therefore be considered the amide of glutamic acid.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">L-Glutamine</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33709"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/131">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/553"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/263"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_729"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are exposed to cytochalasin D (10 microg/ml, TebuBio) for 30 minutes at 4°C. After washing with cold PBS, DCs are stimulated with S. cerevisiae yeast cells or spores at a DC:stimuli ratio of 4:1 for 24 hours. IL-12p70 production is assessed by ELISA.</rdfs:comment>
    <rdfs:label>IL-12p70 inhibition by cytochalasin D</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/51">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/475"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/474"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/476"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/126"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>HLA-A1 and/or HLA-A2 positive patients are immunized with autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24.</rdfs:comment>
    <rdfs:label>Immunization of HLA-A1 and/or HLA-A2 positive patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/70">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Catalina Vasquez</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/504">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/503"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_656"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were used for transcriptional profiling of macrophages  stimulated with different stimuli at different time points in the presence or absence of a kinase inhibitors.</rdfs:comment>
    <rdfs:label>knockout BALB/c mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/296">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/43"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Diana Dudziak</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/186">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_394"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data from our studies demonstrating that DC and other cell types can be activated in vitro by transfection with single stranded viral or synthetic RNA containing 5’ phosphates. This form of activation is mediated by the helicase RIG-I and leads to production of high levels of type I IFNs. Notably, this observation may explain the ability of mRNA transfection to activate DC for immunisation protocols: such RNA, even if synthesised in the presence of cap analog, always contains a certain percentage of uncapped molecules bearing 5’ tri-phosphates. </rdfs:comment>
    <rdfs:label>In vitro activation of DC by transfection with single stranded viral or synthetic RNA containing 5' phosphates</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/109">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/48"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mark Kendall</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/249">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18050"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>2 mM L-glutamine (Sigma) was added to the monocyte cell culture.</rdfs:comment>
    <rdfs:label>L-glutamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_255">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MoDC</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monocyte-derived dendritic cell</rdfs:label>
    <owl:equivalentClass rdf:nodeID="A47"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/256">
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/78"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Chandra Sekhar Boddupalli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0000272">
    <rdfs:label>protocol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000178">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A56"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/421">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We found that the cooperation between IFNalpha,beta and Flt3L (FL) plays an important role in the defense against Herpes simplex virus type 1 (HSV-1) in neonates. Treatment of neonatal mice with recombinant IFNalpha has a short-term, FL-independent and a long-term, FL-dependent protective effect against HSV-1. In mice lacking FL, neonatal resistance against HSV-1 is very low and DC numbers in the spleen are reduced. 

In C57BL/6 mice, treatment with rIFNalpha at birth induced both FL and plasmacytoid DC (pDC) that resulted in enhanced resistance against HSV-1 at day 7. In contrast, in mice lacking FL, IFNalpha treatment at birth did not influence splenic cell composition and had no effect on viral protection. The transfer of pDC to mice lacking FL enhanced viral resistance.</rdfs:comment>
    <rdfs:label>C57BL/6 mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000050">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasCellComponent">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with the biomaterial. As this would make the ontology OWL full, the annotation property hasCellCompenentType is used instead.</rdfs:comment>
    <rdfs:range rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdfs:domain rdf:nodeID="A166"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasCellComponentType</dcr:hasClassAsRangeProperty>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell component</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/52">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/102"/>
    <rdfs:comment>The optimization for the mass spectrometry analysis methods to be used in the generation of a initial proteomic map of mouse DCs (WP2) and stimuli-related phosphorylation cascades (WP5) was carried out by Lyris M. F. de Godoy (Post-doc) and Jesper V. Olsen (PhD student). Recently, our lab has been developing new techniques in quantitative proteomics and has also acquired new instrumentation to assess these types of questions in depth. This, of course, involves a lot of optimization and, consequently, large amounts of sample. However, to obtain high numbers of dendritic cells is not a trivial process, and can also be very expensive. For that reason, we have been using other model systems, like yeast, for all the general optimization steps, to have a basic set-up before we perform the experiments with the DCs.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <rdfs:label>Optimization for the mass spectrometry analysis methods to be used in the generation of a initial proteomic map of mouse DCs</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/95"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000775">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">neutrophil</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/207">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ivo Minarik</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A1">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_637">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">agonist molecule</rdfs:label>
    <owl:equivalentClass rdf:nodeID="A167"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A168">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/247">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:comment>Data were obtained from an ex-vivo analysis of different peptide specific T cell functions like degranulation and production of cytokines such as IFN? and TNF? by 8-color flow cytometry. In general, pre-existing immune-responses were rather mono-functional with dominating “IFN?-only”, “TNF?-only” and “degranulation-only” cells in the CD8+ compartment. Vaccination not only increased some of these monofunctional subpopulations but also induced occurrence of tumorantigen specific polyfunctional subsets. The further course of our melanoma patients will show whether these vaccination induced new T-cell “flavours” as well as different patterns of homing receptors do translate into better clinical efficacy.</rdfs:comment>
    <rdfs:label>Ex-vivo analysis of peptide-specific T cell functions</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/21"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_32692">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endostea</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endosteum</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/132">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_729"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>In order to assess the importance of IL-12p70 in balancing Th1/Th17 response two different experiments are performed.
In one case, DCs are stimulated for 8 hours with live spores of S. cerevisiae and C. albicans hyphae at a stimuli:DC ratio of 4:1 in the presence of different concentration of human recombinant IL12p70 (0, 1, 10 and 100 ng/ml).
In the second experiment, DCs are pre-incubated with different concentrations (0, 0.1, 1, 10, 100 microg/ml) of a monoclonal anti-human IL-12 antibody for 2 hours, then stimulated for 8 hours with live S. cerevisiae cells in a stimuli:DC ratio of 4:1. 
The ability of these stimulated DCs to drive CD4+ T cells polarization towards a Th1 response is assessed by measuring of IFNgamma and IL-17 in T cells 5-day culture supernatants.</rdfs:comment>
    <rdfs:label>IL-12p70 blocking assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000642">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The surface lining of the intestines where the cells absorb nutrients.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intestinal mucosa</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_958">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">drug response experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A design in which a behavior is invoked by a variable controlled by the experimenter - e.g. administration of a drug that effects aggressivity.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/30">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_473"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our laboratory has an electroporator at its disposal. It is used for instance for RNA electroporation into DC.</rdfs:comment>
    <rdfs:label>Electroporator</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/13">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/GO#GO_0001577"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0010259"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/397"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0001466"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdfs:label>Immunization of mice with human DC derived-exosomes and generation of hybridomas that produce antibodies recognizing at least the human exosomes</rdfs:label>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/208"/>
    <rdfs:comment>Data obtained from a proteomic analysis of human exosomes performed by Sebastian AMIGORENA from the DC-THERA consortium allowed us to suspect a number of proteins as a potential candidate target for our hybridoma 13.

We have immunized mice with human DC derived-exosomes and generated hybridomas that produce antibodies recognizing at least the human exosomes. Out of 20 hybridomas, only one appears to recognize specifically DC exosomes and not tumor exosomes nor autologous monocytes or DC or PBL. The Ab produced by this N°13 hybridoma is binding to a protein of about 30kDa. The proteomic analysis of human exosomes allowed us to suspect these proteins as a potential candidate target for our hybridoma 13:

- Signalling: 14-3-3 beta (28 kDa), 14-3-3 eta (28 kDa), 14-3-3 gamma (28 kDa), 14-3-3 zeta (28 kDa)
- Adhesion: CD9 (25 kDa), galectin 3 (27 kDa)
- Enzymes: glucose 6 phosphate isomerase (32 kDa)
- H2-M: MB2d (28 kDa), MB2k1 (28 kDa), MB2p (28 kDa), MB2q1 (28 kDa), MB2r (28 kDa), MB2w3 (28 kDa), MB2w5 (28 kDa)
- Lipid rafts: prohibitin (29 kDa), stomatin (31 kDa)
- Membrane fusion: syntaxin 7 (29 kDa)
- Cytoskeleton: syntenin (32 kDa)
- Others: ribosomal protein L6 (32 kDa)

A mass spectrometry after 2D electrophoresis will be performed on exosomal lysates to formally identify the candidate protein recognized by our hybridoma 13. We hope to obtain a neutralizing Ab to investigate the role of exosome in immunity in vivo.</rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/23"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0010497"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/297">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/24"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Ms Theiner left the Friedrich-Alexander-Universität.</rdfs:comment>
    <rdfs:label>Gabi Theiner</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A169">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/503">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/505"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/504"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These macrophages were used to perform a transcriptional profiling. Stimulation was done with different stimuli at different time points in the presence or absence of a kinase inhibitors.</rdfs:comment>
    <rdfs:label>Macrophages from knockout BALB/c and C57BL/6 mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000843">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">in vivo design experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An experiment design that is conducted entirely in a living organism, e.g. a compound treatment in a mouse model.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/108">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Henri De La Salle</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000382">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nuclear factor NF-kappa B</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rel/NF-kappaB family</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NFkB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF-kappa-B</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NF-kappaB</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nuclear factor-kappa B</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A7"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#MART-1_Antigen">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_MelanA</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC">
    <rdfs:label>Polyinosinic acid:polycytidylic acid</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">poly (I)-poly (C</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">polyI:C</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Polyinosinic acid:polycytidylic acid</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_309"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/259">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rute Marques</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/545">
    <rdfs:label>Dendritic cells used for analysis of microrganism survival following uptake</rdfs:label>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/126"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/125"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/129"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/124"/>
    <rdfs:comment>After 6 hour of stimulation, DCs were collected, washed 3 times with PBS, treated with zymolyase, washed twice and cells, lysated with a hypotonic solution (KCl 0.05%), were plated on YPD. Survival of yeast cells, spores or hyphae after uptake was reported as percentage of colony forming units after 3 days relative to the total number of cells growing in the absence of DCs exposure. To assess the importance of ROS production in DC killing ability, DPI (10 microM) was added 30 minutes before stimulation and survival of microorganisms was assessed using the same method. When evaluating survival after exposure, the possible effect of DMSO and DPI on the stimuli was taken into account.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/130"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/128"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/128"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/123"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/127"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/140"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/126"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/125"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/80"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/124"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/127"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_9637">
    <rdfs:label>Tissue</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tissue</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Textus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tissues</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_633">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antagonist molecule</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: A receptor antagonist is a type of receptor ligand or drug that does not provoke a biological response itself upon binding to a receptor, but blocks or dampens agonist-mediated responses.</OBI:IAO_0000115>
    <owl:equivalentClass rdf:nodeID="A9"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/206">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/136"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/240"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/143"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/239"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/312"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/289"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/141"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/237"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/140"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/466"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/1"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/138"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/464"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/241"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/463"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/473"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/115"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/238"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/470"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/291"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/471"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/142"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/268"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/468"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/139"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/467"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <rdfs:label>Isabel Poschke</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/465"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/272"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/472"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/271"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/469"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/242"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/12"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/267"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/53">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/180"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>We have developed and optimized a robust electroporation procedure to load monocyte derived and cytokine cocktail matured DC with RNA encoding defined tumor antigens (MelanA, Mage3, Survivin). </rdfs:comment>
    <rdfs:label>Electroporation procedure to load monocyte derived and cytokine cocktail matured DC with RNA </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000585">
    <rdfs:label>Interleukin-4</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-4</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 4</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000623">
    <rdfs:label>natural killer cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural killer cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural killer cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NK cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">large granular lymphocyte</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/30">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cristiana Tozzi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/298">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/22"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Michael Erdmann</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/190">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These carcinoma cells were used to pulse autologous DCs for vaccine production for ovarian carcinoma patients.</rdfs:comment>
    <rdfs:label>Apoptotic autologous ovarian carcinoma cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A170">
    <rdf:rest rdf:nodeID="A169"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/16">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0005539"/>
    <rdfs:comment>Agilent and Affymetrix data were obtained from an expression analysis of DC treated +/- poly I:C +/- kinase inhibitors. We have previously shown that activation of Src family kinases is absolutely required for cytokine production in DC stimulated by agonists of several Toll like receptors. Inhibition of these kinases by the specific inhibitors PP1/2 uncoupled cytokine production from the up-regulation of co-stimulatory molecules in DC. 

We investigated gene expression profiles in DC stimulated with PolyI:C, pretreated or not with PP2, microarray analysis was performed. 41 genes were found to be strongly inhibited by PP2; some cytokines, chemokines and the transcription factor IRF-8 are among these genes. 38 genes were partially inhibited by PP2, and the IL-6 gene belongs to this second group. Other 67 genes were not inhibited at all by PP2. The presence of NF-kB inhibitor in this last group confirms that PP2 doesn’t affect the NF-kB pathway from which IkB transcription depends. Another interesting finding is that among the genes that are not inhibited by PP2 there is also the gene of IL-23. To investigate the role of src kinases on IL-23 production, we tested DC supernatants for the presence of IL-12 and IL-23 cytokines after 24 hours of stimulation with R848 (TLR7/8 agonist) or with Poly I:C (TLR3 agonist). We found that PP2 was able to impair IL-12 production, but it did not affect IL-23 production. On the contrary, the amount of IL-23 was higher in PP2-treated MoDC than in untreated cells, especially upon R848 stimulation.

The results obtained with Agilent arrays were compared with those from the Affymetrix platform.</rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/24"/>
    <rdfs:label>Transcriptional / functional pathway profiling of DC treated +/- poly I:C +/- kinase inhibitors</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/167"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704352"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700009"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/166"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701386"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700888"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A171">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <owl:onProperty rdf:resource="http://dc-research.eu#hasStimulus"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/246">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <rdfs:label>Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_337"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/123"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdfs:comment>We obtained data on the T-cell stimulatory capacity of human monocyte-derived DCs co-electroporated with different combinations of CD40L, CD70, and constitutively active toll-like receptor 4 (caTLR4) encoding mRNA.

The effectiveness of the dendritic cell (DC) vaccination protocols that are currently in use could be improved by providing the DCs with a more potent maturation signal. We therefore investigated whether the T-cell stimulatory capacity of human monocyte-derived DCs could be increased by co-electroporation with different combinations of CD40L, CD70, and constitutively active toll-like receptor 4 (caTLR4) encoding mRNA. We show that immature DCs electroporated with CD40L and/or caTLR4 mRNA, but not those electroporated with CD70 mRNA, acquire a mature phenotype along with an enhanced secretion of several cytokines/chemokines. Moreover, these DCs are very potent in inducing naive CD4(+) T cells to differentiate into interferon-gamma (IFN-gamma)-secreting type 1 T helper (Th1) cells. Further, we assessed the capacity of the electroporated DCs to activate naive HLA-A2-restricted MelanA-specific CD8(+) T cells without the addition of any exogenous cytokines. When all three molecules were combined, a &gt;500-fold increase in MelanA-specific CD8(+) T cells was observed when compared with immature DCs, and a &gt;200-fold increase when compared with cytokine cocktail-matured DCs. In correlation, we found a marked increase in cytolytic and IFN-gamma/tumor necrosis factor-alpha (TNF-alpha) secreting CD8(+) T cells. Our data indicate that immature DCs genetically modified to express stimulating molecules can induce tumor antigen-specific T cells in vitro and could prove to be a significant improvement over DCs matured with the methods currently in use.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_452"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/205">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Giorgio Napolitani</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400104">
    <rdfs:label>array scanner</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human immunodeficiency virus 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human immunodeficiency virus type 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human immunodeficiency virus-1 HIV-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HIV-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human immunodeficiency virus type 1 HIV1</dcr:hasExactSynonym>
    <rdfs:label>HIV-1</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HIV-1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human immunodeficiency virus type-1 HIV-1</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human immunodeficiency virus type I HIV-1</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_562">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000322</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Cell line factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/184">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700319"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700314"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001012"/>
    <rdfs:comment>We have further data available on the expression and function of FcgammaR in mice. We had previously shown that conventional DCs express the inhibitory type II FcgammaR and the activatory type I and type III FcgammaRs. Therefore, we next investigated the expression and function of these murine FcgammaR in CD11c+CD11b-B220+ plasmacytoid DCs (pDCs). pDCs express mostly FcgammaRIIB while the expression of FcgammaRI and FcgammaRIII is only detected by RT-PCR at low but significant level. Moreover, the ITAM-containing intracellular chain associated to FcgammaRI and FcgammaRIII is strongly expressed in pDCs as detected by biochemical assay.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700316"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <rdfs:label>Expression and function of murine FcgammaR in CD11c+CD11b-B220+ plasmacytoid DCs (pDCs)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/506">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were exposed to different maturation cocktails and various activators or inhibitors and profiled.</rdfs:comment>
    <rdfs:label>Human monocyte-derived DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/133">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/263"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are stimulated with spores or yeasts, washed, supplemented with 0.1 mg/ml of NBT.</rdfs:comment>
    <rdfs:label>DC stimulation with spores or yeasts</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400147">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_12305">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CMV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cucumber mosaic cucumovirus CMV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cucumber mosaic cucumovirus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cucumber mosaic virus CMV</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cucumber mosaic virus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/310">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ulf Gehrmann</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_253">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001003</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD34</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_28874">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">phosphatidylinositols</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0002090">
    <owl:equivalentClass rdf:nodeID="A123"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antibody</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immunoglobulin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antibodies</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ig</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immunoglobulins</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/258">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/317"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/22"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/24"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Niels Schaft</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_41879">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dexamethasone</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dexamethasonum</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid hormones. It acts as an anti-inflammatory and immunosuppressant.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A163">
    <rdf:rest rdf:nodeID="A172"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/190">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Susan Paulin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_634">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A freezing protocol is a treatment protocol used for freezing biomaterial.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Freezing protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/546">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/137"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/79"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Saccharomyces cerevisiae strain SK1 (MATa/alpha HO gal2 cupS can1R BIO, Kane SM and Roth J. 1974 Bacteriol. 118: 8-14) was cultured in complete medium (YPD, 2% yeast extract, 1% peptone, 2% glucose) for 18 hours, then collected, washed twice with sterile water and resuspended at 108 cells/ml. 

The cells were biotinylated, labeled and - after treatment of DCs - detected using APC-labeled streptavidin and analyzed by flow cytometry.</rdfs:comment>
    <rdfs:label>Saccharomyces cerevisiae strain SK1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000624">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000791"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD4-positive, alpha-beta T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD4 T cell</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/54">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/479"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>We have developed a technology to obtain from melanoma metastases melanin-free total tumor RNA, suitable for in vitro amplification and DC transfection.</rdfs:comment>
    <rdfs:label>Obtaining melanin-free total tumor RNA from melanoma metastases</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/150">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/41"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These 70 patients were evaluated in the DERMA-ER-DC 04 clinical trial of DC-based therapy of melanoma patients (multipeptide loaded cytokine matured moDC +/- CD40L activation). The analysis for the first time showed a clinical correlation of induced immune responses as measured in the blood with outcome, as there have been so far statistically significantly less events in stage III patients showing good CTL reponses (IFN-y Elispot) to multiple class I and II peptides compared to low responders of the stage III cohort. Additional in vitro maturation of DC by CD40L (leucine zipper, Immunex) did not result in better immunity compard to standard cytokine cocktail matured DC.</rdfs:comment>
    <rdfs:label>70 patients, DERMA-ER-DC 04 trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#elementsBiomatTypeOfType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate this aggregate object with a bio-material ontology term of which the elements are a type. Example: the patients in a hospital might be the object aggregate which might be annotated with the ontology type "homo sapiens".</OBI:IAO_0000115>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect aggregates to a biomaterial type. SHORTCUT.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">elements are of biomaterial type</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/40">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/486"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/485"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_771"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>After 10’ of incubation in 65 °C water bath, the samples are incubated on ice.</rdfs:comment>
    <rdfs:label>Incubation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/299">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/318"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/107"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Steve Voland</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33261">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organosulfur compounds</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/15">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000279"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700888"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_615"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
    <rdfs:label>Transcriptional profiling of mouse macrophages with different stimuli +/- kinase inhibitors</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:comment>We obtained transcriptomic data by analysing the effect of the inhibition of Src family kinases by the specific inhibitors PP1/2 on the uncoupling cytokine production in DCs stimulated by agonists of several Toll like receptors. Whole transcriptome analysis indicated the transcription factor IRF-8 and 38 other genes including IL-6 as targets of SRC mediated signalling.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000279"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_615"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/245">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_452"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200674"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <rdfs:comment>Data has been obtained on TriMix DCs co-electroporated with whole tumorantigen encoding mRNA.

A critical factor determining the effectiveness of currently used dendritic cell (DC)-based vaccines, is the DC’s activation or maturation status.  We have shown recently that the T cell stimulatory capacity of DCs pulsed with tumorantigen-derived peptides can be considerably increased by activating the DCs through electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA (TriMix DCs).  Here, we investigate whether TriMix DCs can be co-electroporated with whole tumorantigen encoding mRNA.
The T cell stimulatory capacity of TriMix DCs pulsed with the immunodominant MelanA-A2 peptide and of TriMix DCs co-electroporated with MelanA mRNA was compared in vitro.  TriMix DCs were also co-electroporated with Mage-A3, Mage-C2, Tyrosinase or gp100 mRNA.  The capacity of these DCs to stimulate tumorantigen-specific T cells in melanoma patients, was investigated both in vitro prior to vaccination and after DC-vaccination.  
Like peptide-pulsed TriMix DCs, TriMix DCs co-electroporated with MelanA mRNA are very potent in inducing MelanA-specific CD8+ T cells.  These T cells have an activated phenotype, show cytolytic capacity and produce inflammatory cytokines in response to specific stimulation.  TriMix DCs co-electroporated with Tyrosinase are able to stimulate Tyrosinase-specific CD8+ T cells in vitro from the blood of non-vaccinated melanoma patients.  Furthermore, TriMix DCs co-electroporated with Mage-A3, Mage-C2 or Tyrosinase are able to induce antigen-specific CD8+ T cells through vaccination.
TriMix DCs co-electroporated with whole tumorantigen mRNA stimulate antigen-specific T cells both in vitro and through vaccination and thus form a promising new approach for anti-tumor immunotherapy.</rdfs:comment>
    <rdfs:label>Human dendritic cells activated and loaded with tumorantigen through mRNA electroporation as melanoma vaccine.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_635">
    <OBI:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMID:8647816</OBI:IAO_0000119>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AGN193109, a retinoid analog, is an efficient antagonist of retinoid action in human cervical epithelial cells</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:nodeID="A132"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33839"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AGN193109</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A173">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0003700"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_843">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tumor grading factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/134">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/557"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/556"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_760"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Blue formazan particles are dissolved using 2M KOH and DMSO.</rdfs:comment>
    <rdfs:label>Dissolve blue formazan particles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_30430">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Indium</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33250"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/505">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/503"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_657"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were used for transcriptional profiling of macrophages stimulated with different stimuli at different time points in the presence or absence of a kinase inhibitors.</rdfs:comment>
    <rdfs:label>knockout C57BL/6 mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/185">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000064"/>
    <rdfs:comment>Our lab has obtained data on the molecular signatures for alternatively activated DC.

This type of activation characterizes the state of DC in certain pathophysiological conditions, such as during the resolution of inflammation as well as in chronic inflammatory conditions and in tumors. AA-DC were obtained by culturing immature DC in the presence of a maturative agonists (such as, LPS, CD40L or TNF) and calcitriol, IL-10 or prostaglandin E2. AA-DC showed a decrease in the production of IL-12 but retained most of the ability to secrete other cytokines, such as TNF and CXCL8. The hallmark of AA-DC was the production of the angiogenic cytokine VEGF in vitro, and in vivo when the cells were implanted into the chicken embryo CAM assay. VEGF production by DC was selectively observed only when the DC where alternatively activated. Therefore, VEGF production by DC can be considered a signature of this state of activation. AA-DC induced in the presence of LPS and IL-10 also produced high levels of the long pentraxin PTX3. PTX3 is pattern recognition receptor that plays a pivotal role in humoral innate immunity. DC produced conspicuous amounts of PTX3 when stimulated with LPS and this production is further increased in the presence of IL-10. However, PTX3 production was not increased in other alternative conditions of activation, such as in the presence of dexamethasone or calcitriol. PTX3 has properties similar to antibodies. Its production is induced by pathogen recognition, it recognizes microbial moieties, activates complement and facilitates recognition by phagocytes. Thus, this long pentraxin behaves as a bona fide ante-antibody. In this perspective, it is interesting that IL-10 stimulates B cell differentiation and antibody production. Thus IL-10 stimulates the humoral arm of both innate (PTX3) and adaptive (antibodies) immunity.</rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9031"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdfs:label>Identification of molecular signatures for alternatively activated DC (AA-DC)</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_408"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_15551"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17823"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000625">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000791"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD8-positive, alpha-beta T cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0001577">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">galectin</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Lectin"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">S type lectin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">S-type lectin</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000587">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL8</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-8</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/547">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/120"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/129"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/133"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/137"/>
    <rdfs:label>S. cerevisiae strains BY4741</rdfs:label>
    <rdfs:comment>S. cerevisiae strains BY4741 (genotype, Mata his3delta1 leu2delta0 met15delta0 ura3delta0) was cultured in complete medium till exponentially phase.

The cells were biotinylated, labeled and - after treatment of DCs - detected using APC-labeled streptavidin and analyzed by flow cytometry.</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/130"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000555">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/ID#ID_0000064">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000718</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_pathogen role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/191">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ulricke Dirmeir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/104">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/304"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/303"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/302"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/300"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/77"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Meredith O'Keeffe</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000517">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/253">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/306"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/305"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Madeleine Hipp</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/182">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data on the ability of mMature DCs to efficiently present antigens associated with MHC molecules to T lymphocytes.

Dendritic cells (DCs) are major actors of innate and adaptive immune responses. Immature DCs express a great diversity of receptors at their cell surface, which provide them the ability to uptake antigen and induce an intracellular signal. DCs become mature after encountering soluble mediators or conserved pathogen associated molecular patterns (PAMPs) or after interacting with other cells. Mature DCs acquire the ability to efficiently present antigens associated with MHC molecules to T lymphocytes leading to the efficient priming of CD4+ and/or CD8+ T cells.</rdfs:comment>
    <rdfs:label>Mature DCs acquire the ability to efficiently present antigens associated with MHC molecules to T lymphocytes </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/316">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Denise Bottinelli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/292">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Caterina Vitali</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/244">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells were used to produce a vaccine for prostate carcinoma and were pulsed with apoptotic allogenic prostate carcinoma cell line LNCap cells.</rdfs:comment>
    <rdfs:label>Autologous DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/140">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/566"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>To assess the importance of ROS production in DC killing ability, DPI (10 microM) is added 30 minutes before stimulation.</rdfs:comment>
    <rdfs:label>Addition of DPI</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001440">
    <rdfs:label>Toll like receptor 4</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll-like receptor 4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR-4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR 4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR4</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll like receptor 4</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/203">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Emmanuela Marchi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/16">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Istituto Superiore di Sanità (ISS) is the leading technical and scientific public body of the Italian National Health Service. Its activities include research, control, training and consultation in the interest of public health protection.

- Research and Trial
The Institute conducts scientific research in a wide variety of fields, from cutting-edge molecular and genetic research to population-based studies of risk factors for disease and disability. Research priorities are based on those set forth in the National Health Plan. The Institute is also involved in several major clinical trials, which are frequently conducted in cooperation with the Scientific Institutes for Research and Care (IRCCS) network and Hospitals.

- Inspection, Monitoring and Certification
An important activity of the Institute, which is mandated by the Minister of Health or the Regions, is certification of the chemical and biological purity of drugs and vaccines, as well as inspection and quality control of medical and diagnostic devices and equipment, food products and packaging. It monitors trends in disease, mortality and other health factors and provides technical support for health-related environmental surveys and for investigations of epidemics and other public health problems at national, regional and local level. It also supervises the laboratories engaged in the testing of prohibited substances in sport and the national veterinary institutes. Finally, it has an important role in monitoring and coordinating blood transfusion services and plasma production in Italy.

- Documentation, Information and Publications
The Institute serves as a major source of information relating to public health and biomedicine in Italy through online connections to national and international scientific databases and data banks. It also serves as the national reference centre for MEDLARS (MEDical Literature Analysis and Retrieval System), a comprehensive international data bank coordinated by the US National Library of Medicine (NLM). The Institute produces numerous publications, including a quarterly peer-reviewed journal, technical reports, a monthly newsletter describing the Institute’s major research activities, and a national epidemiological bulletin.

- Training and Scientific Meetings
The Institute plans, implements and evaluates training activities in a wide variety of areas, with courses designed to address the needs of the National Health Service. It develops and tests innovative training methods, including web-based distance learning. Training is provided for various categories of professionals; methods range from short courses and hands-on workshops to more structured and formal courses at national and international level. The topics addressed include health service management and evaluation, epidemiology and biostatistics, training methods, laboratory techniques, diseases control and priority public health issues, and health promotion. The Institute also organises congresses, conferences, workshops and seminars for national and international participants on fundamental public health issues linked to its institutional activities and research. These events are often organised in cooperation with international organisations such as the European Union, specialised UN Agencies and non-governmental organisations with which the Institute maintains close relations.

- International Activities
The Institute plans, implements and evaluates international health projects, ranging from cooperative research and development projects to humanitarian assistance. It actively promotes cooperation at three different levels of involvement: scientific partnerships with industrialised countries (USA, European partners, Japan); scientific and development projects in partnership with economies in transition (including China, South Africa, the Central Asian Republics and countries in Latin America, the Balkans and the Middle East); development partnerships in Africa and countries in turmoil, where humanitarian and technical assistance is provided in close collaboration with the Italian Ministry of Foreign Affairs, various UN Agencies and the World Bank, as well as the Global Fund for AIDS, Tuberculosis and Malaria. Several members of the Institute serve on panels of experts for the Fund as well as on other international committees and commissions. Current projects include research into the prevention and treatment of HIV/AIDS and poverty-related diseases, capacity-building for central health administrations, technology transfer in health management and technical support for national public health authorities, usually within the context of health care reform. There is growing interest and cooperation in the application of telematics to health issues, in keeping with the priorities recently established by the G8 and the Italian government.
</rdfs:comment>
    <rdfs:label>Istituto Superiore di Sanità</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17968">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: Methyl butyrate, also known under the systematic name methyl butanoate, is the methyl ester of butyric acid. Esters are chemical compounds derived formally from an oxoacid (one containing an oxo group, X=O), and a hydroxyl compound such as an alcohol or phenol.[1] Esters consist of an inorganic acid or organic acid in which at least one -OH (hydroxyl) group is replaced by an -O-alkyl (alkoxy) group. They are analogous to salts, using organic alcohols instead of metallic hydroxides.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">butanoate</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Butyrate</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#CD209_Antigen">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD209</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD209 Antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dendritic Cell-Specific ICAM3-Grabbing Nonintegrin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-209</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HIV gp120-Binding Protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 209</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A75"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-SIGN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dendritic Cell Specific Intercellular Cell Adhesion Molecule Grabbing Non-Integrin</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">receptor DC-SIGN</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-SIGN1</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/33">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/211"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_458"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A confocal microscope is available in our laboratory.</rdfs:comment>
    <rdfs:label>Confocal microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_12643">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mouse pox virus Ectromelia</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ectromelia virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ectromelia mousepox virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mousepox virus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mousepox</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A42">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0003700"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/508">
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We infected mice with CD8+ T-cells primed with or without the influence of a reactive lymph node with a flu-virus encoding the specific antigen. After several days we determined the viral load in the lungs with RT-PCR. The results show that in mice with CD8+ T-cells primed with a reactive lymph node the viral load in the lungs was significantly smaller then in a control mice. </rdfs:comment>
    <rdfs:label>Mice with CD8+ T-cells primed with reactive lymph node</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/548">
    <rdfs:label>S. cerevisiae strain BY4741 och1</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/130"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/120"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/137"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/129"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <rdfs:comment>S. cerevisiae strain BY4741 och1 (Mata his3delta1 leu2delta0 met15delta0 ura3delta0 OCH1::kanMX4) was cultured in complete medium till exponentially phase.

The cellswere biotinylated, labeled and - after treatment of DCs - detected using APC-labeled streptavidin and analyzed by flow cytometry.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/136"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/133"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/252">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/154"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/152"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>null</rdfs:comment>
    <rdfs:label>Norman Pavelka</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100031">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcium</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcium ions</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ca2+</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcium ion</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ca(2+)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcium(II)</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcium(2+)</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33250"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/192">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vanessa Durand</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/18">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Pathway-level data have been obtained from a pilot experiment on yeast cells treated with peptides with potential antifungal action. We have compared results from both genomics and proteomics experiments and search for similarities at the level of pathways and have used Eu.Gene to compare the two different data sources demonstrating the feasibility of using this program to this task.

Overall correlation between changes in RNA and protein expression was poor but increased when looking at components of immunologically-relevant pathways and Gene ontology terms. The combination of the two sets of results allows selection of the cellular modules acting as hallmarks of dendritic cell maturation from which a molecular signature can be extracted.</rdfs:comment>
    <rdfs:label>Comparative pathways-based analysis of genomic and proteomic data from same sources</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000516">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/103">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Jürgen Hausmann</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/183">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0002094"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001012"/>
    <rdfs:comment>Among the battery of cell surface receptors expressed by DCs, the receptor for the Fc portion of IgG (FcgammaRs) recognizes the antibodies coupled to their specific antigens, called immune complexes (IC). We have data available from our demonstration that the target of FcgammaRs with the antigen induces the internalization of the IC, leading to the maturation of CD11c+CD11b+ conventional DCs. These DCs become thus efficient to present antigenic peptides to helper CD4 T cells and cytotoxic CD8 T cells via cross-presentation pathway. This capability might then enhance antitumor immunity in vivo. The cross-presentation pathway is selectively performed by DCs.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_402"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001013"/>
    <rdfs:label>The target of FcgammaRs with the antigen induces the internalization of the IC</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/293">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Renato Ostuni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/245">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The patients were vaccinated with a vaccine composed by autologous DCs pulsed with apoptotic allogenic prostate carcinoma cell line LNCap.</rdfs:comment>
    <rdfs:label>Patients with advanced prostate carcinoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/317">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Thomas Duhen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/34">
    <rdfs:label>Advanced imaging platform</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/145"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/30"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/247"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdfs:comment>Led by Figdor (P2), this platform was established between four centres that respectively provide expertise and facilities for a variety of high resolution imaging techniques and MRI of humans in Nijmegen NL (P2, Figdor); MRI of mice in Erlangen DE (P6, Lutz); two photon microscopy in Paris FR (P13, Amigorena); and correlation spectroscopy in Marseilles FR (P22, Pierre). The platform organised several high quality courses and workshops in 2006-7 which continued in 2008.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000050"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/17">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_577"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We generated data on the expression by dendritic cells treated with microbial pathogen derivatives.</rdfs:comment>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Transcriptional profiling of human DC treated with microbial pathogen derivatives</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/202">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Christofer Samuelsson</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/507">
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A quantitative microarray approach that detects 723 human mature miR (miRBase 10.1, Dec 2007), was used to measure miR expression profile in these cells.</rdfs:comment>
    <rdfs:label>moDC, either untreated or stimulated with LPS, R848, or their combination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/17">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/biomaterial/48"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Université de Nice Sophia Antipolis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A174">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000014"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000053">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_antibody role</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_736</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/193">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Victoria McDonald</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_2841">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">[wikipedia:] The National Heart, Lung and Blood Institute defines asthma as a common chronic disorder of the airways characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness (bronchospasm), and an underlying inflammation.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">asthma</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/180">
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704043"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/53"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdfs:label>Priming capacity of RNA transfected DC</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:comment>Data was obtained on RNA transfected DC which proved superior in priming naïve T cells in vitro compared to DC loaded with native peptides.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700880">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A79"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IRF4_HUMAN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IRF 4</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferon regulatory factor 4</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000589">
    <rdfs:label>Interleukin-10</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-10</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 10</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-10</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL10</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin 10</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/255">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/181"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Francesca de Angelis Rigotti</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/246">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/30"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_445"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>PBMC were isolated from this buffy coat. Subsequently, monocytes were isolated from the PBMC and dendritic cells generated from the monocytes.</rdfs:comment>
    <rdfs:label>Buffy coat</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000386">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon-regulating factor function</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferon regulatory factor family</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IRF family</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IRF</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/106">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Henning Lauterbach</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/68">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_733"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Since 1982, Congrex has been instrumental in bringing people together and bridging the gap across cultural, linguistic and geographic borders.

When delivering excellence in meetings management we work in partnership with our clients. We offer consultancy services and help in developing strategies to enable overall objectives to be reached. Whether it is implementing best practice, recommendations on technology solutions, revenue tracking and management expenditure, our team is delighted to work with you to help identify your needs and recommend solutions.

With 25 years of excellence we built our reputation on the ability to successfully organise events from small summits with a few participants to global congresses that shape the future.

No matter where in the world you want to stage an event or meeting, we have the vision and creativity to make it a success. Our reputation also extends to broader Association Management Services, as more and more associations seek state-of-the-art thinking to help them in the high-tech, fast-moving 21st century.

Our integrated solutions are leading edge for associations, corporations and governments.</rdfs:comment>
    <rdfs:label>Concorde Services London</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/90">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_737"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Protocols were developed to measure human immune responses to melanoma antigens to be measured using ELISpot and tetramers. The antigens in question were also inserted into adenovirus, lentivirus and vaccinia vectors for re-stimulation studies.</rdfs:comment>
    <rdfs:label>Measuring of human immune responses to melanoma antigens</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/107">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Maria Rescigno</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/67">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Vaccine &amp; Infectious Disease Institute - VAXINFECTIO	

The Vaccine &amp; Infectious Disease Institute (VAXINFECTIO) was established as a formal Institute of the Faculty of Medicine in the year 2007 (Faculty council decision dd. 04/07/2007) to promote the multidisciplinary research of vaccines and infectious diseases. It is since 01/01/2008 formally recognised as Centre of Excellence of the University of Antwerp with Methusalem funding. Its mission statement is aimed at integrated vaccine and microbiological research with a focus on increasing the understanding of the immune response in prophylactic and therapeutic vaccines (including tumour vaccines) and on the containment of antibiotic resistance. Within this mission statement, the following objectives are pursued: 
O  To study microbiological, immunological, mathematical-biological, statistical, economical, societal and epidemiological aspects of infectious diseases and vaccines. 
O  To create a scientific platform in order: 
 - To consolidate the existing pool of knowledge 
 - To advance knowledge with interdisciplinary focus 
 - To increase scientific output in the listed disciplines 
 - To attract additional funding resources

VAXINFECTIO consists of the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and the Centre for the Evaluation of Vaccination (CEV).</rdfs:comment>
    <rdfs:label>Universitair Ziekenhuis Antwerpen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/294">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Roberto Spreafico</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/201">
    <rdfs:label>Christine Lohmann</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/310"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/313"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/2"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/311"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/309"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/495"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/4"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/5"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/496"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/308"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/499"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/497"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/143"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/65"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/498"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/208"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/500"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/209"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/86"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/87"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/494"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/312"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/18">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>A Medical University

Karolinska Institutet is one of Europe's largest medical universities. It is also Sweden´s largest centre for medical training and research. Our mission is to improve the health of mankind through research and education.</rdfs:comment>
    <rdfs:label>Karolinska Institutet</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A175">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000109"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/31">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000052"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Genopolis hosts a microarray platform that uses the Affymetrix GeneChip® microarray technology for genome and transcriptome analyses. In 2008, this platform was enhanced by the incorporation of a new institute [the Wellcome Trust Centre for Human Genetics] to provide ‘Illumina’ microarray profiling.

The following services are currently available:

Whole genome genotyping applications, which include:
1. family-based association studies
2. cancer genetics
3. population genetics
4. chromosomal copy number analysis

Whole genome gene expression profiling applications:
1. discovery of new and improved molecular diagnostics
2. identification of new molecular targets for therapy
3. find and clarify biological pathways</rdfs:comment>
    <rdfs:label>Functional genomics platform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_638">
    <rdfs:subClassOf rdf:nodeID="A93"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_37163"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">laminaran</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">laminarin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasSupervisor">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a supervised person, such as a DC-THERA PhD student, to his or her (co-)supervisor, i.e., not necessarily the hosting one but any supervisor who follows the student.</OBI:IAO_0000115>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#isSupervisorOf"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has supervisor</rdfs:label>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0005102">
    <oboInOwl:hasNarrowSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">receptor ligand</oboInOwl:hasNarrowSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">receptor binding function</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interacting selectively with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0003674"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_35366">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fatty acids</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Aliphatic monocarboxylic acids derived from or contained in esterified form in an animal or vegetable fat, oil or wax. Natural fatty acids commonly have a chain of 4 to 28 carbons (usually unbranched and even-numbered), which may be saturated or unsaturated.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000263">
    <rdfs:label xml:lang="en">obsolete_homo sapiens</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606</dcr:replaced_by>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_homo sapiens</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000052">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000050"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/194">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/195"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/10"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vuk Cerovic</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/181">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>Data has been obtained on the homing capacity of DC transfected with RNA encoding E/L-Selectin.

We have efficiently transfected DC with RNA encoding a functional protein (E/L-Selectin) which allows entry of DC into LN from HEV. Mouse E/L-S transfected DC, when given i.v.,  homed to LN, whereas non transfected DC home only to the spleen. The novel adherence capacity of human E/L-S transfected DC was demonstrated via sticking to sialyl-LewisX coated slides using a parallel plate flow microscope. RNA transfected human DC could be frozen and thawed without loosing their functionality. 

In an ongoing clinical trial (see WP9) using monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin, we already obtained superior immune responses using E/L-S+ DC compared to E/L-S- DC. 

To demonstrate in-vivo that multiple LN regions can be targeted by i.v. application of  E/L-S DC, we established indium111 labelling of DC and studied its effect on DC migration and T-cell interaction in vitro prior going into patients.  In terms of migratory capacity, which was analyzed using a transwell assay adressing CCR7-mediated migration of DC towards MIP3-ß, we could not find any inhibition by labeling of DC with indium111 up to 4 MBq (100 µCi). In contrast, priming and expansion of MelanA specific naïve CD8 T-cells by DC loaded with MelanA analog peptide or MelanA encoding RNA, was markedly affected by indium111 labeling in a dose dependent manner. Whereas MelanA specific T cell expansion was only slightly reduced using DC labelled with 1MBq of indium111, 2MBq  already completely abrogated specific T cell expansion and labelling with 4MBq even resulted in death of MelanA specific T cells. Therefore Indium111 labelled DC should not be loaded with tumor antigens if applied in patients, which may result in loss of specific immune responses at least at higher labelling intensities usually employed. Interestingly, this aspect had never been uncovered or considered in work done so far by other groups injecting Indium labelled DC previously.</rdfs:comment>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000182"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/257"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_216"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/55"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <rdfs:label>Homing of DC transfected with RNA encoding E/L-Selectin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/254">
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/257"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Arcadi Cipponi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.uniprot.org/taxonomy/NEWT_29278">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000737</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Obsolete_vector</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/69">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Oncology institute Eugène Marquis in Rennes is one of the 20 centers founded in 1945 and now united in a joint structure, the National Federation of French Cancer Centers.

Public founded and based within the teaching hospital campus of Pontchaillou, it brings together the resources required for its triple mission of health care, education and research in cancer.

With a highly specialized team and a high standard facilities and equipment, the center offer to its patients:
- Comprehensive treatment of breast cancer, including surgery.
- Radiotherapy of all kind of diseases, including clinical hematology and pediatric oncology 
- Chemotherapy of solid tumours in adults 
- Therapeutic use of radioactive isotopes, e.g. after surgery of thyroid cancer 
- Medical imaging (PET scan, CT scan, radionuclide scanning, X Ray, Ultrasound, etc.) 
- Laboratory facilities.
</rdfs:comment>
    <rdfs:label>Oncology institute Eugène Marquis (CRLCC)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/105">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/302"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/77"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hubertus Hochrein</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/247">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/31"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/30"/>
    <dcr:hasTissueType rdf:resource="http://dc-research.eu#dctheradir_445"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>PBMC were isolated from buffy coat. Subsequently, monocytes were isolated and differentiated into dendritic cells.</rdfs:comment>
    <rdfs:label>PBMC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_782">
    <rdfs:label>monitoring method</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A monitoring method is a method specifying how to provide awareness of the state of a system.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monitoring method</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/295">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Andreas Baur</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701872">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GATA-BINDING PROTEIN 3</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GATA-3</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A155"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A176">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0003700"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_639">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CyP</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cyanobacterial LPS antagonist</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CyP</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasShortForm rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cyanobacterial LPS antagonist</dcr:hasShortForm>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/249">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/260"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have data available from a comparison of the use of fresh peripheral blood mononuclear cells (PBMC) versus fresh heparinised whole blood. 
 
Only when peptide pools as an antigen source are used PBMC exhibited a slightly higher stimulation capacity compared to whole blood. However, slightly higher background was observed when using PBMC to stimulate with antigen. Lowest background was observed when either peptides or protein were used for stimulation enabling assessment also of rare antigen-specific Th-cells below frequencies of 0.05% of peripheral CD4+ Th-cells. (Meier, Stark et al., 2008). We also tested usage of peptide pool preparations versus recombinant antigen for their stimulation capacity. While working with whole blood no differences in the capacity to elicit antigen-specific activation of Th-cells were observed, stimulation in PBMC induced higher activation (Meier, Stark et al., 2008). 
We also evaluated the influence of the cell density on the stimulation outcome when PBMC were used for induction of Th-cell activation. Optimal Th-cell activation was induced when cultures were initiated with about 5x10E6/ml PBMC. Wrong adjustment of cell densities (e.g. to 1x10E6/ml reduced Th-cell activation to about 1/3 (Meier, Stark et al., 2008). </rdfs:comment>
    <rdfs:label>Comparison of the use of fresh PBMC versus fresh heparinised whole blood</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/200">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/213"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Caroline Coquerelle</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/50">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/282"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/477"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/126"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>MAGE-3 positive patients are immunized with autologous MAGE-3 and TK transduced activated T blasts.</rdfs:comment>
    <rdfs:label>Immunization of MAGE-3 positive patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/32">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our institute, we have a 9-colour FACS cell sorter our disposal. It is used, e.g., for the analysis of various DC populations.</rdfs:comment>
    <rdfs:label>9-colour FACS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/509">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/65"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tumor growth is supported by tumor stroma, such as tumor associated macrophages (TAM) and tumor associated dendritic cells (TADC). We have recently reported that TAM display massive nuclear localization of the p50 NF-kB inhibitory homodimer, which correlates with impaired inflammatory functions.The functional significance of this observation was demonstrated in p50 NF-kB deficient mice, which displayed tumor growth inhibition.</rdfs:comment>
    <rdfs:label>p50 NF-kB deficient mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/19">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Karolinska University Hospital is one of Scandinavia’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in medical break-throughs in Sweden. 

We believe that patient care, research, and education must all play equally strong roles in our effort to extend and enhance people’s lives. As a major teaching hospital we educate and train tomorrow’s medical specialists and healthcare professionals. 

Future Health Care Based on Science and Development

Our vision is clear – we aim to be recognized worldwide as a premier teaching hospital, leading the way in health science and care.</rdfs:comment>
    <rdfs:label>Karolinska University Hospital</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/130">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/552"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>When evaluating survival after exposure, the possible effect of DMSO and DPI on the stimuli is taken into account.</rdfs:comment>
    <rdfs:label>Exposure and assessment of importance of ROS production in DC killing ability</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33697">
    <rdfs:label>ribonucleic acids</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_445">
    <rdfs:label>buffy coat</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">buffy coat</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_9637"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_3972">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_91827"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">European mistletoe</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Viscum album</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/210">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Michal Podrazil</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0100055">
    <rdfs:label>cell line cell</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000279">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">kinase inhibitor PP1</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A174"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000272"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PP1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_332">
    <rdfs:subClassOf rdf:nodeID="A175"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Modified Vaccinia Ankara</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MVA-BN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MVA vector</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Modified Vaccinia Ankara vector</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MVA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MVA vectors</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/429">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/28"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We found that LPS-stimulated mDCs are able to induce up-regulation of co-stimulatory molecules on co-cultured pDCs. Likewise, CpG-stimulated pDCs activate co-cultured mDCs. The cross talk between these two populations of DC is very efficient since it can be observed at mDC/pDC ratio ranging from 1/10 to 10/1. </rdfs:comment>
    <rdfs:label>LPS-stimulated mDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_83022">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">phagosome</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phagocytic vesicles</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phagocytic vesicle</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">phagosomes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/102">
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <rdfs:label>Proliferation assays &amp; ELISPOT analyses of long peptide vaccines; measurement of regulatory T cells</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_192"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001450"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/48"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/520"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/519"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/121"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/437"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained valuable data on chemically well-defined TLR ligand conjugates and their effectiveness to induce a strong immune response via the cross-presentation pathway. 

We have studied long peptides which were covalently conjugated to either the TLR2 ligand or TLR9 ligand, Pam3CysSK4 or CpG, respectively have been used to study the uptake, antigen presentation, and induction of specific T-cells. A pronounced enhancement in antigen presentation by DC in vitro was facilitated by the conjugated peptides compared to peptide alone, or peptide mixed with the free TLR ligand. Importantly, direct injection of the conjugates or pre-loading of the conjugates onto dendritic cells followed by injection into naïve mice, lead to a robust induction of specific CD8 T-cells, as detected by tetramers staining, compared to mice injected with the peptide mixed with the free TLR ligand. 

With regard to TLR2 ligands, we have investigated the behaviour of two diastereomers of the TLR-2 ligand Pam3CSK4 (Pam) derivatives, namely the R- and S-epimers at C-2 of the glycerol moiety. In this respect we have chemically coupled  either the R-epimer of the Pam3CSK4 or the S-epimer of the Pam3CSK4 to long peptides containing a CTL epitope. We found that the Pam(R)-conjugates lead to better activation of dendritic cells than the Pam(S)-conjugates as judged by higher IL-12 secretion, up-regulation of relevant markers for dendritic cell maturation. In contrast, both epimers were internalized equally efficient in a clathrin-dependent manner indicating no qualitative difference in the uptake of the two stereoisomeric Pam-conjugates. We conclude that the enhanced DC activation is due to enhanced TLR-2 triggering by the Pam(R) conjugate in contrast to the Pam(S) conjugate. Importantly, induction of specific CD8+ T-cells was significantly higher in mice injected with the Pam(R)-conjugates compared to mice injected with the Pam(S)-conjugate. 

These results show that chemically well-defined TLR ligand conjugates induce a strong immune response, significantly more effective than combining the free peptide and the TLR ligand. By combining efficient antigen targeting and DC maturation, TLR ligand conjugates are promising vehicles to deliver antigens via the cross-presentation pathway.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/218"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/25">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>In spring 2000, the Institute for Research in Biomedicine (IRB) opened in Bellinzona, the capital of the Italian-speaking Canton of Ticino. The building offers 1,400 square meters of laboratory space including tissue culture rooms, level 2 and 3 biosafety laboratories, and an animal house. Core facilities are available for nucleic acid and protein analysis, cytofluorimetry, cell sorting, and high-resolution microscopy with image analysis. 

The IRB receives support from the city of Bellinzona, the Canton of Ticino, the Swiss Confederation, from private sources as well as from funding agencies. The Helmut Horten Foundation is the major sponsor with an initial contribution covering equipment and running costs for the first five years.

Providing extensive technical and logistic support, the institute offers optimal conditions for high-level research. This environment is expected to foster interaction and collaboration among the research groups, which are active in different areas of biology. The IRB strives to contribute to the progress of biomedical research by studying basic mechanisms of immune defense against bacteria, viruses and tumors, and to find new approaches to diagnostics and therapy.

Eight research groups are established under the guidance of Prof. Antonio Lanzavecchia and their number will grow up to twelve in the forthcoming years. An advisory board of eight internationally known specialists will guarantee standards of personnel appointments and research work. The topics of research range from cellular and functional aspects of the immune response to the molecular mechanisms of inflammation and innate immunity. Basic aspects of cell biology such as ligand-receptor interactions, intracellular signaling, protein structure and folding are also studied. Scientists at the IRB collaborate with several research institutes The IRB organizes seminars, scientific meetings and discussion groups. Moreover, the IRB provides support and training for graduate students from Switzerland and foreign countries.</rdfs:comment>
    <rdfs:label>Istituto di Ricerca in Biomedicina/Institute for Research in Biomedicine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_192">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pam3CysSK4</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_6495"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PAM3CSK4</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/88">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/381"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/379"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/378"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/377"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_751"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Sources for tumor antigens as well as monocytes and T cells will be isolated from the leukapheresis product by elutriation. </rdfs:comment>
    <rdfs:label>Elutriation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7197">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">livers</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">liver</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cellular modification design type is where a modification of the transcriptome, proteome (not genome) is made, for example RNAi, antibody targeting.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cellular modification design experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/152">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/275"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/40"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cindy Aerts</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/191">
    <rdfs:comment>Data was obtained using CpG-DNA as TLR9 ligand, to establish an in vitro system to mature myeloid DCs and plasmacytoid (p) DCs and on the efficacy of CpG-DNA-Ag complexes for cross-presentation of Ag by DCs was analyzed in vivo. Mature DCs upregulated CD80, CD86, MHC class II and produced cell type specific cytokines. CD8+ myeloid DCs “cross-presented” exogeneous Ags (Ovalbumin) while pDCs produce type 1 Interferons. The efficacy of CpG-DNA-Ag complexed for cross-presentation of Ag by DCs was analyzed in vivo. Primary and secondary CTL response against the C8 T cell epitope SIINFEKL was monitored using peptide-tetramer assays. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:label>In vitro system to mature myeloid DCs and plasmacytoid DCs</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/76"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001412"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/111">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mayda Gürsel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/467">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/8"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocytes were cultured in serum free medium in the presence of IL-4 and GM-CSF, and concentrated cytokines were added.</rdfs:comment>
    <rdfs:label>MoDC (monocytes after culture with IL-4 and GM-CSF)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000000001">
    <rdfs:label>protein</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/77">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fosca Bognuda</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701867">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A176"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GATA-binding factor 1</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/48">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:comment>For immuno-monitoring we established methods and protocols for detection of antigen-specific T cell populations in human and mice. Particularly we have identified CD40L as a unifying marker for all antigen-reactive T cells. This will significantly improve the possibilities to characterize specific immune responses, e.g. following vaccinations with dendritic cells.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label>Detection of antigen-specific T cell populations in human and mice</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_487"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/144">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/36"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/35"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These are strains of Saccharomyces cerevisiae that were cultured and collected in different conditions:
- different growth phase (exponential and stationary phase) 
- different growth media (standard and promoting pseudohyphal growth) 
- different cell form (spheroplast, spore and whole cell) </rdfs:comment>
    <rdfs:label>Yeast strains</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A81">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/353">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001452"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Used for stimulation in the evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.</rdfs:comment>
    <rdfs:label>TLR3</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000650">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A164"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LFA 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LFA1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LFA-1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lymphocyte function-associated antigen 1</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/120">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has expertise about ELISPOT analyses from the long peptide trial in end stage cervical carnoma, resected cervical carcinoma and VIN III patients.</rdfs:comment>
    <rdfs:label>ELISPOT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/196">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/34"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Alix Scholer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000278">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PP2B</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ca2+/calmodulin-dependent protein phosphatase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">protein phosphatase type 2B</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcineurin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_9351">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Diabetes Mellitus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/211">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/76"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/74"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mirela Kuka</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/24">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Cancer Research UK is the world's leading independent organisation dedicated to cancer research.

We support research into all aspects of cancer through the work of more than 4,250 scientists, doctors and nurses.

What we do
Cancer is common – around 285,000 new cases are diagnosed each year in the UK. At Cancer Research UK we are working hard to improve our understanding of cancer and develop better ways to prevent, diagnose and treat the disease.

Our research : Cancer Research UK supports scientists, doctors and nurses across the UK, who are working together to investigate all aspects of cancer
providing cancer information – millions of people have benefited from information provided by Cancer Research UK. We produce information for audiences including cancer patients and their families, the general public and health professionals.

Working with Government : with the help of the public, Cancer Research UK works to make sure that cancer stays at the top of the health agenda.</rdfs:comment>
    <rdfs:label>Cancer Research UK</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000064">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">micromolar</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A unit of molarity which is equal to one millionth of a molar or 10^[-6] M.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000051"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">uM</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/428">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have optimized the MAGE-A3 peptides to load onto HLA-DR*1101 tetramers.</rdfs:comment>
    <rdfs:label>MAGE-A3 peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_333">
    <rdfs:subClassOf rdf:nodeID="A168"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor antigens</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumour antigens</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TAA</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TAAs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor-associated antigens</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor associated antigens</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumour antigen</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor-associated antigen</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor associated antigen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_205488">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ebolavirus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EBO</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ebola virus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/87">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/377"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/375"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_752"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Patients will undergo leukapheresis.</rdfs:comment>
    <rdfs:label>Leukapheresis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_24833">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36357"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An oxoacid is a compound which contains oxygen, at least one other element, and at least one hydrogen bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons).</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">oxoacids</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000513">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Genotype factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/240">
    <dcr:hasBodilyPartType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_616"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001128"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data has been obtained from our work aiming at defining the role of CCR6 in directing migration of TH17 cells at sites of inflammation or infection. We found that CCR6–deficient (CCR6-KO) mice were resistant to induction of EAE but became susceptible when transferred with small number of CCR6-sufficient T cells. CCR6 was found to be required on a first wave of TH-17 cells that entered the CNS through the choroid plexus epithelial cells, which constitutively expressed CCL20 in both mice and humans. CCR6+ T cells triggered entry of a second wave of T cells that migrated in large numbers into the CNS by crossing activated parenchymal vessels. These results reveal distinct molecular requirements and anatomical sites of lymphocytes entry during development of EAE and suggest that the CCR6-CCL20 axis controls an evolutionary conserved pathway of immune surveillance in the brain.</rdfs:comment>
    <rdfs:label>Role of CCR6 in directing migration of TH17 cells at sites of inflammation or infection</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/151">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Basav Hangalapura</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/112">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Arpad Alanyi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/466">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>One volume fresh medium containing 2x concentrated cytokines was added to the cell culture of monocytes in serum free medium in the presence of 100 ng/mL GM-CSF (Leukine, Berlex) and 20 ng/mL IL-4 (Cell Genix).</rdfs:comment>
    <rdfs:label>2x concentrated cytokines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001695">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_33709</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_amino acid</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/78">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/76"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/133"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/75"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/132"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/208"/>
    <rdfs:label>Markus Manz</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/134"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/74"/>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/73"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/256"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/83"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/47">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_487"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/401"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/400"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/399"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label>Standardized method for the immuno-monitoring of DC vaccination trials</rdfs:label>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/403"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/78"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/402"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdfs:comment>We are progressing steadily towards the delivery of a standardized method for the immuno-monitoring of DC vaccination trials using a finite number of defined tumor antigens. Our starting point was the method that we had developed previously to estimate blood frequencies of CD8 T lymphocytes against one defined antigenic peptide. It was based on an in vitro restimulation of blood lymphocytes with the peptide and growth factors over two weeks followed by detection with the appropriate HLA class I tetramer. In order to estimate frequencies of responding cells, these mixed lymphocyte peptide cultures (MLPC) are conducted in limiting dilution condition. We have validated two important modifications to this protocol. 

i)  MLPC/tetramer with multiple peptides presented by HLA class I molecules. We now have a stimulation method that can be used for up to 8 antigenic peptides simultaneously, all presented by HLA class I molecules. To avoid competition between the peptides for HLA binding, the initial stimulation of the PBMC is carried out by dividing the initial population into 8 fractions, each of which is pulsed with one peptide, and pooling these individually pulsed fractions before the distribution into the limiting dilution microcultures. For tetramer detection, we obtain similar results with either of two methods. The first is simply to mix all tetramers, a procedure that, if each reagent is carefully titrated, does not generate a disturbing non specific labeling. A positive microculture has then to be retested individually with each tetramer. The advantage of this procedure is that the initial screening has to be carried out only once. This procedure is applicable when the proportion of positive microcultures is low. The second method is to carry out the screening with mixes of three tetramers with an overlap of one. For tetramers 1-8 this gives 1,2,3 and 3,4,5 and 5,6,7 and 7,8,1. Here the initial screening uses four labelings, but one can immediately determine which antigen is recognized in which microculture. 

ii) MLPC/tetramer including a peptide presented by HLA class II molecules. With the availability of a new type of HLA class II tetramer, consisting of recombinant HLA-DP4 molecules folded with the MAGE-A3 peptide presented by DP4, we could test whether the MLPC/tetramer method could be used also for a vaccine peptide recognized by CD4 T cells. We found out that the addition of the MAGE-3.DP4 peptide to the mix of 8 peptides described above allowed for the stimulation, in the same microcultures, of both CD4 and CD8 peptide-specific responder cells. Tetramer detection was as sensitive as for the class I reagents and could be performed simultaneously. This improvement could be very useful for all the trials that combine class I and class II antigenic peptides.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/405"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/398"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_338"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/404"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/143">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/13"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells were stained by Mini67-1KT or Mini26-1KT (PKH67/PKH26 green/red fluorescent cell linker mini kit for general cell membrane labelling, from Sigma) in order to analyse their uptake of dead cells.</rdfs:comment>
    <rdfs:label>D2SC1/Flt3-DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A177">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/23">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Associated member of the Leibniz-Gemeinschaft
Authorized for further training (DGfl-immunologist)

An institute dealing with one syndrome?
The DRFZ has the task to practise basic research in the field of rheumatic diseases. At the moment, 136 men and women work for the institute.
The DRFZ is the only institute in Germany with the exclusive assignment of interdisciplinary research on rheumatic diseases. When recommending an integration of the DRFZ into the Leibniz-Gemeinschaft in 2004, the scientific board emphasised the fact that it is one of the internationally leading institutes in the fields of immunology, experimental rheumatology and epidemiology. 
The concept of cellular pathology, formulated in 1855 by Rudolph Virchow, according to which diseases are caused by a malfunction of cells, is the overall concept of the DRFZ.
The understanding of this malfunction of cells involved in rheumatic diseases is the basic factor in the development of cell therapies at the DRFZ. With the help of those, cells can be treated directly by either correcting their malfunction, removing them from the body or destroying them when still in the body. 
In order to rebuild tissue affected by rheumatic diseases, cells with healing abilities have to be found and activated. The cellular and molecular understanding prepares the ground for effective therapies for rheumatic diseases. 
Our epidemiologists investigate factors influencing the course of inflammatory rheumatic diseases, evaluate the quality degree of medical care today and discuss the necessity of further improvements. This is put into practice in close cooperation with a network of more than 300 rheumatologists from all parts of Germany. In 1993 they started to build up a data bank for the treatment of patients which has become the largest in the world. Separately for adults and children it provides information about the actual state of medical care and possible deficits. More than 200.000 patients informed about their health situation, quality of life and the extend of their pain, some of them over a period of several years. The doctors collected and documented the corresponding medical data.   

Cooperation with other research groups
One important pillar of the DRFZ’s work is the close cooperation with other research groups. The scientists from the DRFZ work together in 11 working groups and 10 so called liaison groups, where they cooperate with colleagues from other institutes and from the Charité Berlin. In 1999 the German Research Council (DFG) installed the first special research sector at the Charité in which the DRFZ was involved. In the following years this was complemented by five more sectors integrated in the research groups of the DRFZ.
Furthermore, the DRFZ is involved in seven research networks of the EU. 
The DRFZ is one of the centres within the competence network “Inflammatory Rheumatic Diseases”, founded by the Federal Ministry of Science in 1998.
Abdreas Radbruch succeeded Henning Zeidler from Hannover and Gerd-Rüdiger Burmester from the Charité as the network’s spokesman and led it into its third funding phase in 2004/2005. In autumn 2005 Angela Zink, vice director of the DRFZ, became spokesperson of the competence network for 2006 and 2007. 
The project “Berlinflame”, a cooperation with partners from the Charité in 2001, made the DRFZ one of five national centres in the research sector “Infection and Inflammation” of the National Genome Research Network (NGFN). In the meantime the project has been renamed SIPAGE and prolonged until 2007.
In the funding programme “Tissue Engineering” of the Federal Ministry of Education and Research several groups of the DRFZ cooperate with partners from the Charité and companies for biotechnology.

Further information about all those projects can be found under “Research”.

Teachings
Through three confounded chairs supported by the DRFZ:
- “Experimental Rheumatology”, Prof. Dr. Andreas Radbruch
- “Clinical Rheumatology”, Prof. Dr. Falk Hiepe, and
-  “Epidemiology”, Prof. Dr. Angela Zink,  
the institute is closely linked to the Charité - Universitätsmedizin Berlin.

Scientific Publications
The effective cooperation of scientists within the DRFZ as well as with partners from the Charité and other research institutes, not only in Berlin, is also reflected in the scientific publications. Most of the ca. 100 publications per year are co-authored by scientists from the DRFZ and those from other institutes. It is especially encouraging that the share of publications in highly estimated international journals like the Journal of Experimental Medicine, Arthritis and Rheumatism, Blood or the Journal of Immunology has constantly increased over the last few years.

Sponsorship
The institute is financed by the Federal State of Berlin. Certain research projects are supported by the Federal Ministry of Research, the German Research Council and the European Union. Further funding is welcome at any time.</rdfs:comment>
    <rdfs:label>Deutsches Rheuma-Forschungszentrum Berlin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33838">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nucleosides</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33595"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/354">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_402"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The expression and function of these murine FcgammaR in CD11c+CD11b-B220+ plasmacytoid DCs (pDCs) was investigated. pDCs express mostly FcgammaRIIB while the expression of FcgammaRI and FcgammaRIII is only detected by RT-PCR at low but significant level. Moreover, the ITAM-containing intracellular chain associated to FcgammaRI and FcgammaRIII is strongly expressed in pDCs as detected by biochemical assay.</rdfs:comment>
    <rdfs:label>Murine FcgammaR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_35701">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ester</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/121">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/102"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have knowhow on ELISPOT analysis of long peptide vaccines.</rdfs:comment>
    <rdfs:label>Elispot analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/195">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/196"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Adriana Flores Langarica</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/27">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Vrije Universiteit Brussel is the offshoot of the French-speaking Université Libre de Bruxelles (ULB) that was founded in 1834 by a Brussels lawyer with Flemish origins, Pierre-Théodore Verhaegen. He wanted to establish a university that would be independent from the state and the church and where academic freedom would reign. 
Although some courses at the ULB's Faculty of Law were already being taught in Dutch in 1935, it was not until 1963 that almost all the faculties offered courses in Dutch. The Dutch-speaking university was finally split off from its French-speaking counterpart on 1 October 1969. 

With the act of 28 May 1970, the Vrije Universiteit Brussel and the Université Libre de Bruxelles officially became two separate legal, administrative and scientific entities.</rdfs:comment>
    <rdfs:label>Vrije Universiteit Brussel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_330">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous natural killer cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous NK T cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous NK T cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous NK cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous natural killer cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_334"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000063">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mM</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000051"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A unit of molarity which is equal to one thousandth of a molar or 10^[-3] M.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">millimolar</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/427">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was found that injection of (presumably agonistic) anti-CTLA-4 mAbs induced regulatory T cells.</rdfs:comment>
    <rdfs:label>Anti-CTLA-4 mAbs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_110369">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1150"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Planktothrix sp. FP1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oscillatoria Planktothrix FP1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cyanobacterium Oscillatoria Planktothrix FP1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/154">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fabiana Saccheri</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_674">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_737</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:subClassOf rdf:nodeID="A171"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Behavioral stimulus protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/100">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200674"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/398"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/36"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/401"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.obolibrary.org/obo/OBI_0000737"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/404"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/402"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label>Immuno-monitoring of CD8 T cell responses in melanoma patients vaccinated with peptides plus adjuvant, viral vectors, or peptide-pulsed DC</rdfs:label>
    <rdfs:comment>Using the MLPC/tetramer method described last year, we obtained data by pursuing the immunological monitoring of melanoma patients vaccinated with 4 peptides (MAGE-A3, gp100, NA17 and tyrosinase) presented by HLA-A2. We measured responses to these peptides injected with Montanide, but did not know whether the Montanide adjuvant was important for these T cell responses. Indeed, melanoma patients may mount spontaneous responses to these antigenic peptides. We therefore injected the same peptides without adjuvant, and no response was observed. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.

Tumor regressions have been observed in a small proportion of melanoma patients vaccinated with a MAGE-A3 peptide presented by HLA-A1, administered as peptide, ALVAC canarypox virus containing a MAGE-A3 minigene, or peptide-pulsed dendritic cells (DC). There was a correlation between tumor regression and detection of anti-MAGE-3.A1 CTL responses. These responses were monoclonal and often of a very low magnitude after vaccination with peptide or ALVAC, and usually polyclonal and of a higher magnitude after DC vaccination. These results suggested that, at least in some patients, surprisingly few anti-MAGE-3.A1 T cells could initiate a tumor regression process. 

To understand the role of these T cells, we performed a functional analysis of anti-MAGE-3.A1 CTL clones derived from vaccinated patients who displayed tumor regression. The functional avidities of these CTL clones, evaluated in lysis assays, were surprisingly low, suggesting that high avidity was not part of the putative capability of these CTL to trigger tumor rejection. Most anti-MAGE-3.A1 CTL clones obtained after DC vaccination, but not after peptide or ALVAC vaccination, produced IL-10. Transcript profiling confirmed this result and indicated that about 20 genes, including CD40L, prostaglandin D2 synthase, granzyme K and granzyme H, were differentially expressed between the anti-MAGE-3.A1 CTL clones derived from patients vaccinated with peptide-ALVAC or with peptide-pulsed DC. These results indicate that the modality of vaccination with a tumor-specific antigen influences the differentiation pathway of the anti-vaccine CD8 T cells, which may have an impact on their capacity to trigger a tumor rejection response.

This data is extremely relevant for the design and performance of the immunomonitoring of the new clinical trial WP19.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_187"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/35"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/400"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/38"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/46"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/80"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/GO#GO_0004278"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#gp100_Antigen"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/78"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/399"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_44088"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/37"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/405"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/403"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200723"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#NA17-A_Antigen"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/79"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/77"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7195">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lung</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lungs</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/291">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Tracy Tompkins</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/86">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/375"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_757"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Patients will undergo surgical removal of a metastatic lesion.</rdfs:comment>
    <rdfs:label>Surgical removal of metastatic lesion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400080">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000010">
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/IAO_0000064"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000377">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">signal transducer and activator of transcription 3</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A173"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">STAT 3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">STAT3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">STAT-3 transcription factor</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/75">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mariagrazia Uguccioni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedDocument">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#has_document"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/469">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/10"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/9"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The tumor antigen derived peptide pulsed monocyte-derived DC were diluted in medium containing 20 ng/mL TNF-?, plus IL-4 and GM-CSF.</rdfs:comment>
    <rdfs:label>Diluted DC (pulsed with tumor antigen derived peptides)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/198">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>From April 2009: scientist at MorphoSys AG.</rdfs:comment>
    <rdfs:label>Andrea Hartl</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/113">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/77"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ben Fancke</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700564">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PROTEIN-TYROSINE KINASE SYK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tyrosine-protein kinase SYK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SYK</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">KSYK_HUMAN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">spleen tyrosine kinase</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">syk kinase</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/355">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The expression and function of murine FcgammaR in these CD11c+CD11b-B220+ plasmacytoid DCs was investigated. </rdfs:comment>
    <rdfs:label>CD11c+CD11b-B220+ plasmacytoid DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/146">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/54"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/60"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/59"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients undergo leukapheresis and later intradermal administration of the produced vaccine (V administrations of autologous dendritic cells generated from adherent peripheral blood monocytes and subject to quality controls - with eventual additional ones depending on clinical outcome).</rdfs:comment>
    <rdfs:label>HLA-A1 positive patients with stage III/IV melanoma </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000498">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A178">
    <owl:unionOf rdf:nodeID="A179"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/122">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_E.05.478.594.410.320.200"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have expertise in western blotting. Western blot was used, for instance, for the demonstration of protein kinase R phosphorylation on transduction. </rdfs:comment>
    <rdfs:label>Western blot</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_126794">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vaccinia virus Ankara</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vaccinia virus strain Ankara</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/426">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Natural regulatory T cells (CD4+ CD25+) were depleted by injection of anti-CD25 mAbs, whereas regulatory T cells were induced by injection of (presumably agonistic) anti-CTLA-4 mAbs. </rdfs:comment>
    <rdfs:label>anti-CD25 mAbs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/26">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The University of Zurich – the largest university and the broadest range of courses in Switzerland

The University of Zurich was founded in 1833, though its origins stretch back as far as 1525 and the days of protestant reformer Ulrich Zwingli. Today the University enjoys international renown as a place of education and research. Two thousand lecturers in 140 special institutes provide the broadest range of subjects and courses available from any Swiss seat of higher education. With 24,000 students and 1,900 graduates every year, Zurich is also Switzerland’s largest university. The University provides academic services, works with the private sector and considers itself part of a national and global network for the acquisition and dissemination of knowledge.

Zurich’s international reputation is based on groundbreaking research, particularly in molecular biology, brain research and anthropology, and on the work of the University Hospital and Veterinary Hospital.

The University’s researchers, lecturers and students benefit from the infrastructure that Zurich provides as a center of teaching and research. Apart from its own institutions, the University offers its members access to archive collections, libraries and the facilities of the Federal Institute of Technology (ETH), as well as to the city’s private institutions. Nine museums and collections, covering subjects from anthropology to zoology, constitute yet another valuable academic resource.</rdfs:comment>
    <rdfs:label>University of Zürich</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000062">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A unit of concentration which expresses a concentration of 1 mole of solute per liter of solution (mol/L).</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">molar</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000051"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/356">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Anti-tumor responses were followed in melanoma patients that were vaccinated with autologous DCs loaded with a combination of tumor Ag peptides.</rdfs:comment>
    <rdfs:label>Melanoma patients that were vaccinated with autologous DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/153">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elisabetta Todisco</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_195">
    <rdfs:label>TIR-domain-containing adapter-inducing interferon beta</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TIR-domain-containing adapter-inducing interferon beta</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TRIF</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TIR-domain-containing adapter-inducing interferon beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TIR-domain-containing adapter-inducing interferon beta (TRIF)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TICAM1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/85">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/318"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/320"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/319"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/321"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_746"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Transfection of CD40L-encoding RNA along with the tumor RNA payload.</rdfs:comment>
    <rdfs:label>Transfection </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7196">
    <rdfs:label>human spleen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/101">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdfs:comment>We are collecting immunological data from a melanoma patient, aiming to identify the antigen(s) recognized by T cells from this patient that experienced an outstanding response to immunotherapy. This patient received several adoptive T cell transfers and regressed from stage IV melanoma to a disease free state and has remained tumor free for several years. In a collaboration with Dr. O. Winqvist, Karolinska Institute, we attempted to improve the adoptive transfer protocol by stimulating T cells with monocyte derived DC pulsed with tumor lysate, instead of simply adding tumor lysate into PBMC cultures. T cells raised exhibited some tumor reactivity and outgrowth of a distinct T cell population could be observed. We intented to identify the target antigen recognized by the tumor reactive T cells in order to further improve T cell stimulations and to possibly complement treatment with DC vaccination. 

We then evaluated the capacity of autologous DC and HEK293 cells transfected with relevant HLA alleles to function as T cell targets in Elispot assays upon transfection with tumor antigen encoding plasmids. Due to strong background from the autologous DC we decided that HEK293 transfected with one HLA-allele at a time plus simultaneously transfected with up to 5 tumor antiges would be optimal to screen for antigen specificity in the patients T cells. However, during a second T cell culture to expand large numbers of T cells for this screening procedure a drastic expansion of regulatory T cells was observed. Since no sufficient number of T cells could be expanded the screening was not performed. The reason for the altered phenotype/function of the expanded T cells from the second bleeding of this patient is currently not known.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/535"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdfs:label>Identification of antigens recognised by T cells from melanoma patients responding to immunotherapy</rdfs:label>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/110"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/81"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/123"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/45"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/537"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/251"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/30"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/536"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/290">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/195"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/12"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/7"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Simon Milling</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/76">
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/211"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/208"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/129"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/71"/>
    <rdfs:label>Antonio Lanzavecchia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/130"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/207"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/114">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Benny Chain</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/49">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/27"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>The company has now successfully developed a technique for the large-scale generation of DC in serum-free medium under GMP conditions, and are willing to share their know-how with Network Partners.</rdfs:comment>
    <rdfs:label>Technique for the large-scale generation of DC in serum-free medium under GMP conditions</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7647">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">spinal cord</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/468">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/9"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/8"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The cultured cells were subsequently pulsed with tumor antigen derived peptides (one per culture) at a concentration of 5 µg/mL in approximately 5 mL and at a cell density of 20 x 10e6/mL for 1 h.</rdfs:comment>
    <rdfs:label>DC (pulsed with tumor antigen derived peptides)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000404">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17823">
    <rdfs:label>calcitriol</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">calcitriol</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">1alpha25(OH)2D3</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_35341"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/197">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/92"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/196"/>
    <rdfs:label>An van Nuffel</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/317"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/93"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/62"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/71"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/201"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/195"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/198"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/122"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/64"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/4"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/236"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/197"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/121"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/258"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/63"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A82">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000499">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/123">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/83"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_458"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A Zeiss LSM 510 confocal microscope is available for use in the lab.</rdfs:comment>
    <rdfs:label>Zeiss confocal microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UBERON#UBERON_0000055">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A tubular structure that contains, conveys body fluid, suchas blood or lymph.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vessel</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A179">
    <rdf:rest rdf:nodeID="A180"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_490"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/145">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/58"/>
    <rdfs:comment>These dendritic cells were generated from adherent peripheral blood monocytes, subject to quality controls, and subsequently used for intradermal administration in HLA-A1 and HLA-A2 positive patients with stage III/IV melanoma (V administrations with eventual additional ones depending on clinical outcome).</rdfs:comment>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/58"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:label>autologous DCs </rdfs:label>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/167"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/59"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/57"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/200">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/81"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <rdfs:label>Prophylactic immunization with DCs loaded with Ag-IgG immune complexes leads to efficient induction of tumor protection in mice</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0002094"/>
    <rdfs:comment>Data has been obtained on DCs loaded with Ag-IgG immune complexes (ICs) as a means of prophylactic immunization in mice.

Therapeutic vaccinations strongly delay tumor growth or even prevent tumors from growing out. By depleting CD4+ and CD8+ cell populations prior to tumor challenge, CD8+ cells were identified as the main effector cells involved. Importantly, DCs pre-loaded in vitro with ICs are at least 1000-fold more potent than ICs injected directly into mice or DCs loaded with the same amount of non-complexed protein. FcgammaRs on DCs were required for efficient priming of Ag-specific CD8+ cells in vivo and induction of tumor protection. These findings show that targeting ICs via the activating FcgammaRs to DCs in vitro is superior to direct IC vaccination to induce protective tumor immunity in vivo. </rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_402"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/243">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data from a phase I long peptide vaccination trial with p53 peptides in Montanide adjuvant in patients with colorectal cancer or ovarium cancer. This vaccine was well tolerated and robust p53-specific T cell responses were induced. 

In the future we intend to combine the p53 vaccine with other cancer therapies such as chemotherapy.  </rdfs:comment>
    <rdfs:label>Phase I long peptide vaccination trial in colorectal or ovarium cancer patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/84">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/317"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/316"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/315"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/314"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/318"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_745"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>This step of the new maturation protocol involves maturation with TNF-alpha, IFN-gamma, and PGE2. </rdfs:comment>
    <rdfs:label>DC maturation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/96">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_170"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Patients with resected HPV16-positive cervical cancer were vaccinated with an overlapping set of long peptides comprising the sequences of the HPV16 E6 and E7 oncoproteins emulsified in Montanide ISA-51.</rdfs:comment>
    <rdfs:label>HPV16 E6 oncoproteins </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/463">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/3"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/5"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The leukapheresis product is taken from a HLA-A2 positive healthy donor and is subsequently separated into monocytes and lymphocytes.</rdfs:comment>
    <rdfs:label>Leukapheresis product of a HLA-A2 positive healthy donor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasPlatformType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type platform.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">platform type</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DCTHERADIR dataset has at least one DCTHERADIR platform. SHORTCUT.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/425">
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/14"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The capacity of splenic DC, pulsed in vitro with protein antigens or peptides, to induce immunity was monitored after transfer into syngeneic animals. To improve existing strategies, the amplitude and polarisation of T cell responses was monitored in the presence or absence of regulatory T cells.</rdfs:comment>
    <rdfs:label>Splenic DC, pulsed in vitro with protein antigens or peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/357">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Antigen-specific CD4+ T cells were followed in these immunized individuals using generated peptide-MHC class II multimers.</rdfs:comment>
    <rdfs:label>Immunized individuals</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000738">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">white blood cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">leucocytes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">leucocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immune cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">immune cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">white blood cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">leukocytes</dcr:hasExactSynonym>
    <rdfs:label>leukocyte</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/106">
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0008996"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7195"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/137"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7197"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11757"/>
    <rdfs:label>Balb-neuT mice model to study new strategies of DC-based and other therapies for advanced breast cancer</rdfs:label>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/1"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_57983"/>
    <rdfs:comment>Data has been obtained from a Balb-neuT mice model to study new strategies for advanced breast cancer. A colony has been established of transgenic Balb-neuT mice (founders provided by Forni, Torino IT) that over-express the rat HER-2/neu oncogene under the MMTV promoter. These mice develop mammary carcinomas with later lung and liver metastases; the course of disease and the type of tumours that develop closely recapitulate many features of human breast cancer. A collaborative study has commenced between Austyn and Cerundolo to use this model to study new strategies of DC-based and other therapies for advanced breast cancer and for which funding has now been secured for 3y from MRC UK. [A postdoctoral scientist was recruited for this Project from an Associated Partner – Josien, Nantes FR – via the DC-THERA website]</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A166">
    <owl:unionOf rdf:nodeID="A181"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/540">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_649"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tissue biopsies of the last vaccination site and of the VIN lesion prior to the first vaccination and 3 months after the last vaccination were analysed for the presence of HPV16-specific T cells.

The IFN?-ELISPOT analysis and proliferation with its accompanying cytokine production revealed a strong and broad vaccine-induced T cell response. The strength of the immune response (defined as breath and magnitude of the response) was significantly higher in the patients with a complete remission (CR) than in the patients with no changes (NC) in the lesion size. Phenotypical anlaysis revealed a strong induction of CD4+ T-cells specifically against HPV16 E6 and E7, whereas CD8+ T cells were found merely against HPV16 E6 and to a less broad array of epitopes within each patient. This analysis was done after one in vitro restimulation, however, by directly ex vivo flow cytometric analysis hardly any CD8+ T cell response could be detected. The T cell cultures obtained from the biopsies taken of the last vaccination site were found to be HPV16 peptides specific in 3/5 tested NR patients and in 4/5 tested CR. However, recognition of the recombinant HPV16 E6 and/or E7 protein was observed in 1/5 cultures from NR patients and 4/5 cultures of the CR patients, suggesting the differences in vaccine-induced T-cell reactivity. Tissue biopsies of the VIN lesion before and after vaccination showed only in one patient a HPV16-specific T-cell response, which was against HPV16 E6 and merely of the type 2 cytokine producing T cells. Notably, no T-cell cultures could be obtained from VIN biopsies taken from the CR patients. In conclusion, the HPV16 E6 and E7 synthetic long peptides vaccine is highly immunogenic, in that it increases the number and activity of HPV16-specific CD4+ and CD8+ T-cells to a broad array of epitopes in all patients. The expansion of CD4+ and CD8+ tumor-specific T-cells, both considered to be important in the anti-tumor response indicates the immunotherapeutic potential of this vaccine. Addition of a strong toll-like receptor ligand might increase the CD8 response in frequency and to a broader set of epitopes.</rdfs:comment>
    <rdfs:label>Tissue biopsies of last vaccination site 3 months after last vaccination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/124">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_L.01.470.750.750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have compiled and evaluated all published information on clinical trials with DC worldwide. Questionnaires to all authors concerning follow-up of their published patients are about to be sent out. This database will be made available for all DC-THERA participants and will serve as a basis for a critical report on the role of DC based immunotherapy in cancer 2009. </rdfs:comment>
    <rdfs:label>Database on clinical trials with DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_263">
    <rdfs:label>CpG</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CpG</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CG</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36976"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_632">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inhibitor molecule</rdfs:label>
    <owl:equivalentClass rdf:nodeID="A182"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">molecules that bind to other molecules and decrease their activity.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/20">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The LUMC is one of several academical medical centres in the Netherlands. The core tasks of the LUMC are: 

Patient care: routine care, high-level clinical care, and in particular, high-level reference care.
Research: both fundamental and bedside, healthcare-oriented research. 
Education for the faculties of Medicine and Biomedical Sciences. 
Specialist medical training. 
Additional training, both post-doctoral and post-vocational. 

The LUMC comprises the Leiden University Hospital and the Faculty of Medicine of Leiden University. The LUMC, which employs approximately 7000 people, is located close to Leiden central station. 

The mission of the Leiden University Medical Center is to perform its core tasks at the highest possible level. Consequently, the LUMC aims to provide the best possible quality regarding both medical technology and patient care and treatment. The keywords are openness and information. 

With regard to research, the LUMC intends to maintain its position among the international elite with its centres of excellence and research focuses. The interaction of fundamental research and patient care forms the basis of our management policy. 

This means that the range of top clinical functions and reference tasks performed by the LUMC, many of them national or international, are built on a strong scientific foundation. In addition to its supraregional and national functions, the LUMC offers quality and quantity across the entire range of medical science. This is a must if the LUMC is to fulfil its public function as an innovator of healthcare and the healthcare system as well as its scientific role as a tester of new and existing medical technology. 

It goes without saying that the same applies to student teaching and specialist training. Clearly, there are some tasks the LUMC cannot, or does not wish to, perform on its own, so close collaboration with qualified general hospitals is required. Consequently, the LUMC continues to create and maintain networking structures in the fields mentioned earlier. In doing so, the 'appropriate use' of healthcare facilities remains a sine qua non. 

Through its teaching facilities, the LUMC will be turning out patient-centred doctors and scientists with a critical scientific attitude and the right dose of scientific curiosity. The gratification offered by academic pursuits is an essential ingredient. Further internationalisation of education is high on the list of priorities. 

Based on the principle of 'life-long learning', the LUMC's Boerhaave Committee plays a pivotal role of increasing importance as the largest post-academic medical training organisation in the Netherlands. 

The LUMC intends to even further consolidate this position, and to elevate the Leiden post-vocational training courses to the same level. Commitment to the team effort by each and every person working at the Leiden University Medical Center is a prerequisite for the realisation of these ambitions.</rdfs:comment>
    <rdfs:label>Leids Universitair Medisch Centrum</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A91">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/140">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/6"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/5"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Cells are separated into lymphocytes (and monocytes) by elutriation in a closed system (Elutra). 
[The fraction richest in lymphocytes contained &gt; 90% lymphocytes and viability was &gt; 95%.]</rdfs:comment>
    <rdfs:label>Lymphocytes separated from cell culture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/IAO_0000100">
    <rdfs:label>data set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/320">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ruth Ferstl</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/97">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_171"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Patients with resected HPV16-positive cervical cancer were vaccinated with an overlapping set of long peptides comprising the sequences of the HPV16 E6 and E7 oncoproteins emulsified in Montanide ISA-51.</rdfs:comment>
    <rdfs:label>HPV16 E7 oncoproteins </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/248">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/309"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/445"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/150"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/308"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/175"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/10"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/9"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ricardo Rajsbaum</rdfs:label>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/52"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/102"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/201">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data addressing the effectiveness of TLR ligand-long peptide conjugates in vivo by either direct vaccination or ex vivo DC loading prior to vaccination. Both approaches show similar effectiveness in CTL priming suggesting that TLRL-peptide conjugates efficiently target DC in vivo.</rdfs:comment>
    <rdfs:label>Effectiveness of TLR ligand-long peptide conjugates in vivo</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu">
    <protege:defaultLanguage rdf:datatype="http://www.w3.org/2001/XMLSchema#string">en</protege:defaultLanguage>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ontology created in the context of DC-THERA, a European Network of Excellence on dendritic cell research on new therapies against cancer and infectious disease. The aim of this ontology was to back a web portal, the DC-THERA Directory, that was to serve as a central point to collect information on research expertise/efforts/results in the network and thus a means of collaboration and sustainability.</dc:description>
    <owl:imports rdf:resource="http://dc-research.eu/classannotations"/>
    <owl:imports rdf:resource="http://dc-research.eu/shortforms"/>
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/"/>
    <owl:imports rdf:resource="http://purl.org/obo/owl/dendritic_cell"/>
    <dc:creator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel / Leaf Bioscience s.r.l.</dc:creator>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Ontology"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700879">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A150"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IRF3, human</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon regulatory factor 3 (human)</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/244">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/76"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>(This trial is expected for 2009 and data will become available.)</rdfs:comment>
    <rdfs:label>Clinical trial in pancreatic carcinoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/107">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_15551"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/80"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/26"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_349"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/79"/>
    <rdfs:label>Proteomic analysis/profiling of human dendritic cells</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700009"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/82"/>
    <rdfs:comment>A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established by using high accuracy, high sensitivity protein identification technology. We have identified 2794 proteins in DCs by liquid chromatography tandem mass spectrometry. Prior to MS analysis, DC were lysed and divided into a soluble fraction containing cytosolic proteins and into an insoluble fraction enriched for membrane containing proteins.  Highly complex protein mixtures of DC cellular fractions were separated on 1 D SDS-PAGE into 20 gel slices (fractions), followed by in-gel digestion with trypsin. Purified tryptic peptides were analysed in triplicate by LC-MS/MS using a linear ion trap/ Fourier Transform (LTQ-FT) hybrid mass spectrometer. 

Iterative calibration algorithms were used to achieve a final, absolute mass accuracy of better than 10 parts per million (p.p.m.) for all peptide ions. These high-accuracy spectra were searched against a human protein database, using MASCOT probability-based scoring in which the fragment ions are matched against the calculated fragments of all tryptic peptides from the human sequences. Additional constraints were set by searches against a reversed human database to minimize false positive protein identifications. These criteria resulted in a list of 2794 unique proteins that were identified with high confidence, comprising of 2623 proteins detected in immature DCs, 1896 proteins in mature DCs, and 1725 proteins in both cell types. Differences were quantified by the exponentially modified Protein Abundance Index (emPAI) method, a label free spectral counting procedure for determining relative protein amounts of LC-MS/MS data.

Protein expression profiles were compared with gene expression profiles generated by microarray technology (M2.2). In total, we could map 96 percent of the detected proteins to expressed genes for the immature DCs and 90 percent for the mature DCs. A Pearson correlation analysis revealed for both cell types, good correlations, respectively 0.57 and 0.50. These correlations are in good agreement with similar correlation studies, where correlation coefficients approximately range from 0.2-0.7 for large scale datasets.  These studies include quantitative highly accurate proteomic data generated by chemically-or metabolically-labeled approaches.  Therefore, we conclude that our data contains sufficient quantitative information to define subsets of up- and down-regulated proteins for functional analysis. We find 202 proteins upregulated by more than 2 fold in mature DCs and 463 proteins upregulated in immature DCs. 

Functional annotation by gene ontology classification and pathway analysis by several bioinformatics approaches have been performed. Preliminary results obtained from querying DAVID (http://david.abcc.ncifcrf.gov/) and Ontologizer (http://www.charite.de/ch/medgen/ontologizer/) show statistically significant enrichment for immunological-relevant signaling pathways and immunology-related GO terms of the upregulated proteins in mature DCs.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/81"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/28"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/82"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704821"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/27"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_66836"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/358">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/38"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_279"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This shRNA was cloned into the pLVTHM lentiviral vector (obtained from the repository Addgene). This vector has been already successfully used to generate self-inactivating lentiviral vectors previously tested in DCs for transfection efficiency and absence of effects on their phenotype. </rdfs:comment>
    <rdfs:label>shRNA specific for IRF4 and STAT3</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/424">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/62"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Down-regulation of CD83 expression on human DC through RNA interference (RNAi) results in a less potent induction of allogeneic T cell proliferation, reduced IFN-gamma secretion by established T cells and decreased capacity in the priming of functional tumor antigen-specific CD8+ T lymphocytes. In addition, CD83 mRNA-electroporated DC are stronger T cell stimulators. However, CD83 overexpression on Melan-A/MART-1-specific tumor-infiltrating lymphocytes (TIL) circumvents the need for CD83 expression on DC. Co-culture of immature DC with TIL or K562 cells overexpressing CD83 results in the production of enhanced levels of pro-inflammatory cytokines, whereas this production is less pronounced or even absent in co-cultures with non-modified TIL or K562 cells. </rdfs:comment>
    <rdfs:label>CD83 mRNA-electroporated DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/126">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/256"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The method is about transfecting CD4(+) and CD8(+) T cells with mRNA encoding recombinant immunoreceptors for use in the adoptive immunotherapy of cancer.
CD4(+) and CD8(+) T cells were efficiently transfected with immunoreceptors specific for ErbB2 and CEA. The immunoreceptor expression was transient with half-maximal expression at day 2 and no detectable immunoreceptor expression at day 9 after electroporation. 

Opposed to  standard procedures using retroviral gene transduction to constitutively express immunoreceptors in T cells, transient immunoreceptor expression by RNA transfection should should minimize the risk of persistence of potential autoaggression.</rdfs:comment>
    <rdfs:label>Transient immunoreceptor expression by RNA transfection</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A181">
    <rdf:rest rdf:nodeID="A183"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000590">
    <rdfs:label>Interleukin-12 cytokine</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-12 cytokine</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL12</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin-12</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 12</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-12</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 12</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0003700">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transcription factor activity function</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The function of binding to a specific DNA sequence in order to modulate transcription. The transcription factor may or may not also interact selectively with a protein or macromolecular complex.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0003674"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A183">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_631">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">(4-(3-chlorophenyl)pyrimidin-2-yl)-(4-trifluoromethyl-phenyl)amine</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A148"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">VAF347</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A182">
    <owl:intersectionOf rdf:nodeID="A139"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/125">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Using MAGE-A3 as a model antigen we established a functional read-out system by transfection of CD4 T cells with RNA encoding T cell receptors recognizing MHC DP4 restricted MAGE-A3 epitopes.</rdfs:comment>
    <rdfs:label>Read-out system for antigen presentation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/43">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/38"/>
    <rdfs:comment>We performed experiments to set up the optimal conditions for both transient transfection of synthetic siRNAs and lentiviral transduction of shRNAs into DC. 

To optimize transfection efficiency, while minimizing toxicity, non targeting FITC-conjugated siRNA were transfected in two different experimental settings: 

a) fresh monocytes and 
b) immature DCs (iDCs) obtained from monocytes in the presence of GM-CSF/IL-4. 

In both experimental settings a considerably high transfection efficiency (up to 75%) was achieved in the absence of significant cell death. Moreover, the percentage of siRNA-FITC+ cells did not decline with time (up to 5 days post-transfection) suggesting high siRNA stability inside the DCs, in agreement with previously published data. 

To optimize lentiviral delivery, experiments using a self-inactivating lentiviral vector (LV) expressing enhanced GFP (eGFP) from an internal CMV promoter were performed. DCs cells were transduced at different multiplicity of infection. FACS analysis indicated a good transfection efficiency (up to 80%). Evaluation of the effect of lentiviral infection on DC phenotype/activation, revealed that LV infection per se neither modified DC phenotype/activation state nor significantly interfered with their capacity to mature upon appropriate stimulation. 

These approaches are currently being used to silence the transcription factor IRF4, and finely dissect its recently discovered function during human myeloid DC differentiation. 

They will also be applied to the selective silencing of ILT3 (see below), based on the working hypothesis that disrupting molecular pathways leading to tolerance may result in the generation of a DC more successful in stimulating the proper immune response against tumours. </rdfs:comment>
    <rdfs:label>Setting up the optimal conditions for both transient transfection of synthetic siRNAs and lentiviral transduction of shRNAs into DC</rdfs:label>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700880"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_279"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/94"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0610"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/199">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Axel Defays</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0002217">
    <rdfs:label>Supernatant</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Supernatant</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/74">
    <rdfs:label>Federica Sallusto</rdfs:label>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/167"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/211"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/207"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/71"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/131"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/314"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/72"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/214"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/316"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/202">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <rdfs:label>Inadequate nature of the antitumor CTL response results from presentation of tumor-derived Ag by nonactivated CD11c(+) APC</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001013"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10535"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdfs:comment>We have data available on the inadequate nature of the antitumor CTL response, generated in a syngeneic mouse tumor model expressing an Ag derived from the early region 1A of human adenovirus type 5.

We demonstrated using this syngeneic mouse tumor model that the inadequate nature of the antitumor CTL response is not due to direct Ag presentation by the tumor cells, but results from presentation of tumor-derived Ag by nonactivated CD11c(+) APC. Although this event results in division of naive CTL in tumor draining lymph nodes, it does not establish a productive immune response. Treatment of tumor-bearing mice with dendritic cell-stimulating agonistic anti-CD40 mAb resulted in systemic efflux of CTL with robust effector function capable to eradicate established tumors. For efficacy of anti-CD40 treatment, CD40 ligation of host APC is required because adoptive transfer of CD40-proficient tumor-specific TCR transgenic CTL into CD40-deficient tumor-bearing mice did not lead to productive antitumor immunity after CD40 triggering in vivo. CpG and detoxified LPS (MPL) acted similarly as agonistic anti-CD40 mAb with respect to CD8(+) CTL efflux and tumor eradication. Together these results indicate that dendritic cells, depending on their activation state, orchestrate the outcome of CTL-mediated immunity against tumors, leading either to an ineffective immune response or potent antitumor immunity.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_264">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Peptidylglycine alpha-amidating monooxygenase 3 Cys</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pam3Cys</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Peptidylglycine alpha-amidating monooxygenase 3 Cys</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/249">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Andrej Mantei</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/1">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/106"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/137"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This colony of transgenic mice that over-express the rat HER-2/neu oncogene under the MMTV promoter were used to study new strategies of DC-based and other therapies for advanced breast cancer. Founders were provided by Forni, Torino IT.</rdfs:comment>
    <rdfs:label>Balb-neuT mouse</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/150">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Alexandros Theodoridis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7199">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intestines</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bowels</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">bowel</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intestine</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/465">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocytes were transferred into culture bags by sterile welding and cultured for 5 days in serum free medium (CellGro, Cell Genix) in the presence of 100 ng/mL GM-CSF (Leukine, Berlex) and 20 ng/mL IL-4 (Cell Genix).</rdfs:comment>
    <rdfs:label>IL-4 (Cell Genix)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/241">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/29"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>The study protocol that will be used for this trial has been reviewed by the local ethical committee and is now ready to be submitted to Läkemedelsverket, the Swedish regulatory authority for clinical trials.

Upon approval by Swedish authorities we plan to include, treat and evaluate 10 patients during a period of one to two years. It will probably start in 2009 and data will become available.</rdfs:comment>
    <rdfs:label>Phase I clinical trial in patients with advanced (stage III or IV) melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/104">
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/335"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_345"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Knowledge and gene expression data were gained on differentiation patterns of T cells.</rdfs:comment>
    <rdfs:label>Effector vs. memory T cell responses</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/542">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>There are lentiviral vectors available in the lab.</rdfs:comment>
    <rdfs:label>Lentiviral vectors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/127">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/307"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000010"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>DC-PathEdit  is a software based on PathVisio (http://www.pathvisio.org) created  for the graphical representation of the pathways and for the establishment of annotations and other properties.
It is used as an intermediate step towards the creation of a complete data model of the DC-ATLAS pathways, as it can represent them graphically and also annotate them using a controlled vocabulary.</rdfs:comment>
    <rdfs:label>DC-PathEdit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasCellType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type "cell".</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A165">
    <rdf:rest rdf:nodeID="A184"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/423">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/40"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Vectors were engineered to express distinct chemokines at the local skin site of mice. In particular, attention has been focussed on the recruitment of distinct subsets of DC to skin.</rdfs:comment>
    <rdfs:label>Vectors engineered to express distinct chemokines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/359">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Commercially available siRNA Smart Pool from Dharmacon targeted against the STAT3 transcription factor have been successfully transfected in these human MDDCs.</rdfs:comment>
    <rdfs:label>Human MDDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_630">
    <rdfs:subClassOf rdf:nodeID="A185"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A145"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Decoy receptor 3</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/142">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>After using frozen MoDC for tumor peptide specific stimulation of autologous T lymphocytes at a ratio of 1 DC per 10 T cells, co-cultures led to antigen specific, IFN-? secreting T cells (1 restimulation at a DC:T cell ratio of 1:20).</rdfs:comment>
    <rdfs:label>antigen specific, IFN-? secreting T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0014166">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rec. Prion-protein</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PRIP</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PRP</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A186">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/22">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The name "San Raffaele" originates from the Hebrew word Raf-el, which means "God’s medicine" or "God heals". The San Raffaele hospital is a private Scientific Institute, belonging to the San Raffaele del Monte Tabor Foundation, recognised by the Italian Ministry of Health as a Scientific Institute carrying out biomedical research and clinical activities of relevant national interest (IRCCS). According to the inspiring principles of its founding Organisation, the mission of the San Raffaele is to cure and assist diseased individuals, following the Gospel proposition: "Go, teach, heal". Such a mission is accomplished by focusing every aspect of the Institute’s activities on Man, viewed as an multifaceted entity endowed with inseparable biological, psychological and spiritual elements.

San Raffaele Institute is relentlessly pursuing its three interrelated lines of clinics, research and education since 1971 when it was established and represented one of the first examples of a fully independent private hospital in Italy. Shortly after its foundation San Raffaele was granted the status of IRCCS (Research Hospital), which favoured its development as a site for clinical research, originally specialized in diabetes and metabolic disorders. 

In 1992 San Raffaele expanded further with the inauguration of DIBIT, a building dedicated to basic science, with a research space of about 12,000 square meters where at present 250 people are employed in basic, translational and clinical research, including scientists, technicians and administrative personnel, along with additional 300 fellows, consultants, trainees and graduate students. DIBIT is part of the largest biomedical science park in Italy, which includes San Raffaele Hospital with more than 1300 beds, Science Park Raf, created to support the Foundation’s development objectives, and the University Vita-Salute San Raffaele.  

The University Vita-Salute San Raffaele was established in 1996 and now hosts the Faculties of Medicine, of Psychology and of Philosophy. Further, the teaching activities include, besides a whole range of Schools of Specialization in different medical branches, international Ph.D. programs in Cellular and Molecular Biology and in Molecular Medicine. 

Within 2007, the DIBIT-2 project will expand almost three-fold the floor space devoted to research and will substantially increase and empower research in the different fields where San Raffaele has become highly renowned. Considering the interactions that DIBIT entails with San Raffaele Hospital, Science Park Raf and the University it is highly plausible to believe that in turn this expansion will allow to improve logistic and organization, to rationalize clinical activity, to catalyse industrial attention and to attract the best students.

Much effort and many resources have been invested in basic, preclinical and clinical research. Our scientific production continues to show quite an impressive progress in terms of both number of publications and overall quality. In 2006, 678 scientific papers were published, with a total impact factor of 3400. These figures confirm the Institute’s leading position in Italy, strongly support the ability to attract support from public (Ministry of Health, Superior Institute of Health, Ministry of University and Research, European Community, NIH and, for a small amount, CNR) and from private sources as well including charity foundations (mainly Telethon, the Italian Association for Cancer Research and Bank Foundations) and are the basis for the solid international reputation acquired over the years. Telethon is funding two research centers at San Raffaele: the San Raffaele-Telethon Institute for Gene Therapy of Genetic Disease (HSR-TIGET) which is pioneering the clinical application of gene transfer technology and the Stem Cell Research Institute (SCRI), which studies the biology and the potential clinical applications of stem cells, a field in which San Raffaele Institute is a world leader.

In the last few years the explosive development and diversification of biomedical technologies, by allowing impressive achievements such as the complete sequencing of the human genome, have revolutionized our approach to medical problems and radically modified the scientific scenario thereby opening the doors to a new type of medicine: “molecular medicine”. In the near future researchers’ efforts will be dedicated to the elucidation of the mechanisms of regulation and expression of different genes and the definition of the functions of their products, to the development of new diagnostic tools able to allow early and presymptomatic diagnosis and to the design of more appropriate, biologically-based and possibly individually-tailored therapeutic approaches. 

San Raffaele Scientific Institute has championed from the very beginning this new type of medicine, whereby basic researchers, clinical investigators and physicians operate together to translate basic research into medical practice, which means to develop molecular endpoints in clinical material and use them to develop pilot studies or clinical trials with the goal of providing both acceleration of cure and optimisation of care. In 2001, San Raffaele Institute was acknowledged, by the Health Minister, as the IRCCS for Molecular Medicine. 

Thanks to the effort and enthusiasm of scientists, physicians, students and of all the people working at San Raffaele, our new molecular medicine center will provide, in the immediate future, either new or less intrusive diagnostic and therapeutical approaches, ready to use within the public Italian health system.</rdfs:comment>
    <rdfs:label>ISTITUTO SCIENTIFICO SAN RAFFAELE </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/46">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <rdfs:comment>In ongoing trials with peptide loaded DC (&gt; 60 pat.) routine immunomonitoring at frequent intervals showed a high correlation between different assays (IFN gamma ELISPOT; modified MLPC = combination of limiting dilution, multiple peptide restimulation, tetramer detection). 

Both assays demonstrated declining responses upon extension of vaccination intervals. We suggest: 
IFN gamma ELISPOT as basic assay (costs, workload) that can be frequently performed in every patient for routine monitoring
Modified MLPC (combination of limiting dilution, multiple peptide restimulation, Tetramer detection) allowing true assessment of precursor frequencies, may only be performed at leukapheresis time points in selected patients due to extensive requisitions (blood volume, costs, workload).</rdfs:comment>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:label>Recommendation of assays for trials with peptide loaded DC (&gt; 60 pat.) routine immunomonitoring at frequent intervals</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/79"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_487"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33839">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">macromolecule</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36357"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A macromolecule is a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/2">
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_126283"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This HSV vector expressing full length tyrosinase, gp100 and MART-1 was used to transduce dendritic cells from melanoma patients which were then to be used for vaccination.</rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001362">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lipid</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lipids</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0240">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fusion protein</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fusion proteins</dcr:hasExactSynonym>
    <owl:equivalentClass rdf:nodeID="A187"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/99">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We set an in vitro system to study ex-vivo responses able to detect fona fide in vivo primed CD4+ T cells. We investigated spontaneous CD4+ T cell responses to these antigens in normal donors and in patients with high-grade cervical lesions, pancreas adenocarcinoma and advanced melanoma. 

The antigens used were: 
i) the E6 and E7 proteins of human papilloma viruses, 
ii) the carcinoembryonic antigen (CEA) and 
iii) the tumour specific antigen MAGE-A3. </rdfs:comment>
    <rdfs:label>Normal donors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/71">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/205"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Oliver Schulz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/464">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocytes were transferred into culture bags by sterile welding and cultured for 5 days  in serum free medium (CellGro, Cell Genix) in the presence of 100 ng/mL GM-CSF (Leukine, Berlex) and 20 ng/mL IL-4 (Cell Genix). </rdfs:comment>
    <rdfs:label>GM-CSF (Leukine, Berlex) </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/242">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>In 2008 we have started a trial in patients with VIN3 disease (similar to the Phase I/II clinical trial  on the use of long peptides plus adjuvant for end-stage cervical cancer or VIN patients), in which we are comparing the efficacy of this vaccine with or without local application at the vaccination site of the TLR ligand imiquimod (Aldara). Results and data will become available.</rdfs:comment>
    <rdfs:label>Clinical trial in patients with VIN3 disease - comparison of efficacy of developed vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000389">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A184">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0702273">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TRAIL</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A188"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TNF-related apoptosis-inducing ligand</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/541">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_649"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tissue biopsies of the last vaccination site and of the VIN lesion prior to the first vaccination and 3 months after the last vaccination were analysed for the presence of HPV16-specific T cells.

The IFN?-ELISPOT analysis and proliferation with its accompanying cytokine production revealed a strong and broad vaccine-induced T cell response. The strength of the immune response (defined as breath and magnitude of the response) was significantly higher in the patients with a complete remission (CR) than in the patients with no changes (NC) in the lesion size. Phenotypical anlaysis revealed a strong induction of CD4+ T-cells specifically against HPV16 E6 and E7, whereas CD8+ T cells were found merely against HPV16 E6 and to a less broad array of epitopes within each patient. This analysis was done after one in vitro restimulation, however, by directly ex vivo flow cytometric analysis hardly any CD8+ T cell response could be detected. The T cell cultures obtained from the biopsies taken of the last vaccination site were found to be HPV16 peptides specific in 3/5 tested NR patients and in 4/5 tested CR. However, recognition of the recombinant HPV16 E6 and/or E7 protein was observed in 1/5 cultures from NR patients and 4/5 cultures of the CR patients, suggesting the differences in vaccine-induced T-cell reactivity. Tissue biopsies of the VIN lesion before and after vaccination showed only in one patient a HPV16-specific T-cell response, which was against HPV16 E6 and merely of the type 2 cytokine producing T cells. Notably, no T-cell cultures could be obtained from VIN biopsies taken from the CR patients. In conclusion, the HPV16 E6 and E7 synthetic long peptides vaccine is highly immunogenic, in that it increases the number and activity of HPV16-specific CD4+ and CD8+ T-cells to a broad array of epitopes in all patients. The expansion of CD4+ and CD8+ tumor-specific T-cells, both considered to be important in the anti-tumor response indicates the immunotherapeutic potential of this vaccine. Addition of a strong toll-like receptor ligand might increase the CD8 response in frequency and to a broader set of epitopes.</rdfs:comment>
    <rdfs:label>Tissue biopsies of VIN lesion prior to vaccination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/128">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/264"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_E.05.200.750.551.512"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Real time and immunohistochemistry analysis was performed in a study to evaluate whether iNOS can serve as a prognostic factor in stage III melanoma survival. The analysis showed that both iNOS and COX-2 alone significantly predicted OS. The BRAF/NRAS mutation status did not significantly differ between patient groups, although iNOS significantly correlated with BRAF mutation frequency. Furthermore, iNOS and COX-2 were significantly linked to a number of metastatic lymph nodes. However, iNOS maintained its statistical significance together with a number of lymph nodes in the multivariate analysis and predicted OS, whereas COX-2 did.</rdfs:comment>
    <rdfs:label>Real time and immunohistochemistry analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000272">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">protein phosphatase</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33595">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36357"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cyclic compound</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A83">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/141">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/8"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The peptides are used in the generation of monocyte-derived DC (pulsing of the cells at a concentration of 5 µg/mL in approximately 5 mL and at a cell density of 20 x 10e6/mL for 1 h.).</rdfs:comment>
    <rdfs:label>tumor antigen derived peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/21">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/8"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Centre d’Immunologie de Marseille-Luminy (CIML) created in 1976 is a Research Institute attached to the CNRS, Inserm and the Université de la Méditerranée.  	

This center of excellence is part of the Luminy science campus, that comprises fundamental research laboratories and biotech start-ups located between Marseilles and Cassis on the mediterranean coast.
Since 2004, the CIML has been relocated in one new and fully equipped 6.000 m2 building, the construction of which was possible thanks to the CNRS, Inserm, ARC, the city of Marseilles, the Bouches-du-Rhône County and the Provence-Alpes-Côte d’Azur Region.

230 people work at CIML. They are distributed among 20 research teams, administration, technical services and scientific common services including imaging, proteomics, transgenesis facilities and three scientific platforms: microscopy (PICsL platform), bio-optics (MOSAIC platform) and functional exploration of the mouse model (RIO-Marseille-Nice Genopole platform).

The main Immunology-based areas of research investigated by CIML teams are: ontogeny, lymphocyte and myeloid cell activation and differentiation, phagocytosis, host-pathogen interactions and cell death. 
Ciml 2000	 


The organization of the CIML is very unique in France. It is a federation of research teams, the size and the duration of which are limited. The Director is elected for a four-year term that can be renewed only once. Mutualisation of most of resources allows synergies and high-scale savings. Another specificity is that CIML has been successful in hiring researchers from foreign countries (eight group leaders are from abroad). In addition, long-term collaborative efforts have been established between CIML, universities, hospitals and private companies (four biotechs emerged from the work of CIML scientists: Immunotech, Innate Pharma, Ipsogen, Oz Bioscience).

The future of the Centre d’Immunologie is guaranteed by the presence of several modules of laboratories that have been kept empty for future new teams with scientific programs able to complement already on site studies and/or to bring forward more relationship with companies. CIML scientific activity is submitted to a strong evaluation system controlled by an external international Scientific Advisory Board working in close contact with the National Evaluation Committees from Inserm and CNRS.</rdfs:comment>
    <rdfs:label>Centre d'Immunology Marseille-Luminy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/3">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>My laboratory continued to analyse the ability of invariant NKT (iNKT) cells to assist priming of antigen specific T and B cell responses. We have demonstrated that activation of human DC by Toll like receptor ligands (TLR-L) modulates the lipid biosynthetic pathway, resulting in enhanced recognition of CD1d-associated lipids by iNKT cells; we have clarified the mechanisms by which CD1d-restricted lymphocytes translate T cell receptor (TCR) recognition of lipids with similar group heads into distinct biological responses; and we demonstrated that pathogen-derived signals to DC mediated via TLRs can be modulated by activated iNKT cells.</rdfs:comment>
    <rdfs:label>invariant NKT (iNKT) cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/204">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_215"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11623"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1637"/>
    <rdfs:comment>In our lab, we have gene expression data in T cells available in responses to LCMV-GP33 protein and listeria-Ova.

We studied TcR-Tg clones specific of each antigen (P14-GP33 specific, 0T-1-OVA specific), as well as endogenous polyclonal T cells, specific for the same antigens, identified by MHC pentamers loaded with specific peptides. In each individual T cell, we studied the expression of twenty different genes either mediating effector functions, or coding for different receptors involved in T cell differentiation and memory generation. We were surprised to observe that each type of infection induced peculiar expression of the effector molecules or receptors expressed by responding cells, thus generating unique divergent differentiation patterns.  Endogenous LCMV polyclonal T cells and P14 T cells showed the same differentiation patterns that were different from those of OT-1 T cells responding to Listeria-OVA. These results suggest that CD8 differentiation is dependent of the infectious context, rather than of the TCR specificity. 

Our present studies aim to confirm this notion.  For that purpose, we will challenge P14 LCMV-GP33 specific T cells with the Listeria-GP33, to identify if these cells now express a pattern of differentiation similar to OT-1 T cells responding to Listeria-OVA. Whatever the mechanisms, these results describe for the first time alternative pathways of CD8 differentiation, that have nothing in common with those of CD4 T cells, since divergent gene expression does not mimic at all Th1 and TH2 differentiation.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:label>Gene expression in T cells in responses to LCMV-GP33 protein and listeria-Ova</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/72">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/205"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/37"/>
    <rdfs:label>Caetano Reis e Sousa</rdfs:label>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/253"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/56"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/206"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/300"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/38"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/176"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/57"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/64"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/68"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/65"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/201"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/220"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/408"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/35"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/202"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/56"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/203"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/39"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/32"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/204"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/36"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/110">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Professor</rdfs:comment>
    <rdfs:label>Annika Scheynius</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606">
    <rdfs:label>Homo sapiens</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/205">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_369"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000377"/>
    <rdfs:label>DC-development from hematopoietic stem and progenitor cells in steady-state and in inflammatory conditions</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_307"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000232"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701867"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/74"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/76"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000050"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000094"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <rdfs:comment>We have data available on dendritic cell development from hematopoietic stem and progenitor cells in steady-state and in inflammatory conditions, and, in particular, gene-expression data of Lin–c-KitintFlt3+M-CSFR+ cells in mouse bone marrow. 

Lymphoid tissue plasmacytoid and conventional dendritic cells (DCs) are continuously regenerated from hematopoietic stem cells. The cytokine dependence and biology of plasmacytoid and conventional DCs suggest that regeneration might proceed through common DC-restricted developmental intermediates. By selecting for cytokine receptor expression relevant to DC development, we were able to identify highly cycling Lin–c-KitintFlt3+M-CSFR+ cells with a distinct gene-expression profile in mouse bone marrow that, on a clonal level in vitro and as a population both in vitro and in vivo, efficiently generated plasmacytoid and conventional DCs but no other lineages, which increased in number after in vivo injection of the cytokine Flt3 ligand. These clonogenic common DC progenitors (CDP) thus define a cytokine-regulated DC developmental pathway that ensures the supply of various DC populations in vivo.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000556"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_83598"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400108">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A189">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/69">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/217"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/194"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/184"/>
    <rdfs:comment>Data have been obtained on the use of nano-particles for intestinal vaccine delivery from our continued investigation of the use of nano-particles as oral vaccine vehicles (Cerovic). We have identified an important role for complement C1q in the uptake of scrapie agent by dendritic cells (Flores-Langarica).We have shown that a protein from Schistosomes has dramatic effects on intestinal physiology, including dendritic cells (Nassar). We have shown that steady-state intestinal denritic cells are not constitutively biased towards stimluating Th2 responses (Milling). We have shown that antigen given orally during intestinal inflammation stimulates a strong response rather than tolerance.(Sebti). We have clarified the roles of dendritic cells and regulatory T cells in a Th2-biased inflammatory bowel disease (McDonald). </rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/68"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/290"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6181"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/193"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_555"/>
    <rdfs:label>Use of nano-particles for intestinal vaccine delivery</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_317"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/195"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A190">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0005102"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/51">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/78"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Dendritic cell (DC) derived-exosomes (Dex) were described as nanovesicles harbouring functional MHC molecules stimulating T cell responses. Mouse studies unraveled the bioactivity of Dex onto NK cells, Dex promoting a IL-15Ra-dependent NK cell proliferation and a NKG2D-dependent activation resulting in an anti-metastatic effect. In humans, Dex bear functional IL-15R? which allow proliferation and IFNg secretion by NK cells. In contrast to immature DC, human Dex harbor NKG2D ligands on their surface leading to a direct engagement of NKG2D and NK cell activation ex vivo. In our phase I clinical trial, we highlight the capacity of Dex based-vaccines to restore the number and NKG2D-dependent function of NK cells.</rdfs:comment>
    <rdfs:label>Peptide-pulsed DC derived-exosomes (Dex) </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/208">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The B16TRex cell line cells were transfected with Bims to induce apoptosis.</rdfs:comment>
    <rdfs:label>B16TRex-Bims/B16TRex-ova-Bims</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000546">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">fibronectin</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/129">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000010"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>"The ArrayExpress Tab2MAGE package consists of a set of scripts and modules which can read in microarray experiment annotation in defined spreadsheet formats, combine it with a set of experiment data files, and output the result in MAGE-ML format. Tools are included for validation of these spreadsheet documents, and automation of the entire process.

This package can handle two distinct spreadsheet formats: MAGE-TAB, the new community-designed spreadsheet format for microarray data representation and interchange, and the eponymous Tab2MAGE, an older, simpler format upon which the design for MAGE-TAB was based."

The tab2MAGE software suite provides the GEOImport and the TabConverter tools. The first one retrieves information from GEO, reannotating the data and creating a tab2MAGE spreadsheet. The second program converts the data from the older tab2MAGE format to MAGE-TAB.

The process is carried out using a semi-automated pipeline written in Perl and Python.</rdfs:comment>
    <rdfs:label>GEO Import Perl program</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/92">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/119"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/27"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients are taking part in a clinical study. They are patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART. They are administered 4 monthly doses of the Arcelis product.</rdfs:comment>
    <rdfs:label>7 HIV patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/81">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience with the exponentially modified Protein Abundance Index (emPAI) method, a label free spectral counting procedure for determining relative protein amounts of LC-MS/MS data. 

A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established by using high accuracy, high sensitivity protein identification technology. The criteria applied resulted in a list of 2794 unique proteins that were identified with high confidence, comprising of 2623 proteins detected in immature DCs, 1896 proteins in mature DCs, and 1725 proteins in both cell types. Differences were quantified by the exponentially modified Protein Abundance Index (emPAI) method.</rdfs:comment>
    <rdfs:label>Exponentially modified Protein Abundance Index (emPAI)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_67165">
    <rdfs:label>Organism part</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Organism part</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400107">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000103">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">principle investigator</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A71">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100067">
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/OBI_1000024"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A191">
    <owl:unionOf rdf:nodeID="A92"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_373">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pore forming protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">perforin 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">perforin gene</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">perforin</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PRF1</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PRF1</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">perforin gene</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/52">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/80"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Stimulation of Mycobacterium tuberculosis (MTb)-antigen specific T cells ex-vivo in the presence of anti-IL-10 antibodies results in their increased proliferation and IFN- production.</rdfs:comment>
    <rdfs:label>MTb-antigen specific T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/296">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DC based vaccines expressing the tumor antigens PSA or Her2/neu were produced in a pre-clinical work.</rdfs:comment>
    <rdfs:label>DC based vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/209">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>B16TRex cell line cells were transfected with Fadd-dd to induce necrosis.</rdfs:comment>
    <rdfs:label>B16TRex-Fadd-dd/B16TRex-ova-Fadd-dd</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/53">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/81"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have analyzed the uptake, conservation and cross-presentation of the model antigen OVA after Fc receptor-mediated uptake by DC. We found that MHC class I presentation is relatively short-lived in contrast to MHC class II. However, CD8 cross-priming capacity of OVA-loaded DC was functionally retained for many days, while peptide-pulsed DC had lost their priming capacity after 24 hours.</rdfs:comment>
    <rdfs:label>OVA-loaded DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/159">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Kurt De Groeve</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_749">
    <rdfs:label>trypsinisation step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">trypsinisation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A trypsinisation step is a step in a protocol the specifies how to perform a protease cleavage which uses enzyme trypsin to act on proteins present in an input material entity.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/91">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/118"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Testing the  improved RCC product PME-CD40L DC it is noteworthy that presence of CD28+ T cells in tumor lymphocytic infiltrates correlates with favorable clinical outcome.</rdfs:comment>
    <rdfs:label>CD28+ T cells in tumor lymphocytic infiltrates </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/82">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has know-how in the functional annotation of upregulated and downregulated genes by gene ontology classification and pathway analysis by several bioinformatics approaches, among them Ontologizer. Preliminary results obtained from querying DAVID (http://david.abcc.ncifcrf.gov/) and Ontologizer (http://www.charite.de/ch/medgen/ontologizer/) show statistically significant enrichment for immunological-relevant signaling pathways and immunology-related GO terms of the upregulated proteins in mature DCs.</rdfs:comment>
    <rdfs:label>Ontologizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0001370">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">THP1 cell</dcr:hasExactSynonym>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human acute monocytic leukemia established from the peripheral blood of a 1-year-old boy with acute monocytic leukemia (AML) at relapse in 1978; the cells can be used for induction of differentiation studies; the cells were described to produce lysozyme and to be phagocytic.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">THP-1 cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_787">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Disease state factor</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000411</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/207">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100388"/>
    <rdfs:comment>We further our understanding of different DC populations and their soluble products in adults but in particular in neonatal mice. We have concentrated on the evaluation of the interplay between the hematopoetic factor Flt3L and IFNalpha,beta and have data available from our studies. We found that the cooperation between IFNalpha,beta and Flt3L (FL) plays an important role in the defense against Herpes simplex virus type 1 (HSV-1) in neonates. Treatment of neonatal mice with recombinant IFNalpha has a short-term, FL-independent and a long-term, FL-dependent protective effect against HSV-1. In mice lacking FL, neonatal resistance against HSV-1 is very low and DC numbers in the spleen are reduced. The treatment of these mice with rIFNalpha at day 6 resulted in an increased resistance against infection with HSV-1 at day 7. In C57BL/6 mice, treatment with rIFNalpha at birth induced both FL and plasmacytoid DC (pDC) that resulted in enhanced resistance against HSV-1 at day 7. In contrast, in mice lacking FL, IFNalpha treatment at birth did not influence splenic cell composition and had no effect on viral protection. The transfer of pDC to mice lacking FL enhanced viral resistance. Therefore, the induction and function of pDC, normally controlled by IFNalpha,beta and FL, are decisive for viral resistance in neonatal mice.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Interplay between the hematopoetic factor Flt3L and IFNalpha,beta</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10298"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_369"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000102">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">responsible party</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400106">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/299">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/88"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were generated with the intention to elucidate in vivo DC developmental regions in steady state and inflammation in situ.</rdfs:comment>
    <rdfs:label>Flt3 reporter mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_24431">
    <rdfs:label>molecular structure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">molecular structure</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6181">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">schistosomes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">schistosome</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">schistosoma</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10298">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_126283"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HSV1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Herpes simplex virus 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HSV-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human herpesvirus 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Herpes simplex virus type 1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/54">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/81"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have analyzed the uptake, conservation and cross-presentation of the model antigen OVA after Fc receptor-mediated uptake by DC. We found that MHC class I presentation is relatively short-lived in contrast to MHC class II. However, CD8 cross-priming capacity of OVA-loaded DC was functionally retained for many days, while peptide-pulsed DC had lost their priming capacity after 24 hours.</rdfs:comment>
    <rdfs:label>peptide-pulsed DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_748">
    <rdfs:label>sample preparation step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sample preparation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A sample preparation step is a step in a protocol that specifies how to prepare a sample involving material enrollments and biomaterial transformations.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/94">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FAO#FAO_0001002"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have stimulated human Monocyte derived Dendritic Cells (hMoDC) with yeast, spheroplasts, pseudohyphae, spores, purified RNA and not purified RNA, LPS. </rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000524"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <rdfs:label>human Monocyte derived Dendritic Cell (hMoDC) </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_9744">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Diabetes Mellitus, Insulin-Dependent</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/461">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have used “conventional” techniques to monitor the vaccine induced specific anti-tumor T cell responses (thymidine-incorporation, ELISA, LDA and ELISPOT assays). We have set the staining conditions for the HLA-DR*1101 tetramers loaded with tetanus toxoid and MAGE-3 peptides corresponding promiscuous CD4+ T cell epitopes. Antigen-specific CD4+ T cells are visualized after in vitro short-term expansion; we are currently optimizing the conditions for the ex-vivo staining.</rdfs:comment>
    <rdfs:label>T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/148">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <rdfs:label>Delivery of antigens in both murine and human DC into either the MHC I or MHC II presentation pathways</rdfs:label>
    <rdfs:comment>We obtained data on antigen delivery by a vector with ovalbumin and CMVpp65 in mice or human, respectively.

We used a MHC II presentation pathway targeting vector originally published by Wang et al. 1999. Proof of principle studies for antigen delivery have been performed with ovalbumin (murine studies) and CMVpp65 (human studies). </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_590"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400105">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A131">
    <rdf:rest rdf:nodeID="A189"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/208">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <rdfs:comment>Data has been generated in HHD2 transgenic mice on dendritic cell derived-exosomes (DEX), nanomeric vesicles harboring MHC/peptide complexes capable of promoting primary T cell responses and  tumor rejection in the presence of adjuvants. We showed that, in the absence of adjuvants, DEX mediate potent antigen dependent-antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide (CTX). 

CTX could 
i) abolish  the suppressive function of CD4+CD25+Foxp3+ regulatory T cells (Treg), 
ii) markedly enhance the magnitude of secondary but not primary CTL responsesinduced by DEX vaccines, 
iii) synergize with DEX in therapy but not prophylaxis tumor models. 

Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of Treg.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_4027"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/13"/>
    <rdfs:label>Preclinical mouse studies in HHD2 transgenic mice</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_236"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/78"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000018">
    <rdfs:label>Granulocyte macrophage colony-stimulating factor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GM-CSF</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Granulocyte macrophage colony-stimulating factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6183">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">schistosoma mansoni</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6181"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/298">
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/UBERON#FMA_9608-MA_0000134-MIAA_0000084-XAO_0000123-ZFA_0000669"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>By selecting for cytokine receptor expression relevant to DC development, we were able to identify highly cycling Lin–c-KitintFlt3+M-CSFR+ cells with a distinct gene-expression profile in mouse bone marrow that, on a clonal level in vitro and as a population both in vitro and in vivo, efficiently generated plasmacytoid and conventional DCs but no other lineages, which increased in number after in vivo injection of the cytokine Flt3 ligand.</rdfs:comment>
    <rdfs:label>Lin–c-KitintFlt3+M-CSFR+ cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_84050">
    <rdfs:label>cytokine</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">what is a cytokine should be classified by reasoning: [wikipedia:] Cytokines (Greek cyto-, cell; and -kinos, movement) are a category of signaling molecules that, like hormones and neurotransmitters, are used extensively in cellular communication. They are proteins, peptides or glycoproteins. The term cytokine encompasses a large and diverse family of polypeptide regulators that are produced widely throughout the body by cells of diverse embryological origin.</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytokine</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cytokines</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A190"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000215">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">legally acceptable representative</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1000049">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_747">
    <rdfs:label>cell coculturing step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell coculturing step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cell coculturing step is a step in a protocol that specifies how to achieve a material combination in which cell cultures of two or more different types are are combined and allowed to culture as one.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/109">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/8"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000227"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/175"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/110"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_353"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000261"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/149"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/9"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/150"/>
    <rdfs:comment>We have microarray data on macrophages and DC from different genetic backgrounds of mice, stimulated with CpG, in the presence or absence of a MEK inhibitor, and further data on the role of certain MAP kinases in the regulation of IL-10 and IL-12, IFN-gamma production.

Using pharmacological inhibitors, or macrophages and DC from mice carrying a null mutation in MAP kinase signalling molecule(s), we have evidence for a role of certain MAP kinases in the regulation of IL-10 and IL-12, IFN-gamma production. The work on the role of the MAP kinases, TPL-2 and ERK in upregulation of IL-10 production and negative regulation of IL-12 and IFN-gamma induction, has been under review with the Journal of Experimental Medicine and is now about to be resubmitted – this has taken longer than expected due to breeding problems with mice and the requirement to make new retroviral transcription factor constructs as requested by the reviewers (Kaiser, Cooke, Rajsbaum, Wu, Papoutsopoulou, Ley,and O’Garra). 

This work forms the basis of the microarray analysis of macrophages and DC from different genetic backgrounds of mice, stimulated with CpG, in the presence or absence of a MEK inhibitor, to identify downstream transcription factors responsible for the regulation of IL-10, IL-12 and IFN-gamma in collaboration with P. Ricciardi Castagnoli. Additional findings on the dominant role of the MAP kinase p38 in TLR ligand induced production of IL-10 were published (Kaiser. Wu, O’Garra et al; and one collaborative paper has been published (Papoutsopoulou et al., 2006). 

Furthermore, R. Rajsbaum has published a manuscript in the European Journal of Immunology, titled “Type-1 Interferon-dependent and independent expression of tripartite motif proteins in immune cells” by Ricardo Rajsbaum, Jonathan P. Stoye and Anne O’Garra. In this paper he has revealed that TRIM molecules can be grouped in clusters based on their patterns of mRNA expression in the different cell populations.  His main work shows that a group of TRIMs that share similar structural features, namely the COS-FN3 domains important in protein-protein interactions and localization to the microtubules, are preferentially expressed in the CD4+ T cell subsets, suggesting they may share a common function in these cells. On the other hand, a different cluster of TRIMs is constitutively expressed at high levels in plasmacytoid dendritic cells (pDC). Conversely, he found that a different group containing a large number of TRIM genes are induced in primary mouse macrophages, myeloid DC (mDC) and pDC upon influenza virus infection in a type-1 IFN dependent manner, suggesting an anti-viral function. However, stimulation of macrophages and mDC with LPS and double stranded RNA also led to type-1 IFN dependent up-regulation of these TRIM genes, demonstrating that their expression is not directly regulated by the virus, and that they may have broader functions in innate immune responses. A subgroup of the TRIMs induced in macrophages and DC by viruses in a type-I IFN dependent manner, mapped to mouse chromosome 7, which is syntenic to human chromosome 11, where TRIMs with known anti-viral activity are localised, suggesting that they may have co-evolved to combat viruses. The study highlights the importance of TRIM molecules as effectors of the innate immune response.

The analysis of this data resulted from R. Rajsbaum training on the Mugen Course run by Castagnoli, and forms the basis of analysis of the data obtained in the microarray study listed below which is a collaboration with Prof. Ricciardi-Castagnoli, which he and Xuemei Wu have been analysing in the last months. 

RNA was sent to Partner P. Ricciardi Castagnoli (UNIMIB) for microarray analysis of macrophages and DC from different genetic backgrounds of mice, stimulated with CpG, in the presence or absence of a MEK inhibitor, to identify downstream transcription factors responsible for the regulation of IL-10, IL-12 and IFN-??. (experiments performed by X. Wu &amp; R.Rajsbaum are accomplished as part of those experiments). We have received the data and Ricardo Rajsbaum and Xuemei Wu are currently analysing.
My group is (Ricardo Rajsbaum and Xuemei Wu) is involved in the pathway analysis database initiative. Regarding the knowledge portal, the microarray data on our experiment will be submitted in the coming year and a manuscript will be submitted for publication in collaboration with Prof. Ricciardi Castagnoli. Information on protocols to generate DCs etc have been submitted by the student, Ricardo Rajsbaum and will be placed on the portal.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700572"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/10"/>
    <rdfs:label>Role of certain MAP kinases in the regulation of IL-10 and IL-12, IFN-gamma production</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000226"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/55">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These K/O mice were studied with regard to responses to viral infections. We used the mouse pox virus Ectromelia and MVA-BN.</rdfs:comment>
    <rdfs:label>TLR9 -/- mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001438">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-14</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 14</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD14</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A66"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0100000">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Function"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasOrganType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type organ.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organ type</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/209">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_551"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_248"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_284"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/167"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_437"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/168"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_550"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36498"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/169"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_249"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/163"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_28874"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/164"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/171"/>
    <rdfs:comment>We have developed structural, kinetic and functional data to study the binding of ligands to CD1 molecules and activation of CD1d restricted iNKT cells. The results of these studies have led to: 

i) The development of protocols to refold in vitro CD1 molecules, which were used for the generation of CD1 tetramers. Ability to generate CD1d tetramers has provided us with the opportunity of comparing a broad panel of CD1d binding compounds for their ability to stimulate iNKT cells. 

ii) Identification of a novel population of NKT cells, which does not express the canonical invariant Valpha24 / Vbeta11 TCR . 

iii) Crystal structures of CD1b molecules loaded with phosphatidylinositol, ganglioside GM2 and glucomonomycolate and more recently of human CD1d loaded with alpha-GalCer. 

iv) Crystal structures of canonical and non canonical NKT TCR.  

v) Demonstration that stimulation of iNKT cells in vivo with the synthetic CD1d ligand alpha-GalCer significantly enhances immune responses to protein and peptide based vaccines, due to rapid iNKT dependent DC maturation. 

vi) We have also described the impact of combining injection of protein vaccines with a combination of iNKT cell-agonist alpha-GalCer and MPL, a detoxified version of LPS that signals through TLR4. This combination treatment stimulates antigen-specific T and B cell responses that are greater than those elicited with alpha-GalCer or MPL alone. Over the next few months we intend to extend these results to a new class of NKT cell agonist, which we have recently described, which are like alpha galactosylceramide have non-glycosidic lipids.  

vii) Characterisation of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Siglec-H functioned as an endocytic receptor and mediated efficient internalization of anti-Siglec-H Abs. By immunizing mice with ovalbumin-conjugated anti-Siglec-H Ab in the presence of CpG, we demonstrate generation of antigen-specific CD8 T cells in vivo. Targeting Siglec-H may therefore be a useful way of delivering antigens to pDCs for cross presentation.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_28892"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/58"/>
    <rdfs:label>Binding of ligands to CD1 molecules and activation of CD1d restricted iNKT cells</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/165"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/93">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/3"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>PBMC are Leukapheresis derived and are loaded with peptide pools, each consisting of 10 15-mers, which overlap with 11 aminoacids.</rdfs:comment>
    <rdfs:label>PBMC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/460">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have demonstrated that the target of FcgammaRs with the antigen induces the internalization of the immune complex, leading to the maturation of CD11c+CD11b+ conventional DCs. These DCs become thus efficient to present antigenic peptides to helper CD4 T cells and cytotoxic CD8 T cells via cross-presentation pathway. </rdfs:comment>
    <rdfs:label>CD11c+CD11b+ conventional DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/80">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000064"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Iterative calibration algorithms were used to achieve a final, absolute mass accuracy of better than 10 parts per million (p.p.m.) for all peptide ions. 

These high-accuracy spectra were searched against a human protein database, using MASCOT probability-based scoring in which the fragment ions are matched against the calculated fragments of all tryptic peptides from the human sequences. Additional constraints were set by searches against a reversed human database to minimize false positive protein identifications.</rdfs:comment>
    <rdfs:label>MASCOT probability-based scoring</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000201">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000051"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A unit of cell concentration which is equal to one cell in a volume of 1 milliliter.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cells per milliliter</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cells per ml</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/65">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/104"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/106"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_81494"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704202"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/191"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/105"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/103"/>
    <rdfs:label>Role of p50 NF-kB in differentiation, survival and APC function</rdfs:label>
    <rdfs:comment>Our lab has obtained data on the role of p50 NF-kB in differentiation, survival and APC function in mice.

Tumor growth is supported by tumor stroma, which is made by matrix and infiltrating cells, such as tumor associated macrophages (TAM) and tumor associated dendritic cells (TADC). We have recently reported that TAM display massive nuclear localization of the p50 NF-kB inhibitory homodimer, which correlates with impaired inflammatory functions (Saccani et al., 2006).The functional significance of this observation was demonstrated in p50 NF-kB deficient mice, which displayed tumor growth inhibition. More recently, in order to evaluate whether this tolerogenic mechanisms may target other compartments of the immune system, we characterized the role of p50 NF-kB in dendritic cells (DC) functions, including their differentiation and maturation. Our new results demonstrate that p50 NF-kB plays a non redundant role in DC survival and APC functions. p50 NF-kB has proapoptotic functions in bone marrow derived DC, as its absence leads to a reduced rate of apoptosis/necrosis in DC activated for 48h with LPS. Moreover, after 48h of LPS stimulation, p50 -/- DC that are still alive (80% vs 40% of WT DC) display higher expression of MHC molecules and CCR7, as well as higher secretion of pro-inflammatory cytokines such as IL-1beta, TNF-alpha and IL-18. This correlates with the enhanced capability of p50-/- DC to activate T cell responses, in vitro and in vivo.
Our data suggest that targeting p50 NF-kB activity may represent a strategy to enhance selective DC functions, with potential application in anti-tumor vaccination strategies.

Protocols of antitumor vaccination will be set to explore the therapeutic potential of p50-/- DC. Both approaches aim to provide additional significant advancements in these topics.</rdfs:comment>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000322"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000601"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/509"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704821"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001128"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/38">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/481"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Cytokine accumulation is evaluated in the supernatants at 24h by ELISA, according to a standard protocol and it is measured at 450nm. </rdfs:comment>
    <rdfs:label>Evaluation of cytokine accumulation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/85">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/211"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/140"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/MESH#MESH_E.05.200.750.551.512"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our labs we have experience in performing immunohistochemistry, e.g., for studying the cellular organization of the marrow of long bones.</rdfs:comment>
    <rdfs:label>Immunohistochemistry for studying the cellular organization of the marrow of long bones</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_402">
    <rdfs:label>Fc-gamma receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FcgammaR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gammaR</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fc-gamma receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000156"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasOrganismType">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type organism.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organism type</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A67">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0008515">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_333"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">carcinoembryonic antigen</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CEA</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/187">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/101"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9600"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Autologous DC were pulsed with apoptotic allogenic prostate carcinoma cell line LNCap to produce the advanced prostate carcinoma vaccine.</rdfs:comment>
    <rdfs:label>Apoptotic allogenic prostate carcinoma cell line LNCap</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/27">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/49"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Philip Reay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/310">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/19"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells are to be stained and are the input for FACS staining for activation markers.</rdfs:comment>
    <rdfs:label>Cells to be stained</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_746">
    <rdfs:label>genetic transformation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A genetic transformation step is a step in a protocol that specifies how to the introduce, alter or integrate genetic material into a cell or organism:</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">genetic transformation step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/156">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Georg Gasteiger</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1000048">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0100026"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_336">
    <rdfs:label>autologous dendritic cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous dendritic cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous DCs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous DC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">autologous dendritic cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/148">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/protocolstep/60"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/67"/>
    <rdfs:label>Melanoma patients</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/77"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/68"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/76"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Patients with stage III or stage IV melanoma who undergo surgical resection of a melanotic lesion. These patients are vaccinated with pulsed and thouroughly tested dendritic cell vaccine.</rdfs:comment>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/76"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_892">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A development or differentiation experiment design type assays events associated with development or differentiation or moving through a life cycle. Development applies to organism(s) acquiring a mature state, and differentiation applies to cells acquiring specialized functions.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">development or differentiation experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_1579">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">respiratory system disease</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/350">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These inhibitors were used to test the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.</rdfs:comment>
    <rdfs:label>Src-family tyrosine kinases inhibitors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_744">
    <rdfs:label>electroporation step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">electroporation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An electroporation step is a step in a protocol that specifies how to perform electroporation, or electropermeabilization, to achieve a significant increase in the electrical conductivity and permeability of the cell plasma membrane,  caused by an externally applied electrical field.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_338">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE-3.DP4 peptides</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAGE-3.DP4 Peptide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A64">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isOfficialSupervisorOf">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect an official supervisor (i.e., the hosting one) of a supervised person, such as a DC-THERA PhD student, to this supervised person.</OBI:IAO_0000115>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#hasOfficialSupervisor"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is official supervisor of</rdfs:label>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#isSupervisorOf"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/86">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/2"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The FACS analyser available to the laboratory is used, for instance, to analyse stained cells.</rdfs:comment>
    <rdfs:label>FACS analyser</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/66">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_245"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_892"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Effects of tumour hypoxia on DC differentiation and maturation</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001310"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_246"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000002025"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000057"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/510"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/6"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/193"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdfs:comment>We investigated the effects of tumour hypoxia on DC differentiation and maturation and gathered data in mice. 

This is a an important topic as sites of inflammation are often characterized by both low oxygen tension and an extensive infiltration of inflammatory leukocytes, including DC, which need to move against oxygen gradients. We showed that oxygen availability is necessary to promote full monocyte-derived DC differentiation and maturation. Low oxygen tension (hypoxia) inhibits expression of several differentiation and maturation markers (CD1a, CD40, CD80, CD83, CD86, and MHC class II molecules) in response to lipopolysaccharide (LPS), as well as their stimulatory capacity for T-cell functions. These events are paralleled by impaired up-regulation of the chemokine receptor CCR7, an otherwise necessary event for the homing of mature DCs to lymph nodes. In contrast, hypoxia strongly up-regulates production of proinflammatory cytokines, particularly TNFalpha and IL-1beta, as well as the inflammatory chemokine receptor CCR5. Subcutaneous injection of hypoxic DCs into the footpads of mice results in defective DC homing to draining lymph nodes, but enhanced leukocyte recruitment at the site of injection. Thus, hypoxia uncouples the promotion of inflammatory and tissue repair from sentinel functions in DCs, which we suggest is a safeguard mechanism against immune reactivity to damaged tissues.

During the next period we wish to characterize the molecular basis of our observations. In particular, an effort will be made to investigate mechanisms underlying the enhanced inflammatory functions of differentiating DC in hypoxia.

Biochemical and functional studies will be focused on the role of the Hypoxia- Inducible Factor-1 and -2, (HIF-1 and HIF-2) as they represent putative mediators of the adaptive response of DC to hypoxia.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000011"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001412"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/190"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000453">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000021</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Langerhans cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/37">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/481"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/480"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Serial diluition of yeast cells and preparations are added to the MoDCs.</rdfs:comment>
    <rdfs:label>Addition of serial dilution of yeast cells and preparations</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0013619">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SCYB4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCL4</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CXCL-4</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000145">
    <owl:equivalentClass rdf:nodeID="A84"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">professional APC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">professional antigen presenting cells</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Professional antigen presenting cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/28">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/117"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/25"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/572"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/213"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/90"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/116"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/436"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/27"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/14"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/88"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/49"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/152"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/573"/>
    <rdfs:label>Robert Coffin</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/26"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/370"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/2"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/88"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_337">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HLA-A2 peptides</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HLA-A2 Peptide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/155">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fernando de Souza Fonseca Guimarães</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_722">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000513</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Individual genetic characteristic factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_745">
    <rdfs:label>induction of process step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">induction of process step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An induction of process step is a step in a protocol that specifies how to initiate a biological or chemical process.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5661">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leishmania donovani</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">L. donovani</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/147">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/54"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/60"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/59"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients undergo leukapheresis and later intradermal administration of the produced vaccine (V administrations of autologous dendritic cells generated from adherent peripheral blood monocytes and subject to quality controls - with eventual additional ones depending on clinical outcome).</rdfs:comment>
    <rdfs:label>HLA-A2 positive patients with stage III/IV melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_743">
    <rdfs:label>cell fixation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell fixation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cell fixation step is a step in a protocol that specifies how to preserve defined qualities of cells or tissues (sample) which may otherwise change over time.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/351">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001461"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Used for stimulation in the evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.</rdfs:comment>
    <rdfs:label>TLR8</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/79">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/39"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/420"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/181"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/256"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/421"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/77"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/55"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/454"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/84"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/135"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <rdfs:label>Mark Suter</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/56"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/117"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/60"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A72">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/67">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/12"/>
    <rdfs:comment>We have obtained data on the immuno-physiology of rat and mouse intestinal dendritic cells. We have used a known adjuvant, E. coli heat-labile toxin (Etx) and a potential adjuvant R-848, a small TLR7/8 ligand. We have shown that R-848 causes massive changes in DC migration and leads to their activation in lymph nodes but not lymph. These changes are due to TNF-alpha (migration) and Type 1 interferons (activation), but are not accompanied by obvious oral adjuvant effects. In contrast Etx causes only minor changes in migration and activation but is a potent oral adjuvant. Current work is centering on understanding the cellular and molecular bases of these differences and examining other TLR7/8 ligands.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/10"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_562"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/9"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_316"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/6"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/7"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/14"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/46"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/8"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <rdfs:label>Studies of rat DC migration and activation in response to TLR agonists in relation to oral adjuvants</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/11"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/312">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>PE-alpha DC80 is used for staining of incubated cells for FACS analysis for activation markers.</rdfs:comment>
    <rdfs:label>PE-alpha DC80</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/29">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/281"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/75"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/283"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/25"/>
    <rdfs:label>Catherine de Greef</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/64"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/282"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/278"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/63"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/120"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/19"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/76"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/277"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/62"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700241">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-CELL GROWTH FACTOR RECEPTOR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IDDM10</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD25 antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2 RECEPTORS</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TAC antigen</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p55</dcr:hasExactSynonym>
    <rdfs:label>CD25 receptor</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD25 receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 25</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TCGFR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2RA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inter</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-2 receptor alpha chain precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-2-RA</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A46"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-25</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2-RA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2 RECEPTOR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-2 receptor alpha subunit</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2R ALPHA CHAIN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL2R</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD25</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A50"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/83">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/195"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400044"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This flow cytometer was used eg., for an analysis of CD11c populations in the lung and spleen during acute aerosol MTb infection.</rdfs:comment>
    <rdfs:label>Flow cytometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000093">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">patient</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/90">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>RCC product that was tested in an RCC phase 2 trial. The product  does indeed lead to restoration of both IL-2 and IFN responses and leads to a gradual decline of the immune effector T cells in the peripheral circulation (i.e., weaker signal after the fifth dose). Using the PME-CD40L DC product we have observed tumor regressions in a number of patients in the current study. At present, 6 of 12 patients that have been restaged using RECIST criteria have less tumor burden that when they enrolled in the study (15 weeks earlier).</rdfs:comment>
    <rdfs:label>PME-CD40L DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_84759">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transport vesicle</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transport vesicles</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0043227"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/189">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These autologous dendritic cells were used for vaccine production. They were pulsed with apoptotic autologous ovarian carcinoma cells.</rdfs:comment>
    <rdfs:label>Autologous DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5664">
    <rdfs:label>Leishmania major</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leishmania major</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leishmania (Leishmania) major</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leishmania tropica major</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/158">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Juli Cazareth</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_334">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">anti-OVA cytotoxic T cells</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">anti-OVA cytotoxic T cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10294">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">simplex virus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/352">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001440"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Used for stimulation in the evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.</rdfs:comment>
    <rdfs:label>TLR4</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_742">
    <rdfs:label>manufacturing step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">manufacturing step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A manufacturing step is a step in a protocol that specifies how to  produce a processed material which will have a function for future use.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100294">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD4 receptor</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001004</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0050147">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107 antigen-like family member A</dcr:hasExactSynonym>
    <rdfs:label>CD107a receptor</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107a receptor</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A177"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107a</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-107a</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LAMP-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD107a antigen</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A186"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000451">
    <rdfs:label>dendritic cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dendritic cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interdigitating cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">veiled cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/68">
    <rdfs:comment>Data have been obtained defining the differential roles of intestinal lymph DC subsets in activation of naïve and memory T cells in rats. We have shown that two of the three DC subsets are highly potent activators of naïve CD4+ T cells, and do not appear to be constitutively suppressed in any way.  

We are currently examining the phenotype of the activated cells and determining if Tregs are induced. We have initiated (in collaboration with Pfizer) a study of nano-particles as potential deliverers of intestinal vaccines.</rdfs:comment>
    <rdfs:label>Roles of rat DC subsets in activation of naïve and memory T cells and Tregs</rdfs:label>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/195"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/1"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/5"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/69"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/162"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A69">
    <owl:onProperty rdf:resource="http://www.obofoundry.org/ro/ro.owl#part_of"/>
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000092">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">certified IRB professional</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/39">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/485"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/484"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/483"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/482"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>The cells are collected and the pellets are resuspended in 3.6 ml AE Buffer (AE=50mM NaAcetate pH 5.2, 10mM EDTA) and then transferred in 15 ml tubes wit 200 µl 10% SDS (w/v). 2 ml of preheated acid phenol (pH 4.3) are added and the falcon is mixed by vortex. </rdfs:comment>
    <rdfs:label>Buffering</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/84">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000049"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This spectrometer was, among other things, used for an analysis of the integral plasma membrane proteome of D1 cells.</rdfs:comment>
    <rdfs:label>Tandem mass spectrometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/311">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/20"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/19"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These cells are incubated in Fc-block (1:50 in PBS + 2 % FCS) 30 min on ice, to be stained for FACS.</rdfs:comment>
    <rdfs:label>Incubated cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0100295">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD8 receptor</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000089</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/149">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/75"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have attempted to identify the antigen-presenting cells (APCs) that are responsible for the development of immune tolerance in mice that have been breast-fed by antigen-exposed lactating mothers. Recent experiments performed in our laboratory have shown that the exposure of a mother to an airborne antigen during lactation impacts asthma development in their progeny. We found that airborne allergens were efficiently transferred from the mother to the neonate through the milk and that this transfer resulted in the development of antigen-specific tolerance.</rdfs:comment>
    <rdfs:label>Breast-fed mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/89">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/376"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Patients will undergo lymphodepletion prior to vaccination and prior to adoptive transfer of autologous T cells.</rdfs:comment>
    <rdfs:label>Lymphodepletion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000211">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">proxy respondent</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/157">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Isabella Pesce</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A192">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/129">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/552"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Survival of yeast cells, spores or hyphae after uptake is reported as percentage of colony forming units after 3 days relative to the total number of cells growing in the absence of DCs exposure. </rdfs:comment>
    <rdfs:label>Exposure and assessment of survival of yeast cells, spores or hyphae after uptake</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/75">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The members of the Division of Research view their role in the context of Wayne State University's mission as a national research university within a diverse urban setting. We are dedicated to providing the students, faculty, and staff of Wayne State University with the best available resources to achieve the highest standards of research and scholarship. These resources include leadership, information, guidance and support.

We accept the challenge of providing leadership in the development of new strategies of scholarship, including those which take full advantage of the strengths of interdisciplinarity. We participate fully in the partnership between our diverse urban community and Wayne State University, a nationally recognized center of excellence in research. We communicate with pride the academic achievements of our university community which enhance the personal, social and economic well-being of the members of our large community.

Our best indicators of success are recognized scholarship, research productivity, and the transfer of knowledge to our students and the community. We evaluate multiple indicators of accomplishment against national norms and an internal commitment to continuous improvements.</rdfs:comment>
    <rdfs:label>Wayne State University</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTermClass_4">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTermClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/306">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/232"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Daniele Godelaine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A193">
    <owl:allValuesFrom rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <owl:onProperty rdf:resource="http://www.obofoundry.org/ro/ro.owl#derives_from"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/254">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/33"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Monocytes were cultured in RPMI 1640 medium (GIBCO BRL) supplemented with 2 mM L-glutamine (Sigma), 1% (vol/vol) non-essential amino acids, 100 mM sodium pyruvate, 50 U/ml of penicillin and 50 mg/ml of streptomycin (Gibco BRL) containing 10% (vol/vol) FCS (Hyclone).</rdfs:comment>
    <rdfs:label>Cultured monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/101">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were used to study « in vivo » responses to Ags. We studied the kinetics of effector genes expression and association in TCR-Tg CD8 cells responding to the male antigen and to Listeria-OVA. </rdfs:comment>
    <rdfs:label>TCR-Tg mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A187">
    <owl:intersectionOf rdf:nodeID="A194"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/20">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/74"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_264"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/73"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_577"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasStimulusType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <rdfs:label>Identification of differentially expressed genes by DC after activation with stimuli typically involved in inducing Th1 or Th2 type responses</rdfs:label>
    <rdfs:comment>Global gene expression data have been obtained using Affymetrix mouse chips by designing dendritic cell-based bioassays. To identify possible differentially expressed genes by DC after activation with stimuli typically involved in inducing Th1 or Th2 type responses we have performed comparative kinetic global gene expression analyses of DC activated with different TLR agonists typically associated with Th1 (LPS, CpG, Poly I:C) or Th2 responses (Pam3Cys). For these analyses, we have used the Affymetrix GeneChip® technology and, in particular, mouse chips showing probes for 22690 genes and expressed sequence tags (ESTs).</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000546"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_416">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">poly(lactic-co-glycolic acid)</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PLGA</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PLGA</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">poly(lactic-co-glycolic acid)</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/186">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/101"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/117"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/130"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The vaccine is composed by autologous DCs pulsed with apoptotic  allogenic prostate carcinoma cell line  LNCap. It is used for vaccination of patients with advanced prostate carcinoma.</rdfs:comment>
    <rdfs:label>Advanced prostate carcinoma DC vaccine </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000351">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Clinical factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/215">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This newly engineered antibody specific for alpha-galactosylceramide (alpha-GalCer)-human CD1d (hCD1d) complexes was used to measure the affinity of binding of iNKT TCR to hCD1d molecules loaded with a panel of alpha-GalCer analogues and to assess the rate of dissociation of alpha-GalCer and alpha-GalCer analogues from hCD1d molecules.</rdfs:comment>
    <rdfs:label>Antibody specific for alpha-GalCer-hCD1d complexes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000246">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Age factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_289">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICOShi regulatory T cells</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICOShi regulatory T cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0000050">
    <rdfs:label>platform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Pathogen">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_pathogen</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_453</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedProtein_2">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasMolecule"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000076">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD324</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001447</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/64">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/188"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/83"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/86"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/459"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/189"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/85"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000109"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0014166"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/185"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/87"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_313"/>
    <dcr:hasCellComponentType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_C0000351"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <rdfs:label>Targeting of co-encapsulated antigens and TLR agonists to DC endosomes using microspheres</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <rdfs:comment>We have obtained data from our work on biodegradable poly (D, L-lactide-co-glycolide) (PLGS) micropsheres (MS) coencapsulating ligands for endosomally expressed TLRs plus exogeneous Antigen (Ag) to deliver its cargo to endosomes of murine Dendritic cells (DCs), thus initiating TLR mediated DC maturation as well as processing of MHC class I and class II restricted epitopes. 

In these studies we used as Ag either Ovalbumin, or rec. Prion-protein. In the latter system, a CD4 T cell response could be initiated. We also found that the DNA sugar backbone determines TLR9 activation. We found that abasic PD 2’ deoxyribose homopolymers act as weak TLR9 agonist and that DNA bases short of CpG-motifs enhance this agonist activity. In contrast phospho-thioate (PS) modified abasic 2’ deoxyribose homopolymers act as TLR9 (and TLR7) agonists, but CpG-motifs convert the antagonistic function into agonist-activity. 

Interestingly, T cell immunity induced was preventive and therapeutic in infectious and tumor models. Since PLGA-MS have a safety history in man, these preclinical vaccination data are promising for use in human.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/84"/>
    <dcr:hasCellComponentType rdf:resource="http://dc-research.eu#dctheradir_244"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/64">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/4"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>There is a Luminex flow cytometer available in the lab. It is used, among other things, for assaying of cytokines in B-CLL patients treated with Apo-DC +/- GM-CSF.</rdfs:comment>
    <rdfs:label>Luminex flow cytometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A195">
    <rdf:rest rdf:nodeID="A196"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/290">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These TcR-Tg clones are specific for the P14-GP33 antigen.
In the individual T cells, we studied the expression of twenty different genes either mediating effector functions, or coding for different receptors involved in T cell differentiation and memory generation.</rdfs:comment>
    <rdfs:label>TcR transgenic clones</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/35">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/144"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Different strains of Saccharomyces cerevisiae are cultured and collected in different conditions:
different growth phase (exponential and stationary phase) 
different growth media (standard and promoting pseudohyphal growth) 
different cell form (spheroplast, spore and whole cell) </rdfs:comment>
    <rdfs:label>Culturing of Saccharomyces cerevisiae</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/327">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/96"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/95"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These monocytes were extracted from a Leukapheresis product from cancer patients using elutriation.</rdfs:comment>
    <rdfs:label>Enriched monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A151">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0005102"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/102">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>For studying in vivo responses to antigens, we initiated a long program comparing the behaviour of TCR-Tg cells specific for GP-33 peptide.</rdfs:comment>
    <rdfs:label>Tg cells specific for GP-33 peptide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/89">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/250"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Pathway analysis performed with Eu.Gene (Cavalieri et al., 2005), following the algorithm developed by Beltrame et al. (2009).</rdfs:comment>
    <rdfs:label>PATHWAY ANALYSIS PROTOCOL</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/307">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/132"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/127"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Damariz Rivero</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/49">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/44"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/43"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Evelyne Mougneau</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTermClass_3">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTermClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/255">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/33"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Differentiation of monocytes into dendritic cells is promoted, along with recombinant IL-4, by addition of granulocyte-macrophage colony-stimulating factor (GMCSF 1000U/ml, Chemicon).</rdfs:comment>
    <rdfs:label>Granulocyte-macrophage colony-stimulating factor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A96">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/76">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Research and Development at Hadassah Medical Organization

In General, the assumption that a physician can keep abreast of the latest developments and scientific knowledge solely by reading the professional literature is unfounded. Although the professional literature is widely available, cutting-edge medicine practiced at a high level of distinction is found only where physicians are involved in vibrant and active research. 

The Hadassah Medical Organization’s perspective embraces a broad view of the needs of the country and the field of medicine. Holding a deep conviction that research is the essence of medicine, Hadassah is committed to advancing and developing the field of medicine in Israel by translating research insights into practical advances that not only prolong but enhance the quality of life. In light of this, Hadassah has set excellence in research as one of the highest of its goals and made research activity its norm. Hadassah is committed to encouraging its physicians to participate in research and to incorporate them into both the Israeli and the international world of research.

Research at Hadassah 

Research at Hadassah hospitals touches every field and area of medicine, be it basic, clinical or applied research. Every department, unit and clinical institute at Hadassah includes a research arm with state-of-the-art laboratories available for the researchers’ use. In addition to those academic researchers at Hadassah for whom research is their main focus, we would like to see every Hadassah physician active in research. A substantial proportion of research at Hadassah is done in cooperation with researchers from the Hebrew University, as well as with researchers from other research institutes in Israel and worldwide. Thus, Hadassah is particularly devoted to openness to interdisciplinary research not only within its schools and departments, but also within its laboratories, institutes and research centers in Israel and abroad. 

Hadassah’s research labs are an inseparable part of the hospital’s clinical departments. In addition, research also takes place in designated research units and in multi-disciplinary research centers, such as the Women’s Health Center, the Gene Therapy Center, the Bone Marrow Transplantation Center, Cancer Immunotherapy and Cell Therapy, the Bone Calcium and Metabolism Research Center, and others. The Ministry of Science recognizes the Gene Therapy Center and Embryonic Stem Cell Center at Hadassah as foundational national centers. These research centers are providing information, help and service to the entire research community in Israel (information on these centers is found in the second chapter of this book).  

In addition to the departmental labs and the multi-disciplinary research centers, our researchers have at their disposal unique basic laboratories, including the cGMP-grade Vector Production Lab; laboratories that meet P3 standards; the Transgenetic Mice Production Unit; the SPF-grade Animal Lab; an Animal MRI Lab, and more.

Hadassah is establishing cooperative centers for the prevention, treatment and research of specific diseases, such as the Diabetes Center, the Lupus Center, the IBD (Inflammatory Bowel Disease) Center, the Cardiovascular Disease Research Center, and others (information on these centers is found in Chapter 3 of this book, under “Information on Various Departments”). These centers, as well, take part in clinical and basic research, each in its own field. 

Funding of research at Hadassah is provided via both internal and external sources. The Hadassah Women’s Zionist Organization of America (HWZOA) has made commitment to research its watchword, and invests heavily in this area. Despite the current financial situation and the deep recession in Israel and worldwide, this year, as well as during the past two previous years, HWZOA have succeeded in continuing to raise funds to finance research. Every year, HWZOA directly distribute Hadassah research funding in the amount of approximately one million dollars – in addition to HWZOA investments in research infrastructure and human resources. Internal research funds are awarded on a competitive basis, with the aim of attracting external competitive funding from Israeli and international sources. In the realm of competitive research, a wide campaign of clinical and applied research is taking place, funded by commercial pharmaceutical and medical equipment companies. A substantial portion of this research originates in the developments that came out of research done at Hadassah.

The high quality of research done at Hadassah can be seen in, among other things, the relatively large number of grants received each year by competitive sources in Israel and worldwide, such as the USA National Institutes of Health, the bi-national funds of Germany, France and USA, the European Union funds, and private funds and organizations.   

Likewise, research excellence is also evidenced in the relatively large number of scientific publications published each year by Hadassah researchers in the leading scientific literature. 

Hadasit Ltd. was founded with the purpose of establishing, supporting and advancing the commercialization of information gained through research done at Hadassah. In the past three years, Hadasit has established twelve technological development subsidiary companies, produced new devices and drugs, and applied for over forty patents created by Hadassah researchers.

Over 200 clinical trials performed each year at the two Hadassah hospitals are facilitated by the Hadasit Company. These clinical trials are part of a series of tests required in the process of authorizing drugs, equipment, methods, or new medical protocols for use in humans. The trials are financed by commercial entities and are used as an important source of data for Evidenced-based Medicine and as a tool for the inculcation of Good Clinical Practices.  (Information on Hadasit can be found in this chapter).

The first chapter of this book presents a selected number of articles and research on various topics, all performed at Hadassah. The second chapter introduces the multi-disciplinary research centers and the national infrastructure found at Hadassah. Finally, the third chapter presents the researchers and a list of their publications in the past three years. The material in this book is organized according to Hadassah divisions and departments. At the end of the book are an index of research topics and an index of researchers. 

The Hadassah Medical Organization’s Division of Research and Development is at your disposal regarding all questions and matters pertaining to researchers and research at Hadassah.</rdfs:comment>
    <rdfs:label>Hadassah Medical Organization</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/185">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0610"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>For transient transfection of synthetic siRNA, commercially available siRNA Smart Pool from Dharmacon targeted against the STAT3 transcription factor have been successfully transfected in human MDDCs (Lipofectamine 2000 as transfection reagent). The efficiency of silencing, as detected by western blot or FACS analysis of the protein was of 50-80% (depending on the donor), and peaked at 72 h post-transfection. Transfection efficiency was reproducibly higher than 80% and did not induce any type I IFN production. </rdfs:comment>
    <rdfs:label>siRNA Smart Pool targeted against the STAT3 transcription factor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/399">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were vaccinated with 4 peptides (MAGE-A3, gp100, NA17 and tyrosinase) presented by HLA-A2 and monitored. We measured responses to these peptides injected with Montanide, but did not know whether the Montanide adjuvant was important for these T cell responses. We therefore injected the same peptides without adjuvant, and no response was observed. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.</rdfs:comment>
    <rdfs:label>gp100 peptide vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000085">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_concretized protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A194">
    <rdf:rest rdf:nodeID="A197"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_63887">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33839"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000008">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_604</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_Experimental factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/214">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We analysed the ability of invariant NKT (iNKT) cells to assist priming of antigen specific T and B cell responses. 

1) We have demonstrated that activation of human DC by Toll like receptor ligands (TLR-L) modulates the lipid biosynthetic pathway, resulting in enhanced recognition of CD1d-associated lipids by iNKT cells.

2) We have clarified the mechanisms by which CD1d-restricted lymphocytes translate T cell receptor (TCR) recognition of lipids with similar group heads into distinct biological responses. Using a soluble iNKT TCR and a newly engineered antibody specific for alpha-galactosylceramide (alpha-GalCer)-human CD1d (hCD1d) complexes, we measured the affinity of binding of iNKT TCR to hCD1d molecules loaded with a panel of alpha-GalCer analogues and assessed the rate of dissociation of alpha-GalCer and alpha-GalCer analogues from hCD1d molecules.

3) We demonstrated that pathogen-derived signals to DC mediated via TLRs can be modulated by activated iNKT cells </rdfs:comment>
    <rdfs:label>iNKT TCR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/24">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_478"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our lab, we have know-how about performing MPLC assays, such as using it in the establishment of immunomonitoring vaccination trials with RNA transfected DC by using overlapping peptides.</rdfs:comment>
    <rdfs:label>MPLC assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000064">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/IAO_0000010"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000044">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/153">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/118"/>
    <rdfs:label>Monitoring of vaccine induced T cell responses for two clinical trials</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/39"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/126"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/154"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/43"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/116"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_170"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_171"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/41"/>
    <rdfs:comment>We have obtained data from  monitoring vaccine induced T cell responses for two clinical trials. We found CD8+ and CD4+ T cell responses against the immunological tracers KLH and TK, and against the NTPs and MAGE-3, respectively. Assays used have been 3H-thymidine-incorporation, ELISA, CBA, LDA and 51Cr-release assays. Autologous tumour specific CD8+ and CD4+ T cell clones have also been obtained from the blood and tumour infiltrating lymphocytes. We investigated the role of spontaneous CD4+ T cell responses against the HPV-18 and 16 E6 and E7 proteins in women with cervical lesions. When HPV-18 E6 was tested, we found a very high percentage of responders among women with high-grade cervical intraepithelial lesions, whose level of IFN gamma produced predicts the clinical outcome after surgery. We have continued the setting of the staining with HLA-DR*1101 tetramers loaded with promiscuous MAGE-3 peptides. We obtained specific staining by the use of peptides modified to contain only one predicted P1 anchor.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0000052">
    <rdfs:label>microarray platform</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_878">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Developmental stage factor</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000399</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/63">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_447"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/227"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000587"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0011134"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/18"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <rdfs:label>Activation of DC by transduction with lentiviral vectors</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:comment>Our lab obtained data on the activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. 

Dendritic cells (DCs) are an attractive tool for immunomodulation, targeting mature DCs (mDCs) for immunization or immature/semimature DCs (iDCs) for tolerization. Therefore, introducing antigens into DCs has become a prime topic in various immunological disciplines. Numerous studies have shown that lentiviruses are an efficient vehicle for this purpose. 

This study evaluates the effects of lentiviral transduction on iDC activation. Immature DCs are efficiently transduced with increasing doses of lentivirus without affecting cell viability. Transduction at low multiplicities of infection (MOIs) did not result in phenotypical or functional maturation. Higher doses of lentivirus, however, resulted in upregulation of adhesion, costimulatory, and HLA molecules, as well as in increased allostimulatory capacity and secretion of interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha. Production of IL-12 p70, IL-10, and interferon-alpha was observed only at extremely high doses. Protein kinase R phosphorylation on transduction at an MOI of 150 was demonstrated by Western blotting. A Toll-like receptor (TLR)-driven luciferase reporter assay showed dose-dependent activation of TLR2, TLR3, and TLR8, which was independent of the pseudotype, production, or transduction protocol and was abrogated on heat inactivation. These data show that lentiviral vectors provide not only the antigen but also appropriate activation signals to iDCs, favoring their use for immunotherapy and vaccine development.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/122"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/80"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000142"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/219"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001461"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001450"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000010"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/79"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001452"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_249">
    <rdfs:label>CD1d molecule</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD1d molecule</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 1d</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-1d</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD1d</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A198"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedProtein_3">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasMolecule"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A172">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A199"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/291">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells are specific for the P14-GP33 antigen.
They were used to study the expression of twenty different genes either mediating effector functions, or coding for different receptors involved in T cell differentiation and memory generation.</rdfs:comment>
    <rdfs:label>Endogenous polyclonal T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A200">
    <rdf:rest rdf:nodeID="A192"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/328">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/97"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/96"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were generated by culturing enriched monocytes for 5 days.</rdfs:comment>
    <rdfs:label>Immature DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/36">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/480"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/144"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Monocyte-derived DCs are added at a final concentration of 5x105 cells/ml into 96-well plates.</rdfs:comment>
    <rdfs:label>Addition of monocyte-derived DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A196">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/398">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/43"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Melanoma patients were vaccinated with 4 peptides (MAGE-A3, gp100, NA17 and tyrosinase) presented by HLA-A2 and monitored. We measured responses to these peptides injected with Montanide, not knowing whether the Montanide adjuvant was important for these T cell responses. We therefore injected the same peptides without adjuvant, and no response was observed. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.</rdfs:comment>
    <rdfs:label>MAGE-A3 peptide vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/184">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were immunized with OVA and used in a DC staining experiment. LN cells were purified 2 days later, and stained with either 2C44, 2F74, 2E60 or 2X8 mAb. None of these mAb stained DC purified from non immunized mice. However, among the 4 mAb, only 2C44 could stain DC in LACK-immunized mice, but not in OVA-immunized mice.</rdfs:comment>
    <rdfs:label>BALB/c mice (OVA)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/88">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/252"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/251"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>RNA preparation, labeling, hybridization on a HT12 array (Illumina), and scanning were performed according to Illumina instructions by Genomics Lab, Wellcome Trust Centre for Human Genetics (Univeristy of Oxford).</rdfs:comment>
    <rdfs:label>ILLUMINA REFERENCE PROTOCOL</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A102">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/252">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17334"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>50 U/ml of penicillin were added to the monocyte cell culture.</rdfs:comment>
    <rdfs:label>Penicillin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_556">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000397</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Imaging function</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTermClass_2">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTermClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/77">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>An Efficient and Modern Institution of Higher Education

With around 75 interdisciplinary and practice-orientated courses of study, Leibniz Universität Hannover provides degree and continuing education courses which are orientated both towards demand and quality.

For graduates today, in addition to the academic qualification, it is absolutely essential to think in terms of interdisciplinary, networked systems. The large choice of subjects at Leibniz Universität Hannover permits students to shape their studies individually through a large number of possible combinations.

With the establishment of new courses of study, such as Mechatronics, Nanotechnology, Computer-aided Engineering, Plant Biotechnology or Industrial Engineering, Leibniz Universität Hannover has reacted to the changing demands of the employment market and offers a range of subjects rarely found in Germany.

As far as research is concerned, the University has a marked profile and a series of interdisciplinary focal points. Collaborative research centres, research groups and cooperation programmes with other institutions of higher education and research institutions are proof of this.
The availability of the appropriate specialist literature is also decisive for the quality of teaching and research: with its Technical Library, Hannover has the German Central Library for all fields of technology and their basic sciences, especially Chemistry, Computer Science, Mathematics and Physics. It is one of the largest specialist libraries in the world for these subjects. The Centre for Applied Linguistics and Special Languages, the Lower Saxony Computer Centre, the Service Center and the Career Service are further facilities which help and support research and study.

Science and industry are also working hand-in-hand. Since 2002 the research centre L3S has been working as a competence centre for innovative learning technology. In the Production Technology Centre at Hannover-Garbsen six institutes of the Faculty of Mechanical Engineering and well-known industrial partners are carrying out research into demanding production technology. In close cooperation with the Hannover Laser Centre and the Institute of Gravitation Physics at Leibniz Universität Hannover, the Max Planck Society has set up a section as an international centre for gravitational astronomy in order to carry out research into the “big bang”.

Leibniz Universität Hannover: an efficient and modern institution of higher education. Its declared aim is constantly to improve the quality of teaching and research so as to ensure that studying, teaching and researching in Hannover continue to be enjoyable.</rdfs:comment>
    <rdfs:label>University of Hannover</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/308">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Enrica Calura</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/48">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Tania Tamburi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/127">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_759"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are washed.</rdfs:comment>
    <rdfs:label>Second washing of DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/213">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/88"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients are involved in a phase II clinical trial for melanoma and are treated with OncoVexGMCSF.  Data so far indicates that OncoVex can destroy both injected and un-injected melanoma deposits. The trial is still in progress.</rdfs:comment>
    <rdfs:label>Metastatic Cutaneous Melanoma Patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/25">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdfs:label>ELISPOT analysis</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/102"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdfs:comment>Our lab has experience in carrying out ELISPOT analyses. For instance, an IFNgamma ELISPOT assay with PBMC loaded with peptide pools (each consisting of 10 15-mers, which overlap with 11 aminoacids) was done for a study on antigen recognition. </rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/154"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/person/21"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/62">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/43"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000787"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/42"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_447"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001310"/>
    <dcr:hasCellLineType rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000664"/>
    <rdfs:label>Modulation of DC-T cell responses via CD83</rdfs:label>
    <rdfs:comment>Data were obtained on the effect of enhanced CD83 expression on dendritic cells and T cells and its correlation with effective immune responses. Human CD83 is a marker molecule for mature dendritic cells (DC) and is also expressed on activated B and T cells. Although CD83 has been implicated in immune responses, its function on DC and T cells remains unclear. 

In this study, we wanted to assess the role of CD83 expressed on DC and T cells in the immune response. Down-regulation of CD83 expression on human DC through RNA interference (RNAi) results in a less potent induction of allogeneic T cell proliferation, reduced IFN-gamma secretion by established T cells and decreased capacity in the priming of functional tumor antigen-specific CD8+ T lymphocytes. In addition, CD83 mRNA-electroporated DC are stronger T cell stimulators. However, CD83 overexpression on Melan-A/MART-1-specific tumor-infiltrating lymphocytes (TIL) circumvents the need for CD83 expression on DC. Co-culture of immature DC with TIL or K562 cells overexpressing CD83 results in the production of enhanced levels of pro-inflammatory cytokines, whereas this production is less pronounced or even absent in co-cultures with non-modified TIL or K562 cells. 
In conclusion, we demonstrate that CD83 expression on T cells and DC modulates the immune response by activating DC and by delivering costimulatory signals for the stimulation of naive and memory T cells, respectively.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/424"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/41"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000322"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_597">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000052</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Microarray facility</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0001784">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UBERON#UBERON_0000029"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Peyer's gland</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000283">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Behavioural stimulus factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/539">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_649"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tissue biopsies of the last vaccination site and of the VIN lesion prior to the first vaccination and 3 months after the last vaccination were analysed for the presence of HPV16-specific T cells.

The IFN?-ELISPOT analysis and proliferation with its accompanying cytokine production revealed a strong and broad vaccine-induced T cell response. The strength of the immune response (defined as breath and magnitude of the response) was significantly higher in the patients with a complete remission (CR) than in the patients with no changes (NC) in the lesion size. Phenotypical anlaysis revealed a strong induction of CD4+ T-cells specifically against HPV16 E6 and E7, whereas CD8+ T cells were found merely against HPV16 E6 and to a less broad array of epitopes within each patient. This analysis was done after one in vitro restimulation, however, by directly ex vivo flow cytometric analysis hardly any CD8+ T cell response could be detected. The T cell cultures obtained from the biopsies taken of the last vaccination site were found to be HPV16 peptides specific in 3/5 tested NR patients and in 4/5 tested CR. However, recognition of the recombinant HPV16 E6 and/or E7 protein was observed in 1/5 cultures from NR patients and 4/5 cultures of the CR patients, suggesting the differences in vaccine-induced T-cell reactivity. Tissue biopsies of the VIN lesion before and after vaccination showed only in one patient a HPV16-specific T-cell response, which was against HPV16 E6 and merely of the type 2 cytokine producing T cells. Notably, no T-cell cultures could be obtained from VIN biopsies taken from the CR patients. In conclusion, the HPV16 E6 and E7 synthetic long peptides vaccine is highly immunogenic, in that it increases the number and activity of HPV16-specific CD4+ and CD8+ T-cells to a broad array of epitopes in all patients. The expansion of CD4+ and CD8+ tumor-specific T-cells, both considered to be important in the anti-tumor response indicates the immunotherapeutic potential of this vaccine. Addition of a strong toll-like receptor ligand might increase the CD8 response in frequency and to a broader set of epitopes.</rdfs:comment>
    <rdfs:label>Tissue biopsies of VIN lesion 3 months after last vaccination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/154">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/42"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10566"/>
    <rdfs:label>Use of “conventional” techniques to monitor the vaccine induced specific anti-tumor T cell responses</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/117"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:comment>We have obtained data monitoring the vaccine induced specific anti-tumor T cell responses (thymidine-incorporation, ELISA, LDA and ELISPOT assays) using “conventional” techniques. We have set the staining conditions for the HLA-DR*1101 tetramers loaded with tetanus toxoid and MAGE-3 peptides corresponding promiscuous CD4+ T cell epitopes. Antigen-specific CD4+ T cells are visualized after in vitro short-term expansion; we are currently optimizing the conditions for the ex-vivo staining. We have identified new MHC class II restricted epitopes on tumor associated antigens (i.e. MAGE-3, carcinoembryonic antigen and E6 and E6 transforming proteins of the human papilloma virus type 18) and we started to use them to follow the naturally occurring anti-tumor CD4+ T cells responses in patients suffering from melanoma, lung carcinoma and different stages of cervical intraepithelial neoplasia. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0008515"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/44"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_15551">
    <rdfs:label>Prostaglandin E2</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">prostaglandin E2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PGE-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PGE 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dinoprostone</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PGE2</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Prostaglandin E2</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000192">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/33">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/256"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/255"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/254"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/257"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_745"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Differentiation of monocytes into dendritic cells is promoted by addition of granulocyte-macrophage colony-stimulating factor (GMCSF 1000U/ml, Chemicon) and recombinant IL-4 (1000U/ml, R&amp;D Systems) for 5 days. </rdfs:comment>
    <rdfs:label>Monocyte differentiation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000272">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A158">
    <owl:unionOf rdf:nodeID="A201"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTermClass_1">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTermClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/325">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4751"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DCs with blocked beta-glucan, mannan and chitin receptors were exposed to these fungi.</rdfs:comment>
    <rdfs:label>Fungi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A199">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/UBERON#FMA_9608-MA_0000134-MIAA_0000084-XAO_0000123-ZFA_0000669"/>
    <owl:onProperty rdf:resource="http://www.obofoundry.org/ro/ro.owl#derives_from"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_357">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OncoVex GMCSF</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OncoVexGMCSF</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/66">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/199"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The FACS analyzer avaiable to the lab is used, among other things, to assess protein expression of tumor antigens or soluble proteins.</rdfs:comment>
    <rdfs:label>FACS analyser</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/BTO#BTO_0000767">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UBERON#UBERON_0000029"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mesenteric lymph node</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/397">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/13"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have immunized mice with human DC derived-exosomes and generated hybridomas that produce antibodies recognizing at least the human exosomes. </rdfs:comment>
    <rdfs:label>Mice immunized with human DC derived-exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A185">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000178">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/183">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_656"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were immunized with LACK and used in a DC staining experiment. LN cells were purified 2 days later, and stained with either 2C44, 2F74, 2E60 or 2X8 mAb. None of these mAb stained DC purified from non immunized mice. Among the 4 mAb, only 2C44 could stain DC in LACK-immunized mice, but not in OVA-immunized mice.</rdfs:comment>
    <rdfs:label>BALB/c mice (LACK)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/309">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Raffaele Paola</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/253">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17076"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>50 mg/ml of streptomycin (Gibco BRL) containing 10% (vol/vol) FCS (Hyclone) were added to the monocyte cell culture.</rdfs:comment>
    <rdfs:label>Streptomycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A101">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/78">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Ghent University, abbreviated to UGent, is one of the major universities in the Dutch-speaking region of Europe.  It distinguishes itself as a socially committed and pluralistic university in a broad international perspective.

Founded in 1817 as a Latin-speaking State University by William I, King of the Netherlands, Ghent University is a relatively young university. After its independence in 1830, the Belgian State was in charge of the administration of Ghent University; French was the new official academic language. In 1930 Ghent University became the first Dutch-speaking university in Belgium. The Decree of 1991 assigned great autonomy to the university.

Over the years eminent scientists such as Joseph Plateau (physicist, considered as a pioneer in the development of motion pictures), Leo Baekeland (inventor of Bakelite) and Corneel Heymans (Nobel Prize winner in Medicine) studied and worked at Ghent University.

With a view to cooperation in research and scientific service, numerous research groups, centres and institutes have been founded over the years. Several of them are renowned worldwide, in various scientific disciplines such as biotechnology, aquaculture, microelectronics, history,...

Today, after decades of uninterrupted growth, Ghent University is one of the leading institutions of higher education and research in the Low Countries. Ghent University is an open, committed and pluralistic university with a broad international perspective.

Located in Flanders, the Dutch-speaking part of Belgium and the cultural and economical heart of Europe, Ghent University is an active partner in national and international educational, scientific and industrial cooperation.

Ghent University's eleven faculties are composed of more than 130 departments all together. These departements offer high-quality courses in every one of their scientific disciplines, each inspired by innovative research.

- Faculty of Arts and Philosophy 
- Faculty of Law 
- Faculty of Sciences 
- Faculty of Medicine and Health Sciences 
- Faculty of Engineering 
- Faculty of Economics and Business Administration 
- Faculty of Veterinary Medicine 
- Faculty of Psychology and Educational Sciences 
- Faculty of Bioscience Engineering 
- Faculty of Pharmaceutical Sciences 
- Faculty of Political and Social Sciences 

In addition to these faculties, Ghent University has five Doctoral Schools just for doctoral researchers. These schools provide support to doctoral students through specialized courses as well transferable skills training, they contribute to a quality culture in research, and take care of the social and international visibility of the doctoral degree.</rdfs:comment>
    <rdfs:label>University of Ghent</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/100">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Concerning « in vivo » responses to Ags, we studied the kinetics of effector genes expression and association in TCR-Tg CD8 cells responding to the male antigen and to Listeria-OVA. </rdfs:comment>
    <rdfs:label>TCR-Tg CD8 cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/47">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/94"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/40"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/264"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/358"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/12"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/50"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/174"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/156"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/27"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/574"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/41"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/175"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/29"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/359"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/43"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/116"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/32"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/51"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/294"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/507"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/451"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/179"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/185"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/35"/>
    <rdfs:label>Sandra Gessani</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/33"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/52"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/115"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/348"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/53"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/38"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A90">
    <owl:unionOf rdf:nodeID="A170"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_557">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:subClassOf rdf:nodeID="A202"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR ligand</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/128">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_743"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Cells, lysated with a hypotonic solution (KCl 0.05%), are plated on YPD. </rdfs:comment>
    <rdfs:label>Plating of DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_1110000">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/26">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000049"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A comprehensive protein inventory of clinical grade immature and cytokine cocktail matured (Il-6, IL-1 beta, TNF alpha, PGE2; 48 hours) monocyte derived human dendritic cells (DC) from a healthy donor has been established by using high accuracy, high sensitivity protein identification technology. We have identified 2794 proteins in DCs by liquid chromatography tandem mass spectrometry. </rdfs:comment>
    <rdfs:label>liquid chromatography tandem mass spectrometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isKnowledgeableAbout">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#hasKnowledgeable"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a knowledgeable contact person to any DC-THERA resource.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is knowledgeable about</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FAO#FAO_0000024">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">conidium</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An asexual, nonmotile spore formed by higher fungi; conidia are usually made from the side or tip of specialized sporogenous cells and do not form by progressive cleavage of the cytoplasm.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000048">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_142">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0100055</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Cell line</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000077">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD33</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001892</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000273">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulator of consumables and medical devices</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_596">
    <rdfs:label>mixed leukocyte reaction assay</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MLR assay</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MLR assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mixed leukocyte reaction assay</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mixed leukocyte reaction assay</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/61">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/416"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/psi-mi#MI_0324"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/81"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/415"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/40"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_243"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/152"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdfs:label>Induction of CD8+ T cell responses by electoporated human DC</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/16"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>Our lab obtained data on the induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. 

The maturation state of dendritic cells (DCs) is an important determinant for the initiation and regulation of adaptive immune responses. In this study, we wanted to assess whether functional activation of human monocyte-derived DCs can be achieved by electroporation of an activation signal in the form of double-stranded (ds) RNA and whether simultaneous electroporation of the dsRNA with tumor antigen encoding mRNA can lead to the induction of a cytotoxic T-lymphocyte (CTL) response. Electroporation of immature DCs with poly(I:C(12)U), a dsRNA analogue, resulted in phenotypic as well as functional changes, indicative of DC maturation. Co-electroporation of DCs with both poly(I:C(12)U) and Melan-A/MART-1 encoding mRNA induced strong anti-Melan-A/MART-1 CD8(+) T-cell responses in vitro. Higher numbers of Melan-A/MART-1-specific CTLs were consistently obtained with poly(I:C(12)U)-activated DCs compared to DCs matured in the presence of an inflammatory cytokine cocktail. These results indicate that DC co-electroporation with both dsRNA and tumor antigen encoding mRNA induces fully activated and antigen-loaded DCs that promote antigen-specific CTL responses and may provide the basis for future immunotherapeutic strategies.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/78"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/179"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/181"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedProtein_1">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasMolecule"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/155">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/31"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000057"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48080"/>
    <rdfs:label>Proteomic assessment of CD4+ Th-cells specific for defined antigens</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_581"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/110"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_582"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_232"/>
    <rdfs:comment>We obtained data assessing the entire CD4+ Th-cells specific for defined antigens also for murine cells (based on the strategies developed in work performed in 2005 (Frentsch et al., Nature Medicine 2005)). For intracellular assessment of CD154 induced in the course of short-term activation target cells are stimulated with antigen for 6h in the presence of the secretion inhibitor BrefA (for 4h). For extracellular analysis of live antigen-specific Th-cells cells are stimulated in the presence of an anti-CD40 blocking antibody and biotinylated anti-CD154 antibody. We have used this system to detect antigen-specific Th-cells after in vitro or ex vivo stimulation.  Since the entire population of antigen-specific Th-cells can be assessed in combination with intracellular cytokine analysis the methodology enables a combined quantitative and qualitative highly sensitive monitoring of Th-cell immunity (also after DC vaccination). </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700621">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tyrosine-protein phosphatase non-receptor type 11</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CFC</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Protein-tyrosine phosphatase 2C</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PTP-2C</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SHP2</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Protein-tyrosine phosphatase 2C</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NS1</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SH-PTP3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PTP2C</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PTPN11</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MGC14433</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NS1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SHP-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TYROSINE PHOSPHATASE SHP2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BPTP3</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/212">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/115"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These primed T cells have been obtained from untouched naive CD4+ T cells co-cultured with fungi -pulsed DCs.</rdfs:comment>
    <rdfs:label>Primed T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A201">
    <rdf:rest rdf:nodeID="A203"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_555">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">compound treatment design experiment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/34">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/259"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/261"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_773"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/258"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label>DC activation</rdfs:label>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/260"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/263"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/262"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/257"/>
    <rdfs:comment>DCs activation is induced by lipopolisaccaride (LPS 1microgram/ml, Sigma, St. Louis, MO), by Curdlan (100 micrograms/ml, Wako), by R848 and yeast RNA  and by yeast cells in different conditions of culture.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/79">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>In many parts of the world it has proved possible to push back the spread of infectious diseases; however, they are not yet defeated   quite the opposite, in fact: microbes are developing resistance to medicines; global trade and foreign travel are transporting pathogens around the world at an ever faster pace. Tuberculosis, AIDS, hepatitis and malaria threaten the health of millions of people. 

At TWINCORE medical personnel and basic research scientists from various disciplines conduct infection research side by side. Our focus is upon translational research   the interface between basic research and clinical development. 
The goal is to enable the latest findings from basic research to lead to new therapies or diagnostic procedures for patients in the shortest of times. At the same time, basic researchers are looking for answers provided by the clinical work. A further key component of these bridges spanning research and practice is the approval procedures that we are required to complete for clinical applications. Our scientists at TWINCORE support the development of new strategies to combat infectious diseases by creating a scientific basis for risk assessment in advance of the clinical trials.

Around 70 scientists at TWINCORE are currently involved in addressing the following question: what occurs during the course of an infection and what can we do to counteract it? The unique aspect of our establishment is that medical experts, virologists, bacteriologists and immunologists join together in addressing pressing matters regarding infection research. TWINCORE incorporates four TWINCORE  groups and two translational research groups of the Hannover Medical School: 

- Institute for Experimental Infection Research
- Department for Experimental Virology
- Institute for Infection Immunology
- Department for Pathophysiology of Bacterial Biofilms 
- Cell and Gene Therapy Clinical Research Group 
- Infection and Cancer Clinical Research Group 

Our researchers analyse how pathogens and host cells interact with one another and which new mechanisms can inhibit this interaction. They are working on new vaccination strategies that train the immune system in a more specific manner than vaccination methods have been able to thus far. Moreover, in order to research severe illnesses such as hepatitis C our researchers are developing new preclinical model systems - from new cell culture systems to mice with an immune system similar to that of humans.</rdfs:comment>
    <rdfs:label>Centre for Experimental and Clinical Infection Research, Twincore</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/65">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/126"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>There is a GMP facility for conduction of phase III clinical trials available. The structural up-grade of this facility has limited the number of patients recruited.</rdfs:comment>
    <rdfs:label>GMP facility for conduction of phase III clinical trials</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasOfficialSupervisor">
    <owl:inverseOf rdf:resource="http://dc-research.eu#isOfficialSupervisorOf"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a supervised person, such as a DC-THERA PhD student, to his or her official - i.e., hosting - supervisor.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has official supervisor</rdfs:label>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasSupervisor"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_356">
    <rdfs:label>vaccine</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vaccines</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33839"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vaccine</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/326">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/95"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The Leukapheresis product  from cancer patients was used to produce enriched monocytes using elutriation.</rdfs:comment>
    <rdfs:label>Leukapheresis product</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/182">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_656"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>To address the issue whether infected DC process pathogen-derived antigen and stimulate antigen-specific CD4+ T cells in vivo, we have infected susceptible BALB/c (H2-d) mice with a recombinant Leishmania major parasite expressing a fluorescent tracer. We have directly visualized antigen-presenting cells using a mAb reacting to an antigenic peptide derived from the parasite LACK antigen bound to I-Ad MHC class II molecule. I-Ad/LACK complexes were readily detected at the surface of freshly purified parasite-containing DC which expressed a CD8?- CD11b+ F4/80+ gp40- surface phenotype. As demonstrated by electron microscopy some DC contained live amastigotes and expressed I-Ad/LACK complexes in the membrane of the parasitophorous vacuole. Therefore, LACK could be processed and presented to T cells by infected DC in vivo.</rdfs:comment>
    <rdfs:label>BALB/c (H2-d) mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/24">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_533"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdfs:label>Proteomic analyses of the integral plasma membrane proteome mouse DC - pilot study</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/78"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000178"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000057"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
    <rdfs:comment>We obtained data on the protein changes that occur at the cell surface of a maturing DC, induced by a prototypical maturation stimulus such as LPS. Results obtained from the LC-MS/MS analysis of the integral plasma membrane proteome of D1 cells stimulated for 24 hours with LPS have been compared to the results obtained from immature D1 cells. As expected, DC up-regulated the cell surface expression of all proteins known to be part of the so-called “immunological synapse”, namely MHC class II (region E and K), CD40, CD80, CD86 and ICAM. Interestingly, LPS stimulation caused down-regulation of the AXL receptor, which has been reported to be associated in vivo with the control of the responsiveness of antigen-presenting cells to LPS. Although these data still need independent validation, we would like to propose that DC need to down-regulate this inhibitory receptor upon encountering a maturation stimulus in order to be released from their immature state and to be licensed to achieve a fully mature phenotype.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#AXL_Protein"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/101"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001412"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/25"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001764"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/59">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/85"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Injection of lentiviral vectors activated OVA-specific CD4+ T cells and this CD4 help was shown to be necessary for an adequate primary and memory CTL response. </rdfs:comment>
    <rdfs:label>OVA-specific CD4+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/27">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000049"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have access to and experience with using a linear ion trap / Fourier Transform (LTQ-FT) hybrid mass spectrometer.  For example, we use it to analyse purified tryptic peptides. </rdfs:comment>
    <rdfs:label>linear ion trap/ Fourier Transform (LTQ-FT) hybrid mass spectrometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000182">
    <rdfs:subClassOf rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Lectin"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">selectin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000088">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_administrative unit role</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000017</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/46">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Letizia Sgalambro</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1773">
    <rdfs:label>mycobacterium tuberculosis</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mycobacterium tuberculosis</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bacillus tuberculosis</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mycobacterium tuberculosis typus humanus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bacterium tuberculosis</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mycobacterium tuberculosis var. hominis</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_000576">
    <rdfs:label>monocyte</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000738"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monocyte</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/71">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment> The University of Milan is a public, multidisciplinary teaching and research institution that offers 9 Faculties, 134 study courses (divided between 1st and 2nd level degree programmes), 19 Doctoral Schools and 92 Specialisation Schools.

Our 2,500 professors represent the highest concentration of scientific expertise in the region and our research is ranked among the best in Italy and Europe.

The University’s departments are housed in important historic edifices in the centre of Milan and in modern buildings in the area known as Città Studi (the City of Studies). </rdfs:comment>
    <rdfs:label>Università degli Studi di Milano</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/125">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/565"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are treated with zymolyase.</rdfs:comment>
    <rdfs:label>Treatment of DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/250">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33709"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>1% (vol/vol) non-essential amino acids were added to the monocyte cell culture.</rdfs:comment>
    <rdfs:label>Non-essential amino acids</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A204">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/86">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>(Basic manufacturing and QC SOPs on the Generation of autologous plasma and serum have been provided to DC-THERA participants and associated partners via DC-THERA intranet. )</rdfs:comment>
    <rdfs:label>Generation of autologous plasma and serum</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5476">
    <rdfs:label>Candida albicans</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Candida stellatoidea type I</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Candida stellatoidea</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C. albicans</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Candida albicans</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000072">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD3</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001027</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A205">
    <rdf:rest rdf:nodeID="A206"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/68">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/196"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_484"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>There is a two-photon intravital microscope available in the laboratory. It was used, among other things, to analyze the infiltration and destruction of solid tumors by CTLs.</rdfs:comment>
    <rdfs:label>Two-photon intravital microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000049">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_18154">
    <rdfs:label>polysaccharide</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_63887"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">polysaccharide</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A macromolecule consisting of large numbers of monosaccharide residues linked glycosidically. This term is commonly used only for those containing more than ten monosaccharide residues.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/105">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Our current efforts in a study of functional homogeinity  involve a transition to 8 colours surface staining, and the evaluation of antigen-specific cell sets identified with MHC tetramers. For the later process, we initiated data collection of EBV, CMV and HIV specific T cell sets.</rdfs:comment>
    <rdfs:label>HIV specific T cell sets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/211">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Untouched naive CD4+ T cells are co-coltured with fungi -pulsed DCs with the aim to prime naive T cells.</rdfs:comment>
    <rdfs:label>Fungi-pulsed DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_36683">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organochlorine compounds</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An organochlorine compound is a compound containing at least one carbon-chlorine bond.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/8">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>BruCells was incorporated in April 2001 in order to further develop therapeutic vaccines cells based on patents and know how developed by Université Libre de Bruxelles (ULB) and Vrije Universiteit Brussel (VUB). The scientific collaboration was extended in 2003 to Université catholique de Louvain (UCL) and to the Brussels branch of the Ludwig Institute for Cancer Research (LICR). The developments are funded in part by the industry partners and by grants from the regional government of Brussels. 

These vaccines are making use of the unique properties of dendritic cells(DCs), a small subpopulation of white blood cells, to activate the sentinels of the immune system (T-lymphocytes). By loading artificially DCs with tumour associated antigens, it is possible to teach the immune system of the patient to destroy its own cancer cells.

The company is currently developing two types of DC vaccines which are both in Phase IIa clinical testing, namely:
DCs fused with whole tumour cells;
DCs loaded ex-vivo with proteins or peptides associated with tumour antigens.

The company also produces and markets a limited number of clinical grade cytokines for use in the preparation of cancer vaccines.</rdfs:comment>
    <rdfs:label>BRUCELLS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/31">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/247"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/248"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_753"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Monocytes are isolated from PBMC using MACS anti-CD14 microbeads and a Midi-MACS® magnetic cell sorting device (both from Miltenyi Biotec, Bergisch- Gladbach,Germany).</rdfs:comment>
    <rdfs:label>Monocyte isolation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/60">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_242"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:comment>Understanding the distribution, function, and lineage relationship of CD8+ T-cell subpopulations is of fundamental value for the monitoring of the immune system in several experimental and clinical situations. However, the available data concerning the description of effector and memory CD8+ subsets in humans remain rather fragmentary because different studies favored the usage of distinct and restricted sets of cell surface markers and functional parameters. 

We obtained coexpression data of 18 genes simultaneously in individual cells from CD8+ T cell subsets (associated to multiple markers to subdivide CD8+ T cells into 14 different cell types, several of which were not described previously). Our results show that each subset has a defined pattern of gene expression. Moreover, effector gene expression of CCR7- cells correlated only with CD27 expression levels and CD27/CD28 coexpression but not with CD45RA/R0 phenotypes. Our findings thus describe new CD8+ cell subsets, allow the identification of relatively homogeneous CD8+ subpopulations, provide a predictable and precise correlation between particular cell surface markers and CD8+ T-cell functional properties, and identify effector cells present in both CCR7-CD45RA+ and CCR7-CD45R0+ compartments. The results also indicate that activated cells might modulate the expression of CD45RA/R0 asynchronously rather than CCR7-CD45RA+ cells always issuing from CD45RA- precursors.</rdfs:comment>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_533"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <rdfs:label>Coexpression of 18 genes simultaneously in individual cells from CD8+ T cell subsets</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000473"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_307"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000082"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/39"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_245"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/156">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86697"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/70"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We obtained data from a study of the correlation between CD8 multiple cell surface markers and functional profiles studied at single cell level. For that purpose, we subdivided peripheral CD8 T cells into eleven different cell subtypes based on the association of multiple cell surface markers. In each subtype, we isolated single-cells. In each single cell, we quantified the expression of multiple genes. Moreover, we isolated and studied cells from different normal donors. These results were published in Blood. 

We showed that

- this strategy allowed the identification of different subclasses of T cells, 
- each of these subclasses were functionally homogeneous at a single cell level, and
- each of these populations was identical in different donors. </rdfs:comment>
    <rdfs:label>Study of the correlation between CD8 multiple cell surface markers and functional profiles studied at single cell level</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/294">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/53"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000798"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T lymphocytes are exposed to HIV-1 to examine if this can directly modulate their functions or interfere with their cross-talk. Preliminary results indicated that, although virus exposure of gamma-delta T cells does not significantly affect their properties, HIV-exposed DCs exhibit a reduced capacity to deliver activation and proliferative signals to gamma-delta T lymphocytes. Moreover, a dysregulated pattern of cytokines and chemokines produced by both cell populations is observed in the presence of the virus.</rdfs:comment>
    <rdfs:label>Gamma-delta T lymphocytes exposed to HIV-1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A207">
    <rdf:rest rdf:nodeID="A208"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/23">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have been following up on the effort to generate proteomics map data of lysosomes purified from non-activated and activated mouse DCs. The decision to focus on the most important organelle for DC activity has been driven from the need to describe in greater detail the proteins involved in the DC response both qualitatively and quantitatively. The partner has been trying to quantify the relative amount of 400 proteins. 

They have also indexed better this list and are currently comparing it to a list of proteins present in macrophages lysosomes (in collaboration with M. Desjardins, Uni of Montreal). They hope to distinguish specific features of DCs to further understand the antigen processing and presentation abilities of these cells in response to pathogens. 

Meanwhile, they have finalized their effort and have been repeating 3 times this analysis to put quantitative figures on the qualitative list of identified proteins. This list has been transferred to Duccio Cavalieri as part of the DC-ATLAS effort. They have identified several proteins of interest and are waiting to have a sufficient staffing to characterize their function in DC response to pathogens. Their laboratory is also involved in the pathway curation program initiated by Duccio Cavalieri. They are participating in the curation of the MHC class II and MHC class  I.</rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/443"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_63836"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Proteomic maps of lysosomes from mouse DC +/- activation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/181">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have worked to strengthen vaccine developments with an improved humanized mouse model. We focus on recombinant vaccines against HIV driven by a powerful poxvirus vaccine system termed MVA BN. To improve our understanding MVA BN has been analyzed thoroughly on the nucleotide level, safety in cell cultures, immune deficient mice as well as in healthy, HIV–infected and other immune deficient humans.</rdfs:comment>
    <rdfs:label>HIV vaccine (MVA BN)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/45">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/431"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/68"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/53"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/121"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/324"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/478"/>
    <rdfs:label>Duccio Cavalieri</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/18"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/66"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/325"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/125"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/67"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/26"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/323"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/89"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/581"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/17"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/94"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/320"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/127"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/127"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/322"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/311"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/39"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/103"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/580"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/132"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/9"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/53"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/122"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/15"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/208"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/58">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/85"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Direct administration of ovalbumin (OVA) encoding lentiviral vectors caused in vivo transduction of cells that were found in draining lymph nodes (LNs) and induced potent anti-OVA cytotoxic T cells similar to those elicited by ex vivo transduced DC.</rdfs:comment>
    <rdfs:label>anti-OVA cytotoxic T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/126">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_759"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are washed.</rdfs:comment>
    <rdfs:label>First washing of DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_555">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_50816"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Endorem</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/395">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/36"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000375"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was evaluated whether STAT-1 was phosphorylated in DC following activation with TLR-dependent Th1 and Th2 stimuli and we found that only in presence of TLR stimuli able to induce Th1 responses STAT-1 was activated.</rdfs:comment>
    <rdfs:label>STAT-1 phosphorylated</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000089">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulator of chemical manufacturer</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/28">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/118"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_463"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience in querying DAVID, the Database for Annotation, Visualization and Integrated Discovery (http://david.abcc.ncifcrf.gov/) . 

For instance, we used DAVID for functional annotation of upregulated and downregulated genes by gene ontology classification and pathway analysis by several bioinformatics approaches. Preliminary results obtained from querying DAVID and Ontologizer (http://www.charite.de/ch/medgen/ontologizer/) show statistically significant enrichment for immunological-relevant signaling pathways and immunology-related GO terms of the upregulated proteins in mature DCs.</rdfs:comment>
    <rdfs:label>DAVID</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/85">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>(Basic manufacturing and QC SOPs on the Generation of cytokines and media components have been provided to DC-THERA participants and associated partners via DC-THERA intranet. )</rdfs:comment>
    <rdfs:label>Generation of cytokines and media components</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_660">
    <rdfs:label>Human Disease-model mouse</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human Disease-model mouse</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A193"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1000048"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">(http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=omimVocab&amp;subset=A)</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/72">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>At the end of the 17th century a monarch decided to survey a group of elderly people with the intent of discovering what they considered to be the change that had the most impact on their lives. What the great majority referred were not the wars or the sovereign changes they had witnessed but the introduction of a fireplace in their homes. The fireplace represented an innovation that allowed families to cook and heat their houses without being asphyxiated by the smoke.

More than political occurrences and sports events, people value their welfare, longevity and health. Practically all the changes that contribute to the improvement of our quality of life result from technological innovations that are a direct outcome of advancements obtained at the level of scientific knowledge. But, paradoxically, most people view science as something odd and quite distant from their daily lives - and nothing could be further from the truth! In fact, each new scientific discovery has the potential to invade and change our daily lives - from the food products we choose to the quality of healthcare services available to us. Naming just a few recent examples: satellite communications, cell phones and the Internet, genetically modified foods, genetic testing for hereditary diseases, and new treatments for AIDS and certain types of cancer.

Science and scientists are commonly viewed as belonging to a strange an impenetrable world. Because it is easy to be scared and terrified by something that one does not understand, it is increasingly important to bring scientists closer to society. Only a scientifically informed society can decide, in freedom, about the risks and benefits intrinsic to each innovation offered by scientific and technological progress.

Scientific research and technological development are costly activities. Progress and innovation lack great investments. Traditionally, it is up to governments to finance the pure pursuit of more knowledge, while the private sector primarily invests in projects targeted at developing new products that can be marketed and, therefore, be profitable. But tradition is not what it used to be and, for the sake of progress, the boundaries between fundamental research and applied research are fading away. Nowadays, all great advancements that take place in the majority of scientific areas depend on access to sophisticated technological platforms, in constant development, that derive from applied research projects. On the other hand, it is the knowledge acquired from fundamental research that supplies the necessary foundations for the birth of new applications.

One characteristic intrinsic to fundamental research is its unpredictability. In most cases, the great discoveries that revolutionised scientific knowledge and/or gave rise to important technological innovations, emerged from a research plan that did not, at the outset, foresee the results obtained. The great lesson to be taken from the history of science is that the pursuit of knowledge cannot be prearranged. Thus, it is crucial that investors are made to understand that what is truly important is to support good science and give thematic research freedom to teams of scientists who have proven their excellency and capacity for innovation. Naturally, this concept is extremely difficult to convey to governments and CEO'. For example, in 2000, the President of the United States announced the attribution of 50 million dollars to academic research in the field of prevention and treatment of Alzheimer's disease. This governmental decision was a direct result of the extensive media coverage given to the discovery of a potential vaccine against the disease by the researchers of a private company in San Francisco. It is easy to imagine the contempt of the President's advisors at the idea of using this money to study Portuguese Familial Polyneuropathy (a hereditary neurodegenerative disease that affects several families in the North of Portugal). However, it was in the process of studying this rare disease that the Portuguese researcher Maria João Saraiva discovered one of the basic concepts that inspired the experiments for the development of a vaccine against Alzheimer's disease. Quoting Lewis Thomas, "If you want a bee to make honey, you do not issue protocols on solar navigation or carbohydrate chemistry, you put him together with other bees (and you'd better do this quickly for solitary bees do not stay alive) and you do what you can to arrange the general environment around the hive. If the air is right, the science will come out in its own season, like pure honey".</rdfs:comment>
    <rdfs:label>Universidade de Lisboa, Institute of Molecular Medicine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_835">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The procedure of separating a BioMaterial into two or more BioMaterials of similar composition e.g. aliquoting a sample. The BioMaterial may be a BioSource (e.g., a tissue) or a BioSample (e.g. RNA extracted from a BioSource).
Non exact Synonym: sample</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">split</oboInOwl:hasRelatedSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sampling protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A209">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/251">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/32"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_50144"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>100 mM sodium pyruvate were added to the monocyte cell culture.</rdfs:comment>
    <rdfs:label>Sodium pyruvate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A208">
    <rdf:rest rdf:nodeID="A210"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_485"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/106">
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was found that lymph nodes that drain sites of mature DC or adjuvant inoculation recruited L-selectin- CCR7- effector cells.</rdfs:comment>
    <rdfs:label>L-selectin- CCR7- effector T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/157">
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have obtained data on CD8T lymphocyte populations in humans from our effort to identify and characterize these populations. We compared the distribution of phenotypically distinct cell sets using seven color staining in the blood, lymph nodes and spleen. Due to our location in a pediatric hospital, we have access to these organs removed from patients that undergo surgery due to clinical situations that do not affect the immune system (most frequently malformations). We found that the addition of other markers allow to subdivide N, CM, TEM and TEMRA populations in additional cell types. These different cell types have a different distribution in the blood as compared to other lymphoïd organs. We characterized these subtypes in the blood by single-cell multiparametric analysis. Our preliminary results indicate these subtypes in the blood correspond to homogeneous different populations, but cells in each sub-type are homogeneous. We are presently analysing cells with the same phenotypes isolated from the LN, to investigate if they have similar characteristics. </rdfs:comment>
    <rdfs:label>Identification and characterization of CD8T lymphocyte populations in humans</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/67">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/120"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>This bioassay is a list of standardized procedures, which enables to use the dendritic cells as tools for the determination of the effects of new chemical compounds on dendritic cell capacity to produce type I IFNs. The selected molecules could be potential new vaccine adjuvants.</rdfs:comment>
    <rdfs:label>DC-based assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/32">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/251"/>
    <rdfs:label>Cell culture</rdfs:label>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/253"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/249"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Cells are cultured in RPMI 1640 medium (GIBCO BRL) supplemented with 2 mM L-glutamine (Sigma), 1% (vol/vol) non-essential amino acids, 100 mM sodium pyruvate, 50 U/ml of penicillin and 50 mg/ml of streptomycin (Gibco BRL) containing 10% (vol/vol) FCS (Hyclone).</rdfs:comment>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/254"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_750"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/250"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/248"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/252"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/210">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/68"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Untouched naive CD4+ T cells are co-coltured with fungi -pulsed DCs to prime naive T cells.</rdfs:comment>
    <rdfs:label>Untouched naive CD4+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/9">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Novartis Vaccines and Diagnostic Srl is part of Novartis Vaccines and Diagnostic, the world’s fifth-largest vaccines business. The company’s portfolio of products includes more than 35 vaccines for influenza, meningitis C, yellow fever, rabies, tick-borne encephalitis, haemophilus influenzae B (Hib), polio, mumps, measles, rubella (MMR) and diphtheria, tetanus and pertussis (whooping cough), which are distributed in over 75 countries all over the world. In Italy, Novartis Vaccines and Diagnostic is located in Siena and Rosia (SI) and is the only Italian vaccines company with Research, Development, Manufacturing and Commercial Operations. Its long tradition of more than one hundred years’ presence, based on Achille Sclavo’s legacies, is focused on preventing infectious diseases and developing new vaccines to improve human health globally.</rdfs:comment>
    <rdfs:label>Chiron - Novartis Vaccines and Diagnostic S.r.l.</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/295">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000214"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Co-cultures of mDCs and pDCs in response to CpGs, LPS and bacterial particles were studied to identify a possible cooperation between myeloid and plasmacytoid DCs in response to different microbial stimuli, and to characterize the mechanisms of this cooperation.</rdfs:comment>
    <rdfs:label>Co-culture of mDCs and pDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/57">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/85"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16991"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Direct administration of ovalbumin (OVA) encoding lentiviral vectors caused in vivo transduction of cells that were found in draining lymph nodes (LNs) and induced potent anti-OVA cytotoxic T cells similar to those elicited by ex vivo transduced DC.</rdfs:comment>
    <rdfs:label>ovalbumin (OVA) encoding lentiviral vectors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/44">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Jean-Michel Oost</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/180">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/100"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Alternatively activated DC (AA-DC) were obtained by culturing immature DC in the presence of maturative agonists (such as, LPS, CD40L or TNF) and calcitriol, IL-10 or prostaglandin E2 for a study of molecular signatures for alternatively activated DC. AA-DC showed a decrease in the production of IL-12 but retained most of the ability to secrete other cytokines, such as TNF and CXCL8. The hallmark of AA-DC was the production of the angiogenic cytokine VEGF in vitro, and in vivo when the cells were implanted into the chicken embryo CAM assay.</rdfs:comment>
    <rdfs:label>AA-DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/288">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Camille Chauvin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_552">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_30430"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">111Indium</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">111In</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">rattus</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">rats</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rat</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/123">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are stimulated over 6 hours.</rdfs:comment>
    <rdfs:label>Stimulation of DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/73">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>With over 600 years of tradition, the Julius Maximilian University of Würzburg is today one of Germany's mid-sized universities. 400 professors in 10 faculties here teach roughly 20,000 students. 

The University of Würzburg is among the leading institutions of higher education in Germany; this has been confirmed by rankings carried out by national and international research organizations, international external assessment committees as well as by the German Federal and State Excellence Initiatives (founded in 2006). Internationally, the University of Würzburg is also one of the top-ranking academic institutions in many fields of research and study. 

As early as the early 1990s, the university had already begun establishing interdisciplinary research centers, in which new topics of research could be addressed and innovative courses of study created. These interdisciplinary centers have become the international trademark of the University of Würzburg. Numerous external assessment committees confirm this. 

Most recently, the university's priorities have been focused on theInternational Graduate School, established in 2004. The school's intention is to provide all doctoral students structured learning opportunities to accompany their first professional academic pursuits. The University of Würzburg is particularly devoted to supporting the next generation of young academics. 

The creation of new centers has acquired incredible momentum and has established Würzburg as one of the top institutions of higher learning in Germany. Currently, the nine Collaborative Research Centers and nine graduate research training groups are an indication of this momentum. The Collaborative Research Centers and graduate research training groups were established with grants from the German Research Institue (DFG). Underpinning the competitive nature of applying for DFG research grants, Axel Haase, President of the University of Würzburg, remarks: "the chances of being awarded a DFG grant are generally around 20 percent." 

Today, the quality of the scientific research is measured by the number of research projects funded by goverment initiatives, private foundations, and industry. The number of publications in internationally-respected journals like Nature or Science is also a gauge of excellence in research. 

Although the number of professors, assistants, and instructors has remained constant over the past few years, the two parameters of success described above have increased at a nearly explosive rate since the mid-1990s. The foundation of this success was the establishment of new research centers and their integration into the larger structures of the university. </rdfs:comment>
    <rdfs:label>Universität Würzburg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_700">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_669"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Klkl/Klkl transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">either: C.Cg-Klkl or (involves: C3H/J * C57BL/6J)</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/394">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/36"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_611"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have identified some genes differentially expressed in different stimulation conditions. In particular, the most relevant gene upregulated in presence of stimuli typically inducing Th1 responses (LPS, CpG, Poly I:C) but not in presence of the Th2 stimulus, Pam3Cys, was Stat-1.</rdfs:comment>
    <rdfs:label>STAT-1 gene upregulated</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/29">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_480"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has expertise in lipofection of tumor-antigen-encoding RNA into DC. The method was compared to RNA electroporation into DC.</rdfs:comment>
    <rdfs:label>Lipofection of tumor-antigen-encoding RNA into DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#elementsTypeOf">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect bio aggregates to an ontological type. As this would make the ontology OWL full, the annoation property elementsTypeOfAnno is used instead.</rdfs:comment>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:elementsTypeOfType</dcr:hasClassAsRangeProperty>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">elements type of</rdfs:label>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/158">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/62"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_555"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_552"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab obtained first data from a new clinical trial of a DC vaccine administered into irradiated tumours in RCC. Three patients were enrolled and DC vaccine was produced. However only one patient received the vaccine due to cancer progression in the other two patients. The DC were labelled with 111In. The following patients will receive DC labelled with Endorem and the vaccine will be imaged with MRI. The patient treated is in complete remission 6 months after treatment.</rdfs:comment>
    <rdfs:label>Clinical trial of a DC vaccine administered into irradiated tumours in RCC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/329">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These constructs were used to transfect immature DCs.</rdfs:comment>
    <rdfs:label>Constructs encoding for the oncogene Her-2/neu</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/103">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Our current efforts in a study of functional homogeinity  involve a transition to 8 colours surface staining, and the evaluation of antigen-specific cell sets identified with MHC tetramers. For the later process, we initiated data collection of EBV, CMV and HIV specific T cell sets.</rdfs:comment>
    <rdfs:label>EBV specific T cell sets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A78">
    <owl:unionOf rdf:nodeID="A200"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_353">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TRIMs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TRIM</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tripartite motif proteins. tripartite motif protein family</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tripartite motif protein</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#IAO_0000104_5">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/1">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdfs:comment>Monocyte source: leukapheresis product (rarely: buffy coats of healthy blood donors, research use only) =&gt; gives high yield of monocytes (15-25 x 10e8)
Monocyte isolation: affinity purification (CliniMacs) or counter-flow centrifugation (Elutra)  =&gt; good recovery, high purity, high viability
Culture: in culture bags (Teflon Bags, Cell Genix) in serum free medium (CellGro from Cell Genix) =&gt; no contact-mediated activation, no interference by serum proteins
For research use (sometimes) generation of adherent DC by plating monocytes on plastic.
Cytokines: clinical grade GM-CSF (Leukine, Berlex) and GMP-grade IL-4 (Cell Genix)
Maturation (usually day 5): clinical grade TNF-? (Cell Genix) or poly I:C (research use only) for 48 hours 
Antigen loading on immature DC: electroporation, viral transduction, pulsing with peptides/cell lysate/apoptotic bodies
Total recovery of usable immature/mature DC: 40/30 % +/- 10%
Application: DC vaccines, generation of CTLs (for adoptive transfer of T cells or research use), immunomonitoring (targets in read-outs for T cell adoptive transfer therapy)</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasBioSourceType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:label>Generation of monocyte-derived DC under GMP conditions</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/115"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/292">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These T cells are specific for the 0T-1-OVA antigen.
They were used to study the expression of twenty different genes either mediating effector functions, or coding for different receptors involved in T cell differentiation and memory generation.</rdfs:comment>
    <rdfs:label>Endogenous polyclonal T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_701">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_669"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fbn1Tsk/Fbn1+ transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">B6.Cg-Fbn1Tsk</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A210">
    <rdf:rest rdf:nodeID="A211"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/84">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>(Basic manufacturing and QC SOPs on the Generation of Peptide loaded DCs have been provided to DC-THERA participants and associated partners via DC-THERA intranet. )</rdfs:comment>
    <rdfs:label>Generation of Peptide loaded DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_35225">
    <rdfs:label>Buffer</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">wikipedia: A buffer solution is an aqueous solution consisting of a mixture of a weak acid and its conjugate base or a weak base and its conjugate acid. It has the property that the pH of the solution changes very little when a small amount of acid or base is added to it. Buffer solutions are used as a means of keeping pH at a nearly constant value in a wide variety of chemical applications.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Buffer</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0302729"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedProtein_4">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasMolecule"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_15422">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ATP</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">adenosine triphosphate</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">adenosine triphosphate</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ATP</dcr:dcthera_label>
    <rdfs:subClassOf rdf:nodeID="A209"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36976"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/43">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/356"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/400"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/398"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/405"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/36"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/399"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/403"/>
    <rdfs:label>Thierry Boon</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/232"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/404"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/401"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/253"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/35"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/402"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/77"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/78"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000006">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">consumer safety officer</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/56">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/84"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were studied with regard to responses to viral infections and compared to TLR K/O mice. We used the mouse pox virus Ectromelia and MVA-BN.</rdfs:comment>
    <rdfs:label>C57Bl/6 mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/289">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Jiannis Ragoussis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/21">
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_577"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_557"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Gene expression data were generated on DC activated with different TLR agonists typically associated with the respective response.</rdfs:comment>
    <rdfs:label>Comparative kinetic global gene expression analyses of DC activated with different TLR agonists typically associated with the respective response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/74">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Team 4 of the INSERM unit 892

Dendritic cell biology :  Application to immune-therapy of cancer

Developed a decade ago on mesothelioma cancer, our work had shown that cell death and, in particular, the apoptotic process could initiate immunogenic properties if triggered in a context of cellular stress. Our more recent studies highlighted the induction of one such apoptosis with a favourable immunogenic context either by viral infection (attenuated vaccine of measles virus), or by methylation of DNA and/or the histone de-acethylation via their inhibitor treatments.     
We also showed, in vitro and in vivo, that dendritic cells, after phagocytosis of these apoptotic cells, could initiate an immune response with activation of a specific T  cell response (by presentation and cross-presentation of antigens).  
The aim of our investigation is to propose alternative therapeutics to conventional therapies of pleural mesothelioma, by initiating immunogenic properties of mesothelioma cancer cells after treatments such as :
1) induction of tumor associated antigen expression by specific epigenetic drugs including DNA methylation and histone de-acethylation inhibitors,
2) induction of immunogenic properties of cancer cells viro-infected (measles virus vaccine)
3) induction of an effective cytotoxic immune response via dendritic cells loaded with apoptotic tumor cells.</rdfs:comment>
    <rdfs:label>INSERM U892</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/124">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_759"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs are collected and washed 3 times with PBS.</rdfs:comment>
    <rdfs:label>Washing of DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/393">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The poly(I:C) was used for stimulating DCs. It was shown in mice that both IL-10 as well as IL-12 production is dependent on the signalling adaptor molecules either MyD88 or TRIF, respectively in response to CpG, LPS or PolyIC.

Manufacturer: Invivogen Life Technologies</rdfs:comment>
    <rdfs:label>poly(I:C) (Invivogen Life Technologies)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedTermClass_5">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasAutoRelatedTermClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/2">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/86"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_228"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_227"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/124"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Staining of D2SC1/Flt3-DC and staining of the cells to be taken up by Mini67-1KT or Mini26-1KT (PKH67/PKH26 green/red fluorescent cell linker mini kit for general cell membrane labelling) from Sigma
Staining of GM-DC/Raw with anti-CD11c antibodies
Coculture of DCs and cells to be taken up (1(-2)x105 + 1(-2)x105 cells in 12-well) for 4 h to 24 h at 37°C 
Take supernatant and freeze at -80°C for analysis of DC-stimulation
Trypsinize cells have and fix in 4 % PFA (or formalin)
FACS analysis</rdfs:comment>
    <rdfs:label>Uptake of dead cells by D2SC1/Raw/Flt3-DC/GM-DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/159">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/292"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.obofoundry.org/obo/OBI_1000036"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdfs:comment>Our laboratory has data on autologous dendritic cells loaded with apoptotic leukemic cells from patients with B-CLL used as vaccine in patients.

In preclinical experiments DC-loaded with apoptotic leukemic cells were shown to induce a strong preferentially Th1 T-cell response. Apoptotic tumor cells were more effective than lysate, RNA and cell hybrids. 

A clinical trial has been initiated where autologous dendritic cells are loaded with apoptotic leukemic cells from patients with B-CLL. So far “vaccines” have been produced for six patients. Four patients are enrolled. A strong type I T cell response has been induced. Preliminary data also indicate reduction of circulating tumor cells. No adverse effects have been observed.</rdfs:comment>
    <rdfs:label>DC VACCINATION OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/2"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_167"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/69">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/196"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_591"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience on performing immunofluorescence assays. As an example, an assay on ordered sequential sections was used to analyze the infiltration and destruction of solid tumors by CTLs. </rdfs:comment>
    <rdfs:label>Immunofluorescence assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/104">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Our current efforts in a study of functional homogeinity  involve a transition to 8 colours surface staining, and the evaluation of antigen-specific cell sets identified with MHC tetramers. For the later process, we initiated data collection of EBV, CMV and HIV specific T cell sets.</rdfs:comment>
    <rdfs:label>CMV specific T cell sets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A206">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_30322">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell membrane</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">membranes</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">membrane</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0005575"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000073">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001292</dcr:replaced_by>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD303</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A211">
    <rdf:rest rdf:nodeID="A195"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/570">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This patient is undergoing i.v. application of indium labelled E/L-S DC (without antigen loading) in a study of DC migration.</rdfs:comment>
    <rdfs:label>Patient undergoing i.v. application of indium labelled E/L-S DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasAutoRelatedProtein_5">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#hasMolecule"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_702">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Systemic Lupus Erythematosus-model mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies involve orthologs</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/83">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/123"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/87"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Phagocytosis assay
Yeasts/spores were biotinylated using 10 mg/ml sulfo-NHS-LC-biotin (Sigma-Aldrich) in 50 mM NaHCO3 pH 8.5 for 2 hours at 4°C. The remaining reactive biotin molecules were inactivated by incubation in 100 mM Tris-HCl pH 8.0 for 40 minutes at 4°C. DCs were then treated with biotinylated spores/yeasts. After 1 hour, cells were permeabilized and labeled with aHLA-DR-FITC. After zymolyase treatment, intracellular yeasts/spores were detected using APC-labeled streptavidin and analyzed by flow cytometry.

Receptor mediated-internalization assay
Immature DCs were allowed to adhere onto fibronectin and subsequently incubated with FITC-labeled yeast or spores for 5, 15, 30 minutes at 37°C. At the end of the incubation period, the samples were fixed in 4% PFA, permeabilized in Methanol, and labeled for DC-SIGN and/or MR using specific mAb and isotype-specific fluorescent secondary Abs. Samples were analyzed using a Zeiss LSM 510 confocal microscope. Alexa647-conjugated goat-anti-mouse IgG, and Alexa568 goat-anti-mouse IgG2b were from Molecular Probes. </rdfs:comment>
    <rdfs:label>Internalization assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/293">
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/UBERON#FMA_9608-MA_0000134-MIAA_0000084-XAO_0000123-ZFA_0000669"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/95"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/107"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These bone marrow derived murine dendritic cells (BM-DC) were generated with GM-CSF according to Lutz et al. (J Immunol Methods 1999, 223: 77-92) and were used for the investigation of chemokine dependent CCR7 signalling.</rdfs:comment>
    <rdfs:label>BM-DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/30">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/246"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/247"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_753"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>PBMC are isolated from buffy coats by density gradient centrifugation using Biocoll (BIOCHROM).</rdfs:comment>
    <rdfs:label>Isolation of PBMC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/29">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/26"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_808"/>
    <rdfs:label>Multi-photon imaging of DC-CD8+ T cell interactions in intact lymph nodes</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/33"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/UBERON#UBERON_0000029"/>
    <rdfs:comment>Multi-photon imaging data on DC-CD8+ T cell interactions in intact lymph nodes (LNs) have been obtained. The initiation of cytotoxic immune responses requires the direct interaction between naïve CD8+ T lymphocytes and dendritic cells. Multi-photon imaging showed that during priming, naïve T cells and dendritic cells (DCs) establish sequentially brief (i.e. minutes) and long (hours) antigen-specific contacts. We observed that ICAM-1 expression by mature DCs is critical for long-lasting contacts with CD8+ T cells, but dispensable for short-lived antigen-specific interactions. Serial brief T cell-dendritic cell contacts induced early CD8+ T cell activation, proliferation and effector CTL differentiation in the first few days after immunization. ICAM-1-deficient mature DCs, however, failed to induce fully effective priming, as CD8+ T in the LNs draining the immunization site produced reduced levels of IFN?, were clonally depleted after 2 weeks, and the mice failed to respond to re-challenge. Our results indicate that ICAM-1-dependent long lasting interactions between mature DCs and naïve CD8+ T cells determine the survival of activated CD8+ T cells and the establishment of effective memory.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/34"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/219"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000618"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_621">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ManLAM</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mannosylated lipoarabinomannan</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000597">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-15</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-15</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/41">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/150"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasBioSourceType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#gp100_Antigen"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_28262"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:comment>In ongoing clinical trials (multipeptide loaded cytokine matured moDC +/- CD40L activation in &gt;60 pat.) we have obtained valuable information with high impact on future DC-trials: 

1) the presence of 2% DMSO in the thawed final vaccine has no negative impact on the quantity and quality of induced immune responses; thus thawed DMSO containing vials do not have to be centrifuged, but simply diluted; 

2) class I peptide loaded cytokine matured DC induce de novo or expand preexisting CD8+ T cell IFN gamma responses in the majority of melanoma patients (&gt;70%), surprisingly without the need for class II peptide loading for T cell help; 

3) a statistical analysis of the whole group of vaccinated melanoma patients showed statistically significant DC induced responses towards the antigens gp100.A2, NY-ESO1.A2, MAGE-3.DR11 and MAGE3.DP4. 

This information will help finalizing the recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion group. </rdfs:comment>
    <rdfs:label>Recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion group</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_8"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/UO#UO_0000180">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/UO#UO_0000051"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A concentration unit which is a standard measure of the mass of a substance in a given volume (density).</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mass per unit volume</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/430">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/28"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We found that LPS-stimulated mDCs are able to induce up-regulation of co-stimulatory molecules on co-cultured pDCs. Likewise, CpG-stimulated pDCs activate co-cultured mDCs. The cross talk between these two populations of DC is very efficient since it can be observed at mDC/pDC ratio ranging from 1/10 to 10/1. </rdfs:comment>
    <rdfs:label>CpG-stimulated pDCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/82">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>To determine ROS production we used the modified version by Choi et al. (2006) of the microscopic Nitroblue tetrazolium (NBT, Sigma-Aldrich) assay. Briefly, DCs were stimulated with spores or yeasts, washed, supplemented with 0.1 mg/ml of NBT, which allows the precipitation of formazan particles in presence of ROS. Blue formazan particles were dissolved using 2M KOH and DMSO and its absorbance was measured using a microplate reader at 620 nm. The absorbance of dissolved NBT increased in proportion to cell number, incubation time, and stimulus concentration.</rdfs:comment>
    <rdfs:label>ROS production</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_703">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves:129P2/OlaHsd * C57BL/6</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_702"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dnase1tm1Tmo/Dnase1tm1Tmo transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/571">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Indium labelled E/L-S DC (without antigen loading) is administered i.v. to a patient to study the reaction with regard to DC migration.</rdfs:comment>
    <rdfs:label>Indium labelled E/L-S DC (without antigen loading)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/247">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/107"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Manfred Lutz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/4">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>About NIMR :: Science at the Institute

Four major research areas at the Institute contain 15 Divisions with over 200 scientists, 100 post-doctoral fellows, and approximately 100 postgraduate students making the Institute the largest of the MRC's research establishments.

Research support
Research at the Institute is underpinned by over 200 scientific support and ancillary staff within the Divisions, together with those providing central services and common facilities.

Funding
The Medical Research Council (MRC) is the principal source of research funding. A total budget of £25m p.a. is set every five years following an Institute-wide review of resources. This review takes place after the quinquennial peer review (conducted by MRC Research Boards) of the programmes of the individual Divisions. 

The Institute also attracts support from a wide range of different agencies, including medical research charities, international sources, particularly the EU, and from industrial and commercial companies.</rdfs:comment>
    <rdfs:label>MRC - The National Institute for Medical Research</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_242">
    <rdfs:label>CD27 receptor</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 27</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-27</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD27</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD27 receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A212"/>
    <rdfs:subClassOf rdf:nodeID="A204"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/IAO_0000310">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/80">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Zeljko Medved</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_663">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_661"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129P2/OlaHsd * BALB/cJ * FVB/N</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Brca1tm1Brn/Brca1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0 transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_550">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glucomonomycolate</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GMM</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/196">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/69"/>
    <rdfs:label>Dynamic analysis of  tumor infiltration and rejection by CTLs</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/68"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data was obtained on the infiltration and destruction of solid tumors by cytotoxic T lymphocytes (CTLs). 

Although the immune system evolved to fight infections, it may also attack and destroy solid tumors. In most cases, tumor rejection is initiated by CD8+ CTLs, which infiltrate solid tumors, recognize tumor antigens and kill tumor cells. We used a combination of two-photon intravital microscopy and immunofluorescence on ordered sequential sections to analyze the infiltration and destruction of solid tumors by CTLs. We show that in the periphery of a thymoma growing subcutaneously, activated CTLs migrate with high instant velocities. When the tumors express cognate antigens the CTLs are arrested in close contact to tumor cells. In regions of the tumors where the tumor cells are dead, CTL motility resumes, using apparently non-guided trajectories, or following collagen fibers or blood vessels. Strikingly, CTLs followed blood vessels for extended lengths, adopting an elongated morphology. CTLs also infiltrated tumors in depth, but only when the tumor cells express the cognate CTL antigen. In tumors that do not express the CTL cognate antigen, we observe peripheral infiltration by CTLs, but the lymphocytes neither stop moving, nor kill tumor cells or infiltrate tumors deeply. Antigen expression by tumor cells therefore determines both CTL motility within the tumor and the depth of tumor infiltration. This work is currently submitted for publication.</rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/120"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_341"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_775">
    <rdfs:label>data transformation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">data transformation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A data transformation step is a step in a protocol that specifies how to produce output data from input data.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701460">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD11c</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001013</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/286">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Georg Doessinger</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/121">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/551"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/550"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>In order to test homogeneous yeast populations, pure spore cultures are obtained by using this strain whose sporulation efficiency is 100%. To prepare spores, cells are grown on YPD plates, replicated on SPOIV medium (2% potassium acetate, 0.25% yeast extract, 0,1% glucose) and sporulation is assessed by optical microscopy. Zymolyase (2 mg/ml) is used to digest ascum and liberate spores. [We initially performed experiments to evaluate zymoliase sensitivity of asci for this specific strain and we assessed that 15 minutes incubation was the minimum time needed to damage the ascus, without touching the spore cell wall.] Zymoliase is inactivated by heat (65°C for 2 minutes) and washed away carefully together with the remainings of the empty ascus, by resuspending twice the spore culture in 500 µl of distilled water centrifuging and discarding the supernatant; the spores are then resuspended to a concentration of 108 cells/ml. In order to exclude damage on the spore cell wall or effects on spore viability 100 µl of a culture of 1000 spores per ml is plated on YPD in triplicate. [The spores showed 100% viability.] The procedure used allows exposing DCs to the pure spore culture and to analyze the response to the spores alone, eliminating confounding effects of the presence of the ascus. Although from a mycological point of view the term ascospores might seem more appropriate than spores, we will use the term spores to specifically indicate that the effects we are observing are only due to the spores and not to the ascus. 
We observed that after 24 hours of culture in RPMI 1640 (GIBCO-BRL), spores were germinating and the exponentially growing cells were starting to divide. Therefore any analyses performed at later time points would be affected by this altered state, while no interference should be present until 24 hours. </rdfs:comment>
    <rdfs:label>Spore stimuli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_602">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Salmonella thiphimurium</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/28">
    <rdfs:comment>Our group has produced in-vivo multi-photon microscopy imaging data on the distribution and motility of NK cells by tracking migration of DC-primed NK cells in vivo. Since LPS-activated DC are potent inducers of NK cell priming and lymph nodes appear to be a key place in which DC and NK cell interactions occur, we have investigated the in vivo capacity of resting and DC-primed NK cells to reach the draining lymph nodes. DC –activated NK cells reach the draining lymph node within 24 hours after intravenous injection and persist there for at least 72 hours. NK cells distribute at the periphery of T cell areas, where also DC are known to be located. By further analysis of the molecular mechanisms responsible for NK cell activation by LPS-primed DC, we have found that three soluble DC-derived molecules, IL-2, type I interferons (IFNs), and IL-18, are necessary and sufficient to elicit efficient production of IFN gamma from NK cells. These analyses have been performed also in vivo by using appropriate mouse models in which conditional ablation of DCs can be achieved and we have confirmed the relevance in vivo of DC-derived IL-18, type I IFNs and IL-2 in NK cell activation.

We plan to study the physiological relevance of NFAT activation in DCs and of CD14-mediated activation of NFAT pathway in vivo. We also plan to describe the TLR4 and CD14 signal transduction pathway in DCs following LPS activation.</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000814"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/14"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/21"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000601"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/89"/>
    <rdfs:label>Multi-photon microscopy to track migration of DC-primed NK cells in vivo</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/15"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/42">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/253"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sophie Lucas</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/234">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/131"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>The initiation of a multi partner trial is planned and data will be generated. The DC-THERA trial will compare the use of ‘TRI-MIX’ RNA in clinical trials that were already underway at each of the three centres (Nijmegen Medical School, Nijmegen; Friedrich-Alexander University, Erlangen; Vrije Universiteit Brussel, Brussels).

It was decided that Friedrich-Alexander University, Erlangen, would apply for a licence to prepare GMP-grade ‘TRI-MIX’ RNA and subsequently supply this for all three centres.

The multi-centre trial is a well-standardised, two-arm, multi-centre clinical trial in melanoma patients comparing DC transfected with mRNA coding for constitutively active TLR-4, CD40 and CD70 (‘TRI-MIX’) with other modalities. The trial will be conducted across the 3 centres mentioned above using standardised SOPs – both for preparation of DC and for subsequent immunomonitoring. At these respective centres the following will be compared:

1) peptide-pulsed DC, matured either with the standard maturation cocktail (IL-1, IL-6, TNF-alpha, PGE2) or transfected with ‘TRI-MIX’, and administered intra-nodally under ultrasound guidance (Nijmegen)
2) antigen mRNA-transfected DC, matured either with the standard maturation cocktail (IL-1, IL-6, TNF-alpha, PGE2) or transfected with ‘TRI-MIX’, and administered subcutaneously (Erlangen)
3) antigen mRNA-transfected DC, co-transfected with ‘TRI-MIX’, comparing intradermal vaccination with intradermal plus intravenous vaccination (Brussels).

The analyses of all DC vaccination trials published has shown that this general vaccination strategy is clearly promising given the fact that the adoptive transfer of antigen-loaded DC (i.e. DC vaccination) appears more immunogenic than other vaccination strategies and clinical effects have also been observed even with first generation DC vaccines. The major deficit in this field is that the obvious variables are simply not addressed in a well-coordinated fashion to allow rapid optimization. This is a pity as DC vaccination is rather unique in that it allows to control ex vivo many biological aspects of DC relevant for optimized DC vaccination but also for other more conventional vaccine strategies (which also depend on DC as antigen in various formats + adjuvant is injected which has to reach and activate DC in situ). The reason for the lack of coordinated testing including combination strategies appears to differ in industry and academia. Biotech companies naturally focus on strategies which are covered by their intellectual property and patents, and in academia there are people with different ideas and visions who in addition have to “publish and perish” even if dealing with mid- to long-term efforts such as clinical trials for which in addition there is insufficient funding. 

After treatment of 50% of the patients (i.e. 15 patients in the Tri-Mix-DC arm) or by the end of 2009, whichever comes first, we will perform an interim analysis of this immunogenicity trial. A final immunogenicity analysis, which might identify a particularly immunogenic superior DC vaccine, will be available by mid 2010. The clinical fate of the patients will be followed further but this is not the endpoint of this immunogenicity trial. </rdfs:comment>
    <rdfs:label>Multi-centre trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A65">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_622">
    <rdfs:label>Cytokine cocktail</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytokine cocktail</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A213"/>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_585"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_241">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">E3-ubiquitin ligase MARCH I</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MARCHI</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MARCH I</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_23367">
    <rdfs:label>Molecular entity</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Molecular entity</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">molecular entities</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0400169">
    <rdfs:label>microscope</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/42">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/90"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Argos successfully developed a manual DC manufacturing method with excellent reproducibility in terms of quality, yield, and viability of DCs. The process developed has the following unique advantages:

- The manufacturing process has been optimized for producing DC from non-frozen day-old pheresis material which allows centralized manufacturing. The pheresis product is sent in a specially designed shipper to the manufacturing facility.

- The final vaccine product is formulated for direct injection (i.e., no clinical site participation required except for bedside thaw and i.d. injection)</rdfs:comment>
    <rdfs:label>Standardization of DC generation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_35222">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A substance that diminishes the rate of a chemical reaction.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inhibitor role</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Subclass of "chemical role".</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_50122">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_26421"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">rosiglitazone</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/431">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/46"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000524"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000522"/>
    <rdfs:comment>We studied the response of human MoDC to yeast, spheroplasts, pseudohyphae and spores. Analysis of IL-6, IL-8, TNF?, IL-1?, IFN?, IL-10, IL-12p70, IL-12p40 secretion was performed with a multiplex assay.</rdfs:comment>
    <rdfs:label>Human MoDC</rdfs:label>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FAO#FAO_0001002"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/31"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000789">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">alpha-beta T cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_704">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fcgr2btm1Ttk/Fcgr2btm1Ttk transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">B6.129-Fcgr2btm1Ttk</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_702"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/81">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/112"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>IL-12p70 inhibition by cytochalasin D
DCs were exposed to cytochalasin D (10 microg/ml, TebuBio) for 30 minutes at 4°C. After washing with cold PBS, DCs were stimulated with S. cerevisiae yeast cells or spores at a DC:stimuli ratio of 4:1 for 24 hours. IL-12p70 production was assessed by ELISA.

IL-12p70 blocking assay
In order to assess the importance of IL-12p70 in balancing Th1/Th17 response two different experiments were performed.
In one case, DCs were stimulated for 8 hours with live spores of S. cerevisiae and C. albicans hyphae at a stimuli:DC ratio of 4:1 in the presence of different concentration of human recombinant IL12p70 (0, 1, 10 and 100 ng/ml).
In the second experiment, DCs were pre-incubated with different concentrations (0, 0.1, 1, 10, 100 microg/ml) of a monoclonal anti-human IL-12 antibody for 2 hours, then stimulated for 8 hours with live S. cerevisiae cells in a stimuli:DC ratio of 4:1. 
The ability of these stimulated DCs to drive CD4+ T cells polarization towards a Th1 response was assessed by measuring of IFNgamma and IL-17 in T cells 5-day culture supernatants.</rdfs:comment>
    <rdfs:label>IL-12p70 blocking assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/572">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>BruCells is developing allogeneic dendritic cell fusion vaccines as a therapeutic cancer immune therapy targeted at treating glioma or renal cell carcinoma (RCC). The active substance consists of hybrid cells resulting from the fusion of allogeneic dendritic cells (DC) with allogeneic glioma or RCC tumour cells. Therefore the fusion vaccine qualifies as a somatic cell therapy medicinal product, as defined in Part IV (Advanced therapy medicinal products) of annex I to Directive 2001/83/EC (1), as amended by Directive 2003/63/EC (2).

(1)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.

(2)  Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use.</rdfs:comment>
    <rdfs:label>Allogeneic dendritic cell fusion vaccines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/5">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The University of Milano - Bicocca was conceived as an open campus with wide spaces at its disposal in the international city of Milan. 
The "Bicocca", as it is commonly known, is a university that strongly believes in the potential of its students and in combining their studies with an active social life.

The University of Milano - Bicocca has twenty-one departments for the scientific areas of Economics, Educational Sciences, Law, Mathematics, Physics and Natural Sciences, Medicine and surgery, Psychology, Sociology, Statistical Sciences.
The departments promote research at the University, and organise the research doctorate programmes.

HISTORY
The University of Milano—Bicocca turned 10 in 2008 but our history is richer than it seems. It was instituted on June 10th, 1998 to serve students from Northern Italy and take some pressure off the historical University of Milan which was getting over-crowded. At that time we did not have an officially nominated teaching staff. Groups of professors and researchers from the same scientific fields chose to come and participate in the project. They were driven by their enthusiasm for the new, and by the chance to broaden academic horizons without having their work undermined by traditional education methods. From the start, this very fertile climate became a unique training ground, which offered something new, even for the most traditional disciplines.

The University stands in an area on the northern outskirts of Milan that up until the late eighties was occupied by the Pirelli tyre industrial complex and is now the product of the biggest urban renewal project ever carried out in Milan since the end of the Second World War. Based on a design by the world-renowned ‘Gregotti Associati International’ design and architectural firm,  the ex industrial area and its warehouses were quickly converted into a new district, which includes our Athenaeum, research laboratories and student residence halls, the Arcimboldi Theatre,  temporary location of the La Scala theatre during its renewal tenure, the state National Research Council (CNR), multinational company offices and the new headquarters of the Pirelli Group, new homes and sports centres, showrooms, a large multi-screen cinema, and a park with the ‘Collina dei ciliegi’ (cherry-tree hill). 

In this cityscape the University of Milano—Bicocca was born and hundreds of lecturers have brought their competences, international networks and research groups. This synergy makes the University a laboratory where tradition and modernity are fused to invent an innovative visionary future. 

But why Bicocca?  The new quarter is named after the ancient villa Bicocca degli Arcimboldi (located at # 202, viale Sarca),  a mid-15th century rural residence of the Arcimboldi family, which now belongs to a financial holding company. In the heart of the Bicocca quarter, University buildings are characterized by red walls and white window shutters: the main complex facing the squares Piazza dell’Ateneo Nuovo and Piazza della Scienza is made of two pre-existing Pirelli warehouses.</rdfs:comment>
    <rdfs:label>Università degli Studi di Milano Bicocca</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000399">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Developmental stage factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/246">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Luis Ferreira Moita</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/197">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_250"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5664"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:comment>Although many bacteria and protozoa can invade dendritic cells (DC), it is not clear whether infected DC process pathogen-derived antigen and stimulate antigen-specific CD4+ T cells in vivo. To address this issue and obtain data on this question, we have infected susceptible BALB/c (H2-d) mice with a recombinant Leishmania major parasite expressing a fluorescent tracer. We have directly visualized antigen-presenting cells using a mAb reacting to an antigenic peptide derived from the parasite LACK antigen bound to I-Ad MHC class II molecule. I-Ad/LACK complexes were readily detected at the surface of freshly purified parasite-containing DC which expressed a CD8?- CD11b+ F4/80+ gp40- surface phenotype. As demonstrated by electron microscopy some DC contained live amastigotes and expressed I-Ad/LACK complexes in the membrane of the parasitophorous vacuole. Therefore, LACK could be processed and presented to T cells by infected DC in vivo .Furthermore, the presence of I-Ad/LACK complexes on the membrane of parasite-containing phagosomes demonstrated that peptide loading was occuring in this cellular compartment.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/GO#GO_0005773"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_30322"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001012"/>
    <rdfs:label>Do infected DC process pathogen-derived antigen and stimulate antigen-specific CD4+ T cells in vivo?</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000062"/>
    <dcr:hasCellComponentType rdf:resource="http://purl.org/obo/owl/FMA#FMA_83022"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_664">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129/Sv</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bard1tm2Thl/Bard1tm2Thl Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0 transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_661"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/233">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have data available from an analysis of the proteome of the phagocytic/endocytic compartments that are formed upon cell entry of antigens via specific pathways. The ultimate goal is to get a better insight into the protein complexes that are involved in antigen processing, and learn whether the different entry routes for antigens into DCs might have distinct functional characteristics.</rdfs:comment>
    <rdfs:label>Analysing the proteome of the phagocytic/endocytic compartments</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_774">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">nucleic acid hybridization step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A nucleic acid hybridization step is a step in a protocol that specifies how to combine totally or partially complementary, single-stranded nucleic acids into a single molecule called heteroduplex or homoduplex to an extent depending on the amount of complementarity.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_551">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36498"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">alpha-Galactosylceramide</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">alpha-GalCer</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">alpha-GalCer</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">alpha-Galactosylceramide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/122">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/552"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Serotype A C. albicans strain SC5314 is cultured overnight in Saboraud medium at 28°C and then shifted to RPMI medium for 18 hours at 37°C to allow hyphal growth. The culture is treated as for yeast cells. After microscopical inspection of the purity of hyphal culture, this is treated as for yeast cells. [It should be noted that in all the experiments performed in this study live microrganisms were used.]</rdfs:comment>
    <rdfs:label>Candida albicans hyphae stimuli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/287">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/269"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Uschi Peeters</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/41">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/77"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/47"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/77"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/252"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/140"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/36"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/37"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/318"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/72"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/100"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/108"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/403"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/404"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/399"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/254"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/398"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/38"/>
    <rdfs:label>Pierre Coulie</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/78"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/253"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/405"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/139"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/400"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/35"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/78"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/402"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/401"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0008996">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HER2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hCG_28177</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">neu oncogene</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HER-2</rdfs:label>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HER-2</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Oncogene"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ErbB2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ErbB2 oncogene</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ErbB2 oncogene</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HER 2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/432">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients with Previously Treated B-cell Chronic Lymphocytic Leukemia are taking part in a clinical study and receive multiple injections of CLL-DCV01. </rdfs:comment>
    <rdfs:label>9 patients with B-cell CLL</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_623">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mmLDL</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_39026"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000786">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">plasma cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">plasma cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0011134">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Eukaryotic translation initiation factor 2 subunit 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eIF-2-beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eukaryotic translation initiation factor 2 beta subunit</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eIF2-beta</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PKR</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">protein kinase R</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000512"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_244">
    <rdfs:label>Microsphere</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Microsphere</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0031988"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/6">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The hallmark of the Friedrich-Alexander University of Erlangen-Nuremberg today, 260 years after its foundation is our commitment to both tradition and innovation. Our university offers a wide spectrum of subjects, the diversity and interdisciplinary integration of which is unique in Germany. We see this "integrated diversity" as the key feature that enables us to enhance our profile in research and teaching while at the same time promoting the process of internationalisation more intensively. 

In addition to giving guidance in the pursuit of academic study, excellence in academic teaching requires us to develop new and innovative courses of study with an international orientation which will qualify our students to face the professional challenges of the future. Our career-focussed orientation is based on close co-operation with influential partners in industry, finance and politics providing a network of steadfast support through international exchange and individual contributions. A further priority in this respect is our commitment to maintaining ties with our alumni. 

Today, new knowledge is increasingly the result of interdisciplinary research which is no longer neatly compartmentalised within the traditional limits of academic subjects. Thanks to the breadth of our subject range, our university offers an ideal environment in which to generate this type of innovative research. This has enabled the university to secure a leading place among the German universities in the German Research Foundation (DFG) rankings and to attract a large number of Humboldt scholars, who have chosen our university as the place to pursue their research. We are committed to the constant improvement of our infrastructure, our study and research conditions and our service-oriented administration, all of which are essential as the university forges ahead on its way to becoming a first-class university of international renown.</rdfs:comment>
    <rdfs:label>Friedrich-Alexander-Universität Erlangen-Nürnberg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/80">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/biomaterial/545"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>After 6 hour of stimulation, DCs were collected, washed 3 times with PBS, treated with zymolyase, washed twice and cells, lysated with a hypotonic solution (KCl 0.05%), were plated on YPD. Survival of yeast cells, spores or hyphae after uptake was reported as percentage of colony forming units after 3 days relative to the total number of cells growing in the absence of DCs exposure. To assess the importance of ROS production in DC killing ability, DPI (10 microM) was added 30 minutes before stimulation and survival of microorganisms was assessed using the same method. When evaluating survival after exposure, the possible effect of DMSO and DPI on the stimuli was taken into account.</rdfs:comment>
    <rdfs:label>Microrganism survival following uptake by DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_705">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rheumatoid Arthritis-model mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/573">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Blood samples and tumour biopsies will be taken from these newly diagnosed glioblastoma patients in order to carry out a preclinical study in which circulating tumour-specific CD8+ T-cells will be detected in their blood.

In order to obtain the blood samples and tumour biopsies, a file has been submitted to the Ethics Committee of the Erasme Hospital and has been recently approved.</rdfs:comment>
    <rdfs:label>Glioblastoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/245">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Silvia della Bella</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/82">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Yasmina Essam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_778">
    <rdfs:label>ELISA assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ELISA assay</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ELISA assay is a method applied mainly in immunology specifying the labeling of antibodies or antigens with fluorescent dyes.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_48080">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">brefeldin A</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">C16H24O4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ascotoxin</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cyanein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BrefA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">decumbin</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_35701"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A metabolite from Penicillium brefeldianum that exhibits a wide range of antibiotic activity.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_777">
    <rdfs:label>assay</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">assay</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_461"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/284">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Dior Kingston</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_661">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Breast cancer-model mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies involve orthologs</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000000">
    <rdfs:label>cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <owl:equivalentClass rdf:resource="http://purl.org/obo/owl/CARO#CARO_0000013"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/198">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_250"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7163"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Visualization of specific activated DCs</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000057"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Data characterizing the antigen-presenting DC in immunized mice is available. 

Our goal was to generate a probe that could allow the visualization of specific activated DCs following either the immunization of mice with an antigen in adjuvant or an infection with leishmania major parasites. We thus tried to prepare a mAb reacting to the immunodominant LACK156-173 peptide of leishmania bound to I-Ad MHC class II molecules.  To this aim, we injected I-Ad/LACK recombinant dimers to TCR transgenic mice which exhibited an increased frequency of LACK-specific T cells. Four out of 600 supernatants, i.e. 2C44, 2F74, 2E60 and 2X8, readily stained LACK156-173-pulsed fibroblasts, but neither unpulsed fibroblasts nor OVA323-339-pulsed cells. BIAcore measurements yielded equilibrium dissociation constants ranging from 1.1 nM for 2C44 mAb to 120 nM for 2F74 mAb. To investigate whether these mAb could be used to detect APC presenting LACK in vivo, BALB/c mice were immunized or not with either LACK or OVA. LN cells were purified 2 days later, and stained with either 2C44, 2F74, 2E60 or 2X8 mAb. None of these mAb stained DC purified from non immunized mice. However, among the 4 mAb, only 2C44 could stain DC in LACK-immunized mice, but not in OVA-immunized mice. Furthermore, 2C44 stained DC from LACK-immunized mice expressing the H2-d haplotype but did not stain DC from LACK-immunized mice of other haplotypes. Thus, the 2C44 mAb allows for the detection of DC which captured and processed LACK in vivo. We next attempted to characterize the DC which carried I-Ad/LACK complexes at the cell surface in LACK-immunized BALB/c mice. Two different populations of DC, could thus be identified both expressing high levels of CD11c and MHC class II complexes but different levels of CD11b, suggesting that both Langerhans cells and dermal DC were actually presenting the LACK peptide. Following an intradermal immunization with LACK in adjuvant. We finally tried to purify these cells by cell sorting, using 2C44 mAb. In preliminary experiments we succeeded in purifying 300 000 cells from 5 immunized mice. 
Having characterized the antigen-presenting DC in immunized mice, we have now started to visualize and characterize the DC which carry I-Ad/LACK complexes at the cell surface in BALB/c mice infected by leishmania major.</rdfs:comment>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_5664"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/531">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/78"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In our phase I clinical trial, we highlight the capacity of Dex based-vaccines to restore the number and NKG2D-dependent function of NK cells in 7/14 cancer patients.</rdfs:comment>
    <rdfs:label>Phase I trial patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/236">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasStimulusType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1476"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We will start a collaboration with G. Schuler (P06) to examine the modulation of dendritic cell function by Denileukin Difitox (ONTAK) and will provide pathway analysis data.</rdfs:comment>
    <rdfs:label>Modulation of dendritic cell function by Denileukin Difitox (ONTAK)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A188">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0005102"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/26">
    <dcr:hasExperimentalFactorType rdf:resource="http://dc-research.eu#dctheradir_580"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_392"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our group has generated pathway data from human DC treated with pathogen derivatives.</rdfs:comment>
    <rdfs:label>Bioinformatic pathways-based analysis of data from human DC treated with pathogen derivatives</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_624">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_39026"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">oxLDL</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/40">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Virginie Bourgeois</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A86">
    <owl:unionOf rdf:nodeID="A214"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_212357">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1150"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oscillatoria planctonica</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oscillatoria Planktothrix FP1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oscillatoria Planktothrix</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_33250">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">atom</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_2615">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">papilloma</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A135">
    <owl:unionOf rdf:nodeID="A207"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000787">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B-cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B-lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B lymphocytes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B lymphocyte</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">memory B-lymphocytes</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A162">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_706">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_705"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dnase2atm1Osa/Dnase2atm1Osa Ifnar1tm1Agt/Ifnar1tm1Agt  transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_243">
    <rdfs:label>poly(I:C(12)U)</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ampligen</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_309"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">poly(I:C(12)U)</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/574">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/38"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A self-inactivating lentiviral vector expressing shRNA specific for STAT3 is now available in the laboratory.</rdfs:comment>
    <rdfs:label>Self-inactivating lentiviral vector expressing shRNA specific for STAT3</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700006">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-5</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin 5</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/7">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/biomaterial/436"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/biomaterial/88"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>BioVex is a Phase II clinical-stage biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Our pipeline of cancer product candidates is built on first-in-class oncolytic virus technology that replicates and spreads within solid tumors, causing the death of cancer cells, accompanied by the induction of a systemic immune response. We believe that this technology, "OncoVEX", is more effective than earlier-generation oncolytic viruses and has the potential to establish a new standard of care in the treatment of solid tumors, while minimizing side effects. 

OncoVEXGM-CSF is completing a 50-patient Phase II clinical trial in the United States for the treatment of unresectable metastatic melanoma, as a monotherapy, in the second line/salvage therapy setting. Data so far indicates that OncoVEX can destroy both injected and un-injected melanoma deposits. Pivotal studies, intended for registration, are currently being planned. 

Additional studies with OncoVEXGM-CSF are ongoing in head &amp; neck cancer and pancreatic cancer. 

Our lead infectious disease product candidate is ImmunoVEXHSV2 , a vaccine for genital herpes. At least 45 million people over the age of 11 in the United States have been infected with HSV-2, the cause of genital herpes. However, even though a number of HSV-2 vaccine candidates have previously been developed, none has proved broadly effective. ImmunoVEXHSV2 is a novel live-attenuated vaccine candidate that expresses approximately 80 HSV-2 proteins intended to stimulate a broad and powerful immune response. In preclinical studies, ImmunoVEXHSV2 completely prevents disease and invokes a powerful immune response, indicating that ImmunoVEX HSV2 is more potent than other HSV-2 vaccines for which published data are available. We intend to initiate a Phase I clinical trial for this product early in 2008.</rdfs:comment>
    <rdfs:label>BioVex Ltd</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_904">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">co-expression design experiment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A co-expression experiment design type identifies genes which are coordinately expressed and are potentially used to infer a role in a biological process(es) non-exact synonym: guilt by association.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/244">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Özcan Met, PhD
Center for Cancer Immune Therapy
Department of Hematology, 65Q9 </rdfs:comment>
    <rdfs:label>Özcan Met</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/300">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/178"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Diego Piccioli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/285">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/207"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Dirk Baumjohann</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_776">
    <rdfs:label>normalization data transformation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_775"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A normalization data transformation step is a step in a protocol that specifies how to  produce normalized output data from input data according to some criteria.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">normalization data transformation step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_662">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_661"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves:129/Sv</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bard1tm1Thl/Bard1tm2Thl Waptm1(cre)Arge/0 transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/81">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment>Myriam Essiaf was replaced by Inge Cornillie.</rdfs:comment>
    <rdfs:label>Myriam Essiaf</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/199">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_236"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Poly_IC"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_234"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_426"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/38"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700241"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdfs:comment>Protein expression data is available for our pre-clinical work aiming at developing DC based vaccines expressing the tumor antigens PSA or Her2/neu. Monocyte rich fractions were produced by elutriation under GMP conditions and cultured for 5 days with GM-CSF and IL-4. Conditions for transfection with electroporation (Amaxa) or with Adenovirus constructs have been established. Protein expression (Her2/neu, PSA) following transfection with a panel of different full length or truncated Her2/neu or PSA constructs was assessed using Facs analysis (Her2/neu) or assessment of soluble protein (PSA). 

Work in progress is investigating conditions for stimulating CD4 and CD8 T cell responses with the transfected DCs, matured for 2 days in poly I:C. The activation status of CD4+/CD25+ T reg in TIL in prostate cancer has been analysed. A higher frequency of CD4+/CD25+/GITR+/ICOS+/FoxP3+ cells in the areas with malignancy as compared to normal prostate tissue or peripheral blood of patients with prostate cancer was found.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/36"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700888"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200878"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10535"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:label>DC based vaccines expressing the tumor antigens PSA or Her2/neu</rdfs:label>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9600"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_G0008996"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/66"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/49"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_625">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">In 1991, a potent 61 amino acid vasodilator peptide, named maxadilan, was isolated from the salivary glands of the sand fly. (PMID 2074892)</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Maxadilan</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A61">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0005102"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/235">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/100"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>A large reference ‘golden experiment’ will be carried out in which the transcriptome of DC vaccines of 50-100 patients will be compared and data transcriptomic data will become available.</rdfs:comment>
    <rdfs:label>Analysis of transcriptome of DC vaccines: The Golden experiment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/25">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/439"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/79"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_764"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/5"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/6"/>
    <rdfs:comment>We have established an in-depth proteomic map of murine dendritic cell subsets. We have been working in the attempt to overcome the limits in sample availability, exploiting the recent significant improvements of proteomic technology. The results allowed to lower the required sample amount significantly, an essential feature to analyze limited cell populations like dendritic cells. The group completed the measurements of murine dendritic cell subsets and established an in-depth proteomic map of them. These preliminary results show more than 4500 identified proteins in each subset. All of the known markers like CD11c, CD11b, DEC-205, Langerin, etc. were found according to their differential expression pattern.  Due to recent major developments in analysis software it is now possible to compare these subsets quantitatively based on the extracted ion current (XIC) and without any need of stable isotope labels. This software is still in development, but preliminary results show a high similarity of all there subsets in the steady state. 

Experiments have been performed to verify these differences in a biological point of view and analysis of the proteomic data itself using novel label-free software has also been completed. In 2008 our group showed the most comprehensive overview of molecular components in yeast (deGodoy et al.). However this study so far required SILAC (stable isotope labelling with amino acids in cell culture) labelling leaving rare cell populations, like in vivo DC subsets, out of reach. In this work package we introduced a robust and generally applicable quantification technology, which allowed us to quantify the dendritic cell subset proteomes to a depth of more than 5000 proteins. Additionally, we were able to make functional predictions about closely related cell types using our large-scale proteomic data set. Biological follow up experiments fully confirmed our proteomic findings. Currently we are wrapping up our data for publication of the DC subset proteome and the quantitation software.  All our data can be accessed and analyzed through the MAPU database (Gnad et al.)

After finishing our proteomic study of steady-state dendritic cell we will now start to analyze proteomic changes of DC subsets after different stimuli. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_270"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/52"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label>Proteomic analysis of mouse DC subsets</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/159"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_267"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/102"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001012"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/34"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/35"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/158"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/7"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001013"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/433">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CLL-DCV01 is used for multiple injections in patients with previously treated B-cell Chronic Lymphocytic Leukemia.</rdfs:comment>
    <rdfs:label>CLL-DCV01</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/40">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/131"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>A protocol for obtaining highly pure integral membrane proteins has been set up in the last two months in the lab of Paola Castagnoli in collaboration with the lab of Juri Rappsilber at IFOM.</rdfs:comment>
    <rdfs:label>Protocol for obtaining highly pure integral membrane proteins </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_32988">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">amide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/120">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/547"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/548"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_764"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Saccharomyces cerevisiae strain SK1 (MATa/alpha HO gal2 cupS can1R BIO, Kane SM and Roth J. 1974 Bacteriol. 118: 8-14) is cultured in complete medium (YPD, 2% yeast extract, 1% peptone, 2% glucose) for 18 hours, then collected, washed twice with sterile water and resuspended at 108 cells/ml. 
S. cerevisiae strains BY4741 (genotype, Mata his3delta1 leu2delta0 met15delta0 ura3delta0) and BY4741 och1 (Mata his3delta1 leu2delta0 met15delta0 ura3delta0 OCH1::kanMX4) are cultured in complete medium till exponentially phase and treated as before.</rdfs:comment>
    <rdfs:label>Saccharomyces cerevisiae cell stimuli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/192">
    <rdfs:comment>We are continuing our studies of the roles of DC in scrapie uptake and dissemination and have obtained data on intestinal DC subsets all of which can acquire scrapie ME7 form the intestinal lumen and transport it via lymph. 

In current studies we are examining the effects of indomethacin-induced small intestinal inflammation on both intestinal DC biology and on scrapie uptake, transport and delivery. We are characterising (in collaboration with Sebastian Amigorena) rat lymph exosomes and will determine if they transport intestinally-delivered scrapie ME7. We are also examining the effects of a schistosome-derived protein on intestinal immune responses, and have shown that oral administration leads to the rapid appearance of cytokines in lymph.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_49662"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_6181"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10114"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7199"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/196"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdfs:label>Roles of DC in scrapie uptake and dissemination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/243">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>A. A. van de Loosdrecht</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700009">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin 6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HEPATOCYTE STIMULATORY FACTOR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BETA-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">INTERFERON</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 6 (interferon</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-6 human</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hybridoma growth factor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CDF</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 6</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon beta-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">B-CELL DIFFERENTIATION FACT</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">beta 2)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CTL differentiation factor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">BETA 2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HSF</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-6</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFNB2</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_246">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001128"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR 5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR-5</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR5</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chemokine receptor CCR5</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/258">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>LPS (1microgram/ml, Sigma, St. Louis, MO) (along with R848, Curdlan, yeast RNA and yeast cells in different conditions of culture) was used to induce DC activation.</rdfs:comment>
    <rdfs:label>LPS</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_707">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_705"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">H2q/? Ncf1m1J/Ncf1m1J transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">B6.Cg-Ncf1m1J H2q</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A198">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_668">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ins1tm1Jja/Ins1tm1Jja Ins2tm1Jja/Ins2tm1Jja transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_666"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S2/SvPas</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/301">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Federica Arcagni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A17">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000784">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferon-producing cell</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pDC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-associated plasma cells</dcr:hasExactSynonym>
    <rdfs:label>plasmacytoid dendritic cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">plasmacytoid dendritic cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">plasmacytoid monocytes</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">plasmacytoid monocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-associated plasma cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphoid dendritic cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IPC</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">plasmacytoid T cell</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_67498">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organs</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ifomis.org/bfo/1.1/snap#Role">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/537">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdfs:label>HEK293 cells transfected with HLA alleles</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/251"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0100055"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/110"/>
    <rdfs:comment>We evaluated the capacity of autologous DC and HEK293 cells transfected with relevant HLA alleles to function as T cell targets in Elispot assays upon transfection with tumor antigen encoding plasmids. Due to strong background from the autologous DC we decided that HEK293 transfected with one HLA-allele at a time plus simultaneously transfected with up to 5 tumor antiges would be optimal to screen for antigen specificity in the patients T cells. However, during a second T cell culture to expand large numbers of T cells for this screening procedure a drastic expansion of regulatory T cells was observed. Since no sufficient number of T cells could be expanded the screening was not performed. The reason for the altered phenotype/function of the expanded T cells from the second bleeding of this patient is currently not known.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A60">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/238">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We will explore the immunogenicity of necrotic cells as a tool to dissect the molecular determinants involved in “danger” recognition and will obtain data on this.</rdfs:comment>
    <rdfs:label>Exploration of the immunogenicity of necrotic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_626">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24431"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Carbon particle</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Clinical treatment factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000351"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A160">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001450">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll like receptor 2</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR-2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_398">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCL21</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001700">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_16670</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_peptide</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_667">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_666"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involved: 129P2/OlaHsd * BALB/c * DBA/2</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hk2tm1Laak/Hk2tm1Laak transgenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/119">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elena Ranieri</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_771">
    <rdfs:label>incubation step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An incubation step is a step in a protocol that specifies how to hold cultures of microorganisms at a controlled temperature to improve their growth.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">incubation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_769"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/282">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brenda De Keersmaeker</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_307">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">macrophage colony stimulating factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Colony stimulating factor 1 (macrophage)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">M-CSF</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/1">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_732"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>A brief history of the University

As the oldest university in the English-speaking world, Oxford is a unique and historic institution. There is no clear date of foundation, but teaching existed at Oxford in some form in 1096 and developed rapidly from 1167, when Henry II banned English students from attending the University of Paris.

In 1188, the historian, Gerald of Wales, gave a public reading to the assembled Oxford dons and in 1190 the arrival of Emo of Friesland, the first known overseas student, set in motion the University's tradition of international scholarly links. By 1201, the University was headed by a magister scolarum Oxonie, on whom the title of Chancellor was conferred in 1214, and in 1231 the masters were recognized as a universitas or corporation.

In the 13th century, rioting between town and gown (townspeople and students) hastened the establishment of primitive halls of residence. These were succeeded by the first of Oxford's colleges, which began as medieval 'halls of residence' or endowed houses under the supervision of a Master. University, Balliol and Merton Colleges, which were established between 1249 and 1264, are the oldest.

Less than a century later, Oxford had achieved eminence above every other seat of learning, and won the praises of popes, kings and sages by virtue of its antiquity, curriculum, doctrine and privileges. In 1355, Edward III paid tribute to the University for its invaluable contribution to learning; he also commented on the services rendered to the state by distinguished Oxford graduates.

From its early days, Oxford was a centre for lively controversy, with scholars involved in religious and political disputes. John Wyclif, a 14th-century Master of Balliol, campaigned for a bible in the vernacular, against the wishes of the papacy. In 1530, Henry VIII forced the University to accept his divorce from Catherine of Aragon, and during the Reformation in the 16th century, the Anglican churchmen Cranmer, Latimer and Ridley were tried for heresy and burnt at the stake in Oxford.

The University was Royalist in the Civil War, and Charles I held a counter-Parliament in Convocation House, and in the late 17th century, the Oxford philosopher John Locke, suspected of treason, was forced to flee the country.

The 18th century, when Oxford was said to have forsaken port for politics, was also an era of scientific discovery and religious revival. Edmund Halley, Professor of Geometry, predicted the return of the comet that bears his name; John and Charles Wesley's prayer meetings laid the foundations of the Methodist Society.

The University assumed a leading role in the Victorian era, especially in religious controversy. From 1833 onwards The Oxford Movement sought to revitalise the Catholic aspects of the Anglican Church. One of its leaders, John Henry Newman, became a Roman Catholic in 1845 and was later made a Cardinal. In 1860 the new University Museum was the scene of a famous debate between Thomas Huxley, champion of evolution, and Bishop Wilberforce.

From 1878, academic halls were established for women and they were admitted to full membership of the University in 1920. Since 1974, all but one of Oxford's 38 colleges has changed their statutes to admit both men and women. St Hilda's remains the only women's college, though it will admit both women and men from October 2008.

During the 20th and early 21st centuries, Oxford added to its humanistic core a major new research capacity in the natural and applied sciences, including medicine. In so doing, it has enhanced and strengthened its traditional role as an international focus for learning and a forum for intellectual debate.</rdfs:comment>
    <rdfs:label>University of Oxford</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:subClassOf rdf:nodeID="A31"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Antigen SK29-AA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">melan A protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Melan-A protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MART1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MART-1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Antigen LB39-AA</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Melan A</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/242">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mark Aloysius</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/302">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Luigi Ricciardi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_669">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Emphysema, Hereditary Pulmonary-model mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/259">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>100 micrograms/ml curdlan (Wako) was used (along with R848, LPS, yeast RNA and yeast cells in different conditions of culture) to induce DC activation.
</rdfs:comment>
    <rdfs:label>Curdlan</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/117">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/384"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/244"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/191"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/187"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/190"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/32"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/186"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/189"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/60"/>
    <rdfs:label>Daniela Rozková</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/59"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/245"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_708">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mmp14tm1Hbh/Mmp14tm1Hbh transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_705"/>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129P2/OlaHsd * Black Swiss</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_245">
    <rdfs:subClassOf rdf:nodeID="A28"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR 7</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD197 </rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR7</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-197</dcr:hasExactSynonym>
    <rdfs:label>CD197</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A26"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 197</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CCR-7</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000079">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD36</dcr:dcthera_label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001905</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/538">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_649"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Tissue biopsies of the last vaccination site and of the VIN lesion prior to the first vaccination and 3 months after the last vaccination were analysed for the presence of HPV16-specific T cells.

The IFN?-ELISPOT analysis and proliferation with its accompanying cytokine production revealed a strong and broad vaccine-induced T cell response. The strength of the immune response (defined as breath and magnitude of the response) was significantly higher in the patients with a complete remission (CR) than in the patients with no changes (NC) in the lesion size. Phenotypical anlaysis revealed a strong induction of CD4+ T-cells specifically against HPV16 E6 and E7, whereas CD8+ T cells were found merely against HPV16 E6 and to a less broad array of epitopes within each patient. This analysis was done after one in vitro restimulation, however, by directly ex vivo flow cytometric analysis hardly any CD8+ T cell response could be detected. The T cell cultures obtained from the biopsies taken of the last vaccination site were found to be HPV16 peptides specific in 3/5 tested NR patients and in 4/5 tested CR. However, recognition of the recombinant HPV16 E6 and/or E7 protein was observed in 1/5 cultures from NR patients and 4/5 cultures of the CR patients, suggesting the differences in vaccine-induced T-cell reactivity. Tissue biopsies of the VIN lesion before and after vaccination showed only in one patient a HPV16-specific T-cell response, which was against HPV16 E6 and merely of the type 2 cytokine producing T cells. Notably, no T-cell cultures could be obtained from VIN biopsies taken from the CR patients. In conclusion, the HPV16 E6 and E7 synthetic long peptides vaccine is highly immunogenic, in that it increases the number and activity of HPV16-specific CD4+ and CD8+ T-cells to a broad array of epitopes in all patients. The expansion of CD4+ and CD8+ tumor-specific T-cells, both considered to be important in the anti-tumor response indicates the immunotherapeutic potential of this vaccine. Addition of a strong toll-like receptor ligand might increase the CD8 response in frequency and to a broader set of epitopes.</rdfs:comment>
    <rdfs:label>Tissue biopsies of last vaccination site prior to first vaccination</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/20">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_473"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We use the electroporator at our disposal, for instance, to electroporate dendritic cells with melanoma antigen RNA .</rdfs:comment>
    <rdfs:label>Electroporator</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A156">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0005102"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001451">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000108</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Toll-like receptor 5</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A59">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_627">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphotoxin-beta receptor</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A22"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A24"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/237">
    <rdfs:comment>We have obtained data based on the characterization of a novel C-type lectin expressed primarily in mouse CD8?+ DC and their putative human equivalents. This lectin, named DNGR-1, can serve as a receptor for antigen targetting to DC. Notably, tumour antigens coupled to anti-DNGR-1 antibodies and given together with a suitable adjuvant elicit potent CTL responses that can promote tumour regression. 

We will continue to explore the use of DNGR-1 as a tool for targeting antigens to DC in vivo. In particular, we will examine if such targeting in the absence of adjuvants allows induction of tolerance. We will further examine whether it can result in MHC class II presentation, allowing for manipulation of the CD4+ T cell compartment. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/201"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label>Identification of a novel C-type lectin (DNGR-1) for antigen targeting to DCs</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000084">
    <rdfs:label>T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T-cell</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">T cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_770">
    <rdfs:label>maintaining cell culture step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_769"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A maintaining cell culture step is a step in a protocol that specifies how to keep cells alive in a defined environment outside of an organism.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">maintaining cell culture step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/118">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/27"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/28"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/26"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/80"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/107"/>
    <rdfs:label>Edwin Lasonder</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/193">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0049521"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have explored fundamental aspects of the anti-tumor responses. We obtained data examining the cell populations which infiltrate progressive versus regressing P815 mastocytoma in order to identify cells which display immunosuppressive properties. We found changes in regulatory T cells populations as well as in the “myeloid suppressor cells”. Our preliminary data suggest that two populations of regulatory T cells coexist (natural and induced) in progressing tumors, and that a population of Gr1+ cells may affect tumor resistance in vivo. </rdfs:comment>
    <rdfs:label>Identification of cells which display immunosuppressive properties</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/283">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Caterina Bodio</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0701393">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-15 mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000007"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interleukin-15 precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL15</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL 15</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL15_MOUSE</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interleukin 15</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IL-15</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_308">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000082</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD45 RA/RO</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBiomaterialInput">
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has biomaterial input</rdfs:label>
    <owl:inverseOf rdf:resource="http://dc-research.eu#isBiomaterialInputOf"/>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relationship between a protocol step and a bio-material used when concretizing and realizing that protocol step.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A202">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0005102"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/303">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Charlotte Sadaka</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#relatedToInstance">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is related to</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To relate a DC-THERA instance to any other DC-THERA instance</OBI:IAO_0000115>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#SymmetricProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_447">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">genetic modification design experiment</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A genetic modification design type is where an organism(s) has had genetic material removed, rearranged, mutagenized or added, such as knock out</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/116">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Addolorata Casamassima</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17939">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">puromycin</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33838"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/2">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Radboud University Nijmegen Medical Centre is a leading academic centre with expertise in medical science and healthcare. Expertise plays an essential part in our organisation and connects research, education and patient care. Our more than 8,000 staff and 2,500 students are committed and ambitious, helping to shape the future of healthcare and medical science.</rdfs:comment>
    <rdfs:label>Nijmegen Medical School</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_248">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monophosphoryl lipid A</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001362"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MPL</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/150">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/127"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:label>Following antigen-specific CD4+ T cells in immunized individuals</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdfs:comment>Data was obtained on CD4+ T cell responses against pathogens or tumors in humans. Our goal was to generate peptide-MHC class II multimers to follow antigen-specific CD4+ T cells in immunized individuals. The study was a collaboration with Monica Moro in P. Dellabona’s lab. to study CD4+ T cell responses against pathogens or tumors in humans. Soluble recombinant HLADR1101 MHC class II molecules receptive for loading with either pathogen or tumor-derived peptides were constructed. Although all these molecules could stain CD4+ T cells that had been stimulated for four days with peptide and IL-2, none of them could stain patients T cells ex vivo. </rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/241">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Thomas Brocker</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/535">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/251"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We attempted to improve the adoptive transfer protocol for immunotherapy by stimulating T cells with monocyte derived DC pulsed with tumor lysate, instead of simply adding tumor lysate into PBMC cultures. T cells raised exhibited some tumor reactivity and outgrowth of a distinct T cell population could be observed.</rdfs:comment>
    <rdfs:label>T cells stimulated with monocyte derived DC pulsed with tumor lysate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_709">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tnftm1Gkl/Tnftm2Gkl transgenic mouse</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves: 129S/SvEv * C57BL/6</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_705"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A157">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001452">
    <rdfs:label>Toll like receptor 3</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR-3</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TLR3</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Toll like receptor 3</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000782">
    <rdfs:label>myeloid dendritic cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000763"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">myeloid dendritic cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Conventional dendritic cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A215">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/ID#ID_0000035"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/21">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/247"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400044"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience in multicolour flow cytometry. Besides ELISPOT, tetramer based 8-colour flow cytometry has become our routine monitoring assay, allowing extended phenotypic and functional characterization of T cell subpopulations. Of special interest has become the identification of polyfunctional T cells (capable to simultaneously exert several functions, i.e. production of various cytokines and killing activity) since these have been shown to elicit more effective immune responses in HIV vaccination trials.</rdfs:comment>
    <rdfs:label>Multicolor flow cytometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_628">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphotoxin-beta receptor (LTbetaR)-immunoglobulin fusion protein</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A19"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A20"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/28">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Institut Necker - INSERM</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/194">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/75"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <rdfs:label>Immunotherapy potential of DC pulsed with tumor antigens</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0049521"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_4027"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_237"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:comment>We obtained data on the immunotherapy potential of DC, pulsed with tumor antigens, through its evaluation in EG7-OVA and P815 tumor models. Depletion of natural regulatory T cells in tumor bearing mice resulted in rejection of P815 cells, but not EG7-OVA, suggesting that regulatory T cells have a stronger impact on immune responses against weakly immunogenic or auto-antigen (P1A). Treg are detected in growing P815 tumor and there is some evidence that 2 regulatory T cells develop sequentially. T cell activation was monitored by tetramer staining and in vivo CTL assay, and revealed strongly increased frequency of P1A-specific T cells after treatment with chemotherapeutic agent cyclophosphamide, but not after T reg depletion. The histological analysis of progressive versus regressing tumors underscores the role of dendritic cells and Gr1+ cells (yet to be defined population) in tumor rejection. </rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#is_document_of">
    <owl:inverseOf rdf:resource="http://dc-research.eu#has_document"/>
    <rdfs:range rdf:nodeID="A191"/>
    <rdfs:domain rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is document about</rdfs:label>
    <rdfs:subPropertyOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000136"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a document to any DC-THERA resource that contains information on the resource.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_773">
    <rdfs:label>activation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An activation step is a step in a protocol that specifies how to modify a material entity status and confer a capability of reacting.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">activation step</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/111">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701872"/>
    <rdfs:comment>Our lab generated data on the mechanisms for DC-induced Th1 development and the molecular pathways for inducing Th1 cells producing IFN-gamma solely, or Th1 cells producing IFN-gamma and IL-10.

We have reported that plasmacytoid precursor dendritic cells (pDC) activated with the TLR-9 ligand CpG induce strong development of Th1 responses (Boonstra et al, 2003). In contrast, bone marrow-derived myeloid DC (BM-myeloid DC) and splenic CD8alpha+ and CD8alpha- DC, despite expression of TLR9 mRNA, were poor at directing Th1 responses when activated with CpG. 

We have determined mechanisms for DC-induced Th1 development and the molecular pathways for inducing Th1 cells producing IFN-gamma solely, or Th1 cells producing IFN-gamma and IL-10, which have important implications for regulation of the immune response to eradicate pathogens with minimum pathology. This manuscript is now submitted for publication (Saraiva, O’Garra et al, 2007 – under review for Immunity). We have already determined that GATA-3 remodels the IL-10 locus specifically in T cells (Shoemaker et al, 2006) but are now also showing that in the absence of GATA-3 other signalling pathways and transcription factors may lead to induction of IL-10.</rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/85"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/118"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/11"/>
    <rdfs:label>Mechanisms for DC-induced Th1 development and the molecular pathways for inducing Th1 cells producing IFN-gamma / IL 10</rdfs:label>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/165"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/117"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7196"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_26421">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">pyridine</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33595"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A95">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/256">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/33"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Differentiation of monocytes into dendritic cells is promoted, along with granulocyte-macrophage colony-stimulating factor, by addition of recombinant IL-4 (1000U/ml, R&amp;D Systems).</rdfs:comment>
    <rdfs:label>Recombinant IL-4 </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_665">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">involves:129S7/SvEvBrd * C57BL/6J</rdfs:comment>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Brca2tm1Arge/Brca2tm2Arge Waptm1(cre)Arge/Wap+ transgenic mouse</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_661"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/577">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9605"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Blood was collected from &gt;10 melanoma patients and the myeloid derived suppressor cells (MDSC) phenotype and function were compared with healthy donor derived cells. This blood was used to investigate phenotypic markers that can be used to further characterize MDSC, focusing on molecules that are related to their suppressive function.</rdfs:comment>
    <rdfs:label>Blood from melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_309">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">double-stranded RNA</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">double-stranded RNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">double stranded RNA</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dsRNA</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/280">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Aparna Venkatesh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/115">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Botond Igyarto</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/304">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Isabelle Basson</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/257">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/34"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/33"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These dendritic cells were obtained from PBMC from which monocytes had been isolated that differentiated into DC after cell culture.</rdfs:comment>
    <rdfs:label>Dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000375">
    <rdfs:label>signal transducer and activator of transcription 1</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">STAT1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">STAT-1 transcription factor</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">signal transducer and activator of transcription 1</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A94">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_247">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/DC_CL#DC_CL_0000059</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_CD1a receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/3">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>ULB in a nutshell

The city of Brussels is the capital of a federal state which has three different administrative regions based on language and has been at the heart of Europe since 1957. It naturally follows that the city should have a university in keeping with its standing and the ULB, with its 20,000 students, 27% of whom come from abroad, and its very cosmopolitan body of staff, is an intrinsically international institution open to both Europe and to the whole world.

It was at the heart of the creation of a network of major universities from different European capitals – UNICA – and is involved in international programmes for research and development and for mobility.

The ULB is a multicultural institution which has 7 faculties and a range of schools and institutes and is, at the same time, a comprehensive university providing academic tuition in all disciplines and study cycles.

With its three Nobel Prize winners, a Fields medal, a Wolf Prize for physics, two Marie Curie Prizes and 29% of the Francqui prizes awarded, the university is also a major research centre which is recognised by the academic community the world over.

Nor does it shirk its social, societal and scientific commitments, which it meets through combining broad access to higher education with excellent quality research and through

its role in furthering economic development in the regions where it is located (Brussels and Wallonia). The ULB also has a teaching hospital – the Hôpital Erasme, a specialist institute for studying cancer – the Institut Bordet, and an extensive hospital network. 

For about a decade now the university has been actively involved in maximising research potential in both Brussels and Charleroi, where it has set up a biotechnology pole around its renowned Institute for Biology and Molecular Medicine (IBMM) and Institute of Medical Immunology( IMI)

In terms of partnerships, it is part of the Wallonia-Brussels Academy, together with the Mons-Hainaut University and the Mons Polytechnic Faculty and, in conjunction with 5 hautes écoles, the royal military school, 2 institutes for architectural studies and 2 colleges for fine arts, it also makes up the Brussels-Wallonia European University Pole.

As a private university, which is recognised and subsidised by the Belgian authorities, the ULB receives government funding today to the tune of 60% of its overall budget.

Founded on the principle of free-thinking analysis which advocates independent reasoning and the rejection of dogma in all its forms, the ULB has remained true to its original ideals – an institution free from any form of control which is committed to defending democratic humanist values, an approach it also extends to the way that it is run.</rdfs:comment>
    <rdfs:label>Université Libre de Bruxelles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0319">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_DNA</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_16991</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/240">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/8"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/39"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sandy Vaddakadathou</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/536">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <rdfs:comment>We evaluated the capacity of autologous DC and HEK293 cells transfected with relevant HLA alleles to function as T cell targets in Elispot assays upon transfection with tumor antigen encoding plasmids. Due to strong background from the autologous DC we decided that HEK293 transfected with one HLA-allele at a time plus simultaneously transfected with up to 5 tumor antiges would be optimal to screen for antigen specificity in the patients T cells. However, during a second T cell culture to expand large numbers of T cells for this screening procedure a drastic expansion of regulatory T cells was observed. Since no sufficient number of T cells could be expanded the screening was not performed. The reason for the altered phenotype/function of the expanded T cells from the second bleeding of this patient is currently not known.</rdfs:comment>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/tool/110"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/251"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <rdfs:label>Autologous DC</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000544">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/151">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We obtained data on anti-tumor responses in melanoma patients that were vaccinated with autologous DCs loaded with a combination of tumor Ag peptides. This study is a collaboration with the lab of Didier Colau and Thierry Boon in Brussels. HLA-DP4/MAGE3 molecules have been prepared to stain ex vivo PBL from immunized melanoma patients.</rdfs:comment>
    <rdfs:label>Following anti-tumor responses in melanoma patients vaccinated with autologous DCs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000042">
    <rdfs:label xml:lang="en">obsolete_data set</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/IAO_0000100</dcr:replaced_by>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A12">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_736"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/29">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>'At home in Bavaria, successful in the world'. That is our motto, linking provenance and posterity. Our graduates are active throughout the globe, our professors at home on an international platform. The secret of our success comprises numerous components: competence in one's field of special interest; communicativity with associate departments; cross-curricular, transdisciplinary team spirit, alliances with professional practice. Unafraid of taking risks, we are breaking new scientific ground. Ingenuity and normality, ivory tower and workbench, lecture room and laboratory, traditional beer brewing and 'virtual reality' – the Technische Universität München nurtures all these features under its collective roof.

True to our origins, ever since the Technische Universität München was founded as a 'polytechnic school' at the heart of Europe in 1868, we have played an active role in transforming Bavaria from an agricultural state to a high-tech location. Rooted in this tradition we created a powerful international network. We are now an international university. One in every four undergraduates within a total student body of approximately 20,000 comes from abroad. The four-leaf clover symbolises our scientific spectrum: natural sciences, engineering sciences, medicine, life sciences.
 

In our capacity as an up-to-date entrepreneurial university, we pin our hopes on the vast range of human skills, identifying and sponsoring talent. We create teams by pooling new strengths. This leads to top performance and supports Corporate Identity.

Creative licence in the multifaceted world of science ranks high at the TU München. This particularly applies in the case of the TUM Institute for Advanced Study currently under development. It is based on the conviction that an atmosphere of creativity and inspiration, freedom and unbureaucratic support is the most productive source of progress for outstanding scientists.

One of our visions is the goal of becoming the most attractive technical university for women in Germany. With the help of unconventional measures, we want to create a seat of learning and a workplace that complies with the special needs of women and young families.</rdfs:comment>
    <rdfs:label>Technische Universität München</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_1110087">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/239">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/204"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/203"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/202"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We have used agonists of the dectin-1/Syk pathway as adjuvants in vivo to induce CD8+ T cell responses and have data available on this. In summary, we have shown that this can result in CTL capable of destroying tumours. </rdfs:comment>
    <rdfs:label>Use of agonists of the dectin-1/Syk pathay as adjuvant in vivo</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A197">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:nodeID="A215"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_629">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">decoy receptor role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/22">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400038"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our laboratory has a FACS Canto II (Manufacturer: BD Biosciences - URL: http://www.bdbiosciences.com/features/products/display_product.php?keyID=594) at its disposal. 

For instance, we used multimers kindly provided by Pierre Coulie (Brussels) together with surface markers (such as CD8, CD4, CD3, CD45RA, CCR7, CD25, CD27, CD137, CD127) in different 8-color panels on this FACSCanto II.</rdfs:comment>
    <rdfs:label>BD FACSCanto II</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/195">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701386"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000782"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9608"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000021"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100386"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/119"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_1773"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_7195"/>
    <rdfs:comment>The importance of alveolar macrophages and more recently DC in the immune response to Mycobacterium tuberculosis (MTb) has been well documented, but the relative contribution of plasmacytoid DC during bacterial infections is largely unknown. Thus, data was obtained on the contribution of pDC in acute MTb infection.

We examined whether plasmacytoid pDC are infected and/or activated by MTb, and whether they play a role in regulating bacterial clearance during acute MTb infection and if so how. We have compared these DC with myeloid DC and macrophages with respect to MTb infection. Flow cytometry analysis of CD11c populations in the lung and spleen during acute aerosol MTb infection showed no significant increase in plasmacytoid pDC; however during intravenous MTb infection the levels of plasmacytoid pDC appear to increase 43 days after infection. Lung CD4+ T cells increase after day 8 post aerosol infection as previously published by others. In addition, depletion of plasmacytoid pDC in vivo during acute intravenous MTb infection suggested that this DC subset plays a minimal role in regulating bacterial clearance during the primary immune response. In vitro MTb infection of BM myeloid DC and BM macrophages induced the pro-inflammatory cytokines IL-12p40 and TNF, as previously reported by others. In contrast, in vitro MTb infection of plasmacytoid pDC did not induce any detectable levels of cytokine. However, CpG stimulation of plasmacytoid pDC induced the cytokines IL-12p40, IL-12p70, TNF and IFN-alpha. Our data suggests that at this stage of infection plasmacytoid pDC may play only a limited role in protection against MTb infection. Our data however, does not address the possibility that plasmacytoid pDC may play a role during chronic infection when death of bacteria may be greater i.e. during memory responses or following antibiotic treatment, which may give release of un-methylated CpG DNA that could potentially activate plasmacytoid pDC via TLR-9, or in response to the virulent strain of MTB HN878 as described by Manca et al., 2001. Since in the mouse CpG stimulates IL-12 and TNF production by macrophages, myeloid and plasmacytoid DC, we also investigated a possible protective role for CpG in protection against MTB infection. We found that administration to mice with CpG could play a role in protection although this was very dependent on the time of administration, the dose of MTb used and the strain of mouse.

The in vitro studies on infections with Mycobacterium tuberculosis (MTb)  of macrophages and DC have been discontinued. </rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <rdfs:label>Relative contribution of plasmacytoid DC during bacterial infections </rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/83"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001013"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_263"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/305">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vassili Soumelis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0704239">
    <rdfs:label>Myeloid differentiation primary response (88)</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Myeloid differentiation primary response protein MyD88</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MYD88</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MyD-88</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">myeloid differentiation primary response gene (88)</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Myeloid differentiation primary response (88)</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/110">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/UBERON#FMA_7196-MA_0000141-MIAA_0000085-XAO_0000328-ZFA_0000436"/>
    <dcr:hasStimulusType rdf:resource="http://dc-research.eu#dctheradir_263"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/84"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/UBERON#FMA_9608-MA_0000134-MIAA_0000084-XAO_0000123-ZFA_0000669"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/221"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001464"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000784"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000589"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/83"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000109"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Our lab has data available on the effect of endogenous IL-10 production by DC subsets resulting in low levels of IL-12p70 production in mice.

We have shown that plasmacytoid pDC respond to both CpG and the TLR-7 ligand R848 to produce very high levels of IL-12p70 (in the ng/ml range per 5 x 105 cells/ml) and IFN-gamma. However, BM-myeloid and splenic CD8alpha+ DC  produced at least fivefold less IL-12p70, and CD8alpha- DC produced undetectable levels of IL-12p70 upon stimulation with CpG. 

We show that induction of endogenous IL-10 production by these latter DC subsets accounts for their low levels of IL-12p70 production, and since the plasmacytoid pDC do not produce IL-10 this explains their production of high levels of IL-12p70.  Neither endogenous IL-10 production nor a lack of TLR9 expression can however explain the lack of IFN-alpha production by the myeloid and splenic CD8alpha+ and CD8alpha- DC. These data suggest that different pathogens may trigger differential cytokine production as a result of their engagement of distinct TLRs on DC, and in addition by their differential ability to induce IL-10 or IFN-alpha in different DC. This work has now been published in the J. Immunology (Boonstra, Rajsbaum et al, 2006) and the microarray studies as discussed above are based on this study but including the plasmacytoid DC and will continue this project in collaboration with P. Ricciardi-Castagnoli, UNIMIB.</rdfs:comment>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/102"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_235"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <rdfs:label>Activation of mouse DC: induction of endogenous IL-10 production by DC subsets accounts for their low levels of IL-12p70 production</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/281">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Attila Szabo</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_730">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Haemophilus ducreyi</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_724"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/578">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9605"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We are collecting blood (and ascitic fluid) of ovarian cancer patients to study the presence of immature myeloid populations as compared to healthy donor blood. We have identified two candidate populations that will be tested for the ability to suppress T cells.</rdfs:comment>
    <rdfs:label>Blood of ovarian cancer patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_666">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Models with phenotypic similarity to human disease where etiologies are distinct</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_660"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Diabetes Mellitus, Insulin-Dependent, 2-model mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_772">
    <rdfs:label>monitoring step</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monitoring step</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A monitoring step is a step in a protocol that specifies how to provide awareness of the state of a system.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasCellComponentType">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell component type</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to annotate the object with an ontology term of type cell component.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000432">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/112">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000386"/>
    <rdfs:comment>Data is available on the interaction between microorganism-associated molecular patterns and individual toll-like receptors on dendritic cells that turn on signal transduction pathways leading to the activation of different transcription factors.

Microbial invasions are perceived by pattern recognition receptor (PRR)-expressing cells of the innate immune system. PRRs bind a number of microbial products collectively referred to as microorganism-associated molecular patterns (MAMPs). Toll-like receptors (TLRs) are the best-characterized PRRs. The interaction of MAMPs with TLRs expressed on dendritic cells (DCs) plays a particularly important role in regulation of immune responses. By interacting with different combinations of adapter proteins, individual TLRs turn on signal transduction pathways leading to the activation of different transcription factors, such as nuclear factor (NF)-kB, activation protein (AP)-1, and interferon regulatory factors (IRFs). </rdfs:comment>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdfs:label>Interaction of MAMPs with TLRs expressed on dendritic cells (DCs)</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701799"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000382"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/74">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Before injection all cell products will be thoroughly tested to exclude contamination and presence of viable tumor cells.</rdfs:comment>
    <rdfs:label>Testing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/439">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The group completed the measurements of murine dendritic cell subsets and established an in-depth proteomic map of them. These preliminary results show more than 4500 identified proteins in each subset. All of the known markers like CD11c, CD11b, DEC-205, Langerin, etc. were found according to their differential expression pattern. </rdfs:comment>
    <rdfs:label>Murine dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_69075">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CARO#CARO_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endo-epithelial cell</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000115">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endothelial cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">endothelial cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A216">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_491"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_342">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GIST</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GISTs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gastrointestinal stromal tumor cells</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">gastrointestinal stromal tumor cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_341"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/166">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Roxane Tussiwand</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/367">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0002217"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This supernatant was used for staining. Four out of 600 supernatants used, i.e. 2C44, 2F74, 2E60 and 2X8, readily stained LACK156-173-pulsed fibroblasts, but neither unpulsed fibroblasts nor OVA323-339-pulsed cells.</rdfs:comment>
    <rdfs:label>2Xa supernatant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_455">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_equipment</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0400002</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/39">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Graduate program

General information

    The Department of Molecular Biology and Genetics Graduate Program leads to M.Sc. and Ph.D. degrees in Molecular Biology and Genetics. The department is equipped with modern facilities for gene analysis, cell biology, protein chemistry, recombinant DNA technology and animal experiments. The education is research oriented. Research laboratories of the department are used for graduate student training a The main research activities of the department are on molecular genetics, molecular biology, molecular cell biology, molecular virology, structure-function relationship of proteins and new biotechnologies. The research laboratories of the department are equipped with facilities and equipment needed for gene analysis, protein chemistry, recombinant DNA technology, cell biology, experimental animal research, monoclonal antibody production and biotechnology. Current research programs are in the fields molecular genetics, molecular biology, cell biology, protein structure-function relationships, molecular virology and new biotechnologies. Genes involved in genetic predisposition to cancer and tumor suppression (p53, SMAD2, SMAD4, BRCA1, BRCA2, MLH1, MSH2) are studied in the Turkish population. The Molecular virology program concentrates on the viral etiology of chronic liver diseases and hepatocellular carcinoma (Hepatitis B and C viruses). Biological functions of proteins involved in tumor suppression (p33, p53, p73, p16, p130, BRCA1), apoptosis (bcl-2, bax, bcl-x), cell cycle (cyclin-dependent kinase inhibitors, retinoblastoma family of proteins), DNA-damage response (p53, BRCA1, DNA-PK), cell-extracellular matrix interactions (syndecans) are studied. Regulation of gene transcription and cell signaling molecules are also studied. DNA- and antibody-based diagnostic tests for cancer and hepatitis viruses are developed. The department has established collaborative projects with national and international research institutions in Europe and The United States. TUBITAK-sponsored program allows selected Ph.D. students to perform long-term research training in foreign research institutions through collaborative research projects.</rdfs:comment>
    <rdfs:label>Bilkent University</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A167">
    <owl:intersectionOf rdf:nodeID="A217"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/110">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/536"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/537"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/101"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has expertise with Elispot assays. We evaluated the capacity of autologous DC and HEK293 cells transfected with relevant HLA alleles to function as T cell targets in Elispot assays upon transfection with tumor antigen encoding plasmids.</rdfs:comment>
    <rdfs:label>Elispot assays using autologous DC/HEK293 cells as T cell targets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/134">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>MAGE-A3 specific CD4+ T cells were found also in a high percentage of melanoma patients but CD4+ T cells showed an unpolarized or Th2 skewed phenotype. We have optimized the MAGE-A3 peptides to load onto HLA-DR*1101 tetramers.</rdfs:comment>
    <rdfs:label>MAGE-A3 specific CD4+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A105">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A87">
    <owl:unionOf rdf:nodeID="A218"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/125">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ihsan Gürsel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/38">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/36"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/199"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Leukapheresis products from cancer patients was used as a starting material for monocyte enrichment by elutriation technology with ELUTRA®  (Gambro). The monocytes were cultured for five days to immature DC (imDC´s) and subsequently transfected with different constructs encoding for the oncogene Her-2/neu and as control PSA using the technology of Amaxa biosystems or an adeno virus Her-2 full length construct. Levels of Her-2 expression was highest following transfection with  3 different truncated Transmembrane-extracellular constructs, in particular a Her-2 rat-human chimeric one, while a full-length mutant Her-2 construct resulted in relatively low expression. Transfection with the adeno-Her-2 construct resulted in a very high expression level (80% positive cells) of Her-2 in combination with high cell viability (90%),  which was in contrast to the relatively low expression observed with the same Her-2 construct as a pDNA construct transfected with the Amaxa based electroporation. We have concluded that when optimized the combination of leukapheresis and elutriation technologies, creates flexible platforms yielding large scale clinical grade enrichment of monocytes with high purity usefull for transfection with Her-2 or other cancer related gene products for DC based cell therapy and vaccination.</rdfs:comment>
    <rdfs:label>Monocyte enrichment by elutriation technology with ELUTRA(R)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/87">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/86"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/85"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/76"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/186"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/310"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/185"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/189"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/84"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/301"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/83"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/64"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/188"/>
    <rdfs:label>Hermann Wagner</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/187"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400140">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/73">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/267"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/268"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_741"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Such prepared DC will be used also to expand T cells (isolated during the elutriation) for subsequent adoptive transfer.</rdfs:comment>
    <rdfs:label>Expansion of T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/579">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9605"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We are collecting ascitic fluid (and blood) of ovarian cancer patients to study the presence of immature myeloid populations as compared to healthy donor blood. We have identified two candidate populations that will be tested for the ability to suppress T cells.</rdfs:comment>
    <rdfs:label>Ascitic fluid of ovarian cancer patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/113">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/13"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/125"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/17"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://dc-research.eu#dctheradir_646"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/86"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/29"/>
    <rdfs:label>Antigen-loading strategies for DC: comparison of lipofection of tumor-antigen-encoding RNA and RNA electroporation into DC; RNA electroporation with loading of DC with anti-DEC205-antigen constructs</rdfs:label>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/30"/>
    <rdfs:comment>We developed additional antigen-loading strategies for DC and obtained data from first experiments on which constructs lead to antigen presentation and which do not. 

On the one hand we compared lipofection of tumor-antigen-encoding RNA to RNA electroporation into DC, and found that electroporation results in antigen expression in all cells, while lipofection results in higher antigen expression only in a portion of the cells (other cells are negative). Interestingly, the priming capacity of MelanA/HLA-A2-specific autologous CD8+ T cells by lipofected DC was higher compared to electroprated DC. On the other hand, we compared RNA electroporation to loading of DC with anti-DEC205-antigen constructs, consisting of a single-chain variable fragment (scFv) directed against DEC-205, genetically linked to different parts of the MAGE-A3 model antigen (i.e. the KKl  and EVDPIGHLY peptides). To quantify presentation of the epitopes by DC, we used bulk T cells electroporated with TCR-encoding RNA in stimulation assays. Cytokine production by these T cells was used as a read-out.  

First experiments showed that loading of DC  with the anti-DEC-205scFv-MAGE-A3-KKL construct led to antigen presentation, whereas heat-inactivated constructs or control constructs did not.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_206"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000634">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Organism factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/438">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DCs pre-loaded in vitro with ICs are at least 1000-fold more potent than ICs injected directly into mice or DCs loaded with the same amount of non-complexed protein. FcgammaRs on DCs were required for efficient priming of Ag-specific CD8+ cells in vivo and induction of tumor protection. </rdfs:comment>
    <rdfs:label>DCs loaded with Ag-IgG immune complexes (ICs)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A217">
    <rdf:rest rdf:nodeID="A3"/>
    <rdf:first rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/38">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Australian Institute for Bioengineering and Nanotechnology (AIBN) is an exciting new research institute which abandons traditional boundaries to focus research effort into areas that will provide great benefit for human health, manufacturing, information technology and the environment. 

The unique capabilities of the AIBN come from merging the skills of the engineer, chemist, biologist and computational scientist to conduct a world-class research program in nano-scale science, technology and engineering, technology transfer and commercialization. The Research Professionals of the AIBN are leaders in the fields of bioengineering and nanotechnology.

The AIBN is making major contributions to advance knowledge in the rapidly developing fields of nanotechnology and bioengineering and provides outstanding training opportunities for the next generation of scientists.</rdfs:comment>
    <rdfs:label>The University of Queensland / Australian Institute for Bioengineering and Nanotechnology (AIBN)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/368">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/55"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have efficiently transfected DC with RNA encoding a functional protein (E/L-Selectin). The mouse E/L-S transfected DC, when given i.v., homed to the lymph nodes, whereas non transfected DC home only to the spleen.</rdfs:comment>
    <rdfs:label>Mouse E/L-S transfected DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_727">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Haemophilus influenzae</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/165">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pia Kvistborg</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/37">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdfs:comment>Protocol for the documentation and the analysis of the interaction between RIG-I, a viral sensing protein, and NS1, an inhibitor of interferon production that is encoded by influenza A virus. This protocol has been made available.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0700621"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_394"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/35"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11320"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:label>Using electron microscopy for documentation of production and secretion of tubulovesicular structures </rdfs:label>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/170"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A218">
    <rdf:rest rdf:nodeID="A219"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/133">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CEA specific CD4+ T cells were found both in normal donors and in patients with high-grade cervical lesions, pancreas adenocarcinoma and advanced melanoma but CD4+ T cells from the patients compared to normal donors showed impaired IFN-gamma production. </rdfs:comment>
    <rdfs:label>CEA specific CD4+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A213">
    <owl:onProperty rdf:resource="http://dc-research.eu#elementsBiomaterialTypeOf"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/111">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_778"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>An ELISA assay using the kit from Biosource was performed according to the manufacturer’s instructions for the measurement of different cytokines. </rdfs:comment>
    <rdfs:label>ELISA assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/88">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/203"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/187"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/299"/>
    <rdfs:label>Tim Sparwasser</rdfs:label>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/85"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/310"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/137"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/174"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/126">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Inge Marie Svane</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_302">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dectin-1</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dectin1 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dectin-1 receptor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dectin1</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/76">
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_763"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Injection</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_19">
    <rdfs:label>evaluation step</rdfs:label>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An evaluation step is a step in a protocol that specifies how to evaluate a certain outcome or a certain condition.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">evaluation step</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/psi-mi#MI_0788">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">genetic modification design: knock-out experiment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_447"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_180">
    <rdfs:label>CD137 receptor</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD137 receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A63"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-137</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 137</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD137</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_0000021">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000840"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/164">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/131"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Paola Larghi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_5034">
    <rdfs:label>human lymph node</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymph nodes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_457">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0400169</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_microscope</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/37">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Etablissement Francais du Sang - Alsace (INSERM U725)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000791">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mature alpha-beta T cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000789"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_344">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">peripheral blood lymphocyte</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_86697"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PBLs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PBL</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">peripheral blood lymphocytes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/114">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/279"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/12"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000182"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdfs:label>DERMA-ER-DC 05 clinical trial of DC-based therapy of melanoma patients +/- ONTAK</rdfs:label>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <rdfs:comment>We have data from a clinical trial with melanoma patients (stage IV, documented progress) receive DC transfected with RNA encoding MelanA, Mage3 and Survivin +/- E/L-selectin by the i.v. route.  This DERMA-ER-DC 05 trial (multipeptide loaded cytokine matured moDC + prior Treg elimination by 3x ONTAK treatment [5µg/kg], 8 evaluated pat.) did not show any enhanced immune reponses compared to the equivalent cohort in the DERMA-ER-DC 04 trial. 

Patient recruitment into the 2nd phase of the DERMA-ER-DC 06 trial has started (sequential adaptive design). Immunomonitoring of first patients showed efficient induction of broad immune responses.

However, we unexpectedly could not demonstrate any depletion of Tregs by ONTAK (ccoperation with P14). ONTAK treatment induced a transient depletion of all known DC subpopulations in the peripheral blood, a novel and very unexpected finding.

One possible reason for the discrepancies between our findings and published data  could be the amount of ONTAK used in patients. We therefore filed an amendment allowing the inclusion of additional 4 patients, who will receive higher doses (12microg/kg 3x and 18microg/kg 1x) before vaccination. Taking into account direct effects of ONTAK on DC, patients will be vaccinated some days after last ONTAK treatment (as soon as blood DC have recovered to 50% of pre ONTAK amount).</rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/41"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1476"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/521"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://dc-research.eu#dctheradir_646"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/87"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/46"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_164"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/280"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704043"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A108">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48706"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A219">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/36">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/11"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/146"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Analysis of protein-inhibitor interaction using fluorescence microscopy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/132">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>HPV-18 E6 specific CD4+ T cells were found in a high percentage of patients with cervical lesions and we showed that the quality of the response (i.e. the level of IFN-? produced) could predict the clinical outcome after surgery.</rdfs:comment>
    <rdfs:label>HPV-18 E6 specific CD4+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/365">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0002217"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This supernatant was used for staining. Four out of 600 supernatants used, i.e. 2C44, 2F74, 2E60 and 2X8, readily stained LACK156-173-pulsed fibroblasts, but neither unpulsed fibroblasts nor OVA323-339-pulsed cells.</rdfs:comment>
    <rdfs:label>2F74 supernatant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/479">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The melanin-free total tumor RNA is obtained from melanoma metastases; it is suitable for in vitro amplification and DC transfection.</rdfs:comment>
    <rdfs:label>Melanin-free total tumor RNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/123">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/137"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Guido Vanham</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17029">
    <rdfs:subClassOf rdf:nodeID="A68"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18154"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">chitin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/89">
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/124"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/209"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/208"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/65"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Georg Hacker</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10376">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Epstein Barr virus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HHV-4</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EBV</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000484">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_18">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MACS separation of cell population</rdfs:label>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0600037"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Magnetic-activated cell sorting</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/75">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/240"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/272"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/271"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_765"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>A portion of pulsed and unpulsed mature dendritic cells will be frozen and used to monitor immunological responses elicited by the DC vaccine and transferred T cells during the clinical trial.</rdfs:comment>
    <rdfs:label>Cell freezing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_738">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">time point experiment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Time point at which a sample or observation is made or taken from a biomaterial as measured from some reference point.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/163">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/319"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/41"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Maria Cristina Gauzzi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_83624">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">stromal cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/IAO_0000010">
    <rdfs:label>software</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_458">
    <rdfs:label>confocal microscope</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">confocal microscopes</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">confocal microscope</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0400169"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_345">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">effector T cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">effector T-cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">effector T-cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">effector T cells</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001444">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LY96</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ESOP1</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MD-2</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MD2</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lymphocyte antigen 96 precursor</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MD-2 protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lymphocyte antigen 96</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ESOP-1</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A62"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MD2 PROTEIN</dcr:hasExactSynonym>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/36">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The latest Research Assessment Exercise (RAE) confirmed The University of Nottingham's position as a world class research-led institution.  Over 60% of the University's RAE scores identified research as being of a level of international excellence.  This achievement has helped put Nottingham within the Sunday Times top ten UK universities.

The purpose of the RAE is to enable higher education funding bodies to distribute public funds for research based on the quality of research carried out at each institution.  The RAE gives quality ratings for research across all disciplines.  A scale ranges from 1 to 5* according to how much of the work is judged to reach national or international standards.

 At the end of 2005-6, the University announced a record £122 million of new research grants and contracts.  Awards for the current year are in line with this figure.  The University derives about 20% of its research income from industry sponsors, reflecting its strengths in taking promising new findings from bench to business.

The University's research strategy is based on the recruitment, promotion and retention of individuals with exceptional research credentials and a policy of encouraging research that crosses academic boundaries.  Collaboration with other international centres of research excellence is actively encouraged.

Significant investment in new research infrastructure at Nottingham is planned for the period 2007-9, which will further improve the quality of equipment and buildings to further the University's research aims.

The University pursues a co-ordinated approach to research management, with two Pro-Vice Chancellors for Research responsible for the University's research strategy through the Research Committee and its Research Strategy Groups.  Delivery of the strategy is the remit of the Research Innovation Services team, which is also responsible for maintaining the University's relationships with external funding organisations.
</rdfs:comment>
    <rdfs:label>The University of Nottingham</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_17076">
    <rdfs:label>streptomycin</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">streptomycin</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_24400"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A146">
    <owl:unionOf rdf:nodeID="A205"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/35">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001412"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001013"/>
    <rdfs:comment>To generate a proteomic map of DCs (WP2) which includes quantitative information that can be used further to study signalling cascades (WP5) it is also necessary to optimize the SILAC labelling of DCs. This work was performed by Christian A. Luber (PhD student). First, we have set up a system for SILAC labelling of bone marrow derived murine dendritic cells (BM-DC). The principal method for generating BM-DC with GM-CSF was adapted from Lutz et al. (J Immunol Methods 1999, 223: 77-92). After some modifications of the protocol the FACS analysis of DC, which were generated in conditions described by Lutz et al. or in modified SILAC conditions did not show differences in the expression levels of the common DC markers CD11c, CD80, CD86. Analysis by mass spectrometry showed successful labelling.</rdfs:comment>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/97"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000018"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/47"/>
    <rdfs:label>Optimization of SILAC labelling of DCs</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/34"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/107"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A113">
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/366">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0002217"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This supernatant was used for staining. Four out of 600 supernatants used, i.e. 2C44, 2F74, 2E60 and 2X8, readily stained LACK156-173-pulsed fibroblasts, but neither unpulsed fibroblasts nor OVA323-339-pulsed cells.</rdfs:comment>
    <rdfs:label>2E60 supernatant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/131">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We set an in vitro system to study ex-vivo responses able to detect fona fide in vivo primed CD4+ T cells. We investigated spontaneous CD4+ T cell responses to these antigens in normal donors and in patients with high-grade cervical lesions, pancreas adenocarcinoma and advanced melanoma. 

The antigens were: 
i) the E6 and E7 proteins of human papilloma viruses, 
ii) the carcinoembryonic antigen (CEA) and 
iii) the tumour specific antigen MAGE-A3. 

</rdfs:comment>
    <rdfs:label>Patients with advanced melanoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/478">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/68"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>From the CD14- PBMCs, untouched naive CD4+ T cells were isolated with a combination of magnetic sorting.</rdfs:comment>
    <rdfs:label>CD14- PBMC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/124">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/144"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/143"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/142"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/141"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ignacio Melero</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_304">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/PRO#PRO_000001128</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_chemokine receptor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000485">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/530">
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We assessed the capacity of the electroporated DCs to activate naive HLA-A2-restricted MelanA-specific CD8(+) T cells without the addition of any exogenous cytokines. A &gt;500-fold increase in MelanA-specific CD8(+) T cells was observed when compared with immature DCs, and a &gt;200-fold increase when compared with cytokine cocktail-matured DCs. In correlation, we found a marked increase in cytolytic and IFN-gamma/tumor necrosis factor-alpha (TNF-alpha) secreting CD8(+) T cells. Our data indicate that immature DCs genetically modified to express stimulating molecules can induce tumor antigen-specific T cells in vitro and could prove to be a significant improvement over DCs matured with the methods currently in use.</rdfs:comment>
    <rdfs:label>Mature DCs electroporated with CD40L and/or caTLR4 mRNA and CD70 mRNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/116">
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/436"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/26"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_208"/>
    <rdfs:label>Prevention of infectious disease is ImmunoVex HSV2 a vaccine for genital herpes</rdfs:label>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Preclinical data is available on the power of preventing disease and invoking immune response of our lead product for the prevention of infectious disease, ImmunoVexHSV2, a vaccine for genital herpes. ImmunoVex HSV2 is a novel live-attenuated vaccine candidate that expresses approximately 80 HSV-2 proteins intended to stimulate a broad and powerful immune response. In preclinical studies, ImmunoVex HSV2 completely prevents disease and invokes a powerful immune response. We intend to initiate a Phase I clinical trial for this product early in 2008.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10310"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/25"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/27"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/7">
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86697"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/167"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Transcriptomic data has been generated on PB-monocytes in healthy controls, RA and SLE.</rdfs:comment>
    <rdfs:label>Transcriptional profiling of PB-monocytes in healthy controls, RA, SLE</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000261">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MEK</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mitogen-activated protein kinase kinase</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000224"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MEK</dcr:dcthera_label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mitogen-activated protein kinase kinase</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MAPKK1/2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MKK1/2</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MEK1/2</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/9">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Tom van Denderen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/35">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Have a look around. Get to know our cosmopolitan university in the heart of Munich. Ludwig-Maximilians-Universität (LMU) Munich enjoys a centuries-old tradition and today is one of the most internationally renowned and strongest research universities in Germany.

People come to LMU Munich seeking its unique academic diversity. Its 18 faculties give around 700 professors and 3,000 academic staff room to research and teach. They offer a wide and well-rounded range of learning opportunities that cover all areas, whether humanities and culture studies, law, economics and sociology, or medicine and the sciences.

Our research statistics speak for themselves: LMU Munich is part of 26 Collaborative Research Centers funded by the German Research Foundation (DFG) and is host university of 14 of them. It also hosts 9 DFG Research Training Groups and four international doctorate programs as part of the Elite Network of Bavaria. It attracts an additional 120 million euros per year in outside funding and is intensively involved in national and international funding initiatives. All this demonstrates why LMU Munich regularly gets top marks in national and international rankings.

With degree programs available in 150 subjects in numerous combinations, the array of courses we have to offer is extremely wide. Some 47,000 students, 16 percent of whom come to us from abroad, are currently taking advantage of these opportunities. They view their studies as an investment in the future, a launching pad for their later careers. We put our faith in imagination, open minds and creative intelligence.

LMU Munich takes the education of young people very seriously. When we speak of academic diversity, we also mean a comprehensive education that encompasses social skills alongside a critical awareness of values and history. This includes the Munich legacy of the Weisse Rose, the student-based resistance group that opposed Nazism.

Professor Dr. Bernd Huber
President, Ludwig-Maximilians-Universität Munich</rdfs:comment>
    <rdfs:label>Ludwig-Maximilians-Universität München - LMU Munich</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/115">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/1"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>In our laboratory we have know-how on Elispot analysis. For instance, an IFN-ELISPOT assay was used to determine that co-cultures of DC and T cells led to antigen specific, IFN-? secreting T cells after 1 restimulation at a DC:T cell ratio of 1:20. </rdfs:comment>
    <rdfs:label>Elispot analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A214">
    <rdf:rest rdf:nodeID="A220"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/435">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/434"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We showed that, in the absence of adjuvants, DEX mediate potent antigen dependent-antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide (CTX).</rdfs:comment>
    <rdfs:label>Mice pretreated with immunopotentiating dosing of cyclophosphamide (CTX)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/162">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Luca Castagna</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/70">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/238"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/267"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/239"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_754"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Elutriation of the leukapheresis product.</rdfs:comment>
    <rdfs:label>Elutriation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0700888">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Icsbp1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICSBP</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Irf8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Icsbp</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IRF8 MOUSE</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A55"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Irf 8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Myls</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">transcription factor IRF-8</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon consensus sequence-binding protein</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interferon regulatory factor 8</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Irf-8</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/239">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Véronique QUILLIEN</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_17">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0302912</dcr:replaced_by>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_electroporation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_24400">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glycosides</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/16">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdfs:label>transfected mouse DC with RNA encoding a functional protein (E/L-selectin)</rdfs:label>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/87"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/11"/>
    <rdfs:comment>We have efficiently transfected DC with RNA encoding a functional protein (E/L-selectin), which allows entry of DC into LN from HEV. These DC rolled in vitro on sialyl-LewisX-coated slides, and in vivo, mouse E/L-selectin-transfected DC homed to LN after i.v. application.</rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/10"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/238">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>M. Pezzoni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/121">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Gerard Bos</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/477">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/282"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/50"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0000125"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The T blasts are used to immunize MAGE-3 positive patients.</rdfs:comment>
    <rdfs:label>Autologous MAGE-3 and TK transduced activated T blasts</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_779">
    <rdfs:label>ELISPOT assay</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An ELISPOT assay is a method specifying how to count the number of cytokine-producing cells within a cell suspension.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ELISPOT assay</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/83">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/122"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/121"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/79"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/229"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/232"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/288"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/122"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/82"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/81"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/279"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/166"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/424"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/92"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/93"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/307"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/222"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/416"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/277"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/78"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/280"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/198"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/4"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/211"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/42"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/122"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/167"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/138"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/282"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/268"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/16"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/85"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/275"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/274"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/530"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/60"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/56"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/40"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/266"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/278"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/317"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/281"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/286"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/61"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/199"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/43"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/63"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/219"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/94"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/226"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/225"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/283"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/264"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/68"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/57"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/18"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/269"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/263"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/70"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/527"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/276"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/228"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/227"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/231"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/230"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/151"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/57"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/41"/>
    <rdfs:label>Kristiaan Thielemans</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/80"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/165"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/164"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/123"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/287"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/415"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/526"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/63"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/62"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/64"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/71"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/273"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/272"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/201"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/95"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/59"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/58"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/265"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/3"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/529"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/528"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_902">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An experiment design type in which the pathological condition of a part, organ, or system of an organism is studied. The etiology may be from infection, genetic defect, or environmental stress.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">disease state design experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/130">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We set an in vitro system to study ex-vivo responses able to detect fona fide in vivo primed CD4+ T cells. We investigated spontaneous CD4+ T cell responses to these antigens in normal donors and in patients with high-grade cervical lesions, pancreas adenocarcinoma and advanced melanoma. 

The antigens were: 
i) the E6 and E7 proteins of human papilloma viruses, 
ii) the carcinoembryonic antigen (CEA) and 
iii) the tumour specific antigen MAGE-A3. </rdfs:comment>
    <rdfs:label>Patients with pancreas adenocarcinoma</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A115">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_48705"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11757">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mouse Mammary Tumor Virus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">murine mammary tumor provirus MMTV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MMTV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mouse mammary tumor virus MMTV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mouse mammary tumor virus MTV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mouse mammary tumor virus MMT</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/34">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/35"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/5"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/46"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/25"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/96"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>For quantitative proteomic studies, our group recently described the SILAC (Stable Isotope Labelling by Amino Acids in Cell Culture) approach. 

In this method, independent populations of cells are grown in medium containing different non-radioactive isotope forms of essential amino acids (e.g. arginine and lysine). Because the cells cannot synthesize these amino acids, after some generations all proteins are labelled and therefore can be distinguished and quantified by the mass spectrometer.</rdfs:comment>
    <rdfs:label>The SILAC approach</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/114">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Knowledge on ELISPOT analyses is available in our lab for immunomonitoring of patients treated with Apo-DC +/- GM-CSF. </rdfs:comment>
    <rdfs:label>Elispot analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/34">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Martinsried facility is located within one of the leading European biotechnology regions – the Biotech Region of Munich, Germany. The new facility consists of approximately 3,300 square meters of office and research &amp; development facilities. The state-of-the-art laboratories are classified and approved according to European regulations.

Currently approximately 100 employees work at the Martinsried facility in the following functions: Research &amp; Development (including Research, Preclinical, Vaccine Development, Clinical Development, Process Development, Analytical Development, Bioinformatics), Regulatory Affairs, Patents and IT.</rdfs:comment>
    <rdfs:label>Bavarian Nordic GmbH</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_739">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Participant in DC-THERA</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000245"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A participant in DC-THERA is a an institution/company/institute or other legal association that collaborates in a scientific way inside the DC-THERA network.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/116">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_778"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>Our lab has expertise in performing ELISA assays. For example, we have monitored vaccine induced T cell responses for two clinical trials. We found CD8+ and CD4+ T cell responses against the immunological tracers KLH and TK, and against the NTPs and MAGE-3, respectively. </rdfs:comment>
    <rdfs:label>ELISA assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A220">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_485"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/8">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/240"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_F0001414"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data has been obtained on expression and regulations of Notch ligands on DC subsets.</rdfs:comment>
    <rdfs:label>Expression and regulation of Notch ligands on DC subsets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/434">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/435"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We showed that, in the absence of adjuvants, DEX mediate potent antigen dependent-antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide (CTX). CTX could 

i) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells (Treg), 
ii) markedly enhance the magnitude of secondary but not primary CTL responsesinduced by DEX vaccines, 
iii) synergize with DEX in therapy but not prophylaxis tumor models.</rdfs:comment>
    <rdfs:label>DC-derived exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_37163">
    <rdfs:label>Glucan</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Glucan</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18154"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">glucans</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/117">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Melan-A_Protein"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/152"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/370"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>First clinical vaccination data has been obtained using an HSV vector expressing full length tyrosinase, gp100 and MART-1 to transduce DC from melanoma patients.

Biovex has developed HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes which usually inhibit DC function. These deliver antigens to DC at very high efficiency and activate the transduced cells similarly to LPS. Based on this technology, Biovex began a clinical program where an HSV vector expressing full length tyrosinase, gp100 and MART-1 was used to transduce DC from melanoma patients which were then to be used for vaccination. Due to a change in emphasis, Biovex is no longer progressing this program but has, as a result, considerable internal expertise, reagents and methodology which could be of use to the project if partners would like to use HSV-based technology for the delivery of antigens to DC. This includes the vectors themselves, and the shuttle plasmids into which antigens are inserted and provides the possibility of using these vectors for a variety of pre-clinical, and ultimately clinical studies.</rdfs:comment>
    <rdfs:label>HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes</rdfs:label>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0200674"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/88"/>
    <dcr:hasMoleculeType rdf:resource="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#gp100_Antigen"/>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10294"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/161">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/132"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Laura Salogni</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/476">
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_229"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/51"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24, are used for vaccination.</rdfs:comment>
    <rdfs:label>Autologous DC loaded with KLH and an allogeneic peptidome</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_16">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_vaccination</rdfs:label>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/VO_0000002</dcr:replaced_by>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/230">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/186"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0704821"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000028"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_2"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We obtained data on the control of innate immunity by the mammalian target of Rapamycin (m-TOR) by enhancing TLR driven production of proinflammatory cytokines and type 1 interferons and by repressing posttranslational processing, via the inflammasome, of IL-1beta.

We will further analyse the impact of the m-TOR inhibitor Rapamycin on innate immunity.</rdfs:comment>
    <rdfs:label>Control of innate immunity by rapamycin ( mTOR)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_12637">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dengue virus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000832">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000512">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">kinases</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">kinase</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/122">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Gianluca Matteoli</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/84">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Dominique Wolf</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasShortForm">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has short form</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_250">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leishmania LACK protein</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">LACK</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/17">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We used dendritic cells loaded with anti-DEC205-antigen constructs, consisting of a single-chain variable fragment (scFv) directed against DEC-205, genetically linked to different parts of the MAGE-A3 model antigen (i.e. the KKl and EVDPIGHLY peptides), in a study to compare antigen-loading strategies.</rdfs:comment>
    <rdfs:label>DC loaded with anti-DEC205-antigen constructs</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/33">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Humanitas is what is known in Italy as an IRCCS (a Scientific Institute of Admission and Care) that has been recognised by the Ministry of Health and Lombardy’s Regional Government as a centre of excellence in terms of quality of its healthcare services and its ability to translate the results of research and innovation into everyday clinical practice.
Humanitas is also a teaching centre for the University of Milan’s degree in Medicine and Surgery, Nursing and Biotechnologies.

Humanitas is a hospital with an integrated highly specialised, multidisciplinary approach. From cardio surgery to orthopaedics, and from oncology to neurosurgery, Humanitas offers the highest international standards. The operating rooms are grouped in blocks near the Intensive Care Units. The surgical process has been designed to ensure perfect operating conditions, including guaranteed absolute environmental sterility.

Ever since it’s opening, Humanitas has adopted quality control systems based on the PDCA approach (Plan Do Check Act), which summarises the virtuous circle of quality and makes it possible to verify processes and outcomes in a continuous manner.
Istituto Clinico Humanitas has always compared itself with the best European hospitals and has taken part in various benchmarking projects as a means of preparing itself to meet the challenge of the opening of the European Health System.
It was this that led to the decision to certify the hospital’s management model with the Joint Commission International.
</rdfs:comment>
    <rdfs:label>Istituto Clinico Humanitas</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/369">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/55"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have efficiently transfected DC with RNA encoding a functional protein (E/L-Selectin) which allows entry of DC into LN from HEV. The novel adherence capacity of human E/L-S transfected DC was demonstrated via sticking to sialyl-LewisX coated slides using a parallel plate flow microscope. RNA transfected human DC could be frozen and thawed without loosing their functionality. </rdfs:comment>
    <rdfs:label>Human E/L-S transfected DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/118">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000082"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/90"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_345"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/124"/>
    <rdfs:label>RCC phase 2 trial</rdfs:label>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_345"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/90"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/26"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86697"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data have been obtained from a phase 2 study testing PME-CD40L DC in RCC patients with clear cell histology.

The Phase 2 trial has the same general design, dosing regimen, endpoints, and immunomonitoring plan as the completed RCC trial. 
However, the Phase 2 study tests the improved RCC product (i.e., PME-CD40L DC) and is restricted to RCC patients with clear cell histology. 

As predicted from the in vitro data, the improved PME-CD40L DC product does indeed lead to restoration of both IL-2 and IFN-? responses. Also consistent with our in vitro observation is the gradual decline of the immune effector T cells in the peripheral circulation (i.e., weaker signal after the fifth dose). This is indicative of T cell effector memory maturation (i.e., CD8+/CD28+/CD45RA- T cells) which are equipped to leave the peripheral circulation and infiltrate the tissues in surveillance of target antigens. It is also noteworthy that presence of CD28+ T cells in tumor lymphocytic infiltrates correlates with favorable clinical outcome.

In contrast to the disease stabilization observed in our first RCC study, using the PME-CD40L DC product we have observed tumor regressions in a number of patients in the current study. At present, 6 of 12 patients that have been restaged using RECIST criteria have less tumor burden that when they enrolled in the study (15 weeks earlier). </rdfs:comment>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000473"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/91"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000008"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A85">
    <owl:unionOf rdf:nodeID="A221"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#offers_access_to">
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <owl:inverseOf rdf:resource="http://dc-research.eu#isAccessibleFrom"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a person or a participant to any DC-THERA Resource that offers access to that Resource in some way.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">offers access to</rdfs:label>
    <rdfs:domain rdf:nodeID="A120"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/437">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/102"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Long peptides which were covalently conjugated to either the TLR2 ligand or TLR9 ligand, Pam3CysSK4 or CpG have been used to study the uptake, antigen presentation, and induction of specific T-cells.</rdfs:comment>
    <rdfs:label>Conjugated long peptides</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_340">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/CHEBI#CHEBI_23367</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_inhibitor of tyrosine kinase receptors</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000524">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sphaeroplasts</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sphaeroplast</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">spheroplasts</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">spheroplast</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/231">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_50816"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_4"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Imaging data is available from MRI tracking of dendritic cells in melanoma patients for cellular therapy. In vivo magnetic resonance tracking of magnetically labeled cells is feasible in humans for detecting very low numbers of dendritic cells in conjunction with detailed anatomical information. MRI cell tracking using iron oxides appears clinically safe and well suited to monitor cellular therapy in humans. </rdfs:comment>
    <rdfs:label>Tracking of dendritic cells in melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/160">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Laura Campisi</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_15">
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_injection</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_0000426</dcr:replaced_by>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/475">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/51"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The patients are immunized with autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24.</rdfs:comment>
    <rdfs:label>HLA-A2 positive patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_292">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural regulatory T cell (CD25+)</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">natural regulatory T cells (CD25+)</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/72">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/242"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/241"/>
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/240"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/243"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>On day 5 of culture immature DC will be pulsed with irradiated tumor cells (apoptotic bodies) prepared from the removed lesion and matured for 48 hours in presence of TNF-alpha. Monocyte and DC viability as well as functionality will be continuously monitored. </rdfs:comment>
    <rdfs:label>DC pulsing</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/85">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Marie Christine Launay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/236">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Manuel Mayhaus</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_251">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-134</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OX40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OX 40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OX-40</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 134</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD134</rdfs:label>
    <rdfs:subClassOf rdf:nodeID="A126"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/18">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/86"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These multipeptide loaded cytokine matured moDC +/- CD40L activation were used for the DERMA-ER-DC 04 trial.</rdfs:comment>
    <rdfs:label>multipeptide loaded cytokine matured moDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_620">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.biology-online.org/dictionary/: yeast cell wall components that are proteins with large numbers of mannose groups attached; highly antigenic.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17089"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mannoprotein</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mannoproteins</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/112">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/81"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_778"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience with ELISA for IL-12p70 from R&amp;D System.</rdfs:comment>
    <rdfs:label>ELISA for IL-12p70</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/32">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/7"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/6"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Max Planck Institute of Biochemistry in Martinsried near Munich was founded in 1973 as the successor of the three formerly independent institutes MPI of Biochemistry (founded in 1912 as Kaiser-Wilhelm-Institut in Berlin-Dahlem), MPI for Protein and Leather Research (founded in 1954 in Regensburg) and the MPI for Cell Chemistry (founded in 1956 in Munich). 

Research at the institute focuses on studies of the relationship between the structure and the activity of biological systems with various degrees of complexity, i.e. nucleic acids as carriers of the genetic information and proteins or peptides as structural components of the three-dimensional organization of the cell. Their folding and function is likewise the subject of the research such as cell organelles, membranes, viruses, oncogenes, archaebacteria, higher cells and whole organisms. These serve as models for the investigation of the molecular bases of biological and pathophysiological phenomena: Cell-cell interactions, cell division, cell growth and - differentiation, gene regulation, signal transmission by nerves, photosynthesis, evolution and cancer. 

A special strength of the institute is the various methodical expertise in the areas of protein chemistry, molecular biology and structure analysis. Research in scientific departments and working groups is supported by central service facilities for DNA- and protein sequence analysis, DNA- and peptide-synthesis, NMR and mass spectrometry, a central library, an information retrieval and managing center, a computing center with bioinformatics unit, an animal house and central workshops. New methods in molecular biology and genetic engineering led to the development of a biomedically oriented basic research of molecular medicine. In this field of research medical questions are connected with molecular-biological techniques, which opens promising possibilities in the pathogenesis research and the development of new diagnostic and therapeutical approaches. The institute cooperates in this area with the pharmaceutical industry on national and international level. Several research groups of the institute are working on this medical orientated field of research, others are dealing with pure basic research. 

At the end of 2005 the institute had 880 employees (including people funded by third parties), of whom 492 were senior scientists and 214 were junior scientists .</rdfs:comment>
    <rdfs:label>Max Planck Institute of Biochemistry</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/32">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/2"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/39"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/11"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>This methodology incorporates a unique sample preparation procedure based on 96 well plate complex sample trypsinization, a nano-LC-based peptide separation coupled to MSMS analysis sequencing. This procedure led us to the identification of 600 phagosomal proteins from murine DC phagosomes.</rdfs:comment>
    <rdfs:label>Protocol for the identification of phagosome proteins in dendritic cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/436">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/116"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/participant/7"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/28"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>ImmunoVexHSV2 is a product for the prevention of infectious disease, it is a vaccine for genital herpes. In preclinical studies, ImmunoVex HSV2 completely prevents disease and invokes a powerful immune response.</rdfs:comment>
    <rdfs:label>ImmunoVex HSV2</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/119">
    <rdfs:comment>Data has been obtained from our phase 1 HIV clinical study described here:

Study Design: Patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART are administered 4 monthly doses of the Arcelis product.

Current status: This trial is fully enrolled. Immune response data is encouraging in the first 7 patients for which the analysis has been completed.  Six of 7 patients developed CD8+ T-cell immune reactivity to several HIV antigens. Importantly, the expanded HIV-specific T cells are CD28+ effector memory cells, known to associated with long-term non-progression. The product was well-tolerated with no serious adverse events reported.</rdfs:comment>
    <dcr:hasExperimentalFactorType rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000355"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_211"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_367"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000473"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/27"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/92"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.obofoundry.org/obo/OBI_0100016"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/77"/>
    <rdfs:label>Phase 1 HIV clinical study</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_341">
    <rdfs:label>tumor cell</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumour cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumour cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor cells</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A221">
    <rdf:rest rdf:nodeID="A216"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_490"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/232">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_3"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>Data will be obtained from a study that we plan on  DC receptor characteristics and signalling, focussing on antigen receptors. </rdfs:comment>
    <rdfs:label>DC receptor characteristics and signalling</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/71">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/239"/>
    <dcr:hasBiomaterialOutput rdf:resource="http://dc-research.eu/rdf/biomaterial/240"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_742"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>DCs will be generated from monocytes.</rdfs:comment>
    <rdfs:label>DC generation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isSupervisorOf">
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect a supervisor of a supervised person, such as a DC-THERA PhD student, to this supervised person. The supervisor is not necessarily the hosting one but any supervisor who follows the supervised person.</OBI:IAO_0000115>
    <owl:inverseOf rdf:resource="http://dc-research.eu#hasSupervisor"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is supervisor of</rdfs:label>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/474">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/51"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The patients are immunized with autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24.</rdfs:comment>
    <rdfs:label>HLA-A1 positive patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_14">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intradermal administering of substance</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0600007"/>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_291">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is this a strain?</rdfs:comment>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">axenic mice</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">axenic mouse</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/86">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/335"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/219"/>
    <rdfs:comment></rdfs:comment>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/289"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/290"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/77"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/371"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/455"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/292"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/373"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/104"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/70"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/291"/>
    <rdfs:label>Benedita Rocha</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/220"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/372"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_300">
    <rdfs:label>OT1 cell</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OT-I cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OT-I cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OT-1 cells</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OT-1 cell</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OT1 cells</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OT1 cell</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/31">
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/58"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/57"/>
    <dcr:manufactures rdf:resource="http://dc-research.eu/rdf/tool/1"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>Genopolis is an alliance of three scientific public Institutions (University of Milano, University of Milano-Bicocca and the Besta Institute of Neurology) that have established a network of excellence aimed to develop, integrate and disseminate Functional Genomics. 

Genopolis intends to develop integrated strategies to raise the value of massive information generated by the genomic revolution and to support interdisciplinary approaches. The Consortium will foster the scientific community to advance translational research in the fields of Cell biology and Molecular medicine, including Immunology, Neuroscience and Genetics and will promote public awareness regarding social and ethical aspects of Genomics.

Genopolis operates as a public, non-profit Consortium, located at the University of Milano-Bicocca. The Consortium has a genomic platform based on microarray technologies and acts as an Affymetrix GeneChip® service provider, to support national and international infrastructures and European networks. 

GENOPOLIS offers support for experimental design of microarray experiments, bioinformatic tools for data mining and data analysis, education and training courses.</rdfs:comment>
    <rdfs:label>Genopolis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/113">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/protocol/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_778"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience with ELISA assay for IL-17 from e-Bioscience.</rdfs:comment>
    <rdfs:label>ELISA for IL-17</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/120">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Frank Nestle</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/31">
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/221"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_11"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/155"/>
    <rdfs:label>SOPs for the cytometric assessment of Th-cell immunity based on antigen-induced CD154 expression</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_232"/>
    <rdfs:comment>We have worked out SOPs for the cytometric assessment of Th-cell immunity based on antigen-induced CD154 expression, a technology developed by us in the frame of previous DC-THERA activities. Now the entire antigen-specific Th-cells specific for defined antigens can be monitored simultaneously with respect to quantity and quality. Tests can either be performed on standard 4 colour cytometers or on 12 colour high-end cytometric analysers. Tests that can be either performed to analyse fixed or isolate live antigen-specific Th-cells have been adapted also to be used with murine cells (Kirchhoff et al., 2007). </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/30">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_730"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Institute Gustave-Roussy (IGR), the leading European anticancer centre, assembles on the same site 2,500 men and women whose missions are to treat patients suffering from cancer, conduct research and develop new therapies, and to pass on knowledge and know-how to the medical and scientific communities in France and world-wide.
Treatment

In the 400-bed hospital with its 124 statutory physicians, annually over 11,000 new patients are recruited, 130,000 patients attend its clinics and 42,000 patients receive treatment.
Research

Research is conducted by 400 research scientists under the oversight of a scientific council, a therapeutic trials commission and a clinical research committee.
Teaching

Over 5,000 hours of instruction are taught in its School of Oncology in collaboration with the University of Paris.

Each of these three missions is founded on principles that are the guiding force behind IGR's actions daily:
the excellence principle, through which efforts are united to establish quality standards in oncology;
the innovation principle, that is urgently needed for many cancers that are still incurable;
the evaluation principle, without which it is impossible to advance in a rigorous and methodical manner along the path to new therapies.

Situated in the heart of Europe, at the gateway to Paris, the Institute Gustave-Roussy is poised to undergo thorough restructuring and renovation at the beginning of the 21st century, to enhance its efficacy in its primary commitment towards patients, the fight against cancer.</rdfs:comment>
    <rdfs:label>Institut de cancérologie Gustave Roussy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/287">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The animal(s) were immunized in vivo with in vitro matured DC and / or treated using a maturation signal.</rdfs:comment>
    <rdfs:label>Mouse</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/4">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/5"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Production of lentiviruses: 

Producing lentivirus in 293 FT Cells:
Day 1: 4 x 106 293 FT in 10 ml DMEM (+10 % FCS (Tet free), +P/S) in a 10cm plate
Day 2: transfection 
Day 3: change of medium
Day 4: harvesting</rdfs:comment>
    <rdfs:label>Production of lentiviruses for RNAi and gene expression</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_775">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The modification of an organism due to the presence of DNA from another individual, e.g. of a different strain, species or breed. These do not include targeted transgenics such as knock-ins and knock-outs.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">non targeted transgenic variation experiment</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/12">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/114"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These patients receive DC transfected with RNA encoding MelanA, Mage3 and Survivin +/- E/L-selectin by the i.v. route. 
2nd phase of the DERMA-ER-DC 06 trial.</rdfs:comment>
    <rdfs:label>stage IV melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/473">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>All lymphocytes (6,4 x 10e9) were frozen in 90% A-plasma and 10% GMP-grade DMSO.</rdfs:comment>
    <rdfs:label>Frozen lymphocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_13">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0600014"/>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">isolation of cells</rdfs:label>
    <oboInOwl:hasDefinition rdf:datatype="http://www.w3.org/2001/XMLSchema#string">extraction of certain cell types from a cell culture</oboInOwl:hasDefinition>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/320">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/85"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This tumor RNA was used to transfect matured DC with the final aim to produce a DC vaccine.</rdfs:comment>
    <rdfs:label>Tumor RNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CL#CL_0000522">
    <rdfs:label>spore</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">spore</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">spores</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A11">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/5">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/protocol/4"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Lentiviral infection of target cells: 
Day 1: seed cells
Day 2: remove the medium from the cells. Mix the medium containing the virus gently by pipetting and add to the cells (+ 6 ?g/ml of polybrene). Incubate the cells at 37°C overnight.
Day 3: change medium and start selection for stably transduced cells</rdfs:comment>
    <rdfs:label>Lentiviral infection of target cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/119">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/97"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/23"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>An Elispot assay was applied in the establishment of immunomonitoring vaccination trials with RNA transfected DC by using overlapping peptides.</rdfs:comment>
    <rdfs:label>Elispot analysis</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_736">
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antibody role</dcr:dcthera_label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">antibody role</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/66">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/91"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/55"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/54"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/52"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The B-CLL patients were vaccinated with autologous, apoptotic, leukemic cells (Apo-DC).

The first cohort of patients received the vaccine without additional adjuvants, while the next cohort of 5 patients who receive the vaccine with GM-CSF as an adjuvant.

Clinical trial on vaccination of B-CLL patients with autologous, apoptotic, leukemic cells (Apo-DC), progressed further in 2007. Cohort 1 with the vaccine alone and cohort 2 (5 patients) combining the vaccine together with GM-CSF as an adjuvant has finished accrual and all patients in these two cohorts have been monitored for 52 weeks. The clinical and immune monitoring data is being currently analyzed.

The third cohort consisting of the vaccine and GM-CSF administered after a single dose of cyclophosphamide (300 mg/ sq. meter) is currently being accrued.  Four of the five patients in this cohort have already received their vaccine and the final patient will be accrued in January. </rdfs:comment>
    <rdfs:label>B-CLL patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/3">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/93"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdfs:comment>Data has been obtained in a study of antigen recognition of blood-derived T cells. In this study, an IFNgamma ELISPOT was done with PBMC loaded with peptide pools, each consisting of 10 15-mers, which overlap with 11 aminoacids.  </rdfs:comment>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:label>Antigen recognition of blood derived T cells</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <dcr:hasBodilyPartType rdf:resource="http://purl.org/obo/owl/FMA#FMA_9670"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/25"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_50801">
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Segment of neuraxis that has as its parts gray matter and white matter that surround the cerebral ventricular system; Examples: There is only one brain.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">brain</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67165"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/286">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/94"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/protocol/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>A significant number of patients was enrolled in the DC-based immunotherapy trial. After vaccination, vaccine-induced depigmentation and vitiligo were observed.</rdfs:comment>
    <rdfs:label>Melanoma patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/360">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These not immunized mice were  used in a DC staining experiment.

To investigate whether several mAb could be used to detect APC presenting LACK in vivo, BALB/c mice were immunized or not with either LACK or OVA. LN cells were purified 2 days later, and stained with either 2C44, 2F74, 2E60 or 2X8 mAb. None of these mAb stained DC purified from non immunized mice. However, among the 4 mAb, only 2C44 could stain DC in LACK-immunized mice, but not in OVA-immunized mice. Furthermore, 2C44 stained DC from LACK-immunized mice expressing the H2-d haplotype but did not stain DC from LACK-immunized mice of other haplotypes. Thus, the 2C44 mAb allows for the detection of DC which captured and processed LACK in vivo.</rdfs:comment>
    <rdfs:label>BALB/c mice (not immunized)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/3">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001438"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/201"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>a) Incubate cells in Fc-block (1:50 in PBS + 2 % FCS) 30 min on ice
b) Staining of the cells in PEalphaDC80 in PBS + 2 % FCS + 
c) Fc-block for 30 min on ice
d) FACS analysis</rdfs:comment>
    <rdfs:label>FACS staining for activation markers (e.g. CD80)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/SO#SO_0000276">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">miRNA</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">micro RNA</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/13">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/113"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/21"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>To quantify presentation of the epitopes by DC, we used bulk T cells electroporated with TCR-encoding RNA in stimulation assays. </rdfs:comment>
    <rdfs:label>bulk T cells electroporated with TCR-encoding RNA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/109">
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These animals were used to test the combined effects of these cytokines on DC development in vivo.</rdfs:comment>
    <rdfs:label>Cytokine deficient animals (GM-CSF-/-Flt3L-/-)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000410">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Disease staging factor</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000351"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isAccessibleFrom">
    <owl:inverseOf rdf:resource="http://dc-research.eu#offers_access_to"/>
    <rdfs:range rdf:nodeID="A178"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <OBI:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Guendel</OBI:IAO_0000117>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relation to connect any DC-THERA Resource to the participant or persion that offers access to it.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is accessible from</rdfs:label>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obofoundry.org/obo/OBI_0000427">
    <rdfs:label>enzyme</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/472">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/6"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The majority of monocytes (1 x 10e9) were frozen in 90% A-plasma and 10% GMP-grade DMSO.</rdfs:comment>
    <rdfs:label>Frozen monocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasBiolexVariant">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has variant</rdfs:label>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">property to be used for form variants (abbreviations etc.) obtained from the BootStrep BioLexicon.</rdfs:comment>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#AnnotationProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0001789">
    <rdfs:label>curdlan</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">curdlan</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">3-glucan</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">beta-1</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A106"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_37163"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_12">
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0600014"/>
    <oboInOwl:hasDefinition rdf:datatype="http://www.w3.org/2001/XMLSchema#string">laboratory procedure in which white blood cells are separated from a sample of blood</oboInOwl:hasDefinition>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">leukapheresis</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/4">
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000236"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000023"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10376"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_5"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_180"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/64"/>
    <dcr:hasMoleculeType rdf:resource="http://www.cellcycleontology.org/ontology/owl/CCO#CCO_B0050147"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdfs:label>Antigen recognition of DTH infiltrating T cells</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100390"/>
    <rdfs:comment>Data have been obtained on the antigen recognition of DTH infiltrating T cells. To obtain the data, activation of CD4 and CD8 T cells upon recognition of EBV-B cells expressing vaccinal antigens was evaluated by CD137 upregulation, CD107a and CD40L expression using flow cytometry. Luminex technology was used to quantify the TNFalpha and IFNgamma secretion.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000492"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000025"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/67">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/93"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Three groups of end stage cervical cancer patients (in total N=35) were subcutaneously vaccinated with HPV16 E6 combined with or separated from HPV16 E7 overlapping long peptides in Montanide ISA-51 adjuvant, 4 times at three week intervals. Group 1 received 300 microgram per peptide at a single site, group 2 received 100 microgram per peptide of the E6 peptides in one limb, and 300 microgram per peptide of the E7 peptides in a second limb. Group 3 received separate injections of E6 and E7 peptides, each at a dose of 50 micrograms per peptide. The primary endpoint was to determine safety and toxicity of the HPV16 long peptide vaccine. In addition, the vaccine-induced T-cell response was assessed by IFN gamma-ELISPOT. No toxicity beyond grade II was observed during and after 4 vaccinations. In a few patients transient flu-like symptoms were observed. ELISPOT analysis of the vaccine-induced immune response revealed that co-injection of the E6 and E7 peptides resulted in a strong and broad T-cell response dominated by immunity against E6. Injection of the E6 and E7 peptides at two different sites increased the E7-response but did not affect the magnitude of the E6-induced immune response.</rdfs:comment>
    <rdfs:label>End stage cervical cancer patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001004">
    <rdfs:label>CD4</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_735">
    <rdfs:label>device</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A device a thing made for a particular purpose; an invention or contrivance, esp. a mechanical or electrical one.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">device</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11646">
    <rdfs:label>Lentivirus</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">lentiviruses</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lentivirinae</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lentivirus</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_28901">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Salmonella enterica</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_884">
    <rdfs:label>Hybridization protocol</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hybridization protocol</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The process of incubating one or more labeled extracts with an array.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Tumor_Infiltrating_Lymphocyte">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor infiltrating lymphocyte</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000542"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TIL</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor-infiltrating lymphocyte</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TILs</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor infiltrating lymphocytes</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">tumor-infiltrating lymphocytes</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/285">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/96"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Exosomes were used to treat a chohort of 77 gastrointestinal stromal tumor (GIST) cancer patients.</rdfs:comment>
    <rdfs:label>Exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/63">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These dendritic cells were generated with interferon-beta and interleukin-3. They were used in a clinical trial in melanoma patients who were randomized to receive immunizations either with these I3 DC or with G4 DC (DC generated with GM-CSF and IL-4).</rdfs:comment>
    <rdfs:label>I3 DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#isBiomaterialOutputOf">
    <owl:inverseOf rdf:resource="http://dc-research.eu#hasBiomaterialOutput"/>
    <rdfs:domain rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedToInstance"/>
    <rdfs:range rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Property to connect a bio-material to a protocol step in which the bio-material is an output.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">is output of ProtocolStep</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/108">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was found that these cells do not migrate to lymph nodes in the steady state.</rdfs:comment>
    <rdfs:label>T lymphocytes lacking the lymph node homing receptors L-selectin and CCR7</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000411">
    <rdfs:subClassOf rdf:resource="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000351"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Disease state factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/57">
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_454"/>
    <dcr:hasTissueType rdf:resource="http://purl.org/obo/owl/FMA#FMA_81494"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/65"/>
    <rdfs:comment>We obtained data on the effect of pro-inflammatory stroma-derived cytokines on DC in vivo. Our investigation has shown that, in the absence of additional stimuli, such inflammatory signals are ineffectual in promoting DC activation and cannot substitute for engagement of innate receptors directly on DC.</rdfs:comment>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_302"/>
    <rdfs:label>Study on the possibility of DC activation via inflammatory signals</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasStimulusType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/38"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/14">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/28"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Since LPS-activated DC are potent inducers of NK cell priming and lymph nodes appear to be a key place in which DC and NK cell interactions occur, we have investigated the in vivo capacity of resting and DC-primed NK cells to reach the draining lymph nodes.</rdfs:comment>
    <rdfs:label>LPS-activated DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DC_CL#DC_CL_1111100">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000116">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">worker</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/7">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/212"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Different strains of Saccharomyces cerevisiae were cultured and collected in different conditions:
* different growth phase (exponential and stationary phase) 
* different growth media (standard and promoting pseudohyphal growth) 
* different cell form (spheroplast, spore and whole cell) 

Monocyte-derived DCs were added at a final concentration of 5x105 cells/ml into 96-well plates. Serial diluition of yeast cells and preparations were added to the MoDCs. Cytokine accumulation was evaluated in the supernatants at 24h by ELISA, according to a standard protocol and it was measured at 450nm. The ELISA kit for IL-12 and IL-10 was from Biosource.</rdfs:comment>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/95"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <rdfs:label>Stimulation of monocyte-derived DCs</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/471">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/11"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The autologous T lymphocytes were stimulated with (frozen) MoDC at a ratio of 1 DC per 10 T cells.</rdfs:comment>
    <rdfs:label>autologous T lymphocytes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A6">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/64">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These dendritic cells were generated with GM-CSF and IL-4. They were used in a clinical trial in melanoma patients who were randomized to receive immunizations either with these G4 DC or with I3 DC (DC generated with interferon-beta and interleukin-3).
</rdfs:comment>
    <rdfs:label>G4 DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/participant/70">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_731"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_490"/>
    <rdfs:comment>The Netherlands Cancer Institute was established on October 10, 1916. The founders, Rotgans, professor of Surgery, De Bussy, publisher, and De Vries, professor of Pathology, wanted to create a cancer institute ‘where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied’. They bought a house on one of the canals in Amsterdam and named it the ‘Antoni van Leeuwenhoek Huis’, after the famous Dutch microscopist. The clinic had room for 17 patients, while the laboratory could accommodate 8 to 10 scientists.

Nowadays, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) accommodates approximately 550 scientists and scientific support personnel, 53 medical specialists, 180 beds, an out-patients clinic that receives 24,000 new patients each year, 5 operating theaters and 9 irradiation units. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training.

The three major areas of research are fundamental, clinical and translational cancer research. A thorough understanding of the biological processes of normal cells is the basis for understanding cancerous cells. The laboratory covers all major areas of cancer research, with special emphasis on cell-based screens, mouse tumor models, cell biology, structural biology and epidemiology. The institute coordinates and participates in many clinical trials; most of these are phase 1, 2 or 3 studies of potential new treatments such as combinations of chemotherapeutics, radiotherapy and/or surgery. Results obtained from fundamental research are translated into clinical applications as part of our translation research program.

From its first inception the NKI-AVL saw close collaboration between scientists and clinicians as essential to fighting cancer. Having a laboratory and hospital under one roof in a single independent organization with an open and collaborative atmosphere has led to many important discoveries and improved therapies</rdfs:comment>
    <rdfs:label>Nederlands Kanker Instituut NKI - Netherlands Cancer Institute</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_11">
    <rdfs:label>Standard operating procedure</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Standard operating procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A standard operating procedure is a protocol that serves as a reference.
A standard operating procedure is a set of instructions having the force of a directive, covering those features of operations that lend themselves to a definite or standardized procedure without loss of effectiveness. Standard Operating Policies and Procedures can be effective catalysts to drive performance improvement and improving organizational results. [1] Every good quality system is based on its standard operating procedures (SOPs).</OBI:IAO_0000115>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SOP</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_738">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Labeling protocol</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A labeling protocol is a treatment protocol applied for labeling of biomaterial. The labelled biomaterial can subsequently be used in a detection process.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000014">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">regulator</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/117">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/154"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_779"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have experience about using Elispot assays for monitoring vaccine induced specific anti-tumor T cell responses.</rdfs:comment>
    <rdfs:label>ELISPOT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001003">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/284">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0002217"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This supernatant contains the infective MAGE-3 encoding viruses and the natural tumour peptides and is needed for metastatic melanoma vaccine production.</rdfs:comment>
    <rdfs:label>Supernatant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A180">
    <rdf:rest rdf:resource="http://www.w3.org/1999/02/22-rdf-syntax-ns#nil"/>
    <rdf:first rdf:resource="http://dc-research.eu#dctheradir_491"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_4241">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110053"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Malignant neoplasm of breast</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/29">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_754"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 3: change medium and start selection for stably transduced cells</rdfs:comment>
    <rdfs:label>Selection of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/107">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000813"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was found that lymph nodes that drain sites of mature DC or adjuvant inoculation recruited memory CD8+ T cells. </rdfs:comment>
    <rdfs:label>Memory CD8+ T cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0010497">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ribosomal protein L6</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neoplasm-related protein C140</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TAXREB107</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TAX-responsive enhancer element binding protein 107</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">60S ribosomal protein L6</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0400079">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/15">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/28"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/18"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000623"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have investigated the in vivo capacity of resting (and of DC-primed) NK cells to reach the draining lymph nodes.</rdfs:comment>
    <rdfs:label>resting natural killer cell</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0100055">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_3083">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chronic Obstructive Airway Disease</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110055"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/6">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_18050"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/59"/>
    <dcr:hasBioSourceType rdf:resource="http://dc-research.eu#dctheradir_445"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/60"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_36706"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/FMA#FMA_86713"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000585"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16412"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_17076"/>
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdfs:label>DCs differentiation and stimulation</rdfs:label>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0001789"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33709"/>
    <rdfs:comment>PBMC were isolated from buffy coats by density gradient centrifugation using Biocoll (BIOCHROM). Monocytes were isolated from PBMC using MACS anti-CD14 microbeads and a Midi-MACS® magnetic cell sorting device (both from Miltenyi Biotec, Bergisch-Gladbach,Germany). Cells were cultured in RPMI 1640 medium (GIBCO BRL) supplemented with 2 mM L-glutamine (Sigma), 1% (vol/vol) non-essential amino acids, 100 mM sodium pyruvate, 50 U/ml of penicillin and 50 mg/ml of streptomycin (Gibco BRL) containing 10% (vol/vol) FCS (Hyclone). Differentiation of monocytes into dendritic cells was promoted by addition of granulocyte-macrophage colony-stimulating factor (GMCSF 1000U/ml, Chemicon) and recombinant IL-4 (1000U/ml, R&amp;D Systems) for 5 days. DCs activation was induced by lipopolisaccharide (LPS 1microgram/ml, Sigma, St. Louis, MO), by Curdlan (100 microgram/ml, Wako), by R848 and yeast RNA  and by yeast cells in different conditions of culture.</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A8">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000237"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/470">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/12"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/11"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/10"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_175"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The mature peptide pulsed DC were frozen at 5 x 10e6 cells per vial in freezing medium for subsequent stimulation of autologous T cells.</rdfs:comment>
    <rdfs:label>Frozen MoDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#hasCell">
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">To connect a dataset with the biomaterial. As this would make the ontology OWL full, the annotation property hasCellType is used instead.</rdfs:comment>
    <rdfs:domain rdf:nodeID="A51"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></OBI:IAO_0000115>
    <rdfs:subPropertyOf rdf:resource="http://dc-research.eu#relatedTo"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cell</rdfs:label>
    <rdfs:range rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <dcr:hasClassAsRangeProperty rdf:datatype="http://www.w3.org/2001/XMLSchema#string">dctheradir:hasCellType</dcr:hasClassAsRangeProperty>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#ObjectProperty"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_737">
    <rdfs:label>Behavioral stimulus protocol</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A behavioral stimulus protocol is a treatment protocol used for a treatment in which a biomaterial is forced to respond to a stimulus with some behavior.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:nodeID="A112"/>
    <rdfs:subClassOf rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_75"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Behavioral stimulus protocol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/65">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/90"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>RCC subjects were deficient in T cell IFN-gamma and IL-2 production pre-vaccination. Their response to DC-based immunotherapy was evaluated.</rdfs:comment>
    <rdfs:label>RCC patients</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_10">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Case report form</rdfs:label>
    <dc:description rdf:datatype="http://www.w3.org/2001/XMLSchema#string"></dc:description>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CRF</dcr:hasExactSynonym>
    <oboInOwl:savedBy rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Michaela Gündel</oboInOwl:savedBy>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A Case Report Form (or CRF) is a paper or electronic questionnaire specifically used in clinical trial research. The Case Report Form is the tool used by the sponsor of the clinical trial to collect data from each participating site. All data on each patient participating in a clinical trial are held and/or documented in the CRF, including adverse events.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/118">
    <dcr:tool_used_in rdf:resource="http://dc-research.eu/rdf/dataset/153"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/63"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_780"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>We have know-how about performing LDA assays. We have, for instance, monitored vaccine induced T cell responses for the two clinical trials. We found CD8+ and CD4+ T cell responses against the immunological tracers KLH and TK, and against the NTPs and MAGE-3, respectively.</rdfs:comment>
    <rdfs:label>LDA assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/PRO#PRO_000001002">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/139">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/7"/>
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/6"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/5"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000576"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Cells from healthy blood donors are separated into monocytes (and lymphocytes) by elutriation in a closed system (Elutra). 
[The two most monocyte-rich fractions collected contained &gt; 80% monocytes, viability was &gt; 95%.]</rdfs:comment>
    <rdfs:label>Monocytes separated from cell culture</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0702411">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NADPH</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DECR1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DECR</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC-receptor</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A100"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DEC receptor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A5">
    <owl:allValuesFrom rdf:resource="http://dc-research.eu#dctheradir_734"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/28">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_771"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 2: remove the medium from the cells. Mix the medium containing virus gently by pipetting and add to the cells (+ 6 migrograms/ml of polybrene). Incubate the cells at 37°C overnight.</rdfs:comment>
    <rdfs:label>Incubation of cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/55">
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_241"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/128"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_892"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdfs:label>Developmental control of translation during DC development</rdfs:label>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_309"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/54"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/61"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000103"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000143"/>
    <rdfs:comment>We have generated data on the developmental control of translation during DC activation. Our work (Lelouard et al., JCB) demonstrates that DCs down-regulate and change the quality of translation in order to increase their survival, however during this process MHC I antigen processing is affected. This has important consequences for the way antigens should be introduced in DCs and how long after stimulation they should be used during vaccination application.

We have also initiated studies on the impact of dsRNA on the regulation of translation and the functional response of DCs (IFN production). We have now demonstrated that DCs enters an “unfolded protein response-like state and controls the phosphorylation of a key translation initiation factor (eIF2-a).  The quality of the translation is not only affected, but the overall capacity of DCs to respond to stress is also modified in order to increase their survival and resistance to viral infection. This observation has important consequences on the use of different adjuvants during DC based vaccination trial. 

We are going to finalize the projects with several publications. We will follow-up our studies on the impact of dsRNA on the regulation of translation and focus on DCs in vivo and on the regulation of IFN production. </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/324">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/113"/>
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/112"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The receptors of these DC were blocked by addition of laminarin, mannan and chitin.</rdfs:comment>
    <rdfs:label>DC with blocked beta-glucan, mannan and chitin receptors</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/61">
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_16670"/>
    <rdfs:comment>This patient has received 9 vaccines with peptides only in a randomized trial to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4).

Up to now, in Cycle 3, immunizations have been continued with peptide-only injections of all 9 peptides except Tyrosinase at 12 weeks intervals. For the continuation of the vaccinations the clinicians have decided to inject the patient at 6 months intervals. The patient who clinically showed Partial Response at the end of cycle 1 is currently doing well under this treatment. The patient is in complete remission.
</rdfs:comment>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000012"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <rdfs:label>I3 patient (E501) </rdfs:label>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_336"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0100388"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000027">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_84050"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferon</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFN</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">interferons</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_731">
    <rdfs:label>DC-THERA Third Party</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA Third Party</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DC-THERA Third Party is a participant in DC-THERA which collaborates in a scientific way in the project yet has not signed the project contract / grant agreement.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_739"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0070062">
    <rdfs:label>extracellular vesicular exosome</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">extracellular vesicular exosome</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0043227"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/363">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/362"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These dimers were injected into TCR transgenic mice which exhibited an increased frequency of LACK-specific T cells with the aim of producing a mAb reacting to the immunodominant LACK156-173 peptide of leishmania bound to I-Ad MHC class II molecules. </rdfs:comment>
    <rdfs:label>I-Ad/LACK recombinant dimers</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/78">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/268"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_761"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>prepared DC will be used as DC vaccine, but also to expand T cells (isolated during the elutriation) for subsequent adoptive transfer</rdfs:comment>
    <rdfs:label>Subsequent adoptive transfer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/138">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/3"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/206"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>An HLA-A2 positive healthy donor underwent leukapheresis with the aim to generate monocyte derived DC under GMP conditions.</rdfs:comment>
    <rdfs:label>HLA-A2 positive healthy donor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ifomis.org/bfo/1.1/snap#Function">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_534"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/218">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Human DC exposed to TLR ligands and activated iNKT cells in vitro. They  had enhanced expression of maturation markers, suggesting that a cooperative action of TLR ligands and iNKT cells on DC function is a generalizable phenomenon across species. These studies highlight the potential for manipulating the interactions between TLR ligands and iNKT cell activation in the design of effective vaccine adjuvants. </rdfs:comment>
    <rdfs:label>Human DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000154">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Institutional Review Board</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#NA17-A_Antigen">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NA17A</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NA17-A Antigens</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:nodeID="A138"/>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">NA17 antigen</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/71">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/197"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0400008"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>A Luminex flow cytometer is available to our lab. It is used, among other things, to quantify the TNFalpha and IFNgamma secretion in a study on antigen recognition.</rdfs:comment>
    <rdfs:label>Luminex flow cytometer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/9">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/1"/>
    <rdf:type rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_884"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_488"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>Array construction:

The yeast oligonucleotide array was constructed using the S. cerevisiae Genome Oligo Set ™ (Operon Technologies, CA, USA) composed of 6240 optimized oligonucleotides (70mers) each representing one yeast gene. 

Probe preparation and hybridization:

We used the indirect labeling method. Briefly, the reactive amine derivative of dUTP, 5-(3-
aminoallyl)-2?-deoxyuridine 5?-triphosphate (Sigma) was incorporated into cDNA using the Superscript II reverse transcriptase (Invitrogen) and oligo dT (Invitrogen) and random examers (Roche). After synthesis of cDNA (2–3 h at 42 °C), RNA was hydrolyzed by addition of sodium hydroxide and EDTA to a final concentration of 100 mM and 10 mM, respectively and incubated at 65 °C for 10 min. The hydrolysis reaction was neutralized with 1 M HEPES. After removing free nucleotides by purification and concentration using Microcon-30 microconcentrators, the aminoallyl-labeled samples were coupled to succinimidyl ester of cyanine-3 (Cy3) and cyanine-5 (Cy5) (Amersham) combined with 1 M NaHCO3, pH 9. Coupling took place in the dark at 25 °C for 1 h. Appropriate Cy3 and Cy5 labeled cDNA samples were purified following Qiagen Qiaquick PCR Purification Kit instructions. Poly-dA (12–18 mer), 20× SSC, and HEPES pH 7.0 were added. After the resultant mix was filtered through a Millipore 0.45 ?M filter, 10% SDS was added. The samples were incubated for 2 min at 100 °C and cooled in a microcentrifuge prior to loading and then applied to microarray. Incubation took place at 65 °C for 12–15 h. Hybridized slides were washed in a solution of water, 20× SSC, and 10% SDS, rinsed in water and 20× SSC, and dried via centrifugation for 2 min at 1000 rpm. 

Image acquisition:

The arrays were scanned immediately. Each comparison was performed in duplicate. Fluorescent cDNA bound to the microarray was detected with a GenePix 4000 microarray scanner (Axon Instruments, Foster City, CA), using the
GenePix 4000 software package to quantify microarray fluorescence. Intensity values were adjusted by subtracting surrounding background from spots. The median of spot intensities was corrected for background. To eliminate signals that are most prone to estimation error, any spot was excluded from analysis if both the Cy3 and Cy5 mean fluorescence signals were within two standard deviations of the mean background signals for that spot. This procedure avoids artificially inflated measurements of expression due to low signals. Additional to eliminating flagged spots, spots were also visually inspected and flawed ones discarded from the analysis. Data were normalized to mean ratio intensity. 

We can provide one experiment with 32 micorarrays, two experiments with 8 microarrays and one experiment with 12 micorarrays.</rdfs:comment>
    <rdfs:label>Yeast experiment: Yeast Microarray Protocol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000436">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_735"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/177">
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>CyP was extracted from the freshwater cyanobacterium Oscillatoria Planktothrix FP1. We found that CyP acts as a potent and selective antagonist of bacterial LPS.</rdfs:comment>
    <rdfs:label>LPS-like molecule (CyP)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0600031">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Enzyme-linked immunosorbent spot assay</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/DOID#DOID_12509">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_1110040"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Colitis, enteritis and gastroenteritis presumed infectious</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A203">
    <rdf:rest rdf:nodeID="A74"/>
    <rdf:first rdf:resource="http://purl.obolibrary.org/obo/IAO_0000100"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/56">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/68"/>
    <rdfs:label>Activation of DC via dectin-1/syk pathways in relation to CD4 T cell priming</rdfs:label>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/220"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/66"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/PRO#PRO_000001004"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/203"/>
    <rdfs:comment>We have obtained data from in vitro studies to demonstrate that DC can be activated via the dectin-1/Syk pathway to become APC capable of priming CD8+ T cells. In addition, we have shown that the same DC can interact with Tregs and convert them into cells that co-express ROR?t and Foxp3 and produce IL-17. 
We have shown that this pathway can serve as an alternative to TLR signalling for allowing DC to become effector cells capable of priming CD4+ T cells. We have used agonists of the dectin-1/Syk pathway as adjuvants in vivo to induce DC activation and CD4+ T cell and antibody responses. We have shown that this operates in a dectin-1-dependent manner. We have also found induction of T-independent antibody responses via the same pathway. In addition, we have shown that tubulovesicular structures generated by cells overexpressing VSV-G act as adjuvants for inducing CD8+ and CD4+ T cell, as well as antibody responses in vivo. This is likely due to their DNA content and ability to trigger TLR9.

We will continue to use DC activation in vitro and, in particular, DC cytokine production as an assay to dissect innate pathways involved in DC activation. In parallel, we will continue to compare effector T cell instruction by DC activated via distinct innate receptors.</rdfs:comment>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/DC_CL#DC_CL_0000089"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_347"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CL#CL_0000815"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_302"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000084"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000124"/>
    <dcr:hasMoleculeType rdf:resource="http://dc-research.eu#dctheradir_236"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/204"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/202"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/323">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/112"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_37163"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Laminarin (500 micrograms/ml) was added to DCs in order to block their beta-glucan receptors.</rdfs:comment>
    <rdfs:label>Laminarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/27">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_750"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 1: seed cells</rdfs:comment>
    <rdfs:label>Cell seeding</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/364">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/BTO#BTO_0002217"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This supernatant was used for staining. Four out of 600 supernatants used, i.e. 2C44, 2F74, 2E60 and 2X8, readily stained LACK156-173-pulsed fibroblasts, but neither unpulsed fibroblasts nor OVA323-339-pulsed cells.</rdfs:comment>
    <rdfs:label>2C44 supernatant</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/62">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/89"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/29"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These autologous DC were used in a phase IB/II study of immunotherapy. Patients  were randomized to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4).</rdfs:comment>
    <rdfs:label>Autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_730">
    <rdfs:label>DC-THERA Partner</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_739"/>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DC-THERA Partner is a participant in DC-THERA which is a contractual partner within the DC-THERA project.</OBI:IAO_0000115>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA Partner</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/FMA#FMA_7163">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_67498"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">skin</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/169">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Zoltan Vereb</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_452">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD70</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdfs:subClassOf rdf:nodeID="A141"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">TNFSF7</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD27LG</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/137">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/88"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The mice were generated with the intention to elucidate in vivo DC developmental regions in steady state and inflammation in situ.</rdfs:comment>
    <rdfs:label>Flt3L reporter mice</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_297">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.org/obo/owl/FAO#FAO_0001002</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_pseudohypha</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_187">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">granzyme K gene</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/FMA#FMA_74402"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/219">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/63"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The immature monocyte-derived dendritic cells where transduced with high doses of lentiviral vectors to monitor activation of the immature DC.</rdfs:comment>
    <rdfs:label>Transduced iDC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/72">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/37"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_596"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>There is know-how on classical MLR assays in our lab. They are used, for instance, for characterization of silenced cells.</rdfs:comment>
    <rdfs:label>Classical MLR assay</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/77">
    <dcr:hasBiomaterialInput rdf:resource="http://dc-research.eu/rdf/biomaterial/148"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_19"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Treatment induced T cell responses will be evaluated by flow cytometry based methods (T cell phenotype, proliferation, perforin degranulation) and cytokine detection (Elispot, Elisa). The patients will be monitored for safety and toxicity of the treatment and for clinical response to immunotherapy.</rdfs:comment>
    <rdfs:label>Evaluation of T cell responses</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A153">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/178">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/92"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/GO#GO_0070062"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>DC exosomes along with various TLR ligands or cytokines such as IL-2 or alpha IFN were used to promote Mart-1 specific T cell priming and/or NK cell triggering in HHD2 mice. We demonstrated that only TLR3 and 9 ligation is able to induce CTL priming in vivo. However, exosomes in the absence of adjuvants can induce NK cell activation. </rdfs:comment>
    <rdfs:label>DC exosomes</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/8">
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>The cells were collected and the pellet were resuspended in 3.6 ml AE Buffer (AE=50mM NaAcetate pH 5.2, 10mM EDTA) and then transferred in 15 ml tubes wit 200 µl 10% SDS (w/v). 2 ml of preheated acid phenol (pH 4.3) were added and the falcon were mixed by vortex. After 10’ of incubation in 65 °C water bath, the samples were incubated on ice and then centrifugated at 5000 rpm in an tabletop centrifuge.
The supernatants were transferred to a new tube and added 2 ml of acid phenol to repeat the extraction. After the centrifugation (10’ at 5000 rpm) the supernatants were transferred into a pre-spun (5’ at 1500 rpm) 50 ml Phase Lock Gel tube (Eppendorf 0032 005.330) and 4 ml of chloroform (Fischer BP1145-1) were added into the falcon. After the spin (10’ at 3,000 rpm), the supernatants were precipitated in RNase-free centrifuge tube by adding 1/10 volume 3 M NaAcetate (pH 5.3) and 2.5 volumes of cold ETOH 100% overnight at -20°C. Then, after a centrifugation (30’ at 12000 rpm) the pellets were washed with 70% Ethanol two times. When the pellets were dry, they were resuspended in RNase-free water.</rdfs:comment>
    <rdfs:label>Total RNA Isolation from S. cerevisiae</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/10">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/109"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/248"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_000235"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Using pharmacological inhibitors, or macrophages and DC from mice carrying a null mutation in MAP kinase signalling molecule(s), we have evidence for a role of certain MAP kinases in the regulation of IL-10 and IL-12, IFN-gamma production. </rdfs:comment>
    <rdfs:label>macrophages from mice carrying a null mutation in MAP kinase signalling molecule(s)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_414">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://dc-research.eu#dctheradir_243</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_polyI:polyC12U</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/GO#GO_0005575">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cellular component</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000439">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A152">
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/26">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_754"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 4: harvesting (virus-containing)</rdfs:comment>
    <rdfs:label>Harvesting</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/289">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/86"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000151"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>The TcR-Tg clones are specific for the 0T-1-OVA antigen.
In the individual T cells, we studied the expression of twenty different genes either mediating effector functions, or coding for different receptors involved in T cell differentiation and memory generation.</rdfs:comment>
    <rdfs:label>TcR transgenic clones</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/361">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These mice were  used in a DC staining experiment. We have started to visualize and characterize the DC which carry I-Ad/LACK complexes at the cell surface in BALB/c mice infected by leishmania major.</rdfs:comment>
    <rdfs:label>BALB/c mice (infected by leishmania major)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000618">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000178"/>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD 45</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD45</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICAM1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ICAM 1</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CD-45</dcr:hasExactSynonym>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intercellular adhesion molecule 1</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_349">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000427"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">trypsin</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">trypsins</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000029">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type II interferon</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type II interferons</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFN type II</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/53">
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/342"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/40"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11676"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/294"/>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/116"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000798"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_176"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/35"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/FMA#FMA_241981"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:label>Cross-talk between HIV-exposed DC and gamma-delta T cells</rdfs:label>
    <rdfs:comment>Data has been obtained on the effect of exposure of DCs or gamma-delta T lymphocytes to HIV-1 and on the miR profile expressed in HIV-exposed DCs.

Based on our previous findings demonstrating a bidirectional activating interaction between immature MDDCs and gamma-delta T lymphocytes (Conti et al., JI. 2005), as well as on the demonstration that HIV-1 exposed MDDCs exhibit an impaired functional maturation (Fantuzzi et al., J Virol  2004), we are currently investigating whether exposure of DCs or gamma-delta T lymphocytes to HIV-1 can directly modulate their functions or interfere with their cross-talk.  Preliminary results indicated that, although virus exposure of gamma-delta T cells does not significantly affect their properties, HIV-exposed DCs exhibit a reduced capacity to deliver activation and proliferative signals to gamma-delta T lymphocytes. Moreover, a dysregulated pattern of cytokines and chemokines produced by both cell populations is observed in the presence of the virus.

Our preliminary results indicating that HIV-exposed MDDCs exhibit a reduced capacity to deliver activation and proliferative signals to gamma-delta T lymphocytes have been reproduced in a statistically significant number of donors during this year. In particular, we have observed that gamma-delta T cells co-coltured with virus-exposed DCs exhibit a reduced capacity to proliferate in response to phosphoantigens and to produce IFN-?. Reciprocally, HIV-1-exposed DCs co-coltured with activated gamma-delta T lymphocytes undergo phenotypic maturation but are impaired in IL-12 production. In contrast, direct exposure of lymphocytes to the virus does not significantly affect their properties. A preliminary analysis of the miR profile expressed in HIV-exposed DCs has also been carried out indicating that interaction of these cells with the virus rapidly induces the modulation of a number of miRs.

A further characterization of the effects of HIV-1 on the functional properties of both cell populations will be performed, and in particular it will be analyzed: 
(a) the capacity of virus-exposed DCs to recruit resting gamma-delta T cells; 
(b) the role of activated lymphocytes in controlling HIV-1 replication in DCs; 
(c) whether active virus replication in these cells is needed to achieve the above described effects; 
(d) the role of HIV-modulated miR in DC functions. </rdfs:comment>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_453"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_733">
    <rdfs:label>DC-THERA Meeting Organisation</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA Meeting Organisation</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DC-THERA meeting organisation is a participant providing support in DC-THERA in the sense that it manages the organisation of DC-THERA meetings.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_740"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_734">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA person role</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#Role"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/168">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Zofia Prokopowicz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000224">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sub investigator</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/CHEBI#CHEBI_16670">
    <rdfs:label>peptide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/216">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In our effort to demonstrate that pathogen-derived signals to DC mediated via TLRs can be modulated by activated iNKT cells, these DC isolated from animals treated simultaneously with TLR and iNKT cell ligands were potent stimulators of naive T cells in vitro compared with DC from animals treated with the ligands individually. </rdfs:comment>
    <rdfs:label>Animal DC, treated simultaneously</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_453">
    <rdfs:label>Biomaterial</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Biomaterial</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A biomaterial is any material, natural or man-made, that comprises whole or part of a living structure which performs, augments, or replaces a natural function.</OBI:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_492"/>
    <rdfs:subClassOf rdf:resource="http://www.ifomis.org/bfo/1.1/snap#MaterialEntity"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/136">
    <rdf:type rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>It was found that lymph nodes that drain sites of mature DC or adjuvant inoculation recruited L-selectin- CCR7- effector and memory CD8+ T cells. This cell recruitment required CXCR3 expression on T cells and occurred through high endothelial cells (HEV) in concert with HEV luminal expression of the CXCR3 ligand CXCL9.</rdfs:comment>
    <rdfs:label>Lymph nodes that drain sites of mature DC or adjuvant inoculation </rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000635">
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_604"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Organism part factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/79">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/dataset/124"/>
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/biomaterial/546"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/dataset/88"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <rdfs:comment>1 Saccharomyces cerevisiae cell stimuli
Saccharomyces cerevisiae strain SK1 (MATa/alpha HO gal2 cupS can1R BIO, Kane SM and Roth J. 1974 Bacteriol. 118: 8-14) was cultured in complete medium (YPD, 2% yeast extract, 1% peptone, 2% glucose) for 18 hours, then collected, washed twice with sterile water and resuspended at 108 cells/ml.  S. cerevisiae strains BY4741 (genotype, Mata his3delta1 leu2delta0 met15delta0 ura3delta0) and BY4741 och1 (Mata his3delta1 leu2delta0 met15delta0 ura3delta0 OCH1::kanMX4) were cultured in complete medium till exponentially phase and treated as before.

2 Spore stimuli
In order to test homogeneous yeast populations, pure spore cultures were obtained by using this strain whose sporulation efficiency is 100%. To prepare spores, cells were grown on YPD plates, replicated on SPOIV medium (2% potassium acetate, 0.25% yeast extract, 0,1% glucose) and sporulation was assessed by optical microscopy. Zymolyase (2 mg/ml) was used to digest ascum and liberate spores. We initially performed experiments to evaluate zymoliase sensitivity of asci for this specific strain and we assessed that 15 minutes incubation was the minimum time needed to damage the ascus, without touching the spore cell wall. Zymoliase was inactivated by heat (65°C for 2 minutes) and washed away carefully together with the remainings of the empty ascus, by resuspending twice the spore culture in 500 µl of distilled water centrifuging and discarding the supernatant; the spores were then resuspended to a concentration of 108 cells/ml. In order to exclude damage on the spore cell wall or effects on spore viability 100 µl of a culture of 1000 spores per ml was plated on YPD in triplicate, the spores showed 100% viability. The procedure used allows exposing DCs to the pure spore culture and to analyze the response to the spores alone, eliminating confounding effects of the presence of the ascus. Although from a mycological point of view the term ascospores might seem more appropriate than spores, we will use the term spores to specifically indicate that the effects we are observing are only due to the spores and not to the ascus. 
We observed that after 24 hours of culture in RPMI 1640 (GIBCO-BRL), spores were germinating and the exponentially growing cells were starting to divide. Therefore any analyses performed at later time points would be affected by this altered state, while no interference should be present until 24 hours. 

3 Candida albicans hyphae stimuli
Serotype A C. albicans strain SC5314 was cultured overnight in Saboraud medium at 28°C and then shifted to RPMI medium for 18 hours at 37°C to allow hyphal growth. The culture was treated as for yeast cells. After microscopical inspection of the purity of hyphal culture, this was treated as for yeast cells. It should be noted that in all the experiments performed in this study live microrganisms were used.</rdfs:comment>
    <rdfs:label>Yeast culture and preparation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_508">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000634</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Organism factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/1">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/protocol/9"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_4932"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We can provide one experiment with 32 micorarrays, two experiments with 8 microarrays and one experiment with 12 micorarrays.

The yeast oligonucleotide array was constructed using the S. cerevisiae Genome Oligo Set ™ (Operon Technologies, CA, USA) composed of 6240 optimized oligonucleotides (70mers) each representing one yeast gene. </rdfs:comment>
    <rdfs:label>Yeast Microarray Dataset (4 experiments)</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/322">
    <dcr:isBiomaterialInputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/112"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/45"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC still have functional receptors and are exposed to the receptor antagonist laminarin in order to block them.</rdfs:comment>
    <rdfs:label>DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/39">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/30"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/23"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/29"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/69"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/208"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/74"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/68"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/216"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/460"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/31"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/49"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/48"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/22"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/174"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/21"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/30"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/13"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/33"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/120"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/101"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/118"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/47"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/215"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/355"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/32"/>
    <dcr:isSupervisorOf rdf:resource="http://dc-research.eu/rdf/person/255"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/34"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/449"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/200"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/29"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/12"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sebastian Amigorena</rdfs:label>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/32"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/11"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/tool/2"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/209"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/protocol/65"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/26"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/88"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/biomaterial/354"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/31"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_415">
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hiltonol</dcr:hasExactSynonym>
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Poly-ICLC</dcr:dcthera_label>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_23367"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Poly-ICLC</rdfs:label>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">hiltonol</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/175">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/50"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/47"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We performed co-cultures of IFN-DCs with zoledronate-stimulated gamma delta T lymphocytes. Gamma delta T-cell activation, as demonstrated by their up-modulation of activation marker expression levels (e.g. CD25 and CD69), was observed. The studies demonstrated for the first time the existence of a bidirectional activating interaction between DCs and gamma delta T lymphocytes activated by aminobiphosphonates.</rdfs:comment>
    <rdfs:label>IFN-DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/73">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_777"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>These bioassays were designed taking advantage of some results obtained by performing global gene expression analyses.  We have optimised a DC-based assay aimed at identifying new adjuvant molecules potentially capable to induce Th1 responses. This bioassay is a list of standardized procedures, which enables to use the dendritic cells as tools for the determination of the effects of new chemical compounds on dendritic cell capacity to produce type I IFNs. </rdfs:comment>
    <rdfs:label>Dendritic cell-based bioassays</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/11">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/111"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/15"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000545"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>We have determined mechanisms for DC-induced Th1 development and the molecular pathways for inducing Th1 cells producing IFN-gamma solely, or Th1 cells producing IFN-gamma and IL-10, which have important implications for regulation of the immune response to eradicate pathogens with minimum pathology. </rdfs:comment>
    <rdfs:label>Th1 cells producing IFN-gamma solely</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/54">
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/50"/>
    <rdfs:label>Dissection of effector vs memory phases of CTL responses inc. studies in K/O mice</rdfs:label>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/47"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0701393"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000590"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/558"/>
    <dcr:hasCellType rdf:resource="http://purl.org/obo/owl/CL#CL_0000794"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/36"/>
    <dcr:hasOrganismType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasOrganType rdf:resource="http://purl.org/obo/owl/FMA#FMA_5034"/>
    <dcr:hasExperimentalDesignType rdf:resource="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_568"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/304"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_6"/>
    <rdfs:comment>Data were produced in our lab on a broad spectrum of priming events and their  impact on the effector and memory phases of the CTL response.

Activation of a cytotoxic T lymphocyte (CTL) response in an antigen-exposed lymph node involves a great diversity of encounters between naive CTLs and APCs that differ in both duration and quality. This broad spectrum of priming events instigates a complex blend of CTL developmental pathways. 

Using an experimental system that allows tight control over CTL priming, we have singled out defined priming events and analyzed the impact of the resulting instructional program on the effector and memory phases of the CTL response. As expected, prolonged antigenic stimulation induces potent CTL expansion, effector function and CTL memory. In contrast, CTL that have received suboptimal stimulation fail to undergo extensive expansion. Nevertheless these arrested CTL persist long term and acquire memory function in the absence of further cell division. Thus our data demonstrate that CTL memory can develop as a result of a suboptimal stimulation that causes arrested clonal expansion. 

The effect of environmental factors on development of high affinity CTL was investigated using a system whereby OT-1 cells were primed in vitro by engineered APC. After a 20 h priming phase, CTL were transferred to recipient mice that were either naïve, or had been injected with activated dendritic cells one day earlier, thus creating a reactive lymph node. Note that the reactive lymph node that is thus created does not harbour specific antigen. Using this system we are able to separate cognate antigenic and co-stimulatory signals that were uniformly delivered by the APC in vitro, from environmental factors such as growth factors, which are present in the reactive lymph node. Although primary responses were not affected by a reactive lymph node environment, responses to secondary antigenic challenge of CTL that had developed in a reactive lymph node were significantly enhanced. Experiments using CD40 and IL-12 knock out mice and IL-7R blocking antibody suggest that these factors do not play a role. IL-15 is a likely candidate molecule mediating the observed effect, but in the (genetic) absence of IL-15 memory cells do not survive and no secondary responses could be detected. </rdfs:comment>
    <dcr:has_document rdf:resource="http://dc-research.eu/rdf/document/46"/>
    <dcr:hasCellType rdf:resource="http://dc-research.eu#dctheradir_300"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000111"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/56"/>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/37"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000057"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/tool/74">
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/dataset/20"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/146"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000052"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_485"/>
    <rdfs:comment>The microarray device at our disposal uses Affymetrix GeneChip® technology.</rdfs:comment>
    <rdfs:label>Microarray device</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://mged.sourceforge.net/ontologies/MGEDOntology.owl#MO_548">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.ebi.ac.uk/experimentalfactors.owl/EFO_0000324</dcr:replaced_by>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Cell type factor</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocolstep/25">
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_770"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_489"/>
    <rdfs:comment>Day 3: change of medium</rdfs:comment>
    <rdfs:label>Change of medium</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/protocol/39">
    <rdfs:comment>We established protocols for the efficient in vitro transfection of primary dendritic cells based on viral and non-viral (nucleofection) methods (A. Mantei). These have been applied to modify DC surface molecules (Notch ligands) in the murine system (S. Vaddakadathou) or deliver antigens in both murine and human DC into either the MHC I or MHC II presentation pathways (A. Sattler, M. Dziubainau). For the latter we used a MHC II presentation pathway targeting vector originally published by Wang et al. 1999. Proof of principle studies for antigen delivery have been performed with ovalbumin (murine studies) and CMVpp65 (human studies). </rdfs:comment>
    <dcr:usesBioMat rdf:resource="http://dc-research.eu/rdf/biomaterial/301"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:applicationGenerates rdf:resource="http://dc-research.eu/rdf/dataset/148"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/249"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_7"/>
    <rdfs:label>Protocols for the efficient in vitro transfection of primary dendritic cells</rdfs:label>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/68"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_9606"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/OBI_0000272"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/240"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/65"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A4">
    <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0004872"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000306"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/362">
    <dcr:relatedToInstance rdf:resource="http://dc-research.eu/rdf/biomaterial/363"/>
    <dcr:hasBioSourceType rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10090"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/50"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/PRO#PRO_000000001"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>An mAb reacting to the immunodominant LACK156-173 peptide of leishmania bound to I-Ad MHC class II molecules was prepared. To this aim, we injected I-Ad/LACK recombinant dimers to TCR transgenic mice which exhibited an increased frequency of LACK-specific T cells. Four out of 600 supernatants, i.e. 2C44, 2F74, 2E60 and 2X8, readily stained LACK156-173-pulsed fibroblasts, but neither unpulsed fibroblasts nor OVA323-339-pulsed cells. BIAcore measurements yielded equilibrium dissociation constants ranging from 1.1 nM for 2C44 mAb to 120 nM for 2F74 mAb.</rdfs:comment>
    <rdfs:label>Monoclonal antibody</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/288">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>These DC were used to elicit CTL responses in a mouse model.</rdfs:comment>
    <rdfs:label>In vitro matured DC</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_732">
    <rdfs:label>DC-THERA Coordinator</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://dc-research.eu#dctheradir_739"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DC-THERA Coordinator</rdfs:label>
    <OBI:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A DC-THERA Coordinator is a participant in DC-THERA one of the tasks of which is the coordination of the work executed in the DC-THERA project.</OBI:IAO_0000115>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000196">
    <dcr:dcthera_label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">impartial witness</dcr:dcthera_label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/IMR#IMR_0000028">
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/IMR#IMR_0000027"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type I interferon</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">type I interferons</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IFN type I</dcr:hasExactSynonym>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/60">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/85"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/83"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000000"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>When we tested in therapeutic tumor experiments with OVA+ melanoma cells, direct administration of lentiviral vectors slowed down tumor growth to a comparable extent with the highest dose of ex vivo transduced DC. </rdfs:comment>
    <rdfs:label>OVA+ melanoma cells</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/217">
    <dcr:isBioMatUsedIn rdf:resource="http://dc-research.eu/rdf/dataset/70"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/5"/>
    <rdf:type rdf:resource="http://purl.org/obo/owl/CL#CL_0000451"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>In our effort to demonstrate that pathogen-derived signals to DC mediated via TLRs can be modulated by activated iNKT cells, DC isolated from animals treated simultaneously with TLR and iNKT cell ligands were potent stimulators of naive T cells in vitro compared with these DC from animals treated with the ligands individually. </rdfs:comment>
    <rdfs:label>Animal DCs, treated individually</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_11320">
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">influenza A virus</rdfs:label>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">influenza A virus INF A</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLUAV</dcr:hasExactSynonym>
    <dcr:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Influenza virus type A</dcr:hasExactSynonym>
    <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/NCBITaxon#NCBITaxon_10239"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/person/167">
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/dataset/7"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/315"/>
    <dcr:isKnowledgeableAbout rdf:resource="http://dc-research.eu/rdf/document/314"/>
    <dcr:hasOfficialSupervisor rdf:resource="http://dc-research.eu/rdf/person/69"/>
    <dcr:hasSupervisor rdf:resource="http://dc-research.eu/rdf/person/74"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_491"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Siegfried Kohler</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="A212">
    <owl:someValuesFrom rdf:resource="http://dc-research.eu#dctheradir_606"/>
    <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000316"/>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Restriction"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu#dctheradir_454">
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/IAO_0000100</dcr:replaced_by>
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">obsolete_Data set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000011">
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/176">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/72"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OBI_0000737"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>Expression vectors for GFP-RIG-I used to analyse the interaction between RIG-I, a viral sensing protein, and NS1, an inhibitor of interferon production that is encoded by influenza A virus have been made available.</rdfs:comment>
    <rdfs:label>Expression vectors for GFP-RIG-I</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/biomaterial/321">
    <dcr:isBiomaterialOutputOf rdf:resource="http://dc-research.eu/rdf/protocolstep/85"/>
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/36"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_356"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_453"/>
    <rdfs:comment>This DC vaccine was produced from matured DC (matured using TNF alpha, IFN alpha and PGE2) which were subsequently transfected with CD40L-encoding RNA and tumor RNA.</rdfs:comment>
    <rdfs:label>DC vaccine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/OBI_0000155">
    <rdfs:subClassOf rdf:resource="http://www.geneontology.org/formats/oboInOwl#ObsoleteClass"/>
    <dcr:replaced_by rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/OBI_1110055</dcr:replaced_by>
    <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">inserted by MG - was in the OBI pre-release version but missing in the first official OBI release</rdfs:comment>
    <rdfs:label xml:lang="en">obsolete_disease</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#Class"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://dc-research.eu/rdf/dataset/2">
    <dcr:hasKnowledgeable rdf:resource="http://dc-research.eu/rdf/person/208"/>
    <dcr:derivedFromAnApplicationOf rdf:resource="http://dc-research.eu/rdf/protocol/13"/>
    <dcr:uses_tool rdf:resource="http://dc-research.eu/rdf/tool/1"/>
    <dcr:hasMoleculeType rdf:resource="http://purl.org/obo/owl/CHEBI#CHEBI_33697"/>
    <rdf:type rdf:resource="http://dc-research.eu#dctheradir_1"/>
    <rdf:type rdf:resource="http://purl.obofoundry.org/obo/IAO_0000100"/>
    <rdfs:comment>We can provide data for two experiments composed of 14 microarrays each. To obtain the data, DCs were stimulated with different form of fungi. We perform RNA preparation, labelling, hybridization, and scanning according to the Affymetrix reference protocols and BioPolo (Prof. Ricciardi-Castagnoli and Dott. Francesca Zolezzi) and preliminary data normalization according to AMDA (BioPolo). </rdfs:comment>
    <rdfs:label>MICROARRAY ANALYSIS OF DC FUNGAL CHALLENGE</rdfs:label>
  </rdf:Description>
</rdf:RDF>
